Clustering O 0 7.394833687612845e-07
of O 0 1.1242531172683812e-07
missense O 0 3.0012340630491963e-06
mutations O 0 1.3223942119111598e-07
in O 0 4.499483452491404e-09
the O 0 4.998697136215924e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 8.170629371306859e-06
in O 0 1.0768145131123674e-07
a O 0 1.2106322166971495e-08
sporadic B-Disease 0 3.0448813959083054e-06
T I-Disease 0 0.00016781843442004174
- I-Disease 0 0.00022591938613913953
cell I-Disease 1 0.9998459815979004
leukaemia I-Disease 1 0.9999998807907104
. O 0 4.54614678346843e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.908132399452427e-11
is O 0 5.2591975913118816e-12
a O 0 5.47788966964724e-11
recessive B-Disease 0 5.446433988254284e-07
multi I-Disease 0 1.1111611456726678e-05
- I-Disease 0 1.2168305147497449e-05
system I-Disease 0 1.634471225031575e-08
disorder I-Disease 0 2.91894457404851e-06
caused O 0 2.3965409656767633e-09
by O 0 7.612114064081688e-12
mutations O 0 3.237524692778493e-10
in O 0 6.25804685849829e-11
the O 0 6.356624671077782e-10
ATM O 0 2.9827042169472406e-08
gene O 0 2.8159090614821025e-09
at O 0 4.7112674650406916e-08
11q22 O 0 1.479035347529134e-07
- O 0 5.899118349361743e-08
q23 O 0 3.313369063562277e-07
( O 0 3.2779081671208132e-09
ref O 0 1.0434475683496203e-07
. O 0 1.908271762829372e-08
3 O 0 1.1241588282473458e-07
) O 0 6.3001626138259326e-09
. O 0 1.580996951133784e-07

The O 0 4.1025532482308336e-07
risk O 0 1.8587342083264957e-06
of O 0 2.6387755269752233e-07
cancer B-Disease 0 0.001165388966910541
, O 0 5.501685329534212e-09
especially O 0 8.314965072031555e-08
lymphoid B-Disease 0 4.606211950886063e-05
neoplasias I-Disease 1 0.9999550580978394
, O 0 4.16462953012342e-09
is O 0 4.835422062754446e-10
substantially O 0 2.2549615508182796e-08
elevated O 0 2.0753765284098336e-07
in O 0 6.732443580403924e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.3586410691223136e-07
and O 0 5.503784095139963e-09
has O 0 6.120035589418649e-10
long O 0 2.0234464104262884e-10
been O 0 5.083333060040829e-11
associated O 0 2.1317878573512417e-09
with O 0 3.061570996720775e-09
chromosomal O 1 1.0
instability O 1 1.0
. O 0 2.0195059278194094e-06

By O 0 2.2075244743291478e-08
analysing O 0 1.3113842669554288e-06
tumour B-Disease 1 0.9999998807907104
DNA O 0 2.6512736894801492e-08
from O 0 9.44172517947095e-10
patients O 0 4.3742905131427534e-11
with O 0 1.2130342737226574e-11
sporadic B-Disease 0 2.290739189447777e-07
T I-Disease 0 2.2002498099027434e-06
- I-Disease 0 1.4714563576490036e-06
cell I-Disease 0 0.0026780397165566683
prolymphocytic I-Disease 1 0.9340749979019165
leukaemia I-Disease 1 0.999998927116394
( O 0 2.946628008260177e-08
T B-Disease 0 1.1891339454450645e-05
- I-Disease 0 3.0078126656007953e-06
PLL I-Disease 0 6.967982244532323e-07
) O 0 1.4735339337601516e-10
, O 0 2.3172557622741508e-11
a O 0 6.393817419958481e-11
rare O 0 3.6906568912087323e-09
clonal B-Disease 0 3.1863112326391274e-07
malignancy I-Disease 0 6.01961119173211e-07
with O 0 1.3580864210993582e-10
similarities O 0 1.1193400872855364e-08
to O 0 1.7180767919455775e-09
a O 0 3.185153119034112e-08
mature B-Disease 0 1.4720808394486085e-07
T I-Disease 0 2.8047372779838042e-06
- I-Disease 0 4.585151316405245e-07
cell I-Disease 0 4.057433784510067e-07
leukaemia I-Disease 0 1.1683182492561173e-05
seen O 0 5.5430802170519655e-09
in O 0 3.2517541992405086e-09
A B-Disease 1 1.0
- I-Disease 1 0.999997615814209
T I-Disease 1 1.0
, O 0 1.751832567897793e-09
we O 0 1.2342402100351535e-10
demonstrate O 0 2.6900143224040107e-10
a O 0 3.120554370461548e-10
high O 0 1.8591018724478658e-09
frequency O 0 2.4183337554717355e-09
of O 0 8.951278829272269e-09
ATM O 0 8.358408194908407e-06
mutations O 0 2.2730216642230516e-06
in O 0 1.96528071683133e-06
T B-Disease 0 0.1033574715256691
- I-Disease 0 0.004142323508858681
PLL I-Disease 0 0.0006948711234144866
. O 0 3.0764108487346675e-06

In O 0 1.972846419562302e-08
marked O 0 5.0250378080818336e-08
contrast O 0 2.116497643811499e-09
to O 0 1.6850446038496614e-10
the O 0 1.8946342272840866e-09
ATM O 0 4.2620274598448304e-07
mutation O 0 8.046971977648809e-09
pattern O 0 1.3893608041826155e-08
in O 0 3.1132671995948158e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 3.3809284261110406e-09
the O 0 1.022191553623486e-09
most O 0 4.089514837879449e-11
frequent O 0 6.00679089801659e-11
nucleotide O 0 1.8848295146867144e-10
changes O 0 2.090889406058949e-10
in O 0 3.5759456507022946e-10
this O 0 3.598423559125763e-09
leukaemia B-Disease 0 8.22487854748033e-05
were O 0 1.1353790085877336e-07
missense O 0 9.494458026892971e-06
mutations O 0 3.784126647587982e-06
. O 0 1.0493306490388932e-06

These O 0 4.640119755094929e-08
clustered O 0 2.629814161991817e-07
in O 0 1.143475647502612e-09
the O 0 4.734451941601492e-09
region O 0 2.6541360220733168e-09
corresponding O 0 1.5848811152352482e-09
to O 0 1.2333324361790687e-09
the O 0 3.992152031173646e-08
kinase O 0 4.030284230793768e-07
domain O 0 7.994960071755486e-08
, O 0 3.0293094699374024e-09
which O 0 7.183996175719187e-10
is O 0 2.4027141387605866e-10
highly O 0 1.2439828056542979e-09
conserved O 0 5.492531762740782e-09
in O 0 2.288536249395179e-09
ATM O 0 1.1613878996286076e-06
- O 0 9.67535882523407e-08
related O 0 1.8897125642070023e-08
proteins O 0 5.121778001715427e-10
in O 0 3.69977520842113e-10
mouse O 0 3.125416370153289e-09
, O 0 6.039512223665611e-10
yeast O 0 6.134881491703936e-09
and O 0 4.1298719999360856e-09
Drosophila O 0 8.524383332542129e-08
. O 0 1.5827953347979928e-07

The O 0 1.7982927147386363e-06
resulting O 0 1.4857080259389477e-06
amino O 0 3.9009577790238836e-07
- O 0 2.849038338581522e-08
acid O 0 3.4547467109291574e-09
substitutions O 0 1.6509952294185837e-09
are O 0 9.417081697771224e-11
predicted O 0 3.494536882087118e-09
to O 0 1.291951989834672e-09
interfere O 0 3.199047071689165e-08
with O 0 9.773621023612122e-09
ATP O 0 2.0737099475809373e-05
binding O 0 2.3114904479371035e-07
or O 0 3.115347979587568e-08
substrate O 0 2.870349646855175e-07
recognition O 0 4.3717284370359266e-07
. O 0 7.52901371470216e-07

Two O 0 8.184007782574554e-08
of O 0 2.1892391544042766e-07
seventeen O 0 4.636519008727191e-07
mutated O 0 2.1473336175859004e-07
T B-Disease 0 6.473866847045429e-07
- I-Disease 0 2.091965001227436e-07
PLL I-Disease 0 4.1406883610761724e-07
samples O 0 2.1540553785115435e-09
had O 0 1.278579353503062e-09
a O 0 1.5834571154282884e-10
previously O 0 1.382481906730959e-09
reported O 0 5.6774023704520005e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
allele O 0 2.4661039788043126e-06
. O 0 4.6542177756236924e-07

In O 0 8.831436559830763e-08
contrast O 0 2.3362720469322085e-07
, O 0 4.7461967689343965e-09
no O 0 5.095744270988689e-09
mutations O 0 1.6598082908103606e-08
were O 0 2.441111091044945e-09
detected O 0 7.335688501086679e-09
in O 0 7.315117955819517e-10
the O 0 1.0630535562938803e-08
p53 O 0 1.0771612934945551e-08
gene O 0 2.9715447880107604e-09
, O 0 1.274629957137563e-09
suggesting O 0 2.3483954780800786e-09
that O 0 1.7501518290163887e-10
this O 0 2.8647904048995088e-09
tumour B-Disease 1 1.0
suppressor O 0 1.2347567462711595e-05
is O 0 9.289531921474747e-10
not O 0 2.85665352484088e-10
frequently O 0 7.696887016628295e-10
altered O 0 5.528319135805759e-09
in O 0 1.0585006204877345e-09
this O 0 9.560099378802533e-09
leukaemia B-Disease 0 9.271648741560057e-05
. O 0 3.6199310216034064e-07

Occasional O 0 3.524135081534041e-06
missense O 0 4.857412932324223e-06
mutations O 0 2.316486558129327e-07
in O 0 6.144976527622248e-09
ATM O 0 2.8217682483955286e-06
were O 0 1.514354330822698e-08
also O 0 5.24170762350451e-10
found O 0 3.3011085531775564e-10
in O 0 5.387804091760984e-10
tumour B-Disease 1 1.0
DNA O 0 9.435574099825317e-09
from O 0 1.0825363938593568e-09
patients O 0 3.4242379765014874e-11
with O 0 3.3428745882524424e-11
B B-Disease 0 1.762905554869576e-07
- I-Disease 0 3.786815838680013e-08
cell I-Disease 0 4.732066372525878e-05
non I-Disease 1 1.0
- I-Disease 1 1.0
Hodgkins I-Disease 1 0.9999992847442627
lymphomas I-Disease 0 1.3535153584598447e-06
( O 0 3.344230004032056e-09
B B-Disease 0 5.005895786780457e-07
- I-Disease 0 2.7553376469313662e-08
NHL I-Disease 1 0.8142399191856384
) O 0 1.1740958205663787e-10
and O 0 2.9827923464509354e-10
a O 0 5.879166486977283e-09
B B-Disease 0 3.6751629295395105e-07
- I-Disease 0 4.2708318659379074e-08
NHL I-Disease 1 0.9637969136238098
cell O 0 1.2211317880428396e-05
line O 0 1.1872257346112747e-05
. O 0 3.7399297525553266e-07

The O 0 2.06737542640667e-08
evidence O 0 2.2035615998561298e-08
of O 0 2.8009372599058224e-09
a O 0 1.5535799036126008e-10
significant O 0 1.7440279220792831e-09
proportion O 0 8.349447355726625e-09
of O 0 1.64843694250294e-09
loss O 0 6.557533183126907e-09
- O 0 1.776379043860743e-08
of O 0 5.591313311015256e-06
- O 0 1.4553052096744068e-07
function O 0 5.87810911056863e-10
mutations O 0 3.8568115368065037e-10
and O 0 1.0293631398650138e-11
a O 0 1.4214357989261739e-11
complete O 0 1.0066084077386961e-10
absence O 0 1.1729714799457724e-07
of O 0 1.978216488396356e-07
the O 0 1.1368803676248262e-08
normal O 0 2.396056464348817e-09
copy O 0 2.4987241165064233e-09
of O 0 1.3705674373198917e-09
ATM O 0 1.2043361152791476e-07
in O 0 7.590547634883649e-10
the O 0 2.314033853423325e-09
majority O 0 2.368782114903212e-10
of O 0 6.49754783310641e-09
mutated O 0 7.437945441779448e-06
tumours B-Disease 1 1.0
establishes O 0 4.033336509223773e-08
somatic O 0 2.473291829119262e-07
inactivation O 0 6.3717669718244e-07
of O 0 3.5390756991660055e-09
this O 0 1.097341453815126e-10
gene O 0 1.1100013269649267e-10
in O 0 2.006405874777073e-10
the O 0 2.4693398437136693e-09
pathogenesis O 0 6.979194608902617e-07
of O 0 1.7539232288754647e-08
sporadic B-Disease 0 3.7662834984075744e-06
T I-Disease 0 2.8797185223083943e-05
- I-Disease 0 0.00013793687685392797
PLL I-Disease 0 0.00019721114949788898
and O 0 1.0359274327242929e-08
suggests O 0 8.263577377931597e-09
that O 0 1.257688397870993e-10
ATM O 0 1.0485268830962013e-07
acts O 0 5.6346896037950955e-09
as O 0 1.1285688827911144e-08
a O 0 7.83921620950423e-08
tumour B-Disease 1 1.0
suppressor O 0 0.0004028729454148561
. O 0 9.154775284514471e-07

As O 0 1.0519102033867966e-07
constitutional O 0 1.8225453857212415e-07
DNA O 0 1.450049040840895e-07
was O 0 2.3100927393215898e-08
not O 0 5.6504186746186846e-11
available O 0 1.114637493415671e-09
, O 0 2.1046052400830462e-10
a O 0 2.8525224404774008e-09
putative O 0 9.490547199675348e-06
hereditary O 1 0.99998939037323
predisposition O 1 1.0
to O 0 0.017428770661354065
T B-Disease 1 0.9999998807907104
- I-Disease 1 0.974790096282959
PLL I-Disease 0 1.7927561202668585e-05
will O 0 1.2498047041731297e-09
require O 0 8.326749290077373e-10
further O 0 1.3470899062895114e-08
investigation O 0 2.3209572930227296e-08
. O 0 2.008375865614198e-08
. O 0 1.353640186607663e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 4.379120946396142e-05
kinase O 0 9.960594979929738e-07
is O 0 1.8376310195744594e-10
involved O 0 1.71755092787107e-11
in O 0 6.871255300855417e-12
the O 0 2.810288460275423e-11
modulation O 0 1.954536948955976e-10
of O 0 1.7233305060759818e-10
the O 0 1.4132136572087006e-09
Ca2 O 0 5.677803116554969e-08
+ O 0 3.702249955495063e-07
homeostasis O 0 2.517497819098935e-07
in O 0 6.6145283028618e-08
skeletal O 0 2.493577267159708e-05
muscle O 0 4.972161605110159e-06
cells O 0 4.430351054907078e-06
. O 0 1.7617055902974244e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.000533458951395005
DM B-Disease 1 1.0
) O 0 4.993048641210862e-09
, O 0 1.2093616386099626e-10
the O 0 9.055351607445417e-11
most O 0 1.3651633989919532e-10
prevalent O 0 1.5055379662953783e-06
muscular B-Disease 0 0.005275322590023279
disorder I-Disease 0 0.06477175652980804
in O 0 1.1225593787855814e-09
adults O 0 1.946390604246062e-09
, O 0 2.3539536639360925e-11
is O 0 1.0908134638609734e-11
caused O 0 5.543500103399879e-10
by O 0 5.893882604190992e-10
( O 0 4.184056656697521e-09
CTG O 0 5.142467216501245e-07
) O 0 2.08275771629296e-10
n O 0 1.5830201594013715e-09
- O 0 3.0864129030305776e-09
repeat O 0 8.197014178534801e-10
expansion O 0 2.4388819852561028e-09
in O 0 7.481378017093476e-11
a O 0 1.4247779345222256e-10
gene O 0 1.4544900006630002e-10
encoding O 0 2.51589726829593e-09
a O 0 2.6886421977678765e-08
protein O 0 6.708703494950896e-07
kinase O 0 4.748644187202444e-06
( O 0 4.181015356152784e-07
DM B-Disease 1 1.0
protein O 0 1.24661858080799e-06
kinase O 0 1.6122869794799044e-07
; O 0 1.1772048225111575e-08
DMPK O 0 7.988288416527212e-06
) O 0 5.980931028215508e-11
and O 0 3.856044650252244e-11
involves O 0 6.20454035371587e-11
changes O 0 3.881955590312458e-10
in O 0 3.6451277551918793e-09
cytoarchitecture O 0 2.797250090225134e-06
and O 0 8.423464237239386e-08
ion O 0 6.7502010097086895e-06
homeostasis O 0 4.5711153688898776e-06
. O 0 4.130838078708621e-06

To O 0 2.293487399995797e-09
obtain O 0 1.3605534476823777e-08
clues O 0 3.2947781392067554e-07
to O 0 5.425030424888178e-10
the O 0 6.6104144380574326e-09
normal O 0 3.3105699515090237e-08
biological O 0 3.071697207701618e-08
role O 0 8.312265542542718e-09
of O 0 2.4499195205862634e-07
DMPK O 1 0.9570176601409912
in O 0 5.4587069087119744e-08
cellular O 0 1.9466037315396534e-07
ion O 0 2.639405010995688e-06
homeostasis O 0 3.604745586471836e-07
, O 0 7.71808927879647e-09
we O 0 1.0698203434245102e-09
have O 0 7.256322209769905e-10
compared O 0 5.898890265143564e-09
the O 0 2.343090166334605e-08
resting O 0 1.7948900676856283e-07
[ O 0 1.1052194714977759e-08
Ca2 O 0 8.446031429798495e-09
+ O 0 2.3176749408548858e-08
] O 0 1.0102023217939404e-08
i O 0 3.879655707805796e-09
, O 0 3.5539557408093003e-10
the O 0 6.085696391266993e-10
amplitude O 0 1.882868527758319e-09
and O 0 4.72710481869143e-10
shape O 0 3.231648548762678e-08
of O 0 4.984325840950987e-08
depolarization O 0 7.160964798913483e-08
- O 0 2.0355379604097834e-07
induced O 0 1.1267604804743314e-07
Ca2 O 0 2.4168823387071825e-08
+ O 0 1.913709901657512e-08
transients O 0 1.2337071808588007e-08
, O 0 8.289664094052185e-11
and O 0 4.208238965630606e-11
the O 0 5.397102209592219e-10
content O 0 1.806500726786453e-09
of O 0 1.0783411497072848e-08
ATP O 0 4.4136746168987884e-07
- O 0 1.2306335861467232e-07
driven O 0 8.676096996396154e-08
ion O 0 2.6679327191914126e-08
pumps O 0 9.119248467470698e-09
in O 0 9.79190284411402e-10
cultured O 0 2.4796733555376704e-07
skeletal O 0 7.664926329198352e-07
muscle O 0 4.545028531310891e-08
cells O 0 3.0921654570192914e-08
of O 0 9.358506503076569e-08
wild O 0 7.167971993737865e-09
- O 0 1.4308162432641325e-09
type O 0 1.91916282865634e-09
and O 0 1.8687862368693686e-09
DMPK O 0 2.9973209620948182e-06
[ O 0 3.1593838656363005e-08
- O 0 3.2147460160558694e-07
/ O 0 2.9158431402720453e-07
- O 0 1.7179849010062753e-06
] O 0 3.542468007822208e-08
knockout O 0 9.216665262101742e-07
mice O 0 2.349615897401236e-07
. O 0 3.450129781867872e-07

In O 0 4.5753535005133017e-07
vitro O 0 2.6974362299370114e-06
- O 0 2.438200681353919e-06
differentiated O 0 6.773944392080011e-07
DMPK O 0 5.209554001339711e-05
[ O 0 1.2438201224540535e-07
- O 0 2.545604331771756e-07
/ O 0 9.295513336837757e-08
- O 0 8.415707952735829e-08
] O 0 7.855677885970636e-09
myotubes O 0 7.919710043324812e-08
exhibit O 0 5.1201101136655325e-09
a O 0 2.1204737965518916e-09
higher O 0 2.077819694079608e-08
resting O 0 2.9775886645211358e-08
[ O 0 2.7254491996586694e-09
Ca2 O 0 3.915032298351662e-09
+ O 0 1.3809408727638584e-08
] O 0 6.336073443691248e-09
i O 0 2.0602179962025957e-09
than O 0 3.0613123147560373e-10
do O 0 5.258159463394918e-10
wild O 0 6.532653085145057e-09
- O 0 1.7196439827671384e-09
type O 0 1.6437650129930148e-09
myotubes O 0 4.192094849031491e-08
because O 0 1.0244127768288536e-09
of O 0 2.213865091249545e-09
an O 0 1.032289809188569e-09
altered O 0 3.8392866663627956e-09
open O 0 2.046213865014579e-09
probability O 0 4.041096346441009e-09
of O 0 4.723952784502217e-09
voltage O 0 4.3811485284095397e-07
- O 0 9.983934745605438e-08
dependent O 0 1.6394487545312586e-07
l O 0 7.38627425889149e-09
- O 0 6.506452265853113e-09
type O 0 1.4171762652281927e-09
Ca2 O 0 1.909818303502675e-09
+ O 0 7.000724444594653e-09
and O 0 3.163572959152816e-09
Na O 0 7.1787811251056155e-09
+ O 0 2.6014816967290244e-08
channels O 0 7.103435706312666e-08
. O 0 8.434508913524041e-08

The O 0 1.3385046031544334e-06
mutant O 0 1.847623252615449e-06
myotubes O 0 4.4522739699459635e-06
exhibit O 0 3.6076684750696586e-08
smaller O 0 1.8323994543933964e-09
and O 0 4.6191783731330815e-10
slower O 0 6.959160803177156e-09
Ca2 O 0 1.171066443816926e-08
+ O 0 8.866200218449194e-09
responses O 0 1.577919683803941e-09
upon O 0 1.972108032433084e-09
triggering O 0 2.652354780252608e-09
by O 0 1.4933566883090776e-10
acetylcholine O 0 3.91299636248732e-07
or O 0 8.16187224472742e-08
high O 0 2.920206725320895e-07
external O 0 1.6626988497137063e-07
K O 0 8.54712482123432e-07
+ O 0 4.028865987493191e-07
. O 0 2.568020249782421e-07

In O 0 5.6032909867553826e-08
addition O 0 4.836958211740239e-08
, O 0 3.900400891154732e-09
we O 0 7.584599615029219e-10
observed O 0 4.788093255214676e-10
that O 0 2.0639840531133657e-11
these O 0 1.315762776510354e-10
Ca2 O 0 5.359409271932236e-08
+ O 0 4.1456829080743773e-07
transients O 0 5.081780045657069e-07
partially O 0 4.81709925281848e-08
result O 0 1.5130717789801906e-09
from O 0 1.1939922384129886e-09
an O 0 3.5958624966525576e-10
influx O 0 6.140184805047966e-09
of O 0 1.7449661715573939e-09
extracellular O 0 3.0991667010482615e-09
Ca2 O 0 7.392122913785215e-09
+ O 0 1.493660128915053e-08
through O 0 7.565401638487401e-09
the O 0 1.0058244903632385e-08
l O 0 1.1019605228312912e-09
- O 0 1.3715742985809243e-09
type O 0 7.579553096270786e-10
Ca2 O 0 5.178607320743822e-09
+ O 0 5.631125787886049e-08
channel O 0 1.7835195365023537e-07
. O 0 8.502299664314705e-08

Neither O 0 8.087517926469445e-07
the O 0 7.13204002522616e-08
content O 0 2.0525472876897766e-08
nor O 0 6.067065783099679e-08
the O 0 5.617434517546371e-09
activity O 0 3.548351301674302e-08
of O 0 1.366704616145853e-08
Na O 0 1.8854139582913376e-08
+ O 0 5.1344986928825165e-08
/ O 0 3.860355235474344e-08
K O 0 7.829832071593046e-08
+ O 0 1.4049688523698478e-08
ATPase O 0 1.845807240385966e-08
and O 0 2.314351599252973e-09
sarcoplasmic O 0 1.6862367147041368e-07
reticulum O 0 2.0281589740989148e-07
Ca2 O 0 2.0155598079441006e-08
+ O 0 9.961792812873682e-08
- O 0 6.21556424107439e-08
ATPase O 0 1.4220942645692958e-08
are O 0 3.4542688154282075e-11
affected O 0 6.047454759183779e-10
by O 0 1.1099299257466555e-09
DMPK O 0 0.006173071451485157
absence O 0 1.3467847566062119e-05
. O 0 1.4511546169160283e-06

In O 0 1.5077895909598737e-07
conclusion O 0 4.100936166651081e-06
, O 0 1.189287957004126e-08
our O 0 5.989773121939379e-09
data O 0 7.44385086903776e-09
suggest O 0 1.0662701832586663e-08
that O 0 2.7217763598486044e-09
DMPK O 0 7.411502883769572e-05
is O 0 4.617918547555888e-10
involved O 0 7.076271513195564e-11
in O 0 1.3847270552425073e-10
modulating O 0 1.890678724691952e-08
the O 0 1.8317179995008814e-09
initial O 0 3.42541728315382e-09
events O 0 4.340285075787875e-10
of O 0 3.4934040105127906e-09
excitation O 0 1.6938810176725383e-06
- O 0 8.614102853243821e-07
contraction O 0 9.404170953075663e-08
coupling O 0 9.67718563060771e-08
in O 0 2.0235486175579354e-08
skeletal O 0 1.920938302646391e-06
muscle O 0 5.318614739735494e-07
. O 0 1.3280029520501557e-07
. O 0 1.8829634029771114e-07

Constitutional O 0 6.333801138680428e-05
RB1 O 0 0.01677670329809189
- O 0 1.1598937135204324e-06
gene O 0 2.0214963925013762e-08
mutations O 0 1.630787416218027e-08
in O 0 1.0911011677494642e-10
patients O 0 5.681325895845468e-11
with O 0 9.005259211936067e-12
isolated O 0 7.450828576338608e-08
unilateral B-Disease 0 9.62611102295341e-06
retinoblastoma I-Disease 1 1.0
. O 0 2.649079578986857e-05

In O 0 8.810385310198399e-09
most O 0 2.1156825180668193e-09
patients O 0 3.969793938018995e-10
with O 0 3.5962174210757425e-11
isolated O 0 7.515929212331685e-08
unilateral B-Disease 0 1.8466050732968142e-06
retinoblastoma I-Disease 1 0.9999997615814209
, O 0 2.1426322049933333e-08
tumor B-Disease 0 2.886906440835446e-05
development O 0 7.305518323619253e-08
is O 0 5.044312884061597e-11
initiated O 0 1.4091379452185748e-10
by O 0 2.0052494387190478e-11
somatic O 0 5.0318092803536274e-08
inactivation O 0 1.3027568002144108e-07
of O 0 2.8949849184556342e-09
both O 0 1.1595392424013085e-09
alleles O 0 1.768029989079878e-08
of O 0 7.636385390696887e-08
the O 0 4.074067589954211e-07
RB1 O 0 0.00011435451597208157
gene O 0 3.9852525901551417e-07
. O 0 3.154406613248284e-06

However O 0 2.244851771138201e-07
, O 0 1.6682627501651837e-09
some O 0 6.085487669338363e-10
of O 0 3.726377428847627e-09
these O 0 5.162884009202173e-10
patients O 0 3.4695962769504263e-10
can O 0 2.600139548114555e-10
transmit O 0 7.77161233145307e-08
retinoblastoma B-Disease 0 0.008386113680899143
predisposition O 0 0.0024041952565312386
to O 0 4.7779625589328134e-08
their O 0 1.9423831076892384e-07
offspring O 0 6.0898760239069816e-06
. O 0 8.817228831503598e-07

To O 0 1.794022708168086e-09
determine O 0 4.736773195901378e-09
the O 0 2.2159731827287033e-09
frequency O 0 4.814405318853687e-09
and O 0 1.49173395858071e-10
nature O 0 4.222143967780312e-09
of O 0 9.820843693830739e-09
constitutional O 0 1.4372002397067263e-06
RB1 O 0 0.06243231147527695
- O 0 5.207106141824625e-07
gene O 0 1.0632482450034786e-08
mutations O 0 1.1322364379395822e-08
in O 0 9.542636819626082e-11
patients O 0 7.757990083678834e-11
with O 0 1.2492696113697299e-11
isolated O 0 1.961369200387253e-08
unilateral B-Disease 0 2.8377857574923837e-07
retinoblastoma I-Disease 0 0.006500452756881714
, O 0 4.451051527354366e-09
we O 0 1.4770575873512826e-09
analyzed O 0 2.7645221667427222e-09
DNA O 0 4.9426400750007815e-09
from O 0 4.552730636930846e-09
peripheral O 0 2.980469560043275e-07
blood O 0 4.001788411756024e-08
and O 0 6.843028366176895e-09
from O 0 4.280585486071686e-08
tumor B-Disease 0 2.0383131413836963e-06
tissue O 0 1.7168240162845905e-07
. O 0 2.3775662327807368e-07

The O 0 5.3638270713918246e-08
analysis O 0 6.638833838223945e-08
of O 0 2.7874213515133306e-07
tumors B-Disease 1 1.0
from O 0 1.1910386632507652e-07
54 O 0 9.721733817968925e-08
( O 0 7.10551562033146e-10
71 O 0 3.906463419411921e-08
% O 0 7.583804140232075e-10
) O 0 1.2314788945533284e-11
of O 0 8.192856393307579e-10
76 O 0 1.6432519345244145e-08
informative O 0 4.432903821793843e-09
patients O 0 3.379572732775671e-10
showed O 0 1.3924401631726369e-09
loss O 0 2.2864377058340324e-09
of O 0 7.118935663186221e-09
constitutional O 0 8.364129371329909e-07
heterozygosity O 1 0.9999994039535522
( O 1 0.8307061791419983
LOH O 1 1.0
) O 0 3.759934585900737e-08
at O 0 3.421824885663227e-07
intragenic O 0 3.857429874187801e-06
loci O 0 3.993737038854306e-07
. O 0 5.170379040464468e-07

Three O 0 2.5195248554155114e-07
of O 0 3.7635800254065543e-07
13 O 0 4.290284323360538e-07
uninformative O 0 3.455880141700618e-05
patients O 0 1.0933108995914154e-07
had O 0 3.048467434041413e-08
constitutional O 0 8.418691663791833e-07
deletions O 0 3.09778843075037e-05
. O 0 3.8023370052542305e-06

For O 0 7.014039482555745e-08
39 O 0 3.6030312458024127e-06
randomly O 0 4.066963867899176e-07
selected O 0 2.1787925561511656e-06
tumors B-Disease 1 1.0
, O 0 5.051455218563206e-07
SSCP O 1 0.9991263747215271
, O 0 1.1571322033887554e-07
hetero O 0 5.111531322654628e-07
- O 0 1.3380892482928175e-07
duplex O 0 5.611804354543892e-08
analysis O 0 6.233132676669584e-09
, O 0 1.0271788281057681e-10
sequencing O 0 2.1127537219722825e-10
, O 0 1.4947929005693084e-10
and O 0 2.7118879364351756e-10
Southern O 0 1.1122806675700758e-08
blot O 0 9.358649322166457e-08
analysis O 0 3.8868628315924525e-09
were O 0 7.486320452443351e-10
used O 0 2.654681474645315e-10
to O 0 1.1172406333415097e-09
identify O 0 1.180729043426254e-07
mutations O 0 4.479159088077722e-06
. O 0 1.950664000105462e-06

Mutations O 0 6.949227895347576e-07
were O 0 1.7377796979189952e-08
detected O 0 8.879231572223034e-09
in O 0 4.693235799990703e-10
21 O 0 9.37147071056188e-09
( O 0 3.167489881494845e-10
91 O 0 3.737676124160316e-08
% O 0 9.393209543517855e-10
) O 0 2.779079223691472e-11
of O 0 7.430728921065111e-09
23 O 0 7.728942364337854e-06
tumors B-Disease 1 1.0
with O 1 0.7838464379310608
LOH O 1 1.0
. O 0 3.622588701546192e-05

In O 0 1.197841470457206e-07
6 O 0 6.36514698726387e-07
( O 0 2.192329651151681e-09
38 O 0 9.137115597468437e-08
% O 0 1.2588169395755244e-09
) O 0 2.190931290557696e-11
of O 0 2.539385368649505e-09
16 O 0 6.711019864269474e-07
tumors B-Disease 1 1.0
without O 1 0.5526584386825562
LOH O 1 1.0
, O 0 7.15548686969214e-09
one O 0 2.0564101532727364e-09
mutation O 0 9.616898388742356e-10
was O 0 1.962831674973131e-09
detected O 0 5.562597049646456e-10
, O 0 6.298798288506546e-11
and O 0 9.547916623997565e-11
in O 0 1.3246725938387272e-09
9 O 0 3.3190676873573466e-08
( O 0 4.585198887241404e-10
56 O 0 3.7039161071561466e-08
% O 0 1.9958190655700037e-09
) O 0 5.4255450826490303e-11
of O 0 8.720156152719483e-09
the O 0 8.239475732807477e-07
tumors B-Disease 1 1.0
without O 0 0.03630410134792328
LOH O 1 1.0
, O 0 4.090816219104454e-08
both O 0 1.514914771405529e-08
mutations O 0 1.163142044902088e-07
were O 0 2.4721169111785457e-08
found O 0 2.4472289084087606e-08
. O 0 1.433926541949404e-07

Thus O 0 7.235556864770842e-08
, O 0 9.737165518330926e-10
a O 0 5.69588987087144e-10
total O 0 1.1336490635116547e-09
of O 0 3.325478559190742e-09
45 O 0 1.691990014762723e-08
mutations O 0 1.198780363864671e-08
were O 0 6.194282420324271e-09
identified O 0 3.86757044168462e-08
in O 0 2.8673500906961635e-08
tumors B-Disease 1 1.0
of O 0 9.853004485194106e-06
36 O 0 9.41360781325784e-07
patients O 0 2.2180463687959673e-08
. O 0 1.912426199623951e-07

Thirty O 0 2.6326852093916386e-06
- O 0 7.998803397413212e-08
nine O 0 7.290359604894547e-08
of O 0 2.1318946608062106e-08
the O 0 7.961811654411122e-09
mutations O 0 3.8857286277504954e-09
- O 0 3.0319511346021955e-09
including O 0 4.4426864964641766e-10
34 O 0 2.032480779234902e-07
small O 0 8.87719941999876e-09
mutations O 0 2.8772936033760743e-08
, O 0 1.7306637234426603e-09
2 O 0 4.967621691776003e-08
large O 0 4.584381230188228e-08
structural O 0 6.490539590231492e-07
alterations O 0 1.2725993201456731e-06
, O 0 2.026476408900635e-08
and O 0 3.0195675293498425e-08
hypermethylation O 0 4.202507989248261e-05
in O 0 7.615867048116343e-07
3 O 0 3.641061994130723e-06
tumors O 1 1.0
- O 0 3.079604837807892e-08
were O 0 1.108220737400245e-09
not O 0 5.692888868646939e-11
detected O 0 4.089251992578369e-10
in O 0 2.9045724159182384e-11
the O 0 6.042992217736298e-10
corresponding O 0 9.746014661971003e-09
peripheral O 0 4.5886770294600865e-07
blood O 0 1.58498849600619e-07
DNA O 0 1.92236393559142e-06
. O 0 8.195456189241668e-07

In O 0 5.970191807591618e-08
6 O 0 7.379010753538751e-07
( O 0 2.4076973748066166e-09
17 O 0 4.2902637886754746e-08
% O 0 5.94467697290213e-10
) O 0 4.726018187906078e-12
of O 0 4.4031300827640507e-10
the O 0 3.159243533445988e-09
36 O 0 9.992485061616208e-09
patients O 0 5.007657621902695e-10
, O 0 1.5604609271413494e-10
a O 0 7.114628886029095e-10
mutation O 0 2.482283489868564e-09
was O 0 2.649674923915768e-09
detected O 0 1.789245418493124e-09
in O 0 2.0585437521258854e-10
constitutional O 0 7.85596210306494e-09
DNA O 0 7.041438010446655e-08
, O 0 1.754685174937265e-09
and O 0 5.267474789683035e-10
1 O 0 2.2381305697649623e-08
of O 0 9.60326573817838e-09
these O 0 3.6195284547346773e-09
mutations O 0 2.2836147195448575e-08
is O 0 5.980911321756821e-10
known O 0 3.428474726341335e-10
to O 0 8.884631363947904e-10
be O 0 2.420414757509093e-09
associated O 0 2.7857065987291207e-08
with O 0 5.552444726220074e-09
reduced O 0 5.313494284564513e-07
expressivity O 0 3.3828720916062593e-05
. O 0 1.4370193639479112e-06

The O 0 8.445616117569443e-08
presence O 0 1.8406284496563785e-08
of O 0 3.077561672171214e-08
a O 0 1.4997741937250453e-09
constitutional O 0 1.1365161256549072e-08
mutation O 0 6.782022055062953e-09
was O 0 3.1035796155265416e-09
not O 0 4.4688260036895855e-11
associated O 0 2.108664354238954e-09
with O 0 5.477910833273647e-11
an O 0 6.22861318078094e-10
early O 0 5.193962593352808e-08
age O 0 8.004374052461571e-08
at O 0 8.924395444864786e-09
treatment O 0 2.2742041139167668e-08
. O 0 6.326186507976672e-08

In O 0 3.203443199595313e-08
1 O 0 1.995181264646817e-07
patient O 0 3.094289624527846e-08
, O 0 1.049458409063675e-09
somatic O 0 1.3907523452871828e-06
mosaicism O 0 1.5856923710089177e-05
was O 0 7.433538939949358e-08
demonstrated O 0 1.6692781601435058e-09
by O 0 4.0648786420183214e-11
molecular O 0 6.058688550858449e-10
analysis O 0 3.766146283723515e-10
of O 0 6.929144480416483e-10
DNA O 0 1.9620753910487565e-09
and O 0 1.5703894851171185e-09
RNA O 0 6.621685599839111e-08
from O 0 4.353255889100183e-08
peripheral O 0 5.56553777641966e-06
blood O 0 1.0076545322590391e-06
. O 0 4.792639174411306e-07

In O 0 5.315947504413998e-08
2 O 0 9.86026194027545e-08
patients O 0 7.176737537584188e-10
without O 0 3.9508796234599686e-10
a O 0 1.3315628599741558e-09
detectable O 0 2.855834395631973e-07
mutation O 0 1.0004461259427444e-08
in O 0 9.108205301089356e-10
peripheral O 0 2.680371267160808e-07
blood O 0 5.096543986837787e-08
, O 0 2.011637301180258e-09
mosaicism O 0 1.6272240372927627e-06
was O 0 3.643252810547892e-08
suggested O 0 2.174920243902534e-09
because O 0 4.824054489205309e-10
1 O 0 9.698912784017466e-09
of O 0 2.8409190555578334e-09
the O 0 3.2397564631025944e-09
patients O 0 5.41188693858885e-09
showed O 0 2.2754241513212037e-07
multifocal O 1 0.7924670577049255
tumors B-Disease 1 1.0
and O 0 1.5510648765371116e-08
the O 0 3.331384235139012e-08
other O 0 2.12859441184321e-09
later O 0 1.1775394881397006e-08
developed O 0 1.783161529544941e-08
bilateral B-Disease 0 9.876662261376623e-07
retinoblastoma I-Disease 0 0.00023403069644700736
. O 0 1.1917265965166735e-06

In O 0 7.2074165302638e-08
conclusion O 0 1.6851207647050614e-06
, O 0 1.0548954598732507e-08
our O 0 9.975612336177164e-09
results O 0 8.514352778377088e-09
emphasize O 0 4.178593471237946e-09
that O 0 1.6838816452313665e-10
the O 0 1.6016864501366967e-09
manifestation O 0 5.644071876531598e-08
and O 0 4.49348697140195e-10
transmissibility O 0 7.018468295427738e-07
of O 0 5.9365889981677356e-09
retinoblastoma B-Disease 0 6.880296723466017e-07
depend O 0 9.460369376768085e-09
on O 0 7.799719980994269e-09
the O 0 1.975624552841282e-09
nature O 0 4.277155962739698e-09
of O 0 4.504189465848185e-09
the O 0 5.515448986415095e-09
first O 0 1.990451137245941e-09
mutation O 0 1.1719842873958441e-09
, O 0 1.6486247089719797e-10
its O 0 4.849091128633631e-10
time O 0 1.782650582704548e-09
in O 0 1.8481347563437112e-09
development O 0 1.583842568209093e-08
, O 0 2.555564371231611e-10
and O 0 2.657604691869153e-10
the O 0 3.234384982064853e-09
number O 0 1.2481562450261663e-09
and O 0 5.32434374367341e-10
types O 0 1.1718685577477572e-08
of O 0 1.9343264767712753e-08
cells O 0 4.264318231861353e-09
that O 0 2.3008133176460888e-09
are O 0 1.0473667488852811e-09
affected O 0 1.9258962424828496e-08
. O 0 2.4062204673214183e-08
. O 0 2.8879773594781e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 0 0.4133453071117401
fifth I-Disease 0 1.7677452888165135e-06
component I-Disease 0 3.5479313709174676e-08
of I-Disease 0 5.278480763593052e-09
complement I-Disease 0 1.8284787017819326e-09
in O 0 1.8084842068333273e-08
man O 0 1.3877017408958636e-05
. O 0 1.54378869865468e-06

I O 0 0.0667080208659172
. O 0 2.4211876734625548e-05

Clinical O 0 1.1677913789753802e-05
, O 0 1.346638356380936e-07
immunochemical O 0 0.00010361266322433949
, O 0 4.995671076812869e-08
and O 0 2.4432598166868047e-08
family O 0 1.567503176147511e-07
studies O 0 5.1342734508352805e-08
. O 0 5.2075428413900227e-08

The O 0 6.07517165462923e-08
first O 0 3.109386081945331e-09
recognized O 0 3.1433273761649616e-09
human O 0 3.20644932827463e-09
kindred O 0 1.6731934010749683e-05
with O 0 2.1740151345817083e-10
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999997615814209
the I-Disease 0 0.0002693987626116723
fifth I-Disease 0 2.2164701931615127e-06
component I-Disease 0 4.6246489660006773e-07
of I-Disease 0 5.289395630825311e-06
complement I-Disease 0 1.957581616807147e-06
( O 0 1.0844566986634163e-06
C5 O 1 0.9999998807907104
) O 0 5.731288332810891e-09
is O 0 2.1843407083110833e-09
described O 0 2.7635376653734056e-08
. O 0 2.0368194952880003e-07

The O 0 2.0716365725093056e-06
proband O 0 1.0853344974748325e-05
, O 0 3.0934499406498617e-09
a O 0 1.8225559950124648e-09
20 O 0 6.4420668799414216e-09
- O 0 8.307000087803829e-10
year O 0 1.982838782055296e-09
- O 0 3.895419986577053e-09
old O 0 1.0415207896130596e-07
black O 0 1.042034458720309e-09
female O 0 4.528081798405026e-10
with O 0 8.824120323325246e-10
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 0.9913995265960693
age O 0 0.0002633371914271265
11 O 0 4.9571440285944846e-08
, O 0 9.56591250655947e-10
lacked O 0 1.1532125654412084e-07
serum O 0 8.821150032645164e-08
hemolytic O 0 6.173785322971526e-07
complement O 0 5.5658183839568665e-08
activity O 0 3.052360284527822e-07
, O 0 1.7591521572768443e-09
even O 0 3.743745757844863e-09
during O 0 2.060030546147118e-08
remission O 0 2.9728792583227914e-07
. O 0 7.556695180710449e-08

C5 O 0 0.21773697435855865
was O 0 4.389367859403137e-06
undetectable O 0 1.2231049595357035e-06
in O 0 3.1775182485205278e-09
her O 0 1.1162374358164584e-09
serum O 0 1.2907523938565646e-09
by O 0 1.5937562380941017e-10
both O 0 6.0662075362927226e-09
immunodiffusion O 0 1.4002216630615294e-05
and O 0 4.976460488137491e-08
hemolytic O 0 6.694473995594308e-05
assays O 0 3.1935530842019944e-06
. O 0 1.6353153569070855e-06

Other O 0 2.9549169777709494e-09
complement O 0 2.196888004846187e-09
components O 0 1.2509907776347973e-08
were O 0 8.01536614858378e-10
normal O 0 5.333494534909278e-09
during O 0 1.1293801449596685e-09
remission O 0 5.3198323968217665e-08
of O 0 6.488853898645175e-09
lupus O 0 1.294025935294485e-07
, O 0 1.1332000227071148e-08
but O 0 1.4856709640298504e-07
C1 O 0 1.8048394849756733e-05
, O 0 1.5403635700295126e-07
C4 O 0 4.977268690709025e-05
, O 0 1.4138055348666967e-07
C2 O 0 1.2584666819748236e-06
, O 0 4.681277943063833e-08
and O 0 3.4996455156033335e-07
C3 O 0 0.1452212929725647
levels O 0 6.531193321279716e-06
fell O 0 0.00015962233010213822
during O 0 2.2512062969326507e-07
exacerbations O 0 0.00013972770830150694
. O 0 1.7342238152195932e-06

A O 0 0.00015028311463538557
younger O 0 1.2199050615890883e-05
half O 0 3.5782941267825663e-06
- O 0 1.5200153313799092e-07
sister O 0 9.5047759884892e-08
, O 0 1.4166844364282838e-09
who O 0 4.669041597793466e-09
had O 0 5.9339178015704874e-09
no O 0 5.1020072611152045e-09
underlying O 0 4.597797271799209e-07
disease O 0 9.342614066554233e-05
, O 0 1.1120616649762383e-09
was O 0 1.869532724185774e-07
also O 0 3.454053154605674e-10
found O 0 6.955547804388118e-10
to O 0 2.555702094397816e-09
lack O 0 3.581724740797654e-05
immunochemically O 0 0.018818829208612442
detectable O 0 0.20073634386062622
C5 O 0 0.3936842679977417
. O 0 3.909045517502818e-06

By O 0 1.0269040018329179e-07
hemolytic O 0 0.00017607132031116635
assay O 0 2.7874500574398553e-06
, O 0 3.73645718809712e-08
she O 0 4.8343733460853855e-09
exhibited O 0 3.1989127791121064e-08
1 O 0 7.588178085882191e-09
- O 0 1.1579811554085495e-09
2 O 0 1.6481853659655599e-09
% O 0 1.5160782351753e-10
of O 0 1.5719020529658678e-10
the O 0 5.425713212048322e-10
normal O 0 1.3182787306220689e-08
serum O 0 1.696326457079067e-08
C5 O 0 1.0423509593238123e-06
level O 0 1.674850480526402e-08
and O 0 9.370412223930202e-10
normal O 0 1.2572458629733774e-08
concentrations O 0 1.1226798157792928e-08
of O 0 2.3394450821001556e-09
other O 0 2.9319382477410727e-09
complement O 0 4.065753245185988e-08
components O 0 7.098274750205746e-07
. O 0 6.274705128817004e-07

C5 O 0 0.0005248989909887314
levels O 0 1.9290621366963023e-07
of O 0 5.455997875714047e-09
other O 0 2.9605171092406124e-10
family O 0 4.3795189696993475e-10
members O 0 1.9640278986488013e-11
were O 0 8.122770511764799e-11
either O 0 1.2484603628681867e-10
normal O 0 3.3783045250146415e-09
or O 0 1.1031481284007327e-10
approximately O 0 1.3999632564321018e-09
half O 0 3.755333111143955e-08
- O 0 1.210595357292732e-08
normal O 0 3.6369346645415135e-08
, O 0 1.0827898300203032e-10
consistent O 0 1.9941903683928786e-09
with O 0 7.796677886640069e-11
autosomal O 0 3.564217365692457e-07
codominant O 0 1.4725317214470124e-06
inheritance O 0 1.1584770476247286e-07
of O 0 8.705050902335643e-09
the O 0 8.163659082072172e-09
gene O 0 5.340021971278475e-07
determining O 0 0.00020689675875473768
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.475731318758335e-06

Normal O 0 7.202856068033725e-05
hemolytic O 0 0.001739754225127399
titers O 0 3.828784974757582e-05
were O 0 1.5922083207442483e-08
restored O 0 2.244247632177121e-08
to O 0 3.5777195095398895e-10
both O 0 4.245838347571862e-09
homozygous O 0 3.507419387460686e-05
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 0.00014663333422504365
C5D B-Disease 1 1.0
) O 0 3.368813672466331e-09
sera O 0 1.6687154769101653e-08
by O 0 1.3202494653086205e-11
addition O 0 5.070688868791251e-10
of O 0 7.217387576474721e-09
highly O 0 3.424340988544827e-08
purified O 0 6.602137858635615e-08
human O 0 3.6890756405227876e-07
C5 O 1 0.998934805393219
. O 0 8.945596050580207e-07

In O 0 6.448781419976513e-08
specific O 0 7.739363354630768e-07
C5 O 0 0.00012536835856735706
titrations O 0 2.8686361019936157e-06
, O 0 5.33825739168492e-09
however O 0 3.881461818622256e-09
, O 0 3.633582046358441e-10
it O 0 2.5168273021236587e-10
was O 0 7.51594075865114e-09
noted O 0 1.2361184298370631e-09
that O 0 4.741351408710237e-11
when O 0 2.2321001991176814e-10
limited O 0 3.2603603150604954e-10
amounts O 0 3.2501608071555665e-09
of O 0 8.250714245150448e-08
C5 O 0 1.66952122526709e-05
were O 0 5.123151325392428e-08
assayed O 0 2.1548439121943375e-07
in O 0 1.4291197114602028e-09
the O 0 3.507157009252637e-09
presence O 0 9.384528709688311e-09
of O 0 1.6880379760664255e-08
low O 0 1.4743822873697354e-07
dilutions O 0 8.478281756651995e-07
of O 0 7.124778989009428e-08
either O 0 1.4290762919699773e-06
C5D B-Disease 1 1.0
serum O 0 7.715545393693901e-07
, O 0 7.740439400549803e-09
curving O 0 2.6602555180943455e-07
rather O 0 2.4309032564673316e-09
than O 0 1.1925583853766852e-09
linear O 0 1.3562654999077495e-08
dose O 0 8.600172130002193e-09
- O 0 6.097097493551473e-09
response O 0 3.58972429559401e-09
plots O 0 4.0708901138941656e-08
were O 0 1.1333232130539272e-08
consistently O 0 6.920060968695907e-09
obtained O 0 2.2802025156920536e-08
, O 0 3.8297037763257435e-10
suggesting O 0 4.92368945614885e-09
some O 0 1.1625997942132926e-09
inhibitory O 0 8.381457519135438e-07
effect O 0 1.1730413689292618e-06
. O 0 9.143998909166839e-07

Further O 0 4.49368002364281e-07
studies O 0 5.24428287462797e-08
suggested O 0 3.5296043865429283e-09
that O 0 1.768348523167873e-10
low O 0 2.380020447390052e-08
dilutions O 0 2.923599595305859e-06
of O 0 2.6003115749517747e-07
C5D B-Disease 1 1.0
serum O 0 4.275950615806323e-08
contain O 0 6.264630481034317e-10
a O 0 1.1188400206307847e-09
factor O 0 5.371810107845931e-09
( O 0 3.474318055474157e-10
or O 0 7.137408997159866e-10
factors O 0 8.607441870367438e-09
) O 0 8.487396896406096e-11
interfering O 0 1.0542412498537601e-09
at O 0 4.741419701304039e-09
some O 0 2.422381184530309e-10
step O 0 2.033910151411078e-09
in O 0 6.053744172618281e-10
the O 0 1.5025955590886042e-08
hemolytic O 0 5.686202257493278e-06
assay O 0 1.433038164577738e-06
of O 0 3.763946097024018e-06
C5 O 0 0.3073003888130188
, O 0 3.2143914197035883e-09
rather O 0 1.0070775324777514e-09
than O 0 4.869648573269103e-10
a O 0 1.4435745931962174e-08
true O 0 3.92518842318168e-07
C5 O 0 1.2771107321896125e-05
inhibitor O 0 1.9085707947397168e-07
or O 0 8.117500982507408e-08
inactivator O 0 1.671697464189492e-05
. O 0 1.573648773955938e-06

Of O 0 3.766387806081184e-07
clinical O 0 1.7698133660815074e-06
interest O 0 2.58306954492582e-06
are O 0 1.4871212039579973e-09
( O 0 5.482617693175484e-10
a O 0 1.6230845556464146e-09
) O 0 2.050446964996233e-11
the O 0 1.1641215075242073e-10
documentation O 0 5.96092917248825e-08
of O 0 4.9136730240206816e-08
membranous O 1 0.9997542500495911
glomerulonephritis B-Disease 1 1.0
, O 0 5.214778866502456e-07
vasculitis B-Disease 1 1.0
, O 0 3.830642469893064e-08
and O 0 7.763167531038562e-08
arthritis B-Disease 1 1.0
in O 0 3.3336076121770475e-09
an O 0 1.7173102939693763e-09
individual O 0 2.1818340467660846e-09
lacking O 0 7.698148692725226e-05
C5 O 1 0.9999672174453735
( O 0 2.167933388363963e-09
and O 0 4.082067184274507e-10
its O 0 5.605412245479613e-10
biologic O 0 9.435613179675784e-08
functions O 0 5.942976111228404e-10
) O 0 4.4348105049385467e-11
, O 0 1.5492182536824828e-10
and O 0 1.1976004632430204e-09
( O 0 5.428301141918723e-10
b O 0 3.0681708285129616e-09
) O 0 3.540422469083815e-11
a O 0 3.2921046444478463e-10
remarkable O 0 5.955437920590612e-09
propensity O 0 6.770728333549414e-08
to O 0 3.788901636880837e-09
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 3.3894623219232756e-10
the O 0 3.3775766627996973e-09
proband O 0 1.331010395233534e-07
, O 0 2.360375228604994e-10
even O 0 8.894923686497691e-10
during O 0 1.3759552386360951e-09
periods O 0 3.4710161855855404e-08
of O 0 1.8106481647350847e-08
low O 0 7.149759539970546e-08
- O 0 5.1601598549666505e-09
dose O 0 5.650424128589293e-09
or O 0 1.909661540011598e-09
alternate O 0 7.609123997553979e-08
- O 0 1.2947086247550033e-07
day O 0 2.0112356224899486e-08
corticosteroid O 0 8.305927963192516e-07
therapy O 0 4.1910237769116065e-07
. O 0 2.992163672388415e-07

Other O 0 3.647355129032803e-08
observations O 0 8.383825189639538e-08
indicate O 0 3.1302247460729404e-09
that O 0 1.1862781590377125e-10
the O 0 9.646296206256011e-09
C5D B-Disease 1 1.0
state O 0 1.2442722407968176e-09
is O 0 5.490798093976679e-11
compatible O 0 6.173578870338758e-10
with O 0 7.922146272321129e-11
normal O 0 6.737605140472169e-09
coagulation O 0 1.6124331869704633e-09
function O 0 2.3058466247505294e-10
and O 0 2.1108766123933975e-10
the O 0 1.1843661607002787e-09
capacity O 0 1.0732498223475773e-09
to O 0 8.977520393749217e-10
mount O 0 9.799082363315392e-07
a O 0 1.9688660302108474e-07
neutrophilic O 1 0.9696115851402283
leukocytosis O 0 0.0002407509455224499
during O 0 7.090440021784161e-07
pyogenic B-Disease 0 0.00017013224714901298
infection I-Disease 0 1.9394104810999124e-07
. O 0 3.668884973606623e-09
. O 0 3.951825533476949e-08

Susceptibility O 0 1.5331747817981523e-06
to O 0 9.347731122488767e-08
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 4.382606846320414e-07
twins O 0 3.227066542876855e-07
: O 0 1.355578704842486e-10
the O 0 9.11667019654061e-10
role O 0 8.051850297619012e-10
of O 0 1.5855624369010002e-08
genes O 0 5.900927302349146e-09
, O 0 2.1843573616564527e-09
HLA O 0 3.444386322826176e-07
, O 0 1.2748494704339919e-08
and O 0 3.8536313695658464e-08
the O 0 3.5531504636310274e-06
environment O 0 9.623510095480015e-07
. O 0 6.114959774095041e-07

OBJECTIVE O 0 3.982269390689908e-06
To O 0 4.1569295228249814e-10
determine O 0 2.036744106703736e-09
the O 0 9.107250509288178e-10
relative O 0 2.872709536916318e-08
effects O 0 1.1286657830567037e-08
of O 0 1.0976601849677081e-09
genetic O 0 5.831922944565804e-09
and O 0 1.1251868881068106e-10
environmental O 0 1.0695531127424829e-09
factors O 0 9.302510983744128e-10
in O 0 3.238196516486269e-11
susceptibility O 0 5.4377160552121495e-08
to O 0 2.6982437617562027e-08
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 3.2159678085008636e-06
AS B-Disease 1 1.0
) O 0 6.6443037738395105e-09
. O 0 3.160800332580038e-08

METHODS O 0 1.499268546467647e-05
Twins O 0 5.453399012367299e-07
with O 0 1.4929815161934812e-09
AS B-Disease 1 1.0
were O 0 1.644403918588111e-10
identified O 0 1.0191152782779156e-10
from O 0 7.459449030688958e-11
the O 0 1.084644485338515e-09
Royal O 0 3.9038788202105934e-08
National O 0 8.592961364684015e-08
Hospital O 0 2.2838405129732564e-05
for O 0 8.232161619048384e-09
Rheumatic B-Disease 1 1.0
Diseases I-Disease 0 0.014701569452881813
database O 0 5.370295639295364e-07
. O 0 5.581673576671164e-07

Clinical O 0 6.875843610032462e-07
and O 0 5.997466967500031e-09
radiographic O 0 1.5499580285904813e-06
examinations O 0 1.4571537576557603e-07
were O 0 5.034590522257076e-09
performed O 0 4.2556380641656233e-10
to O 0 2.9480642926849043e-10
establish O 0 1.6382445622298292e-08
diagnoses O 0 1.2470770343497861e-05
, O 0 2.920685915341892e-09
and O 0 1.5524314056492017e-09
disease O 0 2.1727130388171645e-06
severity O 0 2.8222771106811706e-06
was O 0 4.448259094402829e-09
assessed O 0 2.389356934529019e-09
using O 0 1.0328998767406006e-10
a O 0 8.158829722937355e-10
combination O 0 5.2959774343719346e-09
of O 0 1.2031326157568856e-08
validated O 0 1.6959099014002277e-07
scoring O 0 3.6236477285456203e-07
systems O 0 5.926862058913684e-07
. O 0 1.3251908512756927e-06

HLA O 0 2.9909198929090053e-05
typing O 0 2.6494342364458134e-07
for O 0 2.7391985568669952e-08
HLA O 0 6.123719344941492e-07
- O 0 4.6682382048857107e-07
B27 O 0 4.5313953478398616e-07
, O 0 1.5932890562453395e-09
HLA O 0 9.188982907915033e-09
- O 0 9.202770101524038e-09
B60 O 0 4.062156833128938e-08
, O 0 2.6462287916473315e-10
and O 0 1.7172177568802738e-10
HLA O 0 4.850335599826394e-08
- O 0 4.318930280078348e-07
DR1 O 0 3.882036617142148e-05
was O 0 3.015538752038083e-08
performed O 0 4.0330686706946395e-11
by O 0 2.921307293290987e-11
polymerase O 0 3.4027300976902097e-09
chain O 0 1.547666350631971e-08
reaction O 0 1.0751250556495506e-08
with O 0 5.477474585013908e-10
sequence O 0 1.0192207078318916e-09
- O 0 9.414177215560926e-10
specific O 0 6.440810107477546e-10
primers O 0 1.3824720923594214e-08
, O 0 1.3324469305686648e-09
and O 0 3.83536358228298e-09
zygosity O 0 7.568824571535515e-07
was O 0 2.2510338482106818e-08
assessed O 0 2.7800057367244335e-08
using O 0 1.5935146535639433e-08
microsatellite O 0 5.267689175525447e-06
markers O 0 5.173139470571186e-06
. O 0 3.475310677458765e-06

Genetic O 0 6.726911010446202e-07
and O 0 8.077589264132712e-09
environmental O 0 3.7252206652738096e-08
variance O 0 1.5930407215591913e-08
components O 0 1.094053114769622e-08
were O 0 9.101623898999378e-10
assessed O 0 3.533277137535151e-08
with O 0 2.5972349271263795e-10
the O 0 1.9669588624537937e-08
program O 0 3.1456726112821798e-09
Mx O 0 7.3701893477107205e-09
, O 0 4.900300304422345e-11
using O 0 8.837215681456456e-12
data O 0 2.1901634672527592e-10
from O 0 3.2124714000048016e-10
this O 0 2.224509326742563e-10
and O 0 3.4957348127306886e-10
previous O 0 9.044502924382414e-09
studies O 0 6.325013401919932e-09
of O 0 9.706741188608703e-09
twins O 0 1.2593368126090354e-07
with O 0 1.0183312859624039e-08
AS B-Disease 1 1.0
. O 0 1.3626125792143284e-06

RESULTS O 0 1.9599390270741424e-06
Six O 0 8.52937560580358e-08
of O 0 5.869242158951238e-08
8 O 0 3.4011753768936615e-07
monozygotic O 0 2.4225257675425382e-06
( O 0 7.295032844467642e-08
MZ O 0 0.0002473406493663788
) O 0 1.3819157373973212e-08
twin O 0 3.082685111621686e-07
pairs O 0 3.98535071610695e-08
were O 0 1.4199151188165615e-08
disease O 0 1.2616126241482561e-06
concordant O 0 3.3171440350088233e-07
, O 0 3.114061508657784e-10
compared O 0 5.592970531154151e-10
with O 0 1.6287238918666347e-11
4 O 0 4.283834620366633e-09
of O 0 3.894231159762285e-09
15 O 0 1.822814077456769e-08
B27 O 0 1.2865309884091403e-07
- O 0 2.5017916627234627e-08
positive O 0 4.814552312382148e-09
dizygotic O 0 2.0315893323186174e-07
( O 0 6.488111381486306e-09
DZ O 0 1.099819314731576e-06
) O 0 1.8545331936792309e-09
twin O 0 3.313260776849347e-08
pairs O 0 3.7921554785214084e-09
( O 0 6.76301681323821e-10
27 O 0 1.6588595030953002e-07
% O 0 7.849158545347734e-10
) O 0 2.0142798019817665e-12
and O 0 2.038238154644656e-11
4 O 0 1.1021706880498527e-09
of O 0 2.8797628726096036e-09
32 O 0 5.372201599129767e-07
DZ O 0 3.406250834814273e-05
twin O 0 9.252755717170658e-07
pairs O 0 9.115808552451199e-08
overall O 0 2.8508161449281033e-06
( O 0 3.0975708664726653e-09
12 O 0 1.6207621911235037e-08
. O 0 3.1412896728255646e-09
5 O 0 4.6743007686700366e-08
% O 0 9.018198632304575e-09
) O 0 6.026716348195293e-10
. O 0 3.4721619357469535e-08

Nonsignificant O 0 1.3282846339279786e-05
increases O 0 4.0246142418709496e-08
in O 0 5.456921026159023e-10
similarity O 0 3.5624956318258683e-09
with O 0 2.989620009885563e-11
regard O 0 1.885830158698809e-09
to O 0 2.0243189069457657e-10
age O 0 7.519427214219832e-08
at O 0 5.487662768643986e-09
disease O 0 1.4407578241559804e-08
onset O 0 1.3326509673561304e-08
and O 0 1.3909946978973853e-11
all O 0 2.125906221894791e-11
of O 0 3.461327335863018e-10
the O 0 8.129067974316229e-10
disease O 0 3.2868545662978477e-09
severity O 0 1.1274759792456734e-08
scores O 0 3.663095382577808e-09
assessed O 0 4.303753797785248e-08
were O 0 2.27976637567906e-09
noted O 0 7.606465679543817e-09
in O 0 2.476221006020296e-09
disease O 0 1.6770503918905888e-07
- O 0 5.571488941313874e-07
concordant O 0 0.00011827934940811247
MZ O 0 0.0010908746626228094
twins O 0 2.4533613895982853e-07
compared O 0 1.8537136270424526e-08
with O 0 3.7492622340096204e-09
concordant O 0 0.00033806965802796185
DZ O 0 0.004691231530159712
twins O 0 2.651323848112952e-05
. O 0 2.7954019969911315e-06

HLA O 0 1.2390303709253203e-05
- O 0 2.4251887680293294e-06
B27 O 0 5.557977829084848e-07
and O 0 7.017056935509913e-10
B60 O 0 3.1650834841912e-08
were O 0 5.757556237329098e-11
associated O 0 2.3028842721650733e-10
with O 0 1.3670493556605656e-11
the O 0 8.878008328494502e-10
disease O 0 3.508001711338693e-08
in O 0 1.318923581461462e-10
probands O 0 4.9650584514893126e-06
, O 0 1.450273789949108e-10
and O 0 4.722812765867168e-11
the O 0 1.4880234822101102e-09
rate O 0 1.0926808791111853e-08
of O 0 6.804071195354311e-10
disease O 0 6.731734725207161e-09
concordance O 0 2.275370114546149e-09
was O 0 4.0706998882811263e-10
significantly O 0 4.0222927766286887e-10
increased O 0 4.205515047317476e-09
among O 0 4.135439013452924e-08
DZ O 0 3.924695556634106e-05
twin O 0 5.026878966418735e-07
pairs O 0 1.980635921938756e-08
in O 0 5.321219909149022e-09
which O 0 2.787687636285341e-09
the O 0 5.8405870362321366e-08
co O 0 6.741026936651906e-08
- O 0 2.3696503603787278e-07
twin O 0 3.334747873395827e-07
was O 0 1.610101385551843e-08
positive O 0 3.541180682020695e-10
for O 0 4.960657995489726e-10
both O 0 1.7832839205311757e-08
B27 O 0 1.3594009033113252e-05
and O 0 8.665228961035609e-07
DR1 O 0 0.032291229814291
. O 0 5.117787623021286e-06

Additive O 0 6.475676741501957e-07
genetic O 0 2.479569332081155e-07
effects O 0 1.814904919683613e-07
were O 0 9.74299974032533e-10
estimated O 0 2.5942048509364213e-10
to O 0 2.4946832793970586e-11
contribute O 0 5.520729429164817e-10
97 O 0 1.6470078634256424e-08
% O 0 2.5666235803356585e-10
of O 0 7.096410958862265e-11
the O 0 3.3299832336020074e-10
population O 0 6.057786494650941e-10
variance O 0 2.9282624325333018e-08
. O 0 1.3750278071711364e-07

CONCLUSION O 0 7.71561280998867e-06
Susceptibility O 0 3.377859059128241e-07
to O 0 2.2552841372203147e-08
AS B-Disease 1 1.0
is O 0 2.538697696508052e-09
largely O 0 6.863694501646478e-09
genetically O 0 6.31324659217114e-10
determined O 0 8.538846074657158e-09
, O 0 3.2297597929442645e-10
and O 0 1.8452103733856973e-10
the O 0 1.4387578906038812e-09
environmental O 0 1.2912554581134827e-08
trigger O 0 4.02188256032332e-08
for O 0 2.11186024223764e-09
the O 0 2.1122204429957492e-07
disease O 0 2.0537670479825465e-06
is O 0 1.703374219452769e-09
probably O 0 3.444773355454345e-08
ubiquitous O 0 2.068939465971198e-06
. O 0 7.633908012394386e-07

HLA O 0 4.2115836549783126e-05
- O 0 2.6706140943133505e-06
B27 O 0 5.359910346669494e-07
accounts O 0 3.0652094751282277e-10
for O 0 1.3920430780300919e-11
a O 0 1.0817019502340486e-10
minority O 0 4.2389963067490655e-11
of O 0 3.697009920422545e-10
the O 0 3.081648491942701e-09
overall O 0 3.4285434935554804e-08
genetic O 0 4.387533181215986e-08
susceptibility O 0 1.707920489479875e-07
to O 0 1.0619211820994678e-07
AS B-Disease 1 1.0
. O 0 2.4863870748959016e-06

Cell O 0 5.4972897487459704e-06
cycle O 0 5.907450031372719e-07
- O 0 1.0155967089531259e-07
dependent O 0 6.431756105484965e-08
colocalization O 0 5.331320949153451e-07
of O 0 6.350837367108397e-08
BARD1 O 0 0.00011744733637897298
and O 0 3.343045307246939e-08
BRCA1 O 0 9.194172534421341e-09
proteins O 0 5.245878731408027e-10
in O 0 4.294622713008067e-10
discrete O 0 2.7984876638242895e-08
nuclear O 0 8.366212114196969e-07
domains O 0 2.606148427730659e-06
. O 0 2.049005161097739e-06

Germ O 0 4.484717283048667e-05
- O 0 2.774481572487275e-06
line O 0 1.9207499235562864e-07
mutations O 0 2.3251311986882683e-08
of O 0 8.051178390644509e-09
the O 0 1.2576007790698895e-08
BRCA1 O 0 1.997648091389692e-08
gene O 0 8.904365245143708e-09
predispose O 0 3.0545722893293714e-06
women O 0 4.674548748084817e-09
to O 0 6.741676661370377e-10
early O 0 2.6710317797551397e-06
- O 0 1.9793496903730556e-06
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 2.40360786829541e-10
compromising O 0 9.547270529708385e-09
the O 0 2.389001663161139e-09
genes O 0 7.3090689056698466e-09
presumptive O 0 1.5738963554667862e-07
function O 0 6.773386740377418e-09
as O 0 5.526442414804933e-09
a O 0 2.339562144015872e-08
tumor B-Disease 0 1.8804686305884388e-06
suppressor O 0 6.323841807898134e-05
. O 0 1.2086201195415924e-06

Although O 0 8.354341929361908e-08
the O 0 2.6944123376893003e-08
biochemical O 0 2.414220944046974e-06
properties O 0 3.566261284504435e-06
of O 0 1.2073276138835354e-06
BRCA1 O 0 1.027142957354954e-07
polypeptides O 0 3.3593192227954205e-08
are O 0 2.0222193364283214e-10
not O 0 6.101713023731747e-10
understood O 0 7.98622323827658e-09
, O 0 2.3108395752480249e-10
their O 0 7.219830983062892e-11
expression O 0 6.677437269786424e-09
pattern O 0 2.4972244716536807e-08
and O 0 5.990581364301306e-10
subcellular O 0 1.147191937889147e-06
localization O 0 1.3244262220268865e-07
suggest O 0 2.867158954700244e-08
a O 0 9.97766758104035e-09
role O 0 2.099307216951729e-08
in O 0 3.0016632734941595e-08
cell O 0 3.0894088922650553e-06
- O 0 2.1355244825826958e-06
cycle O 0 1.1289461099295295e-07
regulation O 0 4.9248569666815456e-08
. O 0 2.3924050651658035e-07

When O 0 2.7652572498482186e-06
resting O 0 2.6425846954225563e-05
cells O 0 1.405722684921784e-07
are O 0 7.831617021558657e-10
induced O 0 1.5225332106183487e-08
to O 0 5.119317192381345e-10
proliferate O 0 1.2724395759278195e-08
, O 0 3.141755744451302e-10
the O 0 4.0711212179189715e-09
steady O 0 6.535172758503904e-08
- O 0 6.245720607367389e-10
state O 0 1.8552256952908408e-10
levels O 0 2.1869295263599042e-09
of O 0 2.057151338163976e-09
BRCA1 O 0 1.8566639337080915e-09
increase O 0 3.329081732506012e-10
in O 0 5.839355665671064e-10
late O 0 6.753426191608014e-07
G1 O 0 8.9699291550005e-08
and O 0 2.0925888799538939e-10
reach O 0 1.551351047623939e-09
a O 0 5.283877224648847e-10
maximum O 0 1.2883328182056175e-08
during O 0 1.336337049906433e-07
S O 0 4.597714450937929e-06
phase O 0 9.582262237017858e-07
. O 0 9.925206541083753e-07

Moreover O 0 5.198363055569644e-07
, O 0 7.1778778476527805e-09
in O 0 1.4281940075022703e-08
S O 0 1.3430848184725619e-06
phase O 0 9.865774330819477e-08
cells O 0 2.7320188777935073e-08
, O 0 1.0532287930686834e-08
BRCA1 O 0 1.0650652626509327e-07
polypeptides O 0 5.641607359052614e-08
are O 0 1.3659455788683772e-09
hyperphosphorylated O 0 5.470823225550703e-07
and O 0 3.4951899152702026e-09
accumulate O 0 2.1297365648820232e-08
into O 0 4.240277906575329e-09
discrete O 0 1.0646996173591106e-07
subnuclear O 0 2.2819701825937955e-06
foci O 0 1.6223664260905934e-06
termed O 0 5.181781830287946e-07
" O 0 1.0551634943567478e-07
BRCA1 O 0 7.10573829110217e-07
nuclear O 0 1.2901288073408068e-06
dots O 0 4.390108642837731e-06
. O 0 2.2634390006714966e-06

" O 0 2.1664975520252483e-06
BRCA1 O 0 5.737974788644351e-06
associates O 0 1.1977813301200513e-06
in O 0 2.002404997369922e-08
vivo O 0 6.553658948860175e-08
with O 0 2.4408305931977736e-10
a O 0 8.605487877844098e-09
structurally O 0 2.4209614934989077e-07
related O 0 2.8810563890147023e-07
protein O 0 3.097682201769203e-05
termed O 0 1.2105005225748755e-05
BARD1 O 1 0.9997078776359558
. O 0 3.917442882084288e-06

Here O 0 1.1188111415094681e-07
we O 0 6.816883058036183e-09
show O 0 2.5915851686875158e-09
that O 0 7.780069644081067e-11
the O 0 2.6740702985250664e-09
steady O 0 4.1355022517564066e-08
- O 0 1.1873925176431044e-09
state O 0 1.0539938921638736e-09
levels O 0 1.967165275118532e-08
of O 0 6.272575348020837e-08
BARD1 O 0 0.0002965072635561228
, O 0 4.25261992287318e-10
unlike O 0 2.712208790889292e-10
those O 0 4.1172543152612207e-10
of O 0 2.0926030686041486e-08
BRCA1 O 0 2.8894367787302144e-08
, O 0 3.6039851658564714e-10
remain O 0 2.0033743552971828e-09
relatively O 0 2.665377918376066e-09
constant O 0 1.3100970974733173e-08
during O 0 8.590401279207072e-09
cell O 0 1.0825307299455744e-06
cycle O 0 4.2368205299680994e-07
progression O 0 1.9002776525667286e-06
. O 0 2.4452418756482075e-07

However O 0 2.104339955621981e-06
, O 0 1.026526064151767e-07
immunostaining O 0 2.880569991248194e-05
revealed O 0 1.2932943604937464e-07
that O 0 3.475578935763224e-09
BARD1 O 0 0.00518214562907815
resides O 0 6.924815920683614e-07
within O 0 2.2620607609269427e-08
BRCA1 O 0 8.828202879840319e-08
nuclear O 0 3.2276446404466697e-08
dots O 0 1.628825962995961e-08
during O 0 1.2941821836420786e-08
S O 0 4.925514218712124e-08
phase O 0 1.6632023758234027e-08
of O 0 1.0382338544445702e-08
the O 0 3.0548701346333473e-08
cell O 0 3.2900363322596604e-08
cycle O 0 5.608313369265261e-09
, O 0 8.299947534817775e-11
but O 0 1.1457019361005294e-10
not O 0 2.6460472701828053e-10
during O 0 1.650186831625433e-08
the O 0 1.7144451192052657e-07
G1 O 0 6.0314987422316335e-06
phase O 0 1.2296898148633773e-06
. O 0 1.2821317341149552e-06

Nevertheless O 0 2.2789628928876482e-05
, O 0 3.7567738786492555e-07
BARD1 O 0 0.00043557985918596387
polypeptides O 0 3.590562016597687e-07
are O 0 8.109864446659287e-10
found O 0 5.540287117966614e-10
exclusively O 0 5.001243308377923e-10
in O 0 1.0037785880268046e-10
the O 0 6.05667738184934e-10
nuclear O 0 5.095433408541794e-09
fractions O 0 7.457876982641665e-09
of O 0 1.2299315343966555e-08
both O 0 1.081562750471221e-08
G1 O 0 3.2562624596721435e-07
- O 0 3.454089636534263e-08
and O 0 2.9859716477176335e-08
S O 0 1.7907983647091896e-06
- O 0 9.761645713979306e-08
phase O 0 8.026128739402338e-08
cells O 0 1.160589206961049e-07
. O 0 1.851597630775359e-07

Therefore O 0 2.938132297458651e-07
, O 0 5.592781349150755e-09
progression O 0 4.842146239525391e-08
to O 0 2.5969735251152315e-09
S O 0 2.435490387142636e-07
phase O 0 2.090700057522099e-08
is O 0 1.5305327838444072e-10
accompanied O 0 9.286733049229667e-10
by O 0 1.4645563928272765e-10
the O 0 4.3920356240789715e-09
aggregation O 0 3.808887782952297e-08
of O 0 5.124536350820108e-09
nuclear O 0 5.701601253349509e-07
BARD1 O 0 0.00022698362590745091
polypeptides O 0 2.8878500870632706e-06
into O 0 1.0074296596940258e-06
BRCA1 O 0 3.958573415729916e-06
nuclear O 0 3.9357319110422395e-06
dots O 0 6.203103112056851e-06
. O 0 2.316131940460764e-06

This O 0 6.492074788866375e-08
cell O 0 1.0449158480696497e-06
cycle O 0 1.390944248669257e-07
- O 0 2.5412667525870347e-08
dependent O 0 2.7846120076446823e-08
colocalization O 0 3.3961705980800616e-07
of O 0 2.802141096935884e-08
BARD1 O 0 0.02239658683538437
and O 0 3.916326107855639e-08
BRCA1 O 0 1.9704590670244215e-07
indicates O 0 1.3238447671426457e-08
a O 0 5.790201096367298e-10
role O 0 3.6788827539879776e-10
for O 0 1.8051851125022722e-09
BARD1 O 0 0.03960311412811279
in O 0 1.9821841590328404e-07
BRCA1 O 0 4.196665031486191e-05
- O 0 4.2087005567736924e-05
mediated O 0 1.0332858437323011e-05
tumor B-Disease 0 4.439363692654297e-06
suppression O 0 1.579413037688937e-06
. O 0 1.4464249886714242e-07

Ethnic O 0 3.028742412425345e-07
differences O 0 7.122645939716676e-08
in O 0 3.5821323685070183e-09
the O 0 4.9169635474299866e-08
HFE O 0 0.0002749347186181694
codon O 0 2.3333113858825527e-06
282 O 0 1.8787316093948903e-06
( O 0 1.9973857945387863e-07
Cys O 0 2.98157046927372e-05
/ O 0 5.299746590026189e-06
Tyr O 0 1.9046991610593977e-06
) O 0 1.7280546993347912e-09
polymorphism O 0 4.904552852735833e-08
. O 0 3.029831532330718e-07

Recent O 0 1.0813982243007558e-07
studies O 0 9.898812436404114e-09
have O 0 3.648233104502907e-11
shown O 0 2.749733218898598e-10
that O 0 1.5751322468560147e-09
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.9999898672103882
HH B-Disease 1 1.0
) O 0 2.7984528583324675e-10
is O 0 3.381073199193452e-11
likely O 0 1.2908799029709428e-10
to O 0 4.712806533913039e-11
be O 0 2.395073028793604e-10
caused O 0 6.964976595469352e-09
by O 0 5.734160923864806e-10
homozygosity O 0 2.9378998078755103e-07
for O 0 3.68598374045348e-10
a O 0 4.0910483889433635e-09
Cys282Tyr O 0 2.785228900847869e-07
mutation O 0 5.078589104812181e-09
in O 0 6.821587739125334e-10
the O 0 7.424144143897138e-08
HFE O 0 3.451496013440192e-05
gene O 0 4.861079219153908e-07
located O 0 3.424440592425526e-06
4 O 0 2.9072430152154993e-06
. O 0 8.057124887272948e-07

5 O 0 1.2976996003999375e-05
Mb O 0 2.153043624275597e-06
telomeric O 0 6.243133611860685e-06
to O 0 1.809847560707567e-07
HLA O 0 9.362071068608202e-06
- O 0 5.0297408051847015e-06
A O 0 1.3492890502675436e-05
. O 0 1.9372809845208394e-07

Population O 0 4.1312450349551e-08
studies O 0 8.041294741190086e-09
of O 0 7.535874702035983e-10
this O 0 4.1446086146423866e-11
polymorphism O 0 4.0985753679834147e-10
are O 0 2.7107694561268048e-11
facilitated O 0 2.5685154003696198e-09
by O 0 1.5252231422291374e-10
the O 0 3.697928629975422e-09
fact O 0 1.4493233280177265e-09
that O 0 3.4974823037714486e-10
the O 0 1.399432658644173e-08
Cys282Tyr O 0 2.1704518076148815e-06
mutation O 0 1.0044886522564411e-07
creates O 0 1.366032762462055e-07
a O 0 6.642152072799945e-08
Rsal O 0 5.942726147623034e-06
restriction O 0 5.018753654439934e-06
site O 0 5.041611984779593e-06
. O 0 1.2714748436337686e-06

We O 0 3.2139698902255986e-08
have O 0 2.101365303985858e-09
studied O 0 1.3912913487956757e-08
the O 0 3.53722651169619e-09
codon O 0 1.2965273299414548e-07
282 O 0 2.443908329041733e-07
( O 0 7.77819693098536e-08
Cys O 0 1.3355729606701061e-05
/ O 0 7.52927917346824e-07
Tyr O 0 2.5579964813005063e-07
) O 0 9.369317127694288e-11
polymorphism O 0 1.1500785740414798e-10
in O 0 7.269632118500624e-11
different O 0 2.0085730301211413e-10
ethnic O 0 3.602351306142282e-09
groups O 0 1.6768250121756978e-09
. O 0 4.030990652381661e-08

In O 0 6.127163221236742e-09
agreement O 0 2.3446727226428266e-08
with O 0 4.349450521967668e-10
previous O 0 2.7644393441050852e-08
observations O 0 4.3786211989527146e-08
the O 0 7.060046769424844e-09
Tyr O 0 2.8959976816622657e-07
allele O 0 1.0008698758667833e-08
appeared O 0 8.878521029487274e-09
to O 0 1.526806597818009e-10
be O 0 2.8072844049376044e-10
rare O 0 3.0676734485979296e-09
or O 0 3.1776938858030235e-09
absent O 0 6.502732929902777e-08
in O 0 2.678940624889492e-09
Asiatic O 0 2.465002921780979e-07
( O 0 1.597999510494219e-10
Indian O 0 3.8761477361148877e-10
, O 0 1.5422044197244134e-10
Chinese O 0 1.3929235542775587e-09
) O 0 1.8873658191864706e-10
populations O 0 6.4331522331428914e-09
. O 0 6.062936108719441e-08

The O 0 5.182295836902995e-08
highest O 0 7.481317254587339e-08
allele O 0 1.0314086473783846e-08
frequency O 0 4.966274058659792e-09
( O 0 3.0679350726536825e-10
7 O 0 4.5560057948534904e-09
. O 0 3.6734906783131294e-10
5 O 0 3.877969056986785e-09
% O 0 6.48050169083092e-10
) O 0 1.4783780102889388e-11
was O 0 1.8003574187019922e-09
found O 0 1.5304803258064936e-10
in O 0 1.5629012528606268e-09
Swedes O 0 4.3405958649600507e-07
. O 0 1.2817564538636361e-06

Saamis O 0 3.9373662730213255e-05
( O 0 3.0287793606476043e-08
2 O 0 1.4043881435554795e-07
% O 0 2.9882720742335778e-09
) O 0 4.6000443038041183e-11
and O 0 4.945711618020709e-10
Mordvinians O 0 6.355926984724647e-08
( O 0 2.039775431894597e-10
1 O 0 4.9836672566527795e-09
. O 0 8.280455210396553e-10
8 O 0 8.823687558390247e-09
% O 0 8.762033321119134e-10
) O 0 1.665323608179836e-11
had O 0 1.431306739796412e-10
significantly O 0 4.995065472357396e-10
lower O 0 2.445841529308268e-09
frequencies O 0 3.965588746268622e-09
of O 0 1.8988318473134314e-08
the O 0 2.134063805669939e-07
Tyr O 0 1.117022657126654e-05
allele O 0 6.597756510018371e-07
. O 0 1.4701519148729858e-06

Comparisons O 0 1.1071652750160865e-07
with O 0 6.670864971525248e-10
allele O 0 1.0441538300653974e-08
frequencies O 0 2.3866151277474046e-09
based O 0 6.695033416548313e-10
on O 0 5.559913085484425e-10
prevalence O 0 2.0515022569611574e-08
estimates O 0 7.7295512213027e-09
of O 0 1.053638687409375e-08
HH B-Disease 1 0.9999024868011475
showed O 0 9.486733461017138e-07
some O 0 1.5793295560229126e-08
disagreements O 0 6.729862320753455e-07
with O 0 6.268443542012392e-10
the O 0 2.4010903487692303e-08
RFLP O 0 1.9465777256755246e-07
data O 0 1.763954138311874e-08
, O 0 1.0000679173671756e-09
particularly O 0 7.758679032576765e-09
in O 0 1.3494609873987429e-08
Finns O 0 1.2930689763379632e-06
. O 0 9.892302159641986e-07

The O 0 5.450011030916357e-06
newly O 0 1.0480192941031419e-05
described O 0 9.33445562623092e-07
HFE O 0 0.360889196395874
marker O 0 1.3412391126621515e-06
provides O 0 3.1764290753244495e-08
a O 0 2.0512234133462925e-09
new O 0 2.640054619362786e-09
approach O 0 1.0392476879061974e-09
to O 0 1.4980010287768408e-10
the O 0 1.4132460757210197e-09
screening O 0 1.218029455074543e-09
of O 0 2.260714992985413e-08
HH B-Disease 0 0.00017302893684245646
as O 0 1.0421125296034006e-08
well O 0 5.678046366419665e-10
as O 0 2.0824279800546464e-10
studies O 0 2.995831915875158e-10
of O 0 2.515065933295091e-10
the O 0 1.024010320982427e-09
relationship O 0 1.889109757513552e-09
between O 0 1.1192184068420374e-08
the O 0 2.6585334467199573e-07
HFE O 0 0.0001683059090282768
Tyr O 0 3.860587185045006e-06
allele O 0 4.438015821506269e-08
and O 0 2.9654128042011507e-09
different O 0 4.2203023298270637e-08
disorders O 0 0.03299516439437866
including O 0 3.5946698062616633e-07
cancer B-Disease 1 1.0

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9995205402374268
associated O 0 9.187616889505534e-09
with O 0 3.0375282150663097e-11
a O 0 5.463742791533832e-10
missense O 0 1.1450324244322019e-08
mutation O 0 6.863482004959565e-10
encoding O 0 2.7705608918182634e-09
Gly23 O 0 4.836302878175047e-07
- O 0 1.5310970979953709e-07
- O 0 2.3014163730294968e-07
> O 0 3.220118216518131e-08
Val O 0 1.5389414187438888e-08
in O 0 5.373336886549396e-09
neurophysin O 0 1.0982702178807813e-06
II O 0 6.880040018586442e-05
. O 0 1.7534432572574588e-06

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 1.493061176915944e-06
ADNDI B-Disease 1 1.0
) O 0 4.547607845850621e-10
is O 0 5.45266297391489e-11
an O 0 6.569874089201733e-10
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 1.2056916354197256e-08
by O 0 1.412150691521008e-11
progressive O 0 0.009880284778773785
degeneration O 1 1.0
of O 0 2.568770085531469e-09
the O 0 1.726064957630058e-09
magnocellular O 0 1.4625234712184465e-07
neurons O 0 1.1626338114467671e-08
of O 0 3.111480184614379e-09
the O 0 7.914542798914681e-09
hypothalamus O 0 2.04921430935201e-08
leading O 0 1.130708504604172e-08
to O 0 9.341877271751287e-10
decreased O 0 1.8703918414075815e-08
ability O 0 2.5830859673448003e-10
to O 0 6.694497178827419e-10
produce O 0 1.5264644659396254e-08
the O 0 4.710557988119035e-08
hormone O 0 2.1062503208213457e-07
arginine O 0 9.36828996600525e-07
vasopressin O 0 2.561551127655548e-06
( O 0 5.057278258391307e-07
AVP O 0 2.3294305719900876e-05
) O 0 3.536911563628564e-08
. O 0 2.5994091856773593e-07

Affected O 0 1.9250722971264622e-07
individuals O 0 1.6366105137777254e-09
are O 0 1.2146231243015393e-10
not O 0 2.2555357581666158e-10
symptomatic O 0 1.799254960133112e-06
at O 0 7.145953162535079e-09
birth O 0 1.3601954229613966e-08
, O 0 4.67123062453112e-10
but O 0 7.48054007626564e-10
usually O 0 5.202674735471646e-09
develop O 0 1.1765072116531883e-07
diabetes B-Disease 1 0.9999946355819702
insipidus I-Disease 1 0.9347485303878784
at O 0 2.7673678459905204e-07
1 O 0 7.01406520420278e-07
- O 0 3.422846361900156e-07
6 O 0 1.6808946838864358e-06
yr O 0 2.2662079572910443e-06
of O 0 1.72016072497172e-07
age O 0 1.6358784478143207e-06
. O 0 8.35209391425451e-07

The O 0 2.0518896803878306e-08
genetic O 0 1.6227951959990605e-07
locus O 0 1.1323793813744487e-07
of O 0 1.356909695715558e-08
the O 0 1.3179391800122175e-08
disease O 0 2.1437936936763435e-07
is O 0 7.653219169512226e-10
the O 0 5.3722327919558666e-08
AVP O 0 0.00010479280899744481
- O 0 5.349540515453555e-06
neurophysin O 0 0.00015511736273765564
II O 1 0.9999982118606567
( O 0 2.8271372798371885e-07
NPII O 0 0.3288181722164154
) O 0 9.75631464505966e-10
gene O 0 3.6167060457614753e-09
, O 0 3.569732509589585e-09
and O 0 1.2178389408035173e-09
mutations O 0 7.329031603831027e-09
that O 0 3.8545169833703596e-10
cause O 0 1.0338315803437581e-07
ADNDI B-Disease 0 0.0046338834799826145
have O 0 8.932905526393142e-10
been O 0 8.459312139663666e-10
found O 0 1.9486258440171156e-10
in O 0 5.087076940246682e-11
both O 0 1.4418780058811365e-10
the O 0 1.5440507761255162e-09
signal O 0 4.367441963637475e-09
peptide O 0 2.1308286246579655e-09
of O 0 1.3594199543831564e-08
the O 0 2.518847566079785e-07
prepro O 0 6.364412547554821e-05
- O 0 0.00012447994959075004
AVP O 0 0.00031565921381115913
- O 0 1.886181598820258e-05
NPII O 0 0.0005555988173000515
precursor O 0 4.844090426558978e-07
and O 0 8.6994900172499e-09
within O 0 7.639822996452494e-08
NPII O 0 0.08617161214351654
itself O 0 8.839862886134142e-08
. O 0 3.3992813541772193e-07

An O 0 1.0432302133267513e-08
affected O 0 3.70520254477924e-08
girl O 0 4.6429882161191927e-08
who O 0 1.7767645132948928e-09
presented O 0 4.47603865083579e-09
at O 0 2.6183757384501405e-09
9 O 0 2.290339917720985e-09
months O 0 5.389160784297076e-10
of O 0 1.5630502447905315e-09
age O 0 7.548901237441896e-08
and O 0 3.1302367364816064e-09
her O 0 1.6190465634835505e-09
similarly O 0 3.036001894329843e-09
affected O 0 6.976224931065644e-09
younger O 0 5.2645173553855784e-08
brother O 0 8.32116811011474e-08
and O 0 1.1963225965416768e-08
father O 0 1.2764192547365383e-07
were O 0 6.096132487698469e-09
all O 0 2.1004105399402562e-10
found O 0 1.1840900482340544e-10
to O 0 7.38633737507044e-11
have O 0 8.834321468809136e-11
a O 0 8.195482070760818e-10
novel O 0 1.3647275309836004e-08
missense O 0 1.8918372290954721e-07
mutation O 0 1.3841711776763077e-08
( O 0 3.873408260801625e-09
G1758 O 0 1.2712212082988117e-07
- O 0 2.5985459117805476e-08
- O 0 4.807892395319868e-08
> O 0 5.699196226061076e-09
T O 0 3.491472222449943e-09
) O 0 7.716252983791527e-12
encoding O 0 8.22312912207579e-11
the O 0 3.4968037354587977e-09
amino O 0 1.131730709147405e-09
acid O 0 2.8136634688813444e-10
substitution O 0 2.8653861505745226e-09
Gly23 O 0 1.2027017248783523e-07
- O 0 7.895939546642694e-08
- O 0 1.271467340302479e-07
> O 0 7.642723431899867e-08
Val O 0 4.996852709382438e-08
within O 0 1.2559472395423654e-07
NPII O 0 0.0018279952928423882
. O 0 1.4227651945475372e-06

The O 0 6.375486805154651e-07
mutation O 0 1.8881854657593067e-07
was O 0 3.935270243005107e-08
confirmed O 0 1.8392660727784005e-09
by O 0 5.907937333793356e-11
restriction O 0 2.3107448399173336e-08
endonuclease O 0 6.624287038903276e-07
analysis O 0 1.1451376025206628e-07
. O 0 3.5350640814613143e-07

A O 0 1.7109090549638495e-05
T1 O 0 2.321792271686718e-05
- O 0 9.368829267941692e-08
weighted O 0 1.511007496901584e-08
magnetic O 0 8.128060446921381e-10
resonance O 0 6.018606169000407e-10
imaging O 0 3.5373432183405384e-08
of O 0 3.0136643403011476e-08
the O 0 5.356895371733117e-07
fathers O 0 3.313434717711061e-05
pituitary O 0 0.00017907014989759773
gland O 0 9.530328497930896e-06
demonstrates O 0 4.5820914351679676e-07
an O 0 4.407343823231713e-08
attenuated O 0 0.00015166483353823423
posterior O 0 0.0038853036239743233
pituitary O 1 0.9803068041801453
bright O 1 0.9999544620513916
spot O 0 0.011226357892155647
. O 0 3.2566956633672817e-06

This O 0 1.2025721218833496e-07
mutation O 0 1.394060973325395e-07
may O 0 1.1746143613322602e-08
be O 0 8.977606436033625e-10
valuable O 0 4.617412230345508e-08
for O 0 7.353924691422264e-10
developing O 0 9.492144847911277e-09
models O 0 5.549641812763184e-08
of O 0 9.676374190803472e-08
dominantly B-Disease 0 0.00019075114687439054
inherited I-Disease 1 0.9996583461761475
neurodegeneration I-Disease 1 1.0
, O 0 9.899038921901138e-09
as O 0 5.858878937559098e-10
the O 0 2.325315079376722e-10
early O 0 2.1575834452391973e-09
age O 0 3.4055092079654514e-09
of O 0 6.368492955211025e-10
onset O 0 8.394399628741667e-07
of O 0 6.008160635673221e-09
symptoms O 0 1.7479109715168306e-07
suggests O 0 3.613141341674009e-09
that O 0 4.1072752837711946e-11
this O 0 1.4812209792047781e-10
mutation O 0 2.4480351079603224e-09
may O 0 1.0137263251053241e-09
be O 0 8.333088663547983e-10
particularly O 0 1.0832515329184389e-08
deleterious O 0 2.9268219350342406e-06
to O 0 4.2570711400458094e-08
the O 0 2.3822310595278395e-06
magnocellular O 0 0.00021542131435126066
neuron O 0 2.215474160038866e-05
. O 0 1.66647694754829e-07
. O 0 5.615486884380516e-07

Frequent O 0 1.823868558403774e-07
inactivation O 0 6.061033218429657e-06
of O 0 7.399955279652204e-07
PTEN O 1 0.9999994039535522
/ O 1 0.9998664855957031
MMAC1 O 1 1.0
in O 0 7.400216190944775e-07
primary O 1 1.0
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.748131405245658e-07

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 6.034670008148169e-08
the O 0 3.003815418622935e-09
most O 0 2.8015931241576197e-10
common O 0 4.570163691930418e-10
male B-Disease 0 3.767727241310581e-10
cancer I-Disease 0 1.8383962130386067e-09
in O 0 6.791801843153422e-11
the O 0 2.847972080388672e-09
Western O 0 3.264906212052665e-08
world O 0 6.332542268339125e-10
, O 0 4.0808814660842074e-11
yet O 0 1.0307842079892993e-10
many O 0 7.22851153933668e-11
of O 0 1.1495374652170653e-09
the O 0 1.6359019694434096e-09
major O 0 3.5504816864317945e-09
genetic O 0 3.3900720008972485e-09
events O 0 1.0917803328069908e-09
involved O 0 7.194787543518544e-10
in O 0 7.782745004014657e-10
the O 0 6.499506266521848e-09
progression O 0 3.16908881359268e-07
of O 0 6.251503759102661e-09
this O 0 3.3267475441078886e-09
often O 0 7.975312144026248e-08
fatal O 0 9.216136277245823e-06
cancer B-Disease 0 6.504019256681204e-05
remain O 0 1.0023602925457453e-07
to O 0 6.662476348395785e-09
be O 0 4.16879579745455e-08
elucidated O 0 4.184628414805047e-05
. O 0 1.1090786529166508e-06

Numerous O 0 2.106213287333958e-06
cytogenetic O 0 7.812825060682371e-05
and O 0 1.4494905542505876e-07
allelotype O 0 1.1756646927096881e-05
studies O 0 9.240339160498934e-09
have O 0 2.7613047265395707e-11
reported O 0 6.765455418111799e-10
frequent O 0 2.2387515452582107e-10
loss O 0 1.6568342253719948e-09
of O 0 1.0889982249295826e-08
heterozygosity O 0 0.0003627972037065774
on O 0 8.495570114064321e-07
chromosomal O 0 1.352875005977694e-05
arm O 0 3.1306856271839933e-06
10q O 0 2.3754748781357193e-06
in O 0 1.685027051223642e-08
sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 9.613621614334988e-07

Deletion O 0 9.103209208660701e-07
mapping O 0 2.528913398691657e-07
studies O 0 1.894013657022242e-08
have O 0 1.3031475898372946e-10
unambiguously O 0 9.99763205555837e-09
identified O 0 2.71910938209885e-09
a O 0 8.007847718261019e-10
region O 0 1.0110272619101579e-08
of O 0 1.1450541848034845e-08
chromosome O 0 1.724762732635554e-08
10q23 O 0 5.189754048728901e-08
to O 0 3.5834699096959355e-10
be O 0 2.638115281783371e-10
the O 0 9.804741463170785e-10
minimal O 0 9.039332127258604e-08
area O 0 7.278715088432364e-07
of O 0 1.1295524871002272e-07
loss O 0 2.226049446107936e-06
. O 0 2.5323647605546284e-06

A O 0 1.406079809385119e-05
new O 0 1.8859790884562244e-07
tumor B-Disease 0 2.027137497861986e-06
suppressor O 0 2.3540078473160975e-06
gene O 0 3.2674730476855984e-08
, O 0 3.774924195454332e-08
PTEN O 0 7.40293471608311e-05
/ O 0 7.594333624183491e-07
MMAC1 O 0 0.00039005279541015625
, O 0 1.1034790858843735e-09
was O 0 1.1253124654331259e-08
isolated O 0 1.332356180938632e-08
recently O 0 6.182381273589499e-10
at O 0 1.4809159454287624e-10
this O 0 5.591620916289841e-12
region O 0 2.951541233642274e-10
of O 0 1.1413077150024264e-09
chromosome O 0 1.0654610527183195e-08
10q23 O 0 1.5316943802190508e-07
and O 0 1.4420712401985725e-09
found O 0 1.0595025967674587e-09
to O 0 4.883842774638936e-10
be O 0 4.011030674266891e-10
inactivated O 0 2.09607331491668e-09
by O 0 2.6867360766735793e-11
mutation O 0 6.145093767173648e-09
in O 0 1.9919628169162706e-09
three O 0 3.7924218077023397e-07
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 3.6406800063559785e-06
lines O 0 2.2539173016866698e-07
. O 0 1.3413396970918257e-07

We O 0 1.356130496787955e-06
screened O 0 8.891249308362603e-06
80 O 0 4.7814910431043245e-06
prostate B-Disease 0 9.55963259912096e-05
tumors I-Disease 1 1.0
by O 0 2.57389043412104e-09
microsatellite O 0 6.475021763208133e-08
analysis O 0 2.249101571649703e-09
and O 0 1.9846878307472338e-10
found O 0 3.7344724534982277e-10
chromosome O 0 6.5675838101242334e-09
10q23 O 0 6.697236187847011e-08
to O 0 2.1214567880178947e-09
be O 0 4.523448726700963e-09
deleted O 0 6.168123434235895e-08
in O 0 9.08757780138103e-09
23 O 0 1.348337121953591e-07
cases O 0 3.4994609876548566e-08
. O 0 3.801133630076947e-07

We O 0 3.2794982729456024e-08
then O 0 7.49402495614504e-09
proceeded O 0 1.0745409007029139e-08
with O 0 4.779128481846584e-12
sequence O 0 6.948595865363671e-11
analysis O 0 5.111043255290326e-10
of O 0 4.925284069479119e-10
the O 0 9.248944721207408e-09
entire O 0 4.113216789392027e-07
PTEN O 0 0.00040572768193669617
/ O 0 1.4123892242423608e-06
MMAC1 O 0 7.821465260349214e-06
coding O 0 3.14739665441266e-08
region O 0 1.3633927764544751e-08
and O 0 3.049633323648493e-10
tested O 0 1.2846607111427488e-10
for O 0 9.402920109202739e-11
homozygous O 0 2.805706778019612e-09
deletion O 0 3.453738406378193e-09
with O 0 2.066561227698216e-10
new O 0 1.341300759349906e-08
intragenic O 0 1.193623688777734e-06
markers O 0 7.034994098376046e-08
in O 0 1.268082638894441e-09
these O 0 7.839583426871854e-10
23 O 0 1.1945395783641288e-08
cases O 0 2.980165281218916e-10
with O 0 1.2219031342297626e-10
10q23 O 0 6.111537800279621e-07
loss O 0 7.69403243339184e-08
of O 0 2.5597410058253445e-07
heterozygosity O 0 0.000242530251853168
. O 0 8.892445293895435e-06

The O 0 2.492369644002679e-09
identification O 0 5.491851418071292e-09
of O 0 1.1626692497657132e-08
the O 0 5.965829608101103e-09
second O 0 2.0016871715711204e-08
mutational O 0 2.3589925604028394e-06
event O 0 4.911611029001506e-08
in O 0 7.734535678594057e-09
10 O 0 4.0922834898537985e-08
( O 0 5.386738166635041e-09
43 O 0 2.0756706362590194e-06
% O 0 2.598035848677682e-07
) O 0 1.597940268993625e-08
tumors B-Disease 1 1.0
establishes O 0 1.6880369457794586e-06
PTEN O 1 0.934002161026001
/ O 0 1.2514925401774235e-05
MMAC1 O 0 0.0004662492428906262
as O 0 1.7297924204129345e-09
a O 0 5.904256528133089e-10
main O 0 4.060504377179086e-09
inactivation O 0 1.5517692020239338e-08
target O 0 2.0128003708208553e-09
of O 0 2.7592015339195086e-09
10q O 0 4.028600812944205e-07
loss O 0 8.663809580866655e-08
in O 0 4.880569903775722e-08
sporadic B-Disease 1 0.9999998807907104
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.095530859946848e-08
. O 0 3.441279616822612e-08

Risk O 0 9.754273833095795e-07
reversals O 0 1.4915128758730134e-06
in O 0 1.6469032804167227e-09
predictive O 0 3.531835091052926e-08
testing O 0 1.9921146954260394e-09
for O 0 1.0920016890736406e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 3.751439408006263e-07

The O 0 1.0384398230200986e-08
first O 0 2.915580554763153e-10
predictive O 0 2.8194344636744972e-09
testing O 0 1.8241443078270692e-10
for O 0 3.121698677333029e-09
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.0829906971210335e-09
HD B-Disease 0 4.068034087367778e-08
) O 0 1.4958246447038803e-11
was O 0 2.264216730774038e-10
based O 0 1.850264247371669e-10
on O 0 5.180748607891417e-10
analysis O 0 1.4306906770400474e-09
of O 0 3.414718952043927e-09
linked O 0 2.8202537194488286e-08
polymorphic O 0 1.1857998138964376e-08
DNA O 0 4.1947423312649335e-08
markers O 0 1.9926742922393714e-08
to O 0 3.423599737040206e-10
estimate O 0 4.373579898242497e-08
the O 0 1.2695080542357573e-09
likelihood O 0 6.739522717680302e-08
of O 0 1.9004042783876685e-08
inheriting O 0 6.755751087439421e-07
the O 0 5.622582932574005e-08
mutation O 0 2.5632262534713846e-08
for O 0 1.0773995917645607e-08
HD B-Disease 0 3.611770807765424e-05
. O 0 1.6002023812689004e-06

Limits O 0 6.374951766474624e-08
to O 0 1.9329462475070613e-09
accuracy O 0 3.676760940152235e-08
included O 0 5.852066053968485e-10
recombination O 0 7.443761718128883e-10
between O 0 3.005248050413911e-09
the O 0 2.9423528058458714e-09
DNA O 0 1.7657853845776117e-08
markers O 0 1.1054497406348673e-07
and O 0 1.5442045864233478e-08
the O 0 1.3524427799893601e-07
mutation O 0 8.303046428181915e-08
, O 0 7.347310759797665e-09
pedigree O 0 2.1835009533788252e-07
structure O 0 1.3069666238152422e-07
, O 0 5.727278207245945e-09
and O 0 1.2683052386108784e-09
whether O 0 1.7967862753209829e-09
DNA O 0 1.0298556674115389e-08
samples O 0 1.4180632224025658e-09
were O 0 5.895389176835408e-10
available O 0 2.0920074561558977e-09
from O 0 7.985264005583304e-09
family O 0 1.8817349456412558e-08
members O 0 3.114146274185714e-09
. O 0 1.7780256200694566e-07

With O 0 1.999511223260697e-09
direct O 0 1.4823360316995604e-08
tests O 0 2.0821976087770366e-10
for O 0 7.428642145868025e-10
the O 0 2.0430247715808036e-08
HD B-Disease 0 5.086910164209257e-07
mutation O 0 1.0060892563501511e-08
, O 0 4.6187467739322585e-10
we O 0 4.3056708198818683e-10
have O 0 2.2226685769677346e-10
assessed O 0 2.006978228052958e-08
the O 0 1.7809241859012559e-09
accuracy O 0 2.07523399353704e-07
of O 0 1.9284875918401667e-08
results O 0 4.962060540236735e-09
obtained O 0 5.082126275368637e-09
by O 0 5.533105640331826e-10
linkage O 0 8.573071141881883e-08
approaches O 0 2.4165183631907894e-08
when O 0 7.387171985229202e-10
requested O 0 2.0233161812655e-09
to O 0 1.419529938040398e-09
do O 0 1.4419887506278428e-09
so O 0 1.016173256651598e-09
by O 0 1.1016495493620937e-09
the O 0 6.609468083951242e-09
test O 0 1.3035336143829568e-09
individuals O 0 7.264469026324605e-09
. O 0 6.16490126503777e-07

For O 0 3.933041625714395e-08
six O 0 1.7281676534253165e-08
such O 0 2.112520020025599e-10
individuals O 0 4.760210559062727e-10
, O 0 1.6596167495830372e-10
there O 0 1.0763119562273715e-10
was O 0 2.95946156469995e-10
significant O 0 5.373375078221443e-10
disparity O 0 3.3284244693732035e-08
between O 0 2.3306188978722275e-08
the O 0 9.38942079642402e-08
tests O 0 4.940792663887805e-09
. O 0 1.879898832157778e-07

Three O 0 2.86340508637295e-07
went O 0 2.5343408083244867e-07
from O 0 2.14870454762206e-09
a O 0 3.0256774863346436e-09
decreased O 0 5.273542313943835e-08
risk O 0 5.151404858239061e-10
to O 0 1.9804601014694612e-10
an O 0 7.337867535817111e-10
increased O 0 2.369497043019919e-09
risk O 0 2.0369539388553903e-09
, O 0 8.777350374300497e-11
while O 0 2.0073780138130104e-10
in O 0 2.203820043122917e-10
another O 0 2.9011535396250565e-09
three O 0 1.3017148470240159e-09
the O 0 8.777225168898894e-09
risk O 0 7.955288339189792e-08
was O 0 1.3732324077864178e-07
decreased O 0 6.024619096933748e-07
. O 0 4.05982575557573e-07

Knowledge O 0 5.198621124691272e-07
of O 0 3.1657782528782263e-07
the O 0 2.0298962510878482e-08
potential O 0 1.6777120137589918e-08
reasons O 0 1.0617769774512453e-08
for O 0 6.684056780281722e-11
these O 0 7.195909146329171e-11
changes O 0 1.8846497973346032e-10
in O 0 2.907034613031101e-10
results O 0 2.8632005655282455e-09
and O 0 1.0384590964918061e-09
impact O 0 5.752922049850895e-08
of O 0 2.76516542996319e-09
these O 0 1.2585360531502943e-09
risk O 0 1.0222681368077247e-08
reversals O 0 1.1962227119965974e-07
on O 0 1.3889129846234027e-08
both O 0 6.454830558944025e-10
patients O 0 4.2773329322898235e-10
and O 0 1.0229912472681235e-09
the O 0 9.172173243143789e-09
counseling O 0 4.1060163602502087e-10
team O 0 2.7719548878479827e-10
can O 0 5.7424655308668804e-11
assist O 0 1.883490874377003e-08
in O 0 4.611425019618309e-09
the O 0 9.597373207270721e-08
development O 0 9.196825345725301e-08
of O 0 5.480298881366252e-09
strategies O 0 2.7823012782590695e-09
for O 0 3.6306099793215196e-10
the O 0 6.786007755721357e-09
prevention O 0 1.855450548760018e-08
and O 0 8.035924703442276e-10
, O 0 1.9610717216789197e-10
where O 0 7.217769160128285e-10
necessary O 0 4.4329206971838175e-09
, O 0 1.0378194970073196e-09
management O 0 1.1182426096212339e-09
of O 0 5.398299141035068e-09
a O 0 4.93352247943335e-09
risk O 0 2.913521157665855e-08
reversal O 0 8.039335597231911e-08
in O 0 6.526235662995816e-10
any O 0 5.2611319745210494e-09
predictive O 0 5.5047216562797985e-08
testing O 0 5.541219927351904e-09
program O 0 4.511792539574344e-08
. O 0 3.2260814464279974e-08
. O 0 3.4659561265470984e-07

A O 0 6.054823984413815e-07
novel O 0 2.98352382799294e-08
common O 0 2.7681259506806555e-09
missense O 0 2.062571127225965e-07
mutation O 0 4.844535883563594e-09
G301C O 0 3.365052236858901e-08
in O 0 1.3711871638122375e-09
the O 0 2.460920001112754e-08
N O 0 1.9968220499322342e-07
- O 0 8.097753578795164e-08
acetylgalactosamine O 0 1.5106004411791218e-06
- O 0 2.197983661744729e-07
6 O 0 4.6365809680537495e-07
- O 0 6.323593026991148e-08
sulfate O 0 3.488784372507325e-08
sulfatase O 0 1.1481930783929784e-07
gene O 0 4.575285483809921e-09
in O 0 2.1784586579087772e-08
mucopolysaccharidosis B-Disease 0 0.00016328647325281054
IVA I-Disease 1 0.9999958276748657
. O 0 1.310611787630478e-05

Mucopolysaccharidosis B-Disease 0 0.004320918116718531
IVA I-Disease 1 1.0
( O 0 0.1049836054444313
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 6.1482121616052154e-09
is O 0 1.3034831547464876e-10
an O 0 3.6367246991630964e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 8.93850447027944e-05
by O 0 5.989310436493867e-11
a O 0 4.470407599654891e-09
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 1.8486566721875874e-09
N O 0 1.9559857733497665e-08
- O 0 7.399176382705264e-09
acetylgalactosamine O 0 9.069572826092553e-08
- O 0 2.7647503841876642e-08
6 O 0 1.2142564287387358e-07
- O 0 4.3222136980602954e-08
sulfate O 0 8.408599683207285e-08
sulfatase O 0 1.6228893855441129e-06
( O 0 6.904177496380726e-08
GALNS O 0 0.00018026538600679487
) O 0 4.565576716686337e-08
. O 0 3.3775660313040134e-07

In O 0 1.8780352206704265e-07
previous O 0 1.1990705388598144e-06
studies O 0 4.8601144442272926e-08
, O 0 5.958889492951869e-10
we O 0 4.055177860173842e-10
have O 0 1.686542988599271e-10
found O 0 9.562282077268947e-10
two O 0 4.4927755959989213e-10
common O 0 5.551266668568644e-10
mutations O 0 1.63290925225823e-09
in O 0 6.043476274975035e-10
Caucasians O 0 8.230951920040752e-09
and O 0 2.147282796016725e-09
Japanese O 0 1.4244416490782896e-07
, O 0 3.659715419601639e-09
respectively O 0 8.683281293997425e-08
. O 0 5.208456741456757e-07

To O 0 1.6268730362867245e-08
characterize O 0 5.587888836089405e-07
the O 0 5.176753603564066e-08
mutational O 0 4.3016220843128394e-06
spectrum O 0 1.1911704689282487e-07
in O 0 6.251798523315699e-10
various O 0 9.245940679747378e-10
ethnic O 0 1.0384393345219678e-09
groups O 0 2.612811911273383e-10
, O 0 1.1645945319216366e-10
mutations O 0 6.890673032167172e-10
in O 0 4.331683622904592e-10
the O 0 1.8054338468687092e-08
GALNS O 0 2.6668292321119225e-06
gene O 0 9.543551504620496e-10
in O 0 1.6812381486985828e-09
Colombian O 0 2.070459458991536e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 1.9573517917592653e-08
were O 0 2.142508614966232e-09
investigated O 0 5.883844078624634e-09
, O 0 5.171665318215446e-10
and O 0 5.166203576045802e-10
genetic O 0 6.686103670716648e-09
backgrounds O 0 2.6297783506379346e-08
were O 0 3.858461106176492e-09
extensively O 0 8.61816451536157e-10
analyzed O 0 8.459924982773259e-10
to O 0 8.160786629796135e-11
identify O 0 5.281229675802024e-09
racial O 0 7.381443456466741e-09
origin O 0 4.52937953809851e-09
, O 0 1.1689697820838063e-10
based O 0 4.128318520368879e-10
on O 0 2.033673673906833e-09
mitochondrial O 0 3.6093459332420252e-09
DNA O 0 7.019700376531546e-08
( O 0 2.616469885197148e-08
mtDNA O 0 1.080523901464403e-07
) O 0 1.0664735761167776e-08
lineages O 0 2.788814583709609e-07
. O 0 4.056923330608697e-07

Three O 0 1.5132924602312414e-07
novel O 0 2.403413930096576e-07
missense O 0 2.081379534502048e-06
mutations O 0 4.29104119348267e-07
never O 0 9.770009512521938e-08
identified O 0 3.714769292173514e-08
previously O 0 3.2240989877863058e-09
in O 0 1.0756162627245658e-10
other O 0 1.6950083003841598e-10
populations O 0 7.57579499133243e-10
and O 0 1.4080042687325545e-10
found O 0 1.9941817641644377e-10
in O 0 1.1788034437465456e-10
16 O 0 2.2126958043600098e-09
out O 0 3.6758596166919233e-10
of O 0 1.1482028661191634e-09
19 O 0 1.3446512348025408e-08
Colombian O 0 1.3243519561001449e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
unrelated O 0 4.622593792191765e-07
alleles O 0 4.131148312325195e-09
account O 0 2.4402360132569356e-09
for O 0 3.0177467191805363e-09
84 O 0 9.608168056729482e-07
. O 0 3.4732951803562173e-07

2 O 0 3.8848492067700136e-07
% O 0 1.0474112244196476e-08
of O 0 3.4412253047122476e-09
the O 0 4.01659860926884e-09
alleles O 0 1.5528933694497482e-09
in O 0 7.486691266933576e-10
this O 0 5.524711799154147e-10
study O 0 3.271793280745783e-09
. O 0 3.1659652677262784e-08

The O 0 1.4929045164535637e-06
G301C O 0 5.362136107578408e-06
and O 0 1.710599661919332e-08
S162F O 0 6.163913894852158e-07
mutations O 0 1.7983401434662483e-08
account O 0 7.532630519335726e-09
for O 0 6.342094849287605e-09
68 O 0 1.5586500694553251e-06
. O 0 4.1718828924786067e-07

4 O 0 1.3586362911155447e-05
% O 0 1.8200874762897001e-07
and O 0 1.045283681833098e-08
10 O 0 9.469219719449029e-08
. O 0 3.432732000874239e-07

5 O 0 1.6589116285103955e-06
% O 0 3.3161946078053006e-08
of O 0 1.2137212124230246e-08
mutations O 0 8.643882942749315e-09
, O 0 9.430585201641861e-10
respectively O 0 1.4643503076783304e-09
, O 0 8.883321855890358e-11
whereas O 0 1.4006389381648887e-09
the O 0 6.677554154066456e-08
remaining O 0 0.06607960909605026
F69V O 1 0.9991938471794128
is O 0 2.104139640302094e-10
limited O 0 7.837919896447332e-11
to O 0 1.1538489608220459e-10
a O 0 3.105118828727882e-09
single O 0 6.5497829382366035e-09
allele O 0 2.1040177955455874e-07
. O 0 4.3043002051490475e-07

The O 0 2.3495127265960036e-07
skewed O 0 1.1123273679913837e-06
prevalence O 0 2.1629868740546954e-07
of O 0 3.800323167268971e-09
G301C O 0 8.992095246185272e-08
in O 0 2.877444393867279e-10
only O 0 4.859461166795143e-10
Colombian O 0 6.35905239576573e-09
patients O 0 3.50131368342943e-10
and O 0 7.580820693409152e-11
haplotype O 0 9.358641639423126e-10
analysis O 0 8.005079238371238e-11
by O 0 7.334404784897774e-12
restriction O 0 1.4596432951208271e-09
fragment O 0 3.42254358187688e-09
length O 0 1.0567274832951057e-09
polymorphisms O 0 3.256895553249706e-08
in O 0 1.3189250580580847e-08
the O 0 3.1522154131380375e-07
GALNS O 0 0.00021983636543154716
gene O 0 4.383885965353329e-08
suggest O 0 2.8955495778859586e-08
that O 0 6.755140335990006e-10
G301C O 0 7.734391971325749e-08
originated O 0 4.531202524304945e-09
from O 0 1.0074291401096502e-09
a O 0 9.786655930099641e-10
common O 0 1.9714914145652074e-09
ancestor O 0 3.985860530519858e-07
. O 0 3.508614554448286e-07

Investigation O 0 1.862830316667896e-07
of O 0 7.129605705813447e-08
the O 0 1.1311873215902324e-08
genetic O 0 1.2471978116934679e-08
background O 0 1.7042970368308374e-09
by O 0 6.086343928846105e-11
means O 0 2.2954831369048634e-09
of O 0 6.282618425501596e-09
mtDNA O 0 1.2422952444524071e-08
lineages O 0 1.2333354781901562e-08
indicate O 0 1.846218999901339e-08
that O 0 8.22338475092721e-10
all O 0 1.778961866705231e-09
our O 0 9.181396976032374e-09
patients O 0 4.978667478283683e-10
are O 0 2.9764826020572954e-11
probably O 0 1.8639556564892246e-09
of O 0 2.3042914243376345e-09
native O 0 3.391664549212692e-08
American O 0 1.3012322597205639e-06
descent O 0 2.5811985324253328e-05

Low O 0 2.518501673876017e-07
frequency O 0 5.641112110765789e-08
of O 0 3.735167553031715e-08
BRCA1 O 0 5.21378922258009e-07
germline O 0 3.4377870861135307e-07
mutations O 0 3.332202513917082e-09
in O 0 1.8717104255383532e-10
45 O 0 1.73524252744528e-08
German O 1 0.9998469352722168
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.2890112088825845e-08
. O 0 8.915003846254876e-09

In O 0 4.786627982866776e-08
this O 0 2.4659652098080187e-09
study O 0 4.974149425684971e-10
we O 0 6.296575760789125e-11
investigated O 0 6.841837096871473e-10
45 O 0 1.414816530598273e-08
German O 0 0.00026752310805022717
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.2246633968900937e-10
for O 0 3.7038823397228526e-11
germline O 0 2.8580840805148e-08
mutations O 0 5.555760740350024e-09
in O 0 1.1485271622646565e-09
the O 0 2.9125542866381693e-08
BRCA1 O 0 1.254417441032274e-07
gene O 0 1.88243205911931e-07
. O 0 9.729448038342525e-07

We O 0 3.695956252158794e-08
identified O 0 7.279632541212777e-08
four O 0 2.0340779727234803e-08
germline O 0 9.11441532025492e-07
mutations O 0 1.5959305699198012e-07
in O 0 1.8535086354631858e-08
three O 0 2.734995874220658e-08
breast B-Disease 0 3.0306463827400876e-07
cancer I-Disease 0 2.4628553774164175e-07
families O 0 8.426428999008806e-10
and O 0 1.6827066129376789e-10
in O 0 9.25204979296268e-09
one O 1 0.9999998807907104
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 8.414066776651907e-09
. O 0 1.2821313455368966e-11
among O 0 2.252945009370566e-12
these O 0 7.392139851625235e-12
were O 0 4.629875302586406e-11
one O 0 3.4459524123064966e-10
frameshift O 0 2.55533798565466e-08
mutation O 0 1.772053281889896e-09
, O 0 5.575928052614643e-10
one O 0 2.847418079099384e-09
nonsense O 0 1.4494877120796446e-07
mutation O 0 2.297534074102714e-08
, O 0 3.5466642955839234e-09
one O 0 4.441552903244883e-09
novel O 0 3.472400322834801e-08
splice O 0 7.942353477119468e-07
site O 0 9.67511937233212e-08
mutation O 0 7.342954244649036e-09
, O 0 1.4529214498182341e-09
and O 0 1.9679897711455396e-09
one O 0 4.797074382167921e-08
missense O 0 7.558823199360631e-06
mutation O 0 1.2088162293366622e-06
. O 0 7.229189691315696e-07

The O 0 5.379665708460379e-07
missense O 0 4.4545208766066935e-06
mutation O 0 9.849153315144576e-08
was O 0 8.554548003303353e-08
also O 0 7.079690722555654e-10
found O 0 7.487562792007907e-10
in O 0 1.549484984764149e-09
2 O 0 3.9383496641676174e-07
. O 0 4.960161277267616e-07

8 O 0 1.4069499911784078e-06
% O 0 2.5576930795523367e-08
of O 0 2.478632410429782e-08
the O 0 2.716384095435842e-08
general O 0 1.862716025868849e-08
population O 0 2.8371773819202417e-09
, O 0 1.2621917400146287e-10
suggesting O 0 1.3407093213402277e-09
that O 0 1.3694639866557168e-10
it O 0 2.472859694790941e-10
is O 0 1.9899187853056333e-10
not O 0 1.9211368051941236e-09
disease O 0 7.454539030504748e-08
associated O 0 3.473791991837061e-07
. O 0 1.2780578799720388e-06

The O 0 2.7694529336486085e-08
average O 0 6.9078787134913e-08
age O 0 2.2580476155553697e-08
of O 0 4.5508730117660434e-09
disease O 0 9.203894819620473e-07
onset O 0 4.25772128664903e-07
in O 0 8.434158926817759e-11
those O 0 2.2321512693768142e-10
families O 0 1.3151161271096612e-09
harbouring O 0 7.419176029088703e-08
causative O 0 7.473929741763641e-08
mutations O 0 2.88349077948169e-08
was O 0 2.721907677027957e-08
between O 0 1.3927701658644764e-08
32 O 0 1.5695450201747008e-06
. O 0 6.751037062713294e-07

3 O 0 1.3230921467766166e-05
and O 0 4.004931213330565e-07
37 O 0 9.001100806926843e-06
. O 0 7.764483598293737e-07

4 O 0 3.211511739209527e-06
years O 0 4.853417223671386e-08
, O 0 9.107701814947688e-10
whereas O 0 1.590383491567593e-09
the O 0 1.9287367258868926e-09
family O 0 1.8361885345541396e-09
harbouring O 0 2.7841872807243817e-08
the O 0 3.009108073825928e-09
missense O 0 3.4461272946373356e-08
mutation O 0 2.0299337766260805e-09
had O 0 3.323409880628958e-10
an O 0 4.502724235133648e-11
average O 0 8.947707019757445e-10
age O 0 2.037692237166766e-09
of O 0 1.2376006885972402e-08
onset O 0 0.22855742275714874
of O 0 1.24252244404488e-06
51 O 0 2.6068494207720505e-06
. O 0 5.89271905937494e-07

2 O 0 2.3177395632956177e-05
years O 0 1.30206774429098e-06
. O 0 1.495335482104565e-06

These O 0 4.1237502301783024e-08
findings O 0 6.989039746940762e-08
show O 0 1.2655535286398845e-08
that O 0 1.1732546045806203e-09
BRCA1 O 0 1.3929647479926643e-07
is O 0 1.394986792746522e-09
implicated O 0 2.6515656337267046e-09
in O 0 9.03869964985482e-11
a O 0 7.901864579329398e-11
small O 0 7.36031999237774e-11
fraction O 0 1.4394668568229463e-08
of O 0 8.530528816663718e-07
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.4573872370889944e-10
suggesting O 0 1.1723637338700854e-10
the O 0 1.3896423074755138e-11
involvement O 0 3.368180734319992e-11
of O 0 6.415427217243419e-11
another O 0 3.513227764262439e-10
susceptibility O 0 2.5904993705694324e-08
gene O 0 1.51251910551764e-07
( O 0 1.411305333931523e-06
s O 0 2.080515696434304e-05
) O 0 8.091730023807031e-07

Paternal O 0 0.00035244363243691623
transmission O 0 0.0009463820606470108
of O 0 5.6299618336197454e-06
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 1.4969054973335005e-05

We O 0 8.1383063843532e-08
report O 0 1.1076823014377624e-08
a O 0 2.452347769299479e-10
rare O 0 1.5442803702470087e-09
case O 0 2.905556018006905e-09
of O 0 7.257253464842961e-09
paternally O 0 0.01064831018447876
transmitted O 0 0.0005863480037078261
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 7.110059232218191e-05
DM B-Disease 1 1.0
) O 0 1.769750568314521e-08
. O 0 4.9588084749530026e-08

The O 0 8.449014785583131e-07
proband O 0 1.164053082902683e-05
is O 0 1.3225871509092713e-09
a O 0 1.811365613058058e-09
23 O 0 3.164818096479394e-08
year O 0 8.100067283578483e-09
old O 0 1.1080986041633878e-05
, O 0 6.787615802750224e-08
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 1 0.8627626299858093
who O 0 8.888453351119097e-08
suffers O 0 1.3193045560910832e-05
severe O 0 0.00012947210052516311
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 3.5156492685928242e-06

He O 0 2.2117093934070908e-08
presented O 0 1.4208145771021918e-08
with O 0 5.059250240968538e-10
respiratory O 1 0.9996065497398376
and O 0 1.6888044740426267e-08
feeding O 0 7.201066637207987e-06
difficulties O 0 2.5994935640483163e-05
at O 0 1.4839048162684776e-05
birth O 0 0.0027909213677048683
. O 0 3.3705655368976295e-06

His O 0 1.465248828935728e-06
two O 0 6.398767595783283e-07
sibs O 1 0.8611077070236206
suffer O 0 1.0001781447499525e-05
from O 0 3.746105221580365e-07
childhood O 1 0.9999550580978394
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 2.1376374661485897e-06

Their O 0 2.9447514648950346e-08
late O 0 4.096284101251513e-05
father O 0 6.045869440640672e-07
had O 0 2.409760391230975e-09
the O 0 1.563422308281659e-10
adult O 0 7.260582413071148e-11
type O 0 3.2872479738266236e-10
of O 0 6.2735416861414706e-09
DM B-Disease 1 1.0
, O 0 5.883608711343413e-09
with O 0 9.127230637950845e-10
onset O 1 0.9893711805343628
around O 0 4.856322455282225e-09
30 O 0 7.28791249571259e-08
years O 0 1.2158714035592766e-08
. O 0 1.2172641561392084e-07

Only O 0 1.4641919676705584e-08
six O 0 1.1578751291096978e-09
other O 0 1.95840930278246e-11
cases O 0 8.393605255285763e-11
of O 0 1.8164783566199105e-10
paternal O 0 1.4106210073805414e-05
transmission O 0 0.021327508613467216
of O 0 3.5197666875319555e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 2.024724381044507e-06
been O 0 9.940134049202243e-09
reported O 0 2.1371915792656182e-08
recently O 0 8.638707527097722e-09
. O 0 3.4336345322572015e-08

We O 0 1.725157439125269e-08
review O 0 4.285387156244269e-09
the O 0 4.095558892025508e-10
sex O 0 5.37240911480108e-11
related O 0 2.5397040026575723e-10
effects O 0 9.457424843262174e-10
on O 0 3.9863501388737177e-10
transmission O 0 2.422508771360299e-07
of O 0 6.998777735134354e-08
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 6.746100552845746e-05

Decreased O 0 1.7176490700876457e-06
fertility O 0 4.435561606896954e-08
of O 0 7.23085979981164e-10
males O 0 4.1948878398700984e-11
with O 0 1.1197520775191316e-12
adult O 0 2.571234614112683e-10
onset O 0 9.363149189312026e-08
DM B-Disease 1 1.0
and O 0 8.674958668075661e-11
contraction O 0 4.090548788582282e-09
of O 0 1.023549467404905e-09
the O 0 7.309455263282416e-10
repeat O 0 5.205719744161286e-10
upon O 0 2.8271458507589386e-09
male O 0 9.617816543183721e-10
transmission O 0 5.968330274441769e-10
contribute O 0 4.752261084650655e-11
to O 0 1.0457294058463518e-10
the O 0 1.93210580867742e-09
almost O 0 3.1236284669944325e-09
absent O 0 1.5246079954067682e-08
occurrence O 0 4.968614408795702e-09
of O 0 4.599687020157006e-10
paternal O 0 3.7196234643488424e-06
transmission O 0 7.80964364821557e-06
of O 0 2.148137582480558e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 4.515349064604379e-05

Also O 0 4.077137560898336e-08
the O 0 1.5277169751470865e-08
fathers O 0 1.0450906984260655e-07
of O 0 2.31727703692286e-08
the O 0 1.231668722567747e-08
reported O 0 1.696993123800894e-08
congenitally O 0 1.3349630307857296e-06
affected O 0 8.876319235184837e-09
children O 0 4.125761954298923e-09
showed O 0 1.0200010613914401e-08
, O 0 1.4175215168332755e-10
on O 0 5.53927526070197e-09
average O 0 1.5913704132231032e-08
, O 0 4.93235341458842e-10
shorter O 0 1.615816529465519e-07
CTG O 0 2.6277737106283894e-06
repeat O 0 3.489010680368665e-08
lengths O 0 6.737395210620889e-07
and O 0 2.8556090825304636e-09
hence O 0 7.88732634759981e-09
less O 0 5.873046493576339e-09
severe O 0 1.9314478549858904e-07
clinical O 0 1.942282601419265e-08
symptoms O 0 5.987649043248666e-09
than O 0 1.5498973632288582e-11
the O 0 4.235523320961221e-10
mothers O 0 5.474654063419848e-10
of O 0 5.381560197470492e-10
children O 0 9.653548183052862e-09
with O 0 4.665002251158512e-08
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 2.1640775230480358e-05

We O 0 6.851216483028111e-09
conclude O 0 1.7634967264257284e-08
that O 0 7.47888070917746e-11
paternal O 0 5.213047984398145e-07
transmission O 0 5.254626671558071e-07
of O 0 1.286513793274935e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 4.489830729426103e-09
rare O 0 2.858561165552942e-10
and O 0 1.2586139595816004e-11
preferentially O 0 2.1972682007209698e-10
occurs O 0 6.637723010127772e-11
with O 0 2.889937854994029e-12
onset O 0 6.196152639859065e-07
of O 0 7.70955921325367e-08
DM B-Disease 1 1.0
past O 0 2.0766198360888666e-07
30 O 0 1.6077967401884052e-08
years O 0 1.4850634055818546e-09
in O 0 4.311053181105251e-10
the O 0 1.2966356877086582e-08
father O 0 3.363075862239384e-08
. O 0 1.6665969937434966e-08
. O 0 1.8885872066221054e-07

The O 0 2.4951878003776073e-06
RB1 O 0 0.00023063247499521822
gene O 0 3.8792212109228785e-08
mutation O 0 2.5475076270708996e-08
in O 0 5.713189921152662e-10
a O 0 2.154400435827597e-09
child O 0 7.181659356092496e-08
with O 0 1.7304937216522376e-07
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.00012280790542718023

The O 0 1.8746080741038895e-06
RB1 O 0 8.630173397250473e-05
gene O 0 3.7525410334637854e-08
mutation O 0 3.7424410237463235e-08
was O 0 6.389593742994748e-09
investigated O 0 8.439907661639268e-10
in O 0 4.064258304903312e-11
a O 0 1.1949217171292048e-09
child O 0 6.502348526282731e-08
with O 0 7.932379020303415e-08
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 0 5.861551471753046e-05
using O 0 4.898219052584807e-10
DNA O 0 2.3796786763341515e-09
obtained O 0 3.5992127056516665e-09
from O 0 1.974238328372735e-09
both O 0 6.862931889450863e-10
the O 0 6.174631028699196e-09
pineal B-Disease 0 9.3071284936741e-06
and I-Disease 0 1.1913222408566071e-08
retinal I-Disease 1 0.9998993873596191
tumours I-Disease 1 1.0
of O 0 1.1690461178659461e-05
the O 0 5.447774924505211e-07
patient O 0 3.4776505231093324e-07
. O 0 2.766940383480687e-07

A O 0 2.295128751939046e-06
nonsense O 0 4.2799328525688907e-07
mutation O 0 2.5259479841110988e-08
in O 0 1.8135539736618966e-09
exon O 0 3.2031621799433196e-08
17 O 0 4.718133368442068e-07
( O 0 5.616170195565928e-09
codon O 0 7.070858032420801e-08
556 O 0 3.320333874512471e-08
) O 0 1.170888802581871e-10
of O 0 7.206493179978679e-09
the O 0 2.3255309145042702e-07
RB1 O 0 1.5272707969415933e-05
gene O 0 1.1034711810964382e-08
was O 0 1.0315901022295293e-07
found O 0 1.43510370254063e-10
to O 0 2.992569733684114e-11
be O 0 1.2216513911589288e-10
present O 0 8.603612822177809e-10
homozygously O 0 1.6564155203013797e-07
in O 0 8.02419242162955e-10
both O 0 2.2784840680856178e-09
the O 0 3.2316734177584294e-08
retinal B-Disease 0 8.86059115146054e-06
and I-Disease 0 9.266181422162845e-08
the I-Disease 0 4.619377705239458e-06
pineal I-Disease 1 0.9999827146530151
tumours I-Disease 1 1.0
. O 0 5.764669367636088e-06

The O 0 3.8936686763690886e-08
same O 0 1.4322305563752025e-09
mutation O 0 2.884589456186859e-09
was O 0 1.1974155000871178e-09
present O 0 1.645345110157237e-10
heterozygously O 0 2.980463520430021e-08
in O 0 2.246750840928513e-10
the O 0 7.778352406617728e-10
DNA O 0 1.8590345929325736e-09
from O 0 2.824461775574605e-09
the O 0 6.0932729972762445e-09
constitutional O 0 2.3101851098772386e-08
cells O 0 6.796085472160485e-09
of O 0 7.312052741070829e-09
the O 0 7.544190161468123e-09
patient O 0 7.854824346509304e-09
, O 0 5.04816577429068e-10
proving O 0 1.4845600304624895e-08
it O 0 9.847393039885688e-11
to O 0 2.900266693472986e-10
be O 0 2.6428055299732023e-09
of O 0 6.235251248654095e-08
germline O 0 9.667418453318533e-06
origin O 0 1.6612325453024823e-06
. O 0 1.1984783441221225e-06

The O 0 1.5380179263502214e-07
initial O 0 6.06107448675175e-08
mutation O 0 3.667303793974952e-09
was O 0 1.3495451423040095e-09
shown O 0 3.613613228092838e-11
to O 0 8.732963657775983e-11
have O 0 1.9672607987075708e-10
occurred O 0 4.696365252243595e-08
in O 0 5.699736793651766e-10
the O 0 2.1569753982930706e-08
paternally O 0 3.7392060221463908e-06
derived O 0 1.7098124089898192e-06
RB1 O 0 0.0006811749190092087
allele O 0 2.3564066395920236e-06
. O 0 1.237895503436448e-06

The O 0 3.1303702030527347e-07
mutation O 0 4.207763737440473e-08
is O 0 2.9322499983663874e-10
in O 0 5.6882436261229685e-11
an O 0 1.0915923720489218e-10
area O 0 9.53893408706108e-09
of O 0 1.2402844307146665e-09
the O 0 5.336547204137787e-09
gene O 0 1.4667571601734153e-09
that O 0 2.414416222507043e-09
encodes O 0 5.8052882501158365e-09
the O 0 9.278416257529898e-09
protein O 0 1.3861976455586955e-08
- O 0 3.3919087538691883e-09
binding O 0 1.7457526979569593e-08
region O 0 1.0522192894768523e-07
known O 0 2.852625691218691e-09
as O 0 1.8129763246221842e-09
the O 0 4.1888479351825936e-09
pocket O 0 7.683427725169167e-07
region O 0 1.6514218259544577e-07
and O 0 2.491501049917133e-08
has O 0 3.787789193410163e-09
been O 0 8.98738916621511e-10
detected O 0 2.449155989125984e-09
in O 0 6.58176013690337e-11
other O 0 1.4383949586971312e-10
cases O 0 9.159197289498877e-10
of O 0 1.9622561353571655e-08
retinoblastoma B-Disease 0 1.3275867786433082e-05
. O 0 1.0256492544158391e-07
. O 0 4.643519559976994e-07

Low O 0 2.0225243133609183e-06
levels O 0 3.221912336925925e-08
of O 0 5.2596269561888676e-09
beta O 0 1.107849278980666e-08
hexosaminidase O 0 6.831072596469312e-08
A O 0 1.1092447849136988e-08
in O 0 1.5027973310210996e-10
healthy O 0 4.1863851274470676e-10
individuals O 0 1.516982893468022e-11
with O 0 5.540685618643515e-11
apparent O 0 5.887332463316852e-06
deficiency O 0 0.0007191522163338959
of O 0 1.0080178753923974e-06
this O 0 1.3930518072413633e-08
enzyme O 0 4.396028543851571e-06
. O 0 3.534477741595765e-07

Appreciable O 0 1.0679191291274037e-05
beta O 0 4.992023150407476e-07
hexosaminidase O 0 1.1418345820857212e-05
A O 0 2.9434092994051753e-06
( O 0 1.09886313381935e-08
hex O 0 5.201943622523686e-07
A O 0 2.091446305030331e-07
) O 0 2.3544038940670475e-10
activity O 0 2.9632192255490963e-09
has O 0 6.314761213932485e-11
been O 0 7.694916231981708e-11
detected O 0 1.1144227762827086e-09
in O 0 3.5173244872233056e-10
cultured O 0 3.7365430216595996e-07
skin O 0 1.2566342775244266e-06
fibroblasts O 0 5.020775120101462e-07
and O 0 3.3915998898237376e-08
melanoma B-Disease 0 1.1739668934751535e-06
tissue O 0 7.069992147279436e-09
from O 0 5.5518620811767505e-09
healthy O 0 1.0046007359321152e-09
individuals O 0 2.1172789216317156e-11
previously O 0 4.638593120720458e-10
reported O 0 5.114709766829151e-10
as O 0 1.7694180842742213e-10
having O 0 1.1682304013049816e-09
deficiency B-Disease 0 8.060352456595865e-07
of I-Disease 0 2.8415217457222752e-05
hex I-Disease 0 2.322589534742292e-05
A I-Disease 0 9.586576652509393e-07
activity O 0 4.1483950496967736e-08
indistinguishable O 0 4.883959547896666e-08
from O 0 2.1703110142379245e-10
that O 0 7.176086981586227e-12
of O 0 1.6996532653523744e-11
patients O 0 6.449867723246072e-11
with O 0 1.2047537190085222e-08
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 6.7888204284827225e-06
TSD B-Disease 1 0.9996408224105835
) O 0 2.855844627447368e-08
. O 0 2.863082784188009e-07

Identification O 0 4.734779324166993e-08
and O 0 9.287516533618145e-09
quantitation O 0 0.00015282384993042797
of O 0 0.0003465129993855953
hex O 0 7.326259947149083e-05
A O 0 1.129899737861706e-05
, O 0 2.9211539853690738e-09
amounting O 0 1.013123718252018e-08
to O 0 2.737854831735831e-09
3 O 0 5.1015331337112e-07
. O 0 6.006387138768332e-07

5 O 0 1.9364404579391703e-05
% O 0 8.417454750997422e-07
- O 0 1.905260944567999e-07
6 O 0 8.062597203206678e-07
. O 0 2.3228886902870727e-07

9 O 0 1.429916096640227e-06
% O 0 3.219491873096558e-08
of O 0 1.8384954003636267e-08
total O 0 7.567941828767744e-09
beta O 0 5.617640752575426e-08
hexosaminidase O 0 3.1590047910867725e-07
activity O 0 6.02085066248037e-08
, O 0 9.783109877758989e-10
has O 0 3.893887712269617e-10
been O 0 2.87418616684576e-10
obtained O 0 6.983680300720607e-09
by O 0 5.9269158469987815e-09
cellulose O 0 1.1200147582712816e-06
acetate O 0 5.049817559665826e-07
gel O 0 2.7252121981291566e-07
electrophoresis O 0 7.294365644838763e-08
, O 0 3.914249901981748e-08
DEAE O 0 7.0068176682980265e-06
- O 0 9.16728026822966e-08
cellulose O 0 3.407480164696608e-07
ion O 0 3.851409076105483e-07
- O 0 2.461099199990713e-07
exchange O 0 1.5496785010782332e-07
chromatography O 0 1.3927011544012657e-08
, O 0 2.9409332746865857e-09
radial O 0 2.83876545381645e-07
immunodiffusion O 0 1.2602982906173565e-06
, O 0 2.2930684906441456e-08
and O 0 1.0745473844053777e-07
radioimmunoassay O 0 0.012394187040627003
. O 0 1.2049111319356598e-05

Previous O 0 5.4164738685358316e-05
family O 0 6.592586601072981e-07
studies O 0 4.7437467287636537e-08
suggested O 0 1.2221577083693091e-09
that O 0 1.1305385447246685e-11
these O 0 3.404297677089829e-11
individuals O 0 4.146569546059631e-11
may O 0 4.4054065950760446e-10
be O 0 1.229662899282502e-10
compound O 0 3.7193617075104157e-09
heterozygotes O 0 2.522452469122527e-08
for O 0 1.619342160363857e-10
the O 0 1.7076550173911187e-09
common O 0 8.129207862417331e-10
mutant O 0 3.486688981979569e-08
TSD B-Disease 0 8.280319434561534e-07
gene O 0 1.7972043853120567e-09
and O 0 1.5739578529405662e-09
a O 0 4.1936760730720835e-09
rare O 0 2.9837114112751806e-08
( O 0 6.040829170217421e-09
allelic O 0 1.421848025984218e-07
) O 0 8.307665111395579e-10
mutant O 0 1.9894425662414505e-08
gene O 0 4.1496452496403435e-08
. O 0 5.770350526290713e-07

Thus O 0 7.908751342711184e-08
, O 0 2.287484646146254e-09
the O 0 2.866818116231684e-09
postulated O 0 4.876355319538561e-07
rate O 0 1.0039289399799145e-08
mutant O 0 1.6156039839287928e-09
gene O 0 6.359656135046521e-10
appears O 0 1.2804585169945426e-09
to O 0 1.1177084431601703e-11
code O 0 8.875121124130025e-12
for O 0 1.0396040972526777e-10
the O 0 2.374387575443393e-09
expression O 0 7.118867717537114e-09
of O 0 1.3263520060036171e-08
low O 0 3.1458721849730864e-08
amounts O 0 6.8591137214468745e-09
of O 0 1.0890359902759883e-07
hex O 0 1.0888053111557383e-05
A O 0 8.883875125320628e-06
. O 0 1.9825840809062356e-06

Heterozygotes O 0 1.2245008065292495e-06
for O 0 8.377906368650656e-09
the O 0 2.877732896422458e-08
rare O 0 4.481676807444046e-09
mutant O 0 1.9254041916383358e-08
may O 0 9.872561657076062e-10
be O 0 1.1134958927128125e-10
indistinguishable O 0 2.5446086127089984e-08
from O 0 5.593013274740599e-10
heterozygotes O 0 2.6108816442160787e-08
for O 0 2.7631819055073947e-10
the O 0 7.071987884188502e-09
common O 0 5.7997350921823454e-08
TSD B-Disease 0 2.3985783627722412e-05
mutant O 0 2.1781943360110745e-06
. O 0 1.0040707820735406e-06

However O 0 3.691405368044798e-07
, O 0 3.178427299133091e-09
direct O 0 1.4206357867863062e-08
visualization O 0 8.287398856055006e-08
and O 0 1.6813438419305271e-09
quantitation O 0 5.14585008204449e-05
of O 0 9.570550901116803e-05
hex O 0 5.928234713792335e-06
A O 0 2.0535738087801292e-07
by O 0 8.921736127653901e-10
the O 0 2.706933344143181e-09
methods O 0 3.630722611447368e-09
described O 0 1.2384524517017326e-09
may O 0 3.4912572832723754e-10
prevent O 0 2.9788935762553592e-09
false O 0 7.359150799857161e-08
- O 0 2.389244357914322e-08
positive O 0 3.007381010888821e-09
prenatal O 0 1.274375360793556e-08
diagnosis O 0 2.71374833715754e-08
of O 0 1.1121492171639602e-08
TSD B-Disease 0 2.695320472412277e-05
in O 0 2.3175951824327967e-08
fetuses O 0 2.606742270927498e-07
having O 0 2.5607376219483058e-09
the O 0 2.7531770196986827e-09
incomplete O 0 2.083749848225125e-07
hex B-Disease 0 6.597492756554857e-07
A I-Disease 0 2.5567572947693407e-07
deficiency I-Disease 0 3.336879501603107e-07
of O 0 8.275061418316909e-07
the O 0 4.9925468204037315e-08
type O 0 1.5416855347893943e-08
described O 0 1.59407942401657e-09
in O 0 8.953922048249296e-10
the O 0 1.291923581447918e-07
four O 0 5.139476400017884e-08
healthy O 0 4.251878067407233e-07
individuals O 0 1.6972754224298114e-07

The O 0 1.1074224630647223e-06
tumor B-Disease 0 8.813362910586875e-06
suppressor O 0 1.5471163351321593e-05
gene O 0 5.321983849171374e-07
Smad4 O 0 2.6649388018995523e-05
/ O 0 4.5689657213188184e-07
Dpc4 O 0 1.6403997449288e-07
is O 0 4.0298240439051725e-11
required O 0 3.525503153301024e-11
for O 0 1.0132811950613885e-10
gastrulation O 0 6.667423946282725e-08
and O 0 1.9167693821042775e-10
later O 0 3.1639715292186565e-09
for O 0 1.1058537419117442e-09
anterior O 0 1.4294661241365247e-06
development O 0 7.6030303830521e-08
of O 0 2.6320366330878642e-08
the O 0 4.90447789047721e-08
mouse O 0 1.0246872506058935e-07
embryo O 0 1.4199009683579789e-06
. O 0 9.742225302034058e-07

Mutations O 0 1.4062551372262533e-06
in O 0 4.5653855806904176e-08
the O 0 5.967926313132921e-07
SMAD4 O 1 1.0
/ O 0 0.00013270897034090012
DPC4 O 0 0.0003180389176122844
tumor B-Disease 0 6.342817187032779e-07
suppressor O 0 1.6746595576933032e-07
gene O 0 1.8263526246897754e-09
, O 0 2.2983207004223516e-10
a O 0 2.916086538906626e-10
key O 0 8.620207658793788e-09
signal O 0 5.5662006559487054e-08
transducer O 0 6.643875138934163e-08
in O 0 1.7710068078713448e-08
most O 0 1.1210412509399248e-07
TGFbeta O 0 5.382219569582958e-06
- O 0 1.6075061637366161e-07
related O 0 2.0289716928800772e-07
pathways O 0 7.919423694602301e-08
, O 0 2.8760835379948446e-10
are O 0 7.017290828276179e-12
involved O 0 2.65739045351987e-11
in O 0 1.0339681888460461e-10
50 O 0 2.1414964024302208e-08
% O 0 1.4901493727847992e-07
of O 0 4.873314765063697e-07
pancreatic B-Disease 1 0.9983083009719849
cancers I-Disease 1 0.9986245632171631
. O 0 3.298756837466499e-06

Homozygous O 0 4.892518063570606e-06
Smad4 O 0 5.637188587570563e-05
mutant O 0 8.62724903072376e-07
mice O 0 6.091555349030386e-08
die O 0 7.44019175158428e-08
before O 0 2.248815178518271e-08
day O 0 1.845247510345871e-08
7 O 0 1.2911746694044268e-07
. O 0 1.1280873479790898e-07

5 O 0 1.6326461263815872e-05
of O 0 1.6356178775822627e-06
embryogenesis O 0 1.5542178516625427e-05
. O 0 1.55149893998896e-06

Mutant O 0 3.582746046504326e-07
embryos O 0 5.898914992030768e-07
have O 0 6.443074518358571e-09
reduced O 0 1.2675223537428337e-08
size O 0 5.060594610029057e-09
, O 0 8.175466414961363e-10
fail O 0 4.956526744592793e-09
to O 0 7.178931671347755e-09
gastrulate O 0 5.103609055367997e-06
or O 0 8.503901582912476e-09
express O 0 2.582604352596718e-09
a O 0 1.287457696008687e-09
mesodermal O 0 2.8469642643358384e-07
marker O 0 3.684244802570902e-07
, O 0 5.492311938581906e-09
and O 0 8.211634039412274e-09
show O 0 2.0753211060764443e-07
abnormal O 0 3.513554702294641e-06
visceral O 0 6.973358540562913e-05
endoderm O 0 0.0005084755248390138
development O 0 3.569357659216621e-06
. O 0 6.473021585406968e-07

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 1.2367753697617445e-05
the O 0 4.91710409278312e-07
Smad4 O 0 1.0405819011793938e-05
- O 0 5.312496114129317e-07
deficient O 0 1.063058050476684e-07
embryos O 0 3.4356133937762934e-08
results O 0 1.967052654094914e-08
from O 0 1.3218515171331546e-08
reduced O 0 3.846794527362363e-08
cell O 0 9.452689653244306e-08
proliferation O 0 1.0909882064424892e-07
rather O 0 1.279457650937843e-09
than O 0 6.898365767504799e-10
increased O 0 1.639107338746726e-08
apoptosis O 0 4.9867128382175e-07
. O 0 3.049229633234063e-07

Aggregation O 0 6.36745426163543e-07
of O 0 1.3880396920740168e-07
mutant O 0 1.0588444183667889e-06
Smad4 O 0 3.692728205351159e-05
ES O 0 4.8570473154541105e-06
cells O 0 2.5647899359881876e-09
with O 0 2.3397830895000027e-10
wild O 0 7.245690714086095e-09
- O 0 3.6366831768219754e-09
type O 0 4.0465648609711025e-09
tetraploid O 0 5.81791596232506e-07
morulae O 0 1.0287424174748594e-06
rescues O 0 3.828371575309575e-07
the O 0 7.651591715784889e-08
gastrulation B-Disease 0 1.2704125765594654e-05
defect I-Disease 0 8.609547876403667e-06
. O 0 2.0929558104398893e-06

These O 0 3.9995601497366806e-08
results O 0 7.297899884406434e-08
indicate O 0 5.115203194350215e-08
that O 0 1.131635674056497e-09
Smad4 O 0 3.565519648418558e-07
is O 0 9.892876101647019e-11
initially O 0 7.897163478709501e-11
required O 0 1.0405398764845586e-11
for O 0 8.235748888418826e-11
the O 0 2.904702922634783e-09
differentiation O 0 1.739669919231801e-08
of O 0 1.9960484820558122e-08
the O 0 2.2430878487966766e-08
visceral O 0 1.2460824336812948e-06
endoderm O 0 5.947608201495314e-07
and O 0 5.332047581241284e-10
that O 0 1.9774029635932777e-10
the O 0 2.507006824359337e-09
gastrulation B-Disease 0 1.6009198589017615e-07
defect I-Disease 0 1.799321580620017e-08
in O 0 2.060815518234449e-09
the O 0 4.47575914108711e-08
epiblast O 0 4.831614660361083e-06
is O 0 6.376724925871713e-09
secondary O 0 9.794488420311609e-08
and O 0 5.79538639300381e-09
non O 0 2.7743094506149646e-06
- O 0 1.3511501038010465e-06
cell O 0 0.00012382456043269485
autonomous O 0 6.571050471393391e-05
. O 0 1.3336942856767564e-06

Rescued O 0 1.306877265960793e-06
embryos O 0 5.855544600308349e-07
show O 0 2.7720935236175137e-07
severe O 0 8.224376870202832e-06
anterior O 0 0.0001902164367493242
truncations O 0 3.298641968285665e-05
, O 0 5.50672440979838e-09
indicating O 0 5.720992390934043e-08
a O 0 2.2162689461424634e-09
second O 0 1.0708723685581845e-08
important O 0 5.901703570287964e-09
role O 0 1.3541219257007242e-09
for O 0 2.4843203050295415e-09
Smad4 O 0 1.0762046258605551e-05
in O 0 1.202700588009975e-07
anterior O 0 7.144625851651654e-05
patterning O 0 1.0085677786264569e-05
during O 0 6.216654924173781e-07
embryogenesis O 0 3.6903388718201313e-06
. O 0 3.620366157974786e-07

Prevalence O 0 2.561619339758181e-06
of O 0 8.179763000271123e-08
p16 O 0 7.948461302476062e-07
and O 0 5.465238928081817e-08
CDK4 O 1 0.5559016466140747
germline O 0 1.1098743925685994e-05
mutations O 0 2.1479601741702936e-07
in O 0 1.4151106952908776e-08
48 O 0 3.775083143864322e-07
melanoma B-Disease 0 4.3194136196689215e-06
- O 0 7.523229328398884e-08
prone O 0 7.929837408937601e-08
families O 0 3.4303733187357466e-09
in O 0 4.881628878905531e-09
France O 0 3.702567994423589e-07
. O 0 4.7681851356173865e-07

The O 0 2.3049490209814394e-06
French O 0 0.00030092921224422753
Familial B-Disease 0 0.0003218959318473935
Melanoma I-Disease 0 0.00449723144993186
Study O 0 1.3871128246023545e-08
Group O 0 1.7553613007592617e-09
. O 0 1.5033435829536757e-08

Germline O 0 7.979253132361919e-05
mutations O 0 1.5897403500275686e-06
in O 0 2.1785002246588192e-08
the O 0 2.6679327191914126e-08
p16 O 0 8.539419837916284e-08
and O 0 6.491131632202496e-09
CDK4 O 0 1.023444565362297e-05
genes O 0 4.645492435173537e-09
have O 0 3.4186406483449616e-10
been O 0 2.7059046669997144e-10
reported O 0 4.5910622525902056e-10
in O 0 2.859104966668191e-11
a O 0 3.3864769322100585e-10
subset O 0 2.1558978602342904e-08
of O 0 1.0171805087111352e-07
melanoma B-Disease 0 5.110905931360321e-06
pedigrees O 0 4.1407361095480155e-07
, O 0 4.388451380066272e-09
but O 0 4.607978443260663e-09
their O 0 1.0389786808673307e-08
prevalence O 0 7.621817417202692e-07
is O 0 2.399092036142747e-10
not O 0 4.1260983518753847e-10
well O 0 9.433594350127805e-09
known O 0 8.998426181960895e-08
. O 0 9.581859785612323e-07

We O 0 5.118160117945081e-08
searched O 0 4.3330267374130926e-08
for O 0 4.440890155610333e-10
such O 0 3.790701530448359e-09
germline O 0 3.886170816258527e-06
mutations O 0 1.3952568167496793e-07
in O 0 9.835877001762583e-09
48 O 0 7.559403911727713e-07
French O 0 7.94645347923506e-06
melanoma B-Disease 0 3.7664594856323674e-05
- O 0 2.1382521708801505e-07
prone O 0 1.3442991075862665e-07
families O 0 4.436583544986661e-09
selected O 0 1.325627940751417e-09
according O 0 3.908650625383814e-10
to O 0 9.135533995952017e-11
two O 0 2.1128827853988952e-10
major O 0 2.134180165924704e-09
criteria O 0 1.8265058354671737e-09
families O 0 6.074378222642451e-10
with O 0 3.0445639065401764e-11
at O 0 1.1984231385042676e-09
least O 0 1.5479305337517957e-10
three O 0 1.6913880018787353e-10
affected O 0 1.5024829158605257e-09
members O 0 2.1069267164275374e-10
( O 0 2.507321017475306e-10
n O 0 1.6360143240135017e-09
= O 0 3.4096556689178215e-09
20 O 0 2.2036992231022623e-09
) O 0 4.4894131814854354e-12
or O 0 2.1652905163316305e-11
families O 0 6.86468243360494e-11
with O 0 3.374570805084187e-12
two O 0 6.069951485887515e-11
affected O 0 5.849488671216818e-10
members O 0 2.4305623486098327e-11
, O 0 2.4779289731213794e-11
one O 0 1.5512230389091997e-10
of O 0 6.04158612027561e-10
them O 0 2.8885632774589e-10
affected O 0 3.1868165883963684e-09
before O 0 8.08092814885697e-10
the O 0 1.5879251247241655e-09
age O 0 1.0230464475569079e-08
of O 0 1.1023646884211757e-08
50 O 0 2.0912224840685667e-08
( O 0 1.3577841073697527e-09
n O 0 5.419489745861483e-09
= O 0 2.6329804114766375e-08
28 O 0 1.1781645525843487e-07
) O 0 2.33941283012129e-10
, O 0 1.6727609575273306e-10
and O 0 1.393986037712125e-10
one O 0 1.995121567954783e-10
additional O 0 1.1145758760378044e-09
minor O 0 5.9392196050112034e-08
criterion O 0 1.0251001185679343e-05
. O 0 1.1116698033220018e-06

Sixteen O 0 2.799689355015289e-06
different O 0 1.7830399201557157e-07
p16 O 0 4.644929049391067e-06
germline O 0 3.678841494547669e-06
mutations O 0 8.811027640831526e-08
were O 0 5.216128862173264e-09
found O 0 2.3109453239911204e-10
in O 0 8.711104060310504e-11
21 O 0 3.833549477860743e-09
families O 0 6.45643039032251e-10
, O 0 3.388873903720224e-10
while O 0 1.0174415754349297e-09
one O 0 1.2274871785677988e-08
germline O 0 1.2493618442022125e-06
mutation O 0 1.1825478196669792e-07
, O 0 3.719929253520604e-09
Arg24His O 0 3.1039309078551014e-07
, O 0 2.696462386708731e-09
was O 0 1.4174093898589035e-08
detected O 0 1.440590224888183e-08
in O 0 1.996070420062779e-09
the O 0 2.0870271555395448e-07
CDK4 O 0 0.0001745265326462686
gene O 0 7.400604431495594e-07
. O 0 2.2431363504438195e-06

The O 0 1.2000591631533553e-08
frequency O 0 1.1476430472612265e-08
of O 0 3.4674743076834602e-09
p16 O 0 8.919154304010135e-09
gene O 0 1.2895221557229775e-09
mutation O 0 1.9904282666516337e-09
in O 0 5.792045731922713e-10
our O 0 1.4157442995710312e-09
sample O 0 3.765643907804872e-10
( O 0 4.793785923773441e-10
44 O 0 4.8288466558688015e-08
% O 0 1.6705107297454447e-09
) O 0 1.2893584637463373e-11
is O 0 1.0547731958687745e-11
among O 0 7.976913574125888e-11
the O 0 5.023940152781847e-10
highest O 0 6.871317737022764e-09
rates O 0 1.3075676097429323e-09
yet O 0 6.682683850733895e-10
reported O 0 6.199861513067617e-09
and O 0 2.6408339404149217e-10
the O 0 7.07451031090045e-09
CDK4 O 0 1.9078926925431006e-05
mutation O 0 7.615001074157135e-09
is O 0 1.296041052256669e-10
the O 0 1.2861937070951512e-09
second O 0 7.134091539739984e-09
mutation O 0 6.356021042819293e-09
detected O 0 3.911307722148649e-09
in O 0 2.6539626052368703e-10
this O 0 8.045816790591687e-10
gene O 0 2.5312242968311693e-08
worldwide O 0 6.767319860045973e-08
. O 0 3.5451114399620565e-07

In O 0 1.6279965819876452e-08
summary O 0 7.938022577036463e-07
, O 0 3.0722229205082385e-09
our O 0 1.8111514510366078e-09
results O 0 1.851302999789084e-09
show O 0 8.749040381061945e-10
frequent O 0 1.0316067999838197e-09
involvement O 0 1.5933649955002238e-09
of O 0 1.6117566170592568e-09
the O 0 3.092211153798985e-09
p16 O 0 2.737386139983755e-08
gene O 0 4.422381127966446e-09
in O 0 4.373644113542241e-09
familial B-Disease 0 9.588972034180188e-07
melanoma I-Disease 0 8.6978826630002e-07
and O 0 5.714560075142927e-11
confirm O 0 1.4200769449246309e-09
the O 0 4.85177631404099e-09
role O 0 3.3334293103592927e-09
of O 0 9.57638164322816e-08
the O 0 1.7720482503591484e-07
CDK4 O 0 0.18508289754390717
gene O 0 1.2277681094019499e-08
as O 0 1.8290062797632345e-08
a O 0 2.98500353324016e-08
melanoma B-Disease 0 9.381898848914716e-07
- O 0 2.0925597254972672e-07
predisposing O 0 6.89800288000697e-07
gene O 0 8.052625588561568e-08
. O 0 1.9504578574469633e-07
. O 0 4.7422452098544454e-07

Progression O 0 2.805157237162348e-06
of O 0 1.8637614118688361e-07
somatic O 0 5.73479883314576e-05
CTG O 0 3.0249024348449893e-05
repeat O 0 4.75512464959138e-08
length O 0 5.862906604647833e-09
heterogeneity O 0 1.723227853744902e-07
in O 0 1.1812347766593234e-09
the O 0 7.557685144377047e-09
blood O 0 1.2715273278729455e-08
cells O 0 1.775339164566958e-08
of O 0 1.9203866941097658e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 4.913035240861063e-07
. O 0 1.0167518382786511e-07

The O 0 5.525641721959573e-09
genetic O 0 1.2913836222594455e-08
basis O 0 1.3950913313465207e-08
of O 0 7.281101055411909e-09
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.5989057828846853e-06
DM B-Disease 1 1.0
) O 0 1.185762460442774e-10
is O 0 7.115639674704077e-12
the O 0 2.7098441546247187e-11
expansion O 0 3.550373550709196e-09
of O 0 4.040687784367947e-09
an O 0 2.4646027441121987e-08
unstable O 0 7.374792767222971e-05
CTG O 0 3.15497127303388e-05
repeat O 0 2.9437799753395666e-08
in O 0 4.3066665789126546e-09
the O 0 1.9775329818116916e-08
34 O 0 8.949660923462943e-08
UTR O 0 4.7835219447733834e-05
of O 0 6.934055107876702e-08
the O 0 6.609143383684568e-07
DM B-Disease 1 1.0
protein O 0 5.236556717136409e-07
kinase O 0 2.054063514833615e-07
gene O 0 1.2880700062112282e-08
on O 0 1.8691761738409696e-07
chromosome O 0 2.3524812320374622e-07
19 O 0 1.6724392253308906e-06
. O 0 4.2447231862752233e-07

One O 0 1.0427333307916342e-07
of O 0 8.3249624083237e-08
the O 0 8.237112325559792e-08
principal O 0 1.1447490066984756e-07
features O 0 2.5018955795985676e-09
of O 0 2.583699654223892e-08
the O 0 1.1461049780336907e-06
DM B-Disease 1 1.0
mutation O 0 4.624005001119258e-08
is O 0 7.108670596611688e-11
an O 0 1.4542460291533388e-10
extraordinarily O 0 5.750263820658574e-09
high O 0 7.312153371685781e-08
level O 0 4.3104492419843154e-07
of O 0 4.2410124478919897e-07
somatic O 1 0.9769172668457031
mosaicism O 0 5.400284135248512e-05
, O 0 9.837954895175471e-10
due O 0 1.876601540828915e-09
to O 0 1.1034111818686299e-10
an O 0 1.6533735491819357e-10
extremely O 0 1.6417464610007926e-10
high O 0 7.057296969037452e-10
degree O 0 5.632798227850344e-09
of O 0 1.678783556613439e-09
somatic O 0 1.1062824114560499e-06
instability O 0 3.5651755325716294e-08
both O 0 1.0403186090357508e-09
within O 0 3.014904770282101e-09
and O 0 7.333922358299105e-10
between O 0 2.0660380073422857e-09
different O 0 1.0037834563547676e-08
tissues O 0 5.533654530154308e-07
. O 0 2.9621563157888886e-07

This O 0 8.569622167442503e-08
instability O 0 7.265774115694512e-07
appears O 0 2.787364827838701e-08
to O 0 7.420088987686313e-10
be O 0 9.815445123351196e-10
biased O 0 7.654087852415614e-08
towards O 0 5.297118743641249e-09
further O 0 7.00264402020423e-10
expansion O 0 4.657905172678056e-09
and O 0 2.630718698437562e-10
continuous O 0 5.26581001025761e-09
throughout O 0 1.4362847577942262e-09
the O 0 9.031074554854968e-09
life O 0 7.237348054189852e-09
of O 0 8.107811311219848e-09
an O 0 2.416332467447546e-09
individual O 0 8.983002119933303e-10
, O 0 8.481348956479451e-10
features O 0 2.137455545891953e-09
that O 0 2.4083895988624704e-10
could O 0 6.827340914838942e-10
be O 0 6.122557461019085e-10
associated O 0 9.701873082690327e-09
with O 0 4.301632106074038e-10
the O 0 3.447165752845649e-08
progressive O 0 5.5836562751210295e-06
nature O 0 4.309569945348812e-08
of O 0 1.8517983590982112e-08
the O 0 4.6427931721382265e-08
disease O 0 1.9669218431772606e-07
. O 0 5.7256208663147845e-08

Although O 0 3.727010255971663e-09
increasing O 0 9.770690923005532e-10
measured O 0 1.5113065243710366e-09
allele O 0 1.5037328049416487e-09
size O 0 7.608898511257678e-10
between O 0 5.544811276791961e-10
patients O 0 1.952637607161023e-09
clearly O 0 2.7136692892781866e-09
correlates O 0 5.641421552127213e-09
with O 0 1.979302572535646e-12
an O 0 1.3842509603845254e-11
increased O 0 5.6539758985785227e-11
severity O 0 1.4972197703855272e-08
of O 0 4.437319400807382e-09
symptoms O 0 1.0943081463210547e-07
and O 0 8.724673067339594e-11
an O 0 1.4197294728734988e-10
earlier O 0 8.377327720410221e-10
age O 0 7.257114909009488e-09
of O 0 7.098042154041195e-09
onset O 0 1.2449251585167076e-07
, O 0 1.4908750622932843e-10
this O 0 1.088698090012663e-10
correlation O 0 2.3500486001637455e-09
is O 0 4.137105588664092e-11
not O 0 1.0184623283615579e-10
precise O 0 4.753356463993441e-08
and O 0 4.3623136214421265e-09
measured O 0 4.3324817511347646e-08
allele O 0 1.9985321841886616e-08
length O 0 1.1684003098366702e-08
cannot O 0 7.6442505658747e-09
be O 0 1.5626091531828479e-09
used O 0 1.9032182496658834e-09
as O 0 7.541540170130645e-10
an O 0 3.0687660745876144e-10
accurate O 0 1.2916648017835541e-07
predictor O 0 1.7031139805112616e-06
of O 0 1.2941283955569816e-07
age O 0 2.5210460080415942e-05
of O 0 1.1816796359198634e-05
onset O 0 0.019999666139483452
. O 0 8.781547080616292e-07

In O 0 2.9408098178862474e-09
order O 0 9.01523633523027e-10
to O 0 8.190070843738795e-11
further O 0 1.0228937696865614e-09
characterize O 0 1.6864287744056128e-08
the O 0 3.900386236210807e-09
dynamics O 0 1.6402808000748337e-07
of O 0 4.208020527585177e-07
DM B-Disease 1 1.0
CTG O 0 0.00015303879627026618
repeat O 0 8.311666732652156e-08
somatic O 0 2.873517814805382e-06
instability O 0 2.1701318075884046e-07
, O 0 1.2529888238077547e-09
we O 0 3.642762758104823e-10
have O 0 1.232250274041391e-10
studied O 0 1.7977908051136637e-09
repeat O 0 6.246697048517547e-10
length O 0 4.607923487220944e-10
changes O 0 6.105077554607874e-10
over O 0 6.970315991061682e-10
time O 0 1.1027889712522665e-09
in O 0 1.6582379913643308e-09
111 O 0 5.491381784850091e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 3.040195872827667e-10
with O 0 3.4033416276141315e-12
varying O 0 7.199015827907829e-10
clinical O 0 1.537981075827588e-09
severity O 0 1.2377569191812654e-07
and O 0 5.9905271854177045e-09
CTG O 0 2.1903429114900064e-06
repeat O 0 6.9318444317900685e-09
size O 0 6.4486807005437186e-09
over O 0 1.3662582176721116e-09
time O 0 3.1662170663082634e-09
intervals O 0 1.3768381101897376e-08
of O 0 8.81991812917704e-09
1 O 0 9.766134212441102e-08
- O 0 8.753154645546601e-08
7 O 0 1.9749816715375346e-07
years O 0 7.903262400077438e-08
. O 0 3.029149411304388e-07

We O 0 4.9608519958610486e-08
have O 0 6.409486275060772e-10
found O 0 1.4554697724822319e-10
a O 0 5.7608962739097436e-11
direct O 0 8.361491499186968e-10
progression O 0 1.997929999220105e-08
of O 0 1.7575925159718508e-09
the O 0 3.2443818742677877e-09
size O 0 1.2333002175068941e-08
heterogeneity O 0 2.9900499498580757e-07
over O 0 3.5997347325178453e-09
time O 0 2.9841027426869005e-09
related O 0 3.3301630342208455e-09
to O 0 2.590482939268668e-09
initial O 0 2.065511921500729e-07
CTG O 0 7.113088145160873e-07
repeat O 0 4.244404827602466e-09
size O 0 6.471500224591864e-09
and O 0 2.1859036802851506e-09
the O 0 1.092018386827931e-08
time O 0 3.776290391499515e-09
interval O 0 6.808825947501873e-09
and O 0 1.8480148522570516e-09
always O 0 3.069253518006576e-09
biased O 0 1.6622897192064556e-07
towards O 0 3.252922198271335e-08
further O 0 1.6091586729771734e-08
expansion O 0 1.2136445093346993e-06
. O 0 1.0162027592741651e-06

Attempts O 0 9.854565519162861e-08
to O 0 2.3020114703342642e-09
mathematically O 0 6.390595785887854e-08
model O 0 7.160596027233623e-08
the O 0 4.474444992297322e-08
dynamics O 0 1.5708913281287096e-07
have O 0 3.0882678636601213e-09
proved O 0 2.878227576275094e-07
only O 0 3.630198008863772e-08
partially O 0 1.407603349434794e-07
successful O 0 4.874585624037309e-09
suggesting O 0 4.768855532688576e-09
that O 0 8.77842173951926e-11
individual O 0 1.8678231183955063e-10
specific O 0 2.16545359421616e-09
genetic O 0 3.782116664297064e-08
and O 0 4.787556573404572e-09
/ O 0 3.112485202905191e-08
or O 0 7.644028188202867e-10
environmental O 0 8.00707322667904e-09
factors O 0 1.0266079542020634e-08
also O 0 2.3369375878878884e-10
play O 0 7.870491480765907e-10
a O 0 2.711677327127404e-09
role O 0 7.671594026703588e-09
in O 0 6.1173079934917496e-09
somatic O 0 1.4676998944196384e-05
mosaicism O 0 1.7158075934275985e-05
. O 0 1.7377340100210859e-07
. O 0 5.351391223484825e-07

Aspartylglucosaminuria B-Disease 1 1.0
among O 0 5.004769718652824e-07
Palestinian O 1 0.9848542213439941
Arabs O 0 1.0673387805582024e-05
. O 0 5.790052455267869e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9999662637710571
AGU B-Disease 1 1.0
) O 0 2.3051971442811237e-09
is O 0 5.0643069599010104e-11
a O 0 9.33996630037015e-11
rare O 0 9.680505286269181e-09
disorder B-Disease 1 0.9999997615814209
of I-Disease 0 0.009952718392014503
glycoprotein I-Disease 0 9.378514732816257e-06
metabolism I-Disease 0 3.5807544918498024e-05
caused O 0 9.377532528276333e-09
by O 0 3.099932116557014e-11
the O 0 7.327675799473354e-09
deficiency B-Disease 0 0.0554499477148056
of I-Disease 0 6.192914838720753e-07
the I-Disease 0 1.621010170538284e-07
lysosomal I-Disease 0 7.384614946204238e-07
enzyme I-Disease 0 8.160344577845535e-07
aspartylglucosaminidase I-Disease 0 4.908492428512545e-06
( O 0 3.537748227699922e-08
AGA O 0 3.048675716854632e-05
) O 0 2.0922557908420458e-08
. O 0 2.105523293494116e-07

AGU B-Disease 1 1.0
is O 0 1.9194241929199052e-07
inherited O 0 5.150131528353086e-06
as O 0 8.650018479272603e-09
an O 0 4.248398077777438e-09
autosomal O 0 1.2491958841565065e-05
recessive O 0 2.088166866087704e-06
trait O 0 1.0110083792369551e-07
and O 0 3.842476684057239e-11
occurs O 0 1.1253902323926646e-11
with O 0 1.8120669353048624e-13
a O 0 1.4461849252855874e-11
high O 0 2.6422597443342966e-10
frequency O 0 2.532216381023744e-10
in O 0 1.235738317229007e-10
Finland O 0 4.3758139334215684e-09
because O 0 1.4853360319477815e-08
of O 0 2.1596723343009216e-07
a O 0 1.2281246597467543e-07
founder O 0 9.939793699231814e-07
effect O 0 1.3476470712703303e-06
. O 0 1.2755130001096404e-06

While O 0 1.9198122913621773e-07
very O 0 1.937879012814392e-08
few O 0 1.3833398426754684e-08
patients O 0 2.5632493905192177e-09
with O 0 1.7633746685064011e-09
AGU B-Disease 1 1.0
have O 0 1.6795201895902778e-09
been O 0 1.9255050331956625e-10
reported O 0 6.352927073294268e-10
from O 0 3.080154187262707e-10
non O 0 8.610118840124414e-09
- O 0 7.748322539136154e-10
Finnish O 0 1.2139109273334725e-08
origin O 0 9.791701671701958e-09
, O 0 1.0913534520540225e-09
we O 0 4.1525569649536465e-09
diagnosed O 0 5.756319751526462e-06
the O 0 7.715252792195315e-08
disorder O 0 1.8508032439967792e-07
in O 0 4.5737738596507427e-10
8 O 0 4.728676117338182e-09
patients O 0 9.726840166646156e-11
originating O 0 8.162144848888886e-10
from O 0 3.525478242671909e-10
3 O 0 2.5223261257423246e-09
unrelated O 0 2.7179583028669185e-09
families O 0 2.961980105631312e-10
, O 0 2.606931510940047e-11
all O 0 8.006728613452196e-11
Palestinian O 0 1.9199184464469e-07
Arabs O 0 7.53161089050991e-09
from O 0 1.325056619982945e-09
the O 0 3.0926003979914185e-09
region O 0 7.381472322265381e-09
of O 0 2.0779861387154597e-08
Jerusalem O 0 6.192989530973136e-05
. O 0 1.2184503930257051e-06

The O 0 6.550546771677546e-08
clinical O 0 1.487499901031697e-07
diagnosis O 0 0.0236133374273777
of O 0 0.0552079901099205
AGU B-Disease 1 1.0
is O 0 1.2679834071605e-07
often O 0 1.4220907784689985e-09
difficult O 0 2.164367574053472e-09
, O 0 1.489766504603196e-10
in O 0 3.262318193364422e-11
particular O 0 2.9124624933984933e-10
early O 0 4.112045370874284e-09
in O 0 6.687678189010171e-11
the O 0 2.483344418990896e-09
course O 0 3.063001852154912e-09
of O 0 4.776210538182113e-09
the O 0 1.2810358107628872e-08
disease O 0 1.0103564207497584e-08
, O 0 5.7857604124356143e-11
and O 0 2.2152864612157153e-11
most O 0 1.1277113964869301e-10
of O 0 1.1734784255423847e-09
the O 0 1.049350384363379e-09
patients O 0 1.57416135682098e-10
are O 0 1.1464756921597541e-10
diagnosed O 0 1.922628722894615e-09
after O 0 6.398883645175601e-10
the O 0 2.8695534837197556e-09
age O 0 2.8864951318041676e-08
of O 0 1.8221848918642536e-08
5 O 0 9.311536786071883e-08
years O 0 4.435519329604176e-08
. O 0 4.0053853922472626e-07

However O 0 6.867520596642862e-07
, O 0 1.6393949309190248e-08
since O 0 6.755607184771861e-09
these O 0 2.101910423490949e-09
patients O 0 1.0384313409161905e-09
excrete O 0 1.043847142057075e-08
early O 0 4.496274907950237e-09
large O 0 3.0756514002305835e-10
amounts O 0 3.888360744497277e-09
of O 0 1.819823225446271e-08
aspartylglucosamine O 0 1.7632598883210449e-06
in O 0 8.883110247381865e-09
urine O 0 7.992119854804969e-09
, O 0 5.197038910331742e-10
biochemical O 0 1.4871163855900704e-08
screening O 0 2.32564434377025e-09
is O 0 9.933229794256704e-10
easy O 0 2.0668315059424458e-08
by O 0 2.6419247234343857e-08
urine O 0 4.3119950277059615e-08
chromatography O 0 2.56009002441715e-07
. O 0 6.779463745942849e-08
. O 0 5.875110673514428e-07

Detection O 0 5.187834162256877e-08
of O 0 5.596110241867791e-09
heterozygous O 0 1.0808776096382644e-09
carriers O 0 9.267339673435515e-10
of O 0 2.1005477357505242e-09
the O 0 2.6906153038908087e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 4.1663312003947794e-05
ATM O 0 1.1313887625874486e-05
) O 0 1.6621765075441886e-10
gene O 0 1.2250184200368608e-10
by O 0 9.46866474116348e-11
G2 O 0 5.509553346882967e-08
phase O 0 6.095039584153028e-09
chromosomal O 0 7.929595824407443e-08
radiosensitivity O 0 1.1624672424659366e-06
of O 0 1.2776541780112893e-07
peripheral O 0 0.0021882173605263233
blood O 0 6.181472417665645e-05
lymphocytes O 0 6.050067895557731e-07
. O 0 1.3382577890297398e-07

In O 0 7.264671921802801e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.926389213759762e-10
patients O 0 5.650550582991798e-10
, O 0 9.034144959896295e-12
mutations O 0 4.9937484702944346e-11
in O 0 2.3345931091101058e-11
a O 0 1.165129936975262e-10
single O 0 5.1134395329111015e-11
gene O 0 1.9866799871870455e-10
, O 0 2.1933198313117686e-10
ATM O 0 3.310304563797217e-08
, O 0 4.065033726297074e-11
result O 0 2.2367199759010248e-10
in O 0 6.94463375694454e-11
an O 0 1.7903083460169e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.161059803855835e-09
embraces O 0 2.351676409162451e-09
a O 0 1.1177771902515232e-10
variety O 0 4.745117632154461e-10
of O 0 9.485696672584254e-10
clinical O 0 2.3144619554216206e-09
features O 0 1.164723983926308e-09
and O 0 3.5328423519942476e-10
manifests O 0 5.834782434988028e-09
extreme O 0 8.324390421421413e-08
radiosensitivity O 0 1.5965043758114916e-06
and O 0 4.872289682822384e-09
a O 0 2.0314532278575825e-08
strong O 0 3.9579703070558026e-07
pre O 0 5.347918431652943e-06
- O 0 1.469720132263319e-06
disposition O 0 1.8545519196777605e-05
to O 0 1.7997649592871312e-07
malignancy B-Disease 0 9.177754691336304e-05
. O 0 7.840485523047391e-07

Heterozygotes O 0 1.4989620922278846e-06
for O 0 1.579239317095471e-08
the O 0 9.330844363830693e-08
ATM O 0 1.1627355434029596e-06
gene O 0 1.4690706429121292e-08
have O 0 1.5584064039231293e-09
no O 0 4.969749056726869e-10
clinical O 0 3.3954669631519607e-10
expression O 0 3.413507920768666e-09
of O 0 2.4403318548138486e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 6.047437750567042e-07
may O 0 3.0416835272717435e-08
be O 0 6.250692852205475e-09
cancer B-Disease 0 4.40689014169493e-08
prone O 0 3.948591675850821e-09
with O 0 3.379287127902586e-11
a O 0 1.6399945845790853e-09
moderate O 0 9.436027426090732e-08
increase O 0 2.532072551630904e-09
in O 0 1.4843043460999183e-09
in O 0 9.425392910600294e-09
vitro O 0 1.129315933212638e-06
radiosensitivity O 0 1.289680312765995e-05
. O 0 1.012277834888664e-06

We O 0 4.708159551114477e-08
performed O 0 3.167956563743246e-09
a O 0 1.1066116911706558e-08
blind O 0 1.0554493456993441e-07
chromosomal O 0 1.4710674633988674e-07
analysis O 0 4.4679293154104016e-08
on O 0 7.900473519839579e-08
G2 O 0 1.0981790410369285e-06
- O 0 3.135245663088426e-08
phase O 0 3.114492486133713e-08
lymphocytes O 0 1.3484001692987135e-09
from O 0 7.053824746527937e-10
7 O 0 6.487963055690216e-09
unrelated O 0 9.129447562372661e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.212911193704258e-08
, O 0 1.1160686957945032e-10
13 O 0 1.7443905209191257e-09
obligate O 0 2.4006604348869587e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 3.1130554134506383e-07
( O 0 4.411157827899359e-10
parents O 0 7.472126251073519e-10
of O 0 1.9188919342383315e-09
the O 0 1.2508111213449524e-09
patients O 0 3.922195901395753e-11
) O 0 2.8299363720452053e-12
, O 0 2.1699126870333707e-11
and O 0 2.1643088710110447e-10
14 O 0 3.53540734465696e-08
normal O 0 1.4208313814378926e-07
controls O 0 1.7382205896865344e-08
following O 0 6.039238886756948e-09
X O 0 1.5347883675076446e-07
- O 0 2.0219129481802156e-08
irradiation O 0 6.186846235323173e-08
with O 0 5.410727976773444e-10
1 O 0 3.364820955198411e-08
Gy O 0 2.8363140813780774e-07
in O 0 3.1850527770771464e-10
order O 0 6.393394147430342e-10
to O 0 1.3130307952025078e-09
evaluate O 0 1.0617486445596569e-08
this O 0 3.5038809631515733e-09
cytogenetic O 0 3.954015483031981e-06
method O 0 1.0923479010216397e-07
as O 0 5.470023101139532e-09
a O 0 1.8535571966182829e-09
tool O 0 1.6220177201375918e-08
for O 0 1.6415210857267937e-10
detection O 0 4.056899172155681e-08
of O 0 5.670919733802293e-08
ATM O 0 8.083702414296567e-05
carriers O 0 5.760596195614198e-07
. O 0 1.5778954320921912e-06

Both O 0 4.028395778732374e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 6.010868673911318e-07
and O 0 7.495664644530109e-10
heterozygotes O 0 7.77684618924468e-08
showed O 0 3.1317415327691833e-09
significantly O 0 4.783857199264219e-10
increased O 0 6.43040065639866e-10
levels O 0 8.348615132547366e-10
of O 0 1.2552899830708952e-09
radiation O 0 1.2804649713871186e-06
- O 0 3.483425103922855e-08
induced O 0 5.048613260782986e-08
chromatid O 0 5.259128244006206e-08
damage O 0 6.33646308756397e-08
relative O 0 8.483326929820123e-09
to O 0 1.6553804160768237e-10
that O 0 2.0913998310945203e-10
of O 0 9.089276886697917e-09
normal O 0 1.4525431879519601e-07
controls O 0 2.472534674780036e-07
. O 0 5.47204933809553e-07

These O 0 1.3531828102486543e-08
results O 0 6.19736937323978e-08
show O 0 8.506399140628673e-09
that O 0 4.3214345990527647e-10
the O 0 2.4356106465006633e-08
G2 O 0 2.694418071769178e-06
- O 0 1.9578638443817908e-07
phase O 0 2.1401945105026243e-07
chromosomal O 0 6.79853769725014e-07
radiosensitivity O 0 2.29800866691221e-06
assay O 0 5.3964900104119806e-08
can O 0 6.880783720575323e-10
be O 0 2.319636011050008e-10
used O 0 5.621845003411785e-11
for O 0 1.0647301616761862e-11
the O 0 6.389769963144332e-11
detection O 0 1.1480195460933373e-08
of O 0 3.5010506849175727e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.0001525652623968199
. O 0 4.619584615284111e-06

In O 0 1.346078004615947e-08
combination O 0 6.15927078229106e-08
with O 0 9.165593284343743e-10
molecular O 0 8.49489154575167e-08
genetic O 0 5.993478424670684e-08
analyses O 0 1.0818640205911834e-08
, O 0 1.0540718298202023e-10
this O 0 3.806964465891127e-11
test O 0 6.776584848822154e-11
may O 0 3.6031466699171233e-10
be O 0 2.2853552383850229e-10
of O 0 7.079785091512747e-10
value O 0 2.4729172043436165e-09
in O 0 2.444464630713128e-10
studies O 0 2.642921437256973e-09
of O 0 2.333277571153758e-09
familial B-Disease 0 6.199520896643662e-08
and I-Disease 0 8.511316984538553e-09
sporadic I-Disease 0 2.7717521788872546e-06
cancers I-Disease 0 4.638187419914175e-06
aimed O 0 7.45200807727997e-08
at O 0 7.241849786510102e-09
determination O 0 1.6574159822368983e-09
of O 0 2.491808759330638e-09
the O 0 9.00398089420662e-10
potential O 0 8.79364669970073e-09
involvement O 0 1.5076825121695947e-08
of O 0 9.988849569708691e-08
ATM O 0 0.003216135548427701
mutations O 0 2.5614851892896695e-06
in O 0 3.9259141715319856e-08
tumor B-Disease 0 1.8539383745519444e-05
risk O 0 2.283428131022447e-07
or O 0 6.930575224828317e-09
development O 0 4.9994362427696615e-08
. O 0 5.057689822507427e-09
. O 0 8.562400211076238e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 2.9819876345982266e-08
identification O 0 2.1726314081149667e-09
and O 0 5.0455639666324714e-11
detection O 0 6.001346086748072e-09
of O 0 3.068154796892486e-08
founder O 0 4.904945853922982e-07
- O 0 8.900888559537634e-08
effect O 0 2.704298367461888e-07
mutations O 0 1.14554135066669e-08
in O 0 4.39450531519725e-10
the O 0 8.762199854572827e-10
ATM O 0 8.471571888435392e-09
gene O 0 2.463580450751124e-10
in O 0 7.596167028722789e-10
ethnic O 0 4.162175493149789e-09
populations O 0 1.399731619500244e-08
. O 0 4.9957279202317295e-08

To O 0 2.648552932527082e-09
facilitate O 0 1.022607509781892e-08
the O 0 4.527669350551378e-09
evaluation O 0 2.2973763336153752e-08
of O 0 2.6224505234040407e-08
ATM O 0 0.00013244841829873621
heterozygotes O 0 4.997895302949473e-06
for O 0 1.1383862741354278e-08
susceptibility O 0 1.11778240352578e-06
to O 0 1.080043432466482e-08
other O 0 4.431772993029881e-08
diseases O 0 0.0049470872618258
, O 0 9.337672857157031e-10
such O 0 3.009504201401114e-09
as O 0 1.2532042319435277e-06
breast B-Disease 0 6.451010904129362e-06
cancer I-Disease 0 7.213967364805285e-06
, O 0 6.058479828929819e-10
we O 0 2.4252289065884725e-10
have O 0 6.470111252321331e-11
attempted O 0 1.5999338520700235e-09
to O 0 3.0389377125850103e-10
define O 0 5.646481060495034e-09
the O 0 7.031664583934116e-09
most O 0 1.085915468657106e-09
common O 0 4.571593659186135e-10
mutations O 0 1.2141326832804111e-09
and O 0 6.047693595911952e-11
their O 0 4.668796599327507e-11
frequencies O 0 4.8364761084940255e-09
in O 0 7.522293898887256e-09
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999996423721313
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.852423545782415e-10
homozygotes O 0 4.3129637639083285e-09
from O 0 1.17227039186929e-09
10 O 0 2.2097941254628495e-09
ethnic O 0 2.6409057163334637e-09
populations O 0 2.7819577752552505e-08
. O 0 8.389167760469718e-08

Both O 0 2.0349555995835544e-07
genomic O 0 4.79354412163957e-07
mutations O 0 1.8637577170466102e-07
and O 0 2.45255926678567e-09
their O 0 6.273060404460296e-10
effects O 0 1.9962540065421308e-08
on O 0 1.2381248026827052e-08
cDNA O 0 9.230953423866595e-08
were O 0 1.2820183137307595e-08
characterized O 0 7.310703153962095e-08
. O 0 3.076646351019008e-07

Protein O 0 6.382872470567236e-07
- O 0 6.950554620743787e-08
truncation O 0 1.9165737441539932e-08
testing O 0 5.359495625079091e-10
of O 0 2.3883273136959815e-09
the O 0 3.406262605309962e-09
entire O 0 8.999280431964962e-09
ATM O 0 1.1296138779925968e-07
cDNA O 0 2.8107162819424047e-08
detected O 0 1.3271415078008886e-08
92 O 0 1.6309927630686616e-08
( O 0 5.024822224974912e-10
66 O 0 3.60443550562195e-08
% O 0 2.9833910897281157e-09
) O 0 1.2895336187757067e-10
truncating O 0 2.6798360863722337e-08
mutations O 0 3.963516626015462e-09
in O 0 7.94239396473273e-10
140 O 0 1.1098754804095279e-08
mutant O 0 4.607875325746136e-08
alleles O 0 5.5148838384866394e-08
screened O 0 4.998435088054975e-07
. O 0 3.814126330325962e-07

The O 0 3.4439725027368695e-07
haplotyping O 0 0.00022428265947382897
of O 0 1.6628067101009947e-07
patients O 0 5.68624258789896e-09
with O 0 1.4490102173692065e-10
identical O 0 1.9928073413666425e-08
mutations O 0 1.4284397309438646e-07
indicates O 0 7.639910393208993e-08
that O 0 1.395039361806738e-10
almost O 0 1.7688486231293155e-09
all O 0 1.5704876288324954e-10
of O 0 3.9977868238061376e-10
these O 0 6.353239462297822e-11
represent O 0 6.541015507011139e-10
common O 0 2.4072244197981263e-09
ancestry O 0 1.6759114984665757e-08
and O 0 8.772400583723083e-10
that O 0 4.458517999239575e-10
very O 0 3.403872739227154e-09
few O 0 2.607800908549507e-08
spontaneously O 0 1.5708822331816918e-07
recurring O 0 3.8920097722439095e-07
ATM O 0 2.802622657327447e-05
mutations O 0 2.062686235149158e-06
exist O 0 5.69360850022349e-07
. O 0 1.5673762163714855e-06

Assays O 0 2.0731373240323592e-07
requiring O 0 2.7353820541975438e-08
minimal O 0 7.503423944399401e-07
amounts O 0 8.450385990954601e-08
of O 0 5.6540063297916276e-08
genomic O 0 2.3397317860940348e-08
DNA O 0 5.485729204224299e-08
were O 0 2.902227347334474e-09
designed O 0 6.507615557538315e-10
to O 0 3.919144869746205e-11
allow O 0 1.8731569073615617e-10
rapid O 0 1.6161834093253447e-09
screening O 0 6.118888729034211e-11
for O 0 1.0800732530569235e-10
common O 0 5.134006553220161e-09
ethnic O 0 5.34809494467936e-08
mutations O 0 8.438199756710674e-07
. O 0 3.637982786131033e-07

These O 0 3.451007657417904e-08
rapid O 0 3.255871092733287e-07
assays O 0 8.800597584013303e-08
detected O 0 2.0947954482153364e-08
mutations O 0 1.6661132473672069e-09
in O 0 1.4237891421409188e-10
76 O 0 9.782853638284905e-09
% O 0 2.6212024217819874e-10
of O 0 2.6892857385441005e-10
Costa O 0 6.3405707351194e-09
Rican O 0 6.669064589459595e-08
patients O 0 1.984030273405324e-09
( O 0 3.4269839743750197e-10
3 O 0 4.0733811879078985e-09
) O 0 1.5426038918464613e-11
, O 0 1.6401494745688083e-11
50 O 0 2.0523768795577269e-10
% O 0 2.4830967837452533e-10
of O 0 1.4427260497384964e-09
Norwegian O 0 2.7868125584973313e-07
patients O 0 1.4187774288743071e-09
( O 0 3.057834263575643e-10
1 O 0 1.0440045272730458e-08
) O 0 4.598886202411556e-11
, O 0 6.536534508105873e-11
25 O 0 1.826617301858846e-09
% O 0 5.862053620298013e-10
of O 0 1.0849424691983245e-09
Polish O 0 3.776681367639867e-08
patients O 0 3.604640141929849e-09
( O 0 3.736467801829235e-10
4 O 0 1.1552286238725173e-08
) O 0 4.6452484220305124e-11
, O 0 6.088387433100806e-11
and O 0 5.5114052210925024e-11
14 O 0 3.7419254361736876e-09
% O 0 8.206352819506435e-10
of O 0 1.2911488544986582e-09
Italian O 0 1.2521103265328293e-08
patients O 0 7.353083142369599e-10
( O 0 1.1164285468323598e-10
1 O 0 1.5291542254658452e-08
) O 0 2.531926612814317e-10
, O 0 6.391882023670803e-10
as O 0 1.7366985627376152e-09
well O 0 9.023855551681947e-10
as O 0 6.801774143916361e-10
in O 0 2.008324062607869e-10
patients O 0 1.720167897012459e-10
of O 0 4.568422973250108e-09
Amish O 0 1.4413878091090737e-07
/ O 0 7.868502649444054e-08
Mennonite O 0 4.922119387629209e-07
and O 0 3.3448679381820057e-09
Irish O 0 1.0071817158063823e-08
English O 0 2.515812269621165e-08
backgrounds O 0 2.5357914523738145e-07
. O 0 3.0496892122755526e-07

Additional O 0 1.681499384176277e-07
mutations O 0 3.8154104231580277e-07
were O 0 2.957732014863268e-08
observed O 0 1.6152565507354666e-08
in O 0 5.623542187471742e-10
Japanese O 0 2.7284153603091e-08
, O 0 6.118308082392332e-10
Utah O 0 1.799386772916023e-08
Mormon O 0 3.5679711629654776e-08
, O 0 2.712208790889292e-10
and O 0 3.3018263123629765e-10
African O 0 1.5230144922995237e-09
American O 0 7.4134440808393265e-09
patients O 0 4.276111909007341e-09
. O 0 5.4569269991588953e-08

These O 0 2.2581723158054956e-08
assays O 0 1.2750245304005148e-08
should O 0 2.476763238945523e-10
facilitate O 0 6.872847846395302e-10
screening O 0 2.9021593461742157e-10
for O 0 4.0243897103664494e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 4.544031639852619e-07
in O 0 2.836495482938517e-09
the O 0 3.237180745685464e-09
populations O 0 1.8369625820469082e-09
studied O 0 4.764673100510208e-09
. O 0 2.7988704687231802e-09
. O 0 8.030186648966264e-08

The O 0 1.8028096747002564e-05
von B-Disease 1 1.0
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 0.9996086955070496
tumor I-Disease 0 0.00029612984508275986
suppressor O 0 1.321082436334109e-06
gene O 0 1.5050239943192878e-09
is O 0 4.053698349215651e-11
required O 0 1.2143560462751779e-11
for O 0 9.091694064267131e-11
cell O 0 3.756400701604434e-08
cycle O 0 4.6950578536097964e-08
exit O 0 5.170980443836015e-08
upon O 0 2.5859673513650705e-08
serum O 0 2.4456056735289167e-07
withdrawal O 0 1.2463403891160851e-06
. O 0 2.020819920289796e-06

The O 0 1.8023894199359347e-07
inactivation O 0 1.1773162441386376e-05
of O 0 1.7156749265723192e-07
the O 0 5.015644433115085e-07
von B-Disease 1 1.0
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 1.0
( I-Disease 1 0.8956365585327148
VHL I-Disease 1 1.0
) I-Disease 0 5.577955164426385e-08
tumor I-Disease 0 8.638901817903388e-06
suppressor O 0 2.5616682250984013e-06
gene O 0 3.761498490462145e-08
predisposes O 0 2.5908903467097844e-07
affected O 0 2.0786352639134975e-09
individuals O 0 1.1275043398928375e-11
to O 0 2.1947790806997602e-11
the O 0 5.227639987559485e-10
human O 0 5.7383360285712115e-08
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 0.6983449459075928
and O 0 1.5671264633199122e-11
is O 0 1.589741142546397e-12
associated O 0 5.469182745576617e-11
with O 0 4.277796172846848e-11
sporadic B-Disease 1 0.9998098015785217
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.00394354248419404
RCC B-Disease 1 1.0
) O 0 4.903140293777142e-08
and O 0 1.2718359698737913e-07
brain B-Disease 1 0.9856197834014893
hemangioblastomas I-Disease 0 0.00020515355572570115
. O 0 2.6578362621876295e-07

VHL O 1 0.9958158135414124
- O 0 0.0002332906296942383
negative O 0 1.7374767367073218e-06
786 O 0 2.193085265389527e-06
- O 0 4.03487575795225e-07
0 O 0 1.871184451829322e-07
RCC B-Disease 0 3.925333203369519e-06
cells O 0 1.021751572238827e-08
are O 0 3.7497183136281365e-10
tumorigenic O 0 6.658133315795567e-07
in O 0 1.6962745874593566e-08
nude O 0 2.7130035959999077e-06
mice O 0 5.556258564354266e-09
which O 0 2.6018065479860297e-10
is O 0 3.014591007377554e-11
suppressed O 0 3.056440656123982e-10
by O 0 4.957987492781868e-11
the O 0 2.5648045909321127e-09
reintroduction O 0 2.1629571165249217e-06
of O 0 2.1654162196682591e-07
VHL B-Disease 0 0.0012011611834168434
. O 0 3.5363627830520272e-06

Remarkably O 0 2.436869908706285e-05
, O 0 2.2278734412850554e-09
this O 0 3.652097374517993e-11
occurs O 0 1.0096677660609288e-10
without O 0 1.532946131144186e-10
affecting O 0 3.4992324593474677e-09
the O 0 9.90326487482207e-10
growth O 0 1.792387793742023e-09
rate O 0 1.2999235021737832e-09
and O 0 2.1459674315327248e-10
cell O 0 9.440253911918717e-09
cycle O 0 6.836753385641714e-09
profile O 0 6.63598287431455e-09
of O 0 1.3017106503809828e-08
these O 0 4.683383458825574e-09
cells O 0 6.387790740802757e-09
in O 0 2.4501045636782237e-09
culture O 0 8.228852266256581e-08
. O 0 1.341073669891557e-07

The O 0 2.36539494835597e-06
786 O 0 3.123820079053985e-06
- O 0 1.4484142241144582e-07
0 O 0 4.3571272811959716e-08
cell O 0 2.9753177699376465e-08
line O 0 2.173478748090929e-07
, O 0 9.534818490308794e-10
like O 0 5.260105684357086e-10
many O 0 9.146615020938498e-09
cancer B-Disease 0 7.701138571292176e-08
cells O 0 2.213506267167986e-09
, O 0 7.481134461917449e-11
fails O 0 4.086803395697558e-10
to O 0 1.262097926169048e-10
exit O 0 4.5026542494497335e-08
the O 0 1.8500392329201532e-09
cell O 0 2.4774129414595336e-08
cycle O 0 1.43417766551579e-08
upon O 0 1.7253549700058102e-08
serum O 0 1.3249693608941016e-07
withdrawal O 0 5.471788426802959e-07
. O 0 1.750486035234644e-06

Here O 0 1.0718306384660536e-06
, O 0 1.1987529191515023e-08
it O 0 3.0746247214885614e-10
is O 0 2.5985717050369672e-11
shown O 0 2.059206451188178e-11
that O 0 4.7048914243730255e-12
reintroduction O 0 2.700298118440969e-08
of O 0 5.9523492801361044e-09
the O 0 2.582133085127225e-08
wild O 0 1.8210251084838092e-07
- O 0 1.8828879433385737e-07
type O 0 2.973440587084042e-07
VHL B-Disease 0 3.5971825127489865e-05
gene O 0 5.419606097234464e-08
restores O 0 1.1088512792412075e-06
the O 0 4.638188055849923e-09
ability O 0 7.1604295825977715e-09
of O 0 3.8034505678297137e-07
VHL O 1 1.0
- O 1 0.9999260902404785
negative O 0 0.00022005700157023966
RCC B-Disease 0 0.0009306103456765413
cancer I-Disease 0 1.8354334940795525e-07
cells O 0 3.9846931310094647e-10
to O 0 7.018552405924083e-11
exit O 0 5.423977711416228e-09
the O 0 5.348038678576472e-10
cell O 0 2.9855826699787258e-09
cycle O 0 1.2179782737931077e-09
and O 0 2.6926424978590546e-10
enter O 0 1.079353992849974e-07
G0 O 0 3.5476892662700266e-05
/ O 0 1.2743822708216612e-06
quiescence O 0 1.587641918376903e-06
in O 0 6.047228851002728e-08
low O 0 1.5933710528770462e-06
serum O 0 5.457113161355664e-07
. O 0 2.1801882610361645e-07

Both O 0 4.7330868255812675e-06
VHL O 1 0.9991518259048462
- O 0 2.6183271984336898e-05
positive O 0 1.186956666288097e-07
and O 0 1.326367105036752e-08
VHL O 0 0.3210696280002594
- O 0 5.110890924697742e-06
negative O 0 4.6631387817797076e-07
RCC B-Disease 0 1.0775931514217518e-05
cells O 0 6.094402493772577e-08
exit O 0 1.7048969880306686e-07
the O 0 2.0996024918673584e-09
cell O 0 2.0767725317227814e-09
cycle O 0 4.874396997145425e-10
by O 0 7.447337191379688e-11
contact O 0 3.486363198135223e-08
inhibition O 0 5.488764145411551e-07
. O 0 2.0931824451508874e-07

The O 0 1.6650785255478695e-05
cyclin O 0 1.4046136129763909e-05
- O 0 3.6950229969079373e-06
dependent O 0 8.23404718630627e-07
kinase O 0 2.1958967977298016e-07
inhibitor O 0 7.18449584269365e-08
, O 0 2.5521802449191e-09
p27 O 0 3.550463389956349e-08
, O 0 7.974083893191874e-11
accumulates O 0 2.5228217293005173e-09
upon O 0 7.885306851918017e-10
serum O 0 2.4994915026610443e-09
withdrawal O 0 2.316347780251249e-09
, O 0 1.1943970812389182e-10
only O 0 1.4408663151499468e-10
in O 0 1.1631138413514819e-10
the O 0 2.051192105056998e-09
presence O 0 9.168361181366436e-09
of O 0 3.9010285490803653e-07
VHL B-Disease 1 0.8282947540283203
, O 0 2.7202298191753016e-09
as O 0 3.0023417085800475e-10
a O 0 1.5731468905322288e-10
result O 0 5.81454884240884e-10
of O 0 8.126695982824117e-10
the O 0 1.074433653158735e-09
stabilization O 0 1.456229909990725e-07
of O 0 6.582259004517255e-08
the O 0 2.2802336729910166e-07
protein O 0 2.8924475827807328e-06
. O 0 5.415383839135757e-07

We O 0 1.5111689677382856e-08
propose O 0 5.930251845143175e-09
that O 0 3.2287064688496514e-10
the O 0 2.2226867013586116e-09
loss O 0 1.442391095451967e-08
of O 0 1.708007779654963e-08
wild O 0 7.612375441112817e-08
- O 0 9.149427881993688e-08
type O 0 1.1421601442407336e-07
VHL B-Disease 0 1.2708487702184357e-05
gene O 0 4.469154379904694e-09
results O 0 8.185987887543433e-09
in O 0 1.3741946469636446e-10
a O 0 1.1551261336339991e-10
specific O 0 7.489533992988129e-10
cellular O 0 3.8821891479301485e-08
defect O 0 2.2300177704437374e-07
in O 0 2.264538778717906e-08
serum O 0 1.9336964385274769e-07
- O 0 6.516054895655543e-07
dependent O 0 2.303481096532778e-06
growth O 0 1.082235456806302e-08
control O 0 3.5529545971968446e-09
, O 0 7.205444574331921e-10
which O 0 4.3990505682600656e-10
may O 0 5.388834711794743e-09
initiate O 0 8.578043519946732e-08
tumor B-Disease 0 3.323551254652557e-06
formation O 0 7.256397793753422e-07
. O 0 7.432971642629127e-07

This O 0 2.3293301509852427e-08
is O 0 2.693619771676481e-09
corrected O 0 8.507242910127388e-09
by O 0 1.0645418574428689e-10
the O 0 1.3738730153534107e-09
reintroduction O 0 2.6311738565709675e-07
of O 0 1.1856663206799567e-08
wild O 0 4.711348537966842e-07
- O 0 8.976857657216897e-07
type O 0 3.0973358207120327e-06
VHL B-Disease 1 0.9997122883796692
, O 0 4.986189594546886e-08
implicating O 0 4.82079922221601e-05
VHL B-Disease 1 1.0
as O 0 4.064467020725715e-07
the O 0 2.8349445457820366e-08
first O 0 1.990344999924787e-09
tumor B-Disease 0 1.5204815184688414e-08
suppressor O 0 4.945707487991058e-08
involved O 0 2.2401183685794024e-10
in O 0 2.385271424820701e-10
the O 0 3.3780018782181287e-09
regulation O 0 2.184116887349319e-08
of O 0 7.183714245684314e-08
cell O 0 3.57738230150062e-07
cycle O 0 3.311567908781399e-08
exit O 0 4.2773212527436044e-08
, O 0 3.434640072352835e-10
which O 0 1.5470567882314157e-10
is O 0 1.3230407047704063e-10
consistent O 0 7.265120061106245e-09
with O 0 1.5687960652766009e-10
its O 0 4.99725993918787e-09
gatekeeper O 0 4.30857483024738e-08
function O 0 2.64635136026925e-09
in O 0 4.885270854515511e-09
the O 0 1.6131451729961555e-07
kidney O 0 1.8852755374609842e-06
. O 0 6.252889050983867e-08
. O 0 2.7042418082601216e-07

Piebaldism B-Disease 1 1.0
with O 1 0.9879279732704163
deafness B-Disease 1 1.0
: O 0 4.5422208216905346e-08
molecular O 0 3.368025147665321e-08
evidence O 0 1.953360140305449e-09
for O 0 1.23612731162126e-10
an O 0 2.987907032903081e-09
expanded O 0 1.7143861441581976e-07
syndrome O 1 0.9962213039398193
. O 0 1.2870259524788707e-06

In O 0 1.5082080029316103e-09
a O 0 1.7495052073712714e-09
South O 0 2.7712743211338875e-09
African O 0 7.74244279799774e-10
girl O 0 4.430148248246724e-09
of O 0 1.6657001333797439e-09
Xhosa O 0 1.606147570498706e-08
stock O 0 5.602529107306964e-09
with O 0 8.044442716126365e-12
severe O 0 3.2216416201436004e-08
piebaldism B-Disease 0 2.2650369828625116e-06
and O 0 8.699059250716346e-09
profound O 1 0.9999995231628418
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 1.6702287553016504e-07
identified O 0 1.9948296348104577e-09
a O 0 9.119517641043018e-11
novel O 0 2.377436303380165e-10
missense O 0 8.085743630203979e-09
substitution O 0 7.51010809096897e-09
at O 0 2.3378314395472444e-08
a O 0 2.8811584229515574e-09
highly O 0 9.79065628570197e-09
conserved O 0 1.5654947560506116e-08
residue O 0 1.1129241528351486e-07
in O 0 2.734285242667056e-09
the O 0 2.4936976927847354e-08
intracellular O 0 6.753252534963394e-08
kinase O 0 1.4628777478264965e-07
domain O 0 4.697781363915965e-08
of O 0 2.633172186961019e-07
the O 0 8.270541229649098e-07
KIT O 0 2.5193157853209414e-05
proto O 0 6.040213975211373e-06
- O 0 1.975110990315443e-06
oncogene O 0 4.524772521108389e-06
, O 0 2.951713184984328e-08
R796G O 0 2.3463674097001785e-06
. O 0 3.8558965798074496e-07

Though O 0 2.678876285244769e-07
auditory B-Disease 0 8.400099613936618e-05
anomalies I-Disease 0 1.4253727385948878e-05
have O 0 4.381124796282165e-09
been O 0 2.0681829582258615e-09
observed O 0 3.439899698420845e-09
in O 0 1.4926618274735404e-10
mice O 0 3.142390792021388e-10
with O 0 1.2760985323989615e-10
dominant O 0 6.482386538664286e-07
white O 0 2.954518230069425e-08
spotting O 0 5.5877899285405874e-06
( O 0 9.756226049262295e-09
W O 0 0.00015887098561506718
) O 0 9.52111611773887e-10
due O 0 3.1530987598671345e-08
to O 0 3.7083114357017166e-09
KIT O 0 0.00684991804882884
mutations O 0 1.2377453458611853e-05
, O 0 5.688880833076837e-07
deafness B-Disease 1 1.0
is O 0 1.3560403466783555e-08
not O 0 4.712934487116627e-10
typical O 0 1.8139042268217054e-08
in O 0 8.993014111169373e-10
human O 0 2.9306537641105024e-08
piebaldism B-Disease 0 2.0373128791106865e-05
. O 0 6.944789561202924e-07

Thus O 0 2.2473017224911018e-08
, O 0 2.4624199901346344e-10
the O 0 1.7128540252819846e-10
occurrence O 0 3.39193633180912e-08
of O 0 3.297185102724143e-08
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 3.0154610612953547e-06
this O 0 4.832056976766808e-10
patient O 0 4.661511177062039e-10
extends O 0 1.1280233691568498e-10
considerably O 0 7.610056335094484e-11
the O 0 5.462781615950263e-11
phenotypic O 0 5.529099400547466e-09
range O 0 1.0510699155474867e-07
of O 0 2.5547580051465957e-08
piebaldism B-Disease 0 1.3883218343835324e-06
due O 0 3.019717453867088e-08
to O 0 4.074958592781286e-09
KIT O 0 3.2876343425414234e-07
gene O 0 6.8149588194899025e-09
mutation O 0 5.958960436203142e-09
in O 0 1.3242525132017846e-10
humans O 0 3.48095108293478e-10
and O 0 1.3263608267255478e-10
tightens O 0 5.773574063283604e-09
the O 0 8.365607651050766e-10
clinical O 0 1.3877419213770281e-09
similarity O 0 1.5910181616618502e-08
between O 0 1.352037326540767e-08
piebaldism B-Disease 0 2.1975070012558717e-06
and O 0 5.745437459125924e-10
the O 0 4.861259728095035e-10
various O 0 1.2199585786021316e-10
forms O 0 3.833118267237978e-09
of O 0 4.786801355294301e-08
Waardenburg B-Disease 1 0.9989774227142334
syndrome I-Disease 0 0.031072508543729782
. O 0 5.955271120683392e-08
. O 0 4.171978389422293e-07

Cycloheximide O 0 1.6780417354311794e-05
facilitates O 0 7.912976229818014e-08
the O 0 2.321752790024334e-09
identification O 0 1.6714837514086867e-08
of O 0 1.5468835101728473e-07
aberrant O 0 5.735632271353097e-07
transcripts O 0 8.233107706701048e-08
resulting O 0 5.708642447643797e-08
from O 0 2.0612175077872052e-08
a O 0 4.046580404093447e-09
novel O 0 1.8410675650670782e-08
splice O 0 4.1503110992380243e-07
- O 0 3.11546664022444e-08
site O 0 3.70494781520847e-08
mutation O 0 4.522456187316948e-09
in O 0 1.5163131861228862e-09
COL17A1 O 1 0.6358429193496704
in O 0 1.1494387663901762e-09
a O 0 2.355141859311516e-09
patient O 0 8.542984097914541e-09
with O 0 9.742849860217007e-10
generalized O 1 0.9999964237213135
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999872446060181
. O 0 6.1015716710244305e-06

Patients O 0 9.197806605243386e-08
with O 0 3.3415712419326837e-09
generalized O 1 0.9999887943267822
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 0 0.007803795393556356
often O 0 1.8617526409414609e-09
show O 0 1.1753690243310189e-09
decreased O 0 7.332750850963521e-09
expression O 0 3.08391800984964e-09
of O 0 5.312822626279967e-09
type O 0 9.683001422899906e-08
XVII O 0 5.746337137679802e-06
collagen O 0 1.292941647079715e-07
, O 0 1.421204842699808e-08
a O 0 5.685800985588685e-08
transmembrane O 0 2.009167729966066e-07
hemidesmosomal O 0 3.009029683198605e-07
protein O 0 4.1696232244703424e-08
encoded O 0 2.1484789503034563e-09
by O 0 2.759013639774821e-08
COL17A1 O 0 0.0013169326120987535
. O 0 1.3009644135308918e-06

This O 0 5.8839926708742496e-08
report O 0 4.096195382885526e-08
documents O 0 6.413430497786976e-08
a O 0 2.3478456512293633e-08
novel O 0 6.683466580170716e-08
splice O 0 1.9582164441089844e-06
- O 0 3.910078660851468e-08
site O 0 5.1690872027165824e-08
mutation O 0 3.3215863393110112e-09
in O 0 1.303769869842597e-09
COL17A1 O 1 0.9975904226303101
in O 0 4.68563299271807e-10
a O 0 1.184908504647808e-09
patient O 0 7.794752399092886e-09
with O 0 8.962020570102425e-10
generalized O 1 0.9999996423721313
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.6785415410995483
, O 0 7.929471301793e-09
and O 0 3.3148883638034476e-10
applies O 0 1.2755961620314338e-08
a O 0 1.3540599752559501e-09
new O 0 1.569012253455071e-09
methodology O 0 1.6455218299071817e-09
to O 0 7.685147657143787e-11
define O 0 4.553685872821234e-09
and O 0 2.4950330690387545e-09
characterize O 0 8.882166468993091e-08
the O 0 3.304148066263224e-08
resulting O 0 4.8407883923573536e-08
mRNA O 0 4.951201049152587e-07
splice O 0 2.623701902848552e-06
variants O 0 5.883117069060972e-07
. O 0 1.5469100844711647e-06

Mutational O 0 6.352309719659388e-05
analysis O 0 3.1487181217926263e-07
of O 0 5.611461233456794e-07
COL17A1 O 1 0.9993879795074463
identified O 0 3.198974525275844e-07
a O 0 6.060253809891947e-08
maternally O 0 7.707735107942426e-07
inherited O 0 2.329253021571276e-07
G O 0 3.6819616866523575e-07
- O 0 5.0634646697744756e-08
to O 0 9.632508124468586e-09
- O 0 3.067967782044434e-07
T O 0 1.4292845662566833e-07
transversion O 0 1.9752378932480497e-07
at O 0 1.044498532110083e-08
the O 0 1.7765103832445561e-09
- O 0 3.617697530433617e-10
1 O 0 2.3704282980929747e-09
position O 0 1.516759340347562e-08
of O 0 1.490521128744149e-08
exon O 0 4.378178886099704e-08
32 O 0 1.7642657894612057e-06
. O 0 8.531245043741364e-07

This O 0 5.109703238304064e-08
acceptor O 0 3.70471155974883e-07
splice O 0 1.051293747877935e-05
- O 0 2.6875815706262074e-07
site O 0 7.670588075825435e-08
mutation O 0 1.6532671898161766e-09
led O 0 6.131298802003471e-10
to O 0 1.5739812231352346e-10
the O 0 6.1952043495239195e-09
formation O 0 4.0175123672270274e-08
of O 0 1.2715351260794705e-07
aberrant O 0 3.320650989735441e-07
transcripts O 0 6.924882711700775e-08
present O 0 1.467595183157755e-07
at O 0 2.4232583655248163e-06
extremely O 0 8.154790407388646e-07
low O 0 1.5587807865813375e-05
levels O 0 5.273532224236988e-07
. O 0 2.5577622864148e-07

Based O 0 4.536549340627971e-07
on O 0 1.8515586930334393e-07
our O 0 1.402468274847024e-08
recent O 0 2.002369825504502e-09
finding O 0 2.674978238914605e-09
that O 0 5.844748574013181e-10
cycloheximide O 0 1.570678591633623e-06
stabilized O 0 1.561250655868207e-06
mutant O 0 2.897776880672609e-07
COL17A1 O 0 1.256213363376446e-05
transcripts O 0 1.6453846285457985e-08
in O 0 1.1179952519313474e-09
keratinocytes O 0 9.854114324525654e-08
homozygous O 0 1.1194163374028676e-09
for O 0 2.960313938427106e-10
a O 0 7.549603608936195e-09
frameshift O 0 1.3734199910686584e-06
mutation O 0 1.2862777509781154e-08
, O 0 3.112541335781316e-10
the O 0 1.8127688239388817e-09
effects O 0 1.3959196110135963e-07
of O 0 6.828479399700882e-07
the O 0 5.249607397672662e-07
splice O 0 1.8312302927370183e-06
- O 0 1.670655649377295e-07
site O 0 1.601171817355862e-07
mutation O 0 2.871874960064247e-09
on O 0 4.626966809695432e-09
splicing O 0 5.446632300731835e-08
of O 0 2.3817875671738875e-07
COL17A1 O 0 8.981319115264341e-05
transcripts O 0 1.769771671433773e-07
were O 0 1.74905565586414e-08
determined O 0 4.32960467477983e-09
using O 0 4.2144340794969537e-10
reverse O 0 1.344120459378928e-08
transcriptase O 0 4.535517739157058e-09
polymerase O 0 1.4349128552026968e-09
chain O 0 5.048109930072542e-09
reaction O 0 5.6403024473183905e-09
of O 0 1.9771709602878218e-08
total O 0 8.033032017351616e-09
RNA O 0 1.9510450144366587e-08
from O 0 1.7716589084670886e-08
keratinocytes O 0 2.5517465473967604e-07
incubated O 0 1.2132863957958762e-07
for O 0 4.537247910718634e-09
2 O 0 4.6160388933458307e-07
. O 0 4.356628835466836e-07

5 O 0 7.40875350402348e-07
h O 0 2.8672518581629447e-08
in O 0 1.6588010964824207e-09
the O 0 3.6965182026449384e-09
presence O 0 1.8579923155570555e-09
or O 0 5.411928238885366e-09
absence O 0 1.3176461379771354e-06
of O 0 1.4716779617174325e-07
10 O 0 8.411406327013538e-08
microg O 0 5.3692233450419735e-06
cycloheximide O 0 3.9489696064265445e-06
per O 0 6.417358235921711e-07
ml O 0 9.392157380716526e-07
. O 0 4.889267870566982e-07

Using O 0 6.045485445582699e-09
this O 0 2.481469252302304e-09
approach O 0 4.7855415630237985e-08
, O 0 2.174941116095397e-09
an O 0 1.7100255433888378e-08
abnormally O 0 1.9019968533484644e-07
spliced O 0 1.9984832988484413e-07
transcript O 0 4.801157160727598e-07
was O 0 6.724281575998248e-08
identified O 0 4.245125584390053e-09
that O 0 5.828314914024801e-11
contains O 0 1.2303595642304543e-10
an O 0 1.211213074281403e-10
extra O 0 5.115178280945543e-10
264 O 0 3.0862481459337232e-09
bases O 0 7.409147073644817e-09
upstream O 0 1.1446037717632862e-07
from O 0 8.44693381907291e-09
exon O 0 4.164327549460722e-09
32 O 0 2.3924409120468226e-08
, O 0 1.2237386104452241e-10
resulting O 0 6.840871202840049e-10
in O 0 1.893047663070746e-10
a O 0 5.381603607190755e-09
premature O 0 1.2480400073400233e-06
termination O 0 2.477711632309365e-06
codon O 0 3.3678375075396616e-06
27 O 0 5.830324425915023e-06
bp O 0 1.4942719417376793e-06
downstream O 0 1.1177226951986086e-05
from O 0 3.6451578466767387e-07
the O 0 1.205953594762832e-06
cryptic O 0 4.340614395914599e-06
splice O 0 9.654041605244856e-06
site O 0 3.615519062805106e-06
. O 0 7.491183282581915e-07

Three O 0 1.642270319734962e-07
other O 0 1.981225317138069e-08
splice O 0 2.673501171557291e-07
variants O 0 1.5568385691722142e-08
, O 0 2.9548985480687406e-10
including O 0 3.567482767530272e-11
one O 0 1.6294394999949446e-10
derived O 0 1.2619588707352136e-09
from O 0 4.582403345665398e-09
the O 0 1.3807881948935119e-08
skipping O 0 1.521435954998651e-08
of O 0 1.6723223694725675e-08
exon O 0 9.660585220672147e-09
32 O 0 2.9786602340209356e-07
, O 0 1.993776876929587e-08
were O 0 5.4710689312287286e-08
also O 0 1.6965820748282567e-08
identified O 0 1.9363315573173168e-07
. O 0 5.237656068857177e-07

These O 0 1.3792404551793425e-08
results O 0 3.066651288463618e-08
indicate O 0 4.028193245630973e-08
the O 0 2.9791378253207768e-09
usefulness O 0 5.521599177882308e-08
of O 0 3.748604981979042e-09
cycloheximide O 0 8.271086215927426e-08
treatment O 0 1.1632719232324007e-09
in O 0 9.53947060233773e-11
evaluating O 0 3.2222668977510693e-09
the O 0 8.473624468763319e-09
abnormal O 0 4.2333144989470384e-08
processing O 0 7.075121288835362e-08
of O 0 9.256183375327964e-08
mRNA O 0 2.292918424018353e-07
due O 0 1.132182916308011e-07
to O 0 2.2801373233960476e-08
splice O 0 2.9272459869389422e-06
- O 0 2.3880375010776334e-07
site O 0 7.69946382206399e-08
mutations O 0 1.6475796726922454e-08
, O 0 1.175821995325066e-09
because O 0 9.211006180009917e-09
( O 0 1.7243284133883208e-08
i O 0 1.7129772800217324e-07
) O 0 2.3841126850498995e-09
aberrant O 0 1.2774636459766953e-08
splicing O 0 4.804351583231892e-09
often O 0 4.472341386119183e-10
generates O 0 1.613454481130816e-09
a O 0 8.506946813646721e-10
premature O 0 2.320391274679423e-07
termination O 0 2.3759841383252933e-07
codon O 0 2.3346149191638688e-07
, O 0 7.3641888143072265e-09
( O 0 8.773304860376641e-10
ii O 0 6.427941912079405e-08
) O 0 6.644174099790234e-10
transcripts O 0 7.220375408678592e-09
with O 0 3.880719356974538e-10
premature O 0 4.604739274327585e-07
termination O 0 1.3464764947457297e-07
codons O 0 4.222782479246234e-08
can O 0 1.1511414044207413e-09
occur O 0 1.1035890423727324e-08
at O 0 5.223518684260853e-08
low O 0 8.567142799620342e-07
or O 0 1.8440722726609238e-08
undetectable O 0 2.384303456892667e-07
levels O 0 2.715077496162621e-09
due O 0 1.8940309320925053e-09
to O 0 9.819265400778932e-10
nonsense O 0 5.216161369503425e-08
- O 0 2.945538035703521e-08
mediated O 0 9.052703831002873e-08
mRNA O 0 1.7285566755731452e-08
decay O 0 3.3474989891146834e-08
, O 0 4.934198050143834e-10
and O 0 5.872528574535352e-10
( O 0 2.2649208897274065e-10
iii O 0 1.6799631907815638e-08
) O 0 1.0761709301476685e-09
the O 0 5.675225978052367e-08
levels O 0 2.2835100921270168e-08
of O 0 1.3512922336644806e-08
these O 0 1.2610638089327608e-09
transcripts O 0 3.967116857239716e-09
can O 0 2.9079719188196407e-10
be O 0 7.291798276298778e-10
increased O 0 4.570741563014735e-09
by O 0 3.4422624750618525e-09
cycloheximide O 0 1.8873099179472774e-05
. O 0 1.117799570238276e-06

A O 0 1.2428413356246892e-06
deletion O 0 1.57568351255577e-07
mutation O 0 5.429942717682934e-08
in O 0 2.897354578479394e-09
COL17A1 O 0 0.00013822731852997094
in O 0 3.1554239776632187e-10
five O 0 4.1903877590065974e-10
Austrian O 0 3.058122999277657e-08
families O 0 1.0218017543195401e-09
with O 0 1.2710266172888396e-10
generalized O 0 0.1330922394990921
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9945716261863708
represents O 0 3.920765578868668e-08
propagation O 0 1.9107562820863677e-07
of O 0 1.1786922549106293e-08
an O 0 6.5214114108869126e-09
ancestral O 0 8.160150173353031e-07
allele O 0 1.8848368199542165e-06
. O 0 6.744048732798547e-07

Patients O 0 2.865420256625839e-08
with O 0 1.2115047853811234e-09
generalized O 1 0.9999992847442627
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999994039535522
, O 0 7.337199736667799e-09
a O 0 1.4018657346070995e-09
usually O 0 3.8300176918859563e-10
nonlethal O 0 1.148701258557594e-07
form O 0 7.753235387042423e-09
of O 0 2.9906459531048313e-07
junctional B-Disease 1 0.9999983310699463
epidermolysis I-Disease 1 0.9999992847442627
bullosa I-Disease 1 0.9991244673728943
, O 0 8.427176112490997e-08
have O 0 3.805683324031861e-09
generalized O 0 9.358806778436701e-07
blistering B-Disease 0 2.694418071769178e-06
, O 0 2.1586464171718944e-08
nail B-Disease 0 0.00022330752108246088
dystrophy I-Disease 1 0.999915599822998
, O 0 1.7143220247817226e-06
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 1.5583350432279985e-06
and O 0 0.055424630641937256
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 1 0.9887425899505615

Skin B-Disease 1 0.9992585778236389
fragility I-Disease 0 6.314694473985583e-05
in O 0 1.4853692720251388e-09
most O 0 1.1534770361087965e-10
cases O 0 6.99663244008164e-11
is O 0 4.1842419286342025e-12
due O 0 9.488732022333579e-11
to O 0 9.423262170571434e-11
mutations O 0 4.913407902762401e-09
in O 0 2.294133633062856e-10
the O 0 7.735121987373361e-10
gene O 0 1.5089504090681771e-09
encoding O 0 3.3351863493180645e-08
type O 0 1.3063787491773837e-06
XVII O 0 0.00013529146963264793
collagen O 0 2.7153485007147538e-06
( O 0 8.10897233805008e-07
COL17A1 O 1 0.9835147857666016
) O 0 4.32767457425598e-08
. O 0 3.841867339815508e-07

Recently O 0 2.7597614007390803e-06
, O 0 1.7613318803455513e-08
we O 0 2.3204778099028545e-09
reported O 0 6.9191634644028e-09
five O 0 3.940606729813112e-10
Austrian O 0 4.301062261902189e-08
families O 0 3.3850580116734363e-09
with O 0 6.439409561131981e-10
generalized O 1 0.9993706345558167
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999991655349731
who O 0 1.477470448207896e-07
share O 0 7.329115092602478e-09
the O 0 2.178981217682008e-09
same O 0 5.211792775128288e-09
COL17A1 O 0 6.697966455249116e-05
mutation O 0 2.1607641542686906e-07
. O 0 1.4882434129503963e-07

Affected O 0 1.4326171537959453e-07
individuals O 0 7.632707799132277e-10
in O 0 1.4174330598137885e-09
three O 0 5.965689608977698e-10
families O 0 4.659777563809087e-10
are O 0 2.2892632234317034e-11
homozygous O 0 2.6595622926173235e-10
for O 0 6.948162045716799e-10
4003delTC O 0 5.780342604566613e-08
, O 0 7.494449505429657e-10
whereas O 0 1.9879773383024713e-09
those O 0 1.2604122190396083e-09
in O 0 3.751165156273828e-09
two O 0 6.601027724428832e-09
others O 0 1.316045228350049e-08
are O 0 1.3121019826201064e-09
compound O 0 2.884625018850784e-07
heterozygotes O 0 5.931164196226746e-06
. O 0 1.5242845847751596e-06

To O 0 2.231896889526297e-09
determine O 0 1.049160758270773e-08
if O 0 1.9472521373131713e-09
the O 0 1.3850287583494492e-09
occurrence O 0 3.3815748423648984e-08
of O 0 1.7931093276857268e-09
4003delTC O 0 6.086387571713203e-08
in O 0 1.6608264763462444e-10
these O 0 1.3803602705309004e-10
unrelated O 0 3.186403141341998e-09
families O 0 2.9098862208698506e-10
signifies O 0 1.783181047265714e-09
propagation O 0 1.123656723223121e-08
of O 0 2.318646386001433e-09
an O 0 4.560917865603642e-09
ancestral O 0 6.719191105730715e-07
allele O 0 2.1329650223833596e-07
or O 0 1.18408669536052e-08
a O 0 2.5414896853703794e-08
mutational O 0 1.777987381501589e-05
hot O 0 7.799791092111263e-06
spot O 0 1.2163941391918343e-06
, O 0 2.8796089956983906e-09
haplotypes O 0 5.943117997730951e-08
were O 0 3.3971661039799983e-09
determined O 0 3.909450096983846e-09
for O 0 1.1432467195149343e-09
polymorphisms O 0 9.678164758497587e-08
both O 0 6.035106991930661e-08
within O 0 2.7011100200979854e-07
and O 0 2.4070840254353243e-07
flanking O 0 0.0001632481871638447
COL17A1 O 1 0.9999924898147583
. O 0 6.278587534325197e-06

Five O 0 1.938609329954488e-06
intragenic O 0 4.0917793739936315e-06
polymorphisms O 0 2.0482576701397193e-07
were O 0 1.0272660944110612e-08
chosen O 0 7.129738577305034e-09
based O 0 9.665781952605812e-09
on O 0 2.0742241702009778e-08
their O 0 1.4830175310009963e-08
informativeness O 0 4.7377427108585835e-05
. O 0 1.2665914255194366e-06

One O 0 1.6877714870133786e-07
of O 0 8.379348770404249e-08
these O 0 2.7238433730758516e-09
, O 0 3.4516886571189787e-10
not O 0 1.658389120473558e-10
previously O 0 2.2358763729357634e-09
reported O 0 4.247757701136834e-09
, O 0 1.6226535393126795e-10
was O 0 8.020646369288897e-09
2988 O 0 7.31649208773888e-07
A O 0 1.374177259094722e-06
or O 0 3.4621891131791926e-08
C O 0 6.232972282305127e-06
that O 0 7.729576978476871e-10
introduces O 0 3.896816647142032e-09
a O 0 2.0850203785727217e-09
new O 0 3.624938127444466e-09
restriction O 0 2.9520565547613842e-08
site O 0 6.428567189686873e-08
for O 0 1.0083696544427312e-08
Eco0109 O 0 1.4582671610696707e-05
I O 0 4.801995964953676e-05
. O 0 3.4932172638946213e-06

All O 0 1.6682063730399932e-08
the O 0 2.6383593976220254e-08
4003delTC O 0 2.6049332291222527e-07
alleles O 0 1.3072192217578049e-08
showed O 0 6.611611702567188e-09
the O 0 6.702852717310748e-10
same O 0 1.7017559583720754e-10
haplotype O 0 7.878095509283867e-09
for O 0 3.2872354838175966e-10
these O 0 1.5038532641398206e-09
five O 0 6.140922437225527e-09
polymorphic O 0 1.1910852748542311e-07
markers O 0 2.8122772164351773e-06
. O 0 2.070159325739951e-06

Fourteen O 0 2.119954842783045e-06
microsatellite O 0 3.2609113986836746e-07
polymorphisms O 0 7.248790012681638e-08
were O 0 2.0334292027968104e-09
selected O 0 1.17351428574608e-09
based O 0 1.047426700928611e-09
on O 0 2.5960971150595924e-09
their O 0 6.74859779170589e-10
high O 0 2.4698363176867133e-07
heterozygosity O 0 3.947561253880849e-06
and O 0 1.270572091982558e-08
their O 0 8.092871262022072e-09
location O 0 3.950148766307393e-06
within O 0 3.527970804384495e-08
10q23 O 0 2.70584610007063e-06
- O 0 6.808153329984634e-07
q25 O 0 1.01992700365372e-05
near O 0 7.887321771704592e-06
COL17A1 O 0 0.002052799565717578
. O 0 2.1177118014747975e-06

Three O 0 2.1398999905386518e-08
families O 0 2.621943773206681e-09
shared O 0 2.8179292232977105e-09
microsatellite O 0 1.1151765022532345e-07
polymorphisms O 0 1.1635393093456514e-07
covering O 0 9.029878356159315e-07
at O 0 6.871477467029763e-07
most O 0 1.8413238933590037e-08
19 O 0 7.488311837278161e-08
cM O 0 4.4247880026659914e-08
, O 0 3.7821995535480823e-10
whereas O 0 3.280109739378645e-09
the O 0 2.057933556898206e-08
others O 0 5.577845740845078e-09
shared O 0 9.082807839178031e-10
smaller O 0 1.7925178008582066e-09
regions O 0 1.5514486362278035e-09
consistent O 0 6.398911622795822e-09
with O 0 1.0193544619507833e-10
cross O 0 1.6236860744811565e-08
- O 0 1.8797692291627754e-08
over O 0 4.245846341177639e-09
events O 0 1.9105068638225475e-09
during O 0 2.2269641686278874e-09
passage O 0 8.238648874225873e-09
of O 0 1.419432460458836e-09
this O 0 1.8318009609163965e-10
mutation O 0 1.0695265784121943e-09
through O 0 6.762952975414294e-10
several O 0 4.1225058922123026e-09
generations O 0 1.8450121785917872e-07
. O 0 4.78307754292473e-07

These O 0 3.832820283378169e-08
results O 0 7.219620812293215e-08
indicate O 0 2.7125063084554313e-08
that O 0 2.2547874678480184e-10
4003delTC O 0 3.177301621803963e-08
occurs O 0 1.6881884778996437e-09
on O 0 9.941039103011917e-10
a O 0 5.953867954211489e-10
single O 0 3.2968756613627193e-09
ancestral O 0 1.904143829278837e-07
allele O 0 1.064675245743274e-07
. O 0 7.26020559227436e-08
. O 0 3.3885874017869355e-07

The O 0 2.776498604362132e-06
haptoglobin O 0 5.1586146582849324e-05
- O 0 4.3221231749157596e-07
gene O 0 2.1687409201831542e-08
deletion O 0 4.3949707873025545e-08
responsible O 0 9.519867560925377e-09
for O 0 5.173996342477949e-09
anhaptoglobinemia B-Disease 0 2.7225958547205664e-05
. O 0 1.0362989542045398e-06

We O 0 4.85566715724417e-08
have O 0 8.348455815543332e-10
found O 0 3.085599276086981e-10
an O 0 1.4484824450988754e-10
allelic O 0 2.1112693815439343e-08
deletion O 0 6.348049197413275e-09
of O 0 5.723764573417611e-08
the O 0 5.648239493893925e-07
haptoglobin O 0 2.8665070203715004e-05
( O 0 2.4343844273744253e-08
Hp O 0 1.8088806896798815e-08
) O 0 3.852677551985373e-11
gene O 0 2.625325512539689e-10
from O 0 2.0808100131830543e-08
an O 0 4.781823270683105e-10
individual O 0 1.9765204750665788e-10
with O 0 9.996444783055836e-10
anhaptoglobinemia B-Disease 0 1.6852005501277745e-05
. O 0 8.678047151988721e-07

The O 0 6.433805310734897e-07
Hp O 0 5.4320768327897895e-08
gene O 0 3.6896432575872495e-09
cluster O 0 1.3331339587807634e-08
consists O 0 2.128301146431255e-10
of O 0 2.238563778789171e-10
coding O 0 2.2375785668771186e-09
regions O 0 6.6054859360065166e-09
of O 0 1.438570052414434e-06
the O 0 2.9827955927430594e-07
alpha O 0 3.0289744046285705e-09
chain O 0 1.4444524465417885e-09
and O 0 5.990155593771362e-11
beta O 0 5.757745946688431e-10
chain O 0 1.2158661855110608e-09
of O 0 4.076995629986868e-09
the O 0 2.5263430458721814e-08
haptoglobin O 0 2.6712788780969277e-07
gene O 0 3.4951301852714778e-09
( O 0 1.3190123437922807e-09
Hp O 0 4.62687610447432e-10
) O 0 1.1158589243581707e-12
and O 0 5.521872022129504e-12
of O 0 4.699237110550314e-10
the O 0 2.649831687406845e-09
alpha O 0 8.074826918225142e-10
chain O 0 9.217556717899811e-10
and O 0 2.889362360480874e-10
beta O 0 6.211271497136295e-09
chain O 0 1.0181021359301212e-08
of O 0 2.3225780410029984e-08
the O 0 1.2223243572861975e-07
haptoglobin O 0 2.8468630262068473e-06
- O 0 9.637142284191214e-08
related O 0 3.2940107530521345e-08
gene O 0 2.475202443008584e-08
( O 0 1.0064750810556689e-08
Hpr O 0 8.077622482005609e-08
) O 0 9.59338858352865e-11
, O 0 5.0324737432827504e-11
in O 0 2.2980489733370746e-10
tandem O 0 1.4294040617812698e-08
from O 0 2.9995689487805066e-08
the O 0 2.1449470466450293e-07
5 O 0 2.0951476642494526e-07
side O 0 9.397596159033128e-07
. O 0 1.5981952401489252e-06

Southern O 0 2.651006298037828e-06
blot O 0 5.111276095703943e-06
and O 0 6.410590280836459e-09
PCR O 0 6.309448252750371e-08
analyses O 0 1.5303651679232644e-08
have O 0 1.3576798019165892e-10
indicated O 0 1.3042225077697367e-09
that O 0 2.1956542486933905e-11
the O 0 1.4530038283666613e-10
individual O 0 5.61656103570396e-11
with O 0 6.706596389349784e-11
anhaptoglobinemia B-Disease 0 3.0023795716260793e-07
was O 0 1.8992438732823302e-09
homozygous O 0 1.5696820232502517e-10
for O 0 1.28837079893529e-10
the O 0 1.5228868166516918e-09
gene O 0 1.2021135198381216e-09
deletion O 0 2.4656077179940894e-09
and O 0 3.542038606862974e-10
that O 0 1.4994445962646097e-10
the O 0 1.8602263063272062e-09
gene O 0 8.36193836395438e-10
deletion O 0 4.15556788979643e-09
was O 0 1.0813131723352853e-08
included O 0 2.6218524573629054e-10
at O 0 2.3180670716271834e-09
least O 0 4.37814895448696e-10
from O 0 1.3443582913552632e-09
the O 0 2.402898546804977e-09
promoter O 0 5.421839333052958e-08
region O 0 2.2849393488399983e-08
of O 0 2.360751238938974e-08
Hp O 0 7.215763542234299e-09
to O 0 2.7108446598589353e-09
Hpr O 0 1.8573524585008272e-07
alpha O 0 2.273617516479476e-09
but O 0 6.023797571863554e-10
not O 0 3.9086803238497225e-10
to O 0 6.449984990553048e-09
Hpr O 0 1.936447461048374e-06
beta O 0 5.235119147073419e-07
( O 0 8.157234532291113e-08
Hpdel O 0 2.7236894766247133e-06
) O 0 2.106655472289276e-08
. O 0 2.546036341755098e-07

In O 0 3.1859308080584015e-08
addition O 0 2.004181887116374e-08
, O 0 1.6088448351325724e-09
we O 0 2.6834343080928136e-10
found O 0 2.848589975013027e-10
seven O 0 2.2863580473320155e-10
individuals O 0 5.944537917468296e-11
with O 0 1.356597889579092e-10
hypohaptoglobinemia B-Disease 0 1.7619879599806154e-07
in O 0 2.6526467133969334e-10
three O 0 1.5339346459697367e-10
families O 0 3.586731467386528e-10
, O 0 3.619421082290408e-11
and O 0 3.586763872021059e-11
the O 0 1.923377013213212e-09
genotypes O 0 4.3540531180497055e-08
of O 0 3.1233081898562887e-08
six O 0 1.0259149973990134e-08
of O 0 4.5305398543860065e-08
the O 0 2.7389841505964796e-08
seven O 0 1.987234377054392e-09
individuals O 0 1.683168743271679e-10
were O 0 1.3826381817239053e-08
found O 0 4.538182718505368e-09
to O 0 4.9224313514173446e-09
be O 0 8.330140133239183e-08
Hp2 O 0 0.00012044641334796324
/ O 0 3.221027145627886e-05
Hpdel O 0 8.842838724376634e-05
. O 0 2.5471347271377454e-06

The O 0 2.060876198584083e-07
phenotypes O 0 2.2940491817280417e-07
and O 0 1.9470589585068865e-09
genotypes O 0 3.8965215054531654e-08
in O 0 8.248204341754217e-10
one O 0 5.196999497414367e-10
of O 0 4.761191441104984e-10
these O 0 5.459969282251009e-11
three O 0 1.6206151698394677e-10
families O 0 1.193350196437848e-09
showed O 0 2.899523288135697e-08
the O 0 1.2026049489577417e-08
father O 0 2.2517811615330174e-08
to O 0 5.080062148721254e-09
be O 0 3.807492987562e-08
hypohaptoglobinemic B-Disease 0 2.4482022126903757e-05
( O 0 2.0168748449123086e-08
Hp2 O 0 1.4865668163110968e-06
) O 0 1.1047721626411544e-09
and O 0 8.372428084157946e-09
Hp2 O 0 2.5888527943607187e-06
/ O 0 1.1044402015158994e-07
Hpdel O 0 1.603630494173558e-06
, O 0 4.658598395934632e-09
the O 0 9.69355369306868e-08
mother O 0 6.63974297765435e-09
to O 0 1.960631434982929e-09
be O 0 8.31128321721053e-09
Hp2 O 0 1.136017431235814e-06
- O 0 5.117252754871515e-08
1 O 0 9.762167252347353e-08
and O 0 1.4876836651467329e-08
Hp1 O 0 8.270864100268227e-07
/ O 0 1.5867453129203568e-08
Hp2 O 0 5.366333866163586e-08
, O 0 1.422727630151499e-10
one O 0 3.473046017443693e-10
of O 0 2.1099599845086914e-09
the O 0 7.1328667416992175e-09
two O 0 9.357855601521692e-10
children O 0 1.3161676193362837e-09
to O 0 1.3392089659447493e-09
be O 0 2.6435328592810947e-08
hypohaptoglobinemic B-Disease 0 2.070046502922196e-05
( O 0 1.763335255589027e-08
Hp2 O 0 2.1963167000649264e-06
) O 0 1.9066264123068777e-09
and O 0 1.0261693716984155e-08
Hp2 O 0 2.8427473353076493e-06
/ O 0 1.4104547574333992e-07
Hpdel O 0 1.106001832340553e-06
, O 0 1.6982550921085249e-09
and O 0 1.0976601849677081e-09
the O 0 8.638905590885315e-09
other O 0 1.996946163984603e-09
child O 0 3.3241911445713868e-09
to O 0 1.26878907380501e-09
be O 0 1.0057612520597559e-08
Hp1 O 0 3.7382076243375195e-06
and O 0 3.622078637022241e-08
Hp1 O 0 3.470676165306941e-05
/ O 0 1.2862749372288818e-06
Hpdel O 0 6.563869192177663e-06
, O 0 3.3185088010867503e-09
showing O 0 1.247307235274775e-08
an O 0 9.277597023960027e-10
anomalous O 0 7.88732734235964e-07
inheritance O 0 3.054154262827069e-07
of O 0 2.53939731464925e-07
Hp O 0 7.519843592262987e-08
phenotypes O 0 1.6824169790652377e-07
in O 0 2.9461884043513464e-09
the O 0 4.7161226035541404e-08
child O 0 1.3940406162760155e-08
with O 0 3.861678976591065e-09
Hp1 O 0 3.3873464417411014e-05
. O 0 1.1598251603572862e-06

The O 0 2.0880115698673762e-06
Hp2 O 0 2.655883872648701e-05
/ O 0 2.819593021285982e-07
Hpdel O 0 3.3269810728597804e-07
individuals O 0 1.2555534389946388e-09
had O 0 3.375515644776783e-09
an O 0 2.1745127920524965e-10
extremely O 0 9.593741356894725e-10
low O 0 3.795290481889424e-08
level O 0 2.520558268770401e-07
of O 0 1.4198657254382852e-06
Hp O 0 9.446795701251176e-08
( O 0 2.038959667771678e-09
mean O 0 2.9298041326342172e-08
+ O 0 1.1321414028486743e-08
/ O 0 4.756546267969952e-09
- O 0 4.804113551415412e-09
SD O 0 1.784764158685448e-08
= O 0 8.559358555260133e-09
0 O 0 4.623728955266415e-09
. O 0 1.053352849389455e-09
049 O 0 4.0975084658612104e-08
+ O 0 6.236842597928671e-09
/ O 0 3.613768173593712e-09
- O 0 3.839476736544611e-09
0 O 0 2.5334445652447357e-09
. O 0 6.482454573131236e-10
043 O 0 4.674550524441656e-08
mg O 0 2.2896248452752843e-08
/ O 0 1.7062291579605926e-09
ml O 0 4.4019965450559084e-10
; O 0 2.6169263978026436e-10
n O 0 2.0458147675928018e-10
= O 0 7.716996486273331e-10
6 O 0 1.4718436469607354e-09
) O 0 2.1878399699554185e-12
, O 0 1.854994022970624e-12
compared O 0 8.757412330029357e-12
with O 0 2.990194680405067e-12
the O 0 8.020580866130445e-10
level O 0 3.083864941189063e-09
( O 0 2.6216712828430744e-11
1 O 0 1.1290269830155353e-09
. O 0 3.577746710003993e-10
64 O 0 2.8986537614628105e-09
+ O 0 1.6335260921707118e-09
/ O 0 1.8048167405027016e-09
- O 0 3.273360027478134e-09
1 O 0 3.2032461128039813e-09
. O 0 1.2169426577557374e-09
07 O 0 1.5279500331644158e-08
mg O 0 2.653975350597193e-08
/ O 0 1.4769450107365856e-09
ml O 0 3.085075250819358e-10
) O 0 5.383464073832611e-12
obtained O 0 3.144753069062034e-10
from O 0 1.449472541992236e-09
52 O 0 1.6397295965475678e-08
healthy O 0 8.80007355874568e-09
volunteers O 0 3.078017840607572e-09
having O 0 4.5712296170563604e-09
phenotype O 0 1.4873013753913256e-07
Hp2 O 0 7.321963835238421e-07
, O 0 7.625170495018097e-10
whereas O 0 2.189592285262165e-09
the O 0 4.619673976691274e-09
serum O 0 1.4352393939986996e-08
Hp O 0 3.3084472939037823e-09
level O 0 1.3680739208155046e-08
of O 0 3.4827127848302553e-09
an O 0 6.635713645231078e-10
individual O 0 4.4295797585469643e-10
with O 0 1.2153003048354094e-09
Hp1 O 0 1.4578306036128197e-05
/ O 0 7.928126137812797e-07
Hpdel O 0 1.5032225064715021e-06
was O 0 2.194167763036603e-07
0 O 0 2.915200809638918e-07
. O 0 3.2203612931880343e-07

50 O 0 1.2928741170981084e-06
mg O 0 2.1991254470776767e-06
/ O 0 1.9246551019591607e-08
ml O 0 4.166059497379138e-09
, O 0 5.31961107108625e-11
which O 0 9.265315077666703e-12
was O 0 2.239187169017498e-10
approximately O 0 7.574244703656419e-11
half O 0 3.4011191085703274e-10
the O 0 2.0459758331980993e-09
level O 0 2.603541560119993e-08
of O 0 2.0089430563530186e-08
Hp O 0 4.1151757557145174e-09
in O 0 8.01862354293803e-10
control O 0 4.8402406527259245e-09
sera O 0 1.1730185178748798e-07
from O 0 4.527753727501249e-10
the O 0 1.251453696227145e-08
Hp1 O 0 5.188887826079736e-07
phenotype O 0 1.2895079670727227e-08
( O 0 1.8871858242786033e-10
1 O 0 6.954065323583336e-09
. O 0 2.0908026421295745e-09
26 O 0 3.7596546320628477e-08
+ O 0 5.72578162660875e-09
/ O 0 3.732423703439736e-09
- O 0 4.067349124170505e-09
0 O 0 1.8610603058633046e-09
. O 0 3.971255546630914e-10
33 O 0 4.507557882504898e-09
mg O 0 7.603854434989898e-09
/ O 0 7.534408652531965e-10
ml O 0 4.219123106441458e-10
; O 0 3.238148638118332e-10
n O 0 5.644238965096804e-10
= O 0 2.4345316873564116e-09
9 O 0 1.2156625928128051e-08
) O 0 4.3510247488276477e-11
, O 0 7.407796598357663e-11
showing O 0 9.40326594367491e-10
a O 0 1.4945655824050164e-09
gene O 0 1.4888807964297257e-09
- O 0 7.144784319734754e-08
dosage O 0 1.0478112244527438e-07
effect O 0 1.5280892284863512e-07
. O 0 1.7312993350060424e-07

The O 0 1.9447722365839581e-07
other O 0 2.0363488673069696e-08
allele O 0 2.916424364229897e-07
( O 0 4.614135296066024e-09
Hp2 O 0 1.3803251874833222e-07
) O 0 7.503313248502508e-11
of O 0 9.944944867612548e-10
individuals O 0 2.4825380640081107e-10
with O 0 3.859727648602984e-09
Hp2 O 0 2.9942817491246387e-05
/ O 0 2.853857949958183e-07
Hpdel O 0 8.473383559248759e-07
was O 0 1.6911574363120963e-08
found O 0 1.3741108251252854e-10
to O 0 5.638360958681865e-11
have O 0 1.2582856978582413e-10
, O 0 1.2520183501063542e-10
in O 0 4.450625146201759e-10
all O 0 3.6307918893641045e-09
exons O 0 7.530005063927092e-08
, O 0 9.120257438155477e-09
no O 0 1.0690805574142814e-08
mutation O 0 2.095146056646513e-09
, O 0 1.7277966557482927e-10
by O 0 1.6375338585117305e-10
DNA O 0 2.3481950606196733e-08
sequencing O 0 1.4664732361779897e-07
. O 0 6.050021852388454e-07

On O 0 1.43470614943908e-07
the O 0 3.2880898004350456e-09
basis O 0 1.3035393209293034e-08
of O 0 1.3859484671030486e-09
the O 0 2.6001902853067804e-09
present O 0 1.1803024113632432e-09
study O 0 2.7073554509371434e-10
, O 0 2.8078293162758783e-11
the O 0 3.504747880800352e-10
mechanism O 0 8.313406851812033e-09
of O 0 6.6938108389535955e-09
anhaptoglobinemia B-Disease 0 1.0748718750619446e-06
and O 0 1.5402621400539829e-09
the O 0 1.4230602474185616e-08
mechanism O 0 6.778920891292728e-08
of O 0 8.70965077837127e-09
anomalous O 0 3.6342280509416014e-06
inheritance O 0 2.207256557085202e-06
of O 0 1.1319901886963635e-06
Hp O 0 4.5547830040959525e-07
phenotypes O 0 1.0837928812179598e-06
were O 0 8.687671737561686e-08
well O 0 7.310550387273906e-08
explained O 0 7.077279633449507e-07
. O 0 5.538347522815457e-07

However O 0 4.780468998433207e-07
, O 0 5.087246623958208e-09
the O 0 8.938739526342943e-09
mechanism O 0 2.179439917426862e-07
of O 0 8.262809103598556e-08
hypohaptoglobinemia B-Disease 0 0.0005583058809861541
remains O 0 3.193463271600194e-05
unknown O 0 0.00022683739371132106

ATM O 0 7.903599907876924e-05
mutations O 0 1.6448564110760344e-06
and O 0 1.066937471705387e-08
phenotypes O 0 1.2389466519380221e-06
in O 0 3.6676695458481845e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 1.7428952787668095e-06
in O 0 1.619434863986413e-10
the O 0 9.013723656359218e-10
British O 0 1.5426428190412622e-10
Isles O 0 4.67489380540087e-10
: O 0 2.467703645592234e-11
expression O 0 3.40524719533164e-10
of O 0 1.7392377538172354e-09
mutant O 0 3.855974650690541e-09
ATM O 0 7.354394426783983e-08
and O 0 6.120584594704326e-10
the O 0 2.517035024851566e-09
risk O 0 1.8522326783454446e-08
of O 0 1.0062332300719845e-08
leukemia B-Disease 1 0.8781582117080688
, O 0 3.079549912854418e-07
lymphoma B-Disease 1 1.0
, O 1 0.5770062804222107
and O 1 0.9999849796295166
breast B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.294824525961303e-06

We O 0 1.539006078132843e-08
report O 0 4.906253181502507e-09
the O 0 6.755578318973221e-10
spectrum O 0 1.468541110938304e-08
of O 0 7.815281755085834e-09
59 O 0 8.422050257195224e-08
ATM O 0 2.217480869148858e-06
mutations O 0 6.749904457592493e-08
observed O 0 1.0469118016942502e-08
in O 0 5.695588445320254e-09
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.32517649368225e-11
patients O 0 6.64187663201865e-11
in O 0 4.307418310922628e-11
the O 0 1.96184335443661e-09
British O 0 5.351663556751873e-09
Isles O 0 2.2993934578607877e-07
. O 0 4.772333568325848e-07

Of O 0 9.015809155243915e-06
51 O 0 1.59786686708685e-05
ATM O 0 2.0951942133251578e-05
mutations O 0 1.6889435983102885e-07
identified O 0 1.8043701643932764e-08
in O 0 1.6357701304592354e-10
families O 0 2.2624295492601476e-10
native O 0 1.2445754149492672e-10
to O 0 4.7462735131009737e-11
the O 0 5.419220627800314e-09
British O 0 4.737351400052603e-09
Isles O 0 2.385141861793727e-08
, O 0 2.3063317922122906e-09
11 O 0 4.401715614221757e-08
were O 0 6.901070292997247e-08
founder O 0 5.800730491500872e-07
mutations O 0 2.657034769981692e-08
, O 0 1.3680809818339412e-09
and O 0 5.297884353439031e-10
2 O 0 1.5292155097768045e-08
of O 0 2.2875892291551736e-09
these O 0 6.598380175582008e-10
11 O 0 1.3509159124680536e-08
conferred O 0 7.902325016573286e-09
a O 0 9.252538735182725e-10
milder O 0 9.458027960818072e-08
clinical O 0 4.381434326461431e-09
phenotype O 0 2.605661464372133e-09
with O 0 2.7586306503013525e-11
respect O 0 1.3391912023763552e-09
to O 0 7.661357770416544e-09
both O 0 1.625679431072058e-07
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 9.069520245930107e-08
cellular O 0 2.6027578314824495e-07
features O 0 2.1449511677928967e-07
. O 0 5.482935989675752e-07

We O 0 8.662190964514593e-08
report O 0 3.803660675316678e-08
, O 0 1.7296893084495224e-10
in O 0 2.8162405740772556e-10
two O 0 1.3256033604136519e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
families O 0 5.9101552096763044e-08
, O 0 2.979596569474552e-10
an O 0 1.4354850641495887e-09
ATM O 0 4.1869967049024126e-07
mutation O 0 1.114202330398939e-08
( O 0 1.3983593172284259e-09
7271T O 0 7.406266888665414e-08
- O 0 1.9028380648933307e-08
- O 0 1.7893212245212453e-08
> O 0 2.3801143278490144e-09
G O 0 1.5706449474350848e-08
) O 0 7.695356851744606e-11
that O 0 1.2078673131132867e-11
may O 0 6.980117872590341e-11
be O 0 3.110593033150977e-11
associated O 0 4.0431219483494374e-10
with O 0 3.4047374294909893e-12
an O 0 4.7587829510309376e-11
increased O 0 5.749109521779872e-10
risk O 0 3.108771196025373e-08
of O 0 9.551754942549451e-08
breast B-Disease 0 0.00021341493993531913
cancer I-Disease 0 8.665386849315837e-05
in O 0 7.960198611378644e-10
both O 0 2.3618804689817807e-09
homozygotes O 0 3.021964545268929e-08
and O 0 8.975534759869674e-10
heterozygotes O 0 3.4435384321795937e-08
( O 0 6.331117297087019e-10
relative O 0 8.699759490582437e-08
risk O 0 1.999706711330873e-08
12 O 0 1.7167673505014136e-08
. O 0 2.672066568010223e-09
7 O 0 4.474615522553904e-08
; O 0 3.787400970622912e-08
P O 0 2.6086127036251128e-06
= O 0 9.5176197589808e-08
. O 0 1.7662502571624827e-08
0025 O 0 3.38141433076089e-07
) O 0 2.382147812340918e-10
, O 0 5.531625504873183e-11
although O 0 1.81765325013572e-10
there O 0 1.008709157868104e-10
is O 0 1.020684665259397e-11
a O 0 1.9090260622300903e-11
less O 0 4.6403628162217103e-10
severe O 0 1.0977541023748927e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 6.181512191005822e-09
in O 0 9.817906904130425e-12
terms O 0 8.018986169533449e-11
of O 0 6.74571232206489e-11
the O 0 2.8284713460280386e-10
degree O 0 3.642092494260396e-08
of O 0 5.764026411725354e-08
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
. O 0 6.26221435595653e-06

This O 0 6.519137940586006e-08
mutation O 0 1.0170039388412988e-07
( O 0 4.466035541383917e-09
7271T O 0 2.0339545869774156e-07
- O 0 9.22690190918729e-09
- O 0 5.819045245658572e-09
> O 0 6.369562099983739e-10
G O 0 4.089121485861824e-09
) O 0 8.353226964297189e-12
also O 0 7.202493267598198e-13
allows O 0 7.970609307121623e-13
expression O 0 6.774853594793129e-11
of O 0 1.1743404026987037e-09
full O 0 2.787432507034282e-09
- O 0 3.6419169902046633e-09
length O 0 3.6504850253749055e-09
ATM O 0 2.367813749515335e-07
protein O 0 1.2222625400681864e-07
at O 0 2.2399540000606066e-08
a O 0 1.7612604708006074e-09
level O 0 4.4901047324685806e-09
comparable O 0 1.1649955666825917e-08
with O 0 9.194303651760549e-11
that O 0 1.6123830048897503e-10
in O 0 1.090053269869884e-09
unaffected O 0 1.4362258582423237e-07
individuals O 0 2.22899987356584e-09
. O 0 2.2232397611787746e-07

In O 0 5.000227787377298e-08
addition O 0 1.6539239311441634e-08
, O 0 1.1754094364491152e-09
we O 0 3.29986843405905e-10
have O 0 9.961342167796872e-11
studied O 0 7.032093130021622e-09
18 O 0 3.553648468823667e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 8.232306214495111e-08
, O 0 1.5116805029968816e-10
in O 0 7.299560261797566e-11
15 O 0 2.5540451975558653e-09
families O 0 1.3545687904681358e-09
, O 0 4.72854755351193e-10
who O 0 1.5887189341867725e-09
developed O 0 4.1545082041238857e-08
leukemia B-Disease 1 0.9999747276306152
, O 0 2.432366272842046e-07
lymphoma B-Disease 1 1.0
, O 0 1.1501349916898107e-07
preleukemic O 0 0.47592392563819885
T O 0 0.015011502429842949
- O 0 4.2326977563789114e-05
cell O 0 0.00020810439309570938
proliferation O 0 0.00021722976816818118
, O 0 2.809439125783797e-09
or O 0 9.216527274702457e-08
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 8.489206493322854e-08
mostly O 0 2.422235745314083e-08
in O 0 2.5261583935787257e-09
childhood O 0 2.2086247554398142e-05
. O 0 8.247321261478646e-07

A O 0 1.2975535355508327e-05
wide O 0 1.0413891686766874e-06
variety O 0 1.234903521663e-07
of O 0 1.7004997232561436e-07
ATM O 0 7.585787443531444e-06
mutation O 0 1.6139539482651344e-08
types O 0 6.2394125421860736e-09
, O 0 4.05882244480793e-10
including O 0 8.181675337226579e-10
missense O 0 3.6317226204118924e-07
mutations O 0 1.6796722945855436e-07
and O 0 2.1005327255352313e-08
in O 0 1.9452633281957787e-08
- O 0 6.281111097905523e-08
frame O 0 3.4584675745463755e-07
deletions O 0 7.20098611850517e-08
, O 0 1.4316359653321342e-08
were O 0 3.966104600294784e-08
seen O 0 3.597443765102071e-08
in O 0 1.1236732655461878e-09
these O 0 5.826874982517438e-09
patients O 0 1.956709638761822e-08
. O 0 2.549571718191146e-07

We O 0 4.1079868395854646e-08
also O 0 2.8952720221298023e-09
show O 0 5.473171915681974e-10
that O 0 8.721889530050042e-12
25 O 0 4.996799640721861e-10
% O 0 1.227638130041342e-10
of O 0 4.787608642864427e-10
all O 0 2.92934618784102e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 6.238272476366546e-08
carried O 0 2.102236251744216e-08
in O 0 4.257109775807066e-09
- O 0 1.034018950463178e-07
frame O 0 1.0702473218771047e-06
deletions O 0 1.0565687489361153e-06
or O 0 4.396865449507459e-07
missense O 0 1.163920501312532e-06
mutations O 0 4.871753134239043e-08
, O 0 3.08309294760889e-10
many O 0 1.4311565821323313e-10
of O 0 1.7509808047933006e-09
which O 0 1.6191198382031757e-10
were O 0 4.382911811262602e-10
also O 0 8.841907067624888e-11
associated O 0 3.5247249563497007e-10
with O 0 6.181812700623013e-11
expression O 0 1.6008625536301224e-08
of O 0 4.7846381079352795e-08
mutant O 0 4.039827672386309e-07
ATM O 0 2.6172239813604392e-05
protein O 0 1.19233272926067e-05
. O 0 1.0419634008940193e-06

The O 0 7.778565418448125e-07
DMPK O 0 0.0007043241057544947
gene O 0 6.690749643212257e-08
of O 0 1.196599157538003e-07
severely O 0 0.00015824958973098546
affected O 0 7.861136509745847e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 8.939167628341238e-07
is O 0 1.883988520745561e-10
hypermethylated O 0 3.05947658318928e-08
proximal O 0 2.0106705278521986e-07
to O 0 4.817785725919066e-09
the O 0 6.02193097165582e-07
largely O 0 2.0024477009883412e-07
expanded O 0 7.828995762793056e-08
CTG O 0 1.8291939340997487e-05
repeat O 0 9.143441275227815e-07
. O 0 1.8453024495102e-06

Using O 0 5.0038341470326486e-08
methylation O 0 1.4930469660612289e-06
- O 0 1.8463020978742861e-06
sensitive O 0 2.6447034429111227e-07
restriction O 0 2.9513978816453346e-08
enzymes O 0 4.939247233437527e-09
, O 0 3.3611485816820164e-10
we O 0 5.532638583383154e-11
characterized O 0 2.0800700051282206e-10
the O 0 5.422940985155833e-10
methylation O 0 7.611573593635512e-09
pattern O 0 3.0622029356663916e-08
on O 0 3.459791342308449e-09
the O 0 1.2298980722746933e-09
5 O 0 3.307539131469639e-09
side O 0 8.491874758931317e-09
of O 0 2.374248531111789e-08
the O 0 2.553009892380942e-07
CTG O 0 3.758576212931075e-06
repeat O 0 9.937251910230316e-09
in O 0 5.962234705947367e-09
the O 0 7.188402406654859e-08
DMPK O 0 2.3636863261344843e-05
gene O 0 3.523402902771977e-09
of O 0 3.245708057875163e-08
normal O 0 9.110451060223568e-09
individuals O 0 1.5393832042409628e-10
and O 0 1.191084730844949e-10
of O 0 2.9265173617787354e-10
patients O 0 1.4975497231173307e-10
affected O 0 1.1309235770085024e-09
with O 0 1.1631655638666416e-09
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.6380813372407488e-09
showing O 0 3.5917928631334917e-09
expansions O 0 1.1079548833947683e-08
of O 0 2.3663053738687267e-08
the O 0 5.990769835761967e-08
repetitive O 0 2.9305709858817863e-07
sequence O 0 1.2829386264456843e-07
. O 0 5.375911769078812e-07

The O 0 3.2947090744528396e-07
gene O 0 9.56856709422027e-08
segment O 0 2.5796870772865077e-07
analyzed O 0 1.1237124120100361e-08
corresponds O 0 3.0155833385947517e-09
to O 0 3.6608305276075725e-10
the O 0 1.04606554529596e-08
genomic O 0 8.449046617897693e-07
SacI O 0 1.1154588719364256e-05
- O 0 1.4047469676370383e-07
HindIII O 0 2.3133648596740386e-07
fragment O 0 2.7715294947938673e-08
carrying O 0 1.4347795840308208e-08
exons O 0 1.269671514592119e-07
11 O 0 5.727695224777563e-07
- O 0 3.1549279810860753e-07
15 O 0 6.081368724153435e-07
. O 0 5.073388251730648e-07

There O 0 4.185814717061476e-08
is O 0 2.453850678207914e-09
constitutive O 0 1.7159203480332508e-07
methylation O 0 6.43300779756828e-07
in O 0 8.420283137411388e-08
intron O 0 4.1150979086523876e-06
12 O 0 7.31453155822237e-07
at O 0 9.966997005506073e-09
restriction O 0 8.86867024263438e-09
sites O 0 1.5807218645136345e-08
of O 0 2.019053368940149e-08
SacII O 0 5.300634029481444e-07
and O 0 2.2550562306378197e-08
HhaI O 0 1.5282029153240728e-06
, O 0 2.4937722997719902e-09
localized O 0 4.2883328887910466e-08
1 O 0 2.35553834215807e-08
, O 0 6.989273049207156e-10
159 O 0 6.685350939505952e-09
- O 0 4.934068265072256e-09
1 O 0 1.685895156811057e-08
, O 0 1.138902638864181e-09
232 O 0 1.1539271760341308e-08
bp O 0 1.0375845072019274e-08
upstream O 0 1.3921891195423086e-07
of O 0 8.120412786638553e-08
the O 0 1.6901051367312903e-06
CTG O 0 1.6907655663089827e-05
repeat O 0 1.5651430373964104e-07
, O 0 1.431805252138929e-08
whereas O 0 1.6604543517928505e-08
most O 0 5.923841861488199e-09
, O 0 2.479386418396956e-10
if O 0 1.973356339446397e-10
not O 0 2.3712320995628033e-10
all O 0 1.3821628286336818e-09
, O 0 6.211588465809825e-10
of O 0 3.6430982675028645e-09
the O 0 3.725027175605078e-09
other O 0 1.0370201364295895e-09
sites O 0 8.204357015983987e-08
of O 0 9.23118221862751e-08
SacII O 0 1.7192928680742625e-06
, O 0 7.414405978067862e-09
HhaI O 0 7.062257623147161e-07
, O 0 2.9202402718198073e-09
and O 0 2.3731923093350815e-09
HpaII O 0 1.785565189038607e-07
in O 0 6.891974213552032e-10
this O 0 5.438975381188982e-10
region O 0 7.607132701537012e-09
are O 0 8.930487460645509e-10
unmethylated O 0 2.765932549664285e-07
, O 0 2.438416801808785e-09
in O 0 7.820332714736367e-10
normal O 0 1.0073200940041716e-08
individuals O 0 1.0111227133347e-10
and O 0 2.049814346039014e-10
most O 0 6.332252500129698e-10
of O 0 5.019269000428039e-09
the O 0 1.2236115232155953e-08
patients O 0 4.327804781212308e-09
. O 0 1.0315172715991139e-07

In O 0 4.638692541192313e-09
a O 0 1.0774606762353756e-09
number O 0 3.678428450726301e-09
of O 0 2.9459537032039407e-08
young O 0 2.0165408898265014e-07
and O 0 5.131855473905489e-08
severely O 0 2.754202068899758e-05
affected O 0 1.147682837654429e-07
patients O 0 4.339484327431364e-09
, O 0 2.9700020220957413e-10
however O 0 3.378401114417784e-09
, O 0 1.9315632426852858e-10
complete O 0 2.6280522202881684e-09
methylation O 0 5.6081127297602507e-08
of O 0 5.023351690169875e-08
these O 0 9.48128353606137e-10
restriction O 0 1.6007833281150852e-08
sites O 0 2.9672587942286555e-08
was O 0 1.615771161311841e-08
found O 0 9.028658931597988e-10
in O 0 4.4630188433814055e-10
the O 0 4.230229055934842e-09
mutated O 0 9.442148751759305e-08
allele O 0 2.577500879397121e-07
. O 0 3.154383421133389e-07

In O 0 1.275068228778764e-08
most O 0 4.3918846337476225e-09
of O 0 1.0538070416288292e-09
these O 0 4.821246527009215e-11
patients O 0 4.296333080966441e-11
, O 0 5.912624122944576e-12
the O 0 3.734933542998142e-11
onset O 0 5.4928483450567e-07
of O 0 7.864309203853281e-10
the O 0 1.0691946883412129e-08
disease O 0 0.00012931095261592418
was O 0 8.865035283633915e-07
congenital O 1 0.9999948740005493
. O 0 2.0595177829818567e-06

Preliminary O 0 3.2070279303297866e-06
in O 0 3.745676622202154e-07
vivo O 0 4.285742761567235e-06
footprinting O 0 1.3144483091309667e-05
data O 0 3.550307781097217e-08
gave O 0 2.084758854437041e-08
evidence O 0 4.1101344550042995e-08
for O 0 1.9304076115389535e-09
protein O 0 2.406013877020996e-08
- O 0 2.7115274470190798e-09
DNA O 0 3.593903397103304e-09
contact O 0 1.2972146024026188e-08
in O 0 2.027882972654993e-09
normal O 0 2.1180915155127877e-06
genes O 0 4.031390687941894e-08
at O 0 8.124440853407577e-08
an O 0 3.997331354810285e-09
Sp1 O 0 2.804643628451231e-08
consensus O 0 5.5883244698407e-09
binding O 0 9.182010707320387e-09
site O 0 1.1855797765747411e-07
upstream O 0 4.6335307501976786e-07
of O 0 1.0603120870200655e-07
the O 0 1.7529384876979748e-06
CTG O 0 2.69333158939844e-05
repeat O 0 3.0339890599861974e-08
and O 0 7.411432578763311e-10
for O 0 5.008954015450762e-11
a O 0 5.126740351690806e-11
significant O 0 2.772425622410424e-10
reduction O 0 2.4570308010396502e-09
of O 0 1.0365950320334605e-09
this O 0 3.6143871229299407e-10
interaction O 0 6.914150141312803e-09
in O 0 2.1678754347220774e-09
cells O 0 3.730117548172984e-09
with O 0 4.901714034666327e-10
a O 0 2.9613447694032402e-08
hypermethylated O 0 9.369520739710424e-06
DMPK O 0 3.990377445006743e-05
gene O 0 7.885765285209345e-08
. O 0 1.1424128842918435e-07
. O 0 4.254019643212814e-07

The O 0 8.275083018816076e-06
hemochromatosis B-Disease 1 1.0
gene O 0 3.0607020562456455e-06
product O 0 1.4691006811062834e-07
complexes O 0 1.688430728563617e-08
with O 0 2.2953329514852072e-10
the O 0 7.482912067757752e-09
transferrin O 0 4.257266255081049e-07
receptor O 0 1.6610804323136108e-06
and O 0 2.983313152071787e-08
lowers O 0 5.138025471751462e-08
its O 0 2.364579088087737e-10
affinity O 0 8.510143700846129e-10
for O 0 1.6298902505429425e-10
ligand O 0 1.0528014371402605e-07
binding O 0 5.379665708460379e-07
. O 0 2.4398568712058477e-06

We O 0 2.1293026009061577e-07
recently O 0 4.780223150646634e-08
reported O 0 1.7320218148597633e-08
the O 0 2.3903129475755236e-10
positional O 0 1.5132600950096275e-08
cloning O 0 3.647652402349877e-09
of O 0 3.06054914744891e-09
a O 0 1.149302875091962e-09
candidate O 0 9.896093722261412e-09
gene O 0 2.344923366592866e-08
for O 0 3.944506659081526e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999990463256836
HFE O 1 0.9999998807907104
. O 0 1.0093589253301616e-06

The O 0 2.757536208264355e-07
gene O 0 1.1760490359336018e-08
product O 0 2.372328999911133e-08
, O 0 2.033533064160764e-10
a O 0 1.8859300232598741e-10
member O 0 5.161239768902703e-10
of O 0 4.9516444278197014e-08
the O 0 6.372399070642132e-07
major O 0 2.818506743551552e-07
histocompatibility O 0 7.852550254483504e-08
complex O 0 2.14921030305959e-07
class O 0 2.3605666754633603e-08
I O 0 4.321661890571704e-07
- O 0 2.4942638177094523e-08
like O 0 2.258257358889182e-09
family O 0 1.5514553197704117e-08
, O 0 2.3653776159981987e-10
was O 0 1.557422857345614e-09
found O 0 7.812352154079605e-11
to O 0 1.7933614315790436e-10
have O 0 7.614183172854894e-10
a O 0 1.0708845366025344e-08
mutation O 0 1.5010572340656836e-08
, O 0 2.647835950497779e-09
Cys O 0 1.2845595165345003e-07
- O 0 1.0153216578601132e-07
282 O 0 2.0781791931767657e-07
- O 0 2.7281558345748635e-07
- O 0 2.6993356527782453e-07
> O 0 4.088476046604228e-08
Tyr O 0 2.5422733074265125e-07
( O 0 8.328862044493235e-10
C282Y O 0 3.386234936897381e-08
) O 0 2.3804116663916908e-11
, O 0 1.1446026418338029e-11
in O 0 2.466809395640368e-11
85 O 0 1.0004155726051067e-08
% O 0 1.2379376412852139e-09
of O 0 2.2100721253082156e-09
patient O 0 1.9944424778373104e-08
chromosomes O 0 5.985493203297665e-07
. O 0 2.0008358205814147e-06

This O 0 1.1051773718406821e-08
mutation O 0 1.3587801106496045e-07
eliminates O 0 4.219626248413988e-07
the O 0 1.5338951442345206e-08
ability O 0 1.2813289984592302e-08
of O 0 5.361495141187334e-07
HFE O 0 0.00038516573840752244
to O 0 4.036237655213881e-08
associate O 0 8.329169531862135e-07
with O 0 3.78513131948921e-09
beta2 O 0 0.0008839696529321373
- O 0 1.2223737940075807e-05
microglobulin O 0 4.889768024440855e-05
( O 0 6.302542043812309e-09
beta2m O 0 6.713484594911279e-07
) O 0 3.3573302471445743e-10
and O 0 4.808584641580183e-10
prevents O 0 5.091877586238525e-09
cell O 0 4.3671366256603505e-07
- O 0 9.329987165074272e-07
surface O 0 7.19069066690281e-06
expression O 0 2.0263817077648127e-06
. O 0 5.037662731410819e-07

A O 0 1.4049915080249775e-05
second O 0 1.5389628060802352e-07
mutation O 0 1.4074633014615756e-08
that O 0 4.8479625869291e-10
has O 0 1.4458988173426945e-10
no O 0 4.1802578065741613e-10
effect O 0 1.706763796960331e-08
on O 0 3.6415993776017785e-08
beta2m O 0 4.293187885195948e-06
association O 0 1.6704866823147313e-07
, O 0 2.245956132185256e-08
H63D O 0 0.0003012443776242435
, O 0 1.4501142509004694e-09
was O 0 9.321288629848823e-09
found O 0 1.5042657397490444e-10
in O 0 9.723055693910965e-11
eight O 0 6.287482201550176e-10
out O 0 7.175108840407063e-10
of O 0 2.7376458877625964e-09
nine O 0 4.605035464066987e-09
patients O 0 3.0021182761963416e-10
heterozygous O 0 7.746520092055675e-10
for O 0 1.3428974598994614e-09
the O 0 1.0132980321486684e-07
C282Y O 0 4.5921797209302895e-06
mutant O 0 2.1122275484231068e-06
. O 0 1.29263253256795e-06

In O 0 1.7175699085214546e-08
this O 0 3.4102085599840848e-09
report O 0 5.330829999650177e-09
, O 0 6.063332474992578e-11
we O 0 6.33377170156102e-11
demonstrate O 0 8.25657764380594e-10
in O 0 2.1126822513650723e-09
cultured O 0 1.7368392946082167e-07
293 O 0 1.7928400097844133e-08
cells O 0 1.1848751313436878e-08
overexpressing O 0 4.7298740923906735e-07
wild O 0 6.426471088616381e-08
- O 0 1.7413032793456296e-08
type O 0 6.733275714765341e-09
or O 0 5.428883564917442e-09
mutant O 0 3.4793416148204415e-08
HFE O 0 2.6232814320792386e-07
proteins O 0 2.2533513943656658e-10
that O 0 1.203631638801994e-10
both O 0 9.735977579694577e-10
the O 0 1.6899837973483045e-08
wild O 0 4.299996092527181e-08
- O 0 2.174407143229473e-08
type O 0 3.974389173322379e-08
and O 0 9.850675297684575e-08
H63D O 1 0.9984706044197083
HFE O 0 1.5889938367763534e-05
proteins O 0 8.290415465239676e-09
form O 0 6.064795776694609e-09
stable O 0 4.325265123839017e-08
complexes O 0 2.5773094769476756e-09
with O 0 2.2381026199003173e-10
the O 0 2.2381474451549366e-08
transferrin O 0 1.0174545650443179e-06
receptor O 0 2.3558361590403365e-06
( O 0 4.775648321242443e-08
TfR O 0 1.229406052516424e-06
) O 0 3.606373200071289e-09
. O 0 9.656277910607969e-08

The O 0 3.228503828722751e-07
C282Y O 0 6.74055172567023e-06
mutation O 0 1.8266989343374007e-07
nearly O 0 1.5541980147304457e-08
completely O 0 7.26146254237392e-09
prevents O 0 1.3373201435129545e-09
the O 0 9.296055036855932e-10
association O 0 2.8471682789188435e-09
of O 0 7.684686664788387e-09
the O 0 2.4202176263088404e-08
mutant O 0 2.253199511415005e-07
HFE O 0 7.338150680880062e-06
protein O 0 8.405312712511659e-08
with O 0 1.4858283492458213e-09
the O 0 1.658111443703092e-07
TfR O 0 1.1587931112444494e-05
. O 0 3.857511217120191e-07

Studies O 0 9.755408427736256e-07
on O 0 6.498839155710812e-08
cell O 0 3.394318071059388e-08
- O 0 8.629551295769033e-09
associated O 0 7.349707953352436e-09
transferrin O 0 1.0010706574803407e-07
at O 0 1.9962806518947218e-08
37 O 0 1.1835809665683428e-08
degrees O 0 5.34846194000238e-08
C O 0 1.255135018141118e-08
suggest O 0 2.0212322093815516e-10
that O 0 4.777153325696837e-11
the O 0 6.182078404748381e-09
overexpressed O 0 4.020356811906822e-07
wild O 0 9.72175300262279e-08
- O 0 8.109639537678959e-08
type O 0 8.41346050606262e-08
HFE O 0 1.1928635785807273e-06
protein O 0 2.09909085668869e-08
decreases O 0 3.333632925262009e-09
the O 0 3.058470143812997e-10
affinity O 0 7.540767121838599e-09
of O 0 1.5696477007054455e-08
the O 0 2.6922549523078487e-08
TfR O 0 3.527897547428438e-07
for O 0 5.959415627643239e-09
transferrin O 0 1.4756617019884288e-05
. O 0 3.4148426948377164e-06

The O 0 0.0002318430779268965
overexpressed O 0 0.0013017976889386773
H63D O 0 0.4694388806819916
protein O 0 4.5070876808495086e-07
does O 0 1.465043197867999e-09
not O 0 2.729406700652248e-10
have O 0 4.0308770210550904e-11
this O 0 1.7807456897944718e-11
effect O 0 1.5688865762086834e-09
, O 0 3.2640546515638746e-11
providing O 0 4.289817112645977e-10
the O 0 7.529782908299865e-10
first O 0 7.06085134805079e-10
direct O 0 1.446525788040276e-09
evidence O 0 2.9127638079273765e-09
for O 0 1.2788348158210283e-10
a O 0 1.5217137550038728e-09
functional O 0 8.94430201014984e-08
consequence O 0 8.130995752253511e-07
of O 0 6.843266220357691e-08
the O 0 4.973092586624261e-07
H63D O 0 0.0010043293004855514
mutation O 0 1.203897795676312e-06
. O 0 6.488293138318113e-07

Addition O 0 4.4924459530193417e-07
of O 0 9.120432196141337e-07
soluble O 0 2.3230724764289334e-05
wild O 0 3.3047961096599465e-06
- O 0 1.5124728633963969e-06
type O 0 2.912521040343563e-06
HFE O 0 0.11825379729270935
/ O 0 2.3743838028167374e-05
beta2m O 0 2.741781372606056e-06
heterodimers O 0 1.9290769159852061e-07
to O 0 1.9249404292764893e-09
cultured O 0 6.74121691801588e-09
cells O 0 8.369406279129521e-10
also O 0 2.936468429526329e-11
decreased O 0 3.459888486823104e-10
the O 0 2.271170577994308e-11
apparent O 0 1.3164311862823297e-09
affinity O 0 4.205258363754183e-09
of O 0 1.1447048642310165e-08
the O 0 1.538084681840246e-08
TfR O 0 5.7069765801998074e-08
for O 0 2.0628358743390862e-10
its O 0 3.5017408417381546e-10
ligand O 0 2.1181707055006882e-08
under O 0 1.985916675550925e-08
steady O 0 1.9671432482937234e-07
- O 0 1.7681504038691287e-09
state O 0 7.095656284761276e-10
conditions O 0 2.9238981014145793e-08
, O 0 3.043932328417043e-10
both O 0 3.4774072510401766e-10
in O 0 6.274735731004455e-10
293 O 0 1.2526207848750914e-09
cells O 0 3.736838338763704e-10
and O 0 1.7688418507688652e-09
in O 0 1.256059434240342e-08
HeLa O 0 1.0365666867073742e-06
cells O 0 1.4981003459979547e-07
. O 0 5.639207643071131e-07

Furthermore O 0 8.553957400181389e-07
, O 0 1.6698553650940084e-08
at O 0 3.084848643197802e-08
4 O 0 3.7683776099584065e-08
degrees O 0 5.557787403631664e-07
C O 0 1.84882026132982e-07
, O 0 8.557133890363389e-10
the O 0 2.436242496628438e-08
added O 0 1.2089942913462437e-07
soluble O 0 3.404167046028306e-07
complex O 0 8.398037465440211e-08
of O 0 1.0464485740158125e-06
HFE O 1 0.9955514073371887
/ O 0 2.203373696829658e-05
beta2m O 0 1.6782308875917806e-06
inhibited O 0 1.649032199679823e-08
binding O 0 1.008088901244264e-08
of O 0 2.0446776716198656e-08
transferrin O 0 3.469276350642758e-07
to O 0 1.4625535449397375e-08
HeLa O 0 5.797511448690784e-07
cell O 0 1.727100737980436e-07
TfR O 0 4.4757081241186825e-07
in O 0 1.5543216713709285e-09
a O 0 9.241468035270373e-09
concentration O 0 5.535918603527534e-07
- O 0 2.3731534781745722e-07
dependent O 0 2.3753315758767712e-07
manner O 0 1.6058235985383362e-07
. O 0 3.0013430318831524e-07

Scatchard O 0 0.0009137687738984823
plots O 0 1.1274662483629072e-06
of O 0 2.4603615145224467e-08
these O 0 5.531122226898333e-10
data O 0 2.2968755786223483e-09
indicate O 0 3.8277923053442464e-09
that O 0 2.4021595823597863e-10
the O 0 1.3164519252484297e-08
added O 0 5.2732602284777386e-08
heterodimer O 0 1.137867897682554e-07
substantially O 0 9.582224791415683e-09
reduced O 0 1.5608456749305333e-09
the O 0 1.1909444541657876e-09
affinity O 0 4.105918804953035e-08
of O 0 2.589689174214982e-08
TfR O 0 5.191427021600248e-07
for O 0 1.5733464309164447e-08
transferrin O 0 2.171068626921624e-05
. O 0 3.116803327429807e-06

These O 0 3.8160212767479607e-08
results O 0 5.1255067745614724e-08
establish O 0 3.617252630760959e-08
a O 0 5.621550336343262e-09
molecular O 0 7.056024742269074e-08
link O 0 5.9544078112594434e-08
between O 0 7.03761102727185e-08
HFE O 0 0.006223184987902641
and O 0 1.787622494475727e-08
a O 0 3.223215472303309e-08
key O 0 1.5245885265358083e-07
protein O 0 3.169082418708058e-08
involved O 0 1.7786836448152599e-09
in O 0 2.2545647571092786e-09
iron O 0 8.699483373675321e-07
transport O 0 4.3861027165803534e-07
, O 0 1.889138401267587e-09
the O 0 2.552449984705163e-07
TfR O 0 4.237990651745349e-06
, O 0 1.8265475798528996e-09
and O 0 9.284855106983514e-10
raise O 0 9.312829618579599e-09
the O 0 1.0058456290096274e-08
possibility O 0 2.11984794162845e-08
that O 0 5.896502175417595e-10
alterations O 0 1.0206238520993338e-08
in O 0 1.434072166572875e-10
this O 0 1.2579930153133745e-10
regulatory O 0 1.7237586913410041e-09
mechanism O 0 2.5093807920484323e-08
may O 0 3.3606311067302386e-09
play O 0 2.5921338409062855e-09
a O 0 2.461172377010712e-09
role O 0 6.423315768167015e-10
in O 0 1.4639363332680233e-10
the O 0 1.365961121990722e-09
pathogenesis O 0 1.676480496826116e-05
of O 0 2.112361414674524e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 4.119550794712268e-06
. O 0 1.7489998072051094e-07

Genomic O 0 6.076186309655895e-07
organization O 0 3.9851453692563155e-08
of O 0 5.396870861318348e-08
the O 0 1.249677126224924e-07
UBE3A O 0 2.7283140298095532e-05
/ O 0 3.31217137272688e-07
E6 O 0 4.87351917399792e-06
- O 0 8.853800892438812e-08
AP O 0 5.637494268739829e-06
gene O 0 8.234654069738667e-10
and O 0 8.498805548207145e-10
related O 0 1.7564506293865634e-08
pseudogenes O 0 3.559180413503782e-06
. O 0 5.657743713527452e-07

The O 0 2.282248942719889e-06
UBE3A O 0 4.7909859858918935e-05
gene O 0 9.775974518788644e-08
encodes O 0 2.036361195223435e-07
the O 0 2.746497216321586e-07
E6 O 0 1.3118647984811105e-05
- O 0 8.75281841672404e-07
AP O 0 2.5684572392492555e-05
ubiquitin O 0 1.0645026549127579e-07
- O 0 3.2920322468044105e-08
protein O 0 4.315769519536161e-09
ligase O 0 2.2183750392201773e-09
and O 0 1.0150458251700911e-09
has O 0 2.440639912393294e-10
recently O 0 1.1105074498862777e-10
been O 0 3.312560989399138e-11
shown O 0 1.5147392021241934e-11
to O 0 9.52891845290571e-12
be O 0 4.157593366804768e-11
mutated O 0 5.867194019515409e-08
in O 0 1.743170763290891e-08
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 2.9277989810339022e-08
who O 0 1.162908103147231e-09
lack O 0 2.8023764642171045e-08
15q11 O 0 7.002396387179033e-07
- O 0 1.2328537479788793e-07
q13 O 0 6.274764814406808e-07
deletions O 0 1.0060455224447651e-07
or O 0 1.1176035208393387e-08
chromosome O 0 2.0230939412613225e-07
15 O 0 1.669061362008506e-06
paternal O 0 0.043497875332832336
uniparental B-Disease 0 0.014580289833247662
disomy I-Disease 0 0.0013316059485077858
. O 0 1.0924142770818435e-05

Previous O 0 3.1722686344437534e-06
UBE3A O 0 1.8855969756259583e-05
cDNA O 0 1.2361077494915662e-07
analysis O 0 8.160778719457085e-09
has O 0 1.372740809912898e-10
shown O 0 4.923543864276958e-11
a O 0 1.3657129593891426e-10
coding O 0 2.699175460918468e-08
region O 0 2.8076996727577352e-08
of O 0 5.793355839500691e-08
approximately O 0 5.942301939398931e-08
2 O 0 5.561063858294801e-07
. O 0 6.906257112859748e-07

6 O 0 8.324243026436307e-06
kb O 0 2.0283771391405025e-06
and O 0 1.5981413525878452e-08
a O 0 3.0899133918183e-08
3 O 0 2.4420094746346876e-07
- O 0 1.30704506773327e-07
untranslated O 0 7.590164750581607e-05
region O 0 1.0902705582793715e-07
( O 0 3.1247606724349453e-09
UTR O 0 6.667126399406698e-06
) O 0 6.498461213588769e-10
of O 0 3.471870257953924e-08
< O 0 4.079611670704253e-08
50 O 0 1.489561185508137e-07
bp O 0 3.9376882199348984e-08
, O 0 4.791162466766252e-10
whereas O 0 2.1912762715459166e-09
Northern O 0 4.975783784999521e-09
analysis O 0 6.9452377182699365e-09
has O 0 9.996444783055836e-10
indicated O 0 1.5536429920359751e-09
mRNA O 0 3.3513816166674815e-09
sizes O 0 5.2617064483229115e-08
of O 0 1.0078144185854399e-07
5 O 0 1.019645083033538e-06
- O 0 1.165606704489619e-06
8 O 0 1.464391175431956e-06
kb O 0 1.4970826669014059e-05
. O 0 2.715892378546414e-06

We O 0 1.4138809945052344e-07
have O 0 3.472808929316784e-09
analyzed O 0 9.997060956834503e-09
additional O 0 1.3461542991421993e-09
cDNA O 0 1.0286193230513163e-07
clones O 0 7.746260877183886e-08
and O 0 1.3656433761610742e-09
provide O 0 1.1531059440628155e-09
evidence O 0 6.710940692045142e-09
for O 0 5.302311922861236e-10
an O 0 1.3024847866915934e-09
additional O 0 6.316128509098462e-09
0 O 0 5.296035965329793e-07
. O 0 4.438726932676218e-07

5 O 0 3.0042151593079325e-06
kb O 0 3.621938049036544e-06
of O 0 7.597288913530065e-07
5 O 0 7.285784704436082e-07
- O 0 1.0446722598089764e-07
UTR O 0 4.511346105573466e-06
and O 0 3.0409279538901046e-09
> O 0 7.606145935312725e-09
2 O 0 1.5698512711992407e-08
kb O 0 2.0379660270464228e-07
of O 0 2.320156653468075e-07
3 O 0 1.556629854349012e-06
- O 0 1.5754776541143656e-06
UTR O 0 0.00018800614634528756
. O 0 1.3076926279609324e-06

We O 0 6.686718023729554e-08
have O 0 1.3359690020919857e-09
established O 0 5.514302348075262e-09
the O 0 1.1549372569419347e-09
genomic O 0 1.34227837733647e-08
organization O 0 3.945339166477879e-09
of O 0 8.016960428847142e-09
UBE3A O 0 8.802409865893424e-06
and O 0 8.424858144451264e-09
the O 0 1.46900891451196e-08
sequence O 0 9.126313038620992e-09
of O 0 2.8430237719589968e-08
intron O 0 5.443407076199946e-07
- O 0 6.236863328012987e-07
exon O 0 6.317323908433536e-08
borders O 0 1.209224251397245e-06
. O 0 2.3055908968672156e-06

We O 0 1.0643971393164975e-07
have O 0 5.13383024980385e-09
also O 0 2.1045460929514093e-09
mapped O 0 4.48288481891268e-08
two O 0 2.420991851437293e-09
highly O 0 9.7402166332472e-09
homologous O 0 1.0413971907041741e-08
processed O 0 1.07227890566719e-07
pseudogenes O 0 1.0966519994326518e-06
, O 0 1.4858404284723292e-08
UBE3AP1 O 0 0.0004360531165730208
and O 0 3.7783024708915036e-08
UBE3AP2 O 0 0.028897739946842194
, O 0 2.1316903797696796e-09
to O 0 1.9226835679120313e-09
chromosomes O 0 7.520744027544879e-09
2 O 0 1.5821878918131915e-08
and O 0 1.6245961242944418e-09
21 O 0 2.3869715093383093e-08
, O 0 6.152807707771046e-10
respectively O 0 6.378002126439242e-09
, O 0 8.163780207404159e-10
and O 0 1.6296516358593749e-09
determined O 0 1.3645505170245542e-08
their O 0 1.0460895261132919e-08
genomic O 0 4.3874328525816964e-07
organization O 0 2.8593609613380977e-07
. O 0 2.5279149440393667e-07

These O 0 6.524922468997829e-08
results O 0 7.318055139649005e-08
will O 0 3.949033877681529e-10
form O 0 2.5008350945654456e-10
the O 0 5.108090617156336e-10
basis O 0 1.274080729807281e-09
for O 0 1.82581085667044e-11
studies O 0 7.612310226612351e-10
of O 0 6.2368393782819e-10
mutation O 0 5.194900953853221e-09
and O 0 3.199387199614989e-09
imprinting O 0 5.56842587684514e-06
of O 0 2.8667625429079635e-06
UBE3A O 0 0.02509296126663685
. O 0 1.2336303370830137e-05

Mutation O 0 1.394602264781497e-07
spectrum O 0 1.0256727733803928e-07
and O 0 4.246445417521727e-09
genotype O 0 2.3603850252129632e-07
- O 0 1.802142008955343e-07
phenotype O 0 2.6137465525266634e-08
analyses O 0 2.295570400434599e-09
in O 0 4.890423621617401e-10
Cowden B-Disease 0 6.743258381902706e-06
disease I-Disease 0 3.382950808372698e-06
and O 0 1.8093363252091876e-08
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.5439868817377373e-09
two O 0 5.681331849416438e-09
hamartoma B-Disease 1 0.981423020362854
syndromes I-Disease 0 0.0010570563608780503
with O 0 2.2180721259701386e-07
germline O 1 1.0
PTEN O 1 1.0
mutation O 0 1.6778145436546765e-05
. O 0 4.546250806924945e-07

The O 0 9.235229299520142e-06
tumour B-Disease 1 1.0
suppressor O 0 0.0013764434261247516
gene O 0 8.112538125715218e-06
PTEN O 1 0.6182639002799988
, O 0 7.586093531131155e-09
which O 0 2.271986487833999e-10
maps O 0 1.2364303358936013e-08
to O 0 5.696979332725505e-09
10q23 O 0 1.2583522220666055e-05
. O 0 1.4267476444729255e-06

3 O 0 6.772122560505522e-07
and O 0 2.2770243468528406e-09
encodes O 0 5.952269788167541e-09
a O 0 2.4217956529071216e-09
403 O 0 2.0928216937221578e-09
amino O 0 1.960571704984204e-09
acid O 0 1.3750423022429459e-09
dual O 0 1.1877872907462006e-08
specificity O 0 9.393181699124398e-08
phosphatase O 0 4.2601535824360326e-05
( O 0 1.2405996585584944e-06
protein O 0 1.5248663657985162e-05
tyrosine O 0 7.141785545172752e-07
phosphatase O 0 9.116710089074331e-07
; O 0 1.1986842629596595e-08
PTPase O 0 7.02946820752004e-08
) O 0 4.121998228856505e-11
, O 0 3.979708229628898e-11
was O 0 4.694273858518727e-10
shown O 0 8.542323098881255e-11
recently O 0 1.176593128482395e-10
to O 0 8.586100580521006e-11
play O 0 2.2778192665384722e-09
a O 0 9.719913762751275e-09
broad O 0 1.3012046906624164e-07
role O 0 6.885184866689542e-09
in O 0 5.649626544368402e-09
human O 0 2.9027944492554525e-07
malignancy B-Disease 0 0.00037254978087730706
. O 0 4.762004550684651e-07

Somatic O 0 0.0006018370622768998
PTEN O 0 0.0018809052417054772
deletions O 0 2.997732735821046e-06
and O 0 2.3526602888068737e-08
mutations O 0 1.9719172072996116e-08
were O 0 8.932701245356611e-10
observed O 0 5.185909479621387e-10
in O 0 7.256498874008699e-11
sporadic B-Disease 0 6.63485820950882e-07
breast I-Disease 0 7.289005588972941e-05
, I-Disease 0 2.1602446054203028e-08
brain I-Disease 1 1.0
, I-Disease 0 5.329884061211487e-06
prostate I-Disease 1 1.0
and I-Disease 0 0.016952339559793472
kidney I-Disease 1 0.9999741315841675
cancer I-Disease 0 3.689184950417257e-06
cell O 0 3.048723229426287e-08
lines O 0 2.5416435622815925e-09
and O 0 3.87010284930156e-11
in O 0 8.40363334475569e-11
several O 0 2.1455348608867553e-09
primary O 0 4.600016438871535e-07
tumours B-Disease 1 1.0
such O 0 1.706889851682547e-09
as O 0 2.5108752765845566e-07
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 4.9064667109632865e-05
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9780936241149902
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 1.5354986317106523e-05

In O 0 4.972294931349097e-08
addition O 0 3.55222447012693e-08
, O 0 8.978004117921046e-09
PTEN O 1 0.8977805376052856
was O 0 7.422460157613386e-08
identified O 0 2.425863954158558e-09
as O 0 1.566132223906891e-10
the O 0 1.6349654963221383e-10
susceptibility O 0 8.596166001240135e-10
gene O 0 1.8740037299735945e-10
for O 0 1.1947708100645826e-10
two O 0 6.3389746784991985e-09
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999943971633911
( O 0 4.562745292702175e-09
CD B-Disease 0 3.1740237318444997e-06
; O 0 1.1853231995928581e-07
MIM O 0 7.016158633632585e-06
158350 O 0 2.2088981666001928e-07
) O 0 3.2347532985532723e-10
and O 0 3.177372809304302e-09
Bannayan B-Disease 0 5.640028393827379e-05
- I-Disease 0 0.00011893213377334177
Zonana I-Disease 0 0.0014590062201023102
( I-Disease 0 3.3017957434822165e-07
BZS I-Disease 0 4.556633211905137e-05
) I-Disease 0 1.3634311457622061e-09
or I-Disease 0 2.1964985386091485e-09
Ruvalcaba I-Disease 0 1.4794064782108762e-06
- I-Disease 0 2.3560600936889387e-07
Riley I-Disease 0 4.717877345683519e-06
- I-Disease 1 0.9996426105499268
Smith I-Disease 0 0.00035587005550041795
syndrome I-Disease 1 1.0
( O 0 3.7952545426378492e-06
MIM O 0 0.006281333044171333
153480 O 0 8.627762326796073e-06
) O 0 1.5988364410191025e-08
. O 0 2.574162465407426e-07

Constitutive O 0 1.3488737522493466e-06
DNA O 0 4.961065087627503e-07
from O 0 1.0188815480205449e-07
37 O 0 6.42207211853929e-08
CD B-Disease 0 2.1862300414454694e-08
families O 0 1.3407323029568374e-09
and O 0 2.3923335534803414e-10
seven O 0 2.997474046750881e-09
BZS B-Disease 0 8.47975752549246e-06
families O 0 8.056709077663982e-09
was O 0 1.5251549356776195e-08
screened O 0 6.5111698255293504e-09
for O 0 9.423846591971596e-09
germline O 0 0.0006542711635120213
PTEN O 0 0.00466461107134819
mutations O 0 2.9501476092264056e-05
. O 0 4.608456038113218e-06

PTEN O 0 0.0008829457219690084
mutations O 0 1.3808640915158321e-06
were O 0 1.898918711162878e-08
identified O 0 2.152330536020486e-09
in O 0 1.0567149238971396e-10
30 O 0 4.291627941910292e-09
of O 0 6.3904956881799535e-09
37 O 0 9.24464416129922e-08
( O 0 1.4639621737089215e-09
81 O 0 1.62440542794684e-07
% O 0 9.839062897754047e-10
) O 0 3.1971617193982116e-12
CD B-Disease 0 8.587611177723886e-10
families O 0 3.4012098693025905e-10
, O 0 4.648581519717254e-11
including O 0 6.33497976298969e-11
missense O 0 2.8256818040972576e-07
and O 0 2.193991477383861e-08
nonsense O 0 3.85576782946373e-07
point O 0 1.1706777058861917e-06
mutations O 0 3.312022656132285e-08
, O 0 5.408110403948285e-09
deletions O 0 8.614590285560553e-08
, O 0 9.894395525122945e-09
insertions O 0 1.0917001702637208e-07
, O 0 7.1984982419337484e-09
a O 0 2.3870807552839324e-08
deletion O 0 5.314487339092011e-07
/ O 0 1.2481840485634166e-06
insertion O 0 5.078185267848312e-07
and O 0 1.8240841370698035e-07
splice O 0 3.313390334369615e-05
site O 0 6.524407581309788e-06
mutations O 0 2.696140199986985e-06
. O 0 2.6205909762211377e-06

These O 0 3.446541185780916e-08
mutations O 0 7.485884623292804e-08
were O 0 3.651132729487472e-09
scattered O 0 7.730848849973881e-09
over O 0 2.3719015640466523e-10
the O 0 1.0604629396837595e-09
entire O 0 3.1789972876339334e-09
length O 0 1.7528920537301929e-09
of O 0 1.3821371602773525e-08
PTEN O 0 3.4412878449074924e-06
, O 0 4.3330555810072724e-10
with O 0 1.558134350709839e-11
the O 0 9.563705383186516e-10
exception O 0 1.679302252810544e-09
of O 0 2.1291872709383597e-09
the O 0 3.6626344179779835e-09
first O 0 5.047051221396259e-09
, O 0 1.253792070166071e-09
fourth O 0 6.234216698430828e-08
and O 0 1.7706286215002365e-08
last O 0 3.784051045840897e-07
exons O 0 6.916196980455425e-06
. O 0 5.258483724901453e-06

A O 0 5.2868468628730625e-05
hot O 0 1.55755606101593e-05
spot O 0 1.483959181314276e-06
for O 0 1.584422548717157e-08
PTEN O 0 2.6544001229922287e-05
mutation O 0 1.1196091165288635e-08
in O 0 1.366711743777671e-09
CD B-Disease 0 6.551346842798011e-08
was O 0 8.355696934359003e-08
identified O 0 8.151181063453805e-09
in O 0 1.3475981441857243e-09
exon O 0 7.542046986941386e-09
5 O 0 1.5948465659221256e-08
that O 0 7.785992683917442e-11
contains O 0 4.101234074571636e-10
the O 0 1.3632601714164139e-08
PTPase O 0 9.683146799943643e-07
core O 0 1.0678763828764204e-07
motif O 0 4.22799679711261e-08
, O 0 2.98873203963268e-10
with O 0 5.3557325241371245e-11
13 O 0 1.428248452839398e-08
of O 0 2.1382190240615273e-08
30 O 0 6.115070760870367e-08
( O 0 1.8082589869905519e-09
43 O 0 1.9264146544628602e-07
% O 0 4.110312534777449e-09
) O 0 5.435333086389882e-11
CD B-Disease 0 1.2529009829620463e-08
mutations O 0 1.58769584146512e-08
identified O 0 1.84804047620446e-08
in O 0 1.1062165627961917e-09
this O 0 2.8209083957619896e-09
exon O 0 7.109073862920923e-08
. O 0 6.530587484121497e-07

Seven O 0 4.7520782686660823e-07
of O 0 1.417775052914294e-07
30 O 0 1.2085563128039212e-07
( O 0 8.919728289313866e-10
23 O 0 2.9856639827130493e-08
% O 0 3.867227371667781e-10
) O 0 3.363351481003307e-12
were O 0 1.1445464714876508e-10
within O 0 1.0950086393179959e-09
the O 0 1.0979287701218254e-08
core O 0 4.085357829808345e-08
motif O 0 7.194818962830141e-09
, O 0 1.7013017383771256e-10
the O 0 1.6800616453593875e-09
majority O 0 3.2338032251999493e-10
( O 0 1.0899903896133267e-10
five O 0 2.3489059586268013e-09
of O 0 2.6993401291974806e-08
seven O 0 3.547902860390195e-09
) O 0 3.814174323601982e-11
of O 0 1.6779415634715633e-09
which O 0 4.852088730800119e-10
were O 0 2.816023325635797e-08
missense O 0 2.352051069465233e-06
mutations O 0 2.431489463106118e-07
, O 0 5.540839342899062e-09
possibly O 0 3.5191394687217326e-08
pointing O 0 1.796174302626241e-07
to O 0 1.921484971134646e-09
the O 0 3.2089349844000026e-08
functional O 0 1.2880360600320273e-07
significance O 0 7.980089833381498e-08
of O 0 1.917809733242848e-08
this O 0 4.916951734657005e-09
region O 0 2.309062381300464e-07
. O 0 4.3074905420326104e-07

Germline O 0 0.003587866434827447
PTEN O 0 0.0009438764536753297
mutations O 0 8.651356893096818e-07
were O 0 8.599401191133893e-09
identified O 0 2.2254356135675835e-09
in O 0 1.8179860394873515e-10
four O 0 4.363559791276117e-10
of O 0 4.444646428680699e-09
seven O 0 3.3744986804862265e-09
( O 0 1.397053028817652e-09
57 O 0 4.0093982534017414e-07
% O 0 3.212070254221544e-08
) O 0 5.10587216950853e-09
BZS B-Disease 0 9.213690645992756e-05
families O 0 1.3530748788070923e-07
studied O 0 8.043090815590404e-07
. O 0 2.8287692543926823e-07

Interestingly O 0 1.785459062375594e-06
, O 0 9.683035706586907e-09
none O 0 4.0940165035863174e-08
of O 0 7.49891437834549e-09
these O 0 6.711398103931288e-10
mutations O 0 7.782867683658878e-09
was O 0 7.60396989818446e-09
observed O 0 9.221495789191181e-10
in O 0 2.0678073142654796e-10
the O 0 2.8231060156258536e-08
PTPase O 0 1.1223211913602427e-05
core O 0 2.151364697056124e-06
motif O 0 2.468739467076375e-06
. O 0 4.420452626163751e-07

It O 0 2.4887132354933783e-08
is O 0 1.0079115320138499e-09
also O 0 5.1995054095588245e-11
worthy O 0 6.117156114981981e-09
of O 0 1.7724319789635956e-09
note O 0 1.4414498483716898e-09
that O 0 2.3915156313614183e-11
a O 0 6.159312504472325e-10
single O 0 1.7493217985276033e-09
nonsense O 0 6.927631091002695e-08
point O 0 1.879984807828805e-07
mutation O 0 3.2482954104295914e-09
, O 0 6.318980894093329e-10
R233X O 0 2.4525791175733502e-08
, O 0 6.548955266971745e-10
was O 0 6.632199678335837e-09
observed O 0 1.9859840438840592e-09
in O 0 4.293680688771673e-10
the O 0 9.981322435237416e-09
germline O 0 7.041249716621678e-08
DNA O 0 2.4913491714073643e-08
from O 0 1.9791707828176186e-08
two O 0 2.2117674358668182e-09
unrelated O 0 8.328388645395535e-09
CD B-Disease 0 3.051562558198384e-08
families O 0 7.553492054057642e-09
and O 0 3.2289360074599927e-09
one O 0 8.708558141279354e-08
BZS B-Disease 0 0.0008074535871855915
family O 0 5.557649274123833e-07
. O 0 1.2189211702207103e-06

Genotype O 0 9.129952331932145e-07
- O 0 7.534688393207034e-07
phenotype O 0 5.024826776889313e-08
studies O 0 2.3518289538060344e-09
were O 0 7.783572397723759e-11
not O 0 4.5285893091051577e-11
performed O 0 2.485617545122665e-10
on O 0 1.1659108123396322e-09
this O 0 1.3434091339359355e-10
small O 0 1.1101394248314023e-09
group O 0 8.245121252414833e-10
of O 0 8.522367522800778e-08
BZS B-Disease 0 0.00506574846804142
families O 0 4.4836886559096456e-07
. O 0 1.1437551847848226e-06

However O 0 1.1213021622324959e-07
, O 0 8.138892226838834e-09
genotype O 0 4.802457453934039e-08
- O 0 7.288635828217593e-08
phenotype O 0 2.0659879140794146e-08
analysis O 0 4.447063162160703e-09
inthe O 0 9.695864378045371e-08
group O 0 3.3035524316105125e-10
of O 0 1.0252885207506779e-09
CD B-Disease 0 1.366125275126251e-07
families O 0 2.09275867746328e-08
revealed O 0 3.9955856401263645e-09
two O 0 1.2928609571805083e-10
possible O 0 8.621370284345176e-10
associations O 0 6.145629560805332e-10
worthy O 0 5.947472558887057e-08
of O 0 2.318435399217833e-08
follow O 0 8.830068232157373e-09
- O 0 2.0600344541321647e-08
up O 0 9.64265467473524e-09
in O 0 2.8138529284404967e-09
independent O 0 6.30182341865293e-08
analyses O 0 2.818055122588703e-07
. O 0 2.836616772583511e-07

The O 0 2.4299362166857463e-07
first O 0 4.104869333332317e-08
was O 0 3.6363868360922424e-08
an O 0 3.089603572981048e-10
association O 0 7.500913223879024e-10
noted O 0 4.060504377179086e-09
in O 0 6.743232638939389e-10
the O 0 3.8394055934531934e-08
group O 0 1.7325356427289051e-10
of O 0 8.15285616795336e-10
CD B-Disease 0 9.896037909129518e-07
families O 0 7.95859421032219e-07
with O 0 2.0530804079044174e-07
breast B-Disease 1 0.9999960660934448
disease I-Disease 1 0.8880735635757446
. O 0 1.6761966037392995e-07

A O 0 6.498603966065275e-07
correlation O 0 7.21458235375394e-08
was O 0 8.193110190291009e-09
observed O 0 1.2190939369105536e-09
between O 0 4.415366405829957e-10
the O 0 1.4378361834488373e-09
presence O 0 1.3235872842187746e-08
/ O 0 1.981630362024589e-07
absence O 0 1.414336736615951e-07
of O 0 8.867655054700663e-09
a O 0 1.2721459441422667e-08
PTEN O 0 6.511931587738218e-06
mutation O 0 2.7074860131648393e-09
and O 0 6.83507694887453e-11
the O 0 1.5478064663287938e-10
type O 0 2.50283571645582e-09
of O 0 5.631445088027931e-09
breast O 0 4.2152183254984266e-07
involvement O 0 1.2044968400459766e-07
( O 0 4.4314518277133175e-08
unaffected O 0 0.005061148200184107
versus O 0 0.2933124899864197
benign O 1 0.9999638795852661
versus O 0 3.8904425309738144e-05
malignant O 0 6.516628218378173e-06
) O 0 5.290727411733087e-09
. O 0 7.113820998938536e-08

Specifically O 0 5.770472455424169e-08
and O 0 4.396628394687241e-09
more O 0 9.307054016360894e-10
directly O 0 1.2537113569521807e-08
, O 0 1.2307375951703392e-10
an O 0 2.434233370429695e-10
association O 0 8.854417199444242e-10
was O 0 1.394077830951801e-08
also O 0 3.211930374447114e-11
observed O 0 1.3648197849658317e-10
between O 0 2.2784307773804358e-10
the O 0 1.038377939188706e-09
presence O 0 2.578194546742907e-09
of O 0 2.8461257794987205e-09
a O 0 2.8280101815880698e-08
PTEN O 1 0.9969629645347595
mutation O 0 0.0001797107106540352
and O 0 1.3282072359288577e-05
malignant B-Disease 1 1.0
breast I-Disease 1 0.9999996423721313
disease I-Disease 1 0.9437226057052612
. O 0 1.3477071547640662e-07

Secondly O 0 7.763160283502657e-06
, O 0 4.422982513574425e-08
there O 0 9.497577835304583e-09
appeared O 0 8.456218836272456e-09
to O 0 2.347359806531557e-10
be O 0 5.619639198428672e-10
an O 0 2.646300956143932e-09
interdependent O 0 2.127495974946214e-07
association O 0 4.973376732664292e-08
between O 0 7.000125634704091e-08
mutations O 0 1.4578322407032829e-06
upstream O 0 1.4473828287009383e-06
and O 0 9.349863105967415e-10
within O 0 6.0546714308884475e-09
the O 0 4.8460076840228794e-08
PTPase O 0 5.2295977184257936e-06
core O 0 2.89293922151046e-07
motif O 0 1.9565834463719511e-07
, O 0 1.3847488711249412e-09
the O 0 1.972665764071735e-08
core O 0 7.339834695585523e-08
motif O 0 9.089276886697917e-09
containing O 0 1.830920692835747e-10
the O 0 1.9599657452573638e-09
majority O 0 7.847107963421251e-10
of O 0 5.93147611027689e-08
missense O 0 5.083496148472477e-07
mutations O 0 2.621685268877627e-08
, O 0 5.6097443357217e-10
and O 0 1.054751563867029e-10
the O 0 1.6060793806005336e-09
involvement O 0 1.2703607055186694e-09
of O 0 5.772010425175722e-09
all O 0 2.1240834091607042e-10
major O 0 7.548422331637994e-09
organ O 0 1.0537758043938084e-07
systems O 0 1.5258596874900832e-07
( O 0 1.9680134855093456e-08
central O 0 0.0003291489265393466
nervous O 0 2.854012336683809e-06
system O 0 7.027656465652399e-06
, O 0 2.0120030086445695e-08
thyroid O 0 5.65030404686695e-06
, O 0 7.231445664501734e-08
breast O 1 0.9994359612464905
, O 0 3.787242519592837e-07
skin O 1 1.0
and O 1 0.641869306564331
gastrointestinal O 1 1.0
tract O 0 0.2618327736854553
) O 0 3.8254732714904094e-08
. O 0 2.671655693120556e-06

However O 0 2.4051846594375093e-06
, O 0 1.2700488660755127e-08
these O 0 3.5929164088344123e-09
observations O 0 5.6578034701715296e-08
would O 0 4.356408012107238e-10
need O 0 6.476955083378755e-10
to O 0 1.3262198006458448e-09
be O 0 2.5996547137197012e-09
confirmed O 0 9.110677545720591e-09
by O 0 4.129822872567246e-10
studying O 0 1.0577216880136575e-09
a O 0 1.1204154964916668e-10
larger O 0 8.772835791148736e-10
number O 0 1.1811199795985772e-09
of O 0 7.512142907728503e-09
CD B-Disease 0 8.094925760815386e-07
families O 0 2.986552942729759e-07
. O 0 1.043190309246711e-06

Molecular O 0 7.129163714125752e-05
defects O 1 0.9546641111373901
leading O 0 5.832432066199544e-07
to O 0 5.701781269351613e-10
human O 0 7.68562458119959e-09
complement B-Disease 0 3.7053160895084147e-07
component I-Disease 1 0.9999638795852661
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.4283294547112746e-09
an O 0 1.2180201292011361e-09
African O 0 8.894244785118133e-10
- O 0 2.284898936721902e-09
American O 0 6.552656639513543e-09
family O 0 2.0779028275796918e-08
. O 0 4.4855703151824855e-08

Complement B-Disease 0 8.28371469197009e-07
component I-Disease 0 0.0012193575967103243
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.329725929366532e-08
C6D B-Disease 0 5.973193401587196e-05
) O 0 8.033101267512777e-11
was O 0 1.1774384134355387e-08
diagnosed O 0 1.772208824135646e-09
in O 0 5.4235171909056135e-11
a O 0 2.691153411227276e-10
16 O 0 1.7330321622210931e-09
- O 0 3.75613179448564e-10
year O 0 1.0656677762455047e-09
- O 0 1.1771121855019828e-09
old O 0 1.2297795137783396e-07
African O 0 1.39129063825294e-09
- O 0 7.187984096823641e-10
American O 0 2.3003028648549417e-10
male O 0 1.6600187890958296e-10
with O 0 5.4497933943409294e-11
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.291621742893767e-07

The O 0 3.2869195365492487e-07
patients O 0 2.718519631628169e-08
father O 0 1.0496815150418115e-07
and O 0 3.1725644333846503e-09
two O 0 5.8139755232389234e-09
brothers O 0 6.354436266065022e-08
also O 0 4.448726276251591e-09
had O 0 8.248145277889307e-09
C6D B-Disease 1 0.9884323477745056
, O 0 2.806352927819944e-10
but O 0 2.1319901399863284e-10
gave O 0 3.5623799465867023e-09
no O 0 9.094717201563185e-10
history O 0 6.522257400831677e-09
of O 0 1.706991703542826e-08
meningitis B-Disease 1 1.0
or O 0 9.220796570730272e-09
other O 0 9.803605927061199e-09
neisserial B-Disease 0 2.5818510039243847e-05
infection I-Disease 0 1.6507619875483215e-06
. O 0 1.045964239665409e-07

By O 0 1.2829797668700849e-08
using O 0 4.531833575072142e-09
exon O 0 1.2288622563971785e-08
- O 0 3.749805799202477e-09
specific O 0 2.07192110690535e-10
polymerase O 0 1.269655824920335e-09
chain O 0 2.806568533131326e-09
reaction O 0 1.8486566721875874e-09
( O 0 1.1940917699071463e-10
PCR O 0 5.200707642316615e-10
) O 0 1.4893111049962826e-11
/ O 0 3.2011907014073415e-11
single O 0 3.40284328492757e-11
- O 0 3.446656016148353e-10
strand O 0 1.7260443074818e-10
conformation O 0 5.1061883887815185e-11
polymorphism O 0 4.032245717877636e-11
as O 0 9.932656780398119e-11
a O 0 1.3479342642064296e-10
screening O 0 1.8970705562004753e-10
step O 0 1.1222682783085247e-09
and O 0 4.103323236748224e-10
nucleotide O 0 1.6859071916286439e-09
sequencing O 0 3.797062220201042e-09
of O 0 1.673502936228033e-08
target O 0 3.828276007311615e-08
exons O 0 3.3882443517541105e-08
, O 0 4.115081608802029e-09
we O 0 8.200767287469546e-10
determined O 0 5.3093383023394836e-09
that O 0 7.539181501314829e-10
the O 0 1.4004607251649759e-08
proband O 0 1.7453952523283078e-06
was O 0 4.733669101142368e-08
a O 0 2.7285025350209935e-09
compound O 0 3.3280183941997166e-08
heterozygote O 0 6.301126518337696e-07
for O 0 1.5350776649825093e-08
two O 0 1.4755694621726434e-07
C6 O 0 0.00015624404477421194
gene O 0 8.970303042588057e-07
mutations O 0 5.781412255601026e-06
. O 0 1.052821971825324e-06

The O 0 6.565113039869175e-07
first O 0 5.391140689425811e-08
, O 0 2.7071036523551584e-09
1195delC O 0 2.7825689130622777e-07
located O 0 3.8076311881241054e-08
in O 0 1.8130178469633051e-09
exon O 0 4.651985463510755e-08
7 O 0 7.826650403330859e-07
, O 0 4.3240588887272224e-09
is O 0 4.1933859162845977e-10
a O 0 9.195694206098892e-10
novel O 0 3.6856060425805026e-09
mutation O 0 4.315553470135569e-10
, O 0 6.622989656701606e-11
while O 0 4.1809591899699683e-10
the O 0 1.6903383581734488e-08
second O 0 8.239187110348212e-08
, O 0 5.940848701868617e-09
1936delG O 0 1.445705066771552e-07
in O 0 4.619647775427893e-09
exon O 0 1.2769618251695647e-08
12 O 0 1.2107597058275132e-07
, O 0 8.065626388997771e-09
has O 0 2.3012520777854206e-09
been O 0 1.4278882520812886e-09
described O 0 1.6904988520138886e-09
before O 0 5.802871516635832e-10
to O 0 7.779569211052717e-10
cause O 0 3.8521696410498407e-07
C6D B-Disease 0 0.012233343906700611
in O 0 1.1614340600374362e-09
an O 0 1.0542392514523158e-09
unrelated O 0 1.70355054507354e-08
African O 0 3.791309044487434e-09
- O 0 1.1601836824581824e-08
American O 0 5.76650815986568e-09
individual O 0 1.3754102745622276e-08
. O 0 2.4862086434040975e-07

Both O 0 4.277745802028221e-08
mutations O 0 1.4540719917022216e-07
result O 0 2.1370244240870306e-08
in O 0 2.991248582162598e-09
premature O 0 1.2890785683339345e-06
termination O 0 1.0740449170043576e-06
codons O 0 1.0734858051364427e-06
and O 0 8.95714080684229e-08
C6 O 0 0.0004341286257840693
null O 0 8.928669558372349e-06
alleles O 0 3.862720063807501e-07
. O 0 1.1265042303421069e-06

Allele O 0 2.992374845689483e-07
- O 0 6.482596859314071e-08
specific O 0 1.8106954824403942e-09
PCR O 0 1.2672565219418175e-08
indicated O 0 5.269990221989929e-09
that O 0 5.668986113871455e-11
the O 0 1.2302500129734995e-09
probands O 0 3.2307247010976425e-07
two O 0 6.5657679293451565e-09
brothers O 0 8.819838370754951e-08
also O 0 3.3945883881614236e-09
inherited O 0 5.5092588269189946e-08
the O 0 1.989533515711628e-08
1195delC O 0 5.4397180093701536e-08
mutation O 0 5.517951096045692e-10
from O 0 4.2314857173764153e-10
their O 0 3.2905475566558096e-10
heterozygous O 0 1.0879532830188055e-09
mother O 0 5.0070867452234324e-09
and O 0 3.085769695321261e-10
the O 0 2.9545843549527717e-09
1936delG O 0 2.2010748779166533e-08
mutation O 0 1.3040930557650654e-09
from O 0 1.6490595555751497e-09
their O 0 1.0969402053362387e-09
homozygous O 0 1.3087610106765624e-08
father O 0 5.957144821877591e-07
. O 0 6.559424292618132e-08
. O 0 4.365866459465906e-07

PAX6 O 0 0.00611431710422039
mutations O 0 2.935223892563954e-05
reviewed O 0 1.1099188668595161e-05
. O 0 1.5788423297635745e-06

Mutations O 0 5.2225404942873865e-06
in O 0 2.717615643632598e-07
PAX6 O 0 0.0008941962732933462
are O 0 2.8199134138873205e-09
responsible O 0 1.1074726691262526e-09
for O 0 3.534311732167339e-10
human O 0 1.1024555135463743e-07
aniridia B-Disease 1 1.0
and O 0 6.496311044656977e-08
have O 0 3.0470576062313626e-10
also O 0 1.0393463867330865e-10
been O 0 1.507266186862033e-11
found O 0 1.0516454894415883e-11
in O 0 4.44681921493717e-12
patients O 0 6.4104581018464835e-12
with O 0 1.0221419197153914e-11
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 8.861416489480689e-09
with O 0 1.584795086273516e-07
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 1.5892084093138692e-07
with O 0 4.622908722495822e-09
autosomal B-Disease 1 0.5640929937362671
dominant I-Disease 1 0.9971543550491333
keratitis I-Disease 1 1.0
, O 0 2.7657827139648816e-09
and O 0 4.4984002633974285e-10
with O 0 1.6978209949058964e-09
isolated B-Disease 1 1.0
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.00205801404081285

No O 0 2.0858732341366704e-07
locus O 0 6.296380661297007e-08
other O 0 1.2908805135936063e-09
than O 0 9.91339454969875e-10
chromosome O 0 1.349502198877417e-08
11p13 O 0 3.1407947176376183e-07
has O 0 1.51390311398103e-09
been O 0 1.7374804928138587e-09
implicated O 0 8.142136742605999e-09
in O 0 1.113135983388247e-08
aniridia B-Disease 1 1.0
, O 0 1.4741481813018709e-08
and O 0 1.0280598594647472e-08
PAX6 O 0 0.00010683274740586057
is O 0 3.7119132212382056e-09
clearly O 0 2.1386270532275375e-08
the O 0 2.844965862891513e-08
major O 0 3.4247830171807436e-07
, O 0 2.232752649433678e-09
if O 0 2.5947308746054887e-09
not O 0 8.252689087662191e-10
only O 0 9.507473919256881e-09
, O 0 2.081213867910492e-09
gene O 0 6.645774153213324e-09
responsible O 0 7.610429975102306e-08
. O 0 8.50189223911002e-07

Twenty O 0 5.434176728158491e-06
- O 0 1.63506115313794e-07
eight O 0 4.5493649736272346e-08
percent O 0 1.6116928236442618e-08
of O 0 2.415148303569481e-09
identified O 0 9.556343272265622e-09
PAX6 O 0 1.6510422256033053e-06
mutations O 0 8.878964763425756e-08
are O 0 2.7935747048957182e-09
C O 0 0.0009981917683035135
- O 0 0.0003786850138567388
T O 0 1.2152070667070802e-05
changes O 0 1.7366927451689662e-08
at O 0 3.318864827406287e-08
CpG O 0 1.7275809227612626e-08
dinucleotides O 0 2.0862849225977698e-07
, O 0 1.2826095741047538e-09
20 O 0 6.034667876519961e-09
% O 0 6.175051581180924e-10
are O 0 4.150407448277882e-11
splicing O 0 4.818640597648027e-09
errors O 0 4.820104493319377e-08
, O 0 1.4374494927693604e-09
and O 0 2.4102736473352593e-10
more O 0 1.2712204899845148e-10
than O 0 3.365369649621641e-10
30 O 0 3.03763698639159e-08
% O 0 1.9748935820018687e-09
are O 0 6.78149827959551e-11
deletion O 0 1.326988963157305e-09
or O 0 2.7823279236116605e-09
insertion O 0 4.152123267431307e-08
events O 0 1.3622548067360185e-07
. O 0 2.5659958282631123e-06

There O 0 1.533567584033335e-08
is O 0 4.783884399728322e-10
a O 0 1.9443462395685174e-09
noticeably O 0 3.688125502776529e-07
elevated O 0 1.147304260484816e-07
level O 0 3.940758830367486e-09
of O 0 1.2667844551117469e-09
mutation O 0 7.392570999797954e-10
in O 0 5.131869373897757e-10
the O 0 5.13377163002815e-09
paired O 0 2.918970620768846e-09
domain O 0 9.409832912865568e-10
compared O 0 3.8966219140235125e-10
with O 0 1.244819351764459e-11
the O 0 1.514018577175591e-09
rest O 0 5.000978742231155e-09
of O 0 2.59509702615901e-09
the O 0 1.9156601638314896e-08
gene O 0 4.778481965672654e-08
. O 0 8.105184292617196e-07

Increased O 0 2.4477097682051863e-08
mutation O 0 8.675894669352147e-09
in O 0 4.776380957416393e-10
the O 0 5.423636206813853e-09
homeodomain O 0 3.3367967944286647e-07
is O 0 1.6448306605632013e-10
accounted O 0 9.378869902931797e-10
for O 0 2.2636502047812534e-11
by O 0 4.0071920781592496e-10
the O 0 9.99328904072172e-08
hypermutable O 0 8.924226676754188e-06
CpG O 0 6.340597451526264e-07
dinucleotide O 0 5.151587743057462e-07
in O 0 6.325787893501911e-08
codon O 0 1.6316606661348487e-06
240 O 0 3.9749582469994493e-07
. O 0 3.7875457792324596e-07

Very O 0 1.0298933972308078e-07
nearly O 0 8.136738927078113e-08
all O 0 6.980746536378035e-10
mutations O 0 4.592570768124915e-09
appear O 0 2.794495190805435e-10
to O 0 2.5851794663300787e-11
cause O 0 6.793752671541142e-09
loss O 0 6.424262899429323e-09
of O 0 4.009564236184815e-09
function O 0 1.583781217284752e-09
of O 0 5.1389857702588415e-08
the O 0 1.2947772631832777e-08
mutant O 0 7.79882736168247e-09
allele O 0 2.1053367937895473e-09
, O 0 2.2422301515501175e-10
and O 0 4.8327456619867704e-11
more O 0 1.8455157541064082e-11
than O 0 9.925497229668068e-11
80 O 0 4.119510954581074e-09
% O 0 8.900218895213641e-10
of O 0 1.7213536152027586e-09
exonic O 0 6.820683040587028e-08
substitutions O 0 5.08048847436271e-09
result O 0 1.581946484918717e-08
in O 0 1.2649164382594336e-08
nonsense O 0 1.5241421351674944e-06
codons O 0 6.586581548617687e-06
. O 0 3.481696467133588e-06

In O 0 1.975414321009339e-08
a O 0 4.562797695228937e-09
gene O 0 1.1507879094097007e-09
with O 0 1.5166681799350101e-10
such O 0 3.1418753709822056e-10
extraordinarily O 0 3.620483113309092e-08
high O 0 4.366494721352865e-08
sequence O 0 6.258527585067952e-10
conservation O 0 5.732075702979955e-09
throughout O 0 6.212500514024555e-10
evolution O 0 1.4075222765086437e-08
, O 0 3.5402622500235736e-10
there O 0 8.647704219377772e-10
are O 0 1.21932641761191e-09
presumed O 0 8.715480362297967e-06
undiscovered O 0 1.4544698387908284e-05
missense O 0 3.4413960747770034e-06
mutations O 0 1.5905456507425697e-07
, O 0 5.571869632348125e-09
these O 0 2.275335475587781e-09
are O 0 5.464285135481362e-10
hypothesized O 0 1.6333274288626853e-08
to O 0 1.7264337737188384e-09
exist O 0 2.672078203147521e-08
in O 0 1.761513246378854e-08
as O 0 7.903925336449902e-08
- O 0 9.447246185345648e-08
yet O 0 5.427685323411424e-08
unidentified O 0 1.8075171510645305e-06
phenotypes O 0 2.0859805260897701e-07
. O 0 2.446682856316329e-08
. O 0 2.055690089264317e-07

Genetic O 0 1.7819598951973603e-06
heterogeneity O 0 3.98973452320206e-06
and O 0 8.973416676383295e-09
penetrance O 0 1.0305689102096949e-06
analysis O 0 4.465294800581887e-09
of O 0 4.242996620718031e-09
the O 0 5.796218260911701e-08
BRCA1 O 0 1.8877258298743982e-06
and O 0 2.4283426114379836e-07
BRCA2 O 0 4.947094112139894e-06
genes O 0 7.368294063780922e-07
in O 0 1.5118125418212003e-07
breast B-Disease 0 0.00025290355551987886
cancer I-Disease 0 0.0005277452291920781
families O 0 5.4729060394720364e-08
. O 0 1.6212885611821548e-07

The O 0 0.001487193745560944
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 4.876299044553889e-06
Consortium O 0 6.727463386368981e-08
. O 0 2.2983405401078016e-08

The O 0 1.1261456656086466e-08
contribution O 0 1.4062128350644798e-08
of O 0 2.317860570144603e-08
BRCA1 O 0 3.785747537676798e-07
and O 0 2.254226316722452e-08
BRCA2 O 0 0.00022808178619015962
to O 0 1.6971814602584345e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 8.19078564973097e-08
assessed O 0 1.1511062103508607e-09
by O 0 4.6417859139724627e-11
linkage O 0 2.8049109701555608e-08
and O 0 2.639836682583052e-10
mutation O 0 3.2747382583409035e-10
analysis O 0 1.7763941706494535e-10
in O 0 3.365920042686099e-11
237 O 0 2.1484012346917325e-09
families O 0 6.741933678000578e-10
, O 0 1.6893118848226862e-10
each O 0 1.6786322332151826e-10
with O 0 2.538802779117333e-10
at O 0 1.2916421709974202e-08
least O 0 3.157279770960031e-09
four O 0 1.483523193179792e-09
cases O 0 1.1274845945763445e-08
of O 0 2.9029550319137343e-07
breast B-Disease 0 2.087207121803658e-06
cancer I-Disease 0 9.781476251191634e-08
, O 0 1.3459328096487866e-10
collected O 0 1.2614198574567581e-09
by O 0 1.0753665735663276e-09
the O 0 2.666025693542906e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 5.558465545618674e-07
Consortium O 0 2.8691280462567192e-08
. O 0 3.666900028065356e-08

Families O 0 1.3984453595128343e-08
were O 0 1.2467690213568972e-09
included O 0 3.301528841981316e-11
without O 0 3.811309254309059e-11
regard O 0 2.6327368063405743e-10
to O 0 2.8556169581750446e-11
the O 0 4.608152193164017e-10
occurrence O 0 3.880497388308868e-06
of O 0 4.015286322101019e-06
ovarian B-Disease 1 1.0
or I-Disease 0 0.0016213917406275868
other I-Disease 0 1.3810615655529546e-06
cancers I-Disease 1 0.9939312934875488
. O 0 3.1617290119356767e-07

Overall O 0 8.161335426848382e-05
, O 0 3.6890892118890406e-08
disease O 0 4.4873060687677935e-05
was O 0 4.624851257517548e-08
linked O 0 5.601791475129403e-09
to O 0 7.98681343283647e-10
BRCA1 O 0 6.228274429531666e-08
in O 0 2.656636854947436e-10
an O 0 1.064131768813148e-10
estimated O 0 3.2657127002622133e-10
52 O 0 1.8429602288705382e-09
% O 0 2.5698665417905886e-10
of O 0 1.2704697294196876e-09
families O 0 3.991784680579258e-09
, O 0 1.5520168483718066e-09
to O 0 1.4365458156362365e-08
BRCA2 O 0 1.7479408143117325e-07
in O 0 1.545978012273963e-09
32 O 0 3.894500721912664e-08
% O 0 1.8433189419297946e-09
of O 0 1.9707206977415126e-09
families O 0 2.0004840006748736e-09
, O 0 1.982932013033789e-10
and O 0 1.3897516470962046e-10
to O 0 8.265086393066667e-10
neither O 0 1.0252576565505933e-08
gene O 0 1.1550252976277875e-09
in O 0 2.7430606674982982e-09
16 O 0 3.8542857794254815e-08
% O 0 1.9220200986325153e-09
( O 0 4.282604479377561e-11
95 O 0 7.975643256941112e-09
% O 0 2.446774782782768e-09
confidence O 0 9.133731992960747e-09
interval O 0 7.0878982683098e-08
[ O 0 2.6132136099477066e-07
CI O 0 3.046322262889589e-06
] O 0 3.398710290980489e-08
6 O 0 1.6314881179368967e-07
% O 0 1.5286643062495386e-08
- O 0 7.525910561412275e-09
28 O 0 7.884397490443007e-08
% O 0 5.255635926459945e-09
) O 0 5.357049873144781e-11
, O 0 7.754558106753962e-11
suggesting O 0 2.179887381714707e-09
other O 0 3.6547764814542916e-09
predisposition O 0 3.5018412745557725e-05
genes O 0 2.4372011466766708e-06
. O 0 1.9232588783779647e-06

The O 0 6.833599854871863e-07
majority O 0 2.160054890509855e-08
( O 0 6.193526580489106e-09
81 O 0 2.019612423964645e-07
% O 0 1.0048020193664797e-09
) O 0 8.288347438933918e-12
of O 0 1.4892415078904264e-09
the O 0 3.924733027815819e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.800351310369933e-09
were O 0 1.1397473242968914e-10
due O 0 4.77110906338396e-10
to O 0 4.694157840212654e-10
BRCA1 O 0 9.084250685020834e-09
, O 0 1.3546171129252826e-10
with O 0 1.420590207967809e-11
most O 0 1.0730595301211565e-09
others O 0 3.49861850601485e-09
( O 0 5.598008168128388e-10
14 O 0 5.4927021153616806e-08
% O 0 8.025375031195381e-09
) O 0 7.949346736424445e-11
due O 0 6.3440066533360095e-09
to O 0 8.089802605582008e-08
BRCA2 O 0 3.679416113300249e-05
. O 0 2.2634174001723295e-06

Conversely O 0 4.4290354139775445e-07
, O 0 1.7284172981746337e-09
the O 0 8.036353804641294e-10
majority O 0 2.8768392182354496e-11
of O 0 5.562681426596328e-10
families O 0 3.126786329854525e-10
with O 0 5.6727716274407314e-11
male B-Disease 0 1.4223823541215097e-07
and I-Disease 0 2.17876888086721e-07
female I-Disease 0 1.8032360458164476e-05
breast I-Disease 1 0.9711191654205322
cancer I-Disease 1 0.9999998807907104
were O 0 6.4225962326247554e-09
due O 0 3.897101308325546e-08
to O 0 1.0822850171621212e-08
BRCA2 O 0 2.7588433226810594e-07
( O 0 3.1139797407320202e-09
76 O 0 2.0850816895290336e-07
% O 0 1.1513066056068055e-08
) O 0 1.0539396022579695e-09
. O 0 5.976468742119323e-08

The O 0 2.4987593860714696e-07
largest O 0 1.8127029477454926e-07
proportion O 0 2.4868436199199095e-08
( O 0 4.870261416378696e-10
67 O 0 1.3587510672152803e-08
% O 0 2.061993908952786e-10
) O 0 9.2316887641275e-13
of O 0 1.0324625182578373e-10
families O 0 2.053602565776913e-10
due O 0 1.6644773337404217e-09
to O 0 3.3742908467360166e-10
other O 0 8.54874948608142e-10
genes O 0 1.491071932591126e-09
was O 0 2.7258340029590045e-09
found O 0 4.481031518066558e-11
in O 0 4.9970642207464167e-11
families O 0 5.567128980032976e-10
with O 0 1.0362465746593941e-10
four O 0 9.276819312731277e-10
or O 0 1.3109081875573025e-10
five O 0 2.2344984196287498e-10
cases O 0 1.6234530386682877e-09
of O 0 2.5326301056338707e-07
female O 0 0.00016134459292516112
breast B-Disease 1 0.9772943258285522
cancer I-Disease 0 7.97870525275357e-05
only O 0 9.782689858184312e-08
. O 0 2.4544377197344147e-07

These O 0 5.897250687780797e-08
estimates O 0 2.6287386845069705e-07
were O 0 2.584792380133649e-09
not O 0 2.685646427469379e-10
substantially O 0 6.765446425305299e-09
affected O 0 1.0344618495139457e-09
either O 0 1.793577092401577e-10
by O 0 1.1274770006508561e-10
changing O 0 5.324854779331645e-09
the O 0 9.633334130398907e-09
assumed O 0 1.3052086522691297e-08
penetrance O 0 8.971537113211525e-08
model O 0 1.3028084389077321e-08
for O 0 3.736048803659742e-09
BRCA1 O 0 1.8965007342330864e-08
or O 0 3.1885477591586664e-10
by O 0 5.280448994726683e-11
including O 0 2.386222330841292e-10
or O 0 1.867333487837186e-08
excluding O 0 2.3345126010099193e-07
BRCA1 O 0 4.87508998503472e-07
mutation O 0 7.182426742247117e-08
data O 0 2.3126546011553728e-07
. O 0 5.423659104053513e-07

Among O 0 1.9038218113109906e-08
those O 0 2.0105903608680364e-09
families O 0 5.207778208671243e-09
with O 0 2.590180570027911e-10
disease O 0 2.95790243853844e-07
due O 0 2.869312565323412e-09
to O 0 6.408924502210311e-10
BRCA1 O 0 5.399651215043377e-08
that O 0 7.544705415973851e-10
were O 0 3.337537468617313e-10
tested O 0 5.97557212045352e-11
by O 0 5.916891282486958e-11
one O 0 1.2287960649004503e-09
of O 0 3.3700091606192473e-09
the O 0 3.3974643098844126e-09
standard O 0 9.99465288309409e-10
screening O 0 1.8966327119951387e-10
methods O 0 1.8666310719339663e-09
, O 0 3.5988953484000774e-10
mutations O 0 1.8975998550274653e-09
were O 0 1.1147884837470201e-09
detected O 0 3.119817959529314e-09
in O 0 3.8373368371757977e-10
the O 0 7.977439153705745e-09
coding O 0 2.4954866617576954e-08
sequence O 0 1.4997979747022328e-08
or O 0 1.0686034279672185e-08
splice O 0 2.1629951163504302e-07
sites O 0 1.4611900134298139e-08
in O 0 2.850090163875052e-10
an O 0 7.863529272178482e-10
estimated O 0 1.8493688802578845e-09
63 O 0 1.544817429532941e-08
% O 0 1.7378781747012795e-09
( O 0 1.5831098931773369e-10
95 O 0 4.6299533096316736e-08
% O 0 1.4204514897642184e-08
CI O 0 4.068783141519816e-07
51 O 0 7.567670934349735e-08
% O 0 7.686827174779864e-09
- O 0 6.735369595389784e-09
77 O 0 3.155330929871525e-08
% O 0 3.2612326172909434e-09
) O 0 2.5287363869530566e-10
. O 0 1.530721327469564e-08

The O 0 5.269962599641076e-08
estimated O 0 1.822713358023975e-08
sensitivity O 0 1.3363111506237146e-08
was O 0 5.26157339919564e-09
identical O 0 3.494914913027003e-10
for O 0 5.595870294916594e-11
direct O 0 1.5877676950992736e-09
sequencing O 0 2.907978968735847e-09
and O 0 8.495402159525156e-10
other O 0 3.469260656530082e-09
techniques O 0 2.519097392905678e-07
. O 0 4.462121410142572e-07

The O 0 1.6826813862280687e-06
penetrance O 0 0.0008840300724841654
of O 0 1.981548120966181e-05
BRCA2 O 0 8.24194103188347e-06
was O 0 7.752188224685597e-08
estimated O 0 1.3088026218355253e-09
by O 0 1.3656009656415335e-10
maximizing O 0 1.345390501228394e-07
the O 0 4.8576680455880705e-08
LOD O 0 0.000920102815143764
score O 0 1.7195931434343947e-07
in O 0 3.909176271577053e-08
BRCA2 O 0 3.100546450696129e-07
- O 0 3.94732069253223e-08
mutation O 0 3.936439174623274e-09
families O 0 9.2687185704321e-10
, O 0 8.662458944597162e-11
over O 0 1.4726010688637103e-10
all O 0 5.771501054852024e-10
possible O 0 7.771345167384425e-08
penetrance O 0 1.2761330253852066e-05
functions O 0 2.2860405124447425e-07
. O 0 9.847009323493694e-07

The O 0 9.646259790940803e-09
estimated O 0 9.51120959769014e-09
cumulative O 0 6.60456862533465e-08
risk O 0 5.8915393452707576e-08
of O 0 5.6667460057724384e-08
breast B-Disease 0 2.1150328393559903e-05
cancer I-Disease 0 8.751635505177546e-06
reached O 0 1.57601732553303e-07
28 O 0 5.615830289684709e-08
% O 0 1.0997810440116496e-09
( O 0 3.859811775752675e-11
95 O 0 1.1625472140508464e-08
% O 0 5.3807927002935685e-09
CI O 0 8.962335584783432e-08
9 O 0 1.0321465460094714e-08
% O 0 2.1499055868900996e-09
- O 0 1.0526779448127854e-09
44 O 0 5.4033675311870866e-09
% O 0 1.6765491772652297e-10
) O 0 4.2113339725202703e-13
by O 0 5.92237587096478e-12
age O 0 1.3563812295558364e-09
50 O 0 1.0379719306286006e-09
years O 0 5.543859815659857e-10
and O 0 6.081194436902138e-10
84 O 0 2.7707315553016088e-08
% O 0 5.333278263464081e-10
( O 0 2.124305245598812e-11
95 O 0 6.658843254570002e-09
% O 0 4.308498890992496e-09
CI O 0 1.827941531473698e-07
43 O 0 3.373033052866958e-08
% O 0 1.3592065251089025e-09
- O 0 4.75239070318878e-10
95 O 0 5.216506782090846e-09
% O 0 2.762834128144931e-10
) O 0 1.261860733091369e-12
by O 0 3.341485074748185e-11
age O 0 1.896656343092218e-08
70 O 0 2.6797543739576213e-08
years O 0 2.723761838296923e-08
. O 0 1.6234298527706414e-07

The O 0 1.8759602653517504e-06
corresponding O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 1.2257158914508182e-06
were O 0 2.467499093938841e-09
0 O 0 5.0531220097127516e-08
. O 0 4.2516184350915864e-08

4 O 0 3.852779173030285e-06
% O 0 2.922080355460821e-08
( O 0 2.3247118119407162e-10
95 O 0 1.4677653759065379e-08
% O 0 2.7313140638085542e-09
CI O 0 3.1510726472561146e-08
0 O 0 2.0835810854435977e-09
% O 0 8.152482577905573e-10
- O 0 2.9425756276069137e-10
1 O 0 1.0755306645293672e-09
% O 0 1.0988453202909199e-10
) O 0 3.3751419627886525e-13
by O 0 4.061668102545157e-12
age O 0 4.5905543255564396e-10
50 O 0 2.8490465542319043e-10
years O 0 1.4872650333508375e-10
and O 0 1.810004091051809e-10
27 O 0 1.2586903075373357e-08
% O 0 5.509285250226981e-10
( O 0 2.481324694325604e-11
95 O 0 6.482347103542452e-09
% O 0 3.0751015067664866e-09
CI O 0 3.6048344753680794e-08
0 O 0 2.152753308948263e-09
% O 0 2.6384991969052862e-09
- O 0 1.0589490395673806e-09
47 O 0 1.3279467303561887e-08
% O 0 3.647740720591486e-10
) O 0 2.3103435397436867e-12
by O 0 3.261241970919926e-11
age O 0 1.4945150894618564e-08
70 O 0 2.166384405200006e-08
years O 0 1.9984712551490702e-08
. O 0 1.6860758478287607e-07

The O 0 1.0389692306489451e-07
lifetime O 0 1.20302217965218e-06
risk O 0 3.820185156655498e-05
of O 0 3.456298827586579e-06
breast B-Disease 1 0.9999397993087769
cancer I-Disease 1 0.9979502558708191
appears O 0 1.7888565073675977e-09
similar O 0 9.186936801575118e-12
to O 0 7.351789316212276e-11
the O 0 3.8354515119465304e-09
risk O 0 9.911395260076006e-09
in O 0 2.9467952522566065e-09
BRCA1 O 0 1.4004206683182474e-08
carriers O 0 1.0941234585004622e-09
, O 0 2.388103048645007e-10
but O 0 5.16766240910016e-10
there O 0 7.326064754842321e-10
was O 0 1.3151261191168828e-09
some O 0 7.796826378969612e-11
suggestion O 0 7.847051897158508e-09
of O 0 3.211308996498019e-09
a O 0 8.821735342223747e-09
lower O 0 8.984740418327419e-08
risk O 0 9.367861153464219e-09
in O 0 5.073632181051835e-09
BRCA2 O 0 1.8779630295284733e-08
carriers O 0 5.703325589578867e-10
< O 0 6.517046902132506e-09
50 O 0 1.2930003734368256e-08
years O 0 9.913739162925594e-09
of O 0 8.778735605119437e-08
age O 0 3.121288955298951e-06
. O 0 1.2593707197083859e-06

Eye B-Disease 0 0.0011402576928958297
movement I-Disease 0 3.7373207305790856e-05
abnormalities I-Disease 0 6.082445906940848e-06
correlate O 0 3.8162760063187307e-08
with O 0 5.90826346180684e-11
genotype O 0 4.363730710110758e-08
in O 0 1.8751775687775307e-09
autosomal O 1 0.9987012147903442
dominant O 1 0.9999984502792358
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 1.0
. O 0 3.5666830626723822e-06

We O 0 1.0721684162717793e-07
compared O 0 2.379694024057244e-07
horizontal O 0 1.3589187801699154e-05
eye O 0 0.0004493066226132214
movements O 0 4.584050657285843e-06
( O 0 2.0430364955359437e-08
visually O 0 6.62667645201509e-08
guided O 0 1.028124998470048e-07
saccades O 0 4.2274484712834237e-07
, O 0 5.509329881192571e-09
antisaccades O 0 4.230985837239132e-07
, O 0 1.5804859643253621e-09
and O 0 7.487934161609644e-10
smooth O 0 4.427259447936649e-09
pursuit O 0 1.2755523748353426e-08
) O 0 3.656446326272267e-11
in O 0 3.2052857590336714e-10
control O 0 3.91086008022512e-09
subjects O 0 3.789265079490178e-08
( O 0 6.198179747229915e-10
n O 0 2.4898227923841887e-09
= O 0 1.3063642612110016e-08
14 O 0 2.0082417506728234e-08
) O 0 3.575630069807545e-11
and O 0 3.3898744922211677e-11
patients O 0 4.7393984570209824e-11
with O 0 5.2808994156772204e-12
three O 0 4.691425026237539e-11
forms O 0 2.572830171132523e-09
of O 0 2.055454118021771e-08
autosomal O 0 0.0033721255604177713
dominant O 1 0.9814329743385315
cerebellar B-Disease 1 1.0
ataxias I-Disease 0 0.006938762962818146
type I-Disease 0 0.025152146816253662
I I-Disease 0 0.14773625135421753
spinocerebellar B-Disease 0 0.0003042081370949745
ataxias I-Disease 0 6.459297310357215e-06
1 I-Disease 0 5.136154754836753e-07
and I-Disease 0 8.981738019997465e-09
2 I-Disease 0 1.3843803969848523e-07
( O 0 3.471749332462082e-09
SCA1 B-Disease 0 2.3561333364341408e-05
, O 0 5.425405458225896e-09
n O 0 2.491951311967e-09
= O 0 1.0730845545481316e-08
11 O 0 1.4329144981672925e-08
; O 0 1.478368316654155e-09
SCA2 B-Disease 0 2.1754703993792646e-06
, O 0 1.8512676946969009e-09
n O 0 1.8077140895300658e-09
= O 0 8.374168913860558e-09
10 O 0 8.724780897750861e-09
) O 0 3.602741160957379e-10
and O 0 6.643847250131785e-09
SCA3 B-Disease 1 1.0
/ O 0 1.066972004082345e-06
Machado B-Disease 0 1.854994593486481e-07
- I-Disease 0 1.6261166990716447e-07
Joseph I-Disease 0 6.350146577460691e-07
disease I-Disease 1 0.9817128777503967
( O 0 2.8155184850220394e-08
MJD B-Disease 1 1.0
) O 0 1.392700399449609e-09
( O 0 4.158864641556903e-10
n O 0 1.8068661011838572e-09
= O 0 2.5599772968121215e-08
16 O 0 6.569904087427858e-08
) O 0 1.3398273601694655e-09
. O 0 3.404523241101742e-08

In O 0 3.652876614523848e-07
SCA1 B-Disease 0 0.0004686257161665708
, O 0 9.43920941409715e-09
saccade O 0 6.285210218948123e-08
amplitude O 0 1.052646414478886e-08
was O 0 2.048861524883705e-09
significantly O 0 2.595077042144567e-09
increased O 0 3.417488292356552e-09
, O 0 2.8476121460840886e-10
resulting O 0 1.0897835522882815e-08
in O 0 9.200173067824835e-09
hypermetria B-Disease 0 2.540522655181121e-05
. O 0 1.449901446903823e-06

The O 0 1.0320638921257341e-06
smooth O 0 2.141954382750555e-07
pursuit O 0 6.72943940571713e-07
gain O 0 1.6980928876364487e-06
was O 0 6.647196073572559e-07
decreased O 0 1.4355535995491664e-06
. O 0 2.9967614523229713e-07

In O 0 8.015646812964405e-07
SCA2 B-Disease 0 0.0008996641263365746
, O 0 2.07396322338127e-08
saccade O 0 1.8735987339368876e-07
velocity O 0 2.0669345701662678e-07
was O 0 7.083965414267368e-08
markedly O 0 5.634880153593258e-07
decreased O 0 4.5454012820300704e-07
. O 0 1.9804363660114177e-07

The O 0 5.154477094038157e-07
percentage O 0 4.158910996920895e-06
of O 0 1.4016904970048927e-07
errors O 0 2.96486120987538e-07
in O 0 3.193103381704532e-08
antisaccades O 0 2.9052696390863275e-06
was O 0 9.4498382452457e-09
greatly O 0 2.991979108912801e-09
increased O 0 9.012141588549127e-10
and O 0 2.2581012060207684e-10
was O 0 9.61022372791831e-10
significantly O 0 8.224639302945036e-10
correlated O 0 4.764455052708172e-09
with O 0 8.018099378892529e-11
age O 0 3.650135909083474e-07
at O 0 7.32738527631227e-08
disease O 0 4.922744096802489e-07
onset O 0 1.167473442365008e-06
. O 0 1.040656982809196e-07

In O 0 9.044727633522598e-09
addition O 0 3.074098753330645e-09
, O 0 8.714195337544695e-11
a O 0 9.682581819658864e-11
correlation O 0 9.763759800662797e-10
between O 0 2.8044908062518914e-10
smooth O 0 1.3907255347334058e-09
pursuit O 0 6.974521848945869e-09
gain O 0 1.7749092862118232e-08
and O 0 1.9748774837680116e-10
the O 0 1.3435635937142365e-09
number O 0 4.798124564331374e-09
of O 0 7.36901171194404e-08
trinucleotide O 0 7.635482688783668e-06
repeats O 0 5.42343173037807e-07
was O 0 1.5555183097148984e-07
found O 0 3.28996101472967e-08
. O 0 3.148414862153004e-07

In O 0 2.9769296361337183e-06
SCA3 B-Disease 1 1.0
, O 0 4.991280206922966e-07
gaze B-Disease 0 4.103584069525823e-05
- I-Disease 0 8.132554398798675e-07
evoked I-Disease 0 1.77400067968847e-06
nystagmus I-Disease 0 3.652072109616711e-06
was O 0 1.6345554243457627e-08
often O 0 1.68537253597556e-10
present O 0 3.043827967452728e-10
as O 0 1.2183639652718625e-09
was O 0 1.599507370997344e-08
saccade O 0 1.7718724620863213e-07
hypometria O 0 4.3873825461560045e-07
and O 0 1.0488385271401057e-08
smooth O 0 4.652961749229689e-08
pursuit O 0 2.648964425588929e-07
gain O 0 3.610580563417898e-07
was O 0 1.6369085642509162e-07
markedly O 0 1.3225926522864029e-06
decreased O 0 4.4926858322469343e-07
. O 0 1.9234738601880963e-07

Three O 0 9.533080458368204e-08
major O 0 2.385301911544957e-07
criteria O 0 1.2570018270707806e-07
, O 0 1.1005327316127023e-08
saccade O 0 4.506537436554936e-07
amplitude O 0 6.259082141468753e-08
, O 0 1.8322979800089456e-09
saccade O 0 5.2629712143925644e-08
velocity O 0 1.0502602521000881e-07
, O 0 1.636688451434054e-09
and O 0 9.054820226950255e-10
presence O 0 5.11300868311082e-08
of O 0 9.055206646735314e-06
gaze B-Disease 1 0.6852998733520508
- I-Disease 0 8.009893463167828e-06
evoked I-Disease 0 3.924738393834559e-06
nystagmus I-Disease 0 5.210046083448105e-07
, O 0 3.327303987887831e-10
permitted O 0 3.3426228451816087e-09
the O 0 1.4868772879594871e-09
correct O 0 6.267490082478844e-09
assignment O 0 6.414895725725955e-09
of O 0 2.009830968319193e-09
90 O 0 1.1093336027556688e-08
% O 0 1.678194472276573e-09
of O 0 3.4591114417281688e-09
the O 0 2.2069393423862493e-08
SCA1 B-Disease 0 7.654753062524833e-06
, O 0 5.138823810924009e-10
90 O 0 8.76314043551929e-09
% O 0 9.017541158229392e-10
of O 0 3.150650407235389e-09
the O 0 3.6154524707399105e-08
SCA2 B-Disease 0 7.525908131356118e-06
, O 0 6.479475844756166e-10
and O 0 3.1247532339406803e-10
93 O 0 1.6953690007426303e-08
% O 0 4.012316312529407e-10
of O 0 3.831720218894219e-10
the O 0 1.2297315388209995e-09
patients O 0 5.101625233372431e-10
with O 0 2.19338369689126e-09
SCA3 B-Disease 1 1.0
to O 0 4.9914867794598194e-09
their O 0 3.0291882335831133e-09
genetically O 0 5.5270330534540335e-09
confirmed O 0 1.0537392292064851e-08
patient O 0 2.8063811274847694e-09
group O 0 1.017849249329572e-09
and O 0 1.2569359997272045e-09
, O 0 8.506103599259518e-10
therefore O 0 1.2334978372052774e-08
, O 0 1.0265329697389802e-09
may O 0 5.963258775665281e-09
help O 0 6.779490036024072e-08
orient O 0 9.677695197751746e-05
diagnoses O 0 0.00011149371857754886
of O 0 2.2184729004948167e-06
SCA1 B-Disease 1 0.9990828037261963
, O 0 1.1461821713965037e-07
SCA2 B-Disease 1 0.8120409846305847
, O 0 2.0698452729561723e-08
and O 0 1.0801963412632176e-07
SCA3 B-Disease 1 1.0
at O 0 2.3546944305508077e-07
early O 0 5.4932471016400086e-08
clinical O 0 8.246147764623402e-09
stages O 0 1.1262100585440749e-08
of O 0 1.1206217287451636e-08
the O 0 3.533216386131244e-08
diseases O 0 3.1306868208957894e-07
. O 0 1.546727901313716e-08
. O 0 1.599883603375929e-07

Genetic O 0 8.914498295098383e-08
basis O 0 2.0553523327748735e-08
and O 0 5.570312960889723e-11
molecular O 0 6.360410864658661e-09
mechanism O 0 2.170752289032407e-08
for O 0 1.0710193620866448e-08
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.9999617338180542

Ventricular B-Disease 1 0.9999998807907104
fibrillation I-Disease 1 0.9996498823165894
causes O 0 8.371092917514034e-06
more O 0 3.4768635193138664e-10
than O 0 1.0561567592715093e-10
300 O 0 1.5963422250742099e-10
, O 0 1.462356104264817e-11
000 O 0 9.617229235203695e-10
sudden O 0 1.6476950914778854e-09
deaths O 0 3.8022878179333475e-09
each O 0 1.7350917924652265e-10
year O 0 4.2358139218379165e-10
in O 0 7.796086554101578e-10
the O 0 5.8533561997364814e-08
USA O 0 5.612488962469797e-07
alone O 0 2.1533011818064551e-07
. O 0 5.025949008086172e-07

In O 0 3.368172940554359e-08
approximately O 0 4.6075413706603285e-08
5 O 0 4.7436202521566884e-08
- O 0 6.441894573328e-09
12 O 0 1.1676027256157795e-08
% O 0 8.341325408167677e-10
of O 0 1.5204944248115027e-10
these O 0 2.5968473899018463e-11
cases O 0 1.9548201946051336e-10
, O 0 4.105528764175581e-11
there O 0 6.904891935999302e-11
are O 0 2.5717138488201563e-11
no O 0 4.568806222238209e-09
demonstrable O 0 8.351188444066793e-05
cardiac O 0 0.021672487258911133
or O 0 6.78060605423525e-05
non O 1 1.0
- O 1 0.9996566772460938
cardiac O 0 0.19161593914031982
causes O 0 7.28734264043851e-08
to O 0 3.676559057197437e-11
account O 0 6.531039598023369e-11
for O 0 3.658762529057391e-11
the O 0 1.26576837899961e-08
episode O 0 7.260050338686597e-09
, O 0 1.947766427312647e-11
which O 0 2.183204571987174e-12
is O 0 1.4541890911920485e-12
therefore O 0 4.3875514332825105e-11
classified O 0 1.0065244193668832e-09
as O 0 9.59627133312324e-09
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.738897442817688
IVF B-Disease 1 1.0
) O 0 2.274724764106395e-08
. O 0 7.785944688976087e-08

A O 0 1.0067689117931877e-06
distinct O 0 1.0240581360676515e-07
group O 0 2.539414678537355e-09
of O 0 4.2627753771284915e-08
IVF B-Disease 1 1.0
patients O 0 8.548887819870288e-08
has O 0 1.317121134380983e-10
been O 0 1.7301769392186195e-11
found O 0 2.4835121806288107e-11
to O 0 3.514077223654155e-11
present O 0 2.138457466660526e-10
with O 0 5.7383490320583874e-11
a O 0 4.863023761458862e-09
characteristic O 0 4.7182098228404357e-07
electrocardiographic O 0 1.066064305632608e-05
pattern O 0 3.6670267036242876e-06
. O 0 7.342305252677761e-07

Because O 0 8.686760111231706e-08
of O 0 3.458315802618017e-07
the O 0 3.0670605610794155e-08
small O 0 1.3963763478841429e-09
size O 0 1.2982485086965312e-09
of O 0 3.161799710937885e-09
most O 0 6.043614497741601e-10
pedigrees O 0 9.84575088125439e-09
and O 0 4.766106953546512e-10
the O 0 4.596084846042459e-09
high O 0 5.1062933437151514e-08
incidence O 0 7.187113055806549e-07
of O 0 1.1540173261437303e-08
sudden B-Disease 0 2.544196888720762e-07
death I-Disease 0 1.0269799304296612e-06
, O 0 5.051317586435289e-09
however O 0 2.0582161752713546e-08
, O 0 9.987640714470558e-10
molecular O 0 5.759912546920987e-09
genetic O 0 3.7410905484591694e-09
studies O 0 4.669281850055995e-09
of O 0 8.434327902762107e-09
IVF B-Disease 1 1.0
have O 0 1.5866475910897293e-09
not O 0 6.883251191247552e-10
yet O 0 1.0629197966238735e-08
been O 0 4.455859681229413e-09
done O 0 2.150505373776923e-08
. O 0 5.447203079711471e-07

Because O 0 7.517218847397089e-08
IVF B-Disease 1 1.0
causes O 0 7.982761599123478e-05
cardiac O 0 7.25773861631751e-05
rhythm O 0 4.877415449300315e-07
disturbance O 0 2.7469423002912663e-06
, O 0 1.699705931557105e-10
we O 0 6.560792187304543e-11
investigated O 0 3.971649675804656e-10
whether O 0 7.428528903119513e-10
malfunction O 0 1.8125211909136851e-06
of O 0 7.636468346561287e-09
ion O 0 8.230296799638381e-08
channels O 0 3.2321295861947874e-08
could O 0 3.909741419505508e-09
cause O 0 3.616783885718178e-07
the O 0 9.492000074828866e-09
disorder O 0 1.0227694247078034e-08
by O 0 1.06582784265008e-10
studying O 0 5.54659929097312e-10
mutations O 0 1.4685150873106068e-09
in O 0 1.1760591112075502e-10
the O 0 4.50879644731117e-09
cardiac O 0 2.1217294943198794e-07
sodium O 0 1.7588830587556004e-06
channel O 0 3.192726296674664e-07
gene O 0 2.5965695726881677e-07
SCN5A O 0 0.0010741307632997632
. O 0 1.2713984460788197e-06

We O 0 2.0429787639386632e-07
have O 0 3.88612875212857e-09
now O 0 2.0361186070516624e-09
identified O 0 3.3266713828083994e-09
a O 0 2.3533726078994732e-09
missense O 0 3.095252054663433e-07
mutation O 0 2.402391174882723e-08
, O 0 6.365165616806223e-10
a O 0 9.206435058750628e-10
splice O 0 2.648191639309516e-07
- O 0 2.796161524543095e-08
donor O 0 3.842671514320273e-09
mutation O 0 2.6755242465981155e-09
, O 0 6.382205874899682e-11
and O 0 1.5541718953460126e-11
a O 0 4.1016562368767495e-10
frameshift O 0 2.32666597099751e-08
mutation O 0 1.8649647104407308e-10
in O 0 4.750729670766063e-11
the O 0 2.8401375695708e-10
coding O 0 4.9728239304158706e-09
region O 0 1.1742895544841758e-08
of O 0 2.473229976374114e-08
SCN5A O 0 0.00010558268695604056
in O 0 5.75018743731448e-09
three O 0 4.404856568385185e-08
IVF B-Disease 1 1.0
families O 0 1.541780250136071e-07
. O 0 2.981055331474636e-07

We O 0 3.8656676082382546e-08
show O 0 4.647521922862552e-09
that O 0 5.490902871274628e-11
sodium O 0 9.064410333436967e-10
channels O 0 1.495266271911433e-10
with O 0 5.7652680372777265e-12
the O 0 6.660592077878391e-10
missense O 0 8.935538886589711e-08
mutation O 0 4.417997523376016e-09
recover O 0 2.4000096132681392e-08
from O 0 1.1653067844008547e-08
inactivation O 0 8.268326467941733e-08
more O 0 2.766251117058971e-10
rapidly O 0 1.5941097331051424e-09
than O 0 6.263755486513034e-11
normal O 0 2.155641887213733e-09
and O 0 3.2459011173324726e-11
that O 0 3.093688846766973e-11
the O 0 4.847946932784453e-09
frameshift O 0 3.2655358950250957e-07
mutation O 0 9.420270785653884e-09
causes O 0 1.347781264371406e-08
the O 0 1.140829386514497e-08
sodium O 0 2.6025734456425198e-08
channel O 0 1.0030695385410127e-08
to O 0 1.7590279233203887e-09
be O 0 1.2085143552553745e-08
non O 0 4.998209988116287e-06
- O 0 2.2651729523204267e-06
functional O 0 4.032101060147397e-06
. O 0 7.002656730037415e-07

Our O 0 2.905890994497895e-07
results O 0 7.6932984427458e-08
indicate O 0 5.265531655140876e-08
that O 0 7.331013573974587e-10
mutations O 0 7.820276870518228e-09
in O 0 2.0310297887959905e-09
cardiac O 0 7.52950271021291e-08
ion O 0 1.775647660906543e-06
- O 0 4.619597802957287e-06
channel O 0 1.9133596040887824e-08
genes O 0 3.1407490497237234e-10
contribute O 0 4.7932990909771434e-11
to O 0 2.015733586990809e-11
the O 0 5.144354942032692e-10
risk O 0 2.465194048895114e-09
of O 0 2.1140849071343837e-09
developing O 0 1.1032822300194312e-07
IVF B-Disease 1 1.0
. O 0 1.0751173107337308e-07
. O 0 2.2483484940494236e-07

Molecular O 0 1.2846102208641241e-06
heterogeneity O 0 2.277070279887994e-06
in O 0 1.5470760672542383e-08
mucopolysaccharidosis B-Disease 0 6.242773815756664e-05
IVA I-Disease 1 0.999873161315918
in O 0 8.4556708301875e-09
Australia O 0 2.0710518022770685e-10
and O 0 1.8309277705075289e-10
Northern O 0 1.327759324709632e-08
Ireland O 0 9.36342670065926e-10
: O 0 7.269053137193282e-10
nine O 0 3.8785161748933206e-09
novel O 0 3.28587046460882e-09
mutations O 0 2.483945937825638e-09
including O 0 2.631556916821154e-10
T312S O 0 5.454069764709857e-07
, O 0 5.968830985025875e-10
a O 0 5.176619688462836e-10
common O 0 5.157421711921018e-10
allele O 0 1.2244349978374203e-09
that O 0 1.031035812282255e-10
confers O 0 3.5856476898743495e-08
a O 0 1.1350971718115943e-08
mild O 0 8.814974989945767e-07
phenotype O 0 1.3750214975516428e-06
. O 0 5.868278663001547e-07

Mucopolysaccharidosis B-Disease 0 0.002193589461967349
IVA I-Disease 1 1.0
( O 0 0.017710242420434952
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 4.167426403967056e-09
is O 0 1.3084301697663392e-10
an O 0 4.550022136839971e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.0001148243754869327
by O 0 2.8958656653199633e-11
a O 0 3.6313876350391183e-09
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 1.0014671314451107e-09
N O 0 1.60985553776527e-08
- O 0 8.97964813617591e-09
acetylgalactosamine O 0 1.7037591248936224e-07
- O 0 3.382929492090625e-08
6 O 0 1.2536305860066932e-07
- O 0 4.577216827783559e-08
sulfate O 0 9.48013436641304e-08
sulfatase O 0 7.400117283395957e-07
( O 0 5.7184504242968615e-08
GALNS O 0 0.00013337002019397914
) O 0 2.785812647232433e-08
. O 0 2.3127692827529245e-07

Previous O 0 5.079260745333158e-07
studies O 0 2.2544497824128484e-08
of O 0 7.885728181555862e-10
patients O 0 4.126009950367049e-11
from O 0 9.694538227744687e-11
a O 0 1.2539684568491083e-10
British O 0 5.961128812792538e-10
- O 0 8.105286997128758e-10
Irish O 0 1.9850929233733439e-10
population O 0 2.407617993860356e-10
showed O 0 5.397925995076491e-10
that O 0 1.856470879801897e-11
the O 0 7.801054802136775e-10
I113F O 0 4.618433990799531e-08
mutation O 0 2.1010326811676805e-09
is O 0 7.194482509742528e-11
the O 0 8.503827503281158e-11
most O 0 2.914261540420959e-11
common O 0 2.450410707677264e-11
single O 0 6.558527332334307e-11
mutation O 0 1.4636801770606667e-09
among O 0 3.315023144878637e-09
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 6.576625111165413e-08
and O 0 2.60745480762381e-10
produces O 0 6.106381511550296e-10
a O 0 3.0155244967744466e-10
severe O 0 7.105197141754616e-08
clinical O 0 7.156513248673946e-08
phenotype O 0 1.2404150311340345e-06
. O 0 4.008259111287771e-07

We O 0 7.949236646709323e-08
studied O 0 1.3215041860803467e-07
mutations O 0 1.3430134337966138e-08
in O 0 1.673020166848005e-09
the O 0 1.2313210895342763e-08
GALNS O 0 3.2603409181319876e-06
gene O 0 5.954526871576604e-10
from O 0 1.4794994118716431e-09
23 O 0 2.9739999352074165e-09
additional O 0 6.410015629398913e-09
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 1.5225275262764626e-08
( O 0 6.549139008882321e-11
15 O 0 2.4818858079811434e-09
from O 0 2.8997706458255834e-09
Australia O 0 7.902798554448864e-11
, O 0 4.438694897745954e-11
8 O 0 5.145454062827071e-10
from O 0 1.1995299198375164e-09
Northern O 0 8.714369670315136e-09
Ireland O 0 4.804018849391412e-10
) O 0 8.578865395847401e-11
, O 0 5.491803539703355e-11
with O 0 1.1491176066247277e-11
various O 0 1.0688862017715905e-09
clinical O 0 6.872343050190466e-08
phenotypes O 0 1.4504656746794353e-06
( O 0 1.4474785814400093e-08
severe O 0 2.3488948954764055e-06
, O 0 2.9182467553567903e-09
16 O 0 1.960654749666446e-08
cases O 0 2.0723884830431416e-09
; O 0 1.164346397075633e-09
intermediate O 0 4.24280450772585e-08
, O 0 5.16456821753053e-10
4 O 0 5.981131145915697e-09
cases O 0 3.480859600557551e-09
; O 0 1.5329300495636744e-08
mild O 0 2.7744022190745454e-07
, O 0 1.1360300478102658e-09
3 O 0 7.652478650754801e-09
cases O 0 4.033911427114845e-09
) O 0 5.131539193570234e-09
. O 0 1.296163958386387e-07

We O 0 6.2817584023378e-08
found O 0 1.2893899281607446e-08
two O 0 1.3544577681656733e-09
common O 0 1.3456845637804804e-09
mutations O 0 5.7669264919013585e-09
that O 0 1.1313286418790369e-10
together O 0 4.403505685091069e-11
accounted O 0 8.464864365009817e-10
for O 0 2.036027423046871e-11
32 O 0 8.554560615436912e-09
% O 0 1.7365892057696897e-09
of O 0 2.0286099466915175e-09
the O 0 8.499458026278717e-09
44 O 0 5.500942990011026e-08
unrelated O 0 1.0805297989691098e-08
alleles O 0 2.427400724869244e-09
in O 0 9.808482914763772e-10
these O 0 3.321320329874311e-09
patients O 0 1.1742986139040568e-08
. O 0 1.1588196002776385e-07

One O 0 7.972346338647185e-08
is O 0 3.052084585064563e-09
the O 0 1.3070795112923861e-08
T312S O 0 4.92662366013974e-07
mutation O 0 8.519941196993841e-09
, O 0 2.1007710848675032e-10
a O 0 5.05728237065739e-10
novel O 0 2.5932562763841815e-09
mutation O 0 1.6137868819043888e-09
found O 0 2.5562077454743815e-10
exclusively O 0 6.617651426843452e-10
in O 0 7.877956065271974e-10
milder O 0 1.2558723483380163e-06
patients O 0 2.8041835520298264e-08
. O 0 2.01909074348805e-07

The O 0 3.1405070899381826e-07
other O 0 1.0846180842349895e-08
is O 0 1.3678957966334337e-09
the O 0 3.4268288207073283e-09
previously O 0 2.985178770842367e-09
described O 0 1.7861970791344106e-09
I113F O 0 1.1123977827764975e-07
that O 0 9.756085522782953e-11
produces O 0 1.1462905069592466e-09
a O 0 1.918679659596023e-09
severe O 0 4.5051626784697874e-07
phenotype O 0 3.405300958547741e-06
. O 0 7.190897690634301e-07

The O 0 6.434406714106444e-07
I113F O 0 3.3982091736106668e-06
and O 0 7.929698675468444e-09
T312S O 0 1.377258911361423e-07
mutations O 0 1.6463294727486755e-08
accounted O 0 6.445458833326256e-09
for O 0 1.7849359490451633e-10
8 O 0 9.704390180331757e-09
( O 0 1.8499678178240941e-10
18 O 0 2.4925991937152503e-08
% O 0 1.4981389462320749e-09
) O 0 8.224599820638723e-12
and O 0 1.3384830743756737e-10
6 O 0 7.242430211107376e-09
( O 0 2.1884932754900888e-10
14 O 0 1.812071559470496e-08
% O 0 8.184359301388611e-10
) O 0 5.29286900766146e-12
of O 0 3.7419306542219033e-10
44 O 0 5.642325717758467e-09
unrelated O 0 6.744226510591034e-09
alleles O 0 8.143814511640812e-09
, O 0 7.340055230287135e-09
respectively O 0 5.001744440846778e-08
. O 0 3.270528736720735e-07

The O 0 8.506661401952442e-07
relatively O 0 1.1266504316154169e-06
high O 0 7.689336598559748e-07
residual O 0 0.00012662142398767173
GALNS O 1 0.7317950129508972
activity O 0 2.767748128462699e-07
seen O 0 5.648140177783034e-09
when O 0 3.5529257313982043e-10
the O 0 4.039144574363718e-10
T312S O 0 5.272523750932123e-09
mutant O 0 5.237250633172152e-10
cDNA O 0 5.287468685111207e-09
is O 0 1.6988965789721533e-09
overexpressed O 0 2.407354884326196e-07
in O 0 1.5865143643267743e-09
mutant O 0 1.0259228133691067e-08
cells O 0 1.7546449848637735e-09
provides O 0 6.101398830615778e-10
an O 0 2.277695219932152e-11
explanation O 0 3.8147437986246757e-10
for O 0 4.075483353571663e-11
the O 0 5.22946752568032e-09
mild O 0 1.1846021408246088e-07
phenotype O 0 1.5175638523601265e-08
in O 0 9.844688952931335e-11
patients O 0 4.710972931198931e-11
with O 0 1.239004038255942e-11
this O 0 4.633367023387791e-10
mutation O 0 2.3451558917031434e-08
. O 0 4.832135402921267e-08

The O 0 1.7605190194558418e-08
distribution O 0 5.096026267636944e-09
and O 0 6.769505095371997e-11
relative O 0 2.8114066630280377e-09
frequencies O 0 2.021734557544619e-09
of O 0 2.1781167980350347e-09
the O 0 3.901866829636447e-09
I113F O 0 7.369672516688297e-08
and O 0 2.874220639270675e-09
T312S O 0 8.152319708187861e-08
mutations O 0 5.226017396608995e-09
in O 0 7.946424629423632e-10
Australia O 0 2.792726050415695e-10
corresponded O 0 1.4276539950230926e-09
to O 0 4.012783161311262e-10
those O 0 1.279906736151304e-09
observed O 0 1.0127798155679102e-08
in O 0 6.063797797217774e-10
Northern O 0 2.3974292773232264e-08
Ireland O 0 1.7569289356700324e-09
and O 0 1.1328239679642138e-08
are O 0 6.082609971258535e-10
unique O 0 2.9248223842870402e-09
to O 0 1.441301300530995e-09
these O 0 2.9192599448890633e-09
two O 0 3.811509330375884e-09
populations O 0 1.025993334735631e-08
, O 0 4.0623465702438466e-10
suggesting O 0 4.618696092251184e-09
that O 0 5.769300037705705e-10
both O 0 5.4645590275015365e-09
mutations O 0 1.6013695258720873e-08
were O 0 5.319058082875472e-09
probably O 0 1.5774381800781612e-09
introduced O 0 2.2521826070764916e-10
to O 0 2.613155525299504e-10
Australia O 0 6.80502806882366e-11
by O 0 1.8781545763069118e-10
Irish O 0 4.889586513456834e-09
migrants O 0 5.0014769215067645e-08
during O 0 1.1074837935609594e-08
the O 0 2.9359016551211425e-08
19th O 0 8.286464776574576e-07
century O 0 1.1044145367122837e-06
. O 0 4.1301035480501014e-07

Haplotype O 0 4.001486104243668e-06
analysis O 0 1.8332013951294357e-07
using O 0 2.3130201753929214e-08
6 O 0 9.73975375018199e-07
RFLPs O 0 1.0209430456598056e-06
provides O 0 2.0697970004590616e-09
additional O 0 8.951019370151414e-10
data O 0 2.46154785443764e-09
that O 0 1.4090142941292072e-10
the O 0 4.358172045471065e-09
I113F O 0 1.0387928739419294e-07
mutation O 0 3.360919542672036e-09
originated O 0 3.207917487202394e-09
from O 0 6.319258449849485e-10
a O 0 1.4278228599451381e-09
common O 0 3.67677333024119e-09
ancestor O 0 7.637082717337762e-07
. O 0 2.9270125878611e-07

The O 0 5.430107421489083e-07
other O 0 2.2871368798860203e-08
9 O 0 1.857458755694097e-07
novel O 0 1.5541150588660457e-08
mutations O 0 6.067827129641046e-09
identified O 0 3.1460207772227022e-09
in O 0 1.4096701583810045e-10
these O 0 1.7232647253617728e-10
23 O 0 9.424673486080337e-09
patients O 0 2.1007710848675032e-10
were O 0 4.672977005348855e-10
each O 0 7.025838244523186e-11
limited O 0 1.483245193334426e-10
to O 0 3.3029981527654684e-10
a O 0 6.1660156980281045e-09
single O 0 2.2150953071786716e-08
family O 0 1.9179530852397875e-07
. O 0 8.487747322760697e-07

These O 0 4.016562371589316e-08
data O 0 3.075965437915329e-08
provide O 0 2.367554596816035e-09
further O 0 2.5121285052165376e-09
evidence O 0 7.575278182514467e-09
for O 0 3.4968020146131096e-10
extensive O 0 4.787915486303973e-08
allelic O 0 3.1777597087057075e-07
heterogeneity O 0 3.7443157907546265e-07
in O 0 1.1981951431039306e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
in O 0 1.524273685049593e-08
British O 0 3.279760818486466e-08
- O 0 3.187729902265346e-08
Irish O 0 4.770963624167734e-10
patients O 0 2.6954480314422824e-10
and O 0 1.502263591302011e-11
provide O 0 4.9449357802933136e-11
evidence O 0 1.6170375038981888e-09
for O 0 2.57317223084641e-10
their O 0 1.8161951942374799e-09
transmission O 0 6.3275478190405465e-09
to O 0 1.492377194045602e-10
Australia O 0 2.0151491586517523e-11
by O 0 6.503293736859206e-11
British O 0 3.992835395649763e-09
- O 0 1.2748202493639837e-08
Irish O 0 1.7566372800814634e-09
migrants O 0 1.2098705148844147e-08
. O 0 3.901844625175954e-09
. O 0 8.042233901051077e-08

Identification O 0 1.1823595258420028e-07
of O 0 4.095766996670136e-07
constitutional O 0 2.231885628134478e-05
WT1 O 1 0.9890639185905457
mutations O 0 1.944171117429505e-06
, O 0 9.663749800381538e-10
in O 0 2.5530199482259874e-11
patients O 0 2.1775662870093804e-11
with O 0 1.363918786939644e-11
isolated O 0 3.396096133201354e-07
diffuse B-Disease 1 0.9999998807907104
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 2.5308161122339357e-10
and O 0 1.7413994508538866e-12
analysis O 0 5.7413487158930465e-11
of O 0 2.371277341151057e-10
genotype O 0 6.158801113542722e-08
/ O 0 1.122774548889538e-07
phenotype O 0 7.465647655635621e-09
correlations O 0 4.1128296324188796e-09
by O 0 6.61978249993922e-11
use O 0 6.497804516669703e-10
of O 0 1.1682576683824664e-08
a O 0 2.725464742781014e-09
computerized O 0 6.199887536695314e-08
mutation O 0 2.1411942441318388e-08
database O 0 1.4926298774753377e-07
. O 0 6.551559295076004e-07

Constitutional O 0 1.1001665143339778e-06
mutations O 0 2.937425051641185e-06
of O 0 3.59619235723585e-07
the O 0 1.428813050097233e-07
WT1 O 0 2.879792191379238e-06
gene O 0 3.231585443685958e-09
, O 0 5.221830190471621e-10
encoding O 0 2.24372009860474e-09
a O 0 4.1879392398413984e-08
zinc O 0 1.7510359384687035e-07
- O 0 2.4473269633062955e-08
finger O 0 1.3238699914097651e-08
transcription O 0 2.0687007662445467e-08
factor O 0 7.842144711389665e-09
involved O 0 6.604827795797519e-10
in O 0 9.649296472957758e-09
renal O 1 1.0
and O 1 0.9999281167984009
gonadal O 1 0.9999992847442627
development O 1 0.9999991655349731
, O 0 6.056515844399257e-10
are O 0 1.3121682559957826e-11
found O 0 4.7170149730657585e-11
in O 0 7.796643539115244e-12
most O 0 1.5956898996583035e-11
patients O 0 1.5589874877153242e-11
with O 0 1.9702948994559932e-10
Denys B-Disease 1 0.9999997615814209
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 9.339297321275808e-06
DDS B-Disease 1 1.0
) O 0 1.906524493833217e-09
, O 0 2.3033674967365414e-10
or O 0 4.999414660034063e-09
diffuse B-Disease 1 0.9999959468841553
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 2.466522062150034e-07
DMS B-Disease 0 1.7523433371025021e-06
) O 0 3.2510688585674075e-11
associated O 0 4.3307915587043055e-10
with O 0 1.0866898353389942e-10
pseudohermaphroditism B-Disease 1 1.0
and O 0 1.1758970686059911e-07
/ O 0 1.689004648142145e-06
or O 0 8.182635014009065e-08
Wilms B-Disease 0 4.019058542326093e-05
tumor I-Disease 0 0.00017457728972658515
( O 0 8.904234505280328e-08
WT B-Disease 1 1.0
) O 0 1.1680348244169636e-08
. O 0 7.613697050601331e-08

Most O 0 9.913932785821089e-08
mutations O 0 3.6313414852884307e-07
in O 0 1.716570885434976e-08
DDS B-Disease 1 1.0
patients O 0 1.4679871185308002e-07
lie O 0 3.055557940001563e-08
in O 0 1.5132564090691858e-09
exon O 0 5.266787184154964e-08
8 O 0 3.0103041126494645e-07
or O 0 5.329996000114079e-09
exon O 0 9.789479449295868e-09
9 O 0 4.3412992312141796e-08
, O 0 5.827606175401456e-10
encoding O 0 1.3366883599985613e-08
zinc O 0 1.2282563375265454e-06
finger O 0 1.0051121535070706e-06
2 O 0 1.1571735285542673e-06
or O 0 4.093064660537493e-07
zinc O 0 1.3250847814560984e-06
finger O 0 8.620211389143151e-08
3 O 0 3.3307106406255116e-08
, O 0 4.0515366062088276e-10
respectively O 0 1.5101943029449671e-09
, O 0 9.538087680782681e-11
with O 0 2.373076735118218e-11
a O 0 1.0093086366680382e-08
hot O 0 1.1891826943610795e-05
spot O 0 3.311579121145769e-06
( O 0 2.4332968973084235e-09
R394W O 0 7.59216263190865e-08
) O 0 4.3620118628240334e-10
in O 0 7.739139995521782e-09
exon O 0 9.414257107209778e-08
9 O 0 2.483536036379519e-06
. O 0 1.1780920203818823e-06

We O 0 4.6576765555528254e-08
analyzed O 0 5.821268445060923e-08
a O 0 2.651798336472666e-09
series O 0 1.6283062675981341e-09
of O 0 1.946450112200182e-09
24 O 0 1.2296523799193437e-08
patients O 0 5.287748017224203e-10
, O 0 1.3591151815095515e-10
10 O 0 2.9181246308240816e-09
with O 0 1.13656539735274e-09
isolated B-Disease 1 0.8723668456077576
DMS I-Disease 1 1.0
( O 0 5.297505936141533e-07
IDMS B-Disease 0 0.008351536467671394
) O 0 9.263045330776265e-10
, O 0 2.7962651638624436e-10
10 O 0 1.0095662084097512e-09
with O 0 7.034075544254392e-10
DDS B-Disease 1 1.0
, O 0 1.2137899574327093e-09
and O 0 2.594007231238038e-10
4 O 0 1.114563641380073e-08
with O 0 1.1655817422351333e-09
urogenital B-Disease 0 1.347350098512834e-05
abnormalities I-Disease 0 3.385021409485489e-05
and O 0 1.7810492636272102e-06
/ O 1 0.9967722296714783
or O 0 0.0012514867121353745
WT B-Disease 1 1.0
. O 0 1.8691722516450682e-06

We O 0 6.787627739868185e-07
report O 0 7.667602517358318e-07
WT1 O 0 0.00034306177985854447
heterozygous O 0 3.4521536917964113e-07
mutations O 0 1.9223460867578979e-07
in O 0 1.0428303554022023e-08
16 O 0 4.008770915220339e-08
patients O 0 1.2094913959259657e-09
, O 0 1.729814763651305e-10
4 O 0 1.2717019437502586e-08
of O 0 3.811962301369931e-08
whom O 0 1.3537048459966172e-07
presented O 0 4.2834446389861114e-07
with O 0 9.065629313909085e-08
IDMS B-Disease 1 0.9999978542327881
. O 0 8.167919077095576e-06

One O 0 5.838637662236579e-08
male O 0 1.5348902593359526e-08
and O 0 7.571259175165324e-10
two O 0 1.3705699908328484e-09
female O 0 5.80655035165023e-09
IDMS B-Disease 0 5.698556560673751e-05
patients O 0 3.932731917899446e-09
with O 0 2.6541360220733168e-09
WT1 O 1 1.0
mutations O 1 1.0
underwent O 1 0.9752992391586304
normal O 0 0.0005474727950058877
puberty O 0 5.5439195421058685e-06
. O 0 1.266314768599841e-07

Two O 0 3.7690395515710406e-07
mutations O 0 6.077577268115419e-07
associated O 0 4.4237631868782046e-07
with O 0 8.37123081964819e-09
IDMS B-Disease 1 0.9999699592590332
are O 0 4.337107062379886e-10
different O 0 3.9197597945239693e-10
from O 0 2.8558975184722613e-09
those O 0 3.287900229853591e-10
described O 0 1.1070628858078635e-09
in O 0 3.3541123212188495e-09
DDS B-Disease 1 1.0
patients O 0 4.4201907911656235e-08
. O 0 1.1461340676532927e-07

No O 0 1.8739664255917887e-06
WT1 O 0 4.131261448492296e-05
mutations O 0 2.3006877825082483e-07
were O 0 4.640471562566972e-09
detected O 0 2.1263382166125666e-09
in O 0 7.27967755520531e-11
the O 0 6.679140573950804e-10
six O 0 5.937016989143729e-10
other O 0 2.785651931347388e-09
IDMS B-Disease 1 0.9999985694885254
patients O 0 2.4023638189873964e-08
, O 0 5.866415686561766e-10
suggesting O 0 1.072908606403189e-08
genetic O 0 1.514028724614036e-07
heterogeneity O 0 4.544414423435228e-06
of O 0 4.4990226655272636e-08
this O 0 1.2784825642597752e-08
disease O 0 1.1024908417311963e-06
. O 0 1.4859317332138744e-07

We O 0 7.99552424268768e-08
analyzed O 0 2.657587856447208e-07
genotype O 0 1.259886062143778e-06
/ O 0 2.648987162956473e-07
phenotype O 0 6.659975326783751e-08
correlations O 0 5.047073159403226e-08
, O 0 1.3513759555827676e-10
on O 0 2.8290000897435164e-10
the O 0 7.302874277526072e-11
basis O 0 8.42372949172443e-10
of O 0 1.8763070264160575e-10
the O 0 3.385417779444566e-10
constitution O 0 1.5931916896860798e-09
of O 0 1.2194456999736758e-08
a O 0 3.2067934085944216e-08
WT1 O 0 1.0412687515781727e-05
mutation O 0 1.0514624726454258e-08
database O 0 2.0432587177765527e-08
of O 0 8.351776870085814e-08
84 O 0 4.6163293632162095e-07
germ O 0 6.747690804331796e-06
- O 0 6.623385615966981e-06
line O 0 1.8268119674758054e-06
mutations O 0 5.118381718460796e-09
, O 0 6.974940069959246e-11
to O 0 4.8067112790040056e-11
compare O 0 1.87615767366367e-09
the O 0 4.6723376279089734e-09
distribution O 0 8.667904616288524e-09
and O 0 7.381637523451445e-10
type O 0 5.662154123342589e-08
of O 0 1.3653320252160484e-07
mutations O 0 4.8329187762874426e-08
, O 0 7.071984109430218e-10
according O 0 1.0180589704589238e-09
to O 0 4.2138231792776537e-10
the O 0 9.314179649777543e-09
different O 0 2.5453511298678677e-08
symptoms O 0 2.4573400878580287e-06
. O 0 2.0117042254241824e-07

This O 0 1.7046035694079364e-08
demonstrated O 0 1.9168517439993593e-08
( O 0 4.789481033995457e-10
1 O 0 3.699240691545924e-09
) O 0 2.0992279095577437e-11
the O 0 2.1335604116767826e-10
association O 0 4.746448234449474e-10
between O 0 2.0005372913800556e-09
mutations O 0 3.077759824776649e-09
in O 0 1.4287410143865031e-09
exons O 0 1.2538787785842942e-08
8 O 0 2.8173181121360358e-08
and O 0 1.674146932195697e-09
9 O 0 8.044090549219618e-08
and O 0 2.173246116399241e-08
DMS B-Disease 0 4.9919744924409315e-06
; O 0 2.9657424960305434e-08
( O 0 1.1203006300419815e-09
2 O 0 1.6607360819875794e-08
) O 0 6.175555206100469e-11
among O 0 1.515705200239026e-10
patients O 0 1.2352176226304579e-10
with O 0 1.7751917991137844e-10
DMS B-Disease 0 1.3337338486962835e-06
, O 0 1.2655884673584694e-10
a O 0 9.122440303155344e-11
higher O 0 9.285741620068677e-10
frequency O 0 1.0389742399752322e-09
of O 0 1.6245589318231168e-09
exon O 0 3.341016574509581e-09
8 O 0 2.6244469708558427e-08
mutations O 0 2.3897672729589203e-09
among O 0 2.6326576474389185e-09
46 O 0 7.051181682982133e-08
, O 0 2.1910628866805837e-09
XY O 0 8.780692724030814e-07
patients O 0 1.8495725784273276e-10
with O 0 3.9895125397704234e-11
female O 0 7.686822844910068e-10
phenotype O 0 1.0512053449929226e-09
than O 0 5.3303972347151785e-11
among O 0 6.619078618541607e-10
46 O 0 3.832118622426606e-08
, O 0 2.0821151469618826e-09
XY O 0 4.238398560119094e-06
patients O 0 3.7856059953433885e-10
with O 0 2.630396421510195e-11
sexual O 0 4.838429656928156e-10
ambiguity O 0 2.4015103239349855e-09
or O 0 5.368837041608288e-10
male O 0 1.1123076903984952e-09
phenotype O 0 3.395060899080704e-09
; O 0 8.648661231624999e-10
and O 0 1.9567909514961457e-09
( O 0 9.722634919384632e-10
3 O 0 2.957495048860892e-08
) O 0 1.5132180231081094e-10
statistically O 0 1.2748689215413833e-08
significant O 0 7.504935006785729e-10
evidence O 0 5.824730475723072e-09
that O 0 8.489020042468098e-10
mutations O 0 1.16331246857726e-08
in O 0 5.199183306103805e-09
exons O 0 9.675192558233903e-08
8 O 0 1.433870409073279e-07
and O 0 7.293707859901133e-09
9 O 0 7.350678288275958e-08
preferentially O 0 3.3491211581804237e-08
affect O 0 4.72132448692264e-08
amino O 0 2.2705027191705085e-08
acids O 0 4.453938995396811e-09
with O 0 4.1654041327277014e-11
different O 0 7.288544767725114e-10
functions O 0 1.7699725018971435e-09
. O 0 4.46466463799311e-09
. O 0 6.600853907912096e-08

The O 0 7.246757149914629e-07
185delAG O 0 1.0992280294885859e-05
BRCA1 O 0 4.540929694485385e-07
mutation O 0 4.850851276216872e-09
originated O 0 1.872861199458953e-09
before O 0 1.1084250878257151e-10
the O 0 1.2450360187266085e-10
dispersion O 0 1.846873320943132e-09
of O 0 9.693804647881166e-10
Jews O 0 2.557828171489973e-09
in O 0 5.474434794372485e-10
the O 0 8.894062375475187e-09
diaspora O 0 5.652343038065055e-09
and O 0 7.915202937525123e-10
is O 0 1.419529216395432e-10
not O 0 2.0323115412779202e-10
limited O 0 1.7985177791501883e-09
to O 0 2.4533933995485313e-08
Ashkenazim O 0 9.062229946721345e-05
. O 0 2.555655782998656e-06

The O 0 1.2141198624249228e-07
185delAG O 0 1.0973844837280922e-06
mutation O 0 3.498186273986903e-08
in O 0 7.897577702919989e-09
BRCA1 O 0 4.573778866756584e-08
is O 0 3.247890845159418e-10
detected O 0 1.0626212132436308e-09
in O 0 2.259462755782593e-10
Ashkenazi O 0 7.907314802935161e-09
Jews O 0 7.872957397125901e-09
both O 0 3.286545757763548e-10
in O 0 1.0507041903196068e-09
familial B-Disease 1 0.9133917093276978
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.7920381845115685e-10
in O 0 4.519106616696078e-11
the O 0 3.193288966585328e-10
general O 0 7.662172563094316e-10
population O 0 7.726334017021941e-10
. O 0 1.595126519760015e-08

All O 0 1.0051248722220407e-07
tested O 0 4.222122029773345e-08
Ashkenazi O 0 2.2028009638574986e-08
mutation O 0 1.1663223720148608e-09
carriers O 0 9.285222590804665e-11
share O 0 1.1139122263470469e-10
the O 0 5.012528933590055e-11
same O 0 1.7241950922564087e-10
allelic O 0 1.5640806338979019e-07
pattern O 0 2.2569457769350265e-07
at O 0 5.3199030958239746e-08
the O 0 1.1550925194114825e-07
BRCA1 O 0 7.472103789041284e-07
locus O 0 2.5901144340423343e-07
. O 0 5.160369482837268e-07

Our O 0 5.43585883860942e-07
previous O 0 9.063243311402402e-08
study O 0 1.866933718730479e-09
showed O 0 7.669805346388614e-10
that O 0 1.960173343085181e-11
this O 0 1.492872492292463e-10
Ashkenazi O 0 7.371538934819455e-09
mutation O 0 1.1924128351381569e-09
also O 0 9.539270762193297e-11
occurs O 0 9.998575578595847e-11
in O 0 1.0397587651977958e-10
Iraqi O 0 1.5361328564722498e-07
Jews O 0 6.535982777222671e-08
with O 0 6.029196586432306e-11
a O 0 4.1507339232360607e-10
similar O 0 9.59637591613216e-10
allelic O 0 5.53273082459782e-07
pattern O 0 6.985001164139248e-07
. O 0 4.27905519018168e-07

We O 0 2.520293946872698e-07
extended O 0 7.19457375453203e-07
our O 0 1.8219903807903393e-08
analysis O 0 2.3401591775495945e-09
to O 0 3.6341987752486204e-10
other O 0 3.9589833633613125e-09
non O 0 3.855241743622173e-07
- O 0 8.710004095746626e-08
Ashkenazi O 0 2.5925158908535195e-08
subsets O 0 3.261506398288816e-09
354 O 0 4.399933750676155e-09
of O 0 1.5987320356458667e-09
Moroccan O 0 4.061893221773971e-08
origin O 0 9.481180285320079e-09
, O 0 8.534558615380661e-10
200 O 0 2.8723790013174266e-09
Yemenites O 0 1.6316157314122393e-07
and O 0 3.4788287806009066e-09
150 O 0 1.857968356944184e-08
Iranian O 0 6.112668415880762e-07
Jews O 0 4.6874342274350056e-07
. O 0 5.173570798433502e-07

Heteroduplex O 0 2.0585459424182773e-05
analysis O 0 5.246243972578668e-08
complemented O 0 8.172290399954818e-09
by O 0 1.6513879153023936e-10
direct O 0 5.9782001571306864e-09
DNA O 0 8.630868464365449e-09
sequencing O 0 3.422754346615875e-08
of O 0 9.127447953005685e-08
abnormally O 0 1.5230014582812146e-07
migrating O 0 1.9599816880599974e-08
bands O 0 1.8366026921512457e-08
were O 0 7.3505912467908274e-09
employed O 0 2.787514290503168e-07
. O 0 2.92552812197755e-07

Four O 0 3.737397946679266e-08
of O 0 6.58691874377837e-08
Moroccan O 0 1.7099771412176779e-06
origin O 0 2.47764901928349e-08
( O 0 1.1221178153331124e-10
1 O 0 6.208733527302002e-10
. O 0 5.622713752928554e-11
1 O 0 7.502458654329303e-10
% O 0 7.60097540464244e-11
) O 0 7.500643986121935e-13
and O 0 7.048815090643368e-12
none O 0 1.5024885779979513e-09
of O 0 3.5422633715143093e-09
the O 0 2.5535790371122857e-08
Yemenites O 0 3.169778040046367e-07
or O 0 3.1810474254712062e-09
Iranians O 0 1.1441220415520093e-08
was O 0 6.690377141183035e-09
a O 0 3.864233655281879e-10
carrier O 0 1.5431056432646528e-09
of O 0 3.0842179921108936e-09
the O 0 4.622206262183681e-08
185delAG O 0 1.939474714163225e-06
mutation O 0 8.176173764695704e-07
. O 0 6.225150173122529e-07

BRCA1 O 0 1.5709716535639018e-05
allelic O 0 3.1532756565866293e-06
patterns O 0 2.1387987203524972e-07
were O 0 1.8808585799945376e-09
determined O 0 6.704796717826866e-10
for O 0 1.2708423202667518e-10
four O 0 1.1975982427969711e-09
of O 0 8.999705425338789e-10
these O 0 1.1817750944498329e-10
individuals O 0 5.93422810890587e-11
and O 0 2.878124960581374e-10
for O 0 4.2052081261623186e-10
12 O 0 8.488926894756332e-09
additional O 0 1.8527698486536792e-08
non O 0 6.515074801427545e-06
- O 0 9.399370810569962e-07
Ashkenazi O 0 9.409912848923341e-08
185delAG O 0 2.1364048308214478e-08
mutation O 0 1.1549240452879417e-09
carriers O 0 1.4630884281885415e-09
who O 0 1.967728024965254e-08
had O 0 1.3133720131008886e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.45855540267803e-06

Six O 0 4.829527370020514e-06
non O 0 4.71633902634494e-05
- O 0 1.0704596888899687e-06
Ashkenazi O 0 3.943106818837805e-08
individuals O 0 5.464180774517047e-10
shared O 0 8.996513534142991e-10
the O 0 4.5441569951343297e-10
common O 0 4.0716238713933706e-10
Ashkenazi O 0 4.583714297012875e-09
haplotype O 0 1.0171064879216374e-08
, O 0 6.228945692576815e-10
four O 0 3.6663247993118375e-09
had O 0 5.709488881677771e-09
a O 0 6.388688467140469e-10
closely O 0 2.0583396098672324e-10
related O 0 2.7355788745353493e-09
pattern O 0 2.6610921466385662e-08
, O 0 7.38354863361046e-11
and O 0 5.748558573603901e-11
the O 0 1.1702603330832062e-08
rest O 0 5.0333163414961746e-08
( O 0 6.646759809214586e-10
n O 0 6.441231548137694e-09
= O 0 5.722443674471833e-08
6 O 0 8.196489886813652e-08
) O 0 1.5156069455013466e-10
displayed O 0 9.177843374175154e-09
a O 0 6.628759319227129e-09
distinct O 0 1.4835585204764357e-07
BRCA1 O 0 4.462165634322446e-06
allelic O 0 5.535493073693942e-06
pattern O 0 3.08536641568935e-06
. O 0 1.1046472536690999e-06

We O 0 2.218731687264608e-08
conclude O 0 3.383006941248823e-08
that O 0 2.200136739460845e-10
the O 0 5.197765329256754e-09
185delAG O 0 5.328240604285384e-07
BRCA1 O 0 1.333945789383506e-07
mutation O 0 2.20000351269789e-09
occurs O 0 4.048168467107871e-10
in O 0 4.600404085453036e-11
some O 0 4.515748053268709e-10
non O 0 1.676803890404699e-06
- O 0 3.9980508859116526e-07
Ashkenazi O 0 1.1313237990862035e-07
populations O 0 1.7815365183082577e-08
at O 0 1.799983162520391e-09
rates O 0 3.0543775841884724e-10
comparable O 0 6.347392056404999e-10
with O 0 1.991641747356443e-11
that O 0 5.952278114840226e-10
of O 0 6.529565865776021e-08
Ashkenazim O 0 5.186782800592482e-06
. O 0 6.291123213486571e-07

The O 0 1.8278768720847438e-07
majority O 0 8.668284756652156e-09
of O 0 1.8673374313493696e-07
Jewish O 0 1.5806224837433547e-05
185delAG O 0 2.44452820652441e-07
mutation O 0 5.904721600558105e-09
carriers O 0 5.824571935875156e-10
have O 0 1.410520034106355e-10
a O 0 7.911701294105455e-10
common O 0 3.558705774509008e-09
allelic O 0 4.963577566741151e-07
pattern O 0 6.181750791256491e-07
, O 0 2.2703761093367802e-09
supporting O 0 7.711732585846676e-09
the O 0 1.9143897134199506e-07
founder O 0 2.870420701128751e-07
effect O 0 2.054306520449245e-07
notion O 0 1.5858714164096455e-07
, O 0 7.480853159158585e-10
but O 0 1.4985876983786284e-09
dating O 0 2.7973243277301663e-08
the O 0 1.3217304584145495e-08
mutations O 0 4.187521884801981e-09
origin O 0 1.7136063679146218e-09
to O 0 8.33894009399927e-10
an O 0 2.3017174832773435e-09
earlier O 0 5.859362772753229e-09
date O 0 6.497636917401906e-08
than O 0 4.533899922165574e-09
currently O 0 5.522638790722567e-09
estimated O 0 9.338322115581832e-08
. O 0 4.6756696292504785e-07

However O 0 1.5022722266166966e-07
, O 0 1.1541511080181976e-09
the O 0 3.440186469028106e-10
different O 0 1.926603460100651e-10
allelic O 0 1.7737896484959492e-07
pattern O 0 1.8473785701189627e-07
at O 0 2.226289907980572e-08
the O 0 4.420258292725521e-08
BRCA1 O 0 4.642350504013848e-08
locus O 0 1.0529677574311336e-08
even O 0 2.7587805373485708e-09
in O 0 1.201416743867867e-09
some O 0 2.478418359430634e-09
Jewish O 0 2.4528699782422336e-07
mutation O 0 7.459826534272906e-09
carriers O 0 9.388964050671689e-10
, O 0 4.1533793071479863e-10
might O 0 1.9794266226114132e-09
suggest O 0 1.5206641279519317e-08
that O 0 2.4093833594918124e-09
the O 0 1.4907911349837377e-08
mutation O 0 1.189880194374382e-08
arose O 0 1.1995214599380688e-08
independently O 0 1.037271868398193e-08
. O 0 2.3071070387459258e-08
. O 0 3.091658697940147e-07

Crystal O 0 3.0925659757485846e-06
structure O 0 8.354388114639733e-07
of O 0 1.0599375173114822e-06
the O 0 1.4607632010665839e-06
hemochromatosis B-Disease 1 1.0
protein O 0 0.07302170991897583
HFE O 0 0.010864854790270329
and O 0 1.120035730828306e-09
characterization O 0 1.2954410522070248e-07
of O 0 2.6677852815737424e-08
its O 0 1.8605242901870156e-09
interaction O 0 1.0628427915548855e-08
with O 0 8.891022917900671e-10
transferrin O 0 3.5493708310241345e-06
receptor O 0 1.5401594282593578e-05
. O 0 1.0535261480981717e-06

HFE O 1 0.999887228012085
is O 0 1.0585819154584897e-06
an O 0 1.9648857119136665e-07
MHC O 0 2.627578169267508e-06
- O 0 3.3964147405640688e-06
related O 0 4.2056535676238127e-07
protein O 0 1.547879691088383e-07
that O 0 3.679266960543437e-11
is O 0 6.477195516052525e-12
mutated O 0 2.2477882055671472e-10
in O 0 3.1132299516123396e-10
the O 0 5.6070970089194816e-08
iron B-Disease 1 0.9999972581863403
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9999665021896362

HFE O 0 0.00018443587759975344
binds O 0 1.7736645929744554e-07
to O 0 1.9607968582135982e-08
transferrin O 0 6.86569990193675e-07
receptor O 0 7.018140308900911e-07
( O 0 1.9278772356301488e-08
TfR O 0 1.6950433234796947e-07
) O 0 1.329263088489796e-10
and O 0 1.048061637476394e-10
reduces O 0 3.316888985693822e-09
its O 0 8.31762214659193e-10
affinity O 0 8.190047751099883e-09
for O 0 7.793251377563593e-09
iron O 0 9.666630376159446e-07
- O 0 1.3929141573498782e-07
loaded O 0 2.3254200698374916e-07
transferrin O 0 1.9561148292268626e-06
, O 0 7.092455689416965e-08
implicating O 0 2.68141484411899e-05
HFE O 1 0.9999294281005859
in O 0 4.283823000150733e-05
iron O 1 0.9999978542327881
metabolism O 1 0.9999117851257324
. O 0 5.364033768273657e-06

The O 0 9.211074939230457e-06
2 O 0 1.5606459783157334e-05
. O 0 1.6175940800167155e-06

6 O 0 0.000130105996504426
A O 0 2.230038990091998e-05
crystal O 0 1.293079367314931e-05
structure O 0 5.957149824098451e-06
of O 0 1.977176361833699e-05
HFE O 1 0.9999978542327881
reveals O 0 1.8531538614752208e-07
the O 0 5.622043719455405e-09
locations O 0 3.2593188592500155e-08
of O 0 2.4652194952068385e-07
hemochromatosis B-Disease 1 1.0
mutations O 0 0.1482074111700058
and O 0 9.407381895698563e-08
a O 0 6.601356972169015e-08
patch O 0 2.458181597830844e-06
of O 0 1.7600274077267386e-05
histidines O 0 1.5233227713906672e-05
that O 0 1.4886140098369083e-09
could O 0 1.5884189519255187e-09
be O 0 1.3772734064332326e-09
involved O 0 4.512116902333219e-09
in O 0 3.736229103878941e-08
pH O 0 4.123643066122895e-06
- O 0 1.1084844118158799e-05
dependent O 0 6.095366643421585e-06
interactions O 0 1.1037153626602958e-06
. O 0 1.0488224688742775e-06

We O 0 1.2611323541023012e-07
also O 0 1.0942743600139693e-08
demonstrate O 0 1.2900147616790036e-08
that O 0 1.3950646859939297e-08
soluble O 0 3.7334300486691063e-06
TfR O 0 3.0511193926940905e-06
and O 0 1.379771941145691e-08
HFE O 0 7.780348823871464e-06
bind O 0 2.981163049753377e-08
tightly O 0 4.9948422287116045e-08
at O 0 3.960329664209894e-08
the O 0 4.740280168391564e-09
basic O 0 7.393166967517573e-09
pH O 0 8.643801230334702e-09
of O 0 1.875464405998173e-08
the O 0 2.9750001573347618e-08
cell O 0 1.891688761190835e-08
surface O 0 5.685866000249007e-08
, O 0 5.446014195165105e-10
but O 0 5.655100276946712e-10
not O 0 2.1042609876786855e-09
at O 0 1.2769720569849596e-07
the O 0 3.6263372749090195e-07
acidic O 0 8.075070581980981e-06
pH O 0 2.4744765596551588e-06
of O 0 1.970552148122806e-06
intracellular O 0 7.451363671862055e-06
vesicles O 0 6.951461546123028e-05
. O 0 7.377607289527077e-06

TfR O 0 0.002543441252782941
HFE O 0 0.0013510840944945812
stoichiometry O 0 1.0300353096681647e-05
( O 0 6.623668724614618e-08
2 O 0 7.890489683859414e-08
1 O 0 1.5833169442203143e-08
) O 0 1.866433223252084e-11
differs O 0 5.076688514016325e-10
from O 0 8.170010779018355e-10
TfR O 0 1.0391317317726134e-07
transferrin O 0 5.382612755511218e-08
stoichiometry O 0 1.461441456740431e-07
( O 0 2.5788831070627793e-09
2 O 0 1.539011940110413e-08
2 O 0 1.598046850403989e-08
) O 0 1.9451129595893235e-10
, O 0 1.4492229638563003e-10
implying O 0 1.6550593118225265e-09
a O 0 1.0022213614568898e-10
different O 0 4.351456348028471e-11
mode O 0 3.932237202519673e-09
of O 0 8.608471713245081e-10
binding O 0 2.5276141180086142e-09
for O 0 2.7233877375465454e-08
HFE O 0 5.6673310609767213e-05
and O 0 4.156331101512478e-08
transferrin O 0 7.882950967541547e-07
to O 0 3.2181905140760136e-08
TfR O 0 2.5042227207450196e-06
, O 0 2.1326174159952416e-09
consistent O 0 3.437173035081287e-08
with O 0 5.40735456411312e-10
our O 0 3.5141159315799086e-08
demonstration O 0 1.385109271723195e-07
that O 0 1.117096282143848e-08
HFE O 0 7.720529538346455e-06
, O 0 6.340159952600288e-09
transferrin O 0 2.394550904227799e-07
, O 0 5.701936256485851e-09
and O 0 6.305812760842855e-09
TfR O 0 6.547918474097969e-07
form O 0 2.8487108227892577e-09
a O 0 2.443241164939991e-08
ternary O 0 3.955740055516799e-07
complex O 0 4.9017749006452505e-06
. O 0 2.1883467979932902e-06

Identification O 0 3.286524119516798e-08
of O 0 5.941281600030379e-08
three O 0 2.5467972175619025e-09
novel O 0 2.385168063057108e-09
mutations O 0 7.895179510164496e-10
and O 0 4.7267686292817856e-11
a O 0 1.0532358318826596e-10
high O 0 3.5006991749853e-10
frequency O 0 6.660414442194451e-10
of O 0 1.545255701174142e-09
the O 0 7.573169646946099e-09
Arg778Leu O 0 4.0804059153742855e-07
mutation O 0 5.2888604606948775e-09
in O 0 9.770988462776131e-10
Korean O 0 2.332317627917746e-08
patients O 0 7.453564432324811e-10
with O 0 1.17979370717336e-09
Wilson B-Disease 0 2.7885673148375645e-07
disease I-Disease 0 2.4502330688846996e-06
. O 0 1.5640939921013342e-07

Four O 0 1.962583837666898e-06
mutations O 0 4.649643585707963e-07
- O 0 2.746408256371069e-07
- O 0 1.3721498248742137e-07
R778L O 0 2.491848931640561e-07
, O 0 9.057393723921336e-10
A874V O 0 2.8527196604954952e-08
, O 0 2.5325205821324914e-10
L1083F O 0 1.0637431380189355e-08
, O 0 1.3824363875869494e-10
and O 0 1.5467853387018948e-10
2304delC O 0 5.257540625080992e-09
- O 0 1.659066883874516e-09
- O 0 5.692113003163968e-09
in O 0 1.60050852571203e-08
the O 0 6.706618478347082e-07
copper O 0 6.90003076897483e-08
- O 0 3.734481612838181e-09
transporting O 0 3.73051634028343e-09
enzyme O 0 6.9570109673122715e-09
, O 0 5.352081888787552e-09
P O 0 2.078645820802194e-06
- O 0 1.3971275336643885e-07
type O 0 1.030052558803618e-07
ATPase O 0 2.322303913615542e-07
( O 0 5.476526787617786e-09
ATP7B O 0 3.119479742963449e-06
) O 0 2.9270575546691546e-11
, O 0 2.447407207450958e-11
were O 0 4.903254538501933e-11
identified O 0 1.7967749510461317e-10
in O 0 9.471301520846964e-11
Korean O 0 4.498367900396261e-09
Patients O 0 3.695550532256675e-10
with O 0 4.4746281679941546e-10
Wilson B-Disease 0 2.0299083303143561e-07
disease I-Disease 1 0.8419691920280457
. O 0 4.72354969360822e-07

Arg778Leu O 0 0.0002505937882233411
, O 0 4.253938001852475e-08
the O 0 1.2265159554658567e-08
most O 0 2.6453017554217695e-09
frequently O 0 1.7267334229131848e-09
reported O 0 3.3502822738284976e-09
mutation O 0 2.9022051428739815e-09
of O 0 2.5894357769118415e-09
this O 0 3.8374398103613316e-10
enzyme O 0 2.545524679931077e-09
, O 0 3.032181172812898e-10
was O 0 2.802342580210393e-09
found O 0 1.0313053189214827e-10
in O 0 7.473775071042965e-11
six O 0 6.440208366598199e-10
of O 0 2.939688048542166e-09
eight O 0 2.713798519238253e-09
unrelated O 0 1.0641815428868995e-08
patients O 0 3.54141715952494e-10
studied O 0 3.3634335316889974e-09
, O 0 3.599470027593199e-11
an O 0 9.085523305918386e-11
allele O 0 1.761835011215851e-09
frequency O 0 6.972739274857531e-09
of O 0 2.507323593192723e-08
37 O 0 1.5961938970576739e-06
. O 0 9.809190260057221e-07

5 O 0 5.844146926392568e-06
% O 0 7.049985129015113e-08
, O 0 4.348919557806141e-10
which O 0 8.877088647496478e-11
is O 0 2.0022072541592273e-11
considerably O 0 8.450200539300567e-10
higher O 0 1.4200173259482085e-09
than O 0 4.546651249937028e-11
those O 0 1.0800485505946256e-10
in O 0 2.3843207963558655e-10
other O 0 1.7973244004210187e-09
Asian O 0 9.569768089079389e-09
populations O 0 2.1271018724178248e-08
. O 0 8.77296173484865e-08

The O 0 1.7443389310756174e-07
novel O 0 5.919146417454613e-08
single O 0 2.8183699818384866e-09
nucleotide O 0 1.8456628225749228e-08
deletion O 0 2.801595933021872e-08
, O 0 3.5469487347228323e-09
2304delC O 0 1.4505359047234379e-07
, O 0 2.184374015001822e-09
was O 0 1.455129794436516e-08
found O 0 7.473180962946913e-10
in O 0 4.025969280174735e-10
one O 0 3.318610053426596e-09
patient O 0 1.7588408951496604e-08
. O 0 1.0462155586310473e-07

Since O 0 4.1499145453371966e-08
a O 0 1.2761753431789202e-08
mutation O 0 2.0626648833399486e-08
at O 0 1.1431906088432697e-08
cDNA O 0 5.11878539555255e-08
nucleotide O 0 1.4373576107118424e-07
2302 O 0 1.2351620171102695e-06
( O 0 4.194172120719486e-09
2302insC O 0 5.918694512274669e-08
) O 0 5.143688253106404e-10
had O 0 5.452180040776966e-09
been O 0 1.045831643509132e-09
previously O 0 4.012341126014007e-09
described O 0 1.125187498729474e-09
, O 0 2.448228945961528e-11
this O 0 1.850962091931585e-11
region O 0 1.7009261776834705e-09
of O 0 5.527728497156659e-09
the O 0 1.135398548512967e-07
ATP7B O 0 0.02386934496462345
gene O 0 5.1392969879771044e-09
may O 0 8.855317368272608e-09
be O 0 9.203116602130024e-10
susceptible O 0 1.6316212381184414e-08
to O 0 1.7608271507540962e-09
gene O 0 4.88746366045234e-07
rearrangements O 0 5.478556704474613e-05
causing O 0 0.0006591288256458938
Wilson B-Disease 0 5.724829406972276e-06
disease I-Disease 0 0.0005545021267607808
. O 0 2.48575844352672e-07

Disruption O 0 3.283620753791183e-05
of O 0 7.191487725322077e-07
splicing O 0 5.072696467323112e-07
regulated O 0 2.2492663731554785e-07
by O 0 6.0407598923006844e-09
a O 0 7.089858655717762e-08
CUG O 0 2.3926246285554953e-05
- O 0 2.3327359599534248e-08
binding O 0 9.734645090020422e-09
protein O 0 6.474552805002531e-08
in O 0 4.518464713498815e-09
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 1.3866552762920037e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.20496203005313873
DM B-Disease 1 1.0
) O 0 4.739999504010939e-09
is O 0 2.0055258842521795e-10
caused O 0 9.885487983751773e-10
by O 0 5.870778863048542e-11
a O 0 5.058172547478534e-09
CTG O 0 1.2908610642625717e-06
expansion O 0 3.9416477193299215e-08
in O 0 2.608763205458331e-10
the O 0 1.1314111869609178e-09
3 O 0 4.434273837006231e-09
untranslated O 0 1.4061586171010276e-06
region O 0 9.374474529977306e-09
of O 0 3.389090608152401e-08
the O 0 1.3543689192374586e-06
DM B-Disease 1 1.0
gene O 0 6.430395274037437e-07
. O 0 2.9593654744530795e-06

One O 0 1.2585751107963006e-08
model O 0 5.9217210690576394e-08
of O 0 2.3062499110437784e-07
DM B-Disease 1 1.0
pathogenesis O 0 0.45913273096084595
suggests O 0 9.847722637346124e-09
that O 0 8.294092496141658e-11
RNAs O 0 5.928416091371957e-10
from O 0 3.8769906729463344e-10
the O 0 7.914296995537029e-10
expanded O 0 8.113237304208099e-10
allele O 0 4.817066745488319e-10
create O 0 1.9681802021498385e-10
a O 0 7.035229065976978e-10
gain O 0 4.385107033044733e-08
- O 0 2.6605086134168232e-08
of O 0 1.9254670746704505e-07
- O 0 4.622082272476291e-08
function O 0 5.89183701826812e-10
mutation O 0 1.4900961020636316e-10
by O 0 7.126577106220111e-11
the O 0 1.901353297029118e-09
inappropriate O 0 1.928928128336338e-09
binding O 0 8.512372140501157e-09
of O 0 3.9791828498891846e-08
proteins O 0 9.70694080670853e-10
to O 0 2.407968269224625e-09
the O 0 2.462188319896086e-07
CUG O 0 0.15793024003505707
repeats O 0 2.303753490195959e-06
. O 0 4.833605657950102e-07

Data O 0 2.585807692412345e-07
presented O 0 1.5425332833274297e-07
here O 0 9.973215142622394e-09
indicate O 0 2.2154628354087436e-08
that O 0 7.035926841147955e-10
the O 0 9.308319448564362e-09
conserved O 0 9.747802920401227e-08
heterogeneous O 0 2.9525250511142076e-07
nuclear O 0 2.6898685518972343e-06
ribonucleoprotein O 0 1.55721754708793e-05
, O 0 1.7489897174982616e-07
CUG O 0 4.4738164433510974e-05
- O 0 1.2422601969319658e-07
binding O 0 8.532207118605584e-08
protein O 0 6.091846671552048e-07
( O 0 1.2570636975794969e-08
CUG O 0 7.934939640108496e-05
- O 0 7.950644658194506e-07
BP O 0 3.5268277542854776e-07
) O 0 1.2199818932856488e-10
, O 0 7.90433621333797e-11
may O 0 4.021801780496048e-10
mediate O 0 1.174143982041187e-08
the O 0 6.10947452628352e-08
trans O 0 7.74726327534836e-09
- O 0 7.883024899513202e-09
dominant O 0 2.6907814643095662e-08
effect O 0 1.2503709001521202e-07
of O 0 7.349262176603588e-08
the O 0 6.10048545013342e-08
RNA O 0 1.0534943584161738e-07
. O 0 1.8816530200638226e-07

CUG O 1 0.9938767552375793
- O 0 0.001018308219499886
BP O 0 8.208148938138038e-05
was O 0 6.555946896469322e-08
found O 0 1.5263580677160604e-10
to O 0 1.0268922864820063e-11
bind O 0 1.1079368672506362e-10
to O 0 1.0942899364430048e-10
the O 0 3.5630662864605256e-09
human O 0 8.28041493150522e-08
cardiac O 1 0.9976403713226318
troponin O 0 2.54642654908821e-05
T O 0 0.00022325282043311745
( O 0 2.3764776813095523e-08
cTNT O 0 3.8433663007708674e-07
) O 0 5.204042197171077e-10
pre O 0 1.8801062040552097e-08
- O 0 2.7934414781327632e-09
messenger O 0 2.3418647021600236e-09
RNA O 0 3.855813002218156e-09
and O 0 3.8940362045991606e-10
regulate O 0 6.665422103147023e-10
its O 0 1.8304606719254934e-09
alternative O 0 3.43049926243566e-08
splicing O 0 5.839467007717758e-07
. O 0 5.722726541534939e-07

Splicing O 0 4.70538083163774e-07
of O 0 9.70863084148732e-07
cTNT O 0 6.851200396340573e-06
was O 0 2.2565755841696955e-07
disrupted O 0 5.880211801922997e-07
in O 0 2.381096386727677e-08
DM B-Disease 1 1.0
striated O 0 5.289115847517678e-07
muscle O 0 4.3423096229844305e-08
and O 0 5.3236561825542594e-09
in O 0 2.769525497825498e-09
normal O 0 2.320300467317793e-07
cells O 0 1.0674097161711416e-08
expressing O 0 5.713494677372921e-10
transcripts O 0 2.8158553266877107e-09
that O 0 5.27632382230081e-10
contain O 0 3.481565258312003e-08
CUG O 0 0.00017868193390313536
repeats O 0 5.55246799649467e-07
. O 0 4.601920693403372e-07

Altered O 0 4.77860066894209e-06
expression O 0 4.1360258364875335e-06
of O 0 1.1037448075512657e-06
genes O 0 4.136165614454512e-07
regulated O 0 3.6671386283160246e-07
posttranscriptionally O 0 9.778992762221606e-07
by O 0 2.1410880179928427e-08
CUG O 1 0.9999253749847412
- O 0 1.370841528114397e-05
BP O 0 1.2228692867211066e-06
therefore O 0 6.233037197489466e-09
may O 0 1.1841493341435694e-09
contribute O 0 3.083112209978367e-09
to O 0 7.837213189532122e-08
DM B-Disease 1 1.0
pathogenesis O 0 0.0019205567659810185
. O 0 8.335480572441156e-08
. O 0 2.1030307095770695e-07

Identification O 0 2.62572861231547e-08
of O 0 1.9659948335970512e-08
a O 0 2.645564212144791e-09
novel O 0 1.1247846209982981e-08
nonsense O 0 1.4897394429169708e-08
mutation O 0 8.229723569286307e-10
and O 0 5.742016931375993e-11
a O 0 1.684813261126905e-10
missense O 0 1.106246649840159e-08
substitution O 0 3.378904045447939e-09
in O 0 1.558245976696071e-09
the O 0 2.6203103686839313e-08
vasopressin O 0 2.4478293880747515e-07
- O 0 1.1277688827249222e-07
neurophysin O 0 2.37941279124243e-07
II O 0 1.8279624214301293e-07
gene O 0 3.23746279784487e-10
in O 0 6.299053501024332e-10
two O 0 5.085653009828661e-10
Spanish O 0 5.2311460052578695e-08
kindreds O 0 1.6540334399905987e-06
with O 0 9.860183780574516e-09
familial B-Disease 1 0.9998785257339478
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
. O 0 4.1496878111502156e-06

Familial B-Disease 1 0.9999992847442627
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 9.46062027651351e-06
FNDI B-Disease 1 1.0
) O 0 6.746873615348647e-10
is O 0 5.402393463138644e-11
an O 0 3.049807628663359e-10
autosomal B-Disease 1 0.9999992847442627
dominant I-Disease 1 0.9998146891593933
disease I-Disease 1 0.9999992847442627
caused O 0 3.107431112425729e-08
by O 0 2.2395714449618964e-10
deficiency O 0 0.027693530544638634
in O 0 7.284462810730474e-09
the O 0 3.040402418719168e-07
antidiuretic O 0 3.0639037618129805e-07
hormone O 0 7.356568687555409e-08
arginine O 0 1.891276326659863e-07
vasopressin O 0 1.6961752180577605e-07
( O 0 1.3201658433104058e-08
AVP O 0 8.548464336399775e-08
) O 0 1.1888552642336236e-11
encoded O 0 8.956713842822595e-12
by O 0 2.105159241372334e-10
the O 0 5.826067095426879e-08
AVP O 0 3.646976665550028e-06
- O 0 1.6981627481982287e-07
neurophysin O 0 1.8622296238390845e-06
II O 0 0.0006794564542360604
( O 0 4.043762942274043e-07
AVP O 0 9.31366957956925e-05
- O 0 3.981319878221257e-06
NPII O 0 0.00010731660586316139
) O 0 5.204160991034712e-10
gene O 0 1.2957647177458398e-09
on O 0 3.003243875809858e-08
chromosome O 0 7.475240693111118e-08
20p13 O 0 2.8269155336602125e-06
. O 0 4.024323061457835e-07

In O 0 3.604050746730536e-08
this O 0 2.7189952511719184e-09
study O 0 2.365902140866183e-09
, O 0 1.1218845991090021e-10
we O 0 1.0886149620636942e-10
analyzed O 0 1.193336540694645e-09
two O 0 4.3626108281458187e-10
families O 0 2.659538145266538e-09
with O 0 7.064731022410342e-10
FNDI B-Disease 1 1.0
using O 0 8.063792411583393e-10
direct O 0 9.564677050377668e-09
automated O 0 7.09058980419286e-08
fluorescent O 0 4.77917474484002e-08
, O 0 1.6560981475066683e-09
solid O 0 4.228811434359159e-08
phase O 0 5.9531018337111163e-08
, O 0 8.61316906686227e-10
single O 0 2.5417503657365614e-09
- O 0 1.1516734232941417e-08
stranded O 0 1.786831660410826e-08
DNA O 0 1.2388634562654488e-09
sequencing O 0 1.7932189066982573e-09
of O 0 1.4405710402343175e-08
PCR O 0 2.5954309990083857e-07
- O 0 2.697145646379795e-06
amplified O 0 6.2369917941396125e-06
AVP O 0 7.297866250155494e-05
- O 0 6.476518592535285e-06
NPII O 0 0.00012977985898032784
DNA O 0 2.0589247924363008e-06
. O 0 9.868725783235277e-07

In O 0 2.3696520301541568e-08
one O 0 1.3727395220541894e-08
of O 0 1.3148434341303528e-08
the O 0 4.8610298009066355e-09
families O 0 5.198387276195149e-10
, O 0 2.285123132383937e-11
affected O 0 3.968580672419897e-11
individuals O 0 4.885562007034272e-12
presented O 0 1.0366226765867737e-09
a O 0 4.652530860571602e-10
novel O 0 1.4876346821068864e-09
nonsense O 0 3.653703117834084e-09
mutation O 0 9.942479062274856e-10
in O 0 4.062741532084857e-10
exon O 0 3.7127700913686112e-09
3 O 0 3.894351863209522e-08
of O 0 2.8736410584428995e-08
the O 0 2.540389587579739e-08
gene O 0 1.6355494736330911e-09
, O 0 5.878748599030814e-10
consisting O 0 8.643429721955087e-11
in O 0 1.3303334822634127e-10
a O 0 2.3245712021946474e-09
G O 0 4.650521745475089e-08
to O 0 6.905230520715122e-08
T O 0 6.159004897199338e-06
transition O 0 3.9015569086586765e-07
at O 0 1.4460553643402818e-07
nucleotide O 0 7.224703324482107e-08
2101 O 0 2.03440595214488e-06
, O 0 6.159711629649678e-10
which O 0 3.512575993958045e-11
produces O 0 6.40576827692918e-11
a O 0 3.765965317370501e-11
stop O 0 4.398698072449747e-10
signal O 0 1.9233780790273158e-08
in O 0 7.250557043647632e-09
codon O 0 2.0630209291994106e-06
82 O 0 5.276377123664133e-06
( O 0 8.23769426006038e-08
Glu O 0 1.5369122365882504e-06
) O 0 9.421115443331018e-09
of O 0 3.1720040283289563e-07
NPII O 1 0.9400514364242554
. O 0 2.6667198653740343e-06

The O 0 3.980975122885866e-07
premature O 0 8.682767656864598e-06
termination O 0 1.3530687965612742e-06
eliminates O 0 3.9986073829823e-07
part O 0 4.233110750817559e-09
of O 0 3.216447552745194e-08
the O 0 7.113237643352477e-08
C O 0 8.872089551914542e-07
- O 0 1.5265111841245016e-08
terminal O 0 2.5877733733636887e-08
domain O 0 3.147418992099915e-09
of O 0 2.535756848942583e-08
NPII O 0 0.00016628531739115715
, O 0 2.39561792625409e-09
including O 0 6.619911285810076e-10
a O 0 1.2533336146702823e-08
cysteine O 0 3.9420595676631365e-09
residue O 0 5.17453244697208e-08
in O 0 1.6521701784455445e-09
position O 0 3.5258988617670184e-08
85 O 0 3.2735798072280886e-08
, O 0 8.223380310035111e-11
which O 0 4.0643512860816244e-11
could O 0 1.069026325795086e-10
be O 0 1.2032919105564588e-10
involved O 0 4.1087189206479025e-10
in O 0 9.437080006335918e-10
the O 0 4.858400259877271e-08
correct O 0 7.068369427543075e-07
folding O 0 4.097440978512168e-06
of O 0 1.5589577628816187e-07
the O 0 7.904647532086528e-07
prohormone O 0 0.0004969405708834529
. O 0 2.6137024633499095e-06

In O 0 3.5952762544866346e-08
the O 0 1.4131839520814538e-07
second O 0 1.1602749339090224e-07
family O 0 4.6272048415119116e-09
, O 0 1.2677628391521978e-10
a O 0 2.3395868575804e-10
G279A O 0 1.075354827406727e-08
substitution O 0 7.000697355152852e-09
at O 0 1.0030638541991266e-08
position O 0 1.2952218853001796e-08
- O 0 1.7447299160977536e-09
1 O 0 1.3158921952083347e-08
of O 0 5.170859296299568e-09
the O 0 2.084415751113511e-09
signal O 0 1.9711527965426967e-09
peptide O 0 3.581925589468682e-10
was O 0 8.704071241538713e-09
observed O 0 1.6833878735411645e-09
in O 0 3.178637908440862e-10
all O 0 1.6139346525889664e-09
affected O 0 1.6750645315255497e-08
individuals O 0 7.950931468769795e-09
. O 0 7.009584805928171e-07

This O 0 2.1806119576694982e-08
missense O 0 3.4148622489738045e-06
mutation O 0 9.503796860599323e-08
, O 0 4.3580725694880584e-09
which O 0 4.674263198722883e-09
replaces O 0 1.0244855275232112e-06
Ala O 0 1.2438455314622843e-06
with O 0 2.7837412375220083e-08
Thr O 0 8.193117537302896e-06
, O 0 3.258117775573055e-09
is O 0 1.3299528145438444e-10
frequent O 0 2.0019648161451187e-09
among O 0 6.288121134900848e-09
FNDI B-Disease 1 1.0
patients O 0 2.2709569748258218e-05
and O 0 4.134601105931779e-09
is O 0 3.1402216937870264e-10
thought O 0 3.334489628858961e-10
to O 0 9.839657560961612e-11
reduce O 0 1.6782200074061393e-09
the O 0 5.309925388274905e-09
efficiency O 0 3.534989190256965e-08
of O 0 1.112499248279164e-08
cleavage O 0 6.741219493733297e-08
by O 0 4.7269090863721885e-09
signal O 0 2.4267274056910537e-06
peptidases O 0 5.128228622197639e-06
. O 0 1.449919011520251e-07
. O 0 9.54019014898222e-07

Genetic O 0 5.658407644659746e-07
heterogeneity O 0 1.0143060535483528e-05
of O 0 1.7676088646112476e-06
Saethre B-Disease 1 0.9999949932098389
- I-Disease 1 0.9999990463256836
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 8.013975594245437e-10
due O 0 8.682714991437024e-09
to O 0 1.9692665276238586e-09
TWIST O 1 0.9963117241859436
and O 0 4.2799896959877515e-07
FGFR O 1 0.9999006986618042
mutations O 0 1.1949395229748916e-05
. O 0 1.2169801948402892e-06

Thirty O 0 7.205384463304654e-05
- O 0 1.199148300656816e-06
two O 0 3.3152063316777003e-09
unrelated O 0 4.457559210635509e-09
patients O 0 7.40560668344159e-11
with O 0 1.6280524020931275e-12
features O 0 3.7266667529678443e-10
of O 0 1.1319625770056518e-07
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.1646396069764364e-09
a O 0 6.66968202889251e-10
common O 0 6.2963181335362606e-09
autosomal B-Disease 0 6.53602764941752e-05
dominant I-Disease 0 2.8343738449621014e-05
condition I-Disease 0 6.1497958085965365e-06
of O 0 1.4830776251528732e-07
craniosynostosis B-Disease 0 0.0004999645170755684
and O 0 9.598178962733073e-08
limb B-Disease 1 0.5202128291130066
anomalies I-Disease 0 1.3991963896842208e-05
, O 0 4.672569442476515e-09
were O 0 3.5970442180399687e-09
screened O 0 2.1748289835699097e-09
for O 0 4.158182409508271e-10
mutations O 0 1.2060413112635615e-08
in O 0 4.021389443664702e-09
TWIST O 0 1.2393044926284347e-05
, O 0 4.00536208644553e-08
FGFR2 O 0 0.0011327945394441485
, O 0 4.7662840785278604e-08
and O 0 2.3416610872573074e-07
FGFR3 O 1 0.9776113033294678
. O 0 3.2945374641712988e-06

Nine O 0 6.961107601455296e-07
novel O 0 1.0821678131378576e-07
and O 0 3.3452953740464864e-09
three O 0 6.743017255672612e-09
recurrent O 0 5.436014589577098e-07
TWIST O 0 2.486636049070512e-06
mutations O 0 7.45836459259408e-08
were O 0 4.473350134759357e-09
found O 0 1.588240206018554e-09
in O 0 8.988932376219338e-10
12 O 0 2.5537152836818677e-08
families O 0 3.940077064612524e-08
. O 0 2.56230549666725e-07

Seven O 0 2.895453974360862e-07
families O 0 1.8724763961586177e-08
were O 0 1.8441980165206928e-09
found O 0 1.7171751520717038e-10
to O 0 6.063401863931617e-11
have O 0 2.5930921299099907e-10
the O 0 1.7465721313669746e-08
FGFR3 O 0 4.691541471402161e-05
P250R O 0 1.7818499031818646e-07
mutation O 0 2.5327779873407508e-09
, O 0 1.180686798329944e-10
and O 0 1.4305262530101004e-10
one O 0 4.401795039576939e-10
individual O 0 1.1282691447789261e-09
was O 0 7.614684705004038e-08
found O 0 7.648680577787559e-10
to O 0 1.073194533240951e-09
have O 0 2.6555642129721946e-09
an O 0 2.9762768249952387e-08
FGFR2 O 0 3.1787210900802165e-05
VV269 O 0 2.0959039375156863e-06
- O 0 3.28769090174319e-07
270 O 0 1.8322785422242305e-07
deletion O 0 1.3633101048071694e-07
. O 0 6.83483847296884e-07

To O 0 4.610125969861656e-08
date O 0 1.6726435205782764e-06
, O 0 2.161026468883165e-09
our O 0 9.541859524730967e-10
detection O 0 6.286406062372407e-09
rate O 0 2.1290491591940963e-09
for O 0 1.6295886862138786e-10
TWIST O 0 2.7506334845384117e-06
or O 0 1.108084219936245e-07
FGFR O 0 8.498873648932204e-05
mutations O 0 6.146303377363438e-08
is O 0 1.959891138270109e-09
68 O 0 4.712957135666329e-08
% O 0 1.9678396689926103e-09
in O 0 9.309610859986606e-10
our O 0 3.060241624552873e-07
Saethre B-Disease 1 0.808047890663147
- I-Disease 1 0.9999018907546997
Chotzen I-Disease 0 0.01793489046394825
syndrome I-Disease 0 8.669957605889067e-05
patients O 0 3.5102889484051047e-09
, O 0 1.4801844472334125e-10
including O 0 1.9609072698933971e-10
our O 0 3.489330069328389e-08
five O 0 1.8248204058934903e-09
patients O 0 2.931176135145819e-10
elsewhere O 0 2.178341063086009e-09
reported O 0 4.889027405141633e-09
with O 0 3.005567461578096e-10
TWIST O 0 1.099330711440416e-05
mutations O 0 8.43948782858206e-07
. O 0 5.889875751563522e-07

More O 0 1.3045540647738108e-08
than O 0 2.525378128837019e-09
35 O 0 3.3710328750657936e-08
different O 0 2.3521922187796918e-09
TWIST O 0 2.9867837270103337e-07
mutations O 0 1.4277365067982828e-08
are O 0 3.8855635375867337e-10
now O 0 4.680541509927139e-10
known O 0 4.5843245866095117e-10
in O 0 7.955690550787153e-10
the O 0 9.775243725584915e-09
literature O 0 5.596956853537449e-08
. O 0 7.606221430478399e-08

The O 0 1.0952123119523094e-07
most O 0 5.1113580035178074e-09
common O 0 1.9661776651247465e-09
phenotypic O 0 2.29605330304139e-08
features O 0 2.3713701224892247e-08
, O 0 4.756888771773049e-10
present O 0 4.840294276498014e-10
in O 0 7.143574620727122e-11
more O 0 2.572474178119677e-11
than O 0 4.747495799262147e-11
a O 0 1.2510353863959267e-09
third O 0 1.2669132409826034e-08
of O 0 1.0590343713090533e-08
our O 0 2.6049473689226943e-08
patients O 0 2.6623090398913973e-09
with O 0 3.122782477049668e-09
TWIST O 0 6.767040758859366e-05
mutations O 0 6.082859158595966e-07
, O 0 1.534462867880393e-08
are O 0 9.52895096162365e-09
coronal B-Disease 0 0.0003483208711259067
synostosis I-Disease 0 7.933577580843121e-05
, O 0 1.3848108437741757e-07
brachycephaly B-Disease 0 0.0003926345962099731
, O 0 4.971897169525619e-07
low B-Disease 1 0.9990485310554504
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 3.2067068787000608e-06
facial B-Disease 1 1.0
asymmetry I-Disease 1 1.0
, O 0 3.660873517219443e-06
ptosis B-Disease 0 0.006918126251548529
, O 0 1.731378489466806e-07
hypertelorism B-Disease 0 0.00010571446910034865
, O 0 1.8746568741789815e-07
broad B-Disease 0 0.0013797467108815908
great I-Disease 1 0.9999847412109375
toes I-Disease 1 0.9997511506080627
, O 0 2.2714390013334196e-07
and O 0 2.6512086037655536e-07
clinodactyly B-Disease 0 0.009278015233576298
. O 0 3.912790361937368e-06

Significant O 0 3.6198659927322296e-06
intra O 0 6.015138205839321e-05
- O 0 2.032504085036635e-07
and O 0 1.495449541977223e-09
interfamilial O 0 1.942623981676661e-07
phenotypic O 0 3.293979489171761e-08
variability O 0 5.892387662242982e-07
is O 0 3.310692830993389e-10
present O 0 1.358887030677991e-10
for O 0 1.0577655418231302e-10
either O 0 9.380734411479352e-09
TWIST O 0 1.3647839296027087e-05
mutations O 0 1.0431565442559076e-06
or O 0 2.795714237890934e-07
FGFR O 0 0.000286811962723732
mutations O 0 3.6834335332969204e-06
. O 0 9.8717384844349e-07

The O 0 6.707065836053516e-07
overlap O 0 2.785627657431178e-07
in O 0 2.875591542661482e-09
clinical O 0 9.92047333170376e-09
features O 0 1.1936940325085743e-09
and O 0 1.8762283393591872e-10
the O 0 5.456767926403927e-09
presence O 0 2.4721438229846626e-09
, O 0 2.385175668084827e-10
in O 0 2.0181235849126011e-10
the O 0 3.6768152966715206e-09
same O 0 1.0272303008207473e-09
genes O 0 1.5771072225945204e-09
, O 0 3.13387343853222e-10
of O 0 1.134791260959389e-09
mutations O 0 2.607534743681583e-10
for O 0 9.806457729188978e-11
more O 0 1.8241722021805629e-10
than O 0 2.327676718039129e-09
one O 0 3.641669010789883e-08
craniosynostotic B-Disease 0 2.9646225812030025e-06
condition I-Disease 0 3.394823693270155e-07
- O 0 6.812452824078719e-08
such O 0 7.860264439329967e-09
as O 0 1.397852571471958e-07
Saethre B-Disease 0 5.654595042869914e-06
- I-Disease 0 7.062837426019541e-07
Chotzen I-Disease 0 4.1383891584700905e-06
, I-Disease 0 8.025604181227664e-09
Crouzon I-Disease 0 1.5434353599630413e-06
, I-Disease 0 1.0517753779026862e-08
and I-Disease 0 3.9196887513526235e-08
Pfeiffer I-Disease 0 1.5339777746703476e-05
syndromes I-Disease 0 0.0032652774825692177
- O 0 1.1073971108999103e-05
support O 0 3.088794073846657e-07
the O 0 6.389401505657588e-07
hypothesis O 0 2.4751175331516606e-08
that O 0 5.128168029111535e-11
TWIST O 0 9.868427497394805e-08
and O 0 7.409510227596172e-10
FGFRs O 0 6.777757022291553e-08
are O 0 3.805933693201702e-11
components O 0 8.607885959577288e-09
of O 0 5.8388014423371715e-09
the O 0 2.841991975088831e-09
same O 0 5.747936571154355e-10
molecular O 0 2.5156479122045994e-09
pathway O 0 2.0294073088678033e-09
involved O 0 9.036006318186018e-12
in O 0 8.92215207964897e-12
the O 0 4.6885717530642523e-11
modulation O 0 2.490582851066847e-09
of O 0 5.972615291227612e-09
craniofacial O 1 0.9999988079071045
and O 0 9.908174433803651e-06
limb O 1 0.9999996423721313
development O 0 2.388252369200927e-06
in O 0 3.066602527468376e-09
humans O 0 1.3792824660185943e-08
. O 0 5.667391889119244e-09
. O 0 6.102474969793548e-08

Mutation O 0 1.7997642487443954e-08
analysis O 0 3.491119393572717e-09
of O 0 8.784091676261596e-09
UBE3A O 1 0.9998031258583069
in O 0 1.771262077454594e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 1.2825657904613763e-06
. O 0 3.6564379968240246e-08

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.02163090743124485
AS B-Disease 1 1.0
) O 0 4.506249262625772e-10
is O 0 5.555373869259306e-11
caused O 0 5.691371818272728e-10
by O 0 1.3355452854746375e-10
chromosome O 0 8.047251753851015e-08
15q11 O 0 8.094076520137605e-07
- O 0 4.7070731312715e-08
q13 O 0 1.4165425454848446e-07
deletions O 0 3.278798033079511e-08
of O 0 4.41777814330635e-09
maternal O 0 3.0831429853606096e-08
origin O 0 3.5649287966066368e-09
, O 0 2.1531178229228232e-10
by O 0 1.121365333922597e-09
paternal O 1 0.9967746138572693
uniparental B-Disease 1 0.9999791383743286
disomy I-Disease 1 0.9999904632568359
( O 0 5.037051778344903e-06
UPD B-Disease 1 1.0
) O 0 3.97264399154551e-09
15 O 0 4.51564936554405e-08
, O 0 3.048319097143093e-10
by O 0 4.997696145814245e-10
imprinting O 0 0.0001100511581171304
defects O 0 0.005376304965466261
, O 0 4.231665684528707e-09
and O 0 2.805592980159588e-10
by O 0 3.455140062946782e-10
mutations O 0 2.972935142508959e-08
in O 0 3.629323952480945e-09
the O 0 2.380870114393474e-07
UBE3A O 0 3.522043698467314e-05
gene O 0 5.947755994384352e-07
. O 0 1.9156639154971344e-06

UBE3A O 0 0.001120083499699831
encodes O 0 6.018061071699776e-07
a O 0 1.1431168900344346e-07
ubiquitin O 0 7.45997184026237e-08
- O 0 4.8023203191860375e-08
protein O 0 1.612569278108822e-08
ligase O 0 1.2576919061757508e-08
and O 0 1.1371406039017984e-08
shows O 0 8.572433785047906e-08
brain O 0 2.0321408555901144e-06
- O 0 7.404685220535612e-08
specific O 0 3.224420552783158e-08
imprinting O 0 6.621144166274462e-06
. O 0 3.3454060144322284e-07

Here O 0 3.5256741170996975e-07
we O 0 1.6372638356187963e-08
describe O 0 1.261663982177197e-07
UBE3A O 0 1.6275223970296793e-05
coding O 0 2.891509893743205e-06
- O 0 2.413622269159532e-06
region O 0 1.1819030021342769e-07
mutations O 0 5.8000665603685775e-08
detected O 0 1.0922141413516329e-08
by O 0 4.748177406810328e-10
SSCP O 0 9.487978786637541e-06
analysis O 0 1.8410419855285909e-09
in O 0 9.136549850019549e-10
13 O 0 4.311049295324665e-08
AS B-Disease 1 1.0
individuals O 0 4.2563685909158266e-10
or O 0 3.0408120466063338e-09
families O 0 4.8540904629135184e-09
. O 0 3.576911211666811e-08

Two O 0 9.257927899852803e-07
identical O 0 2.9125376386218704e-06
de O 0 6.609511274291435e-06
novo O 0 2.3412108021148015e-06
5 O 0 1.2239544275871594e-06
- O 0 3.002299138188391e-07
bp O 0 1.7073929825528467e-07
duplications O 0 6.518665429666726e-08
in O 0 1.675451244409487e-08
exon O 0 3.0559657915318894e-08
16 O 0 3.2861547083484766e-07
were O 0 3.987494778812106e-08
found O 0 4.270815878726353e-08
. O 0 2.1034759356552968e-07

Among O 0 4.160729929481022e-07
the O 0 1.2683088357334782e-07
other O 0 1.3470693893680163e-08
11 O 0 4.044552781579114e-08
unique O 0 5.493296928449354e-09
mutations O 0 1.7486721404225136e-08
, O 0 1.2064502730169124e-09
8 O 0 2.738044280192753e-08
were O 0 8.16683609627944e-09
small O 0 2.53157192986464e-08
deletions O 0 3.3452593584115675e-07
or O 0 4.520035190580529e-08
insertions O 0 3.2956393170024967e-07
predicted O 0 1.1247229281252658e-07
to O 0 4.879906700949732e-09
cause O 0 1.0767482763185399e-06
frameshifts O 0 2.4156062863767147e-05
, O 0 2.1391683979743448e-09
1 O 0 4.8918657569174684e-08
was O 0 2.2911624597554692e-08
a O 0 8.479246194070811e-10
mutation O 0 8.307316501365847e-10
to O 0 2.629203799120461e-10
a O 0 6.836596622150637e-09
stop O 0 2.8456279110855576e-08
codon O 0 1.5916290863060567e-07
, O 0 3.2494975599206555e-09
1 O 0 5.428834981557884e-08
was O 0 3.694095696005206e-08
a O 0 6.769460547673134e-09
missense O 0 1.3331471393485117e-07
mutation O 0 4.871917980153739e-09
, O 0 4.383588769751867e-10
and O 0 1.959052919886517e-10
1 O 0 2.600667947660895e-08
was O 0 2.5315138429959916e-08
predicted O 0 4.6513353169075344e-09
to O 0 9.135708162189005e-11
cause O 0 2.4074080506863993e-09
insertion O 0 1.3319877645301403e-08
of O 0 3.672247217423319e-08
an O 0 3.740464293855439e-08
isoleucine O 0 9.293010521105316e-07
in O 0 2.4918611618574005e-09
the O 0 8.615674573775323e-08
hect O 0 2.1039948023826582e-06
domain O 0 7.054114092852615e-08
of O 0 1.5679427178838523e-07
the O 0 1.0552677167652291e-06
UBE3A O 0 2.386528649367392e-05
protein O 0 3.3693686418700963e-07
, O 0 1.8523131917191904e-09
which O 0 4.678399334601124e-10
functions O 0 7.829525916491775e-10
in O 0 2.509408458806206e-09
E2 O 0 2.6261724883624993e-07
binding O 0 7.58554374868936e-09
and O 0 6.8971850453181105e-09
ubiquitin O 0 1.8044670468952972e-07
transfer O 0 5.1583992899395525e-06
. O 0 2.556479785198462e-06

Eight O 0 6.536718615279824e-07
of O 0 7.67893126862873e-08
the O 0 7.459484585581322e-09
cases O 0 1.564267160247823e-09
were O 0 1.7674828267644216e-09
familial O 0 7.1657577649375526e-09
, O 0 3.2049310427773037e-10
and O 0 4.6428597078040923e-10
five O 0 9.147434809619881e-09
were O 0 2.0429391511811446e-08
sporadic O 0 2.561619339758181e-06
. O 0 5.045287707616808e-07

In O 0 8.554907537927647e-08
two O 0 1.3664100073640384e-08
familial O 0 4.9629431231323906e-08
cases O 0 2.101437468482459e-09
and O 0 1.5749661297359552e-10
one O 0 4.413581722317872e-10
sporadic O 0 2.424949308021951e-08
case O 0 3.4206446564155613e-09
, O 0 1.3931865661120924e-09
mosaicism O 0 8.823706593830138e-06
for O 0 4.410371445828787e-08
UBE3A O 0 7.360881136264652e-05
mutations O 0 2.0378377030283445e-07
was O 0 1.1864807802908217e-08
detected O 0 1.0310303721894343e-09
in O 0 4.232387704194984e-11
the O 0 9.103915954433717e-10
mother O 0 3.073242771378659e-09
of O 0 7.702133153486557e-09
three O 0 1.3016708599877802e-08
AS B-Disease 1 1.0
sons O 0 1.813790646565394e-07
, O 0 4.246346052561023e-10
in O 0 1.9720619581775622e-10
the O 0 4.337936676535037e-09
maternal O 0 8.140666096778659e-08
grandfather O 0 2.8665090212598443e-07
of O 0 1.3657488295848452e-07
two O 0 1.8309259885995743e-08
AS B-Disease 1 1.0
first O 0 8.274397167440384e-09
cousins O 0 8.79906636441774e-09
, O 0 4.208497994540039e-10
and O 0 1.833618673563464e-10
in O 0 8.480378621555928e-10
the O 0 1.0750394352498915e-07
mother O 0 7.938962909292968e-08
of O 0 5.19478504656945e-08
an O 0 1.7129838170149014e-07
AS B-Disease 1 1.0
daughter O 0 2.1693631424568594e-05
. O 0 3.577379857233609e-06

The O 0 1.1271819033709107e-07
frequencies O 0 1.8606565177492485e-08
with O 0 1.296268370420961e-10
which O 0 2.2882777617194705e-10
we O 0 2.7657864887231653e-10
detected O 0 1.8472043894490753e-09
mutations O 0 1.8937815760011745e-09
were O 0 3.1539573175365376e-09
5 O 0 1.5715469814381322e-08
( O 0 7.956070247061575e-10
14 O 0 4.444886059218334e-08
% O 0 1.6358084886647362e-09
) O 0 1.6424785143076548e-11
of O 0 8.279460450566489e-10
35 O 0 6.5391976278306174e-09
in O 0 2.0815067724999636e-10
sporadic O 0 3.069126464083638e-08
cases O 0 9.277632551096815e-10
and O 0 1.1345792083616857e-09
8 O 0 2.3252820113839334e-08
( O 0 3.749360544258451e-10
80 O 0 1.9895260550129024e-08
% O 0 9.054337279934543e-10
) O 0 1.2735983274947404e-11
of O 0 1.732162968615114e-09
10 O 0 6.059408086400708e-09
in O 0 1.7620298553566727e-09
familial O 0 7.707588878247407e-08
cases O 0 4.511617746061347e-09
. O 0 1.1480371320260474e-08
. O 0 1.538846845505759e-07

The O 0 5.855181825609179e-06
hemochromatosis B-Disease 1 1.0
845 O 0 3.900398951373063e-06
G O 0 4.636660833057249e-07
- O 0 3.2276631145577994e-08
- O 0 6.453233503123101e-09
> O 0 9.82147585482096e-10
A O 0 4.803270226005907e-09
and O 0 2.4326308328825874e-11
187 O 0 6.390330625771767e-11
C O 0 2.236499208052578e-09
- O 0 2.237897783752274e-10
- O 0 5.174685124842426e-10
> O 0 5.79677639223064e-10
G O 0 9.489248498084635e-09
mutations O 0 2.8104680804830195e-09
: O 0 2.3473911703320027e-10
prevalence O 0 2.526486131415595e-09
in O 0 2.808516197383426e-10
non O 0 1.262224884612806e-07
- O 0 5.7996462743403754e-08
Caucasian O 0 2.827929357351877e-08
populations O 0 2.3095815038232104e-08
. O 0 6.070295199833708e-08

Hemochromatosis B-Disease 0 0.01745331473648548
, O 0 1.9523895389284007e-07
the O 0 1.960301597137004e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 0.9999994039535522
, O 0 2.4458010727812507e-08
leads O 0 2.632538598845713e-05
, O 0 2.9508111509812807e-09
if O 0 2.2966891322084848e-07
untreated O 1 1.0
, O 0 5.104204281458635e-10
to O 0 3.714385021780231e-09
progressive O 1 0.9999996423721313
iron B-Disease 1 0.9999929666519165
overload I-Disease 1 0.9999992847442627
and O 0 2.4354492325073807e-06
premature B-Disease 0 0.0022692508064210415
death I-Disease 0 3.4011387469945475e-05
. O 0 1.8920911770692328e-06

The O 0 2.7901316570932977e-05
hemochromatosis B-Disease 1 1.0
gene O 1 0.8060932755470276
, O 0 3.3177336717926664e-06
HFE O 1 0.9997469782829285
, O 0 2.6326640423235403e-08
recently O 0 6.643974259645802e-09
has O 0 1.4513584778441668e-10
been O 0 1.4068068932004962e-10
identified O 0 8.248298155599798e-10
, O 0 9.613390639096053e-11
and O 0 1.3282290545202358e-10
characterization O 0 2.656432513958862e-07
of O 0 7.39421324169598e-08
this O 0 2.449202840537623e-09
gene O 0 1.874773447596567e-09
has O 0 5.445598416642383e-10
shown O 0 1.0439597103450993e-10
that O 0 2.7747465783378722e-11
it O 0 2.963894407681522e-11
contains O 0 4.3188286280582133e-11
two O 0 7.158305198595727e-11
mutations O 0 4.48116210804983e-10
that O 0 1.0200701394680323e-10
result O 0 3.681938309796351e-09
in O 0 7.306615312785425e-09
amino O 0 4.813324139263386e-08
acid O 0 4.372092465843025e-09
substitutions O 0 4.041404544352645e-09
- O 0 1.0025014596237725e-08
cDNA O 0 1.792600734518146e-08
nucleotides O 0 7.45791961520581e-09
845 O 0 1.2858460074482991e-08
G O 0 1.8380815092200464e-08
- O 0 1.1356190654510101e-08
- O 0 6.9044117090300006e-09
> O 0 3.2184217513275826e-09
A O 0 6.821476716822872e-08
( O 0 5.217131171519895e-10
C282Y O 0 1.3826277012185528e-08
) O 0 1.7195439516726196e-11
and O 0 2.3705525389883242e-11
187 O 0 3.7335895486378945e-10
C O 0 4.323893687541158e-09
- O 0 1.1411682709905335e-09
- O 0 2.756019634730933e-09
> O 0 3.50221718292687e-09
G O 0 2.4904898054955993e-07
( O 0 2.1577902131753035e-08
H63D O 0 3.801658021984622e-05
) O 0 9.797362920949126e-09
. O 0 7.931289758289495e-08

Although O 0 3.666113741473964e-07
hemochromatosis B-Disease 1 1.0
is O 0 1.062396837170354e-08
common O 0 1.4603395159795696e-09
in O 0 4.94969398801004e-10
Caucasians O 0 1.6055595963848646e-08
, O 0 1.1781028375068558e-09
affecting O 0 1.1430205226758972e-08
> O 0 7.208334817931927e-09
= O 0 1.4302466766480393e-08
1 O 0 1.6238843159044336e-08
/ O 0 7.085512732096788e-10
300 O 0 9.825329438939434e-11
individuals O 0 8.760285899467313e-12
of O 0 1.5071267567279278e-09
northern O 0 2.3637554136257677e-09
European O 0 1.1885391559829372e-09
origin O 0 1.023395768129376e-08
, O 0 4.5216519417579093e-10
it O 0 2.1255262827590826e-10
has O 0 1.462674842356293e-10
not O 0 1.2991148434782218e-10
been O 0 1.2488896583562337e-09
recognized O 0 2.58347143677895e-09
in O 0 1.029764828963664e-09
other O 0 3.5604033055136597e-09
populations O 0 7.078293151607795e-08
. O 0 1.620823155690232e-07

The O 0 4.0860288663679967e-07
present O 0 1.3076082439056336e-08
study O 0 6.05318961621748e-10
used O 0 6.999382323735759e-11
PCR O 0 5.0323540889962715e-09
and O 0 6.400397434269678e-10
restriction O 0 7.041142424668578e-08
- O 0 1.839610774823086e-08
enzyme O 0 3.986701635483314e-09
digestion O 0 1.228465662528322e-09
to O 0 5.070280306718189e-11
analyze O 0 4.185539137502303e-10
the O 0 7.52788775759683e-10
frequency O 0 3.5257086139495186e-09
of O 0 6.002376373714924e-09
the O 0 2.206063953735793e-08
845 O 0 2.524830478023432e-08
G O 0 1.808280636339532e-08
- O 0 1.375530800373781e-08
- O 0 1.3740834248210376e-08
> O 0 1.7281007735903131e-09
A O 0 1.1632481644596737e-08
and O 0 1.591854564830797e-10
187 O 0 2.0956245072589752e-10
C O 0 1.1726059012673318e-09
- O 0 1.9471767254142236e-10
- O 0 6.914634975707656e-10
> O 0 4.466203795683299e-10
G O 0 6.364222038257594e-09
mutations O 0 1.223655288207226e-09
in O 0 1.337631339026757e-09
HLA O 0 1.944335892289928e-08
- O 0 6.94632396047723e-09
typed O 0 4.78171391371518e-10
samples O 0 5.561862082004154e-11
from O 0 2.8216712300022095e-10
non O 0 6.6816672195102456e-09
- O 0 1.4300850503801144e-09
Caucasian O 0 3.735954601236102e-10
populations O 0 3.822945571219094e-10
, O 0 2.845797035522235e-11
comprising O 0 7.874001450858259e-11
Australian O 0 9.778445830832538e-10
Aboriginal O 0 8.907949933245618e-09
, O 0 2.2466309368418536e-10
Chinese O 0 5.119622059623907e-09
, O 0 6.959223752822652e-10
and O 0 3.0049156496403384e-09
Pacific O 0 4.0626680686273176e-08
Islanders O 0 4.3079344891339133e-07
. O 0 2.5478729526184907e-07

Results O 0 5.979114803267294e-07
showed O 0 1.6953730153090874e-07
that O 0 6.805901398010406e-10
the O 0 8.079021007745268e-09
845 O 0 1.3325848868817047e-08
G O 0 2.6827205346080518e-08
- O 0 1.7506575744619113e-08
- O 0 1.1964230495209449e-08
> O 0 2.2411836830826815e-09
A O 0 6.36915187257614e-09
mutation O 0 3.9256703443513175e-10
was O 0 4.851385404514019e-10
present O 0 2.8170719229558827e-11
in O 0 2.5354628119256262e-11
these O 0 2.753595962357025e-10
populations O 0 4.984123780360505e-09
( O 0 1.8583599936672357e-10
allele O 0 5.544409931168559e-10
frequency O 0 5.177133166611725e-10
0 O 0 9.244988663503761e-10
. O 0 5.65415159137217e-10
32 O 0 1.495952339780615e-08
% O 0 2.0912054310429085e-09
) O 0 4.4553447736683793e-11
, O 0 2.0946815115774342e-10
and O 0 4.984881951664022e-10
, O 0 3.828111716508431e-10
furthermore O 0 2.210923888412708e-09
, O 0 1.8241164134735754e-10
it O 0 3.7337033464979186e-10
was O 0 3.232635137351281e-08
always O 0 2.9147424474018635e-09
seen O 0 5.128603763893125e-09
in O 0 4.852496182650157e-10
conjunction O 0 2.8282032271675916e-09
with O 0 1.8545119884194605e-09
HLA O 0 9.597118150850292e-06
haplotypes O 0 1.968287932641033e-07
common O 0 2.209996408097936e-09
in O 0 9.232724029750727e-10
Caucasians O 0 1.1527501619923441e-08
, O 0 3.933645353892956e-10
suggesting O 0 3.0974882658796332e-09
that O 0 6.941711094832215e-10
845 O 0 1.7645533034738037e-08
G O 0 6.735230329013575e-08
- O 0 8.384289174045989e-08
- O 0 1.3267192855437315e-07
> O 0 3.0305649545425695e-08
A O 0 3.4129220694012474e-06
may O 0 1.2889375788915913e-08
have O 0 1.1614053052610984e-09
been O 0 8.719868715978407e-10
introduced O 0 1.7211886083057237e-10
into O 0 4.416073895452399e-10
these O 0 5.452829854313279e-11
populations O 0 4.831088862289334e-10
by O 0 1.4186827268503066e-09
Caucasian O 0 4.99688155741751e-07
admixture O 0 5.042193606641376e-06
. O 0 7.802057666594919e-07

187 O 0 2.904816085447237e-07
C O 0 1.1243860598142419e-07
- O 0 1.591727749605809e-09
- O 0 7.996523443409842e-10
> O 0 1.5810157349971377e-10
G O 0 2.1325770038771452e-09
was O 0 7.586103967227587e-10
present O 0 3.670925369236855e-11
at O 0 1.4515662283276498e-10
an O 0 1.3025157341584048e-11
allele O 0 1.391908394099417e-10
frequency O 0 8.806936291350098e-10
of O 0 1.634083979240586e-09
2 O 0 2.254571001003569e-07
. O 0 5.945929615336354e-07

68 O 0 3.8715670598321594e-06
% O 0 1.0427945618118883e-08
in O 0 4.748358928274854e-10
the O 0 9.670239053960472e-10
two O 0 1.0894749685741445e-10
populations O 0 4.3142697747633463e-10
analyzed O 0 1.7125345586066487e-09
( O 0 1.8058385342634153e-10
Australian O 0 2.786836983403873e-09
Aboriginal O 0 1.5179287160549393e-08
and O 0 1.7185816103548746e-09
Chinese O 0 1.9798502393086892e-08
) O 0 1.5154747456946893e-09
. O 0 5.794582236262613e-08

In O 0 1.130486282363563e-08
the O 0 4.822504351409407e-08
Australian O 0 1.675617333773971e-08
Aboriginal O 0 8.811611884596005e-09
samples O 0 1.2376801805658033e-09
, O 0 2.5466015407538123e-10
187 O 0 7.217315078911213e-10
C O 0 5.16332976374656e-09
- O 0 8.871711143498828e-10
- O 0 3.0384930127524967e-09
> O 0 1.1832778090692386e-09
G O 0 2.3777834812221954e-08
was O 0 1.435288776718835e-08
found O 0 9.398563177720476e-11
to O 0 2.3184848138568803e-11
be O 0 9.600435724177458e-11
associated O 0 4.938936370990632e-09
with O 0 2.691688649747448e-09
HLA O 0 0.0004787348734680563
haplotypes O 0 6.960981409065425e-07
common O 0 2.6233758276816843e-08
in O 0 2.3213633237872955e-09
Caucasians O 0 2.0990029270251398e-08
, O 0 3.2056160503834974e-10
suggesting O 0 1.5441097289681238e-09
that O 0 1.0263621202932782e-10
it O 0 2.2306616276335234e-10
was O 0 1.2429866025343017e-09
introduced O 0 1.3697748491026118e-10
by O 0 2.3761762002472153e-10
recent O 0 1.8553407699073432e-08
admixture O 0 1.7886990235638223e-06
. O 0 3.34841928406604e-07

In O 0 3.443052420948334e-08
the O 0 3.8092217380381044e-08
Chinese O 0 3.1380560372440414e-09
samples O 0 3.2375063740985865e-10
analyzed O 0 1.6003000036235449e-09
, O 0 2.2792868981102998e-10
187 O 0 7.798243162326912e-10
C O 0 4.5133048409695675e-09
- O 0 3.3455810344307224e-10
- O 0 6.002282004757831e-10
> O 0 3.367193468495344e-10
G O 0 6.2475340456558115e-09
was O 0 4.018782195913673e-09
present O 0 2.9948779567412487e-10
in O 0 2.438573787344467e-10
association O 0 1.6824666104753305e-09
with O 0 6.741608660210119e-11
a O 0 1.7411428965274922e-09
wide O 0 5.210559983481744e-09
variety O 0 4.307890932864211e-09
of O 0 3.9993238942770404e-08
HLA O 0 4.362775598565349e-06
haplotypes O 0 4.703205433997937e-07
, O 0 4.503141415312939e-09
showing O 0 8.765146830569392e-09
this O 0 2.2204568739248032e-10
mutation O 0 2.4610724569384956e-10
to O 0 8.114610372533804e-11
be O 0 3.411052551527405e-10
widespread O 0 1.171629460117174e-08
and O 0 1.325997089907105e-09
likely O 0 9.098591213785312e-09
to O 0 3.801990722251958e-09
predate O 0 1.8857214172385284e-06
the O 0 3.835979711652726e-08
more O 0 2.2197041982252586e-09
genetically O 0 1.7665197304950198e-08
restricted O 0 3.803210546493574e-08
845 O 0 4.355315752491151e-08
G O 0 1.7854425493624149e-07
- O 0 1.5607785996962775e-07
- O 0 1.4996584241089295e-07
> O 0 3.792331071394983e-08
A O 0 1.7769356475128006e-07
mutation O 0 4.812543963339522e-08
. O 0 7.32738527631227e-08

Genotype O 0 6.446392490033759e-06
- O 0 1.5731895928183803e-06
phenotype O 0 2.2681487621412089e-07
correlations O 0 4.153807822149247e-07
in O 0 1.512431957451099e-08
attenuated B-Disease 1 0.9999986886978149
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 1.6899031834327616e-05

Germ O 0 0.0003053669643122703
- O 0 6.106910586822778e-05
line O 0 3.865664439217653e-06
mutations O 0 1.367836972576697e-07
of O 0 2.0940124301205287e-08
the O 0 1.2824415307477466e-08
tumor B-Disease 0 8.604258709965507e-07
suppressor O 0 9.078787115868181e-06
APC O 0 6.134767005505637e-08
are O 0 1.145385106204877e-10
implicated O 0 2.4841875223557963e-09
in O 0 3.570277407050071e-09
attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.9999357461929321
AAPC B-Disease 1 1.0
) O 0 1.2010586969424253e-10
, O 0 1.5025779015118146e-12
a O 0 2.9442570343568564e-12
variant O 0 3.809759618889075e-08
of O 0 9.85789029073203e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 4.085185992153129e-06
FAP B-Disease 0 3.4859724564739736e-06
) O 0 2.5752162624570474e-09
. O 0 1.9160035336085457e-08

AAPC B-Disease 1 1.0
is O 0 9.637524556183052e-09
recognized O 0 2.4249895425043633e-09
by O 0 1.1580468528560317e-10
the O 0 7.174588700920026e-10
occurrence O 0 9.775578568849141e-09
of O 0 2.3959514372506874e-09
< O 0 5.533132707569166e-08
100 O 0 5.2255515470278624e-08
colonic B-Disease 0 3.1638755899621174e-06
adenomas I-Disease 0 6.177884870339767e-07
and O 0 1.5432491395905856e-10
a O 0 1.4090249800258192e-10
later O 0 9.269213729901082e-10
onset O 0 0.0001679309643805027
of O 0 1.4728407222719397e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.218691341759893e-10
age O 0 1.6847113704088201e-09
> O 0 1.2426594198089447e-09
40 O 0 8.373562287999903e-09
years O 0 4.102933992555791e-09
) O 0 1.933941895515545e-09
. O 0 7.668188573006773e-08

The O 0 2.982573903409502e-07
aim O 0 1.8278664981608017e-07
of O 0 1.9759871960900455e-08
this O 0 5.852959228391796e-10
study O 0 2.2670126886836783e-10
was O 0 3.429966033419163e-10
to O 0 7.541248181475169e-11
assess O 0 3.354517019715786e-08
genotype O 0 1.2215266451676143e-06
- O 0 5.096027507534018e-06
phenotype O 0 9.308657240580942e-07
correlations O 0 1.9721144326467765e-06
in O 0 1.9309064214212412e-07
AAPC B-Disease 1 1.0
families O 0 1.6995930991470232e-06
. O 0 9.774536238182918e-07

By O 0 1.7831887078045838e-08
protein O 0 2.3043811836487293e-07
- O 0 9.96071065628712e-08
truncation O 0 1.1397207089203221e-07
test O 0 4.284193888537402e-09
( O 0 8.654605920810354e-09
PTT O 0 2.5661228164608474e-07
) O 0 5.542863043550561e-11
assay O 0 3.4813976146352843e-09
, O 0 7.593063677813205e-11
the O 0 2.6177252032688614e-10
entire O 0 6.956449860595626e-10
coding O 0 2.178091929039283e-09
region O 0 6.770674243483654e-09
of O 0 1.2223309475700717e-08
the O 0 6.625261050885456e-08
APC B-Disease 0 1.029698548649094e-08
gene O 0 1.4558841909817488e-09
was O 0 3.2781912295831717e-08
screened O 0 7.309761684837213e-10
in O 0 4.475001272319368e-11
affected O 0 1.8659999934111937e-10
individuals O 0 1.690149686872644e-10
from O 0 6.09806534157542e-08
11 O 0 1.0509390904189786e-06
AAPC B-Disease 1 1.0
kindreds O 0 2.505245220163488e-06
, O 0 1.990276388141865e-09
and O 0 6.25447027502446e-10
their O 0 3.308548546243628e-09
phenotypic O 0 1.8737631535259425e-07
differences O 0 9.742308293425594e-07
were O 0 2.0380319654123014e-07
examined O 0 1.1988532833129284e-06
. O 0 1.0573429563009995e-06

Five O 0 4.974667149326706e-07
novel O 0 2.854837930499343e-07
germ O 0 2.3791910734871635e-06
- O 0 8.520528353983536e-07
line O 0 9.704872354632244e-07
APC B-Disease 0 3.109049728777791e-08
mutations O 0 1.0048714749189003e-08
were O 0 2.4491935146642163e-09
identified O 0 2.880905514146548e-09
in O 0 2.293618628357308e-09
seven O 0 1.1232371832647914e-07
kindreds O 0 2.6793850338435732e-05
. O 0 2.538157787057571e-06

Mutations O 0 6.688669600407593e-07
were O 0 4.118468055480662e-08
located O 0 7.821499892202155e-09
in O 0 5.177496278929716e-11
three O 0 4.988700424979342e-12
different O 0 4.6302441047973986e-12
regions O 0 3.8004732694219e-10
of O 0 6.245973516172398e-09
the O 0 7.893228826105769e-08
APC B-Disease 0 2.3431438123111548e-08
gene O 0 2.2426547285903098e-09
( O 0 1.2645900993035752e-09
1 O 0 1.846198038890634e-08
) O 0 5.52167443712559e-11
at O 0 7.110766198081819e-09
the O 0 4.337556092082195e-09
5 O 0 8.527029748961468e-09
end O 0 1.1927273391165727e-08
spanning O 0 1.6244481315652592e-08
exons O 0 1.653116576960656e-08
4 O 0 3.627097555636283e-08
and O 0 3.964257366817492e-09
5 O 0 5.4682526950955435e-08
, O 0 2.139131760614532e-09
( O 0 3.0146846130563176e-10
2 O 0 7.739376250981422e-09
) O 0 5.547844475484176e-11
within O 0 4.300516609490046e-10
exon O 0 1.3993892711283706e-09
9 O 0 2.0501136788197982e-08
, O 0 5.465451979880243e-10
and O 0 6.216198666919581e-10
( O 0 7.972168064585006e-11
3 O 0 3.220067323894682e-09
) O 0 5.1831282321668226e-11
at O 0 6.286610343408938e-09
the O 0 2.48037124173095e-09
3 O 0 1.0041625309042956e-08
distal O 0 1.2247303970980283e-07
end O 0 8.362026449049154e-08
of O 0 1.016131463416059e-07
the O 0 1.261861370949191e-07
gene O 0 1.3735258619362867e-07
. O 0 6.981617843848653e-07

Variability O 0 3.137195335511933e-06
in O 0 2.5879396403638566e-09
the O 0 1.9449211130506683e-09
number O 0 4.937005471106204e-09
of O 0 6.517217343571247e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 1.6896615662176373e-08
most O 0 8.138713314398416e-11
apparent O 0 5.6251971969345504e-09
in O 0 6.594099571932688e-11
individuals O 0 2.7580307829233597e-11
with O 0 6.014012898791776e-11
mutations O 0 2.6834765520789006e-09
in O 0 4.800914110703047e-10
region O 0 4.011155407823708e-09
1 O 0 2.2331542837150664e-08
, O 0 4.339376413753371e-09
and O 0 1.1621663986716158e-07
upper O 1 0.9995612502098083
- O 0 0.3069077730178833
gastrointestinal O 0 0.00016947682888712734
manifestations O 0 2.2040629119146615e-05
were O 0 3.770964429605783e-09
more O 0 8.481575441976474e-10
severe O 0 1.6276278813620593e-07
in O 0 1.9234944748092175e-09
them O 0 1.2454696829422574e-08
. O 0 6.725666708007338e-07

In O 0 4.611003134868952e-09
individuals O 0 3.985711483078802e-10
with O 0 1.196700238903503e-10
mutations O 0 1.6101250333022676e-09
in O 0 1.231094393094878e-10
either O 0 7.668517487680049e-10
region O 0 2.3553035077839013e-09
2 O 0 3.300083983859281e-09
or O 0 9.194729422290493e-10
region O 0 4.555310351150865e-09
3 O 0 7.797250844987502e-09
, O 0 2.793658360200624e-10
the O 0 2.8540569907420377e-09
average O 0 1.4806180281823345e-08
number O 0 6.982641576058768e-09
of O 0 1.230567931997939e-07
adenomas B-Disease 0 5.433526553133561e-07
tended O 0 9.357060548609297e-08
to O 0 3.1689719737215682e-09
be O 0 4.482309634568082e-09
lower O 0 2.029408285864065e-08
than O 0 3.2802521809927043e-10
those O 0 2.665366538590064e-10
in O 0 1.7956376663352813e-10
individuals O 0 5.343671338753353e-11
with O 0 1.3815507071690547e-10
mutations O 0 2.083052619283876e-09
in O 0 3.2295133234327977e-10
region O 0 1.7362348225802293e-09
1 O 0 1.1441001923628846e-08
, O 0 6.277644515328973e-10
although O 0 4.137551634642023e-09
age O 0 2.010166184618356e-07
at O 0 4.0206245444096567e-08
diagnosis O 0 5.6327586150928255e-08
was O 0 8.063519629786242e-09
similar O 0 5.0499591175423575e-09
. O 0 2.644009953201021e-07

In O 0 1.7999296630932804e-07
all O 0 2.741817979767802e-06
AAPC B-Disease 1 1.0
kindreds O 0 3.798968464252539e-05
, O 0 2.3685211569812736e-09
a O 0 3.766909895119852e-09
predominance O 0 1.1753014405258e-05
of O 0 2.4240294806077145e-05
right O 1 1.0
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.0003027539642062038
rectal B-Disease 1 0.999976634979248
polyp I-Disease 0 2.3357561076409183e-06
sparing O 0 3.2224627943833184e-07
was O 0 1.791010362239831e-07
observed O 0 7.28179898601411e-08
. O 0 1.1331788130064524e-07

No O 0 3.0199536922737025e-05
desmoid B-Disease 1 0.9998158812522888
tumors I-Disease 1 1.0
were O 0 1.3656367059411423e-07
found O 0 2.2008430633491116e-09
in O 0 4.953056298440117e-10
these O 0 6.1161413711374735e-09
kindreds O 0 8.863277798809577e-06
. O 0 5.742008397646714e-07

Our O 0 7.575251288471918e-07
data O 0 9.964587377453427e-08
suggest O 0 2.633331952495155e-08
that O 0 6.326820178870207e-10
, O 0 7.512582778090859e-10
in O 0 3.510490120817167e-09
AAPC B-Disease 1 1.0
families O 0 4.598618819073863e-09
, O 0 1.2493227286025643e-10
the O 0 2.3598348275477576e-10
location O 0 2.3491004697007156e-07
of O 0 3.358358213745305e-08
the O 0 3.0346203061526467e-07
APC B-Disease 0 6.398963137144165e-07
mutation O 0 7.082384456680302e-08
may O 0 1.1691002832492359e-08
partially O 0 3.136178960971847e-08
predict O 0 6.880052083602095e-09
specific O 0 6.561536203264495e-09
phenotypic O 0 6.442597850764287e-07
expression O 0 1.1929856555070728e-05
. O 0 4.976639957021689e-06

This O 0 1.8590389672112906e-08
should O 0 2.6942879038927003e-09
help O 0 1.547423522652025e-09
in O 0 1.0943113082362288e-09
the O 0 4.412868293002248e-09
design O 0 6.660267359848149e-08
of O 0 1.9298122211353075e-08
tailored O 0 2.6747457582132483e-07
clinical O 0 2.2282510769855435e-07
- O 0 3.0940034889681556e-07
management O 0 1.9341483969981255e-09
protocols O 0 4.166663458704534e-09
in O 0 5.01295172039562e-10
this O 0 2.7684043946152315e-10
subset O 0 2.7275307346030786e-08
of O 0 2.4627842876157047e-08
FAP B-Disease 0 8.658108185954916e-07
patients O 0 6.060621338122019e-09
. O 0 1.8738841589538424e-08
. O 0 2.792500595205638e-07

Wilms B-Disease 0 0.011871620081365108
' I-Disease 0 9.367608981847297e-06
tumor I-Disease 0 8.52485982250073e-07
1 O 0 1.584550233246773e-07
and O 0 2.3649817659787686e-09
Dax O 0 1.6726829926483333e-05
- O 0 6.104020844333036e-09
1 O 0 5.991886986578265e-09
modulate O 0 3.3053313419628694e-09
the O 0 3.274321702662064e-09
orphan O 0 1.701527274633463e-08
nuclear O 0 1.0693558039065465e-08
receptor O 0 1.0970101982366032e-07
SF O 0 1.2887975572084542e-05
- O 0 1.0574925823902959e-07
1 O 0 4.513995932597936e-08
in O 0 7.34181604400419e-10
sex O 0 1.1095356577950355e-10
- O 0 2.569386370332438e-10
specific O 0 1.2312634245503773e-10
gene O 0 1.0489480395392548e-09
expression O 0 4.124175134734287e-08
. O 0 1.8150018377127708e-07

Products O 0 1.6068592856299801e-07
of O 0 1.6730074037241138e-07
steroidogenic O 0 5.51063249076833e-06
factor O 0 1.0832643937419562e-07
1 O 0 1.5456093649390823e-07
( O 0 2.5467292719127954e-09
SF O 0 2.861744633264607e-06
- O 0 3.0363047187620396e-08
1 O 0 2.077031169278598e-08
) O 0 3.17333131993891e-10
and O 0 2.957933675773461e-09
Wilms B-Disease 0 9.886265388558968e-07
tumor I-Disease 0 1.5903802932371036e-06
1 O 0 1.5679756870667916e-06
( O 0 2.3180993125038185e-08
WT1 O 0 2.4312907953571994e-06
) O 0 4.0884093333026783e-10
genes O 0 2.547748123582494e-10
are O 0 7.181919989274199e-12
essential O 0 1.5445741907704758e-10
for O 0 2.5252999691360856e-10
mammalian O 0 3.6211707765687606e-07
gonadogenesis O 0 8.991037816485914e-07
prior O 0 1.971996255178965e-08
to O 0 4.1917331827789894e-09
sexual O 0 2.3872900101196137e-08
differentiation O 0 1.4365041351993568e-06
. O 0 1.0309561275789747e-06

In O 0 1.1982408842925452e-08
males O 0 3.990825447885982e-09
, O 0 3.001478621200704e-09
SF O 0 2.9580383852589875e-05
- O 0 7.769727972117835e-07
1 O 0 6.743379685758555e-07
participates O 0 3.286785510425716e-09
in O 0 2.3050990283213224e-10
sexual O 0 6.741172203783563e-11
development O 0 3.0482418672539424e-11
by O 0 3.7727139121090936e-12
regulating O 0 6.017160103510832e-10
expression O 0 6.499246474334086e-09
of O 0 9.247145271729096e-09
the O 0 3.473970267009463e-08
polypeptide O 0 7.873184131312883e-07
hormone O 0 4.809543341366407e-08
Mullerian O 0 3.4641485058273247e-07
inhibiting O 0 1.1319831116907153e-07
substance O 0 2.765964381978847e-07
( O 0 2.888919539145718e-07
MIS O 0 7.502458902308717e-05
) O 0 2.1461334043237912e-08
. O 0 1.1914431752302335e-07

Here O 0 4.565324331906595e-07
, O 0 2.2824563572498846e-08
we O 0 4.810274845112872e-09
show O 0 9.886340635034685e-09
that O 0 2.6171873557245817e-09
WT1 O 0 1.583587254572194e-05
- O 0 1.6244378002738813e-06
KTS O 0 2.82971523120068e-05
isoforms O 0 2.1695234408980468e-07
associate O 0 5.163884111425432e-07
and O 0 5.784144274656455e-09
synergize O 0 1.091652208629057e-07
with O 0 2.8499174131724203e-09
SF O 0 0.0001826351071940735
- O 0 8.253891223830578e-07
1 O 0 3.8632214227618533e-07
to O 0 1.1783326314684928e-08
promote O 0 3.053862656088313e-07
MIS O 0 4.627459202311002e-05
expression O 0 3.74396933011667e-07
. O 0 7.608236956002656e-07

In O 0 6.695651677546266e-08
contrast O 0 5.656777943841007e-07
, O 0 1.3391515096827789e-07
WT1 O 0 0.0001976644853129983
missense O 0 6.4783598645590246e-06
mutations O 0 3.236189058952732e-07
, O 0 1.4090311140080303e-09
associated O 0 4.228276839768341e-09
with O 0 2.1698019769811339e-10
male B-Disease 0 2.0686542256953544e-07
pseudohermaphroditism I-Disease 1 1.0
in O 0 1.1765296648036383e-07
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 7.285105141363601e-08
fail O 0 3.25272360157669e-08
to O 0 8.815814744878026e-09
synergize O 0 8.081465807663335e-07
with O 0 5.137094660767616e-08
SF O 0 0.2673097550868988
- O 0 5.201373642194085e-05
1 O 0 3.496451972750947e-05
. O 0 1.052801962941885e-06

Additionally O 0 1.3502522051567212e-06
, O 0 7.665334145201541e-09
the O 0 3.733094544600135e-08
X O 0 1.24467824207386e-05
- O 0 2.139048774552066e-06
linked O 0 1.4766562799195526e-06
, O 0 2.509733754152421e-09
candidate O 0 1.0262281691097996e-08
dosage O 0 8.947441898499164e-08
- O 0 1.9719585964139696e-08
sensitive O 0 1.670753668747693e-08
sex O 0 1.0117522375452381e-09
- O 0 8.018872676984756e-09
reversal O 0 1.8914361632482724e-08
gene O 0 1.8765800025022372e-09
, O 0 4.150419119497428e-09
Dax O 0 4.332764547143597e-06
- O 0 5.1196806793996075e-09
1 O 0 1.0771818104160502e-08
, O 0 7.313303851397279e-10
antagonizes O 0 2.8406496710431384e-08
synergy O 0 1.9378862958774334e-08
between O 0 3.646103152732394e-08
SF O 0 2.2362231902661733e-05
- O 0 6.620700219173159e-07
1 O 0 9.83208906291111e-07
and O 0 4.265117325985557e-08
WT1 O 0 4.451535460248124e-06
, O 0 1.419730333296343e-09
most O 0 5.483244969184398e-10
likely O 0 1.5627104055226937e-09
through O 0 1.087589740489392e-10
a O 0 3.734657583187584e-10
direct O 0 3.94613675069877e-09
interaction O 0 1.5222312299556506e-08
with O 0 1.1850537440238895e-08
SF O 0 0.38586151599884033
- O 0 7.55919172661379e-05
1 O 0 4.8278376198140904e-05
. O 0 1.354049800283974e-06

We O 0 6.703881894054575e-08
propose O 0 5.4655306058748465e-08
that O 0 1.1672153021891063e-08
WT1 O 0 2.3130098270485178e-05
and O 0 1.693207707376132e-07
Dax O 0 0.018552180379629135
- O 0 1.3580222457676427e-07
1 O 0 5.904847810711544e-08
functionally O 0 8.01578359244104e-09
oppose O 0 1.0789722448834027e-09
each O 0 1.3259079945093788e-10
other O 0 2.837159673862999e-10
in O 0 1.2992293907387875e-09
testis O 0 6.384248507629309e-08
development O 0 2.424217271368434e-09
by O 0 1.0134594274902042e-09
modulating O 0 2.6323536417294235e-07
SF O 0 4.799944508704357e-05
- O 0 9.76426917986828e-07
1 O 0 1.8250984794576652e-06
- O 0 2.3124694337184337e-07
mediated O 0 5.270113661026699e-07
transactivation O 0 8.423220947406662e-07
. O 0 2.8403462692949688e-08
. O 0 6.886487824431242e-08

A O 0 1.7826874909587787e-06
mouse O 0 3.0123139538318355e-08
model O 0 4.60631106591336e-08
for O 0 4.500138217622407e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 1.0
- O 1 1.0
centre O 1 0.9999303817749023
mutations O 0 1.811347942748398e-06
. O 0 2.5360139943586546e-07

Imprinting O 0 9.514508747088257e-06
in O 0 5.566030480963491e-08
the O 0 1.6258871937679942e-07
15q11 O 0 2.3806094304745784e-06
- O 0 9.084479302146065e-08
q13 O 0 4.597380609538959e-07
region O 0 3.2253415493954662e-09
involves O 0 1.3971809265100887e-09
an O 0 3.331243059179201e-09
imprinting O 0 2.887236178139574e-06
centre O 0 1.4660450688097626e-05
( O 0 8.409863028191467e-09
IC O 0 5.157719351700507e-05
) O 0 1.585703679474193e-09
, O 0 7.10242642476544e-10
mapping O 0 1.1347004447159748e-09
in O 0 2.813062560669266e-10
part O 0 4.467669012520048e-10
to O 0 5.270952563307674e-10
the O 0 1.7977297872562303e-08
promoter O 0 1.0443395126458199e-07
and O 0 4.882653392712655e-09
first O 0 1.9629823100331123e-08
exon O 0 1.0324718857646076e-07
of O 0 1.5673463167331647e-06
SNRPN O 1 0.9911976456642151
. O 0 7.345537596847862e-06

Deletion O 0 2.504468454844755e-07
of O 0 4.328549607635068e-08
this O 0 2.1522359450187878e-09
IC O 0 4.1674074964248575e-06
abolishes O 0 1.5342601500378805e-06
local O 0 1.1480670991659281e-07
paternally O 0 2.3727371001314168e-07
derived O 0 1.6745078657010026e-09
gene O 0 4.302674327938405e-10
expression O 0 1.3747379901118961e-09
and O 0 3.406181239840045e-11
results O 0 8.119614980373058e-10
in O 0 1.3511350260841937e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
PWS B-Disease 1 1.0
) O 0 2.8322270395619853e-07
. O 0 1.8843179816485645e-07

We O 0 5.548721304649007e-08
have O 0 2.0498780450850518e-09
created O 0 4.238903450470843e-09
two O 0 1.4590977315265263e-09
deletion O 0 6.9561876259172095e-09
mutations O 0 1.5106184747537554e-08
in O 0 6.704719557326655e-10
mice O 0 6.199527002870298e-10
to O 0 2.954199662674739e-10
understand O 0 4.736640235591949e-08
PWS B-Disease 1 1.0
and O 0 1.0668357752763313e-08
the O 0 4.711588452721571e-09
mechanism O 0 8.951774432830462e-09
of O 0 1.4801597725266902e-09
this O 0 2.1063490951434005e-09
IC O 0 8.772573346504942e-05
. O 0 1.6343486777259386e-06

Mice O 0 8.303588401759043e-06
harbouring O 0 2.294870137120597e-05
an O 0 5.79627368324509e-08
intragenic O 0 2.239998138975352e-06
deletion O 0 3.3082724115729434e-08
in O 0 7.02273750263771e-09
Snrpn O 0 6.0847733038826846e-06
are O 0 5.039547890106633e-09
phenotypically O 0 0.00010396370635135099
normal O 0 8.029976925172377e-06
, O 0 1.3462776449202352e-09
suggesting O 0 2.7255582235596876e-09
that O 0 2.2280252642836729e-10
mutations O 0 4.537907827284471e-08
of O 0 8.862620859417802e-08
SNRPN O 0 0.01583016850054264
are O 0 1.2205411126231525e-09
not O 0 8.093283820898023e-10
sufficient O 0 2.957077605003633e-08
to O 0 1.838320073943578e-08
induce O 0 0.0011521830456331372
PWS B-Disease 1 1.0
. O 0 5.226462599239312e-05

Mice O 0 9.471676065686552e-08
with O 0 2.136040233580161e-10
a O 0 6.367497085157936e-10
larger O 0 9.981622195454065e-10
deletion O 0 1.3397097875511577e-09
involving O 0 1.3442659207996144e-09
both O 0 4.164645517334975e-09
Snrpn O 0 9.876126796370954e-07
and O 0 1.298654628278939e-09
the O 0 1.365472179770677e-08
putative O 0 6.971265520405723e-06
PWS O 1 1.0
- O 0 5.506474849426013e-07
IC O 0 7.841607839509379e-06
lack O 0 3.6118269264306946e-08
expression O 0 7.151775616165423e-09
of O 0 1.4655414659614507e-08
the O 0 1.9037566190149846e-08
imprinted O 0 1.603018944251744e-07
genes O 0 1.0553466722740268e-07
Zfp127 O 0 2.3996126401470974e-06
( O 0 2.681399546844432e-09
mouse O 0 5.662777802228902e-09
homologue O 0 2.1030990637882496e-07
of O 0 5.968175997850267e-08
ZNF127 O 0 5.908546881983057e-05
) O 0 3.4201161902558397e-09
, O 0 9.26490528740942e-09
Ndn O 0 7.211596084744087e-07
and O 0 7.86434295463323e-09
Ipw O 0 4.9071354624175e-07
, O 0 5.075441844581974e-09
and O 0 8.118159477987774e-10
manifest O 0 9.481505358621689e-09
several O 0 1.6241251676873958e-09
phenotypes O 0 4.085241869233869e-07
common O 0 2.0773402553686537e-08
to O 0 1.73609066678182e-07
PWS B-Disease 1 1.0
infants O 1 0.9999960660934448
. O 0 3.535486030159518e-06

These O 0 1.0257466875884802e-08
data O 0 6.716037059817381e-09
demonstrate O 0 3.995730413208776e-09
that O 0 3.021016492521511e-10
both O 0 5.639869682383392e-10
the O 0 4.120846774924303e-09
position O 0 1.021165108028299e-08
of O 0 5.110451173351294e-09
the O 0 8.165839560092536e-09
IC O 0 1.815394625737099e-06
and O 0 8.087250313870697e-10
its O 0 4.662009112088583e-10
role O 0 3.8217937148310455e-10
in O 0 1.231355156727787e-10
the O 0 8.022080777436713e-10
coordinate O 0 1.6055649032509223e-09
expression O 0 8.851922750352514e-09
of O 0 2.7656417600496752e-08
genes O 0 3.840839202240431e-09
is O 0 2.735483506377534e-10
conserved O 0 4.869632252990641e-09
between O 0 3.854901287070334e-09
mouse O 0 8.108491655889338e-09
and O 0 2.064112214483771e-09
human O 0 1.9701231757096593e-09
, O 0 2.066884580154138e-10
and O 0 5.956704574039406e-11
indicate O 0 2.6339483927273477e-09
that O 0 1.6050435980297095e-10
the O 0 8.149440233751193e-09
mouse O 0 2.5378747992022e-09
is O 0 1.533940474640616e-10
a O 0 2.1858234666716214e-10
suitable O 0 8.007027041401216e-09
model O 0 3.955631822094574e-09
system O 0 7.043258198891067e-10
in O 0 4.34189934006568e-10
which O 0 1.393119508641405e-10
to O 0 5.329546248766803e-10
investigate O 0 1.117803982708665e-08
the O 0 1.2762557233259031e-08
molecular O 0 2.2204336147524373e-08
mechanisms O 0 2.852376823625491e-08
of O 0 9.055913352540301e-09
imprinting O 0 3.4299169726637047e-08
in O 0 2.1966230223657845e-10
this O 0 1.1159410201466713e-10
region O 0 3.866388542661525e-09
of O 0 1.1669036403816335e-08
the O 0 1.2371875968142376e-08
genome O 0 5.14031661680292e-09
. O 0 1.2177791219869505e-08
. O 0 1.3836834966696188e-07

Mutations O 0 2.5761886490727193e-07
of O 0 6.239391581175369e-08
the O 0 1.07321973530361e-08
ATM O 0 4.2676239786487713e-07
gene O 0 4.252264762527602e-09
detected O 0 5.4321565023940366e-09
in O 0 2.2434536173232544e-10
Japanese O 0 0.00013210558972787112
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9985768795013428
: O 0 6.754157649835335e-11
possible O 0 4.4245473951320946e-10
preponderance O 0 2.164011448257952e-06
of O 0 6.937667507145306e-08
the O 0 1.0816663120749581e-07
two O 0 1.3076605576145539e-08
founder O 0 2.4050143565546023e-07
mutations O 0 7.197072449116604e-08
4612del165 O 0 7.700152764300583e-07
and O 0 4.3956667639122315e-08
7883del5 O 0 7.159515007515438e-06
. O 0 9.806991556615685e-07

The O 0 4.05594818175814e-07
ATM O 0 0.00029580085538327694
( O 0 4.98494046041742e-05
A O 1 1.0
- O 1 1.0
T O 1 1.0
, O 0 4.968178313191629e-09
mutated O 0 4.277922904805109e-09
) O 0 3.465929973578419e-11
gene O 0 1.9176542298549037e-10
on O 0 2.536577836664833e-09
human O 0 4.116690988098526e-09
chromosome O 0 1.3114951968873356e-07
11q22 O 0 4.08061077905586e-06
. O 0 2.7652731660054997e-07

3 O 0 2.4546241547795944e-05
has O 0 4.174238199539104e-08
recently O 0 9.003417567043925e-09
been O 0 4.5330764142370583e-10
identified O 0 1.0825074170384141e-09
as O 0 8.446442156806455e-11
the O 0 6.067311930646468e-11
gene O 0 5.184462928409239e-11
responsible O 0 9.022456393115164e-11
for O 0 1.5864523236763795e-11
the O 0 1.2336476284957598e-09
human O 0 1.1796395682495131e-07
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.4300612249940059e-08
. O 0 6.416341591375385e-08

In O 0 5.261352686858345e-09
order O 0 1.8829331427383522e-09
to O 0 4.115260354708994e-10
define O 0 5.0090354086762545e-09
the O 0 9.471161632745861e-10
types O 0 1.3409784394013968e-08
of O 0 1.1003228550521271e-08
disease O 0 6.683173836563583e-08
- O 0 1.5417059628930474e-08
causing O 0 1.3279619182071656e-08
ATM O 0 3.740315150935203e-07
mutations O 0 3.6260581204317077e-09
in O 0 5.818232562404546e-10
Japanese O 0 3.5615639717434533e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 6.688236453555874e-08
as O 0 3.025492745223346e-09
well O 0 2.8254570905161813e-10
as O 0 2.0833297587063981e-10
to O 0 2.2772793373260214e-10
look O 0 1.206724054014785e-09
for O 0 3.17961434959102e-10
possible O 0 5.798208491114565e-08
mutational O 0 5.937174591963412e-06
hotspots O 0 3.221390443286509e-07
, O 0 1.229284229964378e-08
reverse O 0 1.1784813835902241e-07
- O 0 6.672932784113073e-08
transcribed O 0 1.1754369033667444e-08
RNA O 0 5.4677906646816155e-09
derived O 0 1.3756324968028366e-09
from O 0 3.7962349930253936e-10
ten O 0 2.017874312087997e-09
patients O 0 1.1274533390226438e-10
belonging O 0 4.147584220515199e-10
to O 0 3.3576630364962057e-10
eight O 0 1.7052399492456516e-09
unrelated O 0 1.8115670741281065e-08
Japanese O 0 1.0565828461039928e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999923706054688
T I-Disease 1 1.0
families O 0 3.926902536477428e-08
was O 0 8.584406963052515e-09
analyzed O 0 4.2723269366717886e-10
for O 0 1.2488295120238746e-10
mutations O 0 2.263155662873828e-09
by O 0 9.086879582120844e-10
the O 0 8.226761494256607e-09
restriction O 0 9.22233027722541e-08
endonuclease O 0 1.6320328199981304e-07
fingerprinting O 0 3.134773152169146e-08
method O 0 4.400246780278394e-07
. O 0 1.029922373163572e-06

As O 0 7.247489861583745e-07
has O 0 3.3121221321152916e-09
been O 0 5.88588400241008e-10
reported O 0 7.211494179593103e-10
by O 0 1.2405416971450478e-10
others O 0 1.7938585061827439e-09
, O 0 4.663227581858109e-10
mutations O 0 2.3574473484444525e-09
that O 0 3.375179302711473e-10
lead O 0 4.584501667181939e-09
to O 0 5.21999021785291e-09
exon O 0 1.506343636492602e-07
skipping O 0 5.231046884546231e-07
or O 0 1.4092904621065827e-07
premature O 0 6.455156267293205e-07
protein O 0 1.4324641028906626e-07
truncation O 0 4.0591831407255086e-07
were O 0 1.328600429673088e-08
also O 0 1.1291648727151937e-09
predominant O 0 1.2387157255489e-07
in O 0 2.1718029596939914e-09
our O 0 1.404473692900865e-07
mutants O 0 5.846370640938403e-07
. O 0 7.118917437765049e-07

Six O 0 6.638213534415627e-08
different O 0 2.1866501942469085e-09
mutations O 0 1.2379571145970658e-08
were O 0 1.0383006676661921e-09
identified O 0 7.899156329038703e-10
on O 0 5.272500769315513e-10
12 O 0 2.0598096561741386e-09
of O 0 2.790091935267469e-09
the O 0 2.790157260790238e-08
16 O 0 1.1605958150084916e-07
alleles O 0 6.53553371421367e-08
examined O 0 1.1679678664222592e-06
. O 0 1.427003439857799e-06

Four O 0 1.5617553117408534e-07
were O 0 6.8804326680549366e-09
deletions O 0 4.3706279484467814e-08
involving O 0 2.1080051038069314e-09
a O 0 1.6333111529931443e-09
loss O 0 3.190558572896407e-08
of O 0 5.330578645157402e-08
a O 0 1.508594316135259e-08
single O 0 1.1262637045206247e-08
exon O 0 2.8920226213813294e-08
exon O 0 1.1387319887035119e-07
7 O 0 1.795597086129419e-06
, O 0 4.0845321791493916e-08
exon O 0 6.797228024879587e-08
16 O 0 1.2719319784082472e-06
, O 0 2.8108450678132613e-08
exon O 0 8.477280744045856e-08
33 O 0 1.6996498288790463e-06
or O 0 5.462342045348123e-08
exon O 0 1.4190140973369125e-07
35 O 0 4.050763436680427e-06
. O 0 1.0606070190988248e-06

The O 0 4.845628609473351e-07
others O 0 7.244505439985005e-08
were O 0 9.189895067152065e-09
minute O 0 1.7755195358404308e-07
deletions O 0 9.907845566203832e-08
, O 0 2.9880211638300125e-09
4649delA O 0 1.8645330612798716e-07
in O 0 4.490310345772741e-09
exon O 0 2.623145611835298e-08
33 O 0 3.8374585642486636e-07
and O 0 1.3413826494002024e-08
7883del5 O 0 2.990303755723289e-07
in O 0 8.726079414600463e-09
exon O 0 1.9984604193723499e-07
55 O 0 2.114091785188066e-06
. O 0 1.1286667813692475e-06

The O 0 2.22728522203397e-06
mutations O 0 7.29846988178906e-07
4612del165 O 0 9.568536825099727e-07
and O 0 2.0849446613624423e-09
7883del5 O 0 7.521478551097971e-08
were O 0 1.8167495285936752e-09
found O 0 2.3163378159996029e-10
in O 0 3.681990823345416e-11
more O 0 2.119679085033077e-11
than O 0 7.275235275328029e-11
two O 0 1.4628644129377477e-10
unrelated O 0 2.067011672934882e-09
families O 0 1.7109862138209309e-10
; O 0 1.0677730921671014e-10
44 O 0 1.1547043321513684e-08
% O 0 4.822435228923894e-10
( O 0 1.937868789048114e-11
7 O 0 3.6148162241289583e-09
of O 0 4.460706470865716e-09
16 O 0 6.318502165925111e-09
) O 0 2.3103536445079342e-11
of O 0 7.84836529099664e-10
the O 0 6.614080949596257e-10
mutant O 0 5.345122122690782e-10
alleles O 0 2.3323509790174057e-10
had O 0 8.168795084806391e-10
one O 0 5.191936880422077e-10
of O 0 3.2280247364013803e-09
the O 0 3.2426143548036634e-08
two O 0 3.3434407242793895e-08
mutations O 0 8.567249096813612e-07
. O 0 7.549066367573687e-07

The O 0 8.144383514263609e-07
4612del165 O 0 5.98872532009409e-07
mutations O 0 8.173069332428895e-09
in O 0 2.1660845339610546e-10
three O 0 2.391351526520591e-11
different O 0 7.959598258278078e-12
families O 0 7.22364668082065e-11
were O 0 7.70278701933691e-11
all O 0 2.129055091948384e-11
ascribed O 0 3.276270366114886e-09
to O 0 3.0677305140613953e-10
the O 0 1.6730815843857272e-08
same O 0 1.5601024472289282e-08
T O 0 6.541345243249452e-08
- O 0 1.8051274253139127e-08
- O 0 1.9546877894072168e-08
> O 0 2.7381470424359122e-09
A O 0 7.806535862187047e-09
substitution O 0 1.8613123264898945e-09
at O 0 9.203577455707546e-09
the O 0 6.362401272497209e-09
splice O 0 4.0683019619791594e-07
donor O 0 3.7490927695671417e-08
site O 0 3.050486157007981e-07
in O 0 1.8969711135241596e-08
intron O 0 9.445627256354783e-06
33 O 0 1.7116139133577235e-05
. O 0 1.5721307136118412e-06

Microsatellite O 0 4.974874627805548e-06
genotyping O 0 4.4062309711989656e-07
around O 0 2.621970374150351e-08
the O 0 3.251222935318765e-08
ATM O 0 1.2739503290504217e-05
locus O 0 1.455202607303363e-07
also O 0 4.188408286864842e-09
indicated O 0 1.727665788209265e-09
that O 0 1.821087725062398e-11
a O 0 7.004684332567734e-11
common O 0 1.7510400074360888e-10
haplotype O 0 2.300344625894013e-08
was O 0 6.151942510967956e-09
shared O 0 2.3114743452623543e-10
by O 0 1.2406836669143217e-10
the O 0 1.8665953227525733e-09
mutant O 0 4.223923877333391e-09
alleles O 0 1.883342592989834e-09
in O 0 2.0422641355821725e-09
both O 0 1.4084299948535772e-08
mutations O 0 9.494897312833928e-07
. O 0 1.0201468967352412e-06

This O 0 1.9459314160030772e-08
suggests O 0 3.556447936148288e-08
that O 0 2.537215160192119e-10
these O 0 1.473534627649542e-09
two O 0 5.419138471296492e-09
founder O 0 1.358570216325461e-07
mutations O 0 1.1730404203547096e-08
may O 0 1.054484610740758e-09
be O 0 1.5266581054884654e-10
predominant O 0 1.531498128315434e-08
among O 0 2.6124080676481753e-10
Japanese O 0 1.7227801407670995e-08
ATM O 0 1.3646177876580623e-06
mutant O 0 3.741627949693793e-07
alleles O 0 2.72444310667197e-07
. O 0 8.186035529433866e-07

W474C O 0 2.516683889552951e-05
amino O 0 4.482850499698543e-07
acid O 0 6.933431162536863e-09
substitution O 0 7.457123807341759e-09
affects O 0 1.5207155534824324e-09
early O 0 4.984387347306551e-10
processing O 0 3.959526928554169e-09
of O 0 5.663026048097208e-09
the O 0 5.070130537632167e-09
alpha O 0 4.078129500761918e-10
- O 0 1.0551701873362518e-10
subunit O 0 5.264258473580696e-11
of O 0 8.97419916157105e-10
beta O 0 2.485690098197324e-09
- O 0 3.6905087874572473e-09
hexosaminidase O 0 4.4867338289122927e-08
A O 0 5.324735496969879e-08
and O 0 2.4534752007809857e-10
is O 0 5.7058142932664424e-11
associated O 0 1.637010083044288e-09
with O 0 2.4445543367335176e-09
subacute O 0 0.0007178984233178198
G B-Disease 1 0.9974752068519592
( I-Disease 0 2.3155258531915024e-05
M2 I-Disease 1 0.9999966621398926
) I-Disease 0 6.818368092353921e-08
gangliosidosis I-Disease 0 7.193369674496353e-05
. O 0 1.1761262612708379e-06

Mutations O 0 3.838922850718518e-07
in O 0 1.8607275720228245e-08
the O 0 6.956960163506665e-08
HEXA O 0 1.0427864935991238e-06
gene O 0 2.6738511405000054e-09
, O 0 2.514859986924023e-10
encoding O 0 4.3407483163449e-10
the O 0 4.664893360484257e-09
alpha O 0 2.428436896018127e-10
- O 0 3.1479503032061373e-11
subunit O 0 2.6678216927256138e-11
of O 0 3.3357303030889796e-10
beta O 0 1.117466563727021e-09
- O 0 2.945716337521276e-09
hexosaminidase O 0 7.525496670268694e-08
A O 0 9.3450898930314e-07
( O 0 2.187309222634326e-09
Hex O 0 8.481680424665683e-08
A O 0 1.8532210788180237e-07
) O 0 1.437481800259377e-10
, O 0 1.0178079212774804e-10
that O 0 6.953819464694533e-11
abolish O 0 3.709402562890318e-08
Hex O 0 1.3565789913627668e-07
A O 0 2.8959581399590206e-08
enzyme O 0 4.7216577314657115e-08
activity O 0 5.620288234808868e-08
cause O 0 0.007830886170268059
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 7.841740590208701e-09
TSD B-Disease 0 8.896678082237486e-06
) O 0 4.4822538042277316e-11
, O 0 1.6555437576393217e-11
the O 0 2.3828294892780377e-10
fatal O 0 6.235203642290799e-08
infantile B-Disease 0 5.061451702204067e-07
form I-Disease 0 1.3664771536525677e-09
of I-Disease 0 3.4392331826893496e-07
G I-Disease 0 1.0540945368120447e-05
( I-Disease 0 1.7016043329931563e-07
M2 I-Disease 0 6.443446909543127e-05
) I-Disease 0 5.271699077269432e-09
gangliosidosis I-Disease 0 6.325468007162272e-07
, I-Disease 0 1.694773321680998e-09
Type I-Disease 0 2.1594370736011115e-08
1 I-Disease 0 4.0329945250050514e-07
. O 0 4.328863667524274e-07

Less O 0 1.4806101944486727e-07
severe O 0 3.1989744456950575e-05
, O 0 1.1122998522239413e-08
subacute O 0 5.284979124553502e-06
( O 0 9.520062516088501e-10
juvenile O 0 5.357377631298732e-06
- O 0 1.6588516018600785e-06
onset O 1 0.9999899864196777
) O 0 2.335734383684951e-10
and O 0 4.7895842847367476e-09
chronic O 1 0.8090976476669312
( O 0 3.5671171572104754e-10
adult O 0 0.0005490184994414449
- O 0 2.9341086360545887e-07
onset O 0 5.710912205358909e-07
) O 0 3.072465892817178e-11
variants O 0 2.301097229429061e-10
are O 0 1.2073789884547992e-11
characterized O 0 3.967861456066757e-11
by O 0 1.7080573067040916e-11
a O 0 8.671521833925055e-10
broad O 0 1.917882919144631e-08
spectrum O 0 2.8056172496349063e-08
of O 0 4.010917820096438e-09
clinical O 0 1.0459278776409064e-08
manifestations O 0 1.3819552613369979e-08
and O 0 2.607788152086954e-10
are O 0 2.0239934728216724e-11
associated O 0 6.723826495580454e-10
with O 0 6.569619154239703e-11
residual O 0 0.00020816869800910354
levels O 0 1.5021403498849395e-07
of O 0 3.4282695082765713e-07
Hex O 0 1.560277155476797e-06
A O 0 8.012199259610497e-07
enzyme O 0 6.086939379201795e-07
activity O 0 9.724996061777347e-07
. O 0 3.265236898641888e-07

We O 0 4.1445037624043835e-08
identified O 0 3.343262022781346e-08
a O 0 1.2060643150846317e-08
1422 O 0 6.485218477791932e-07
G O 0 2.1908974190409936e-07
- O 0 1.1235500352313466e-07
- O 0 8.510233584502203e-08
> O 0 1.4677626225534368e-08
C O 0 1.1506418218232284e-07
( O 0 2.8013580344321554e-10
amino O 0 6.29163332543925e-10
acid O 0 7.314807787262012e-11
W474C O 0 1.8185236649870262e-10
) O 0 3.543930285950653e-14
substitution O 0 3.8801310255076604e-12
in O 0 5.698643813778492e-12
the O 0 6.212568653962691e-11
first O 0 1.4090949240763706e-10
position O 0 2.844948054914198e-09
of O 0 2.777015506438829e-09
exon O 0 3.1977398506910504e-09
13 O 0 6.629773707800268e-08
of O 0 4.120460630474554e-07
HEXA O 0 0.00022585887927561998
of O 0 1.1307429303997196e-06
a O 0 1.0463173083508082e-07
non O 0 2.6771220291266218e-05
- O 0 6.984241736063268e-07
Jewish O 0 0.06676371395587921
proband O 0 0.0004637198871932924
who O 0 5.544327663642434e-09
manifested O 0 6.216889669730108e-09
a O 0 1.1483212158935885e-09
subacute O 0 1.792180768234175e-07
variant O 0 1.7109887551214342e-07
of O 0 2.0591782231349498e-05
G B-Disease 1 0.9999982118606567
( I-Disease 0 0.023498836904764175
M2 I-Disease 1 0.9999988079071045
) I-Disease 0 1.4077832588554884e-07
gangliosidosis I-Disease 0 4.6662426029797643e-05
. O 0 1.2055983233949519e-06

On O 0 2.395551064182655e-07
the O 0 6.596575019557349e-08
second O 0 2.1723225529513002e-07
maternally O 0 1.531018256173411e-06
inherited O 0 5.371401812226395e-07
allele O 0 6.600954804980574e-08
, O 0 8.480798840970749e-10
we O 0 7.102910620782055e-11
identified O 0 8.226647696396583e-10
the O 0 1.0356168145264633e-09
common O 0 5.627088839332828e-08
infantile O 1 1.0
disease O 1 0.9245894551277161
- O 0 4.685610690557951e-07
causing O 0 0.000847935676574707
4 O 0 0.00034925289219245315
- O 0 3.760146455533686e-06
bp O 0 7.649650513030792e-08
insertion O 0 4.9115080003048206e-08
, O 0 8.740505208493232e-09
+ O 0 8.842695820021618e-08
TATC O 0 4.004100264864974e-05
1278 O 0 3.0922888072382193e-06
, O 0 6.559158993724168e-09
in O 0 1.0784892090498488e-08
exon O 0 1.567879905906011e-07
11 O 0 1.2647109315366833e-06
. O 0 1.0231087799184024e-06

Pulse O 0 4.557391548587475e-06
- O 0 4.672277782447054e-07
chase O 0 2.0817070733869514e-08
analysis O 0 8.591150013614879e-10
using O 0 8.445479870999861e-10
proband O 0 5.681436618942826e-07
fibroblasts O 0 1.0247888582171072e-07
revealed O 0 3.887568666982588e-08
that O 0 4.394698216447779e-10
the O 0 7.556749004322683e-09
W474C O 0 1.3888493910485522e-08
- O 0 9.002057432816457e-10
containing O 0 1.5433344879856037e-10
alpha O 0 3.717912921974431e-10
- O 0 4.124202368505081e-10
subunit O 0 1.5479481585423116e-10
precursor O 0 8.442134102892851e-09
was O 0 1.2172961305623176e-08
normally O 0 3.479961874219839e-10
synthesized O 0 1.6309825712212955e-09
, O 0 5.996789176343498e-10
but O 0 1.2669004734178202e-09
not O 0 6.808355546006339e-10
phosphorylated O 0 2.1501568525650328e-08
or O 0 2.60233856685943e-09
secreted O 0 7.931650003456525e-09
, O 0 6.165800647828235e-10
and O 0 1.599579912969773e-09
the O 0 6.238771987909786e-08
mature O 0 5.000628178208899e-08
lysosomal O 0 2.835058978689631e-07
alpha O 0 1.4504496270717482e-08
- O 0 6.0619278485773975e-09
subunit O 0 4.3535526295102045e-09
was O 0 1.7377962180376016e-08
not O 0 1.3251401087543968e-09
detected O 0 1.9754979518893379e-07
. O 0 1.8775266141801694e-07

When O 0 2.6266661734553054e-07
the O 0 1.2578699681853323e-07
W474C O 0 1.2487622313983593e-07
- O 0 1.5726405733218485e-09
containing O 0 1.2070296151467375e-10
alpha O 0 1.549886330387551e-10
- O 0 8.22018147994541e-11
subunit O 0 5.295840502239635e-11
was O 0 3.2371438862810464e-09
transiently O 0 2.816188393595098e-09
co O 0 1.354057310720691e-09
- O 0 4.6542261711302046e-10
expressed O 0 1.9001270001872683e-10
with O 0 1.2441025640241854e-11
the O 0 3.0993246857846657e-10
beta O 0 6.646121847309061e-11
- O 0 1.4451591832942423e-11
subunit O 0 2.1535672550809792e-12
to O 0 1.4173423719399114e-11
produce O 0 1.6844221573109053e-09
Hex O 0 1.5150801857544138e-07
A O 0 9.779328138392884e-07
( O 0 6.490042281370734e-09
alphabeta O 0 2.7319623541188776e-07
) O 0 1.602810245637798e-10
in O 0 1.888140754857659e-09
COS O 0 3.1457516342925373e-06
- O 0 4.0548648883032e-08
7 O 0 1.2218996481294653e-08
cells O 0 1.684454242756317e-09
, O 0 3.938660508850944e-10
the O 0 1.8882848618062553e-09
mature O 0 3.206092891172574e-10
alpha O 0 6.523843271155627e-11
- O 0 6.89909934736832e-11
subunit O 0 2.2098886956478658e-11
was O 0 8.867481748886519e-10
present O 0 2.251611397330322e-10
, O 0 4.85553021400964e-11
but O 0 1.0813430012523995e-10
its O 0 3.362206624224484e-10
level O 0 4.920479135250844e-09
was O 0 3.4597846809703015e-09
much O 0 3.53419682408429e-10
lower O 0 2.8954376674050764e-09
than O 0 1.3648640551089386e-10
that O 0 4.0419112501410837e-10
from O 0 9.155778357694544e-09
normal O 0 4.637270833995899e-08
alpha O 0 4.501337969031738e-09
- O 0 4.089651728378385e-09
subunit O 0 1.867126009358344e-09
transfections O 0 6.358254722726997e-08
, O 0 1.6925305601489526e-10
although O 0 1.8007205448977714e-10
higher O 0 9.540075396330394e-10
than O 0 6.764084431454265e-11
in O 0 4.122456542798858e-10
those O 0 2.1645825132310392e-09
cells O 0 7.595417628181167e-09
transfected O 0 3.196180387021741e-08
with O 0 1.254683718032723e-10
an O 0 1.3471740389903175e-09
alpha O 0 4.2374867503802705e-10
- O 0 4.3214182232631515e-10
subunit O 0 1.990298342802177e-10
associated O 0 8.388107985979332e-09
with O 0 1.1447529146835222e-08
infantile O 1 0.999996542930603
TSD B-Disease 1 0.8337394595146179
. O 0 2.274561438753153e-06

Furthermore O 0 7.921815949885058e-07
, O 0 2.821833877675317e-09
the O 0 1.86644233401978e-09
precursor O 0 8.41967278120137e-08
level O 0 7.186359596289549e-08
of O 0 2.3360309242548283e-08
the O 0 2.5986151896972842e-08
W474C O 0 3.2768348035006056e-08
alpha O 0 5.759140941918872e-10
- O 0 1.8133006207676772e-10
subunit O 0 6.803522328846512e-11
was O 0 1.295641149923199e-09
found O 0 4.056157840159891e-11
to O 0 4.896805877452337e-11
accumulate O 0 4.4746364946668393e-10
in O 0 2.5557692073796545e-10
comparison O 0 1.0118877291631634e-08
to O 0 1.4358109146073161e-09
the O 0 1.597276479969878e-07
normal O 0 4.503126547206193e-07
alpha O 0 7.812170110810257e-08
- O 0 3.7424911170091946e-08
subunit O 0 1.7509615091171327e-08
precursor O 0 3.593741269014572e-07
levels O 0 1.076543441058675e-07
. O 0 1.7041459443589702e-07

We O 0 5.7783474005645985e-08
conclude O 0 1.457041207686416e-07
that O 0 1.2770926538507865e-09
the O 0 1.2704461482826446e-08
1422 O 0 9.21585751711973e-07
G O 0 5.714034045922745e-07
- O 0 2.6499120053813385e-07
- O 0 1.7961313858450012e-07
> O 0 2.21398028799058e-08
C O 0 2.91009989439317e-08
mutation O 0 9.166568198937242e-11
is O 0 1.655650334712877e-12
the O 0 5.580327432780363e-12
cause O 0 6.899418814043656e-10
of O 0 4.23574331165355e-09
Hex B-Disease 0 2.407286729066982e-06
A I-Disease 0 0.0012103698682039976
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.88259310363037e-08
the O 0 1.601379437943251e-07
proband O 0 6.358585778798442e-06
. O 0 1.9886351765308063e-07

The O 0 2.028414485266694e-07
resulting O 0 2.616694985135837e-07
W474C O 0 3.8375867461581947e-07
substitution O 0 1.285932427208536e-07
clearly O 0 6.350873604787921e-08
interferes O 0 2.756057604358375e-08
with O 0 5.307108086327617e-10
alpha O 0 9.109352716585306e-10
- O 0 2.0711703185849473e-10
subunit O 0 3.759585004425858e-11
processing O 0 1.578765562726403e-09
, O 0 4.1707783060562775e-11
but O 0 5.189429441720961e-11
because O 0 4.710460840828823e-11
the O 0 1.7608228763954514e-10
base O 0 2.6746962977775013e-10
substitution O 0 3.3679592448265794e-09
falls O 0 1.962105073971543e-07
at O 0 5.070168729304214e-09
the O 0 5.763957311444301e-09
first O 0 5.913557643566492e-09
position O 0 4.71595171802619e-08
of O 0 7.849151018035627e-08
exon O 0 6.50647962174844e-08
13 O 0 9.536896641293424e-07
, O 0 2.7563521243223477e-08
aberrant O 0 4.5362291700712376e-08
splicing O 0 3.57078278057088e-08
may O 0 1.6145142112122812e-08
also O 0 9.589093963313644e-10
contribute O 0 1.0781000536752572e-09
to O 0 4.774225015324873e-09
Hex B-Disease 0 3.4586326364660636e-05
A I-Disease 0 5.918308306718245e-05
deficiency I-Disease 0 1.782199069566559e-05
in O 0 2.1847876396918764e-08
this O 0 1.609944710878608e-08
proband O 0 5.83182054469944e-06
. O 0 4.268584419264698e-08
. O 0 2.6066578584504896e-07

Two O 0 4.548635956780345e-08
frequent O 0 2.1908681446802802e-07
missense O 0 7.267635282914853e-06
mutations O 0 2.1832520360476337e-06
in O 0 2.8827409437326423e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.6230491130263545e-06

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 3.6981966378135667e-09
an O 0 4.5468493681255495e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 1.300886598443185e-08
by O 0 6.05595565014716e-12
early O 0 5.500984912032436e-08
childhood O 1 0.9999996423721313
deafness B-Disease 1 1.0
and O 1 0.8911797404289246
goiter B-Disease 1 1.0
. O 0 4.1493317439744715e-06

A O 0 4.448560503078625e-06
century O 0 3.085843900407781e-07
after O 0 1.6133252511707497e-09
its O 0 3.0845739157348007e-11
recognition O 0 7.479098451668165e-10
as O 0 8.893973890700124e-10
a O 0 3.511360757713078e-09
syndrome O 0 5.9173405730916784e-08
by O 0 6.286031695168504e-10
Vaughan O 0 2.00967548380504e-07
Pendred O 0 9.023980965139344e-06
, O 0 7.797246737162311e-10
the O 0 2.919950725654985e-09
disease O 0 2.2814466760223695e-08
gene O 0 7.594664452881261e-09
( O 0 9.26013576929563e-09
PDS O 0 7.459241896867752e-05
) O 0 2.145484484517013e-10
was O 0 6.078646475060623e-09
mapped O 0 5.709815731336221e-09
to O 0 4.234459005658664e-09
chromosome O 0 7.576963980682194e-07
7q22 O 0 1.5672383597120643e-05
- O 0 6.926864443812519e-06
q31 O 0 2.707397288759239e-05
. O 0 1.3165796417524689e-06

1 O 0 4.5309084271139e-06
and O 0 1.3971609291729692e-07
, O 0 1.819135952985107e-08
recently O 0 1.1661894561143527e-08
, O 0 5.283987691839798e-10
found O 0 2.855711223048729e-10
to O 0 3.86497084337023e-10
encode O 0 3.3088024764538204e-08
a O 0 7.330558560170175e-08
putative O 0 6.673774350929307e-06
sulfate O 0 5.188440354686463e-06
transporter O 0 1.8763446860248223e-05
. O 0 1.612122332517174e-06

We O 0 2.5342385967519476e-08
performed O 0 8.563828535201878e-10
mutation O 0 1.0942987627160505e-09
analysis O 0 8.514641214318885e-10
of O 0 1.3166622236937542e-09
the O 0 2.1967760943653047e-08
PDS B-Disease 0 5.0710150389932096e-05
gene O 0 2.5420412441690132e-09
in O 0 1.124972892618814e-09
patients O 0 4.802461761599375e-10
from O 0 3.09814995880231e-09
14 O 0 2.07563317644599e-08
Pendred B-Disease 0 6.969204946472018e-08
families O 0 6.188115020400176e-10
originating O 0 7.705171500838048e-10
from O 0 3.6393735247663983e-10
seven O 0 1.3965888168154805e-10
countries O 0 6.285896109181621e-11
and O 0 5.835258387598685e-10
identified O 0 2.335910309625433e-08
all O 0 2.0514043796993064e-08
mutations O 0 6.600677693313628e-07
. O 0 5.392682282945316e-07

The O 0 3.891939002187428e-07
mutations O 0 3.183233943104824e-08
include O 0 9.572574954930246e-10
three O 0 8.662512929191735e-10
single O 0 6.773822613936886e-10
base O 0 9.182763882620293e-09
deletions O 0 4.639252537685934e-08
, O 0 4.238160045133554e-09
one O 0 8.931275274903783e-09
splice O 0 1.0930289136013016e-06
site O 0 9.606915085669243e-08
mutation O 0 1.2142097105538596e-08
and O 0 1.552953499128762e-08
10 O 0 4.1971429709519725e-07
missense O 0 1.4521732737193815e-05
mutations O 0 1.7847605704446323e-05
. O 0 6.1095784076314885e-06

One O 0 2.554402840360126e-07
missense O 0 5.257219982013339e-06
mutation O 0 6.992932810589991e-08
( O 0 4.92759788528474e-09
L236P O 0 5.5926136610651156e-08
) O 0 6.668712110302621e-11
was O 0 1.945804184444455e-09
found O 0 3.980437160433503e-11
in O 0 1.2216577575940857e-11
a O 0 1.533881910376067e-10
homozygous O 0 3.2192798427033154e-10
state O 0 6.889345760541232e-10
in O 0 7.815739722083492e-10
two O 0 9.12155739829501e-10
consanguineous O 0 6.263751828328168e-08
families O 0 5.432848060316076e-10
and O 0 1.1001161093204814e-10
in O 0 1.0726537713612316e-10
a O 0 1.1851434278398187e-09
heterozygous O 0 7.914629507332904e-10
state O 0 1.152107742541375e-09
in O 0 9.998981642667104e-10
five O 0 1.191714837922575e-09
additional O 0 1.8988897565463958e-08
non O 0 2.7188259537069825e-06
- O 0 3.963551989727421e-06
consanguineous O 0 2.348544330743607e-05
families O 0 4.831310889130691e-07
. O 0 6.600160986636183e-07

Another O 0 4.827943484997377e-07
missense O 0 6.403201950888615e-06
mutation O 0 1.775211302401658e-07
( O 0 6.6421241839975664e-09
T416P O 0 5.937419089718787e-08
) O 0 3.601846251810592e-11
was O 0 1.289812256999312e-09
found O 0 3.9569406778960925e-11
in O 0 3.0874344747466864e-11
a O 0 1.2976511531981316e-10
homozygous O 0 1.9538808071484226e-10
state O 0 3.863334652187689e-10
in O 0 3.645813928532249e-10
one O 0 1.4063945563691505e-09
family O 0 9.133413469974982e-10
and O 0 7.971073107126969e-11
in O 0 7.599931794999293e-11
a O 0 3.6020336713349366e-10
heterozygous O 0 4.3838985219757376e-10
state O 0 1.4156039673807186e-09
in O 0 2.2158210821743296e-09
four O 0 1.9851594146302887e-08
families O 0 6.952556219630424e-08
. O 0 4.5599199438584037e-07

Pendred B-Disease 0 5.830093869008124e-05
patients O 0 1.1165599289597594e-07
in O 0 1.0216736789914194e-08
three O 0 1.0715424991758482e-08
non O 0 3.2157302598534443e-07
- O 0 7.078347152855713e-08
consanguineous O 0 4.3653790271491744e-07
families O 0 7.960688108710201e-09
were O 0 1.1815435296824717e-09
shown O 0 2.826023026702984e-10
to O 0 4.526682639838242e-10
be O 0 9.553896562763953e-10
compound O 0 1.456595999371757e-08
heterozygotes O 0 1.0431987362835571e-07
for O 0 1.1604294414269134e-08
L236P O 0 1.3687742921320023e-06
and O 0 6.468627589129028e-08
T416P O 0 8.476636139675975e-06
. O 0 1.095485572477628e-06

In O 0 1.8712768223849707e-08
total O 0 2.1687698747996365e-08
, O 0 6.844904643088512e-10
one O 0 3.8525471701689185e-10
or O 0 5.25878174340022e-10
both O 0 1.3824765776604409e-09
of O 0 5.294432003921656e-09
these O 0 3.5128860931266104e-10
mutations O 0 4.1768406511266676e-09
were O 0 1.167878349583873e-09
found O 0 5.360845101165523e-10
in O 0 4.147995558145823e-10
nine O 0 1.327602294765029e-08
of O 0 2.1128968796801928e-08
the O 0 7.39421324169598e-08
14 O 0 1.1247400522051976e-07
families O 0 3.2615201206454e-08
analyzed O 0 2.7425818416304537e-07
. O 0 6.080226739868522e-07

The O 0 6.180922884624351e-09
identification O 0 1.5126742525239933e-08
of O 0 2.201843329885378e-08
two O 0 1.8860890627081517e-09
frequent O 0 6.094658289157451e-08
PDS B-Disease 0 0.001230011461302638
mutations O 0 1.2030131557594359e-08
will O 0 2.7433000315824074e-10
facilitate O 0 7.567768633975902e-09
the O 0 1.981708130927018e-09
molecular O 0 2.3563657691738626e-07
diagnosis O 0 9.883753955364227e-05
of O 0 2.4916544134612195e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.1664479845640017e-06

Insertional O 0 6.306738941930234e-05
mutation O 0 1.328927794475021e-07
by O 0 1.741886967998596e-09
transposable O 0 5.832960141560761e-07
element O 0 9.327516181656392e-08
, O 0 6.5447003372298695e-09
L1 O 0 8.949009497882798e-07
, O 0 5.220714416331873e-10
in O 0 2.9960833813902354e-10
the O 0 6.1144753260578e-08
DMD B-Disease 1 1.0
gene O 0 5.9577814681688324e-08
results O 0 9.397697908752889e-08
in O 0 1.2393226889173548e-08
X B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999357461929321
linked I-Disease 0 0.20326711237430573
dilated I-Disease 0 0.05925943702459335
cardiomyopathy I-Disease 1 1.0
. O 0 1.7808792108553462e-05

X B-Disease 1 0.9999961853027344
- I-Disease 1 0.9999783039093018
linked I-Disease 1 0.9996002316474915
dilated I-Disease 1 0.9999986886978149
cardiomyopathy I-Disease 1 1.0
( O 0 2.9212918889243156e-05
XLDCM B-Disease 1 1.0
) O 0 1.273050137529097e-10
is O 0 8.601438138133854e-12
a O 0 1.5429952454626417e-11
clinical O 0 1.9874883960824263e-09
phenotype O 0 1.0374444059380039e-07
of O 0 3.401343207087848e-08
dystrophinopathy B-Disease 0 2.466245177856763e-06
which O 0 3.066835119192035e-10
is O 0 1.2307040803127833e-11
characterized O 0 1.489561078649171e-11
by O 0 2.413147633106849e-11
preferential O 0 3.9441079024982173e-07
myocardial B-Disease 0 8.82897620613221e-06
involvement I-Disease 0 8.318704836085544e-09
without O 0 2.170602142470557e-09
any O 0 3.0045830268221607e-09
overt O 0 1.2000070626072556e-07
clinical O 0 3.46019533026265e-08
signs O 0 3.6994828178649186e-07
of O 0 3.190884854120668e-07
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 5.0255785026820377e-05

To O 0 9.62387680658594e-09
date O 0 4.3755827050517837e-07
, O 0 7.836563065133362e-10
several O 0 2.119991404647692e-10
mutations O 0 5.581953566036191e-09
in O 0 4.625781979683552e-10
the O 0 4.5874955389990646e-08
Duchenne B-Disease 0 0.0027067591436207294
muscular I-Disease 1 0.9828220009803772
dystrophy I-Disease 1 0.9999665021896362
gene O 0 7.229073526104912e-05
, O 0 3.020397798536578e-07
DMD O 1 1.0
, O 0 1.0131792071987888e-09
have O 0 7.31176647006393e-11
been O 0 1.266752536199789e-10
identified O 0 4.245925000478934e-10
in O 0 7.446939592758994e-11
patients O 0 1.2775354385485826e-10
with O 0 2.907145357777807e-10
XLDCM B-Disease 1 1.0
, O 0 8.010735408348069e-10
but O 0 2.0463454541985726e-10
a O 0 1.1443936770438867e-10
pathogenic O 0 1.7989021383613135e-09
correlation O 0 1.2070999311220021e-08
of O 0 9.124602740051557e-10
these O 0 1.0013773144024185e-09
cardiospecific O 0 3.1160496405391314e-07
mutations O 0 3.5561836142505854e-08
in O 0 2.9436830750739773e-09
DMD O 1 1.0
with O 0 6.584500722439657e-10
the O 0 1.1819795275869183e-07
XLDCM B-Disease 1 0.9999785423278809
phenotype O 0 3.6716525642077613e-07
has O 0 2.667259746402806e-09
remained O 0 6.046121825420414e-08
to O 0 2.475021743109096e-09
be O 0 3.078970678416226e-08
elucidated O 0 3.408977499930188e-05
. O 0 1.3691319509234745e-06

We O 0 9.249335874983444e-08
report O 0 1.9162301967412532e-08
here O 0 4.743452297617523e-10
the O 0 1.4278629667519027e-10
identification O 0 6.557195231238211e-09
of O 0 5.3379114461904464e-09
a O 0 4.937212860767204e-09
unique O 0 5.9223989268275545e-08
de O 0 1.291954617954616e-06
novo O 0 1.278306513086136e-06
L1 O 0 1.6771414266258944e-06
insertion O 0 2.3297213047612786e-08
in O 0 6.146946063267933e-09
the O 0 3.5169119172451246e-08
muscle O 0 2.31290560037678e-08
exon O 0 1.740602506572486e-08
1 O 0 7.228411647020039e-08
in O 0 1.2980684971353185e-08
DMD O 1 1.0
in O 0 3.1630861485609785e-08
three O 0 1.7418148701153768e-08
XLDCM B-Disease 0 3.3747746783774346e-05
patients O 0 1.117014813978301e-09
from O 0 3.305300033673575e-09
two O 0 1.1058600701829846e-09
unrelated O 0 2.278107125164297e-08
Japanese O 0 4.044560597549207e-08
families O 0 9.588733362875246e-09
. O 0 1.2450735198399343e-07

The O 0 5.445448536534059e-08
insertion O 0 6.922505946249657e-08
was O 0 6.170347432998824e-08
a O 0 2.1765802493689534e-09
5 O 0 1.7681783148759678e-08
- O 0 2.626308504005692e-09
truncated O 0 1.0965935715034902e-08
form O 0 2.9166430381977193e-10
of O 0 1.477316935449835e-09
human O 0 1.9280563812174023e-09
L1 O 0 4.3214473066655046e-07
inversely O 0 6.563879395571348e-08
integrated O 0 4.83806283924082e-09
in O 0 4.78508899171004e-10
the O 0 4.51874848650391e-09
5 O 0 1.578907848909239e-08
- O 0 6.1192451106251156e-09
untranslated O 0 5.137798780197045e-06
region O 0 2.032212620406426e-08
in O 0 3.8386205325480205e-09
the O 0 6.96850079862088e-08
muscle O 0 1.4213457966150145e-08
exon O 0 6.954516518220544e-09
1 O 0 2.1819765549935255e-08
, O 0 1.4783532731321714e-10
which O 0 4.586613727708411e-11
affected O 0 7.089460685172355e-10
the O 0 7.038530314140701e-10
transcription O 0 1.7532064688907667e-09
or O 0 2.4560503630866037e-10
the O 0 1.2317409314732686e-09
stability O 0 1.980537689405537e-08
of O 0 2.1384515491718048e-08
the O 0 1.5091755400931106e-08
muscle O 0 3.2810856254172904e-09
form O 0 3.985431984432353e-09
of O 0 7.007326274788284e-08
dystrophin O 0 1.6370739785998012e-07
transcripts O 0 2.2695287427154653e-08
but O 0 8.347724178570104e-10
not O 0 7.907111077010143e-11
that O 0 2.8636143456495233e-10
of O 0 9.770956488353022e-09
the O 0 6.178072453622008e-08
brain O 0 8.351520364158205e-07
or O 0 3.233214584952293e-08
Purkinje O 0 1.5887370636846754e-06
cell O 0 6.186103007621568e-08
form O 0 1.1277146327870469e-08
, O 0 3.491365641039579e-09
probably O 0 2.282721922597375e-08
due O 0 1.5844770828721266e-08
to O 0 1.0811641582009202e-09
its O 0 1.8053160077968755e-09
unique O 0 5.609532838235509e-09
site O 0 9.413000157110218e-08
of O 0 2.2156108059334656e-08
integration O 0 2.1209932299370848e-07
. O 0 1.0446308351674816e-06

We O 0 4.9670724422412604e-08
speculate O 0 7.654262645928611e-08
that O 0 6.316170503284368e-11
this O 0 1.5685229157180736e-11
insertion O 0 5.978359585157023e-09
of O 0 4.12008427375099e-09
an O 0 5.014733073238631e-09
L1 O 0 2.2038407223590184e-06
sequence O 0 5.605094166583058e-09
in O 0 1.3032906309717873e-08
DMD O 1 1.0
is O 0 2.0627424213159884e-09
responsible O 0 1.4613084353687356e-10
for O 0 2.2548721570481156e-11
some O 0 6.57623885902403e-11
of O 0 2.861976211576689e-10
the O 0 2.0824637847471905e-10
population O 0 1.1879083827714965e-10
of O 0 2.550120670186118e-10
Japanese O 0 2.991031866628191e-09
patients O 0 1.679618666372562e-10
with O 0 1.1639689212472604e-09
XLDCM B-Disease 0 0.0006739718373864889
. O 0 7.413970593006525e-08
. O 0 4.226444900723436e-07

Severe O 0 2.0057928850292228e-05
early O 0 0.49443718791007996
- O 0 0.4345717430114746
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 6.496259086219425e-09
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 2.3482964195409295e-07
red O 0 0.0008008452714420855
hair O 0 4.881744825979695e-05
pigmentation O 0 2.4667795514687896e-05
caused O 0 1.8566773860584362e-06
by O 0 7.291819770216534e-08
POMC O 1 0.9333510398864746
mutations O 0 9.959568387785112e-07
in O 0 7.984776395630888e-09
humans O 0 7.950040270543468e-08
. O 0 9.684109869567692e-08

Sequential O 0 1.7531357343614218e-06
cleavage O 0 7.404868824778532e-07
of O 0 1.974650274405576e-07
the O 0 2.888951833313058e-08
precursor O 0 8.847217003449259e-08
protein O 0 5.75400882496524e-08
pre O 0 1.744907933698414e-07
- O 0 7.024106452035994e-08
pro O 0 2.6252837415086105e-06
- O 0 5.864872036909219e-06
opiomelanocortin O 0 1.3998183931107633e-05
( O 0 1.0987038834286977e-08
POMC O 0 1.2843786407756852e-06
) O 0 1.1005358430127288e-10
generates O 0 8.403941986756536e-10
the O 0 1.82036374862804e-09
melanocortin O 0 1.806068041787512e-07
peptides O 0 2.4624743133472293e-08
adrenocorticotrophin O 0 2.347023155380157e-06
( O 0 1.6376073830315363e-08
ACTH O 0 2.737585589329683e-07
) O 0 5.087487098265342e-10
, O 0 1.8734043205625994e-09
melanocyte O 0 2.9621837711601984e-06
- O 0 6.614865014853422e-06
stimulating O 0 2.842894559762499e-07
hormones O 0 1.503754276654945e-07
( O 0 4.570392952985003e-09
MSH O 0 6.362689077832329e-07
) O 0 9.203988959871623e-11
alpha O 0 8.360658693140621e-11
, O 0 1.3759433696580725e-11
beta O 0 4.607376632992377e-11
and O 0 1.2561174322911484e-11
gamma O 0 1.9003154605456984e-10
as O 0 3.215560873126577e-10
well O 0 2.212838107196191e-10
as O 0 7.012788683091742e-10
the O 0 1.1568773716774672e-09
opioid O 0 2.933998466403409e-08
- O 0 1.5817231968640044e-08
receptor O 0 4.0409670276631005e-08
ligand O 0 2.9892487418692326e-07
beta O 0 5.661149202751403e-07
- O 0 7.925601153146999e-07
endorphin O 0 1.599609458935447e-05
. O 0 4.071279136041994e-07

While O 0 1.1888888984401547e-08
a O 0 5.885625875556855e-10
few O 0 3.003704784898531e-10
cases O 0 2.462133552594281e-10
of O 0 1.3535958132138148e-08
isolated O 1 0.8412080407142639
ACTH B-Disease 1 0.9998718500137329
deficiency I-Disease 1 0.7298306226730347
have O 0 6.335542312996267e-09
been O 0 4.446961021642437e-09
reported O 0 4.2976182612619596e-08
( O 0 4.521214513886207e-09
OMIM O 0 0.0002076922683045268
201400 O 0 1.6314459116983926e-06
) O 0 1.854986164673278e-09
, O 0 2.002209287255141e-09
an O 0 7.268963031492603e-08
inherited O 1 0.9999897480010986
POMC O 1 1.0
defect O 1 0.9999939203262329
has O 0 4.032366973660828e-08
not O 0 1.5295209543353394e-09
been O 0 2.0876547157655523e-09
described O 0 2.2259576404337622e-09
so O 0 2.313151448163353e-09
far O 0 6.714284950248839e-08
. O 0 2.3688618000505812e-07

Recent O 0 3.729180946265842e-07
studies O 0 2.3389912229276888e-08
in O 0 3.208858179171159e-10
animal O 0 3.859587760501881e-09
models O 0 4.078255955164423e-09
elucidated O 0 9.381668775176877e-08
a O 0 2.0281767376673088e-09
central O 0 3.483664556824806e-08
role O 0 4.138719589263928e-09
of O 0 5.5306319524106584e-08
alpha O 0 3.156619143851458e-08
- O 0 1.0653436532948035e-07
MSH O 0 6.145650786493206e-06
in O 0 1.3931839015768333e-09
the O 0 3.0832298936189773e-09
regulation O 0 4.231011541122598e-09
of O 0 3.115043112345006e-09
food O 0 6.635134663923736e-09
intake O 0 2.735410509213665e-10
by O 0 1.1228837304422257e-11
activation O 0 4.6676102982701195e-08
of O 0 2.763148643225577e-07
the O 0 7.266799570970761e-07
brain O 0 1.1226454716961598e-06
melanocortin O 0 5.87446038480266e-07
- O 0 1.5062546765420848e-07
4 O 0 1.321136124943223e-07
- O 0 2.1342138722957316e-08
receptor O 0 3.113779456498378e-08
( O 0 4.7598773811330375e-09
MC4 O 0 3.208780981367454e-06
- O 0 4.28300310773011e-08
R O 0 1.5740848624545833e-08
; O 0 2.5386397428661667e-09
refs O 0 1.6048277373670317e-08
3 O 0 1.2456169429242436e-08
- O 0 7.646550614914815e-10
5 O 0 3.9059080969572335e-10
) O 0 1.0527286507799882e-12
and O 0 1.9102453993613544e-12
the O 0 8.911731075311735e-11
linkage O 0 3.922246349929992e-08
of O 0 3.993178232519767e-09
human O 0 7.759531399642583e-07
obesity B-Disease 1 1.0
to O 0 2.9873716833606068e-09
chromosome O 0 8.793009875773805e-09
2 O 0 8.114603211595295e-09
in O 0 5.432651550840717e-10
close O 0 2.0971139491621216e-08
proximity O 0 5.547229164903911e-08
to O 0 2.172200641581412e-09
the O 0 2.036656496784417e-07
POMC O 0 2.6457393687451258e-05
locus O 0 5.378528200594701e-08
, O 0 1.3328332881812344e-09
led O 0 1.3586648472951879e-09
to O 0 2.955789224490246e-10
the O 0 4.4713712732402655e-09
proposal O 0 7.853400596502524e-09
of O 0 4.1066838818437645e-09
an O 0 2.788469455339282e-09
association O 0 6.429229415516602e-08
of O 0 1.921797547765891e-06
POMC O 1 0.9999955892562866
with O 0 4.0163094183753856e-08
human O 1 0.584524393081665
obesity B-Disease 1 1.0
. O 0 4.2161912006122293e-07

The O 0 1.2895527845557808e-07
dual O 0 9.912267984191203e-08
role O 0 6.29127896445425e-08
of O 0 5.833172167513112e-07
alpha O 0 2.0297748903885804e-07
- O 0 3.1064774930200656e-07
MSH O 0 4.850297955272254e-06
in O 0 1.630307666644626e-09
regulating O 0 1.539041249998263e-08
food O 0 5.690769810939855e-08
intake O 0 1.8760690778663047e-08
and O 0 9.078979790189123e-10
influencing O 0 1.0657496432031621e-06
hair O 0 0.0009064025362022221
pigmentation O 0 2.2484422515844926e-05
predicts O 0 8.357494252209108e-09
that O 0 3.353987573784245e-11
the O 0 3.6713615481076545e-10
phenotype O 0 1.7324173207100557e-09
associated O 0 5.308524730907038e-10
with O 0 2.7483369746672537e-11
a O 0 1.5916458151465918e-09
defect O 0 1.5411423248679057e-07
in O 0 1.1787282261366272e-08
POMC O 0 0.0005710339755751193
function O 0 3.156725991715348e-09
would O 0 7.311951044641773e-10
include O 0 3.6765557265283633e-09
obesity B-Disease 1 1.0
, O 0 1.697834095537587e-09
alteration O 0 6.4421431034134e-07
in O 0 2.4555937727654964e-08
pigmentation O 1 0.9999992847442627
and O 0 0.00010322804155293852
ACTH B-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.7043180465698242
. O 0 4.100959813513327e-06

The O 0 1.2721464770493185e-07
observation O 0 2.759975723165553e-05
of O 0 8.720987487720322e-09
these O 0 1.6878118902496908e-09
symptoms O 0 3.99920463678427e-06
in O 0 6.904500304827366e-10
two O 0 1.522532322439929e-09
probands O 0 1.8547200397733832e-06
prompted O 0 1.8135512647177165e-08
us O 0 1.4282205418325589e-09
to O 0 2.273638083361007e-10
search O 0 4.5594914510616036e-09
for O 0 4.191818558929583e-10
mutations O 0 7.667149759527092e-08
within O 0 5.5162196588298684e-08
their O 0 7.365104011114454e-07
POMC O 0 0.0024322867393493652
genes O 0 6.981417755014263e-06
. O 0 2.228237235613051e-06

Patient O 0 1.1723273729558059e-07
1 O 0 3.9825397379900096e-07
was O 0 3.7144573639125156e-08
found O 0 2.2388199627521033e-10
to O 0 6.09173267385188e-11
be O 0 1.4571169271171414e-10
a O 0 6.222426462976216e-10
compound O 0 6.888114079117713e-09
heterozygote O 0 2.3711875485332712e-07
for O 0 1.201558852415019e-09
two O 0 1.6761854126912112e-09
mutations O 0 7.863892648174442e-09
in O 0 1.5088295057807954e-09
exon O 0 1.0627677404784208e-08
3 O 0 1.419525830215207e-07
( O 0 5.063326646848054e-09
G7013T O 0 3.687084699777188e-07
, O 0 4.3865768795114946e-09
C7133delta O 0 7.11232885919344e-08
) O 0 3.307724580348115e-11
which O 0 1.0942642625355603e-11
interfere O 0 1.245798603166648e-10
with O 0 7.59931961108462e-12
appropriate O 0 1.3755458994069159e-09
synthesis O 0 7.389589029571653e-08
of O 0 4.0883051610762777e-07
ACTH O 0 1.6301197319990024e-05
and O 0 3.603294942422508e-07
alpha O 0 2.5855440526356688e-06
- O 0 1.1116168934677262e-05
MSH O 0 0.0005236858269199729
. O 0 1.7612364899832755e-06

Patient O 0 2.527028186705138e-07
2 O 0 1.0913378645227567e-07
was O 0 8.655233862953082e-09
homozygous O 0 2.5477189802280975e-10
for O 0 5.0347202101841404e-11
a O 0 4.974623490916485e-10
mutation O 0 7.944939706128196e-10
in O 0 4.5809681048503137e-10
exon O 0 1.4333764397633786e-08
2 O 0 1.8145554747661663e-07
( O 0 1.021455364735857e-08
C3804A O 0 1.9081340951743186e-07
) O 0 4.0493269848340674e-10
which O 0 1.2035588081715787e-09
abolishes O 0 1.9664526007545646e-06
POMC O 0 0.0001214090152643621
translation O 0 2.8959532301087165e-06
. O 0 2.2954197902436135e-06

These O 0 1.2753309519553113e-08
findings O 0 2.1419703344349728e-08
represent O 0 1.7064373247777098e-09
the O 0 5.330034191786126e-10
first O 0 8.23992957199593e-11
examples O 0 2.651392161379107e-10
of O 0 7.941965834978859e-11
a O 0 7.659279321892143e-10
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
within O 0 4.254244512225114e-09
the O 0 7.917532407475392e-09
POMC O 0 7.077252917042642e-07
gene O 0 4.617742299650729e-10
and O 0 1.2364315127300074e-10
define O 0 4.2540473921270916e-10
a O 0 3.3735639282106433e-10
new O 0 1.1855329162813177e-08
monogenic B-Disease 1 0.9992538094520569
endocrine I-Disease 1 0.998871386051178
disorder I-Disease 0 0.04252982512116432
resulting O 0 1.896131962553227e-08
in O 0 3.724485442280212e-10
early O 0 2.1716112314607017e-05
- O 0 2.4457962354063056e-05
onset O 1 0.9999988079071045
obesity B-Disease 1 1.0
, O 0 8.635347548135996e-09
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 7.657396054128185e-06
red O 0 0.030033232644200325
hair O 0 9.537639016343746e-06
pigmentation O 0 3.087046934524551e-06
. O 0 6.504494365344726e-08
. O 0 2.263356151388507e-07

A O 0 1.321657009611954e-06
European O 0 3.613332921759138e-07
multicenter O 0 6.681094237137586e-05
study O 0 2.6538995001601506e-08
of O 0 1.6704785821275436e-06
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 2.484496874899378e-08
classification O 0 5.095086308415375e-08
of O 0 2.570227053411145e-08
105 O 0 5.83564272460535e-08
mutations O 0 1.818795114516547e-09
and O 0 1.214773698299254e-10
a O 0 2.7804006319520624e-10
general O 0 6.400079910484635e-10
system O 0 7.309201160987655e-11
for O 0 9.284054081071247e-11
genotype O 0 6.017576659189672e-09
- O 0 5.0314326038858326e-09
based O 0 3.0691540420235697e-09
prediction O 0 3.654371312222793e-07
of O 0 5.582414175364647e-08
metabolic O 0 0.0004935598117299378
phenotype O 0 9.65080107562244e-06
. O 0 2.1743526303907856e-06

Phenylketonuria B-Disease 0 0.00016216991934925318
( O 0 2.523680393551331e-07
PKU B-Disease 0 1.3008107998757623e-05
) O 0 1.5727216196026461e-09
and O 0 1.2998143672504625e-09
mild B-Disease 1 0.9999784231185913
hyperphenylalaninemia I-Disease 1 1.0
( O 0 9.520444109512027e-06
MHP B-Disease 1 1.0
) O 0 1.2557163087123513e-09
are O 0 2.71500349979803e-10
allelic B-Disease 0 1.7553406905790325e-06
disorders I-Disease 0 2.7083456188847777e-07
caused O 0 4.5008743398966544e-09
by O 0 4.736849801290077e-11
mutations O 0 1.485612965979044e-09
in O 0 6.168997257471887e-11
the O 0 3.6167593919778085e-10
gene O 0 2.955813149796427e-09
encoding O 0 2.1559149843142222e-07
phenylalanine O 0 4.304244612285402e-06
hydroxylase O 0 1.3574654076364823e-05
( O 0 2.4396143771809875e-07
PAH O 0 9.256409975932911e-05
) O 0 6.619854531209057e-08
. O 0 1.6823945259147877e-07

Previous O 0 1.2412243677317747e-06
studies O 0 4.1915992454732987e-08
have O 0 9.958150970490465e-11
suggested O 0 8.029673592702125e-10
that O 0 5.721187846391418e-12
the O 0 1.2565709583967077e-10
highly O 0 2.310281077555487e-09
variable O 0 2.0133752514084335e-06
metabolic O 1 0.9138888120651245
phenotypes O 0 0.2284858077764511
of O 0 0.0007801778265275061
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.00026328174863010645
with O 0 2.897616866448516e-07
PAH O 1 1.0
genotypes O 0 0.00035766794462688267
. O 0 7.030607207525463e-07

We O 0 6.931423968126182e-08
identified O 0 7.563443205071962e-08
both O 0 1.487956069468055e-08
causative O 0 4.19145521846076e-07
mutations O 0 5.984214368481844e-08
in O 0 1.367113311445678e-09
686 O 0 4.393956487547257e-08
patients O 0 4.958434773882914e-10
from O 0 1.66575180315931e-08
seven O 0 1.4019813754373445e-08
European O 0 3.843215523602339e-08
centers O 0 1.1664457133520045e-07
. O 0 2.0066190131728945e-07

On O 0 3.136860726726809e-08
the O 0 1.459409482151841e-09
basis O 0 6.093842319643272e-09
of O 0 3.590003017084342e-10
the O 0 5.28766808116643e-10
phenotypic O 0 3.673249082680741e-08
characteristics O 0 4.4060459458705736e-07
of O 0 2.61342051999236e-07
297 O 0 1.230607153956953e-06
functionally O 0 3.1449058042198885e-06
hemizygous O 0 1.7564123027113965e-06
patients O 0 2.6008650788611476e-09
, O 0 1.7583025313516742e-10
105 O 0 1.917572056697736e-08
of O 0 6.6826357780769285e-09
the O 0 4.447504142746084e-09
mutations O 0 2.3541986138297943e-09
were O 0 4.747091053580732e-10
assigned O 0 1.3315620828180386e-10
to O 0 5.934183006095495e-11
one O 0 1.0995083732368016e-09
of O 0 6.6660228448256476e-09
four O 0 2.051438574568465e-09
arbitrary O 0 2.504293945548852e-07
phenotype O 0 6.157738994261308e-07
categories O 0 1.225324353981705e-06
. O 0 9.432910701434594e-07

We O 0 3.0728809718993944e-08
proposed O 0 1.986064468439963e-08
and O 0 1.8581022276364934e-09
tested O 0 4.3437714536409544e-10
a O 0 1.0452189114218413e-10
simple O 0 4.8276969227822875e-11
model O 0 5.991206836197804e-11
for O 0 5.256860918789741e-12
correlation O 0 6.633955051960072e-10
between O 0 4.049226509650339e-10
genotype O 0 6.756689874265476e-09
and O 0 1.174692121352905e-09
phenotypic O 0 8.203528523154091e-08
outcome O 0 6.5763820202846546e-06
. O 0 1.7087039623220335e-06

The O 0 2.455467296158531e-08
observed O 0 1.1118627796236069e-08
phenotype O 0 3.160354111741981e-08
matched O 0 1.627304335727331e-08
the O 0 4.8700039556592856e-09
predicted O 0 4.183475965646721e-08
phenotype O 0 5.418518078670331e-09
in O 0 3.6506850320527917e-10
79 O 0 2.9445381244386226e-08
% O 0 7.088014064571269e-10
of O 0 3.9451716893346145e-10
the O 0 2.742588656179379e-10
cases O 0 6.042692457519649e-10
, O 0 1.824944778627824e-10
and O 0 1.651145470349391e-10
in O 0 2.673635479677472e-10
only O 0 7.581273386847442e-10
5 O 0 3.6225809019185817e-09
of O 0 1.0954495088810745e-09
184 O 0 1.8123644807133132e-09
patients O 0 2.1432758345873992e-10
was O 0 1.2084521827659955e-08
the O 0 6.190786105975121e-09
observed O 0 7.469023621808901e-09
phenotype O 0 4.424524302493182e-09
more O 0 7.571081261925627e-11
than O 0 2.900012452400347e-10
one O 0 1.1827655521656766e-09
category O 0 3.890830768682463e-09
away O 0 1.187800879876022e-08
from O 0 1.0844816600297236e-08
that O 0 2.1929651428109764e-09
expected O 0 2.0610217177363666e-07
. O 0 6.25028974354791e-07

Among O 0 3.6878162745779264e-07
the O 0 9.396747913115178e-08
seven O 0 9.17829900970446e-09
contributing O 0 1.6001726166336994e-08
centers O 0 3.929478076258874e-09
, O 0 1.0933094013454436e-10
the O 0 6.340192815201817e-10
proportion O 0 3.0285296492849056e-09
of O 0 5.144158987668845e-10
patients O 0 5.675520470260764e-11
for O 0 2.1157135765559332e-10
whom O 0 3.265155257281549e-08
the O 0 3.355182442987825e-08
observed O 0 5.52123768926549e-09
phenotype O 0 1.4199307285522877e-09
did O 0 2.4692303757234413e-10
not O 0 2.241879459852214e-10
match O 0 8.64096616481902e-09
the O 0 3.4423035089048426e-08
predicted O 0 1.9583531241096352e-07
phenotype O 0 3.15509041115547e-08
was O 0 2.919595765149552e-08
4 O 0 1.732662724407419e-08
% O 0 5.544285475167499e-09
- O 0 3.1392173305277993e-09
23 O 0 2.3014901984197422e-08
% O 0 1.2084267808631921e-08
( O 0 2.607142945976193e-09
P O 0 4.5732508624496404e-07
< O 0 8.946977381185661e-09
. O 0 2.249427533129733e-09
0001 O 0 1.217247369567076e-08
) O 0 2.2224143358950954e-10
, O 0 5.7056512292597006e-11
suggesting O 0 7.011504710163763e-10
that O 0 8.533073553307347e-11
differences O 0 1.877715094522614e-09
in O 0 2.0341575646121157e-10
methods O 0 6.59619137088896e-10
used O 0 7.738231583287458e-11
for O 0 3.889090785524907e-11
mutation O 0 3.260511194369542e-09
detection O 0 1.146575279165063e-08
or O 0 9.166996051135357e-09
phenotype O 0 1.7212700242907886e-07
classification O 0 1.0766477487322845e-08
may O 0 9.5219154783166e-10
account O 0 5.491806454038795e-10
for O 0 3.441392656955422e-11
a O 0 3.2702254793015584e-10
considerable O 0 7.335352769644032e-09
proportion O 0 3.743961940472218e-08
of O 0 2.3618007105596917e-08
genotype O 0 2.5646329504525056e-06
- O 0 2.359843892918434e-05
phenotype O 0 7.341440777963726e-06
inconsistencies O 0 6.696112905046903e-06
. O 0 2.990610937558813e-06

Our O 0 2.2848310265999316e-07
data O 0 5.329104624252068e-08
indicate O 0 3.4440770235733e-08
that O 0 7.230115395273629e-10
the O 0 1.1554049272888278e-08
PAH O 0 5.7225806813221425e-06
- O 0 8.815881358259503e-09
mutation O 0 6.235423843925503e-10
genotype O 0 1.5694455457460066e-10
is O 0 2.920625980645797e-12
the O 0 2.414459777944078e-11
main O 0 1.6750284492772494e-09
determinant O 0 1.3859866498933116e-07
of O 0 7.866236728659715e-08
metabolic O 1 0.9997201561927795
phenotype O 0 7.365792384916858e-07
in O 0 1.4572926199107883e-09
most O 0 1.8210235541715747e-09
patients O 0 1.208758781956476e-08
with O 0 2.7354445819582907e-08
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 9.165231313090771e-05

In O 0 1.4238312751047033e-08
the O 0 3.579852858592858e-08
present O 0 2.8234652393877013e-09
study O 0 3.9494479908697144e-10
, O 0 1.7355245712780132e-11
the O 0 1.6151348314341618e-10
classification O 0 7.154640879747376e-09
of O 0 2.2800980659098968e-08
105 O 0 8.835039579935255e-07
PAH O 0 1.3273918739287183e-05
mutations O 0 2.7886303044510896e-08
may O 0 1.2920103875657674e-10
allow O 0 4.872321643367705e-11
the O 0 4.619944704575829e-10
prediction O 0 3.1917029019723486e-08
of O 0 6.44828357376781e-10
the O 0 2.7035846894563065e-09
biochemical O 0 2.1966174301724095e-07
phenotype O 0 5.9277216024611334e-08
in O 0 2.2118349374267154e-09
> O 0 3.2113227632635244e-08
10 O 0 3.5409684073783865e-08
, O 0 2.3953345973382056e-09
000 O 0 8.306532350843554e-08
genotypes O 0 2.9191235739745025e-07
, O 0 3.768648948465625e-09
which O 0 9.824115965173519e-10
may O 0 5.762591515079407e-10
be O 0 1.594546855665513e-10
useful O 0 2.3842217089509177e-09
for O 0 3.430332129461533e-10
the O 0 1.3523983710683751e-08
management O 0 8.204337653694438e-09
of O 0 2.3914972757665964e-07
hyperphenylalaninemia B-Disease 1 1.0
in O 0 1.9067914536208264e-07
newborns O 0 5.698818199562083e-07
. O 0 2.864754264919611e-07

Somatic O 0 1.2590292499226052e-05
instability O 0 1.7262327673961408e-06
of O 0 2.469445234964951e-07
the O 0 3.9639877513764077e-07
CTG O 0 0.00012756307842209935
repeat O 0 3.117131086582958e-08
in O 0 1.9505121962026806e-09
mice O 0 1.4314713858709638e-09
transgenic O 0 4.282004528732841e-09
for O 0 5.7315013846093166e-11
the O 0 9.833888370280874e-09
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 4.505897095441469e-07
is O 0 7.257610068478471e-10
age O 0 4.466989889095885e-09
dependent O 0 3.774756507368693e-09
but O 0 1.7261002349666654e-10
not O 0 9.409505119517547e-11
correlated O 0 1.974652663605525e-09
to O 0 1.649429898220589e-10
the O 0 3.651264846027402e-09
relative O 0 7.947384688122838e-07
intertissue O 0 3.013601144630229e-06
transcription O 0 1.06103288999293e-06
levels O 0 2.865984072286665e-07
and O 0 1.3737169979322061e-07
proliferative O 1 0.9999268054962158
capacities O 0 5.49973665329162e-05
. O 0 4.744090801978018e-06

A O 0 0.04662667587399483
( O 0 1.4254827647164348e-06
CTG O 0 9.986171789932996e-05
) O 0 5.8646847378440725e-09
nexpansion O 0 1.1313037475702004e-06
in O 0 2.555058609132743e-09
the O 0 1.3596714865116155e-08
3 O 0 8.625194425349036e-08
- O 0 6.406350649967862e-08
untranslated O 0 6.598742038477212e-05
region O 0 1.095715802534869e-07
( O 0 5.218606435875017e-09
UTR O 0 6.15684621152468e-05
) O 0 6.533608654102352e-10
of O 0 3.458282193946616e-08
the O 0 1.2652911891564145e-06
DM O 1 1.0
protein O 0 5.0360331442789175e-06
kinase O 0 6.653690434177406e-07
gene O 0 9.410307910684423e-08
( O 0 5.519471528714348e-07
DMPK O 1 1.0
) O 0 1.2886411382417862e-10
is O 0 1.156417409747812e-11
responsible O 0 6.122504846856058e-12
for O 0 1.4951971952226195e-11
causing O 0 1.8434133153277799e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0012908627977594733
DM B-Disease 1 1.0
) O 0 2.4095132999946145e-08
. O 0 8.675468166075007e-08

Major O 0 7.690408529015258e-05
instability O 0 9.149494871962816e-05
, O 0 1.2181972763869453e-08
with O 0 1.4807351178536265e-10
very O 0 3.006725701748536e-10
large O 0 2.080601663179138e-10
expansions O 0 1.69102776226282e-09
between O 0 1.2195124909908373e-09
generations O 0 1.1167384350585507e-08
and O 0 1.558317253014252e-09
high O 0 1.6642813349676544e-08
levels O 0 3.6657792357175367e-09
of O 0 2.085935202345013e-09
somatic O 0 1.109676418309391e-06
mosaicism O 0 4.061191702930955e-06
, O 0 4.355031002489795e-09
is O 0 9.265077038911329e-10
observed O 0 6.326557944191791e-09
in O 0 1.9901473802264036e-09
patients O 0 9.647621368458204e-09
. O 0 2.1930966909167182e-07

There O 0 4.604466496971327e-08
is O 0 9.316787341617783e-10
a O 0 7.598645046513752e-10
good O 0 1.7751216052630525e-09
correlation O 0 9.551022195353198e-09
between O 0 3.120520286614692e-09
repeat O 0 1.0056653287904282e-08
size O 0 4.783543161579473e-08
( O 0 2.1655734983028196e-09
at O 0 1.1172454961183576e-08
least O 0 9.738094775002537e-10
in O 0 1.259141124698715e-09
leucocytes O 0 1.566286869092437e-07
) O 0 5.371425526590201e-11
, O 0 2.04054498992301e-11
clinical O 0 5.891331311680403e-10
severity O 0 2.3077408428662238e-08
and O 0 1.0959281260269904e-09
age O 0 7.790191034473537e-07
of O 0 3.009506031048659e-07
onset O 0 2.771335857687518e-05
. O 0 4.3290827989039826e-07

The O 0 1.5377861473098164e-06
trinucleotide O 0 0.0061049554497003555
repeat O 0 1.1239352488701115e-06
instability O 0 8.987531145976391e-07
mechanisms O 0 5.176674378049029e-08
involved O 0 2.0700259284467393e-09
in O 0 3.4869331866360653e-09
DM B-Disease 1 1.0
and O 0 4.301962786001923e-09
other O 0 1.3218658390101723e-09
human O 0 1.4244717476685764e-06
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 2.776855134722922e-10
unknown O 0 3.3196727144968463e-07
. O 0 7.442661598133782e-08

We O 0 3.1897126717694846e-08
studied O 0 8.776977722391166e-08
somatic O 0 4.245921445544809e-07
instability O 0 1.895900503257053e-08
by O 0 2.7770299948493005e-10
measuring O 0 8.095313575040564e-08
the O 0 8.910112825333272e-08
CTG O 0 3.869588908855803e-06
repeat O 0 1.6129014568377897e-08
length O 0 1.1614014638894332e-08
at O 0 1.2575767982525576e-08
several O 0 1.3421881384090284e-09
ages O 0 1.9854168087363178e-08
in O 0 2.0068650907756336e-10
various O 0 1.207467681396679e-09
tissues O 0 8.098739456841031e-09
of O 0 7.726868034296785e-09
transgenic O 0 2.203607962769638e-08
mice O 0 1.5071267567279278e-09
carrying O 0 5.518447920849212e-09
a O 0 2.707533752754898e-08
( O 0 5.390461765841792e-08
CTG O 0 1.0758905773400329e-05
) O 0 5.6205853304902575e-09
55expansion O 0 5.081867584522115e-07
surrounded O 0 2.4434555712105066e-08
by O 0 6.844160238550501e-10
45 O 0 3.694616879101886e-08
kb O 0 1.5357490212863922e-07
of O 0 9.068171635817635e-08
the O 0 9.780227117062168e-08
human O 0 3.2633005275783944e-07
DM B-Disease 1 1.0
region O 0 6.70957405191075e-08
, O 0 3.9813199959048973e-10
using O 0 5.414259041103264e-10
small O 0 2.977940916082389e-08
- O 0 1.8633632237197162e-07
pool O 0 7.574847131763818e-07
PCR O 0 1.2837982694691163e-06
. O 0 1.138723746407777e-06

These O 0 7.787399880498924e-08
mice O 0 3.4150463790183494e-08
have O 0 5.194046304168864e-10
been O 0 8.201842677246773e-11
shown O 0 1.8809571955547e-11
to O 0 6.78998480704851e-12
reproduce O 0 7.677093405433766e-10
the O 0 6.719569900504041e-10
intergenerational O 0 1.0217359402986403e-08
and O 0 2.3846799535043317e-10
somatic O 0 4.4710751012644323e-07
instability O 0 1.720032685170736e-07
of O 0 4.466685155080086e-08
the O 0 1.8235276399991562e-07
55 O 0 8.631256491753447e-07
CTG O 0 6.693444447591901e-06
repeat O 0 3.286198335672452e-08
suggesting O 0 5.0976325383089716e-08
that O 0 1.0262941607663834e-09
surrounding O 0 3.3494644835485587e-09
sequences O 0 8.228985826086443e-10
and O 0 3.2431446417291454e-09
the O 0 1.2291059725555442e-08
chromatin O 0 6.034957777956151e-08
environment O 0 1.1146742195933257e-08
are O 0 1.1543024175386662e-10
involved O 0 3.522843128322961e-10
in O 0 7.923480760396728e-10
instability O 0 2.446520284138387e-07
mechanisms O 0 1.0970223911499488e-06
. O 0 8.047088044804696e-07

As O 0 6.748848591087153e-08
observed O 0 1.4627431710323435e-08
in O 0 2.0940302269956135e-10
some O 0 1.584837955315166e-10
of O 0 3.2548073125582277e-09
the O 0 2.4029582768037017e-09
tissues O 0 1.3492190475972166e-08
of O 0 8.864886069659406e-08
DM B-Disease 1 1.0
patients O 0 3.162463180217401e-09
, O 0 5.547431958241589e-11
there O 0 8.82314013517238e-11
is O 0 1.9715833132760707e-11
a O 0 1.1043354425366303e-10
tendency O 0 2.415959432511272e-09
for O 0 2.0115942245269025e-10
repeat O 0 5.756354504171668e-09
length O 0 6.4461720405972756e-09
and O 0 3.886884591963735e-09
somatic O 0 1.6374751794501208e-06
mosaicism O 0 4.579920300784579e-07
to O 0 5.108752865190525e-10
increase O 0 8.833719311596155e-10
with O 0 5.932485752646599e-11
the O 0 2.2310031599914737e-09
age O 0 3.104694101807581e-08
of O 0 1.1504439179077508e-08
the O 0 3.212719335010661e-08
mouse O 0 1.0582795795244238e-07
. O 0 2.9461401140906673e-07

Furthermore O 0 1.6860290088516194e-06
, O 0 1.856629339158644e-08
we O 0 1.263782301030858e-09
observed O 0 1.2952260375342917e-09
no O 0 2.910263419142467e-10
correlation O 0 1.3651537678072145e-09
between O 0 2.5700530592587256e-10
the O 0 8.673209372922486e-10
somatic O 0 8.189112463696802e-07
mutation O 0 5.8427705340591274e-08
rate O 0 2.7210823816403718e-08
and O 0 3.122306191372104e-09
tissue O 0 5.78202332235378e-07
proliferation O 0 0.0001421180641045794
capacity O 0 6.725435923726764e-07
. O 0 4.2075433270838403e-07

The O 0 2.259974110074836e-07
somatic O 0 2.3820334718038794e-06
mutation O 0 5.271571268394837e-08
rates O 0 3.5652618635140243e-09
in O 0 4.708978346146253e-11
different O 0 1.4421200345005047e-10
tissues O 0 6.679577335688691e-09
were O 0 3.893362521267818e-09
also O 0 9.399818423627693e-11
not O 0 3.3008550753832466e-11
correlated O 0 1.6552234027855661e-09
to O 0 1.1279072120728983e-10
the O 0 4.756682603357376e-09
relative O 0 4.557704414764885e-06
inter O 0 5.343050361261703e-06
- O 0 2.146436912653371e-07
tissue O 0 2.980815949626958e-08
difference O 0 1.3094650697098587e-08
in O 0 1.612936728623282e-10
transcriptional O 0 9.447260751471731e-09
levels O 0 6.4249121578541235e-09
of O 0 5.8786056023052424e-09
the O 0 2.970826429304907e-08
three O 0 7.11384551266292e-09
genes O 0 2.255624131919376e-08
( O 0 9.56487777870052e-09
DMAHP O 0 5.232446710579097e-05
, O 0 1.6313878248297442e-08
DMPK O 0 7.172641926445067e-05
and O 0 1.9216397362242787e-08
59 O 0 1.4968064476761356e-07
) O 0 5.21620580062887e-10
surrounding O 0 8.999301570611351e-08
the O 0 1.6334091412772977e-07
repeat O 0 8.830290454397982e-08
. O 0 7.681788360969222e-08
. O 0 3.3242187669202394e-07

A O 0 9.303225851908792e-07
novel O 0 1.5663853503156133e-07
missense O 0 8.055941407292266e-07
mutation O 0 1.1453687775997423e-08
in O 0 1.9335499867878525e-10
patients O 0 1.1853192039001925e-10
from O 0 5.178061868171824e-10
a O 0 2.007180199825598e-09
retinoblastoma B-Disease 0 4.58954855275806e-06
pedigree O 0 6.119445572494442e-08
showing O 0 6.161007704008625e-09
only O 0 6.390321605209692e-10
mild O 0 1.973192631510301e-08
expression O 0 4.596190095185193e-09
of O 0 9.522718613652614e-09
the O 0 1.904679081121685e-08
tumor B-Disease 0 1.9059893929807004e-06
phenotype O 0 8.411918202000379e-07
. O 0 2.05334274028246e-07

We O 0 2.362999396154919e-08
have O 0 2.69936850649799e-10
used O 0 2.2476125127735003e-10
single O 0 8.472698653783084e-10
strand O 0 7.406645963214942e-09
conformation O 0 2.506337359875488e-09
polymorphism O 0 9.243966148098082e-10
analysis O 0 6.742036928741868e-10
to O 0 2.679915456216264e-10
study O 0 7.69590391413999e-10
the O 0 2.285657441092326e-09
27 O 0 6.132977148354257e-08
exons O 0 1.929779642750873e-07
of O 0 2.909423812980094e-07
the O 0 1.0194252126893844e-06
RB1 O 0 1.1703054951794911e-05
gene O 0 1.041899344578212e-09
in O 0 2.793882347695842e-10
individuals O 0 1.9946029203299354e-11
from O 0 2.4285431998727347e-10
a O 0 1.1381115494479843e-10
family O 0 2.819901256945201e-10
showing O 0 2.1821420226331156e-09
mild O 0 3.7234788585749357e-09
expression O 0 9.474738771331204e-10
of O 0 2.330733384070527e-09
the O 0 3.144372584529265e-08
retinoblastoma B-Disease 0 1.12706502477522e-05
phenotype O 0 1.2164279041826376e-06
. O 0 4.395679127355834e-07

In O 0 1.553089745698344e-08
this O 0 1.4465560971288483e-09
family O 0 2.263967457949434e-09
affected O 0 4.015056620509938e-10
individuals O 0 5.504639799536193e-11
developed O 0 1.1647111719526038e-08
unilateral B-Disease 0 6.654439062003803e-07
tumors I-Disease 1 1.0
and O 0 2.4600177450651017e-09
, O 0 7.256138745415086e-11
as O 0 5.140046721585634e-11
a O 0 7.063380436100886e-11
result O 0 1.7186078116182557e-09
of O 0 8.110610849598743e-09
linkage O 0 3.089725169047597e-07
analysis O 0 2.1582430065336666e-08
, O 0 4.916951734657005e-09
unaffected O 0 5.13441094085465e-08
mutation O 0 1.1032224023210802e-09
carriers O 0 6.231511973098236e-10
were O 0 1.9366956927058254e-09
also O 0 1.0802386762875926e-09
identified O 0 9.504155684680882e-09
within O 0 8.754553526557629e-09
the O 0 1.2040788988088025e-07
pedigree O 0 1.03627598946332e-05
. O 0 1.5262367014656775e-06

A O 0 7.412156719510676e-06
single O 0 3.8865010765221086e-08
band O 0 1.2780607683282597e-08
shift O 0 1.685110539995094e-08
using O 0 3.4674609850071647e-09
SSCP O 0 0.00015500291192438453
was O 0 6.000890806490133e-08
identified O 0 5.564944949298933e-09
in O 0 8.071855406299733e-10
exon O 0 9.605060746764593e-09
21 O 0 3.814282223402188e-08
which O 0 2.0940582601269853e-10
resulted O 0 3.2743590061556915e-09
in O 0 4.031201761289793e-10
a O 0 1.445172426173258e-08
missense O 0 1.0087112514156615e-06
mutation O 0 2.9439203075298792e-08
converting O 0 7.48031823150086e-08
a O 0 4.4169208734956555e-08
cys O 0 9.861519174592104e-07
- O 0 2.938249963335693e-07
- O 0 3.376174788627395e-07
> O 0 1.999760179671739e-08
arg O 0 1.0318080612137237e-08
at O 0 4.153563271103167e-09
nucleotide O 0 4.2766012953165955e-09
position O 0 5.2126107874528316e-08
28 O 0 8.699095843667237e-08
in O 0 2.376294938599699e-09
the O 0 5.086793564146319e-08
exon O 0 1.8460434603184694e-07
. O 0 9.846238526733941e-07

The O 0 2.1402568108896958e-06
mutation O 0 2.0369820958876517e-06
destroyed O 0 9.935217349266168e-06
an O 0 8.699013420709889e-08
NdeI O 0 3.9830065361456946e-06
restriction O 0 8.44026772028883e-07
enzyme O 0 1.3491722938852035e-06
site O 0 1.7887331296151388e-06
. O 0 4.061374738739687e-07

Analysis O 0 1.4939052661588903e-08
of O 0 2.3193376108565644e-08
all O 0 1.0963064900337827e-09
family O 0 1.424303119890169e-09
members O 0 1.728781354182196e-11
demonstrated O 0 7.853977190830363e-11
that O 0 5.3477678015056984e-12
the O 0 2.092477163762041e-10
missense O 0 3.517012459042235e-08
mutation O 0 1.6006733716267263e-08
co O 0 2.3495127265960036e-07
- O 0 3.1101855711312965e-05
segregated O 0 4.0873618445402826e-07
with O 0 1.0941986205992293e-09
patients O 0 8.287120726890862e-05
with O 0 4.3065418253718235e-07
tumors B-Disease 1 1.0
or O 1 0.9999995231628418
who O 0 0.002294051693752408
, O 0 1.2629022827503888e-10
as O 0 1.2237200142095617e-10
a O 0 9.03985497568982e-11
result O 0 1.1026775048605941e-09
of O 0 3.77115139116313e-09
linkage O 0 4.881817616819717e-08
analysis O 0 1.2824488138107881e-08
had O 0 1.8507037680137728e-08
been O 0 4.685885457433869e-09
predicted O 0 1.3876552351632654e-08
to O 0 6.066898650125552e-10
carry O 0 1.3182106961551199e-08
the O 0 7.267021828738507e-08
predisposing O 0 4.316353806643747e-05
mutation O 0 3.2701780128263636e-06
. O 0 1.1984279808530118e-06

These O 0 2.3639865176505737e-08
observations O 0 1.3248531161025312e-07
point O 0 2.3227729073482806e-08
to O 0 5.731195032443459e-11
another O 0 5.841037653553371e-10
region O 0 5.158496740875762e-09
of O 0 1.2853138997570568e-08
the O 0 2.404743781880825e-07
RB1 O 0 5.468796007335186e-05
gene O 0 9.364556241564514e-09
where O 0 1.7677939112559216e-08
mutations O 0 3.0467801614975087e-09
only O 0 2.1735589716964654e-10
modify O 0 9.823536428754664e-10
the O 0 1.1627084850474034e-09
function O 0 5.608010722468748e-10
of O 0 4.9046811056996376e-09
the O 0 6.0622746822502904e-09
gene O 0 1.3240460949859312e-09
and O 0 3.483078048205357e-09
raise O 0 3.873267484522103e-09
important O 0 7.229774112715859e-09
questions O 0 5.6950666404986805e-09
for O 0 2.9946151114401687e-10
genetic O 0 8.451059407832417e-09
counseling O 0 8.348981506145492e-10
in O 0 2.639021223771465e-10
families O 0 5.229554567165451e-10
with O 0 5.3081379569608345e-11
these O 0 9.590704896922375e-10
distinctive O 0 8.988545374677415e-08
phenotypes O 0 2.9671153356503055e-07
. O 0 3.0041604759389884e-08
. O 0 1.914526563950858e-07

Maternal B-Disease 0 6.725380080752075e-05
disomy I-Disease 0 0.0002021091931965202
and O 0 2.5524673219479155e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 8.615232218289748e-06
with O 0 9.878960843812123e-11
gamete O 0 5.079076004221861e-08
complementation O 0 2.2867965299155912e-08
in O 0 1.952077041678102e-11
a O 0 2.5931845212823212e-11
case O 0 5.658337132175006e-10
of O 0 3.3087377282470243e-09
familial O 0 3.1271827793943885e-08
translocation O 0 1.066984722797315e-07
( O 0 2.3235515733688317e-09
3 O 0 5.971455863118535e-08
; O 0 3.809190740611257e-09
15 O 0 3.3621716966081294e-08
) O 0 2.5808008508043656e-10
( O 0 2.280635125195829e-10
p25 O 0 2.9790200528623245e-08
; O 0 1.5818673038126008e-09
q11 O 0 4.425674404728852e-08
. O 0 1.7511745387110977e-09
2 O 0 2.5469926612231575e-08
) O 0 3.3633051899073507e-09
. O 0 1.028674176950517e-07

Maternal B-Disease 1 0.9978892207145691
uniparental I-Disease 1 1.0
disomy I-Disease 1 1.0
( I-Disease 0 0.00042410421883687377
UPD I-Disease 1 1.0
) I-Disease 0 1.1813181544084728e-09
for I-Disease 0 3.012534943724887e-10
chromosome I-Disease 0 8.58892690303037e-09
15 I-Disease 0 1.0545796236272054e-08
is O 0 8.025229092378794e-11
responsible O 0 5.562201393916055e-11
for O 0 3.2495933027787416e-11
an O 0 3.6934574842995005e-10
estimated O 0 8.583091459790637e-10
30 O 0 2.2222628182078097e-09
% O 0 1.2094147905372665e-10
of O 0 2.4165790896146788e-11
cases O 0 1.3736155268784245e-10
of O 0 1.1727656357152227e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
PWS B-Disease 1 1.0
) O 0 8.586965094536936e-08
. O 0 1.3708523738387157e-07

We O 0 1.0516433945895187e-07
report O 0 3.2464882337990275e-08
on O 0 3.5335852022200243e-09
an O 0 1.9409621132560062e-10
unusual O 0 1.4807923776061216e-09
case O 0 3.234311041211413e-09
of O 0 2.250535935388598e-08
maternal B-Disease 0 0.0033020926639437675
disomy I-Disease 0 0.012417444959282875
15 I-Disease 0 4.120048231470719e-07
in O 0 1.7863239776261253e-08
PWS B-Disease 1 1.0
that O 0 1.1020445667142553e-09
is O 0 8.926735739489544e-11
most O 0 1.0200604250165668e-10
consistent O 0 4.856609336911788e-09
with O 0 1.207407229752988e-10
adjacent O 0 4.574075163077396e-08
- O 0 1.2192386655840437e-08
1 O 0 3.614700716525476e-08
segregation O 0 1.5392057406415915e-08
of O 0 3.9472811685925535e-09
a O 0 2.1005890360470403e-08
paternal O 0 2.0460707673919387e-05
t O 0 3.7745209624517884e-08
( O 0 1.7583370315321645e-09
3 O 0 2.3010864325101466e-08
; O 0 1.5985367474158352e-09
15 O 0 6.544188746460122e-09
) O 0 6.224382120834093e-11
( O 0 5.82282555505742e-11
p25 O 0 5.434955152594512e-09
; O 0 1.8138748836271645e-10
q11 O 0 7.298049720105837e-09
. O 0 7.860046641328111e-11
2 O 0 3.364047651555069e-10
) O 0 1.8732871157056685e-12
with O 0 2.691366227103309e-12
simultaneous O 0 3.203563636589024e-09
maternal O 0 6.402247549885942e-07
meiotic O 0 2.7527539714355953e-06
nondisjunction O 0 5.646091722155688e-06
for O 0 5.782338519111363e-08
chromosome O 0 1.1007384728145553e-06
15 O 0 2.283293952132226e-06
. O 0 6.504208727164951e-07

The O 0 2.2116277875738888e-07
patient O 0 1.0612266265752623e-07
( O 0 7.735390994412228e-09
J O 0 6.231553584257199e-07
. O 0 1.8616106434166113e-09
B O 0 1.276611172329467e-08
. O 0 5.836279376447706e-11
) O 0 4.160034729888684e-12
, O 0 1.6553289988729958e-11
a O 0 1.752443329339215e-10
17 O 0 4.764037164761703e-09
- O 0 1.2087166822993822e-09
year O 0 7.750070807333032e-09
- O 0 5.892764320947208e-08
old O 0 5.615783720713807e-06
white O 0 2.132948218047659e-08
male O 0 5.444749540117755e-09
with O 0 1.067209653982104e-09
PWS B-Disease 1 1.0
, O 0 4.349751225873888e-09
was O 0 9.285603397302111e-09
found O 0 1.305892061154168e-10
to O 0 2.971027590614739e-10
have O 0 1.2245517932996108e-09
47 O 0 8.792913064326058e-08
chromosomes O 0 7.84346099180766e-09
with O 0 4.393558017401489e-10
a O 0 1.5834739741649173e-08
supernumerary O 0 2.9949214876978658e-05
, O 0 5.1961723812610217e-08
paternal O 0 0.004338423255831003
der O 0 6.0726641095243394e-05
( O 0 1.6399945845790853e-09
15 O 0 6.107142347389072e-09
) O 0 5.0808194457241385e-12
consisting O 0 3.576366633395445e-11
of O 0 4.024174771188882e-09
the O 0 2.81645853306145e-08
short O 0 7.120904754742696e-09
arm O 0 4.485148696886654e-09
and O 0 1.175647024176385e-09
the O 0 6.25850944402373e-08
proximal O 0 0.0001935550244525075
long O 0 1.816359400663714e-07
arm O 0 9.282136659294338e-08
of O 0 3.8469998742129974e-08
chromosome O 0 2.8774035598644332e-08
15 O 0 4.037720486849139e-07
, O 0 4.531349961922615e-09
and O 0 1.5561528954322057e-08
distal O 0 1.3923585356678814e-05
chromosome O 0 2.5100349375861697e-05
arm O 0 9.812560165300965e-05
3p O 0 0.0006047364440746605
. O 0 4.178749804850668e-06

The O 0 7.535771874245256e-05
t O 0 1.219557788090242e-07
( O 0 2.0171972980875807e-09
3 O 0 9.023670699548347e-09
; O 0 1.281379030659835e-10
15 O 0 7.869425666662266e-10
) O 0 3.251085815489385e-12
was O 0 2.7443886052580524e-10
present O 0 1.2949209413082308e-11
in O 0 5.59175171443993e-11
the O 0 8.310343524442487e-10
balanced O 0 1.1475417283079992e-09
state O 0 1.7981841016201372e-10
in O 0 3.7216446591159524e-10
the O 0 6.080015158005381e-09
patients O 0 1.5937084985040428e-09
father O 0 4.226053818001674e-08
and O 0 2.293514711482203e-08
a O 0 1.548412598140203e-07
sister O 0 4.448462732398184e-06
. O 0 1.7967105350180645e-06

Fluorescent O 0 4.359398189990316e-06
in O 0 8.274937357555245e-08
situ O 0 2.767225453226274e-07
hybridization O 0 2.0371482278846997e-09
analysis O 0 2.9469174323004665e-10
demonstrated O 0 3.4229077905401084e-10
that O 0 5.33885297082648e-11
the O 0 3.445625784692652e-09
PWS B-Disease 1 1.0
critical O 0 6.636908977952771e-08
region O 0 3.6961885996333876e-08
resided O 0 7.568037858618482e-07
on O 0 2.3587304553984723e-08
the O 0 4.239000261918591e-09
derivative O 0 4.770529304920501e-09
chromosome O 0 1.5928879326665424e-09
3 O 0 4.219865346044571e-09
and O 0 1.2236686663946728e-10
that O 0 3.992983374501158e-11
there O 0 1.5672169118019497e-10
was O 0 1.3534660059377757e-09
no O 0 1.0667491195937018e-10
deletion O 0 4.4294362622210315e-10
of O 0 1.7651177186550626e-09
the O 0 2.1319030096833558e-08
PWS B-Disease 1 1.0
region O 0 1.4081471988447447e-07
on O 0 3.813467586155639e-08
the O 0 8.520234295872342e-09
normal O 0 2.2639211394448466e-08
pair O 0 3.922693725399995e-09
of O 0 8.967599107734259e-09
15s O 0 1.5022406785192288e-07
present O 0 2.171116619820168e-08
in O 0 5.5529877585058784e-08
J O 0 0.00010650004696799442
. O 0 2.2692054244544124e-06

B O 0 0.001029202830977738
. O 0 6.522932835650863e-06

Methylation O 0 2.740610511864361e-07
analysis O 0 3.790537306258557e-08
at O 0 1.2993243814207744e-08
exon O 0 3.2694038587521845e-09
alpha O 0 3.243119772733394e-09
of O 0 2.177410696191373e-09
the O 0 2.724976244650179e-09
small O 0 3.4974974028045835e-09
nuclear O 0 2.4621032324034786e-08
ribonucleoprotein O 0 2.937143221970473e-07
- O 0 4.222452432145474e-08
associated O 0 5.5131064158331355e-08
polypeptide O 0 9.289900617659441e-07
N O 0 2.1289939411417436e-07
( O 0 1.0804405148334695e-09
SNRPN O 0 1.459707505091501e-06
) O 0 2.2790075382417285e-11
gene O 0 6.700024562933393e-11
showed O 0 8.073564039534631e-10
a O 0 5.7830684685455935e-11
pattern O 0 1.9049868349441113e-09
characteristic O 0 9.54941459241354e-10
of O 0 4.860072899681711e-10
only O 0 1.1186479520475245e-09
the O 0 1.6590613327593928e-08
maternal O 0 1.9241562654315203e-07
chromosome O 0 6.318215639566915e-08
15 O 0 3.7600213431687735e-07
in O 0 1.2079685518529004e-07
J O 0 9.000497811939567e-05
. O 0 1.954486833710689e-06

B O 0 0.001650970196351409
. O 0 1.140685344580561e-05

Maternal B-Disease 0 0.0010956707410514355
disomy I-Disease 0 0.0003900009032804519
was O 0 2.6126954821847903e-07
confirmed O 0 5.086305598922536e-09
by O 0 4.473414347283544e-11
polymerase O 0 2.303957469251827e-09
chain O 0 1.1369102326241887e-09
reaction O 0 6.56929732834044e-10
analysis O 0 2.6923599460992875e-10
of O 0 6.726520451749707e-10
microsatellite O 0 1.3621638572658412e-07
repeats O 0 6.562414966992947e-08
at O 0 1.935666205099551e-08
the O 0 9.998604610927941e-09
gamma O 0 5.278614167991691e-08
- O 0 2.635618301383147e-08
aminobutyric O 0 9.122087618607111e-08
acid O 0 9.779532739173646e-09
receptor O 0 4.2439051384235427e-08
beta3 O 0 7.222127607064976e-08
subunit O 0 6.34507113517202e-09
( O 0 7.946762359267723e-09
GABRB3 O 0 6.635100817220518e-06
) O 0 3.6730509744842266e-09
locus O 0 1.3200681792113755e-07
. O 0 1.7158909315639903e-07

A O 0 4.2742001824080944e-05
niece O 0 8.492220331390854e-06
( O 0 1.4345661547565669e-08
B O 0 1.3370433293857786e-07
. O 0 4.821184562686653e-10
B O 0 2.283491618015887e-09
. O 0 1.603298743768633e-11
) O 0 7.354755368095545e-13
with O 0 2.5201726556317583e-12
45 O 0 9.493262842497074e-10
chromosomes O 0 1.7398209262164954e-10
and O 0 1.7275693375840007e-10
the O 0 6.675905384057046e-10
derivative O 0 5.821562676366909e-10
3 O 0 6.886218817392376e-10
but O 0 1.024347828781913e-10
without O 0 1.4375071133443384e-09
the O 0 1.0553185347816907e-07
der O 0 1.4694398942083353e-06
( O 0 9.48674694356555e-10
15 O 0 1.3409784394013968e-08
) O 0 1.2512209324189172e-10
demonstrated O 0 2.804320997640275e-09
a O 0 2.4593422853769198e-09
phenotype O 0 3.422088568072468e-08
consistent O 0 8.50140313701786e-09
with O 0 3.6388444341062254e-11
that O 0 6.943257080394005e-11
reported O 0 1.898599055749628e-09
for O 0 3.229057576881189e-10
haploinsufficiency O 0 4.848809112445451e-06
of O 0 3.114011519755877e-07
distal O 0 4.5654360292246565e-05
3 O 0 8.200709999073297e-05
p O 0 3.451729571679607e-05
. O 0 1.5904045085335383e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
associated O 0 3.557541504051187e-06
with O 0 1.3556783251544857e-08
unbalanced O 1 0.5874497890472412
segregation O 0 8.591700861870777e-06
of O 0 2.3025322661851533e-06
non O 0 2.5855542844510637e-05
- O 0 1.0132707757293247e-06
Robertsonian O 0 4.914834903502197e-07
translocations O 0 1.518146461876313e-07
has O 0 3.051269903409093e-09
been O 0 6.395149965143787e-10
reported O 0 2.9440201387842535e-09
previously O 0 1.6409081871060494e-09
but O 0 1.0167684472150995e-09
has O 0 2.563741996475244e-10
not O 0 1.3171765067543362e-10
, O 0 9.93326254583593e-11
to O 0 6.662752016772799e-10
our O 0 1.2401999427424926e-08
knowledge O 0 5.538834457752273e-08
, O 0 1.6072132513755832e-09
been O 0 1.757103129662596e-09
observed O 0 2.720987435367306e-09
in O 0 2.3676255400673085e-10
a O 0 1.4812838733391231e-09
case O 0 3.457438069176533e-08
of O 0 1.2827101727452828e-06
PWS B-Disease 1 1.0
. O 0 1.02960711956257e-05

Furthermore O 0 1.9750261344597675e-05
, O 0 1.8169554039104696e-07
our O 0 1.4173451745591592e-07
findings O 0 5.4505086666267744e-08
are O 0 1.2551935879567822e-10
best O 0 1.1010004019595954e-09
interpreted O 0 3.0631652769841367e-09
as O 0 6.019789111633145e-10
true O 0 1.3097198880984706e-08
gamete O 0 5.038061203777033e-07
complementation O 0 1.0339642813050887e-06
resulting O 0 7.701505921886564e-08
in O 0 3.900909106846484e-08
maternal B-Disease 1 0.9999594688415527
UPD I-Disease 1 1.0
15 I-Disease 0 0.0034086345694959164
and O 0 3.6626021028496325e-05
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
Jampel I-Disease 1 1.0
syndrome I-Disease 1 0.9999996423721313
type I-Disease 0 1.4785402413508564e-07
2 I-Disease 0 5.3343516270842883e-08
and O 0 1.63578972589562e-09
Stuve B-Disease 1 0.9988874793052673
- I-Disease 1 0.9999793767929077
Wiedemann I-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
: O 0 4.018857191478986e-10
a O 0 1.5093007399435976e-10
case O 0 1.1629408547264575e-10
for O 0 1.0133546085588918e-10
" O 0 6.658102957857182e-10
lumping O 0 7.243894817321461e-09
" O 0 3.627028277719546e-08
. O 0 2.5008381498992094e-07

Recent O 0 3.48082167533903e-08
studies O 0 3.187424324480048e-09
demonstrated O 0 1.4446646101617944e-09
the O 0 3.6101976963465177e-10
existence O 0 3.4577789520540136e-09
of O 0 8.62717786098699e-10
a O 0 7.21165904771226e-10
genetically O 0 7.573183857800814e-09
distinct O 0 9.810433354573433e-09
, O 0 9.673592482606352e-11
usually O 0 1.6781671538512732e-11
lethal O 0 1.915274744357376e-10
form O 0 7.141395114151905e-11
of O 0 1.2088618994710032e-09
the O 0 3.1894696661538546e-08
Schwartz B-Disease 1 0.9998804330825806
- I-Disease 1 1.0
Jampel I-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
( O 0 1.518528733868152e-07
SJS B-Disease 0 5.951837374595925e-05
) O 0 2.291274947552324e-09
of O 0 4.1288942043138377e-07
myotonia B-Disease 1 0.999997615814209
and O 0 2.306120404682588e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 4.0220058394879743e-07
which O 0 1.3992885961044976e-08
we O 0 9.097341546748794e-09
called O 0 4.334671999117745e-08
SJS B-Disease 0 9.44988914852729e-06
type I-Disease 0 3.2109819585457444e-06
2 I-Disease 0 1.431666714779567e-05
. O 0 1.0867966011574026e-06

This O 0 1.6341003217235084e-08
disorder O 0 0.006857864558696747
is O 0 5.810003589346024e-10
reminiscent O 0 3.862881570171339e-08
of O 0 1.445982333869722e-09
another O 0 5.13265263624163e-10
rare O 0 1.2225913614827277e-09
condition O 0 3.082884347804793e-08
, O 0 1.3378552432552482e-10
the O 0 7.873978802308557e-09
Stuve B-Disease 1 0.9999052286148071
- I-Disease 1 0.9999998807907104
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.026136815547943115
SWS B-Disease 1 0.9999817609786987
) O 0 1.6814552528110482e-10
, O 0 5.042581283087877e-11
which O 0 6.88952644933849e-11
comprises O 0 4.5284270777656843e-10
campomelia B-Disease 0 7.935986104712356e-06
at O 0 2.106957310843427e-07
birth O 0 2.468918410158949e-06
with O 0 2.548256183843023e-08
skeletal B-Disease 1 0.9992548823356628
dysplasia I-Disease 1 0.7784231901168823
, O 0 1.0981030129642022e-07
contractures B-Disease 0 0.001939724083058536
, O 0 2.3860611264581166e-08
and O 0 4.6602335324053e-09
early B-Disease 0 1.9028182123292936e-06
death I-Disease 0 2.0788640995306196e-06
. O 0 5.387644819165871e-07

To O 0 3.387318425751573e-09
test O 0 3.810700366368991e-10
for O 0 1.8030645032585113e-10
possible O 0 1.749459244138052e-08
nosologic O 0 2.50889365815965e-06
identity O 0 2.8806818264115464e-08
between O 0 3.803515724598583e-08
these O 0 3.2283651307807304e-08
disorders O 0 1.483688834014174e-07
, O 0 6.187985124306294e-10
we O 0 1.6495181609510468e-10
reviewed O 0 1.722696985062555e-09
the O 0 2.160647216697953e-09
literature O 0 2.5273441117690254e-09
and O 0 6.836928245768092e-11
obtained O 0 1.5481792514648873e-09
a O 0 4.5980641516507603e-10
follow O 0 1.8662393852508785e-09
- O 0 2.277450006360482e-09
up O 0 3.297561113058123e-09
of O 0 1.0282109386139382e-08
the O 0 5.3780531139580035e-09
only O 0 5.603391639574795e-10
two O 0 4.034878819947352e-10
surviving O 0 2.571369783765931e-08
patients O 0 1.8974505300306532e-10
, O 0 1.1266429456036064e-10
one O 0 1.6132575275662475e-09
with O 0 2.861475500992583e-09
SJS B-Disease 0 1.6731891037125024e-06
type I-Disease 0 8.520628114183637e-08
2 I-Disease 0 1.1409735378720143e-07
at O 0 1.9078713719977713e-08
age O 0 4.125605190807846e-09
10 O 0 4.1500927694393397e-10
years O 0 1.2046513786501123e-10
and O 0 4.5457672348536704e-11
another O 0 8.455633970783083e-10
with O 0 1.980416053370959e-09
SWS B-Disease 0 6.75925039104186e-05
at O 0 7.451282613146759e-08
age O 0 1.826810489546915e-07
7 O 0 2.5954926741178497e-07
years O 0 8.178110277867745e-08
. O 0 4.987478519069555e-07

Patients O 0 5.8440409844706664e-08
reported O 0 2.8626343961946077e-08
as O 0 1.0196425925812491e-09
having O 0 8.724793665315644e-10
either O 0 1.2971383966942085e-07
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 0.4254336953163147
SWS B-Disease 1 0.9999642372131348
presented O 0 7.584469718935338e-10
a O 0 2.572317185645101e-11
combination O 0 9.924740196343151e-11
of O 0 1.0656225901684024e-10
a O 0 1.0920005871772887e-10
severe O 0 6.916762274045141e-09
, O 0 5.782100909179633e-10
prenatal O 0 3.3769583751563914e-06
- O 0 1.0123539141204674e-05
onset O 1 0.9999998807907104
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 1.0868443034439679e-08
with O 0 3.2548257422604365e-09
congenital B-Disease 1 1.0
joint I-Disease 0 6.217947543518676e-07
contractures I-Disease 1 1.0
, O 0 2.1396427740683066e-08
respiratory O 1 1.0
and O 0 1.4038150197848154e-07
feeding O 1 0.8727615475654602
difficulties O 0 1.942990638781339e-05
, O 0 4.294764543999463e-09
tendency O 0 8.674656726270769e-08
to O 0 3.0031506170757893e-09
hyperthermia B-Disease 0 0.0029537484515458345
, O 0 4.729467373287832e-10
and O 0 4.2731151950192725e-11
frequent O 0 5.077511189277573e-10
death O 0 1.893356404991664e-08
in O 0 4.387472607447762e-09
infancy O 0 1.0723847481131088e-06
) O 0 6.428840099159672e-11
with O 0 5.7298832345509254e-11
a O 0 2.4562387679338826e-09
distinct O 0 1.2262813697816455e-07
campomelic B-Disease 0 0.0005404904950410128
- I-Disease 0 0.002794012427330017
metaphyseal I-Disease 0 0.0007615333306603134
skeletal I-Disease 0 0.0508153922855854
dysplasia I-Disease 1 0.9892988204956055
. O 0 4.64274016849231e-05

The O 0 7.275676239260065e-08
similarity O 0 6.866957278361951e-07
of O 0 4.223773260036978e-07
the O 0 2.431879124742409e-07
clinical O 0 1.390811661394764e-07
and O 0 9.565479075490657e-09
radiographic O 0 5.893100751563907e-05
findings O 0 1.0822003559951554e-06
is O 0 4.085908944517769e-09
so O 0 2.487022587871479e-09
extensive O 0 3.375749457745769e-08
that O 0 2.5051234420203627e-09
these O 0 1.52273660347646e-08
disorders O 0 9.481002649636139e-08
appear O 0 3.835260997675505e-09
to O 0 3.3181399294868186e-10
be O 0 3.8948086422685435e-10
a O 0 1.7905871230183834e-09
single O 0 3.2957376827624785e-09
entity O 0 7.317747758861515e-07
. O 0 1.2370210242806934e-06

The O 0 5.033277830079896e-07
follow O 0 4.997319535959832e-08
- O 0 1.5704921807468963e-08
up O 0 6.977818323150586e-10
observation O 0 1.978318380224664e-07
of O 0 3.6869260422456307e-10
an O 0 1.6718997020159776e-10
identical O 0 1.9284600305535804e-10
and O 0 1.5620412949224338e-11
unique O 0 3.807518189624659e-10
pattern O 0 1.4382312656380236e-06
of O 0 3.7923459217381605e-07
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 0.9999954700469971
in O 0 5.379061462917889e-08
the O 0 1.1569843394454438e-07
two O 0 3.0290711605651666e-10
patients O 0 1.0296739849646741e-10
( O 0 4.139726061946902e-11
one O 0 8.78670136650328e-10
with O 0 1.9978452225899446e-09
SJS B-Disease 0 6.480037768596958e-07
type I-Disease 0 7.741475371858542e-08
2 I-Disease 0 1.3751640892678552e-07
, O 0 4.739708070466975e-10
one O 0 2.2912529651364366e-09
with O 0 5.565528482520676e-09
SWS B-Disease 0 2.304898043803405e-05
) O 0 5.266420077809641e-10
surviving O 0 1.4295192158897407e-06
beyond O 0 3.5827536066790344e-06
infancy O 0 4.3701047616195865e-06
adds O 0 1.874634847354173e-08
to O 0 6.227804938419013e-10
the O 0 1.7900441129370392e-09
evidence O 0 5.597199592699553e-09
in O 0 3.188201092019227e-10
favor O 0 2.0295901848044196e-08
of O 0 9.259605526779069e-09
identity O 0 9.428273273215382e-08
. O 0 5.428523195405432e-07

The O 0 4.819056584892678e-07
hypothesis O 0 1.1324448223604122e-06
that O 0 1.77748393781485e-08
SWS B-Disease 0 1.71877854882041e-05
and O 0 3.687773642013781e-08
SJS B-Disease 0 1.215611405314121e-06
type I-Disease 0 1.0855954002408907e-07
2 I-Disease 0 5.31507566847722e-07
are O 0 3.5137706633214805e-10
the O 0 1.2226246681734665e-08
same O 0 3.747789634189758e-09
disorder O 0 7.806822566180927e-08
should O 0 4.990637347823679e-10
be O 0 7.359846621035615e-10
testable O 0 1.3034402002176648e-07
by O 0 7.556384962192908e-10
molecular O 0 3.1339361328264204e-08
methods O 0 3.265803272256562e-08
. O 0 2.4491107808444212e-08
. O 0 2.5027947003763984e-07

A O 0 2.43706097080576e-07
mouse O 0 3.1800402311432663e-09
model O 0 2.9496181053190185e-09
of O 0 7.580912009252927e-10
severe O 0 8.15386010799557e-05
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.016866888850927353
defects O 1 0.9999984502792358
in O 0 6.921053596897764e-08
hemostasis O 0 3.1316259992308915e-05
and O 0 5.7152991672637654e-08
thrombosis B-Disease 0 1.2101761967642233e-05
. O 0 3.8319365103234304e-07

von B-Disease 1 0.9996898174285889
Willebrand I-Disease 1 0.9999984502792358
factor I-Disease 0 0.23409005999565125
( I-Disease 0 0.00028722931165248156
vWf I-Disease 1 0.9999464750289917
) I-Disease 0 1.1490445785966585e-06
deficiency I-Disease 1 0.9999998807907104
causes O 1 0.9999998807907104
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 8.306181484840636e-07
humans O 0 1.8006130630965345e-07
. O 0 6.070489444454097e-09

We O 0 8.197143408494867e-09
generated O 0 1.8663997014556344e-09
a O 0 9.559182334584193e-10
mouse O 0 9.766852882009402e-10
model O 0 8.328321365880242e-10
for O 0 5.637349961840066e-11
this O 0 1.4449449969866635e-10
disease O 0 1.8084451713917815e-09
by O 0 5.459885668579467e-11
using O 0 5.739664854509385e-10
gene O 0 1.3265341713974976e-08
targeting O 0 7.741696208540816e-07
. O 0 3.128997434487246e-07

vWf B-Disease 0 0.002069887239485979
- I-Disease 0 0.0032071368768811226
deficient I-Disease 0 2.0880534066236578e-05
mice O 0 1.6845426387135376e-07
appeared O 0 1.7228532556146092e-07
normal O 0 5.461956575913973e-08
at O 0 1.3374272800348308e-09
birth O 0 5.81601322657832e-10
; O 0 1.3061111914236534e-10
they O 0 1.393204579480667e-10
were O 0 1.811977234922324e-09
viable O 0 5.53720667539892e-07
and O 0 4.889841420663288e-08
fertile O 0 2.587392009445466e-05
. O 0 2.01591524273681e-06

Neither O 0 8.756326860748231e-05
vWf O 0 0.004110836889594793
nor O 0 0.000375194736989215
vWf O 0 0.006961312610656023
propolypeptide O 0 0.01519903726875782
( O 0 1.0705219892770401e-06
von B-Disease 0 0.020641537383198738
Willebrand I-Disease 0 2.4451990611851215e-05
antigen O 0 7.044755534479918e-08
II O 0 0.00031322857830673456
) O 0 4.257434405019467e-09
were O 0 3.871007514533176e-09
detectable O 0 5.9319742007346576e-08
in O 0 7.122028522488222e-10
plasma O 0 1.7635437998819725e-08
, O 0 2.144085464728107e-10
platelets O 0 8.07999267493642e-09
, O 0 1.8531567946844518e-10
or O 0 2.706477819636177e-10
endothelial O 0 1.1023115753516777e-09
cells O 0 1.0933056682205233e-09
of O 0 1.8607835272632656e-09
the O 0 8.979271548525958e-09
homozygous O 0 2.030279411258107e-08
mutant O 0 4.678100538058061e-07
mice O 0 2.1627515423006116e-07
. O 0 2.8322918410594866e-07

The O 0 1.5342060066814156e-07
mutant O 0 2.182077025736362e-07
mice O 0 7.187799155872199e-08
exhibited O 0 1.5585283108521253e-07
defects O 0 6.502348810499825e-07
in O 0 3.014634319953302e-09
hemostasis O 0 2.9230682230263483e-07
with O 0 4.742735024154676e-11
a O 0 1.2380887426388654e-09
highly O 0 1.033362018176831e-08
prolonged O 0 5.3942485465086065e-06
bleeding O 0 7.303789857360243e-07
time O 0 9.058538807948935e-09
and O 0 2.354513028990368e-09
spontaneous O 0 2.621550947878859e-06
bleeding O 0 3.314285379474313e-07
events O 0 5.309456763136211e-10
in O 0 1.992052911514719e-10
approximately O 0 1.3146196353730488e-09
10 O 0 4.632564998274802e-09
% O 0 3.2607787581184766e-09
of O 0 1.0450365017788954e-08
neonates O 0 8.668129680700076e-07
. O 0 1.1469152241261327e-06

As O 0 7.010000047102949e-08
in O 0 4.542131559759355e-09
the O 0 6.367232963100378e-09
human O 0 7.266090396029767e-09
disease O 0 9.345663443127705e-08
, O 0 2.861963790956601e-11
the O 0 2.817954758427277e-10
factor O 0 4.055156654914072e-09
VIII O 0 1.0567218851065263e-06
level O 0 4.974543799107778e-07
in O 0 5.0421635755526495e-09
these O 0 5.458423046889038e-09
mice O 0 4.011331267150808e-09
was O 0 9.594313787886222e-09
reduced O 0 1.7367149940383797e-09
strongly O 0 3.0995905841990634e-10
as O 0 2.0670185008064834e-10
a O 0 2.8057214884746884e-10
result O 0 5.629468891044098e-09
of O 0 1.2667417337297593e-08
the O 0 3.093575529078407e-08
lack O 0 1.0663519844911207e-07
of O 0 1.0765655922284623e-08
protection O 0 4.312611778800601e-08
provided O 0 4.741575665434539e-08
by O 0 2.9697048375965096e-08
vWf O 0 0.00011501844710437581
. O 0 2.284605216118507e-06

Defective O 0 9.042926831170917e-05
thrombosis B-Disease 0 1.695326682238374e-05
in O 0 1.4567571149370906e-08
mutant O 0 4.741648140793586e-08
mice O 0 8.36672864323873e-09
was O 0 3.615160837355802e-09
also O 0 2.4089490818779424e-11
evident O 0 1.1297572877211337e-09
in O 0 4.476307519096778e-11
an O 0 1.4495603328779083e-10
in O 0 4.510607165553182e-11
vivo O 0 2.8525386497335603e-09
model O 0 5.3664543919751395e-09
of O 0 5.3796259891214504e-08
vascular B-Disease 0 0.025101421400904655
injury I-Disease 1 1.0
. O 0 9.381234121974558e-05

In O 0 9.411057710906334e-09
this O 0 1.1153457046830795e-09
model O 0 1.3434514833932099e-08
, O 0 4.88857732072745e-10
the O 0 6.601531321592802e-09
exteriorized O 0 6.5612780417723116e-06
mesentery O 0 1.163121032732306e-05
was O 0 3.421528163016774e-07
superfused O 0 1.3942075156592182e-06
with O 0 5.116703061247563e-09
ferric O 0 1.9677098350712185e-07
chloride O 0 4.490920844091306e-07
and O 0 6.481781156253419e-08
the O 0 2.0743239304010785e-07
accumulation O 0 0.0011718347668647766
of O 0 1.3512142686522566e-05
fluorescently O 0 6.633886187046301e-06
labeled O 0 2.059276908994434e-07
platelets O 0 2.4885241600713925e-07
was O 0 5.593264518211072e-08
observed O 0 4.959165078588512e-09
by O 0 1.5739038961015694e-09
intravital O 0 2.558687128839665e-06
microscopy O 0 6.90677097736625e-07
. O 0 3.923930762539385e-07

We O 0 1.2642173885524244e-07
conclude O 0 3.8947908365116746e-07
that O 0 1.632395552064736e-09
these O 0 2.1871295885489417e-09
mice O 0 5.948740167127653e-09
very O 0 2.0570494196903155e-09
closely O 0 4.1735117584096315e-09
mimic O 0 6.181850835673686e-07
severe O 0 0.00022335736139211804
human O 0 0.012197671458125114
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 0.0015559950843453407
will O 0 9.406028178560177e-10
be O 0 1.3947652754975337e-10
very O 0 4.9917868449878e-11
useful O 0 4.0186270977571326e-10
for O 0 4.6781117174488074e-11
investigating O 0 2.839857460301687e-09
the O 0 4.42867831296212e-09
role O 0 2.7137518898712187e-09
of O 0 2.175477220589528e-08
vWf O 0 7.807074098309386e-07
in O 0 1.4896429867405914e-08
normal O 0 3.313322849862743e-06
physiology O 0 1.2157894957454118e-07
and O 0 1.107552938250933e-09
in O 0 9.796741196055336e-10
disease O 0 9.66143165470612e-09
models O 0 9.30556787182013e-09
. O 0 7.307563443248455e-09
. O 0 1.0480491141606763e-07

Oral O 0 6.137751711321471e-07
contraceptives O 0 2.02436396534722e-07
and O 0 4.565049727123238e-10
the O 0 3.2579128284027092e-09
risk O 0 3.2643013128108578e-06
of O 1 0.9966290593147278
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.397287618005066e-07

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 0 3.6792414448427735e-06
Study O 0 1.2074815591844867e-09
Group O 0 3.795438408005225e-10
. O 0 4.376515150283922e-09

BACKGROUND O 1 0.5073778033256531
Women O 0 1.4514375479279806e-08
with O 0 2.0595883332141796e-10
mutations O 0 2.1121906446097682e-09
in O 0 9.71951408246241e-11
either O 0 7.984589101006634e-10
the O 0 1.0744608758272989e-08
BRCA1 O 0 9.049579574593736e-08
or O 0 4.777723106030862e-09
the O 0 1.9124620109778334e-08
BRCA2 O 0 3.496124989510463e-08
gene O 0 4.888437432626347e-10
have O 0 1.8866638806791514e-10
a O 0 4.4534612109181637e-10
high O 0 2.753534067423402e-09
lifetime O 0 3.025644090826063e-08
risk O 0 0.057097140699625015
of O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.902550697101105e-07

Oral O 0 1.181517382065067e-05
contraceptives O 0 3.604455923778005e-05
protect O 0 7.435621228069067e-05
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 4.4657291198291205e-09
general O 0 3.9711745003501164e-09
, O 0 1.470203646325441e-11
but O 0 4.2877045663969326e-11
it O 0 4.9807165336535064e-11
is O 0 1.1393445215057696e-11
not O 0 3.335537401838451e-11
known O 0 5.308181116880917e-10
whether O 0 1.7429571119720322e-09
they O 0 1.98352334557228e-09
also O 0 1.2365711787865052e-09
protect O 0 1.4086521948897257e-09
against O 0 1.1147125000832148e-08
hereditary B-Disease 1 1.0
forms I-Disease 1 1.0
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.0780622378424596e-07

METHODS O 0 6.367939704432501e-07
We O 0 3.967124406756284e-09
enrolled O 0 1.0361210556197875e-08
207 O 0 4.105900952566799e-09
women O 0 1.3917870189672499e-09
with O 0 1.619022782506363e-08
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.6435528205647216e-11
161 O 0 2.1952910322919905e-10
of O 0 4.060386749049627e-10
their O 0 1.2747077837715892e-09
sisters O 0 1.290674411791315e-08
as O 0 2.520056385790781e-09
controls O 0 6.512039352202237e-09
in O 0 2.7426840798483454e-09
a O 0 1.2994135545341123e-08
case O 0 9.079091967123532e-08
- O 0 2.9404054657788947e-07
control O 0 1.0495934787968508e-07
study O 0 4.444029855221743e-08
. O 0 1.344518381074522e-07

All O 0 2.74032725400275e-08
the O 0 1.6020905491131998e-08
patients O 0 9.030208247828853e-10
carried O 0 2.2863669291162125e-10
a O 0 3.109359297814862e-11
pathogenic O 0 1.2227080459226158e-09
mutation O 0 7.101152998956195e-10
in O 0 1.8230243703509785e-10
either O 0 6.814750541650483e-09
BRCA1 O 0 3.164763739960108e-08
( O 0 1.049810793851691e-09
179 O 0 7.555177816698233e-09
women O 0 1.3489405148447986e-09
) O 0 2.788829722710773e-10
or O 0 2.8650376293626323e-08
BRCA2 O 0 4.69178161210948e-07
( O 0 3.129926318123921e-09
28 O 0 1.1974341305176495e-06
women O 0 1.1018059353773424e-07
) O 0 1.9730647338178642e-08
. O 0 4.13242787544732e-07

The O 0 3.910873545009963e-07
control O 0 7.015417224920384e-08
women O 0 1.664747983909365e-08
were O 0 5.740303343770847e-09
enrolled O 0 3.501562595431551e-09
regardless O 0 1.7182275602323216e-09
of O 0 1.3211853833183795e-09
whether O 0 3.0514546445203905e-10
or O 0 8.335854784213836e-10
not O 0 3.9911890459265464e-10
they O 0 7.416948166749648e-10
had O 0 4.439367984332421e-09
either O 0 1.4198527686914986e-08
mutation O 0 2.995803924932261e-07
. O 0 4.2756167317747895e-07

Lifetime O 0 2.1632561129081296e-06
histories O 0 4.551232450467069e-06
of O 0 1.64426035098586e-06
oral O 0 1.3544460841785622e-07
- O 0 1.7218471981550465e-08
contraceptive O 0 8.828968667273784e-10
use O 0 1.5588871860039433e-10
were O 0 2.2091607709828764e-10
obtained O 0 2.112472641258023e-09
by O 0 5.039429984421417e-10
interview O 0 1.9921224669872117e-09
or O 0 1.0726414895190217e-10
by O 0 5.329421279287594e-11
written O 0 2.339308781407201e-11
questionnaire O 0 1.1132893218412931e-11
and O 0 1.2482668544644415e-11
were O 0 5.282080675628187e-11
compared O 0 2.3567942042390655e-10
between O 0 5.266168612294564e-10
patients O 0 1.272984495592766e-10
and O 0 1.9900855963150832e-10
control O 0 5.662745383716583e-09
women O 0 4.865918779017875e-09
, O 0 2.8943647478740786e-10
after O 0 2.78266604203381e-10
adjustment O 0 1.836227059293094e-09
for O 0 7.518240890957983e-11
year O 0 1.2194031340229117e-09
of O 0 6.771216920498091e-09
birth O 0 6.445117151088198e-08
and O 0 4.352857629896789e-08
parity O 0 5.979713023407385e-06
. O 0 2.376515112700872e-06

RESULTS O 0 7.669016667932738e-06
The O 0 6.669903740430527e-08
adjusted O 0 1.089301463252923e-06
odds O 0 6.771257403670461e-07
ratio O 0 1.2880140332072187e-07
for O 0 2.3529659642917977e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 6.768016902469753e-08
with O 0 9.24684894626493e-12
any O 0 2.4506596751905363e-10
past O 0 1.887420664203887e-09
use O 0 2.680007327171552e-10
of O 0 2.039807434073282e-09
oral O 0 8.221318736900685e-09
contraceptives O 0 5.077623299598599e-08
was O 0 1.4986562746344134e-07
0 O 0 7.071477625686384e-07
. O 0 8.174154686457769e-07

5 O 0 8.866845178090443e-07
( O 0 2.6867645885886304e-09
95 O 0 6.371292471385459e-08
percent O 0 1.0690518692513251e-08
confidence O 0 3.991069252862189e-09
interval O 0 9.480708662579218e-09
, O 0 3.3885122485699526e-10
0 O 0 1.6690011594988619e-09
. O 0 3.9717024113983257e-10
3 O 0 2.037342516914009e-09
to O 0 7.823585113087006e-10
0 O 0 1.030311480576529e-08
. O 0 4.519300489391753e-09
8 O 0 9.097153963466553e-08
) O 0 3.00348879100909e-09
. O 0 7.441412464004316e-08

The O 0 1.1057491633437166e-07
risk O 0 2.0055858840350993e-07
decreased O 0 1.5931316710293686e-08
with O 0 7.162876628635795e-12
increasing O 0 3.174324136878681e-10
duration O 0 4.218022819912903e-09
of O 0 7.768922172246562e-10
use O 0 1.7191389423132364e-09
( O 0 2.1531763039206453e-09
P O 0 2.8452865308281616e-07
for O 0 2.2040271829837366e-09
trend O 0 1.924769321703934e-07
, O 0 3.065460663087549e-10
< O 0 1.1675799216348537e-09
0 O 0 4.5487640321084655e-09
. O 0 2.670359933176769e-09
001 O 0 1.0701535657631212e-08
) O 0 2.4137046528149853e-11
; O 0 1.649976683060217e-11
use O 0 2.0095071440184853e-11
for O 0 2.2532997689950207e-10
six O 0 1.3293018907845067e-09
or O 0 1.717823661095963e-10
more O 0 2.0625132157725545e-10
years O 0 8.941906659565291e-10
was O 0 2.043000435492104e-09
associated O 0 3.4312419572302133e-10
with O 0 1.8326772391330515e-11
a O 0 5.528158486534096e-10
60 O 0 5.769280608802774e-09
percent O 0 1.4070599130278083e-09
reduction O 0 2.2351089867811424e-09
in O 0 1.2208484223563687e-09
risk O 0 2.048968781309668e-07
. O 0 5.084232839180913e-07

Oral O 0 1.7360688389089773e-06
- O 0 1.269766016775975e-07
contraceptive O 0 6.245651995584467e-09
use O 0 8.6763524143052e-10
protected O 1 0.9611976146697998
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 1.0793684522558689e-11
for O 0 1.9729130709775916e-13
carriers O 0 7.360091702768301e-12
of O 0 4.500938510787478e-11
the O 0 5.409926284727362e-09
BRCA1 O 0 9.596055150495886e-08
mutation O 0 1.4630389344461037e-08
( O 0 4.431602196319773e-09
odds O 0 2.8294732601352734e-07
ratio O 0 2.7092953658325314e-08
, O 0 2.1393971039174176e-09
0 O 0 7.853999228757402e-09
. O 0 1.3116191466266969e-09
5 O 0 3.2079723322198106e-09
; O 0 1.8708180837823107e-10
95 O 0 9.152792301847512e-09
percent O 0 6.512586026019562e-09
confidence O 0 3.6399030456379933e-09
interval O 0 3.931472036811101e-09
, O 0 5.437440497857438e-10
0 O 0 2.1700721219986008e-09
. O 0 7.476003704987022e-10
3 O 0 3.558814576365421e-09
to O 0 1.340957345163929e-09
0 O 0 9.503666298371627e-09
. O 0 1.5667603880942238e-09
9 O 0 1.391859427712916e-08
) O 0 1.6781671538512732e-11
and O 0 4.960236648504646e-12
for O 0 2.7981458296244544e-12
carriers O 0 6.271095448484587e-11
of O 0 6.607549507542387e-10
the O 0 1.0089953406122731e-07
BRCA2 O 0 3.966456461057533e-06
mutation O 0 9.761385655338017e-08
( O 0 1.236751234756639e-08
odds O 0 8.332427228197048e-07
ratio O 0 4.7322785690084856e-08
, O 0 3.4259597381236517e-09
0 O 0 6.406031261008138e-09
. O 0 1.2117151726442899e-09
4 O 0 4.1294310193507044e-09
; O 0 4.2000378175366393e-10
95 O 0 1.8141948388006313e-08
percent O 0 1.1357100149211874e-08
confidence O 0 1.3062023462850902e-08
interval O 0 1.3864039694055919e-08
, O 0 8.618624702805278e-10
0 O 0 3.420846717006043e-09
. O 0 9.467693296016932e-10
2 O 0 4.266181186096674e-09
to O 0 1.8911610055738493e-09
1 O 0 3.543940962913439e-08
. O 0 6.475723068888328e-09
1 O 0 9.973637560278803e-08
) O 0 7.924239930900967e-09
. O 0 2.0592690930243407e-07

CONCLUSIONS O 0 0.0016707597533240914
Oral O 0 9.082657925318927e-06
- O 0 4.0342294482798025e-07
contraceptive O 0 7.966612258769601e-09
use O 0 1.6555130877282664e-10
may O 0 2.397605169957018e-10
reduce O 0 3.1024768865073327e-10
the O 0 4.983817247783406e-10
risk O 0 4.879574362348649e-07
of O 1 0.9375694394111633
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 7.256395484489531e-09
women O 0 6.550525399884322e-11
with O 0 6.1229485023850394e-12
pathogenic O 0 5.245678336152082e-10
mutations O 0 1.2168777097087968e-09
in O 0 3.581119567552804e-10
the O 0 2.0557992641556666e-08
BRCA1 O 0 3.046124675165629e-06
or O 0 9.173836588161066e-07
BRCA2 O 0 2.8450625904952176e-05
gene O 0 3.097918670391664e-05

A O 0 1.3417815125649213e-06
Japanese O 0 1.8967763537602877e-07
family O 0 8.683608498927242e-09
with O 0 5.590335971916716e-10
adrenoleukodystrophy B-Disease 1 1.0
with O 0 1.5698077560077905e-10
a O 0 1.4130897563191525e-09
codon O 0 3.855189945056736e-08
291 O 0 1.0531986838202556e-08
deletion O 0 3.5532594644394067e-09
: O 0 7.094844711730275e-10
a O 0 1.8540947666068064e-09
clinical O 0 1.641491209625201e-08
, O 0 1.3478449467640985e-09
biochemical O 0 6.27140309461538e-07
, O 0 6.0251332811844804e-09
pathological O 0 0.0005904779536649585
, O 0 2.2052896397894983e-08
and O 0 8.878723534166966e-09
genetic O 0 5.609802542494435e-07
report O 0 1.9784788207743986e-07
. O 0 1.6575438621657668e-07

We O 0 1.991914366783476e-08
report O 0 6.567784538447086e-09
a O 0 1.8906119725325965e-10
Japanese O 0 4.293716049375007e-09
family O 0 2.425632583680226e-09
with O 0 1.2144222294452334e-09
adrenoleukodystrophy B-Disease 1 1.0
( O 0 3.4455624131624063e-07
ALD B-Disease 1 1.0
) O 0 2.061521092722174e-11
with O 0 1.7061288362998916e-12
a O 0 6.059124035839858e-11
three O 0 9.58230647607472e-11
base O 0 1.1269578159556204e-08
pair O 0 1.1931983401325397e-08
deletion O 0 4.574241074806196e-08
( O 0 9.910299247906096e-09
delGAG O 0 3.7143021813790256e-07
291 O 0 2.3036070828652555e-08
) O 0 1.025417042943566e-10
in O 0 8.963149111806956e-10
the O 0 2.62551679952594e-07
ALD B-Disease 1 1.0
gene O 0 1.6485295191159821e-06
. O 0 1.5406867532874458e-06

A O 0 1.265414312001667e-06
variety O 0 4.342491877196153e-08
of O 0 2.0841026682205666e-08
phenotypes O 0 1.1846541525528664e-07
were O 0 3.471405163324448e-09
observed O 0 3.757653299629737e-09
within O 0 1.4113308299812388e-09
this O 0 1.0327112498487168e-09
family O 0 7.896542086882619e-08
. O 0 2.396849367869436e-07

While O 0 6.559386633853137e-08
the O 0 2.554841387336637e-07
proband O 0 2.4811051844153553e-05
( O 0 3.957111083252585e-09
patient O 0 1.4525841862678135e-08
1 O 0 1.8530384338077965e-08
) O 0 1.0400662275866779e-10
was O 0 3.0725275657061957e-09
classified O 0 3.8524516909888007e-10
as O 0 2.6689070398155934e-10
having O 0 6.774800859199459e-11
a O 0 1.3010638399979513e-10
rare O 0 4.5564638173622996e-10
intermediate O 0 4.423123645125315e-09
type O 0 2.4706685586295407e-09
of O 0 3.0204532208699675e-09
adult O 0 1.8151629888052412e-07
cerebral O 0 1.4680960703117307e-05
and O 0 1.3671849785623635e-07
cerebello O 1 0.9501708149909973
- O 0 0.0005585052422247827
brain O 0 1.3876460798201151e-05
stem O 0 5.173940209601824e-08
forms O 0 6.790824347291391e-09
, O 0 2.4913798801762255e-10
his O 0 1.0064693078959408e-08
younger O 0 4.5399514192467905e-07
brother O 0 7.639108048351773e-07
( O 0 9.764468122952508e-10
patient O 0 5.3846842540394846e-09
2 O 0 5.592930563125265e-09
) O 0 6.951088316053955e-11
and O 0 1.1380469899791024e-09
nephew O 0 2.5261078917537816e-06
( O 0 2.8593150069866624e-09
patient O 0 1.4039676443644566e-07
3 O 0 3.506544032916281e-07
) O 0 5.657160850880416e-10
had O 0 5.1875539419654615e-09
a O 0 1.333055088537094e-08
childhood O 0 5.413115559349535e-06
ALD B-Disease 1 1.0
type O 0 2.91898049908923e-05
. O 0 5.683740482709254e-07

Another O 0 1.395186473018839e-06
nephew O 0 8.748364052735269e-05
( O 0 2.520740416400713e-08
patient O 0 5.441004802264615e-08
4 O 0 2.879269977995591e-08
) O 0 2.757304974621011e-11
of O 0 8.126386230600247e-10
patient O 0 2.5049848861868895e-09
1 O 0 3.347965105149342e-08
was O 0 1.516238690157934e-08
classified O 0 2.3465775988995574e-09
as O 0 2.8031230669967044e-09
having O 0 3.221062527813956e-09
an O 0 1.1273490585494983e-08
adolescent O 0 2.973207280376755e-08
form O 0 2.220958883469848e-08
. O 0 3.639676435795991e-07

The O 0 5.267299485467447e-08
tau O 0 2.0373201792267537e-08
level O 0 4.9402082424876426e-09
in O 0 1.9164547726546743e-10
the O 0 9.616940133128082e-09
cerebrospinal O 0 2.833604185070726e-06
fluid O 0 3.214588105038274e-06
( O 0 1.456807723343445e-07
CSF O 1 0.9977127313613892
) O 0 1.1057945670245317e-09
in O 0 1.4363833455988129e-09
patient O 0 2.4739188475564333e-08
1 O 0 1.8527032352722017e-07
was O 0 1.4816356497249217e-07
as O 0 2.2493202855855543e-09
high O 0 1.2042161934289197e-08
as O 0 1.9849982768604946e-10
that O 0 9.000078460275063e-11
of O 0 5.770774968993919e-10
patients O 0 1.8617278829680117e-09
with O 0 1.029396123897186e-08
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.5227974653244019
( O 0 8.999349709881699e-09
AD B-Disease 0 0.00012184581282781437
) O 0 8.51849524252657e-09
. O 0 8.264526485390888e-08

His O 0 4.7238651745828975e-07
brain O 0 9.641587439546129e-07
magnetic O 0 1.1001994693060624e-07
resonance O 0 2.958386602358587e-08
image O 0 2.2524039522409112e-08
( O 0 1.1314759129632534e-09
MRI O 0 3.040350122773816e-07
) O 0 1.5413428866573042e-10
showed O 0 4.5463441900039925e-09
abnormalities B-Disease 0 9.971161674116047e-09
in I-Disease 0 3.9252284755875166e-10
the I-Disease 0 1.2738237131770802e-08
bilateral I-Disease 0 1.480128958064597e-06
cerebellar I-Disease 1 1.0
hemispheres I-Disease 1 0.9999713897705078
and O 0 7.545459652646969e-07
brain O 0 5.7130739151034504e-05
stem O 0 2.2270806709911994e-07
, O 0 2.6147758958039446e-10
but O 0 9.461263023036182e-11
not O 0 7.234608051520652e-11
in O 0 8.113856253544327e-10
the O 0 4.1029281305782206e-08
cerebral O 0 2.983597369166091e-06
white O 0 4.169875555959379e-09
matter O 0 8.412285090741989e-09
, O 0 1.1597798416085325e-10
where O 0 1.0315551191020234e-10
marked O 0 4.892243277154762e-10
reductions O 0 2.3453337050227674e-09
of O 0 4.838117906302841e-09
the O 0 3.3266854160274306e-08
cerebral O 0 9.264711025025463e-07
blood O 0 2.9118655930915338e-08
flow O 0 6.95292712293849e-08
and O 0 1.6807923941541958e-09
oxygen O 0 1.1667100174861389e-08
metabolism O 0 6.791668738515e-08
were O 0 9.546215373745781e-09
clearly O 0 1.1046568104688959e-08
demonstrated O 0 2.5184228036323475e-09
by O 0 8.59003645992118e-10
positron O 0 3.980238716394524e-07
emission O 0 1.5351193383139616e-07
tomography O 0 6.707462603117165e-07
( O 0 5.565605931678874e-08
PET O 0 7.148639269871637e-06
) O 0 2.9065166273767318e-08
. O 0 2.339304074894244e-07

In O 0 2.6440925893211897e-08
patients O 0 6.290580056855788e-09
2 O 0 2.389039188699371e-08
and O 0 9.013242374678043e-10
3 O 0 2.920860175947837e-08
, O 0 3.576873242039369e-10
the O 0 7.006705216028308e-10
autopsy O 0 4.23465493781805e-08
findings O 0 7.469622254063779e-09
showed O 0 5.038260475487277e-09
massive O 0 3.617156352220263e-08
demyelination B-Disease 1 1.0
of I-Disease 0 3.054228955079452e-06
the I-Disease 0 3.223856765544042e-06
cerebral I-Disease 0 5.691095066140406e-05
white I-Disease 0 2.656658448785265e-09
matter I-Disease 0 3.68848729337401e-10
with O 0 3.5084229358522956e-12
sparing O 0 4.667064956720424e-09
of O 0 1.8452546157732286e-08
the O 0 1.3146558330845437e-07
U O 0 1.6195746184166637e-06
- O 0 6.295858270277677e-07
fibers O 0 2.1592110499568662e-07
, O 0 8.759493130838791e-10
compatible O 0 4.5643817614404725e-09
with O 0 5.4870292337527715e-11
the O 0 5.128368840701114e-09
findings O 0 1.80230994573094e-08
of O 0 2.9246230326407385e-08
childhood O 0 0.0001695647370070219
ALD B-Disease 1 1.0
. O 0 6.7555524765339214e-06

Oleic O 0 0.00017757047316990793
and O 0 1.6691632254151045e-06
erucic O 0 0.0002273028512718156
acids O 0 8.339204214280471e-06
( O 0 4.547838017288086e-08
Lorenzos O 0 8.426177942055801e-07
Oil O 0 3.576897995571926e-07
) O 0 8.358602004987503e-11
were O 0 2.1393467553032508e-10
administered O 0 2.569218275627616e-11
to O 0 5.856776175150458e-11
patients O 0 1.507080016338591e-10
1 O 0 2.965107492869379e-09
and O 0 1.2869911802937395e-09
4 O 0 1.9532791384335724e-08
, O 0 1.4802269132641044e-10
but O 0 9.59637161401794e-11
sufficient O 0 1.5759706872842116e-09
effectiveness O 0 8.035008214335448e-09
was O 0 1.536091076559387e-08
not O 0 1.4442292917138388e-09
obtained O 0 4.945575255987933e-07
. O 0 8.083354146037891e-07

The O 0 1.4292779724200955e-06
findings O 0 1.5082957816048292e-07
in O 0 1.2495664503120452e-09
this O 0 5.652965318070358e-10
family O 0 1.6565878668828304e-09
suggest O 0 4.912431017523033e-10
that O 0 1.7397104590255452e-11
delGAG291 O 0 7.423377024196043e-09
is O 0 1.5004251313621708e-11
part O 0 2.4059735106995994e-11
of O 0 1.8781116939425857e-10
the O 0 5.186720497540875e-10
cause O 0 1.2213567934793446e-08
of O 0 1.3301799661746827e-08
Japanese O 0 1.0205731086898595e-06
ALD B-Disease 1 1.0
with O 0 7.193854956177859e-10
phenotypic O 0 1.8295406789547997e-07
variations O 0 1.4531904071191093e-06
. O 0 4.2428368374203274e-07

Moreover O 0 1.0675969406293007e-06
, O 0 1.7944025154648102e-09
although O 0 4.5349271560191085e-10
the O 0 4.988400803540571e-10
scale O 0 6.9060970275813816e-09
of O 0 5.2113553472565854e-09
the O 0 5.463506091984982e-09
study O 0 4.3532352722586154e-10
is O 0 3.8993409195997586e-11
limited O 0 5.663045032910929e-10
, O 0 3.2102906444286816e-10
there O 0 2.4551756183655016e-09
is O 0 1.0486099766282564e-09
a O 0 3.119264402329236e-09
possibility O 0 9.436710968202533e-08
that O 0 2.25156622235545e-08
PET O 0 4.148231710132677e-06
can O 0 8.04856803426901e-09
detect O 0 1.4704994555359008e-07
an O 0 8.851014854371897e-08
insidious B-Disease 0 4.487190381041728e-05
lesion I-Disease 1 0.9443787932395935
which O 0 2.8242139737955085e-09
is O 0 1.32836652788626e-09
undetectable O 0 2.338875226826076e-08
by O 0 2.485015526687562e-10
computed O 0 2.912083232331497e-07
tomogram O 0 9.18463683774462e-06
( O 0 4.0267948975269974e-08
CT O 0 3.769172508327756e-06
) O 0 7.660637679762772e-10
or O 0 2.1936219507523447e-09
MRI O 0 1.8257183853620518e-07
analysis O 0 3.1219011820127207e-09
, O 0 8.384069133393623e-11
and O 0 3.160795236656355e-11
that O 0 2.2450019274145028e-11
the O 0 4.3843498276352477e-10
higher O 0 5.104411560097333e-09
level O 0 4.950112320045719e-09
of O 0 1.4072371046225385e-09
tau O 0 8.821836594563592e-09
reflects O 0 6.233560778667879e-09
the O 0 8.674201912306501e-10
process O 0 5.730676377879718e-09
of O 0 2.1124495930280318e-08
neuronal B-Disease 0 0.0006997497985139489
degeneration I-Disease 1 0.9999504089355469
in O 0 4.921382696920773e-07
ALD B-Disease 1 1.0
. O 0 3.8124931052152533e-06

Lorenzos O 0 7.744285539956763e-05
Oil O 0 4.399417321110377e-06
should O 0 9.629672614863694e-10
be O 0 1.4787086832779295e-10
given O 0 2.908831786552213e-10
in O 0 2.8843680222045975e-10
the O 0 3.2930860260904637e-09
early O 0 1.0549180018415427e-07
stage O 0 1.7859116852037005e-08
. O 0 1.3084165750854027e-08
. O 0 1.682538908198694e-07

Nonsense O 0 4.43882163381204e-06
mutation O 0 6.899701787688173e-08
in O 0 3.570822082465952e-09
exon O 0 5.98207989810362e-08
4 O 0 1.7782544148303714e-07
of O 0 4.986110635485375e-09
human O 0 3.603760179160531e-09
complement O 0 5.894394305983042e-08
C9 O 0 5.77975224587135e-05
gene O 0 4.317630253325433e-09
is O 0 4.913667805972466e-10
the O 0 4.192882152587174e-10
major O 0 2.5524480307126396e-09
cause O 0 1.5489924010125833e-08
of O 0 1.3572539536710337e-08
Japanese O 0 1.181564243779576e-06
complement B-Disease 0 1.3859122191206552e-05
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.5488470792770386
. O 0 3.3969331525440793e-06

Deficiency B-Disease 0 1.2827693353756331e-05
of I-Disease 0 7.135847681638552e-06
the I-Disease 0 5.301346845953958e-07
ninth I-Disease 0 1.4628208191425074e-06
component I-Disease 0 4.317434942890941e-08
of I-Disease 0 2.5737822983984415e-09
human I-Disease 0 3.3275027178092387e-09
complement I-Disease 0 7.468656804121565e-08
( O 0 6.715268341395131e-09
C9 O 1 0.5117936730384827
) O 0 1.281366818206564e-10
is O 0 2.0249432339247697e-11
the O 0 3.922824565183447e-11
most O 0 1.0012392304137308e-10
common O 0 6.098062943493687e-09
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 8.937306894551966e-09
Japan O 0 7.129058676724753e-09
but O 0 8.036230569885561e-10
is O 0 9.667228823007079e-11
rare O 0 2.880772287383593e-10
in O 0 3.531939463119471e-10
other O 0 1.1898568796908648e-09
countries O 0 1.977803698594016e-09
. O 0 2.132110950014976e-07

We O 0 3.050421781836121e-08
studied O 0 2.3405085869399045e-08
the O 0 5.902556221570876e-10
molecular O 0 4.274170795071086e-09
basis O 0 1.1804381472302339e-08
of O 0 1.475495636782398e-08
C9 B-Disease 1 0.9999998807907104
deficiency I-Disease 0 6.734723865520209e-05
in O 0 7.840532845193593e-08
four O 0 1.2375893732041732e-07
Japanese O 0 4.1926814446924254e-06
C9 B-Disease 1 0.9995085000991821
- I-Disease 0 5.9861263252969366e-06
deficient I-Disease 0 7.589715522726692e-08
patients O 0 1.4052314867285531e-08
who O 0 5.456268326042846e-09
had O 0 3.992393526885962e-09
suffered O 0 1.5327523783525976e-07
from O 0 1.300933760717271e-08
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 2.2527954968154518e-07

Direct O 0 1.2685337935636198e-07
sequencing O 0 3.7370412542259146e-08
of O 0 8.904267900788909e-08
amplified O 0 1.8616759689393803e-07
C9 O 0 1.066883032763144e-05
cDNA O 0 5.727171981106949e-08
and O 0 4.128572594908064e-09
DNA O 0 4.5193974784751845e-08
revealed O 0 1.949192807160216e-08
a O 0 3.6225464850048184e-09
nonsense O 0 2.4172649659703893e-08
substitution O 0 4.001116593599363e-08
( O 0 3.2336633370988466e-09
CGA O 0 4.6342029236257076e-07
- O 0 6.030585097960284e-08
- O 0 4.6588581881223945e-08
> O 0 1.009362549098114e-08
TGA O 0 1.260842452666111e-07
) O 0 1.3102356699601359e-10
at O 0 1.8098254006559955e-09
codon O 0 3.37133343464302e-09
95 O 0 3.6105438638855958e-09
in O 0 3.551096361409378e-10
exon O 0 1.3625940376016388e-09
4 O 0 2.152709299707567e-08
in O 0 4.549770338257986e-09
the O 0 1.5096729555352795e-07
four O 0 1.3703372303552896e-07
C9 B-Disease 0 0.002291696611791849
- I-Disease 0 2.1766307327197865e-05
deficient I-Disease 0 8.372493311981088e-07
individuals O 0 1.8173222926520793e-08
. O 0 4.028524074328743e-07

An O 0 1.0690910556832023e-07
allele O 0 3.5188108427064435e-08
- O 0 9.179244031543021e-09
specific O 0 1.1121591425578004e-09
polymerase O 0 1.0023561536343095e-08
chain O 0 2.0910988496325444e-08
reaction O 0 1.4635692657805066e-08
system O 0 1.5515374540697735e-09
designed O 0 1.3764697159857064e-09
to O 0 1.5662308949782044e-10
detect O 0 5.058845564676062e-10
exclusively O 0 2.4285570776605425e-10
only O 0 3.020703825962201e-11
one O 0 7.109226402013391e-11
of O 0 7.025011683481353e-10
the O 0 3.9378211802443275e-09
normal O 0 7.228863729835666e-09
and O 0 2.6958799081988616e-10
mutant O 0 2.0057717708965583e-09
alleles O 0 5.256074464554672e-10
indicated O 0 1.7754839820582902e-09
that O 0 6.06120501012164e-11
all O 0 1.0438003933410656e-10
the O 0 7.76474495811641e-10
four O 0 1.215040151825164e-10
patients O 0 4.23594145870787e-11
were O 0 2.1381475756587776e-10
homozygous O 0 3.1299129954476257e-10
for O 0 7.48856199273007e-10
the O 0 1.5710494238874162e-08
mutation O 0 3.757509858814956e-09
in O 0 7.017672554177068e-10
exon O 0 4.323844393638865e-09
4 O 0 3.44424790910125e-08
and O 0 1.0803169470108287e-09
that O 0 2.823178357758138e-10
the O 0 6.795139118054294e-09
parents O 0 2.988579606011399e-09
of O 0 2.85646417630403e-09
patient O 0 3.2318689946464474e-09
2 O 0 9.290851465948435e-08
were O 0 3.407609483474516e-08
heterozygous O 0 2.679842054931214e-07
. O 0 1.442109919480572e-06

The O 0 5.7901296202089725e-08
common O 0 2.843067292701562e-08
mutation O 0 3.5653386021294864e-08
at O 0 1.3944926990916429e-08
codon O 0 6.283939768536584e-08
95 O 0 3.520381852695209e-08
in O 0 2.7873952035406546e-09
exon O 0 1.0237783953925828e-08
4 O 0 4.996938329782097e-08
might O 0 4.18225365450553e-09
be O 0 1.177941078012168e-09
responsible O 0 6.563711241192038e-10
for O 0 4.382844642769612e-10
most O 0 7.302714433166102e-09
Japanese O 0 2.633704752952326e-06
C9 B-Disease 1 0.8499372005462646
deficiency I-Disease 0 8.39970562083181e-06
. O 0 7.839351212624024e-08
. O 0 3.1250490906131745e-07

BRCA1 O 0 1.104254351957934e-06
required O 0 2.98221500827367e-08
for O 0 1.0773831604637962e-08
transcription O 0 7.033154815871967e-06
- O 0 1.3041920283285435e-05
coupled O 0 4.572279522108147e-06
repair O 0 4.1392022467334755e-06
of O 0 1.1343844619204901e-07
oxidative O 0 1.0300058420398273e-05
DNA O 0 0.00010673183714970946
damage O 1 0.9999971389770508
. O 0 2.2540430109074805e-06

The O 0 2.558811729613808e-06
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 1.8708455229443643e-07
gene O 0 1.838372654106024e-08
BRCA1 O 0 6.572336275212365e-08
encodes O 0 5.1187920568906975e-09
a O 0 8.881094082369145e-09
zinc O 0 1.2771802460065373e-07
finger O 0 8.962301478732115e-08
protein O 0 2.0607858175480942e-07
of O 0 1.3420689981558098e-07
unknown O 0 1.9608046386565547e-06
function O 0 3.505673973336343e-08
. O 0 1.0929022664640797e-07

Association O 0 1.2736132930513122e-06
of O 0 9.137478400589316e-07
the O 0 7.168999900386552e-07
BRCA1 O 0 7.29465767790316e-08
protein O 0 1.138338490136448e-08
with O 0 1.5426487864900196e-10
the O 0 3.1613351936243816e-09
DNA O 0 2.989904146488698e-08
repair O 0 2.987578682223102e-07
protein O 0 5.230652391219337e-07
Rad51 O 0 2.3455478981304623e-07
and O 0 3.5783748186801745e-10
changes O 0 1.795079362931773e-10
in O 0 1.1473923200444602e-10
the O 0 2.641624974319967e-10
phosphorylation O 0 1.1461680493596305e-09
and O 0 1.3090742378984999e-10
cellular O 0 1.765279367127448e-09
localization O 0 8.467100798270621e-08
of O 0 6.941002794746964e-08
the O 0 4.331440450755508e-08
protein O 0 7.144634395217508e-08
after O 0 1.2445078745315641e-08
exposure O 0 2.0033104064509644e-08
to O 0 2.949426702869573e-09
DNA O 0 1.4550916205280373e-07
- O 0 1.3325929160146188e-07
damaging O 0 3.1575285674989573e-07
agents O 0 3.6734926212034225e-09
are O 0 8.920047339655568e-11
consistent O 0 3.0564071273886384e-09
with O 0 1.0435829284061171e-11
a O 0 2.73842781783884e-10
role O 0 6.108769601276265e-10
for O 0 2.377532837272156e-09
BRCA1 O 0 2.2893459572514985e-07
in O 0 1.834250085153144e-08
DNA O 0 1.5418596603922197e-06
repair O 0 4.946687477058731e-05
. O 0 4.923475898976903e-06

Here O 0 3.7446122291839856e-07
, O 0 3.1270501743563273e-09
it O 0 1.0386726201350172e-10
is O 0 2.2600950624895866e-11
shown O 0 1.184559811351349e-10
that O 0 1.3758076622405468e-10
mouse O 0 7.899792819898721e-09
embryonic O 0 2.0772934306023672e-07
stem O 0 6.216583869900205e-07
cells O 0 1.473077873015427e-07
deficient B-Disease 0 1.4714758833633823e-07
in I-Disease 0 7.44725880963415e-09
BRCA1 I-Disease 0 5.8191702123622235e-08
are O 0 2.9056376749103663e-10
defective O 0 3.7481488135426844e-08
in O 0 3.2406526351280718e-09
the O 0 1.035014918215893e-08
ability O 0 6.437089195010515e-10
to O 0 1.1597538485119685e-09
carry O 0 7.905219590043089e-09
out O 0 6.124277973640346e-09
transcription O 0 4.844852696805901e-07
- O 0 1.6239298474829411e-06
coupled O 0 3.219466179871233e-06
repair O 0 3.2012037536333082e-06
of O 0 2.4117346697494213e-07
oxidative O 0 9.01118482943275e-07
DNA O 0 1.8976388673763722e-06
damage O 0 0.26310092210769653
, O 0 9.77416192426972e-09
and O 0 2.8212958635975838e-09
are O 0 9.713533311028755e-10
hypersensitive O 0 7.985150318745582e-07
to O 0 6.435855226527565e-08
ionizing O 0 6.544341158587486e-05
radiation O 0 6.300078530330211e-05
and O 0 2.425828071750402e-08
hydrogen O 0 1.2487907952163368e-07
peroxide O 0 1.7273260937145096e-06
. O 0 3.134827579742705e-07

These O 0 8.996092049073923e-08
results O 0 3.336026850320195e-07
suggest O 0 2.9457129357979284e-07
that O 0 4.743230874737492e-08
BRCA1 O 0 5.155018243385712e-07
participates O 0 3.6637750611134834e-08
, O 0 1.7658721152002954e-09
directly O 0 7.776220556365843e-09
or O 0 3.999375053354015e-09
indirectly O 0 4.9991310646646525e-08
, O 0 5.302382977134812e-10
in O 0 7.391640632903318e-10
transcription O 0 4.202069590064639e-07
- O 0 8.319706239490188e-07
coupled O 0 1.0886056998060667e-06
repair O 0 2.139554680979927e-06
of O 0 1.653527306189062e-07
oxidative O 0 2.58610134551418e-06
DNA O 0 8.682386578584556e-06
damage O 0 0.22497974336147308
. O 0 1.2711568331269518e-07
. O 0 2.494102488981298e-07

Truncation O 0 6.281569767452311e-06
mutations O 0 1.1411475497880019e-07
in O 0 2.5504527378927833e-09
the O 0 3.766119860415529e-09
transactivation O 0 1.0952107913908549e-06
region O 0 2.7107427413852747e-08
of O 0 5.5424379752366804e-08
PAX6 O 0 4.5084649173077196e-05
result O 0 4.6565838829337736e-07
in O 0 6.637339566850642e-08
dominant O 0 0.004275862593203783
- O 0 4.813067789655179e-06
negative O 0 2.588949143955688e-07
mutants O 0 1.5806924125172372e-07
. O 0 1.23836144894085e-07

PAX6 O 0 0.0028916860464960337
is O 0 3.142765692132343e-08
a O 0 7.541571811486847e-09
transcription O 0 4.0628695074929055e-08
factor O 0 1.305382824057233e-08
with O 0 3.448977492492844e-10
two O 0 1.082462008916707e-09
DNA O 0 1.4184263541494602e-08
- O 0 1.7723381873224753e-08
binding O 0 4.442216550160083e-08
domains O 0 2.0268133482659323e-07
( O 0 9.500549680296899e-09
paired O 0 8.375829807505397e-09
box O 0 1.3649253283176677e-08
and O 0 7.50285888972968e-10
homeobox O 0 2.854254610440421e-08
) O 0 9.514811161182024e-11
and O 0 5.760151799982793e-10
a O 0 7.82320075387588e-09
proline O 0 5.687221715788837e-08
- O 0 5.514978056453401e-07
serine O 0 1.0406728989664771e-07
- O 0 1.02386036360258e-06
threonine O 0 2.3264314563675725e-07
( O 0 5.545089276637327e-09
PST O 0 7.339144303841749e-06
) O 0 3.5904776929385207e-09
- O 0 2.5852179064145275e-08
rich O 0 1.992533782413375e-08
transactivation O 0 2.071352128041326e-06
domain O 0 3.795211398482934e-07
. O 0 2.7942854785578675e-07

PAX6 O 1 0.9871631264686584
regulates O 0 5.452747063827701e-05
eye O 1 0.7023604512214661
development O 0 1.6160615246008092e-07
in O 0 5.031439154201678e-10
animals O 0 3.3618410832936263e-10
ranging O 0 3.0926594618563286e-09
from O 0 2.1566699537345357e-09
jellyfish O 0 3.5006991749853e-10
to O 0 6.015266618142334e-10
Drosophila O 0 2.920652386606548e-09
to O 0 7.69768027097939e-10
humans O 0 2.1675994332781556e-08
. O 0 2.349705567894489e-07

Heterozygous O 0 2.3248966840583307e-07
mutations O 0 2.1823143470101058e-07
in O 0 3.3247302688721447e-09
the O 0 4.369224981815023e-09
human O 0 1.2189247833305217e-08
PAX6 O 0 8.570063073420897e-06
gene O 0 1.163949470139869e-08
result O 0 1.898332158134508e-08
in O 0 1.7668481955279702e-10
various O 0 5.310398787372606e-10
phenotypes O 0 2.7653145551198577e-08
, O 0 1.3423590017325182e-10
including O 0 2.7972574256907023e-10
aniridia B-Disease 1 1.0
, O 0 2.3513637259497955e-08
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 2.6710997858003793e-08
autosomal B-Disease 0 8.474583410134073e-06
dominant I-Disease 0 1.1477432963147294e-05
keratitis I-Disease 1 0.9999998807907104
, O 0 1.7437027821642914e-08
and O 0 9.272670098425806e-08
familial B-Disease 1 0.9999998807907104
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.1814012974500656

It O 0 8.256157535413422e-09
is O 0 5.198129704453436e-10
believed O 0 6.582089873141683e-10
that O 0 7.002262918803792e-12
the O 0 9.595035876941438e-11
mutated O 0 1.186962883537035e-08
allele O 0 2.1558156149126262e-08
of O 0 1.6962681925747347e-08
PAX6 O 0 4.298267958802171e-05
produces O 0 4.2192159099840865e-08
an O 0 3.305054230295923e-09
inactive O 0 3.1439405745459226e-08
protein O 0 4.4527350695489076e-08
and O 0 3.3352736128478e-09
aniridia B-Disease 1 1.0
is O 0 3.815168181375839e-09
caused O 0 3.838424333935109e-08
due O 0 1.0409026529600851e-08
to O 0 3.658696456909638e-09
genetic O 0 2.59300622929004e-06
haploinsufficiency O 0 4.5905304432380944e-05
. O 0 6.733097848155012e-07

However O 0 9.214626857101393e-07
, O 0 1.6902836463827953e-08
several O 0 1.3684392285995273e-08
truncation O 0 6.531907388307445e-07
mutations O 0 6.164289345633733e-08
have O 0 5.542252767831712e-10
been O 0 2.9990968042348243e-10
found O 0 5.491772314680787e-11
to O 0 3.254481059644654e-11
occur O 0 2.742682747580716e-10
in O 0 1.4172890638874946e-10
the O 0 7.475266627920973e-09
C O 0 1.498368931152072e-07
- O 0 1.0403390149349434e-08
terminal O 0 2.8944119989660066e-08
half O 0 3.993779973399114e-09
of O 0 5.2507562742221126e-09
PAX6 O 0 3.775248842430301e-07
in O 0 2.9026686609867625e-10
patients O 0 4.714948431683297e-10
with O 0 6.757073234275879e-10
Aniridia B-Disease 1 1.0
resulting O 0 1.328882035522838e-07
in O 0 1.506184177380021e-09
mutant O 0 9.23584675405209e-09
proteins O 0 2.763720585718943e-09
that O 0 5.811244818687555e-10
retain O 0 1.3403340659579044e-08
the O 0 1.202082557938411e-07
DNA O 0 7.325959927584336e-08
- O 0 2.349247729682702e-08
binding O 0 2.312411417904059e-08
domains O 0 2.4120376806990862e-08
but O 0 5.254633173024104e-09
have O 0 1.19412890686732e-09
lost O 0 4.519647589518172e-08
most O 0 2.8836544263555197e-09
of O 0 1.1984282899391019e-08
the O 0 4.603114334145175e-08
transactivation O 0 3.12873976326955e-06
domain O 0 9.67939854490396e-07
. O 0 9.193533969664713e-07

It O 0 4.993137281417148e-08
is O 0 1.2511451874530621e-09
not O 0 2.470125215481289e-10
clear O 0 5.31515365054247e-09
whether O 0 2.1935665783789915e-10
such O 0 6.99560853689718e-10
mutants O 0 7.207114549601101e-08
really O 0 1.2193899223689186e-08
behave O 0 3.6855918317257874e-09
as O 0 5.85450354861905e-09
loss O 0 3.0632723024837105e-08
- O 0 3.528394643126376e-08
of O 0 6.79913398471399e-07
- O 0 2.2117164633073116e-07
function O 0 2.504483287424364e-09
mutants O 0 3.2090128332384893e-09
as O 0 9.08130015631059e-10
predicted O 0 1.005908956130952e-08
by O 0 2.7045592432273224e-09
haploinsufficiency O 0 3.0292874726001173e-05
. O 0 1.5615975144100958e-06

Contrary O 0 2.0836912426602794e-06
to O 0 2.5990349872273555e-09
this O 0 9.5815988476744e-10
theory O 0 1.0194452215728234e-07
, O 0 1.0704878095069148e-09
our O 0 1.990663855977459e-09
data O 0 7.336695695414619e-09
showed O 0 1.2902411583581852e-08
that O 0 1.552400985538327e-10
these O 0 5.584890327980929e-10
mutants O 0 2.633367301996259e-08
are O 0 1.2295650053673057e-09
dominant O 0 1.9139842777349259e-07
- O 0 8.794758343810827e-08
negative O 0 1.5439161060726292e-08
in O 0 1.3185872393961517e-09
transient O 0 6.018589004952446e-08
transfection O 0 1.3892361927503316e-08
assays O 0 3.4158784689708455e-09
when O 0 7.506413268743017e-09
they O 0 2.5769359979221917e-09
are O 0 1.6346169973147084e-09
coexpressed O 0 1.3517583283828571e-06
with O 0 6.102693905774004e-09
wild O 0 7.346528718699119e-07
- O 0 8.490774803249224e-07
type O 0 1.5744864185762708e-06
PAX6 O 0 0.00016936793690547347
. O 0 2.830973471645848e-06

We O 0 1.25071633050311e-08
found O 0 2.9387632327626534e-09
that O 0 1.8363627285467032e-10
the O 0 4.00261868094276e-09
dominant O 0 1.9702410725130903e-07
- O 0 1.9667112383103813e-08
negative O 0 3.5285072641499937e-09
effects O 0 2.5751425436482123e-09
result O 0 2.5978652562486104e-09
from O 0 3.644071044917041e-09
the O 0 3.2625890877824304e-09
enhanced O 0 1.4060619335509728e-09
DNA O 0 3.955979099856677e-09
binding O 0 4.518145413356933e-09
ability O 0 7.023380543813573e-09
of O 0 7.308681659878857e-08
these O 0 1.3857640368541979e-08
mutants O 0 8.737855523577309e-07
. O 0 4.2180732862107106e-07

Kinetic O 0 1.878797888821282e-06
studies O 0 2.5145169502138742e-08
of O 0 1.9086858760175573e-09
binding O 0 3.902901557495397e-09
and O 0 1.9415704599623496e-09
dissociation O 0 3.1717373616402256e-08
revealed O 0 2.2332338200925506e-09
that O 0 2.8160243234487403e-11
various O 0 4.543186382655051e-10
truncation O 0 1.103339073438292e-07
mutants O 0 1.4813156923310089e-08
have O 0 9.063304551304441e-10
3 O 0 1.2777414681863775e-08
- O 0 5.606708874950073e-09
5 O 0 4.682983956172393e-08
- O 0 1.546040628852552e-08
fold O 0 3.1205214412466376e-08
higher O 0 1.6858821894061293e-08
affinity O 0 1.3620898853261565e-09
to O 0 1.1503138441781857e-09
various O 0 2.220025940857795e-09
DNA O 0 2.068628823792551e-09
- O 0 6.707444044629085e-10
binding O 0 5.852869855438314e-10
sites O 0 4.85446971509873e-09
when O 0 5.303778527476766e-10
compared O 0 7.1575995130857e-10
with O 0 4.178071430493979e-11
the O 0 1.1439234448573643e-08
wild O 0 2.637217377809975e-08
- O 0 6.226456861213592e-08
type O 0 2.510808201350301e-07
PAX6 O 0 4.651492417906411e-05
. O 0 1.4276922684075544e-06

These O 0 1.5425619892539544e-08
results O 0 1.2458996501152342e-08
provide O 0 1.999881149572502e-09
a O 0 1.342236766177507e-09
new O 0 2.7415230086091924e-09
insight O 0 8.284724906104657e-09
into O 0 6.825804366172861e-10
the O 0 1.1504345254209625e-09
role O 0 7.668766732749077e-10
of O 0 3.4782183799819677e-09
mutant O 0 1.2106673352718644e-07
PAX6 O 0 2.2455109501606785e-05
in O 0 3.0126987127232496e-08
causing O 0 3.5984023725177394e-06
aniridia B-Disease 1 1.0
. O 0 2.0956710500286135e-07
. O 0 3.5446112178760814e-07

Reversal O 0 4.195569545117905e-06
of O 0 9.780487886246192e-08
severe O 0 0.015804767608642578
hypertrophic B-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
and O 0 1.5424450339196483e-07
excellent O 0 6.239771721539e-08
neuropsychologic O 0 6.673494226561161e-06
outcome O 0 3.2037662549555534e-06
in O 0 1.5902475780649183e-08
very B-Disease 0 4.6014992705067925e-08
- I-Disease 0 1.7839855104284652e-07
long I-Disease 0 1.6328610286109324e-07
- I-Disease 0 1.204026034429262e-07
chain I-Disease 0 1.2022637463360297e-07
acyl I-Disease 0 4.732432330456504e-07
- I-Disease 0 3.913183377335372e-07
coenzyme I-Disease 0 4.9087361730926204e-08
A I-Disease 0 1.0389913768449333e-05
dehydrogenase I-Disease 0 1.816121039155405e-05
deficiency I-Disease 0 0.0011219489388167858
. O 0 6.86416854023264e-07

Very B-Disease 0 2.403861572020105e-06
- I-Disease 0 4.2484593905101065e-06
long I-Disease 0 3.113468096671568e-07
- I-Disease 0 7.332628371159444e-08
chain I-Disease 0 2.1568931529714064e-08
acyl I-Disease 0 5.483365228542425e-08
- I-Disease 0 3.4020812833546188e-09
coenzyme I-Disease 0 7.626799747306734e-10
A I-Disease 0 1.8408954360893404e-08
dehydrogenase I-Disease 0 2.9715121030449154e-08
( I-Disease 0 2.346107530470931e-09
VLCAD I-Disease 0 6.933930126251653e-05
) I-Disease 0 1.938150612224021e-10
deficiency I-Disease 0 2.5348318999363073e-09
is O 0 2.121143018174454e-11
a O 0 1.7470767887939331e-10
disorder O 0 2.555091487010941e-05
of O 0 8.226965292124078e-06
fatty O 0 8.788081231614342e-07
acid O 0 1.1513175302013678e-08
beta O 0 5.158021787465827e-10
oxidation O 0 1.1759745399686494e-09
that O 0 1.3489655226184283e-10
reportedly O 0 3.893436684165863e-09
has O 0 5.415867407321251e-11
high O 0 1.3240916141299408e-09
rates O 0 3.0782059123879435e-09
of O 0 3.370201895336322e-09
morbidity O 0 1.1578773410292342e-05
and O 0 1.0471279665580369e-07
mortality O 0 1.181419338536216e-05
. O 0 6.567811396962497e-07

We O 0 3.925103797541851e-09
describe O 0 5.743304054561804e-09
the O 0 2.99266389447439e-09
outcome O 0 4.686692278710325e-08
of O 0 8.80173445239052e-09
a O 0 2.674820365200503e-09
5 O 0 9.592795002788534e-09
- O 0 2.069244331437403e-09
year O 0 6.1629350511793746e-09
- O 0 3.218227107026905e-08
old O 0 9.73847136265249e-07
girl O 0 2.365682405525149e-08
with O 0 2.6429818333895128e-09
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 3.282076477262308e-08
was O 0 5.427061466889427e-09
first O 0 5.91133308969205e-10
seen O 0 1.8620545105818564e-09
at O 0 6.306771216380014e-10
5 O 0 1.2956163919497499e-09
months O 0 3.5653419105941e-10
of O 0 1.4085796973262177e-09
age O 0 1.4897850064699014e-08
with O 0 5.098385602586575e-10
severe O 0 7.3042047006310895e-06
hypertrophic B-Disease 1 0.9999936819076538
cardiomyopathy I-Disease 1 1.0
, O 0 3.2198659027926624e-05
hepatomegaly B-Disease 1 1.0
, O 0 5.1982765398861375e-06
encephalopathy B-Disease 1 0.8373903632164001
, O 0 5.435994410163403e-08
and O 0 1.0610646938857826e-07
hypotonia B-Disease 0 0.001742830267176032
. O 0 4.6442287384707015e-06

Biochemical O 0 7.918719347799197e-06
studies O 0 7.587050845359045e-07
indicated O 0 2.782718001981266e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 1.2710905821222696e-06
by O 0 7.392401690786699e-10
a O 0 1.9267707429548864e-08
stable O 0 3.4858960589190247e-06
yet O 0 3.194011100049465e-08
inactive O 0 1.7233132609817403e-07
enzyme O 0 2.2525550491536706e-07
. O 0 2.6123515795006824e-07

Molecular O 0 2.6467523639439605e-07
genetic O 0 3.822847460810408e-08
analysis O 0 2.379434782540102e-08
of O 0 4.825936628094496e-08
her O 0 6.033254607018534e-08
VLCAD O 1 0.9967647790908813
gene O 0 8.884148172683126e-08
revealed O 0 1.1845366998386453e-07
a O 0 7.686240088844443e-09
T1372C O 0 1.1861735771390158e-07
( O 0 1.4236160028602285e-09
F458L O 0 8.946315688262985e-08
) O 0 4.598125769028627e-10
missense O 0 1.4261584624364332e-07
mutation O 0 2.6559098031953e-08
and O 0 6.3584102427682865e-09
a O 0 1.6547230075047992e-07
1668 O 0 0.00036719904164783657
ACAG O 1 0.9995594620704651
1669 O 0 0.00028208864387124777
splice O 0 0.00015170125698205084
site O 0 8.579188943258487e-06
mutation O 0 1.7036289818861405e-06
. O 0 8.756475153859355e-07

After O 0 8.733126577453731e-08
initial O 0 7.272443980355092e-08
treatment O 0 1.521871340059988e-08
with O 0 5.439795280892668e-10
intravenous O 0 3.141087745461846e-08
glucose O 0 9.851351734369018e-08
and O 0 2.157966028093483e-09
carnitine O 0 7.262130452545534e-08
, O 0 4.3559345019872353e-10
the O 0 2.800547349579574e-09
patient O 0 7.423773595860439e-09
has O 0 6.657366324880343e-10
thrived O 0 2.41565185632453e-08
on O 0 2.3020696460207546e-08
a O 0 5.920377077472949e-08
low O 0 1.3660813920068904e-06
- O 0 1.9874595125202177e-07
fat O 0 1.637080231375876e-07
diet O 0 1.3581525237782444e-08
supplemented O 0 3.2625391277463223e-09
with O 0 2.505408658315389e-10
medium O 0 1.7960613263312553e-07
- O 0 8.376552074196297e-08
chain O 0 1.1154359924603341e-07
triglyceride O 0 6.806873784626077e-07
oil O 0 7.376984854090551e-07
and O 0 3.759344835430056e-09
carnitine O 0 7.957549286174981e-08
and O 0 1.5897283489607617e-09
avoidance O 0 1.984747086680727e-07
of O 0 3.267435886300518e-07
fasting O 0 1.82645646873425e-06
. O 0 1.0840473123607808e-06

Her O 0 3.7012230222899234e-06
ventricular O 1 0.9993950128555298
hypertrophy O 1 0.9999451637268066
resolved O 0 1.4070170664126636e-06
significantly O 0 5.357436805297766e-08
over O 0 1.614747557887597e-09
1 O 0 4.1097791836364195e-09
year O 0 7.392260137351059e-10
, O 0 1.1569253888232822e-10
and O 0 2.1746288103585698e-10
cognitively O 0 5.456531226855077e-08
, O 0 1.919770342695415e-09
she O 0 1.6961185789199362e-09
is O 0 1.9415064000938287e-10
in O 0 4.4971820711836585e-10
the O 0 9.654763211131012e-09
superior O 0 3.5440129408925714e-07
range O 0 1.4767462630516093e-07
for O 0 1.4852794549824466e-08
age O 0 4.751271717395866e-06
. O 0 1.5839988236621139e-06

Clinical O 0 5.815192594127438e-07
recognition O 0 1.8585640646051615e-05
of O 1 1.0
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 8.163317133380588e-09
important O 0 2.22988849607475e-09
because O 0 1.5234931372010152e-10
it O 0 2.189744739700128e-11
is O 0 1.3850538771453813e-11
one O 0 8.53966827807362e-11
of O 0 1.8235748466821633e-09
the O 0 6.543564801120283e-09
few O 0 1.536600890972295e-08
directly O 0 3.454623254128819e-08
treatable O 0 8.889197488315403e-06
causes O 0 8.220334279940289e-08
of O 0 1.906587421274253e-08
cardiomyopathy B-Disease 1 1.0
in O 0 4.100252581906716e-08
children O 0 2.309775481990073e-08
. O 0 8.379441140959898e-09
. O 0 8.982787136346815e-08

Cloning O 0 2.3887210431894346e-07
of O 0 8.748047974904694e-08
a O 0 4.264065989190158e-09
novel O 0 9.103503728624673e-09
member O 0 2.6449586965071603e-09
of O 0 2.8246088135119862e-08
the O 0 2.762005237855192e-07
low O 0 1.7430697880627122e-06
- O 0 7.467260587645796e-08
density O 0 6.239105942995593e-08
lipoprotein O 0 2.970130594803777e-07
receptor O 0 0.0002087956527248025
family O 0 2.231349571957253e-05
. O 0 1.57578131165792e-06

A O 0 7.054853199406352e-07
gene O 0 1.758468570756122e-08
encoding O 0 3.3393746434740024e-08
a O 0 4.278137311075625e-08
novel O 0 2.8929440176739263e-08
transmembrane O 0 9.014793356243445e-09
protein O 0 1.0151044449457913e-08
was O 0 2.204052274024093e-09
identified O 0 6.020440396214966e-11
by O 0 8.702232510982011e-12
DNA O 0 1.1053574722197368e-10
sequence O 0 3.6369428302318596e-11
analysis O 0 2.4583548738355e-11
within O 0 4.22682132350527e-11
the O 0 6.909005589861295e-10
insulin B-Disease 0 0.00011041632387787104
- I-Disease 0 0.0006869555218145251
dependent I-Disease 1 0.9151760339736938
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 1.5783991003104347e-08
IDDM B-Disease 0 2.8366155675030313e-05
) O 0 3.6582337159529743e-10
locus O 0 2.1987043297144737e-08
IDDM4 O 0 1.2826200872950722e-05
on O 0 9.814760204562845e-08
chromosome O 0 3.930305183530436e-07
11q13 O 0 6.8010285758646205e-06
. O 0 1.3531797549148905e-06

Based O 0 1.3110874874655565e-07
on O 0 2.8191347922756904e-08
its O 0 1.3149104027831982e-09
chromosomal O 0 4.0028274383985263e-07
position O 0 3.156136926918407e-06
, O 0 1.0384629822723923e-09
this O 0 1.0622175361518771e-10
gene O 0 5.227440702526565e-10
is O 0 2.33141700389794e-10
a O 0 2.35091307532187e-10
candidate O 0 1.1033044478026e-09
for O 0 2.333329918169369e-10
conferring O 0 9.353848895443662e-08
susceptibility O 0 1.0295776519342326e-05
to O 0 3.6646213175117737e-07
diabetes B-Disease 1 1.0
. O 0 3.0349899589054985e-06

The O 0 4.985229224985233e-07
gene O 0 1.637686182220932e-07
, O 0 3.338763221449881e-08
termed O 0 2.97874834132017e-07
low O 0 5.559971327784297e-07
- O 0 9.051837501772297e-09
density O 0 1.3888089567259954e-09
lipoprotein O 0 1.586146147758427e-08
receptor O 0 8.541586282717617e-08
related O 0 3.588726471548398e-08
protein O 0 1.8862202466607414e-07
5 O 0 3.7697578392226205e-08
( O 0 6.131790075691868e-10
LRP5 O 0 5.627721293421928e-07
) O 0 1.9710229975933302e-11
, O 0 1.8114882857633852e-11
encodes O 0 1.6311209327657394e-11
a O 0 9.653373239659757e-11
protein O 0 7.538322854827584e-09
of O 0 2.450124725328351e-08
1615 O 0 1.2307903034525225e-06
amino O 0 1.356933552187911e-07
acids O 0 1.7782738837013312e-08
that O 0 2.33841779273547e-10
contains O 0 1.0994825883070547e-10
conserved O 0 3.455232489013582e-10
modules O 0 4.17265631769137e-11
which O 0 3.039429125051285e-11
are O 0 1.0783147812165605e-11
characteristic O 0 1.1301866997825982e-08
of O 0 1.3948224797388775e-08
the O 0 3.277210112173634e-07
low O 0 2.3150269043981098e-05
- O 0 1.07446294350666e-06
density O 0 9.650271977079683e-07
lipoprotein O 0 2.3386444354400737e-06
( O 0 1.1425091770433937e-06
LDL O 0 3.712746183737181e-05
) O 0 2.7879549335807496e-08
receptor O 0 7.196755632321583e-06
family O 0 2.8245935368431674e-07
. O 0 8.999026590572612e-08

These O 0 1.7164172305683678e-08
modules O 0 9.419965252277507e-09
include O 0 6.467597568615702e-10
a O 0 5.050594609201653e-09
putative O 0 3.435456790157332e-07
signal O 0 2.5791992541712716e-08
peptide O 0 1.0329989086343971e-09
for O 0 1.5459712676690884e-10
protein O 0 7.49233830532603e-09
export O 0 3.955166150149125e-08
, O 0 3.406273874073662e-10
four O 0 9.85472592418546e-10
epidermal O 0 3.607283005635509e-08
growth O 0 1.820468931157393e-08
factor O 0 2.3839138663106496e-08
( O 0 1.1399202470840919e-08
EGF O 0 1.7507497886981582e-06
) O 0 1.2755833056488086e-09
repeats O 0 4.074819148769393e-09
with O 0 7.327654455435706e-11
associated O 0 1.9035205411910283e-08
spacer O 0 1.9656768301956618e-07
domains O 0 7.241134625246559e-08
, O 0 9.885718021962475e-09
three O 0 1.4890463084782368e-08
LDL O 0 1.0397269534223597e-06
- O 0 1.184841039503226e-06
receptor O 0 5.088257694296772e-06
( O 0 1.0845978692941571e-07
LDLR O 0 0.43241560459136963
) O 0 6.042934486139018e-10
repeats O 0 2.7320123940910435e-09
, O 0 5.951582976448933e-11
a O 0 3.569703699302096e-10
single O 0 1.0657694726745603e-09
transmembrane O 0 9.356469377053145e-09
spanning O 0 6.229379323485773e-08
domain O 0 7.017116843144322e-08
, O 0 1.243826819319338e-08
and O 0 7.529528112115713e-09
a O 0 1.0009274831190851e-07
cytoplasmic O 0 4.881230779574253e-06
domain O 0 7.74171098782972e-07
. O 0 1.1094286946899956e-06

The O 0 3.1840482961342786e-07
encoded O 0 2.8023654508047002e-08
protein O 0 4.128772275180381e-07
has O 0 5.196444385902055e-10
a O 0 2.400208642949764e-10
unique O 0 8.481219615497082e-10
organization O 0 7.07617076045608e-09
of O 0 5.945952707975266e-08
EGF O 0 0.018470467999577522
and O 0 2.046802364930045e-06
LDLR O 1 0.9999992847442627
repeats O 0 3.0192774147508317e-07
; O 0 7.074605345991358e-09
therefore O 0 1.936833271543037e-08
, O 0 2.4826907196739967e-09
LRP5 O 0 0.0023124536965042353
likely O 0 6.035855193431416e-08
represents O 0 8.50273362829057e-09
a O 0 1.681731975899936e-09
new O 0 2.5782633805704336e-09
category O 0 1.640327162988342e-08
of O 0 2.7462293772373414e-08
the O 0 4.161130959801085e-07
LDLR O 0 0.0020324878860265017
family O 0 1.2752308293784154e-06
. O 0 1.2422772215359146e-06

Both O 0 3.0067005241107836e-07
human O 0 6.170642450342712e-07
and O 0 5.399599345423667e-08
mouse O 0 9.036919124127962e-08
LRP5 O 0 4.834914579987526e-05
cDNAs O 0 2.1649101711318508e-07
have O 0 3.210229304606571e-10
been O 0 7.43377304157633e-10
isolated O 0 6.213972891799813e-09
and O 0 8.827857889137647e-10
the O 0 1.3719568592307496e-08
encoded O 0 3.0098830094971163e-09
mature O 0 9.070537210220664e-09
proteins O 0 7.478085928269707e-10
are O 0 7.944298691109353e-11
95 O 0 9.651744292682451e-09
% O 0 8.750175584104625e-10
identical O 0 1.2059188092550244e-09
, O 0 1.6676765524081816e-10
indicating O 0 3.555971517243961e-09
a O 0 8.651201977016854e-10
high O 0 1.676506045100723e-08
degree O 0 1.3166433632250119e-07
of O 0 1.3053953473729507e-08
evolutionary O 0 2.0881599027688935e-07
conservation O 0 1.2083258127404406e-07
. O 0 1.9075802271117936e-08
. O 0 3.098710408266925e-07

The O 0 2.93927450911724e-06
APC B-Disease 0 1.1281900924586807e-06
variants O 0 1.230333168678044e-07
I1307K O 0 9.723827361085569e-07
and O 0 6.54932064136915e-09
E1317Q O 0 2.7610411734713125e-07
are O 0 5.184722651208062e-10
associated O 0 8.315827244587126e-07
with O 0 0.0011122084688395262
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.2057398957618943e-09
but O 0 1.0912010878216805e-10
not O 0 6.574332744868627e-11
always O 0 3.872571152641058e-10
with O 0 4.860181354593429e-11
a O 0 4.664270747412047e-09
family O 0 2.562449097354147e-08
history O 0 2.572942605638673e-07
. O 0 3.82980289259649e-07

Classical O 1 0.9999850988388062
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 3.2234752325166482e-06
FAP B-Disease 0 3.5670843772095395e-06
) O 0 1.8352176722746805e-10
is O 0 4.2785549408952406e-11
a O 0 3.455669306262621e-09
high O 1 1.0
- O 1 1.0
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
that O 0 7.917312638827667e-11
predisposes O 0 7.143705182954818e-09
to O 0 1.0412591622266376e-10
hundreds O 0 7.318872174977287e-10
or O 0 1.4126577685402708e-10
thousands O 0 1.626009771271697e-09
of O 0 7.502136867287845e-08
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 5.631125077343313e-07
carcinoma I-Disease 1 1.0
and O 0 6.598179225214551e-10
that O 0 5.242934905669294e-11
results O 0 1.2917942271428728e-09
from O 0 6.119746931432246e-09
truncating O 0 5.5296723644460144e-08
mutations O 0 1.4460050934417268e-08
in O 0 3.113006075139424e-09
the O 0 1.059907788203418e-07
APC B-Disease 0 4.863017011302873e-07
gene O 0 3.586876005101658e-07
. O 0 2.3621848868060624e-06

A O 0 3.6799676195187203e-07
variant O 0 4.0777297272143187e-07
of O 0 4.7091205601645925e-08
FAP B-Disease 0 8.47966020955937e-06
is O 0 7.795287970679965e-09
attenuated B-Disease 1 0.998191773891449
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
, O 0 1.7168451105220583e-09
which O 0 5.899941646347884e-11
results O 0 4.196874792139482e-10
from O 0 1.6315520046106258e-09
germ O 0 2.9297018500074046e-07
- O 0 5.352431742267072e-08
line O 0 1.5818686449620145e-07
mutations O 0 1.2553091899292212e-09
in O 0 4.857329538587862e-10
the O 0 6.03150374089978e-09
5 O 0 3.6396949898431785e-09
and O 0 1.5333320724231214e-10
3 O 0 4.415537269153447e-09
regions O 0 1.171940144928385e-08
of O 0 2.1170041009099805e-07
the O 0 1.1577916438909597e-06
APC B-Disease 0 5.26103463016625e-07
gene O 0 3.2155034546121897e-07
. O 0 2.4865316845534835e-06

Attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 1.5141844755817147e-07
have O 0 4.2186139997957284e-11
" O 0 1.0912760278758427e-10
multiple O 0 7.991510564409054e-09
" O 0 1.0905532690230757e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 2.3360831047369857e-09
typically O 0 2.0480481199847134e-10
fewer O 0 2.8969607268614084e-10
than O 0 2.4145243096573843e-11
100 O 0 3.7021186116703575e-10
) O 0 1.8634445115434106e-12
without O 0 7.463860779433062e-11
the O 0 1.3261084452764749e-09
florid O 0 1.668173723601285e-07
phenotype O 0 1.1378027409136848e-07
of O 0 5.604947617143807e-08
classical O 0 1.879530941550911e-06
FAP B-Disease 0 2.0768684407812543e-05
. O 0 1.1569439948289073e-06

Another O 0 2.7684924930326815e-07
group O 0 1.0501877589774722e-08
of O 0 3.971007966896423e-09
patients O 0 7.533245138802158e-10
with O 0 4.951230744842938e-11
multiple O 0 3.127094032606692e-07
adenomas B-Disease 1 0.9999915361404419
has O 0 4.956895782726178e-09
no O 0 2.4316173519167705e-09
mutations O 0 8.727444544831542e-09
in O 0 1.519851577924669e-09
the O 0 1.076664180033049e-08
APC B-Disease 0 4.585402280099515e-09
gene O 0 4.77285655442472e-10
, O 0 2.9932789580300323e-10
and O 0 1.369625940439434e-10
their O 0 6.881649694534531e-10
phenotype O 0 2.077934624367117e-08
probably O 0 2.3146606853430285e-09
results O 0 1.4744679921463444e-09
from O 0 2.5609037113127897e-09
variation O 0 5.4239912117282074e-08
at O 0 2.3043057240101916e-08
a O 0 1.1876649885778079e-08
locus O 0 2.20324647415282e-08
, O 0 2.2326505089154125e-09
or O 0 1.7577568289794954e-09
loci O 0 6.439610178432531e-09
, O 0 4.1075592926986815e-10
elsewhere O 0 3.402379711303638e-09
in O 0 1.7369105043130162e-09
the O 0 3.6549039350575185e-08
genome O 0 1.3476609694862418e-07
. O 0 3.7820379361619416e-07

Recently O 0 1.0638689218467334e-06
, O 0 3.283909366658122e-09
however O 0 2.336537630043267e-09
, O 0 5.1003583301234556e-11
a O 0 9.459548422352526e-11
missense O 0 6.057584300833696e-08
variant O 0 4.144061449551373e-08
of O 0 2.7777647915172565e-07
APC B-Disease 0 4.4828249201600556e-07
( O 0 1.4385747704181995e-08
I1307K O 0 3.1925435450830264e-07
) O 0 2.521526598631141e-10
was O 0 2.369257456891205e-09
described O 0 2.2585663894680863e-10
that O 0 1.465176070747365e-11
confers O 0 3.3522640219274535e-09
an O 0 7.482205827136212e-11
increased O 0 1.5538533792991416e-09
risk O 0 1.7834344134826097e-07
of O 0 0.02127925679087639
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.851813978883456e-09
including O 0 3.6889657994976233e-10
multiple O 0 7.404908686226008e-09
adenomas B-Disease 0 1.0756583606053027e-06
, O 0 2.9187032790645162e-09
in O 0 1.3248828700795912e-08
Ashkenazim O 0 3.153876241412945e-05
. O 0 8.309905297210207e-07

We O 0 5.172657324692409e-08
have O 0 2.9734099626921306e-09
studied O 0 1.456284870471336e-08
a O 0 5.730760865851892e-10
set O 0 6.993327583693087e-10
of O 0 4.1440414988436203e-10
164 O 0 7.232128784728786e-10
patients O 0 2.946241514645287e-11
with O 0 4.077831475268745e-11
multiple O 0 2.9896251362515613e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 3.5377286167204147e-07
/ I-Disease 0 0.030423689633607864
or I-Disease 0 1.7049667349056108e-06
carcinoma I-Disease 1 1.0
and O 0 1.6954263548640824e-09
analyzed O 0 7.1548318381076115e-09
codons O 0 8.838362219876217e-08
1263 O 0 3.712931857080548e-06
- O 0 1.5430630639912124e-07
1377 O 0 8.751816835683712e-07
( O 0 5.413136605625368e-09
exon O 0 1.7474516056381617e-08
15G O 0 3.056549360280769e-07
) O 0 1.7093944315593745e-10
of O 0 5.379489742551868e-09
the O 0 2.0919365795180056e-08
APC B-Disease 0 6.2941207801259225e-09
gene O 0 3.8650002642803827e-10
for O 0 2.6933064667389317e-09
germ O 0 4.659134447138058e-06
- O 0 1.507336605754972e-06
line O 0 6.088779969104507e-07
variants O 0 4.043310752877005e-08
. O 0 2.686961408926436e-07

Three O 0 4.3642799596455006e-08
patients O 0 1.3315170077632388e-09
with O 0 7.689341524619309e-11
the O 0 3.2637592628503853e-09
I1307K O 0 6.892230430821655e-08
allele O 0 3.0677025364411747e-09
were O 0 6.858979495483197e-10
detected O 0 1.9888268809609144e-09
, O 0 3.525577399465796e-11
each O 0 1.543908473289335e-10
of O 0 2.5002078629654534e-08
Ashkenazi O 0 1.7393268763044034e-06
descent O 0 6.7266300902701914e-06
. O 0 8.279039889202977e-07

Four O 0 4.0874320461625757e-07
patients O 0 6.730273582888913e-08
had O 0 2.058416370687155e-08
a O 0 7.812673175067175e-09
germ O 0 3.009781266882783e-06
- O 0 3.067423790525936e-07
line O 0 2.478183773746423e-07
E1317Q O 0 1.031830123565669e-07
missense O 0 3.333132170268982e-08
variant O 0 1.6218228537923096e-08
of O 0 1.0474731304555007e-08
APC O 0 1.0728328447839885e-08
that O 0 3.791307268130595e-10
was O 0 2.9800983902816824e-09
not O 0 1.2801722182320674e-10
present O 0 6.839358523968997e-10
in O 0 5.163327543300511e-10
controls O 0 3.919462532309126e-09
; O 0 1.2622959344454898e-09
one O 0 3.803905634924831e-09
of O 0 3.89611098938758e-09
these O 0 4.960127863995467e-10
individuals O 0 1.4283376703616568e-09
had O 0 3.866611564262712e-08
an O 0 1.53042267747594e-09
unusually O 0 2.6777093875551827e-09
large O 0 1.47866430211252e-09
number O 0 7.369008514501729e-09
of O 0 1.6954118109424599e-07
metaplastic B-Disease 0 0.00016606760618742555
polyps I-Disease 0 2.097399601552752e-06
of I-Disease 0 4.6152376853569876e-07
the I-Disease 0 1.0042355143013992e-06
colorectum I-Disease 0 5.220041930442676e-05
. O 0 1.2575452501550899e-06

There O 0 1.683344663661046e-07
is O 0 1.1881379213818377e-09
increasing O 0 1.146819639252783e-09
evidence O 0 4.781825158062247e-09
that O 0 2.819707523027404e-10
there O 0 6.03352534600532e-10
exist O 0 3.72624953115519e-09
germ O 0 2.903270797105506e-07
- O 0 1.024686824280252e-08
line O 0 5.6701487949339935e-09
variants O 0 9.565748193551826e-10
of O 0 4.303768008639963e-09
the O 0 1.1707471436750438e-08
APC B-Disease 0 8.99555629985116e-09
gene O 0 7.031795146161812e-10
that O 0 2.770342844016227e-10
predispose O 0 7.282826430810019e-08
to O 0 7.701939086501852e-10
the O 0 2.4799078346404713e-09
development O 0 4.966321576205246e-09
of O 0 5.630585775406871e-09
multiple O 0 0.0028857504948973656
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.0295263659209013
carcinoma I-Disease 1 1.0
, O 0 2.7133262303635775e-10
but O 0 4.9362854082080077e-11
without O 0 3.6154626514850463e-10
the O 0 2.5328552588632647e-09
florid O 0 4.84892495933309e-07
phenotype O 0 8.236877135914256e-08
of O 0 1.4485862287472173e-08
classical O 0 1.630141355235537e-07
FAP B-Disease 0 1.710578999336576e-06
, O 0 1.4503963585710267e-09
and O 0 1.4093261280212488e-10
possibly O 0 1.4186961605489046e-09
with O 0 6.396073948256031e-11
importance O 0 4.471765890912138e-08
for O 0 3.3574940516700735e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 1.9556425812083944e-08
in O 0 4.762324215534797e-11
the O 0 2.597978221441366e-10
general O 0 4.123195673777502e-10
population O 0 2.158035000698888e-10
. O 0 9.457802319090547e-10
. O 0 4.1279054840970275e-08

Genomic O 0 9.599533257187431e-08
structure O 0 1.5082546767075655e-08
of O 0 3.395378200821142e-09
the O 0 2.35947741344944e-08
human O 1 0.6217385530471802
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9132131338119507
CLD B-Disease 1 1.0
) O 0 1.0328418120764127e-08
gene O 0 3.946169613300299e-07
. O 0 6.182659149089886e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999998807907104
CLD B-Disease 1 1.0
) O 0 3.9078176250484375e-09
is O 0 9.316320631613806e-11
caused O 0 3.696981887291173e-10
by O 0 2.5080564361457114e-11
mutations O 0 2.225664763599866e-09
in O 0 1.1602533517285352e-10
a O 0 1.349783895765455e-10
gene O 0 2.234511187193533e-10
which O 0 1.3222510586441416e-10
encodes O 0 2.1120092341675445e-09
an O 0 7.560064574363423e-09
intestinal O 0 4.3042919628533127e-07
anion O 0 2.9895102215959923e-06
transporter O 0 1.688021802692674e-05
. O 0 1.5260911823133938e-06

We O 0 4.947896314888567e-08
report O 0 2.3759698208891677e-08
here O 0 9.43697231470253e-10
the O 0 6.897418747264794e-10
complete O 0 6.331358770594875e-10
genomic O 0 2.1298220076459984e-08
organization O 0 3.6424170346549545e-09
of O 0 6.8747523229717444e-09
the O 0 1.1433563429363858e-08
human O 0 6.801054297511655e-08
CLD B-Disease 1 0.9996942281723022
gene O 0 1.086831868946092e-08
which O 0 1.265144988771283e-09
spans O 0 6.004689190319823e-09
approximately O 0 4.7871340225214e-10
39kb O 0 1.7503747073988052e-07
, O 0 1.7125934004269538e-09
and O 0 7.007056712637905e-09
comprises O 0 3.1685747359233574e-08
21 O 0 9.346676961285993e-07
exons O 0 3.615629339037696e-06
. O 0 3.802699438892887e-06

All O 0 3.093127247666416e-07
exon O 0 2.5587432901374996e-06
/ O 0 2.519414692869759e-06
intron O 0 4.572356999688054e-07
boundaries O 0 2.742800475630247e-08
conform O 0 8.9959684146379e-09
to O 0 2.611393323803668e-09
the O 0 9.127430899980027e-08
GT O 0 3.905654466507258e-06
/ O 0 2.071063818220864e-06
AG O 0 4.475455352803692e-05
rule O 0 1.5150584431466996e-06
. O 0 1.8830743329090183e-06

An O 0 2.7166573435266628e-09
analysis O 0 3.0289919461523596e-09
of O 0 4.193500213744983e-09
the O 0 6.307641076119808e-09
putative O 0 2.3536033211257745e-07
promoter O 0 4.336702659202274e-07
region O 0 2.8212435054797425e-08
sequence O 0 5.882486053820912e-09
shows O 0 1.4816603943756945e-08
a O 0 1.8015468228327336e-08
putative O 0 1.3145636330591515e-05
TATA O 0 1.4448671208810993e-05
box O 0 1.4338734217744786e-06
and O 0 1.072540669611044e-07
predicts O 0 8.599074590165401e-07
multiple O 0 4.353787375066531e-08
transcription O 0 1.6848716768436134e-06
factor O 0 2.852755756066472e-07
binding O 0 5.394132358560455e-07
sites O 0 5.0124494919145945e-06
. O 0 1.5516958455918939e-06

The O 0 6.386592303897487e-07
genomic O 0 6.557084475389274e-07
structure O 0 2.3075631361280102e-07
was O 0 4.790728880266215e-08
determined O 0 1.5336808489863074e-09
using O 0 1.3465131787349094e-10
DNA O 0 4.244048668056166e-09
from O 0 1.6334700259079682e-09
several O 0 6.650728856527621e-10
sources O 0 8.685132613095448e-09
including O 0 1.4033552098169366e-10
multiple O 0 3.1102165287677508e-09
large O 0 5.871862285289353e-08
- O 0 5.648993806062208e-08
insert O 0 1.1740839056528785e-07
libaries O 0 7.364921543739911e-07
and O 0 1.6152127413349149e-09
genomic O 0 5.364632293947125e-09
DNA O 0 1.7775008132048242e-08
from O 0 4.024337840746739e-08
Finnish O 0 1.6491743735969067e-05
CLD B-Disease 1 0.949507474899292
patients O 0 5.102788236399647e-08
and O 0 1.6655482326655147e-08
controls O 0 1.617287125554867e-06
. O 0 1.3104966001264984e-06

Exon O 0 9.260638762498274e-07
- O 0 1.5832783617497626e-07
specific O 0 6.228259685769899e-09
primers O 0 4.2833544711129434e-08
developed O 0 4.8203045999173355e-09
in O 0 1.8677874524808402e-10
this O 0 4.900889069570091e-11
study O 0 2.479375732500344e-11
will O 0 1.035740243571226e-11
facilitate O 0 1.8447925409503796e-09
mutation O 0 8.396203177163386e-10
screening O 0 3.1160637958826953e-10
studies O 0 8.351625502278637e-10
of O 0 3.4385860825381087e-10
patients O 0 4.954757160113843e-10
with O 0 1.5340603787272755e-10
the O 0 4.704568823399313e-08
disease O 0 2.1242318837266794e-07
. O 0 5.133196268047868e-08

Genomic O 0 1.1778971753528822e-07
sequencing O 0 5.9279024355873844e-08
of O 0 3.3808721155992316e-08
a O 0 6.451070078128396e-08
BAC O 0 6.377600129781058e-06
clone O 0 1.40842786322537e-07
H O 1 1.0
_ O 0 7.078735375642964e-09
RG364P16 O 0 9.890248264809998e-08
revealed O 0 2.5675359616172955e-09
the O 0 1.7211919389747976e-10
presence O 0 3.05148933898991e-10
of O 0 3.6218004151322702e-09
another O 0 8.149408259328084e-09
, O 0 6.288513598740053e-10
highly O 0 2.30867303052662e-09
homologous O 0 6.599689683639554e-10
gene O 0 2.4625057548632867e-09
3 O 0 3.1179698112282495e-07
of O 0 1.6557505944092554e-07
the O 0 7.043183245514228e-07
CLD B-Disease 0 0.00017054461932275444
gene O 0 1.04180051252456e-08
, O 0 2.0861499194779753e-09
with O 0 3.491828354240667e-11
a O 0 4.432360589667894e-10
similar O 0 1.423764717234377e-10
genomic O 0 1.3590309322353278e-08
structure O 0 6.332883994986105e-09
, O 0 2.93114282845508e-10
recently O 0 1.577001168540093e-10
identified O 0 5.18195431009616e-10
as O 0 2.78274042697646e-10
the O 0 1.9228497905032782e-08
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 2.5297188699369144e-07
( O 0 6.017900489041494e-08
PDS B-Disease 0 2.0526023945421912e-05
) O 0 1.1319638559825762e-09
. O 0 5.143523829076457e-09
. O 0 9.083213825533676e-08

The O 0 4.1642988435341977e-07
APCI1307K O 1 0.9769723415374756
allele O 0 2.436257773297257e-06
and O 0 3.99715034404835e-08
cancer B-Disease 0 8.331346066370315e-07
risk O 0 6.766284865733496e-09
in O 0 1.5877123227259204e-10
a O 0 1.267246085845386e-09
community O 0 1.7143517716533552e-09
- O 0 2.3058082110338773e-09
based O 0 1.4712092655244646e-09
study O 0 9.55488022036377e-10
of O 0 4.8097428262394715e-09
Ashkenazi O 0 6.455661605286878e-08
Jews O 0 2.5538329850860464e-07
. O 0 4.802466833098151e-07

Mutations O 0 1.456932778864939e-07
in O 0 1.3373105289815612e-08
APC O 0 3.243288304588532e-08
are O 0 5.862543089873995e-11
classically O 0 1.0224729507513075e-08
associated O 0 2.3306901297814875e-08
with O 0 4.7502661004727997e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 4.96783759444952e-05
FAP B-Disease 0 7.298105174413649e-06
) O 0 4.085679364274064e-11
, O 0 4.5921083775823934e-12
a O 0 5.2004876099909225e-11
highly O 0 2.5066285047614656e-07
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 1.153450099877773e-07
by O 0 2.8877369939728226e-10
multiple O 0 1.3969631673660388e-08
intestinal O 0 3.6079978599445894e-05
polyps B-Disease 0 7.543676616705852e-08
and O 0 7.40271177690488e-11
, O 0 7.416034800145077e-12
without O 0 2.712176316865822e-11
surgical O 0 1.1046420667071288e-08
intervention O 0 4.507162643108131e-09
, O 0 4.0601830925135474e-11
the O 0 3.178838026141051e-10
development O 0 2.8036060584213374e-08
of O 0 1.0296513437424437e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 7.13085697157112e-08
CRC B-Disease 0 5.249534751783358e-06
) O 0 5.408698378062127e-09
. O 0 1.099159163686636e-07

APC B-Disease 0 1.4593217201763764e-05
is O 0 3.483491539668648e-08
a O 0 5.971695316020487e-08
tumour O 1 0.9999998807907104
- O 0 2.1536214944717358e-07
suppressor O 0 8.511872806593601e-08
gene O 0 1.187378972922204e-09
, O 0 1.605459931663944e-10
and O 0 6.784900419276596e-11
somatic O 0 1.6622230702978413e-07
loss O 0 3.894485800515213e-08
occurs O 0 2.7589978301989504e-08
in O 0 3.397063963461733e-08
tumours B-Disease 1 1.0
. O 0 6.551312253577635e-06

The O 0 1.3337108612176962e-05
germline O 0 2.4903596568037756e-05
T O 0 7.994408406375442e-07
- O 0 1.8268272228283422e-08
to O 0 2.204022964136243e-09
- O 0 3.5597851333335484e-09
A O 0 1.315337527785232e-08
transversion O 0 1.3862980985379636e-08
responsible O 0 1.1494404039691375e-10
for O 0 8.102160609091413e-11
the O 0 5.263621094542259e-09
APC O 0 1.6630277599460896e-08
I1307K O 0 5.0804036533236285e-08
allele O 0 1.7772253668724147e-09
converts O 0 3.6985281504087197e-09
the O 0 2.7343529662715582e-09
wild O 0 4.769273864724255e-09
- O 0 9.282199453508611e-10
type O 0 5.03687425101873e-10
sequence O 0 7.744536262288548e-11
to O 0 2.1984251918905073e-10
a O 0 1.1546294587105876e-08
homopolymer O 0 1.2617386346391868e-05
tract O 0 1.2267812053323723e-05
( O 0 1.0419897478186613e-07
A8 O 0 1.4626850315835327e-05
) O 0 1.309708591579195e-10
that O 0 1.0567430958063895e-10
is O 0 3.613277455016828e-10
genetically O 0 2.806832277713056e-08
unstable O 0 1.2846302524849307e-05
and O 0 2.0505515507807104e-08
prone O 0 2.792822897390579e-07
to O 0 2.6706617362037832e-08
somatic O 0 0.0002092608337989077
mutation O 0 3.5605996799858985e-06
. O 0 5.605973001365783e-07

The O 0 3.9561174958180345e-07
I1307K O 0 1.4531101442116778e-06
allele O 0 6.724641110622542e-08
was O 0 2.9466056261640006e-08
found O 0 5.983079032212402e-10
in O 0 1.6455405926762978e-09
6 O 0 3.5803074638351973e-07
. O 0 2.620785721774155e-07

1 O 0 2.190313580285874e-06
% O 0 7.191583506482857e-08
of O 0 4.7929404445312684e-08
unselected O 0 0.00014675782585982233
Ashkenazi O 0 1.0236148995090844e-07
Jews O 0 2.7136394464832847e-08
and O 0 1.856669956668e-10
higher O 0 6.961497600599387e-09
proportions O 0 8.155706332502177e-09
of O 0 1.157540108209787e-08
Ashkenazim O 0 1.0394548866088371e-07
with O 0 7.372181753950713e-10
family O 0 6.725497492254817e-09
or O 0 4.209557702417044e-10
personal O 0 7.712732674747258e-09
histories O 0 6.729939627803105e-08
of O 0 1.7969555301533546e-06
CRC B-Disease 1 0.9389976859092712
( O 0 1.5089921134858741e-07
ref O 0 3.777794745474239e-06
. O 0 1.4043425267118437e-07
2 O 0 6.38579479073087e-07
) O 0 1.3517071906221645e-08
. O 0 2.402194922979106e-07

To O 0 7.182081596113221e-09
evaluate O 0 2.8915096095261106e-08
the O 0 1.0515106119157736e-08
role O 0 6.240364669451992e-09
of O 0 3.972585460587652e-08
I1307K O 0 1.5849567489567562e-06
in O 0 7.134214108361903e-09
cancer B-Disease 0 2.429213452614931e-07
, O 0 1.7752332936993298e-09
we O 0 5.1306781045923344e-09
genotyped O 0 1.5152578498600633e-06
5 O 0 2.649166503942979e-07
, O 0 2.524146758275947e-08
081 O 0 5.354328095563687e-06
Ashkenazi O 0 2.6596768520903424e-07
volunteers O 0 1.807273619647276e-08
in O 0 1.4601388986790198e-09
a O 0 6.3277405537576215e-09
community O 0 1.7893997394935468e-08
survey O 0 1.0335280364870414e-07
. O 0 8.843336729569273e-08

Risk O 0 4.9327441047353204e-06
of O 0 8.617965363555413e-07
developing O 0 0.02237711474299431
colorectal B-Disease 1 1.0
, I-Disease 0 2.419342081338982e-06
breast I-Disease 0 0.18824975192546844
and I-Disease 0 8.88907614182699e-09
other I-Disease 0 7.101441212853388e-09
cancers I-Disease 0 0.00016878610767889768
were O 0 2.130223109020335e-09
compared O 0 3.3523919196198904e-09
between O 0 4.081057269900157e-09
genotyped O 0 1.8197542317466286e-07
I1307K O 0 1.4734144571093566e-08
carriers O 0 4.225340355379359e-10
and O 0 6.442321121014061e-10
non O 0 8.252834859945324e-09
- O 0 1.5279376652799215e-09
carriers O 0 6.425521226205433e-10
and O 0 6.412237407715793e-10
their O 0 2.3088888578826072e-09
first O 0 5.2998196053977153e-08
- O 0 4.915978735198223e-08
degree O 0 2.72998278205705e-07
relatives O 0 9.690370461612474e-07
. O 0 1.327057475464244e-06

Sperm O 0 1.553069637338922e-07
DNA O 0 3.2949849071428616e-08
analysis O 0 4.7942640968301475e-09
in O 0 9.448697380065596e-10
a O 0 3.3648724695467536e-08
Friedreich B-Disease 0 0.06899834424257278
ataxia I-Disease 1 1.0
premutation O 1 0.9998565912246704
carrier O 0 1.3755681038674084e-07
suggests O 0 2.3282286321091306e-08
both O 0 5.698304939016907e-09
meiotic O 0 3.113619584382832e-07
and O 0 1.419297745997028e-08
mitotic O 0 2.3401297255531972e-07
expansion O 0 6.771231824131974e-07
in O 0 1.724137810299453e-08
the O 0 5.07787547121552e-07
FRDA B-Disease 0 0.00018417769751977175
gene O 0 9.184026339426055e-07
. O 0 2.3536667868029326e-06

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 1.927985749716754e-06
usually O 0 1.7082651737609922e-08
caused O 0 7.119533407262679e-09
by O 0 1.7095238419306824e-11
an O 0 2.0949122644942086e-11
expansion O 0 1.8901800125092905e-09
of O 0 1.1448439973804625e-09
a O 0 3.1723480731216114e-08
GAA O 1 0.9999961853027344
trinucleotide O 1 0.9995601773262024
repeat O 0 4.110699478587776e-07
in O 0 1.19230882944521e-08
intron O 0 3.094596650043968e-07
1 O 0 1.1974324820585025e-07
of O 0 5.234150179944663e-08
the O 0 1.5588628343721211e-07
FRDA B-Disease 0 4.954580799676478e-05
gene O 0 2.5920272150870005e-07
. O 0 1.5351441788880038e-06

Occasionally O 0 1.0288582643624977e-06
, O 0 8.284503749678152e-09
a O 0 1.0537753780681669e-08
fully O 0 1.2381034864006324e-08
expanded O 0 7.361337761579989e-09
allele O 0 8.291047848274502e-09
has O 0 4.0037997917075074e-10
been O 0 1.4443167495326037e-10
found O 0 6.115038336806933e-11
to O 0 7.052018691222628e-11
arise O 0 2.9961935155142783e-09
from O 0 2.479189076254329e-09
a O 0 2.1839157149372568e-09
premutation O 0 5.017309376853518e-07
of O 0 1.703985930134877e-08
100 O 0 1.4018103122737102e-08
or O 0 4.669780562238657e-09
less O 0 1.1879917138912788e-07
triplet O 0 9.108505764743313e-06
repeats O 0 2.656607193785021e-06
. O 0 1.1694312433974119e-06

We O 0 9.964035285747741e-08
have O 0 2.426317369241815e-09
examined O 0 2.3806242310797643e-08
the O 0 1.3840781853957651e-09
sperm O 0 2.7628774823540425e-09
DNA O 0 9.081790430798264e-09
of O 0 7.0944281560514355e-09
a O 0 2.072958693588589e-08
premutation O 0 6.821542228863109e-06
carrier O 0 2.417537814380921e-07
. O 0 5.18578644914669e-07

This O 0 5.791543600253135e-08
mans O 0 1.3217099876783323e-05
leucocyte O 0 9.280487347496091e-07
DNA O 0 4.185351798469128e-08
showed O 0 1.3055048597720997e-08
one O 0 1.0014135076730213e-09
normal O 0 3.806823301033546e-09
allele O 0 8.534086770595195e-10
and O 0 5.862386270871767e-11
one O 0 1.4918308255396084e-10
allele O 0 2.7554465376056214e-09
of O 0 2.2088753048876697e-09
approximately O 0 4.0180156979374715e-09
100 O 0 3.56425040592967e-08
repeats O 0 1.6119825829719048e-07
. O 0 2.1646955872256513e-07

His O 0 9.64683067650185e-07
sperm O 0 3.4547292671049945e-07
showed O 0 1.2704316709744035e-08
an O 0 1.8148162139741686e-10
expanded O 0 2.362266771083199e-10
allele O 0 8.207464152754085e-10
in O 0 4.833632938350263e-10
a O 0 6.6299983281226105e-09
tight O 0 4.8356024962004085e-08
range O 0 1.7867677115646075e-07
centering O 0 1.254293096053516e-07
on O 0 5.8789195733766064e-09
a O 0 5.695781069015027e-10
size O 0 2.7972908434037436e-09
of O 0 1.4447700813491338e-08
approximately O 0 1.8905994991769148e-08
320 O 0 1.7026904686190392e-07
trinucleotide O 0 2.503522773622535e-05
repeats O 0 3.828440640063491e-06
. O 0 9.037536869982432e-07

His O 0 1.106290937968879e-06
affected O 0 1.532403075543698e-05
son O 0 0.0006009076605550945
has O 0 6.737797431100034e-09
repeat O 0 4.390745544924357e-09
sizes O 0 4.674782516644882e-08
of O 0 3.7799171792585184e-08
1040 O 0 1.3651836638928216e-07
and O 0 1.7156478904212236e-08
540 O 0 6.582196192539413e-07
. O 0 4.5349921151682793e-07

These O 0 1.6479409836733794e-08
data O 0 1.8638816712268635e-08
suggest O 0 4.222441951640121e-09
that O 0 5.844812828170731e-11
expansion O 0 2.7913640288090846e-09
occurs O 0 3.5886682514529866e-10
in O 0 5.692671681267747e-11
two O 0 1.354260731334378e-10
stages O 0 1.568413843244798e-09
, O 0 7.702434523526591e-11
the O 0 1.5313921242210426e-09
first O 0 1.3899830175745365e-09
during O 0 6.915835126797276e-10
meiosis O 0 2.8927660267186184e-09
followed O 0 1.8006046653695762e-09
by O 0 2.845103874715704e-10
a O 0 4.6675276976770874e-09
second O 0 3.633564915617171e-08
mitotic O 0 4.1188226873600797e-07
expansion O 0 3.0985913781478303e-06
. O 0 1.2314852710915147e-06

We O 0 3.425928696287883e-08
also O 0 4.3954209161256586e-09
show O 0 8.066268764039819e-10
that O 0 3.310540036549625e-11
in O 0 8.174651927594923e-11
all O 0 1.5142950782198739e-10
informative O 0 1.017205430997592e-08
carrier O 0 5.654755552697566e-10
father O 0 1.9880304069630483e-09
to O 0 9.579222970401702e-10
affected O 0 2.7860677320745708e-08
child O 0 1.2988262909630066e-08
transmissions O 0 1.311152573180152e-07
, O 0 1.6497414545568745e-10
with O 0 1.0574542977370704e-11
the O 0 5.438851036210224e-10
notable O 0 1.592991294430135e-09
exception O 0 6.857308942898044e-09
of O 0 9.484290686145869e-09
the O 0 1.9091199732201858e-08
premutation O 0 1.7108746419580712e-07
carrier O 0 4.976030698600198e-09
, O 0 8.410099283651107e-10
the O 0 2.858071779243687e-09
expansion O 0 2.0667604516688698e-08
size O 0 3.2899734492275456e-08
decreases O 0 7.595711082331036e-08
. O 0 2.314608948950081e-08
. O 0 3.5250084806648374e-07

The O 0 1.7989377454341593e-07
R496H O 0 4.419054675963707e-06
mutation O 0 1.521419221717224e-07
of O 0 4.569627876094273e-08
arylsulfatase O 0 1.2427367437339853e-05
A O 0 6.36889978977706e-07
does O 0 2.660704989665419e-09
not O 0 4.696300237583273e-09
cause O 0 9.553199197398499e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 2.411963123449823e-06

Deficiency B-Disease 0 0.0007395556312985718
of I-Disease 0 7.97897155280225e-05
arylsulfatase I-Disease 1 1.0
A I-Disease 1 0.9999996423721313
( O 0 2.8921192551933927e-06
ARSA O 0 0.0013058242620900273
) O 0 2.373993668314256e-09
enzyme O 0 1.750601796857154e-07
activity O 0 5.6432106987358566e-08
causes O 0 5.886209237360163e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 8.696605391378398e-07
MLD B-Disease 1 1.0
) O 0 7.314731043095435e-09
. O 0 5.442302253300113e-08

A O 0 1.2245416201039916e-06
number O 0 1.5472980408048898e-07
of O 0 7.468213993888639e-07
ARSA O 0 6.449883221648633e-05
gene O 0 1.8239380494833313e-07
mutations O 0 2.915693073646253e-07
responsible O 0 1.3567777124023905e-08
for O 0 5.667867064573784e-09
MLD B-Disease 1 1.0
have O 0 2.3479309163576545e-08
been O 0 9.17590003979285e-09
identified O 0 5.6421775695980614e-08
. O 0 9.237206199941284e-08

Recently O 0 6.200774578246637e-07
, O 0 2.7016620052222606e-09
the O 0 2.8759423731372635e-09
R496H O 0 2.153613252176001e-07
mutation O 0 1.4281232196822202e-08
of O 0 3.8727375084590676e-08
ARSA O 0 4.354078191681765e-05
was O 0 5.2476647027788204e-08
proposed O 0 1.4997285635587332e-09
to O 0 4.376362605640338e-10
be O 0 3.967780271008081e-10
a O 0 2.1318733445241378e-09
cause O 0 3.8794067336311855e-07
of O 0 2.2929214082978433e-06
MLD B-Disease 1 1.0
( O 0 4.917320097774791e-07
Draghia O 0 2.1541198293562047e-05
et O 0 3.4891420455096522e-06
al O 0 1.1640004231594503e-06
. O 0 1.1609097683162872e-08
, O 0 4.177007628669571e-09
1997 O 0 1.7616342162796172e-08
) O 0 6.7235861322956225e-09
. O 0 1.3417619015854143e-07

We O 0 1.9081777224982943e-07
have O 0 2.4856626978930763e-08
investigated O 0 1.4866375863675785e-07
the O 0 1.6611510389452633e-08
R496H O 0 1.7480826386417903e-07
mutation O 0 3.101236156766163e-09
and O 0 1.3907619500486135e-10
found O 0 9.9659037966493e-11
this O 0 5.5553946859410175e-11
mutation O 0 1.008109595801443e-09
at O 0 1.3370983209526344e-09
a O 0 2.1611078204752943e-10
relatively O 0 7.839298654666038e-10
high O 0 2.569650880968055e-10
frequency O 0 1.055415685402572e-10
in O 0 1.0619920741417044e-11
an O 0 9.098269360130473e-11
African O 0 6.487337056437781e-11
American O 0 8.635475112761526e-10
population O 0 3.031290496391392e-10
( O 0 3.4177258245726705e-11
f O 0 4.739466596959119e-09
= O 0 4.21581081155864e-09
0 O 0 4.716830925843851e-09
. O 0 3.056010999813452e-09
09 O 0 4.922208773905368e-08
, O 0 3.4294962425462927e-09
n O 0 9.650786836346015e-09
= O 0 1.46468138950695e-07
61 O 0 5.218450382926676e-07
subjects O 0 2.616023948576185e-07
) O 0 1.2299080864863754e-08
. O 0 1.5346040527219884e-07

The O 0 3.589900734368712e-05
ARSA O 0 8.781479846220464e-05
enzyme O 0 9.062517136726456e-08
activity O 0 4.122546926055293e-08
in O 0 4.077382598222101e-10
subjects O 0 2.1163564234427668e-09
with O 0 1.2728211713775028e-11
and O 0 4.7703424543854567e-11
without O 0 4.5093273559615454e-10
the O 0 4.577075163325617e-09
R496H O 0 1.9710562071395543e-08
mutation O 0 8.046292521157739e-10
was O 0 1.831228946258534e-09
determined O 0 1.25664589845087e-09
and O 0 1.0632376090669027e-09
found O 0 2.3387938252739104e-09
to O 0 2.9875650842114965e-09
be O 0 2.305672985869478e-08
normal O 0 1.0755219364000368e-06
. O 0 6.347113412630279e-07

It O 0 2.7640702171538578e-08
is O 0 2.1580690567901684e-09
therefore O 0 4.206028414444063e-09
concluded O 0 2.6839475086859466e-09
that O 0 4.650302018460728e-11
the O 0 6.523696582938499e-10
R496H O 0 8.645783111660421e-08
mutation O 0 1.6140155878474616e-08
of O 0 2.5475221931969827e-08
ARSA O 0 7.244612334034173e-06
does O 0 3.412017335335804e-09
not O 0 1.4437224749030975e-09
negatively O 0 1.0153793361666885e-08
influence O 0 9.383151144959356e-09
the O 0 7.796715273400423e-09
activity O 0 6.924631890115052e-08
of O 0 2.750827121644761e-08
ARSA O 0 2.8094569643144496e-05
and O 0 8.026737496891201e-09
is O 0 3.7553940512857764e-10
not O 0 1.0438322428640845e-10
a O 0 3.9165106713312525e-09
cause O 0 2.650617034305469e-06
of O 0 1.671633799560368e-05
MLD B-Disease 1 1.0

Down O 0 3.711823865160113e-06
- O 0 4.7916518752799675e-08
regulation O 0 2.1251191029136862e-08
of O 0 2.608268445669637e-08
transmembrane O 0 3.305185600765981e-07
carbonic O 0 2.2927573809283786e-05
anhydrases O 0 2.607841270219069e-05
in O 0 1.7178754774249683e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999983310699463
lines O 0 1.977375205797216e-07
by O 0 1.591138887313548e-09
wild O 0 1.7707576205339137e-07
- O 0 3.385266111877172e-08
type O 0 2.8766743298547226e-07
von B-Disease 1 0.8856545090675354
Hippel I-Disease 0 0.4321175813674927
- I-Disease 1 0.9924904704093933
Lindau I-Disease 0 0.0038553490303456783
transgenes O 0 0.0006036322447471321
. O 0 9.406183380633593e-06

To O 0 8.040316856749996e-08
discover O 0 1.9932831207825075e-07
genes O 0 4.027962319241851e-08
involved O 0 6.9187411355642325e-09
in O 0 8.986570598779053e-09
von B-Disease 1 1.0
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 1.0
( O 0 2.988821142935194e-05
VHL B-Disease 1 1.0
) O 0 3.422271177555558e-08
- O 0 5.432335115074238e-07
mediated O 0 7.552870556537528e-06
carcinogenesis O 0 4.2883188143605366e-05
, O 0 5.367884470253159e-10
we O 0 1.556899331678352e-10
used O 0 2.8569544507917044e-09
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999997615814209
lines O 0 7.453836587956175e-06
stably O 0 5.437595973489806e-07
transfected O 0 1.724342268971668e-07
with O 0 1.214396694315667e-09
wild O 0 6.405581132185034e-08
- O 0 6.419733011853168e-08
type O 0 2.8166095944470726e-07
VHL O 0 0.0003406088799238205
- O 0 3.011469516422949e-06
expressing O 0 9.679512658067324e-08
transgenes O 0 1.5216095562209375e-05
. O 0 6.181715548336797e-07

Large O 0 1.041722953232238e-06
- O 0 1.8533042123181076e-07
scale O 0 7.548685232450225e-08
RNA O 0 4.9280142633278956e-08
differential O 0 4.206495773928509e-08
display O 0 6.106303462871665e-09
technology O 0 2.289904266206122e-08
applied O 0 1.8900442100289183e-08
to O 0 5.601821229106463e-10
these O 0 9.93281346062247e-10
cell O 0 3.8677917757468094e-08
lines O 0 7.0531558371556e-09
identified O 0 1.9855068700280754e-09
several O 0 1.0720857535062578e-09
differentially O 0 3.8495360854540195e-07
expressed O 0 5.777374134652291e-09
genes O 0 6.7473400200412925e-09
, O 0 4.846557599691437e-10
including O 0 2.2712065561591999e-10
an O 0 1.0976523689976148e-08
alpha O 0 1.0777247183568761e-07
carbonic O 0 1.0122817002411466e-06
anhydrase O 0 9.460487717660726e-07
gene O 0 1.9729223765807546e-07
, O 0 1.6444973027773813e-07
termed O 0 7.081559033395024e-06
CA12 O 1 0.5016375184059143
. O 0 4.5738670451100916e-06

The O 0 2.933189989562379e-06
deduced O 0 2.714527909120079e-06
protein O 0 9.626541697116409e-08
sequence O 0 8.14456058151336e-09
was O 0 1.0149708629114684e-08
classified O 0 2.035334567551672e-09
as O 0 1.328858134641564e-09
a O 0 2.8314199873591406e-09
one O 0 1.1537621524837505e-08
- O 0 6.66993003051175e-08
pass O 0 3.722294934505044e-07
transmembrane O 0 6.564706040990131e-07
CA O 0 6.259876386138785e-07
possessing O 0 1.347247149396935e-07
an O 0 3.8923695910852985e-07
apparently O 0 4.818459160560451e-07
intact O 0 5.681313197669624e-08
catalytic O 0 1.2518094116842349e-08
domain O 0 4.949085763428229e-08
in O 0 1.1528864973797681e-08
the O 0 6.817131747993699e-07
extracellular O 0 2.011202013818547e-05
CA O 0 5.988033444737084e-05
module O 0 1.4414690667763352e-06
. O 0 9.052166660694638e-07

Reintroduced O 0 5.730062184738927e-06
wild O 0 4.890008767688414e-06
- O 0 9.913286476148642e-07
type O 0 4.953099050908349e-07
VHL B-Disease 0 0.00043032667599618435
strongly O 0 3.487041411176506e-08
inhibited O 0 2.1003565109367628e-08
the O 0 1.1385854481460456e-09
overexpression O 0 8.86373570097021e-08
of O 0 3.197282438804905e-09
the O 0 6.059523549595269e-09
CA12 O 0 5.547823093365878e-06
gene O 0 9.883960316869889e-10
in O 0 7.055950823620094e-10
the O 0 3.0790175742367865e-08
parental O 0 0.023852618411183357
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 0.0039038092363625765
. O 0 4.4628322370954265e-07

Similar O 0 2.78291309996348e-08
results O 0 8.013768848513791e-08
were O 0 4.319113067197122e-09
obtained O 0 1.671464566754821e-08
with O 0 1.2098513302305491e-09
CA9 O 0 7.627251306985272e-06
, O 0 7.369482801777849e-10
encoding O 0 2.8066646784452587e-09
another O 0 7.471791008129003e-08
transmembrane O 0 3.9274760865737335e-07
CA O 0 2.0564873466355493e-06
with O 0 4.608488257673571e-09
an O 0 6.96302748792732e-08
intact O 0 3.009592148828233e-07
catalytic O 0 1.6868222019184032e-07
domain O 0 1.1628731044766027e-06
. O 0 7.027650781310513e-07

Although O 0 8.769431047994658e-08
both O 0 7.869204843302668e-09
domains O 0 9.22166165651106e-08
of O 0 5.147516617398651e-07
the O 0 3.375753010459448e-07
VHL B-Disease 0 5.1330975111341104e-05
protein O 0 8.44519760789808e-08
contribute O 0 6.45980546831737e-10
to O 0 2.202462795475313e-10
regulation O 0 5.187279938922984e-08
of O 0 1.7925207203006721e-06
CA12 O 1 0.9999985694885254
expression O 0 1.292144474973611e-06
, O 0 9.271215795081389e-09
the O 0 2.509017171803407e-08
elongin O 0 1.6614069409115473e-07
binding O 0 2.635291806996065e-08
domain O 0 6.648311767776249e-08
alone O 0 9.897302533090624e-09
could O 0 5.617048604023012e-09
effectively O 0 7.477793673160704e-08
regulate O 0 1.8885272083934979e-06
CA9 O 0 0.031080061569809914
expression O 0 1.0215117981715593e-05
. O 0 2.7425605821917998e-06

We O 0 5.146715693626902e-07
mapped O 0 6.318881332845194e-06
CA12 O 0 0.004447277635335922
and O 0 6.015433200445841e-07
CA9 O 0 0.0012364084832370281
loci O 0 1.9046179033921362e-07
to O 0 6.476835068269793e-09
chromosome O 0 1.8729693351815513e-08
bands O 0 4.015796406520167e-08
15q22 O 0 5.989387545923819e-07
and O 0 1.0918558501771258e-08
17q21 O 0 2.3524796688434435e-06
. O 0 2.789742836739606e-07

2 O 0 2.279399268445559e-06
respectively O 0 1.9835172793136735e-07
, O 0 5.8303215588750845e-09
regions O 0 1.4502918865844094e-08
prone O 0 3.0147337071184666e-08
to O 0 9.549159241117877e-10
amplification O 0 4.410632215012811e-08
in O 0 7.246561573026611e-09
some O 0 1.4496723821366686e-08
human O 0 8.274761285065324e-07
cancers B-Disease 0 0.44900134205818176
. O 0 4.5005504034634214e-07

Additional O 0 1.575289871880159e-07
experiments O 0 8.278409779904905e-08
are O 0 1.2233418444917987e-10
needed O 0 1.1789074161328017e-09
to O 0 2.8995533751796643e-10
define O 0 1.309440200714107e-08
the O 0 3.800897374617307e-08
role O 0 2.3968896201154166e-08
of O 0 1.2699708804575494e-06
CA O 0 4.825375526706921e-06
IX O 1 0.9939430356025696
and O 0 2.199613481934648e-05
CA O 0 2.698190655792132e-05
XII O 0 1.2152231647633016e-05
enzymes O 0 3.345276278210463e-09
in O 0 6.045758893513664e-10
the O 0 6.965478194231878e-10
regulation O 0 2.5474480302989377e-09
of O 0 2.222649619909589e-08
pH O 0 3.1424061575080486e-08
in O 0 3.7175886813400894e-09
the O 0 6.983483302747118e-08
extracellular O 0 1.7784444139579136e-07
microenvironment O 0 8.134595077535778e-07
and O 0 1.5206982340032482e-09
its O 0 9.882923368564889e-10
potential O 0 4.335110048714341e-08
impact O 0 3.35100799020438e-06
on O 0 1.1667989383568056e-06
cancer B-Disease 0 3.4905197026091628e-06
cell O 0 3.680147074192064e-06
growth O 0 2.1299362629179086e-07
. O 0 1.2622356848623895e-07

A O 0 2.78699076261546e-07
gene O 0 4.8693911125496925e-09
encoding O 0 1.621173417731825e-08
a O 0 5.5189559589052806e-08
transmembrane O 0 8.991786160095216e-08
protein O 0 1.8166812054687398e-08
is O 0 4.28621652059924e-11
mutated O 0 4.662845110026126e-10
in O 0 2.4491303082796456e-11
patients O 0 3.326663389202622e-10
with O 0 8.482416435917628e-10
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 1.1479149719662018e-07
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 0 1.3671957503902377e-06
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.5457951585418073e-09
. O 0 1.5775173167753564e-08

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 7.905273378128186e-05
WFS B-Disease 1 0.6044963598251343
; O 0 7.16494028552006e-08
OMIM O 1 0.7484830021858215
222300 O 0 5.388615704760014e-07
) O 0 6.247218020671852e-11
is O 0 1.9679464655086853e-11
an O 0 1.965716478480317e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 2.3234982826636497e-09
by O 0 1.036297922474283e-10
young O 0 4.293357847018342e-08
- O 0 1.4170412896419293e-06
onset O 1 1.0
non O 1 0.9999994039535522
- O 0 0.00019076130411121994
immune O 0 0.06586919724941254
insulin B-Disease 1 0.9999998807907104
- I-Disease 0 0.12401261180639267
dependent I-Disease 0 6.37019329587929e-05
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 8.337829981996947e-09
progressive O 0 1.1987563084403519e-05
optic B-Disease 0 5.8848789194598794e-05
atrophy I-Disease 0 6.478347586380551e-06
. O 0 2.718878135965497e-07

Linkage O 0 2.1625712633976946e-06
to O 0 1.2696467877049145e-08
markers O 0 2.1728942556364927e-07
on O 0 7.725486028675732e-08
chromosome O 0 2.811939623370563e-07
4p O 0 3.396574902581051e-05
was O 0 9.262364386586341e-08
confirmed O 0 4.706038225776865e-09
in O 0 6.275777120201553e-10
five O 0 2.957459832586551e-09
families O 0 1.697481799567413e-08
. O 0 1.3025629641560954e-07

On O 0 7.104126353851825e-08
the O 0 4.513012186180276e-09
basis O 0 4.744714843241127e-08
of O 0 1.521975789842145e-08
meiotic O 0 3.8242385926423594e-05
recombinants O 1 0.9951664209365845
and O 0 2.417671396415244e-07
disease O 0 1.8310346376892994e-06
- O 0 3.4049911334932403e-08
associated O 0 1.0031885011585473e-07
haplotypes O 0 4.203472201425029e-07
, O 0 8.530083306368397e-10
the O 0 2.7065889085520212e-08
WFS B-Disease 0 1.8413646785120363e-06
gene O 0 7.773017784984404e-09
was O 0 2.2441833280595347e-08
localized O 0 2.0268087652652866e-08
to O 0 1.2635918977821348e-09
a O 0 9.000640233125523e-08
BAC O 0 3.435382677707821e-05
/ O 0 5.292536684464721e-07
P1 O 0 1.2926498129672837e-06
contig O 0 1.1165881232955144e-06
of O 0 1.0138486494781773e-08
less O 0 3.721022157066045e-09
than O 0 2.4591029212928106e-09
250 O 0 2.1991235499285722e-08
kb O 0 3.1330750971392263e-06
. O 0 8.517895366821904e-07

Mutations O 0 2.0831696190271032e-07
in O 0 4.68129357500402e-09
a O 0 3.816739813089498e-09
novel O 0 1.9152436081526503e-08
gene O 0 1.7956153897102922e-08
( O 0 4.65242031566504e-08
WFS1 O 0 4.488841659622267e-05
) O 0 2.741610549694684e-10
encoding O 0 1.6610933739613643e-09
a O 0 2.611603733271295e-08
putative O 0 1.637739330817567e-07
transmembrane O 0 7.778326427398952e-09
protein O 0 8.379952731729645e-09
were O 0 9.596523575794436e-10
found O 0 1.9689425090341217e-10
in O 0 1.032872259942863e-10
all O 0 1.39966357948218e-10
affected O 0 1.352410627930567e-09
individuals O 0 7.945541447007543e-11
in O 0 1.8003540880329183e-09
six O 0 4.47966215233464e-08
WFS B-Disease 0 9.076881724467967e-06
families O 0 1.4704413686672524e-08
, O 0 7.914175981227345e-10
and O 0 3.423299421712045e-10
these O 0 4.613991966273545e-10
mutations O 0 5.832479388345746e-09
were O 0 7.68740904266707e-10
associated O 0 2.4322668323861762e-09
with O 0 1.5084547499988332e-10
the O 0 3.762423617104105e-08
disease O 0 4.5386528313429153e-07
phenotype O 0 2.493529507319181e-07
. O 0 6.40191686329672e-08

WFS1 O 0 0.0204593688249588
appears O 0 4.965907152154614e-08
to O 0 4.829025512798069e-10
function O 0 3.7633027250016937e-10
in O 0 3.030804773818119e-10
survival O 0 8.921657013161166e-07
of O 0 3.946394855347535e-08
islet O 0 1.3288541822475963e-07
beta O 0 1.5651056628485094e-07
- O 0 1.507729052718787e-07
cells O 0 2.177553071192051e-08
and O 0 6.497362203816692e-09
neurons O 0 7.98788732936373e-08
. O 0 1.424738638178269e-08
. O 0 1.0074261780346205e-07

Stable O 0 2.1914127046329668e-06
interaction O 0 2.5572248318894708e-08
between O 0 5.172457129276609e-09
the O 0 1.021618567520477e-09
products O 0 1.8879966479090626e-09
of O 0 2.1883983514214833e-09
the O 0 3.084590005641985e-08
BRCA1 O 0 8.668658324495482e-07
and O 0 8.309764609748527e-08
BRCA2 O 0 2.299074139955337e-06
tumor B-Disease 0 3.797915724135237e-07
suppressor O 0 8.556772854717565e-07
genes O 0 1.3602628357034519e-08
in O 0 3.6775094081065163e-09
mitotic O 0 4.436535050444945e-07
and O 0 1.4475233456323622e-07
meiotic O 0 6.873574420751538e-06
cells O 0 2.8942413337063044e-06
. O 0 1.2685050023719668e-06

BRCA1 O 0 0.00023401263752020895
and O 0 2.066251909127459e-06
BRCA2 O 0 2.3459667772840476e-06
account O 0 1.7377721484024278e-09
for O 0 4.940768627559322e-11
most O 0 9.44456735041399e-11
cases O 0 3.0119834404374046e-10
of O 0 1.1927039356152136e-09
familial O 0 1.1827369306161017e-08
, O 0 2.5755195198762237e-10
early O 0 1.1920859854797072e-08
onset O 0 1.5511054698436055e-06
breast B-Disease 0 1.0583477205727831e-06
and I-Disease 0 4.944287752550736e-07
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.7108751915184683e-10
encode O 0 9.573027093257025e-11
products O 0 1.1742486982768696e-09
that O 0 6.492362897292381e-11
each O 0 1.3838345747085867e-10
interact O 0 7.320198336380201e-10
with O 0 1.7496520898774293e-09
hRAD51 O 0 2.6329312277084682e-06
. O 0 6.240176730898384e-07

Results O 0 1.7949858488464088e-07
presented O 0 7.31806935050372e-08
here O 0 7.0167658350328566e-09
show O 0 6.472117508593556e-09
that O 0 5.642623590595974e-10
BRCA1 O 0 2.2398129573275583e-08
and O 0 5.826697346833498e-09
BRCA2 O 0 9.958602475990119e-08
coexist O 0 4.866512526291444e-09
in O 0 3.438966611479799e-10
a O 0 2.335071913606157e-09
biochemical O 0 1.759885321916954e-07
complex O 0 6.41451904925816e-08
and O 0 7.262099810390055e-09
colocalize O 0 5.982222319289576e-06
in O 0 1.4851519125613777e-08
subnuclear O 0 1.9610044546425343e-05
foci O 0 1.2336433883319842e-06
in O 0 6.227024673677306e-09
somatic O 0 1.710559587309035e-07
cells O 0 7.082624708942831e-09
and O 0 8.628625591811101e-10
on O 0 3.0923996696685663e-09
the O 0 1.4798436920315794e-09
axial O 0 2.2125785648086094e-08
elements O 0 2.442559710047476e-09
of O 0 1.8206147700539077e-08
developing O 0 1.1976906932886777e-07
synaptonemal O 0 5.468906238093041e-06
complexes O 0 2.320781732123578e-06
. O 0 2.74081912721158e-06

Like O 0 2.4151695470209233e-06
BRCA1 O 0 2.625879096740391e-05
and O 0 1.4492114814856905e-06
RAD51 O 0 0.0021063433960080147
, O 0 4.845758212468354e-07
BRCA2 O 0 3.3118190003733616e-06
relocates O 0 1.2060227163601667e-06
to O 0 1.7080663994306633e-08
PCNA O 0 3.5776797631115187e-06
+ O 0 2.0319181004424536e-08
replication O 0 2.159843859317334e-09
sites O 0 8.72639127624808e-10
following O 0 3.0281352425554076e-10
exposure O 0 2.9304302984201058e-08
of O 0 5.620438159326113e-08
S O 0 1.5854933508308022e-06
phase O 0 5.678809955611541e-08
cells O 0 2.171315394150497e-08
to O 0 3.070150711437236e-08
hydroxyurea O 0 5.290828539727954e-06
or O 0 3.466908253813017e-07
UV O 0 0.0002553735685069114
irradiation O 0 8.26997074909741e-06
. O 0 4.897019039162842e-07

Thus O 0 6.613064442717587e-07
, O 0 8.991563049676188e-08
BRCA1 O 0 7.792033898113004e-07
and O 0 3.5516961816028925e-08
BRCA2 O 0 1.2915134561808372e-07
participate O 0 1.3126827402842878e-09
, O 0 2.392602782563813e-10
together O 0 2.8958986250660068e-11
, O 0 5.917861339854724e-11
in O 0 6.696332377487124e-11
a O 0 1.6372317945823056e-09
pathway O 0 3.391586744783126e-08
( O 0 6.276219544076866e-10
s O 0 1.9830543873666784e-09
) O 0 1.3381428777547999e-11
associated O 0 3.9473771473730324e-10
with O 0 2.663586538831364e-11
the O 0 9.389932165149162e-10
activation O 0 2.8973823340550098e-09
of O 0 2.684029443145164e-09
double O 0 2.3978488083997718e-09
- O 0 2.7719472939224943e-08
strand O 0 2.1556964213687024e-08
break O 0 2.4292358347111076e-08
repair O 0 1.2485401157391607e-06
and O 0 5.082187044536113e-07
/ O 0 3.7445408906933153e-06
or O 0 8.848871146938109e-08
homologous O 0 2.4541046528270272e-08
recombination O 0 3.814769655718919e-08
. O 0 1.686978094994629e-07

Dysfunction O 0 5.5563221394550055e-05
of O 0 6.347480393742444e-06
this O 0 2.509494390068312e-09
pathway O 0 1.1561107982061003e-07
may O 0 2.7242783029457485e-10
be O 0 9.570671338776648e-11
a O 0 5.833177829650538e-10
general O 0 4.98887908761958e-09
phenomenon O 0 2.367912443901332e-08
in O 0 1.49866397070042e-10
the O 0 5.051961071700362e-10
majority O 0 1.602555761703872e-11
of O 0 6.697890853057942e-11
cases O 0 1.8460236117512352e-10
of O 0 2.9174678228827133e-09
hereditary B-Disease 0 0.006892457138746977
breast I-Disease 1 0.9999997615814209
and I-Disease 1 0.9989176988601685
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.0582966138488246e-09
. O 0 1.1373487929233761e-08

A O 0 1.5949035514495336e-06
novel O 0 1.8013550118212152e-07
Arg362Ser O 0 9.738007520354586e-07
mutation O 0 3.6410281456511484e-09
in O 0 3.6755792853782054e-10
the O 0 4.232424188899131e-09
sterol O 0 3.054314277051162e-07
27 O 0 7.652845397387864e-07
- O 0 2.201982596261587e-07
hydroxylase O 0 2.9616057872772217e-07
gene O 0 8.267206652590176e-08
( O 0 7.394763912316193e-08
CYP27 O 0 0.0030380776152014732
) O 0 2.7982394179559833e-10
: O 0 4.176685386436674e-11
its O 0 1.4666975967081441e-10
effects O 0 9.790618982208343e-09
on O 0 2.270611254573396e-08
pre O 0 3.9254199890592645e-08
- O 0 9.708871040459144e-09
mRNA O 0 1.0259345373242468e-08
splicing O 0 1.3479818150585743e-08
and O 0 7.0187740064397985e-09
enzyme O 0 6.390388307409012e-08
activity O 0 2.801025118515099e-07
. O 0 1.9494014225074352e-07

A O 0 3.0752812563150655e-06
novel O 0 2.0066113393113483e-07
C O 0 1.5460059898941836e-07
to O 0 4.0117806299200254e-10
A O 0 2.388346764803373e-08
mutation O 0 2.211134830787387e-09
in O 0 4.006802389877606e-10
the O 0 6.720714651464732e-09
sterol O 0 4.933694413011835e-07
27 O 0 1.1583416608118569e-06
- O 0 2.7972396310360637e-07
hydroxylase O 0 3.9317558275797637e-07
gene O 0 4.91415086401048e-08
( O 0 6.16381896634266e-08
CYP27 O 0 6.31267175776884e-05
) O 0 2.5325735952819173e-10
was O 0 1.6986567707988343e-09
identified O 0 6.814080549810697e-11
by O 0 4.660335659045778e-11
sequencing O 0 4.451705226671265e-09
amplified O 0 3.907208423470365e-08
CYP27 O 0 1.571035113556718e-06
gene O 0 1.1454184267734036e-09
products O 0 6.6269771892280005e-09
from O 0 1.5044729906321663e-09
a O 0 2.7124777424170077e-10
patient O 0 1.3419603206443753e-09
with O 0 5.771985667202273e-10
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 3.1285676982406585e-07
CTX B-Disease 0 0.00016393516852986068
) O 0 5.5470490423203955e-08
. O 0 3.478048427041358e-07

The O 0 1.3291229095102608e-07
mutation O 0 1.2895036149984662e-07
changed O 0 1.8993171480019555e-08
the O 0 6.5653296132950345e-09
adrenodoxin O 0 1.3198365422795177e-07
cofactor O 0 1.4347276255932684e-08
binding O 0 4.440860834620253e-08
residue O 0 9.027958185470197e-07
362Arg O 0 4.0647384480507753e-07
to O 0 2.155215206300909e-08
362Ser O 0 7.085004654072691e-06
( O 0 2.1233327629488485e-07
CGT O 0 0.0003134890866931528
362Arg O 0 3.121515192106017e-06
to O 0 7.325414941306008e-08
AGT O 0 2.1780677343485877e-05
362Ser O 0 1.7164080645670765e-07
) O 0 1.2257476977861614e-10
, O 0 8.484288965826536e-11
and O 0 7.123614198523143e-11
was O 0 3.6146918791502003e-09
responsible O 0 3.7119324280965316e-10
for O 0 2.375252883268786e-09
deficiency O 0 0.0016696967650204897
in O 0 3.3478255545560387e-07
the O 0 1.2897405213152524e-05
sterol O 0 2.4849528017512057e-06
27 O 0 2.9564741907961434e-06
- O 0 2.392008298102155e-07
hydroxylase O 0 2.0335471617727308e-07
activity O 0 5.0301203202707256e-08
, O 0 5.884320114502017e-11
as O 0 2.577533152192668e-11
confirmed O 0 3.9053701245128636e-11
by O 0 1.0042969927903656e-11
expression O 0 5.470813246866157e-10
of O 0 2.1668542515840272e-09
mutant O 0 2.5392596914031174e-09
cDNA O 0 1.7596127221963798e-08
into O 0 8.259421235834452e-08
COS O 0 4.8802277888171375e-05
- O 0 5.927483925916022e-07
1 O 0 5.364792627915449e-07
cells O 0 9.019183266900654e-08
. O 0 2.687904441245337e-07

Quantitative O 0 2.2814865019427089e-07
analysis O 0 2.501133344878781e-08
showed O 0 7.908431243208724e-09
that O 0 8.804983131494026e-11
the O 0 9.5151797552262e-10
expression O 0 8.552211383516806e-09
of O 0 4.6131866326959425e-08
CYP27 O 0 2.2067176814744016e-06
gene O 0 1.3317151825731344e-09
mRNA O 0 6.193952017952142e-09
in O 0 5.259393476286789e-10
the O 0 1.4654847335648924e-09
patient O 0 5.3990611981191705e-09
represented O 0 2.7730790108648762e-08
52 O 0 2.693472652026685e-06
. O 0 5.432169132291165e-07

5 O 0 7.569272497676138e-07
% O 0 2.0812386480884015e-08
of O 0 1.306072672235814e-08
the O 0 5.794117896584794e-08
normal O 0 2.87245757135679e-06
level O 0 1.773902681634354e-06
. O 0 3.6360890476316854e-07

As O 0 5.5275393151532626e-09
the O 0 1.3837191392696013e-09
mutation O 0 1.6043281148014898e-09
occurred O 0 1.4251001267950869e-08
at O 0 4.762898964116857e-10
the O 0 2.3629426193494396e-10
penultimate O 0 6.857308942898044e-09
nucleotide O 0 5.438314687467027e-09
of O 0 7.3796702082518095e-09
exon O 0 1.1447048642310165e-08
6 O 0 3.545415836470056e-07
( O 0 3.2124116700060767e-09
- O 0 2.448246583242053e-08
2 O 0 2.8052856038129903e-08
position O 0 1.0624519575230806e-07
of O 0 4.3752066858360195e-08
exon O 0 4.06883309267414e-08
6 O 0 2.115741608577082e-06
- O 0 8.93376409294433e-07
intron O 0 5.927483925916022e-07
6 O 0 5.740737947235175e-07
splice O 0 3.5292973166178854e-07
site O 0 6.785570860756707e-08
) O 0 2.2053463222260206e-10
of O 0 1.570821694940605e-08
the O 0 4.278030729665261e-08
gene O 0 7.395056567105485e-09
, O 0 2.4237145623828837e-08
we O 0 1.958945672342338e-09
hypothesized O 0 6.995064971704323e-09
that O 0 8.96801799488145e-11
the O 0 1.5725954982670487e-09
mutation O 0 8.323593370107574e-09
may O 0 4.372326500856616e-09
partially O 0 9.300850933868787e-08
affect O 0 3.0790236138500404e-08
the O 0 2.645252727973002e-08
normal O 0 2.7013077996684842e-08
splicing O 0 1.4912291845803338e-08
efficiency O 0 1.5472826575546605e-08
in O 0 3.5483900262534007e-09
exon O 0 3.5088916661152325e-08
6 O 0 2.3780879132573318e-07
and O 0 4.491269578466017e-09
cause O 0 1.0947294626362236e-08
alternative O 0 5.8290092752599776e-09
splicing O 0 8.99445851132441e-09
elsewhere O 0 1.1336453553667525e-08
, O 0 6.405095898109892e-11
which O 0 2.681376128077506e-11
resulted O 0 1.2713424757393454e-09
in O 0 2.386122410769076e-10
decreased O 0 2.0839040715259216e-08
transcript O 0 9.396099009961745e-09
in O 0 6.664074292395128e-10
the O 0 1.941634231172884e-08
patient O 0 5.957543436352353e-08
. O 0 1.7420880737972766e-07

Transfection O 0 3.078751979046501e-05
of O 0 1.7907915434989263e-06
constructed O 0 1.4008822972755297e-06
minigenes O 0 2.9189915949245915e-05
, O 0 1.0527302363172453e-09
with O 0 2.5323262584087125e-11
or O 0 1.2561802986699178e-10
without O 0 5.584315232454173e-10
the O 0 2.0491821572932167e-09
mutation O 0 5.425899729516459e-10
, O 0 6.350622805406658e-11
into O 0 4.4968757606511645e-09
COS O 0 8.984465239336714e-06
- O 0 1.3292141431975324e-07
1 O 0 6.586780187944896e-08
cells O 0 4.424110855438812e-09
confirmed O 0 2.7983901862427274e-09
that O 0 3.816837818026997e-11
the O 0 5.401345481992337e-10
mutant O 0 4.9717430172790955e-09
minigene O 0 3.080851058712142e-07
was O 0 9.247180798865884e-09
responsible O 0 2.1981569342521823e-10
for O 0 2.6047755619096336e-10
a O 0 3.895999522995908e-09
mRNA O 0 1.744414745985523e-08
species O 0 4.0550618418677686e-10
alternatively O 0 1.443249786348133e-08
spliced O 0 1.4673058785774629e-06
at O 0 3.8334573559950513e-07
an O 0 3.820106897478581e-08
activated O 0 2.3608555466125836e-07
cryptic O 0 7.299346975742083e-07
5 O 0 1.157721669642342e-07
splice O 0 1.761219550644455e-06
site O 0 9.037916584020422e-07
88 O 0 2.290630050083564e-07
bp O 0 5.4160413043291555e-08
upstream O 0 8.453158528709537e-08
from O 0 6.8582370893466305e-09
the O 0 2.3050485964404288e-08
3 O 0 3.7737653002523075e-08
end O 0 6.128112062242508e-08
of O 0 8.292537501120023e-08
exon O 0 7.008770097627348e-08
6 O 0 2.561707560744253e-06
. O 0 1.2973304137631203e-06

Our O 0 2.1437936936763435e-07
data O 0 1.4351052790573249e-08
suggest O 0 9.65977431377496e-09
that O 0 1.880326727654591e-10
the O 0 1.7644580241338303e-09
C O 0 4.429793420968053e-09
to O 0 3.447798296862814e-11
A O 0 5.2616737633570665e-09
mutation O 0 1.174009001125853e-09
at O 0 9.745768636548746e-10
the O 0 1.5865568858686174e-09
penultimate O 0 3.926662728304109e-08
nucleotide O 0 1.4624056632328575e-08
of O 0 1.127409365864196e-08
exon O 0 1.0405295292059691e-08
6 O 0 3.046747565349506e-07
of O 0 8.503273107862697e-08
the O 0 3.2037891628533544e-07
CYP27 O 0 9.903903446684126e-06
gene O 0 1.1938420252377568e-09
not O 0 2.2095231200225385e-10
only O 0 6.702648436274217e-10
causes O 0 2.829618139799095e-08
the O 0 1.025371165752631e-08
deficiency B-Disease 0 4.782247486900815e-08
in I-Disease 0 3.237248691334571e-09
the I-Disease 0 9.542559098463244e-08
sterol I-Disease 0 7.919602467154618e-07
27 I-Disease 0 8.884349540494441e-07
- I-Disease 0 2.1595612054170488e-07
hydroxylase I-Disease 0 2.002298771230926e-07
activity I-Disease 0 8.023481257168896e-08
, O 0 2.580968216925328e-10
but O 0 1.1581998693444007e-09
also O 0 2.387502862077895e-09
partially O 0 3.0898544167712316e-08
leads O 0 2.48163001259627e-09
to O 0 5.631463628752442e-10
alternative O 0 5.23523837614448e-08
pre O 0 3.615121357825046e-08
- O 0 5.445040418550207e-09
mRNA O 0 6.769667049155714e-09
splicing O 0 1.424706042030266e-08
of O 0 1.7319919720648613e-08
the O 0 3.6107937972928994e-08
gene O 0 1.1801864019389541e-07
. O 0 1.0007333912653849e-06

To O 0 2.8550768860213793e-08
our O 0 5.220132592853588e-08
knowledge O 0 2.681242072810619e-08
, O 0 1.6539412894811534e-10
this O 0 3.070328019605384e-11
is O 0 2.10617842610894e-11
the O 0 8.856895772346718e-11
first O 0 2.9683652758016876e-10
report O 0 5.852222595414958e-10
regarding O 0 4.1012047091726345e-09
effects O 0 5.144860537598106e-08
on O 0 8.580710897376775e-08
pre O 0 6.301871025016226e-08
- O 0 3.741868148665617e-09
mRNA O 0 2.267978249648195e-09
splicing O 0 3.0660647354352477e-09
of O 0 2.524511266699392e-09
a O 0 8.315259036884015e-10
mutation O 0 2.6661408636385886e-09
at O 0 9.727592065189583e-09
the O 0 2.014326128119137e-08
- O 0 1.1301435343114008e-08
2 O 0 3.2303667296673666e-08
position O 0 1.886820939489553e-07
of O 0 1.1000211230793866e-07
a O 0 1.2703449669970723e-07
5 O 0 6.693136356261675e-07
splice O 0 5.364499429560965e-06
site O 0 5.0828111852752045e-06
. O 0 1.3237167877377942e-06

ATM O 0 0.00023279889137484133
germline O 0 1.66019508469617e-05
mutations O 0 1.1128031474072486e-07
in O 0 4.591204749715416e-09
classical O 1 0.9872238636016846
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.8624796271324158
in O 0 1.0453190535386625e-09
the O 0 2.309289870439102e-09
Dutch O 0 4.636421735426666e-08
population O 0 1.3217903438444978e-09
. O 0 7.84064901893089e-09

Germline O 0 2.7322899768478237e-05
mutations O 0 5.095533310850442e-07
in O 0 5.538810743388467e-09
the O 0 4.5939199111444395e-09
ATM O 0 1.4632767886268994e-07
gene O 0 3.499203982126886e-10
are O 0 4.9048235091497805e-12
responsible O 0 7.801195453516208e-12
for O 0 1.4888566074455767e-11
the O 0 2.539872184570413e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.1158782342590712e-08
. O 0 2.4631365391769577e-08

In O 0 2.0091178498660156e-07
our O 0 9.648453414001779e-08
study O 0 5.304185979326803e-09
, O 0 1.4613028842536124e-10
we O 0 5.26077549578563e-11
have O 0 2.4351980501546855e-11
determined O 0 1.0256993032697892e-09
the O 0 3.85337228792082e-09
ATM O 0 2.502906681911554e-07
mutation O 0 4.85340523326272e-09
spectrum O 0 6.495515680882136e-09
in O 0 4.053236912771041e-10
19 O 0 3.049072105909545e-08
classical O 0 0.007948687300086021
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.5012204812592245e-08
, O 0 4.909131087749152e-11
including O 0 4.550171437550654e-12
some O 0 9.283646767999088e-11
immigrant O 0 1.9613132451468118e-08
populations O 0 1.4919453450445985e-09
, O 0 9.607066531192032e-11
as O 0 5.861069407586683e-10
well O 0 3.6754529975091543e-10
as O 0 1.1313421310887861e-09
12 O 0 6.702497667987473e-09
of O 0 8.452026634131471e-09
Dutch O 0 1.3399562703853007e-07
ethnic O 0 4.47203873932267e-08
origin O 0 3.0361894687302993e-07
. O 0 6.847090503470099e-07

Both O 0 3.338368514960166e-08
the O 0 3.048781493930619e-08
protein O 0 7.126641321519855e-08
truncation O 0 6.794195428483363e-08
test O 0 3.2992595322411944e-09
( O 0 2.345397476233302e-08
PTT O 0 1.1087836355727632e-06
) O 0 2.617500660662131e-10
and O 0 2.0604763728560016e-10
the O 0 8.192230782633203e-10
restriction O 0 8.171931575873259e-09
endonuclease O 0 2.5703203121452134e-08
fingerprinting O 0 1.924618331372585e-08
( O 0 2.2484851314175103e-08
REF O 0 2.384719550718728e-07
) O 0 1.1655278131517122e-10
method O 0 1.203026456231271e-09
were O 0 1.319895165385887e-10
used O 0 1.6187369500375581e-10
and O 0 2.9298014014855767e-10
compared O 0 2.2716364345143347e-09
for O 0 1.6498390154051634e-10
their O 0 6.457883672261744e-10
detection O 0 1.2457451958880483e-08
efficiency O 0 8.815074892254415e-09
, O 0 1.7946821806447133e-10
identifying O 0 8.355246272628847e-09
76 O 0 5.067290587135176e-08
% O 0 1.2060314968920238e-09
and O 0 7.553110220603898e-11
60 O 0 2.7633095811552266e-09
% O 0 1.2952631189833141e-09
of O 0 2.015597244664491e-09
the O 0 9.492072905459281e-09
mutations O 0 4.8181099998600985e-08
, O 0 6.978833066995094e-09
respectively O 0 5.8070181552238864e-08
. O 0 6.408887429643073e-07

Most O 0 1.1096557273049257e-07
patients O 0 1.181568975994196e-08
were O 0 2.617352112821436e-09
found O 0 8.409442031620529e-10
to O 0 4.100076667068464e-10
be O 0 2.937244447664966e-09
compound O 0 1.2792431789421244e-06
heterozygote O 0 9.363162098452449e-05
. O 0 2.7576568299991777e-06

Seventeen O 0 8.148041160893627e-06
mutations O 0 2.891819406158902e-07
were O 0 1.6449012818497977e-08
distinct O 0 1.4049715169051069e-08
, O 0 7.917980715532735e-10
of O 0 1.655608650175111e-09
which O 0 1.188969339649404e-10
10 O 0 1.3233897311337728e-09
were O 0 1.0737515321324054e-09
not O 0 1.6119102719258649e-09
reported O 0 8.813734098112036e-08
previously O 0 3.139242821248445e-08
. O 0 2.3155720896284038e-07

Mutations O 0 1.5473792700504418e-06
are O 0 9.02828478643869e-09
small O 0 1.4411673632253041e-08
deletions O 0 8.768274710746482e-07
or O 0 1.4874319731461583e-06
point O 0 1.4053371160116512e-05
mutations O 0 4.453661404113518e-07
frequently O 0 5.680966097543205e-08
affecting O 0 6.989466072582218e-08
splice O 0 8.235011591750663e-06
sites O 0 3.633569576777518e-06
. O 0 1.5506720956182107e-06

Moreover O 0 6.032108558429172e-06
, O 0 6.026078125387357e-08
a O 0 1.510694147555114e-07
16 O 0 1.945146777870832e-06
. O 0 1.160624037765956e-06

7 O 0 8.87273381522391e-06
- O 0 5.776010425506684e-07
kb O 0 2.61422087532992e-07
genomic O 0 1.818123074315281e-08
deletion O 0 6.808930308466188e-09
of O 0 1.0810348172185513e-08
the O 0 5.526548108036877e-09
3 O 0 8.66516103315007e-09
end O 0 1.4525287639344242e-08
of O 0 2.8708360133578026e-08
the O 0 1.0634429337130769e-08
gene O 0 6.197162227827846e-10
, O 0 1.573356861461761e-10
most O 0 7.52603188103329e-11
likely O 0 6.605281321903078e-10
a O 0 1.980339225937655e-10
result O 0 1.4917518331714064e-09
of O 0 1.5606820280567035e-09
recombination O 0 1.0591141158533546e-10
between O 0 3.397490067058584e-09
two O 0 7.174017824240764e-09
LINE O 0 4.397210886963876e-06
elements O 0 4.279864906919784e-09
, O 0 1.957630724191972e-09
was O 0 4.4971180557240586e-08
identified O 0 6.714387268402788e-08
. O 0 4.7077466547307267e-07

The O 0 6.502373253169935e-07
most O 0 2.0212226559124247e-08
frequently O 0 4.585900992282177e-09
found O 0 2.265594933881232e-10
mutation O 0 2.6198529456955555e-10
, O 0 2.7063472990418447e-11
identified O 0 3.5734640246865013e-10
in O 0 1.490414458515943e-10
three O 0 4.1157624530718806e-10
unrelated O 0 3.345794752362963e-08
Turkish O 0 5.896277343708789e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
individuals O 0 4.960035493439818e-09
, O 0 1.9613644042237866e-09
was O 0 2.55106709090569e-08
previously O 0 9.712385340421292e-10
described O 0 2.9561217362861214e-10
to O 0 7.601758111874801e-11
be O 0 1.7805835972328765e-10
a O 0 3.4606559840000273e-09
Turkish O 0 1.2217935363878496e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
founder O 0 8.527279715053737e-05
mutation O 0 6.740357889611914e-07
. O 0 1.1545869682549892e-07

The O 0 2.1659428739440045e-07
presence O 0 1.8633384968325117e-07
of O 0 6.625790547332144e-07
a O 0 3.683520688468889e-08
founder O 0 3.605632628023159e-07
mutation O 0 2.8559359321889133e-09
among O 0 1.4884712906670927e-10
relatively O 0 5.30717858548968e-10
small O 0 2.5020230332017945e-10
ethnic O 0 2.1976791220179592e-10
population O 0 1.3836808435141457e-11
groups O 0 2.039485550928144e-12
in O 0 2.81885643299562e-11
Western O 0 3.0566169595402926e-09
Europe O 0 3.047941343758964e-10
could O 0 6.97358726320374e-10
indicate O 0 6.081255943257702e-09
a O 0 1.7562388210379254e-09
high O 0 5.1874948781005514e-09
carrier O 0 2.033257728850657e-10
frequency O 0 2.064411308566605e-09
in O 0 2.5849686280388084e-10
such O 0 3.0119733374078805e-09
communities O 0 1.5212465598324343e-07
. O 0 1.0043485190180945e-06

In O 0 8.869244894071926e-09
patients O 0 6.4665650612028e-09
of O 0 2.0743824435953684e-08
Dutch O 0 1.0073490557260811e-06
ethnic O 0 2.9609832807864223e-08
origin O 0 5.368873345901193e-08
, O 0 4.907111939012054e-10
however O 0 3.116023661320355e-09
, O 0 4.3436387819895117e-10
no O 0 4.4297427947981305e-09
significant O 0 1.1670955757381307e-07
founder O 0 1.0212448842139565e-06
effect O 0 5.098556812299648e-07
could O 0 3.474593057717357e-08
be O 0 1.8164385551244777e-08
identified O 0 6.274627253333165e-07
. O 0 6.931317670932913e-07

The O 0 7.413842695314088e-08
observed O 0 4.94517919946702e-08
genetic O 0 1.8921108235758766e-08
heterogeneity O 0 6.630506987903573e-08
including O 0 2.2273964617181008e-10
the O 0 4.201137659975984e-09
relative O 0 2.1356813704187516e-06
high O 0 4.028119292343035e-06
percentage O 0 1.0711806908147992e-06
of O 0 7.255941625317064e-08
splice O 0 1.1700526556523982e-06
- O 0 2.121996516279978e-07
site O 0 1.8303015281162516e-07
mutations O 0 1.811390859529638e-08
had O 0 6.98216195971213e-09
no O 0 1.746464528551428e-09
reflection O 0 2.1661778148995836e-08
on O 0 3.2099571001253935e-08
the O 0 1.2105287794383912e-07
phenotype O 0 2.8027561711496674e-06
. O 0 4.958326371706789e-07

All O 0 4.995059033063853e-09
patients O 0 1.9667290018787753e-09
manifested O 0 9.888471375063546e-09
classical O 0 1.9235251613736182e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999669790267944
T I-Disease 1 1.0
and O 0 3.578970453332886e-09
increased O 0 1.1654644360703514e-08
cellular O 0 1.0756502355491193e-08
radioresistant O 0 7.402482538054755e-08
DNA O 0 2.755616179683784e-08
synthesis O 0 2.876734583878715e-07
. O 0 2.1470141575719026e-07

Determination O 0 4.567380074149696e-08
of O 0 9.117129451396977e-08
the O 0 6.526089890712683e-09
genomic O 0 2.602623183634023e-08
structure O 0 6.339434310831393e-09
of O 0 3.257614622498295e-09
the O 0 9.8471399923028e-09
COL4A4 O 0 1.756643905537203e-05
gene O 0 8.93893958853198e-10
and O 0 1.4757052524405623e-10
of O 0 2.640763163697102e-10
novel O 0 2.4087585259735533e-09
mutations O 0 4.6400398900914297e-07
causing O 0 4.4692254164147016e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.3391631000558846e-05

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 7.419667991115375e-09
a O 0 6.082798709172721e-09
progressive O 1 0.896721601486206
hematuric B-Disease 1 0.9999912977218628
glomerulonephritis I-Disease 1 1.0
characterized O 0 1.0762661872831814e-07
by O 0 5.9026379339854884e-09
glomerular B-Disease 1 0.9999994039535522
basement I-Disease 0 0.13647590577602386
membrane I-Disease 0 6.211984668880177e-07
abnormalities I-Disease 0 2.8944626251359296e-07
and O 0 2.6567989475090314e-10
associated O 0 8.077203794698562e-09
with O 0 1.366635415944728e-10
mutations O 0 8.493834080525176e-09
in O 0 7.496193665801343e-10
either O 0 4.701507183568765e-09
the O 0 1.0511601544749283e-07
COL4A3 O 0 0.0010548029094934464
or O 0 7.966520776392372e-09
the O 0 9.070420503576315e-08
COL4A4 O 0 4.7482867557846475e-06
gene O 0 3.86450826894702e-09
, O 0 7.384115541242409e-10
which O 0 2.462185177964926e-10
encode O 0 5.0960360375995606e-09
the O 0 1.021545443791183e-07
alpha3 O 0 9.556011718814261e-06
and O 0 5.8589296969557836e-08
alpha4 O 0 3.5047160054091364e-06
type O 0 3.371142724972742e-07
IV O 0 8.486767183057964e-05
collagen O 0 3.685042656798032e-06
chains O 0 5.9649723880284e-06
, O 0 2.043598357204246e-07
respectively O 0 6.972941264393739e-07
. O 0 8.866135203788872e-07

To O 0 2.9651994637447388e-08
date O 0 7.790057452439214e-07
, O 0 1.1200484983930892e-09
mutation O 0 1.009330813372955e-10
screening O 0 1.0176468695499707e-10
in O 0 2.904186058305669e-10
the O 0 8.459767997237577e-09
two O 0 2.5687554305875437e-09
genes O 0 3.4354346034604077e-09
has O 0 6.062271240558914e-10
been O 0 4.372741058134011e-10
hampered O 0 1.7329867318949255e-08
by O 0 2.649946373445289e-10
the O 0 2.497205464635499e-08
lack O 0 3.311303089503781e-07
of O 0 5.797434354803954e-08
genomic O 0 1.203764270485408e-07
structure O 0 7.892100484241382e-08
information O 0 1.022071671741287e-07
. O 0 8.527437671546068e-07

We O 0 7.225572318247941e-08
report O 0 2.4185196068060577e-08
here O 0 1.0563083741033097e-09
the O 0 4.908412565285403e-10
complete O 0 7.391527390154806e-10
characterization O 0 3.702178830167213e-08
of O 0 8.679402974109962e-09
the O 0 1.1262873300665888e-08
48 O 0 8.747780810836048e-08
exons O 0 1.7485861292243499e-07
of O 0 2.364668034715578e-07
the O 0 9.021210303217231e-07
COL4A4 O 0 0.06071586161851883
gene O 0 1.9349243984834175e-08
, O 0 3.543925819471383e-09
a O 0 9.73497504830334e-10
comprehensive O 0 4.358653882263752e-09
gene O 0 9.624091523718903e-10
screen O 0 2.5591473828967537e-08
, O 0 7.936548085396566e-10
and O 0 1.854702086356852e-10
the O 0 2.0495798114250618e-10
subsequent O 0 2.562827727814465e-10
detection O 0 2.9213209629119774e-09
of O 0 1.3022810607665747e-09
10 O 0 2.3151112138464214e-09
novel O 0 1.0763022695314817e-09
mutations O 0 1.7255976647589932e-09
in O 0 1.9484548696713233e-10
eight O 0 3.21494919575116e-09
patients O 0 8.282291297234678e-09
diagnosed O 0 3.5002494769287296e-07
with O 0 7.751712161052637e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.3308673487699707e-06

Furthermore O 0 1.192888589685026e-06
, O 0 1.692574258527202e-08
we O 0 5.575462758145022e-09
identified O 0 1.7327321799598394e-08
a O 0 3.4638651946750088e-09
glycine O 0 4.412338050485687e-09
to O 0 1.5656700380617394e-09
alanine O 0 1.9669625928031564e-08
substitution O 0 1.483948519620526e-08
in O 0 3.683975347001933e-09
the O 0 3.0062984990308905e-08
collagenous O 0 4.0662035871719127e-07
domain O 0 4.023614774695261e-09
that O 0 2.7294586035786494e-10
is O 0 1.9559689978798644e-10
apparently O 0 4.2218135654081834e-09
silent O 0 1.7686226927438042e-09
in O 0 1.6198457852834025e-10
the O 0 1.6322242446520363e-09
heterozygous O 0 3.375507651171006e-10
carriers O 0 1.6110189848816958e-09
, O 0 9.941266698731965e-10
in O 0 7.122915590684897e-09
11 O 0 5.706257866222586e-07
. O 0 1.1541910680534784e-06

5 O 0 7.68062932365865e-07
% O 0 1.1606396732588564e-08
of O 0 2.95621904733423e-09
all O 0 8.256132583150944e-11
control O 0 3.003951254409998e-10
individuals O 0 1.0618669832318517e-10
, O 0 6.737457119987411e-11
and O 0 4.758819033279238e-11
in O 0 1.1857895221289994e-10
one O 0 2.1864571264629262e-10
control O 0 3.970596629265799e-10
individual O 0 3.1125532706788306e-10
homozygous O 0 1.9664889716608513e-09
for O 0 1.0205707390298357e-09
this O 0 2.6245656759016356e-09
glycine O 0 4.097633521382704e-08
substitution O 0 5.56314319055673e-07
. O 0 8.361784580301901e-07

There O 0 1.7595229451217165e-07
has O 0 3.3539138133420465e-09
been O 0 4.824698418559592e-10
no O 0 3.0361335667805633e-10
previous O 0 1.7412159492025125e-09
finding O 0 9.408150702938656e-09
of O 0 4.5834349648998796e-09
a O 0 9.084644148060761e-10
glycine O 0 8.860211453409761e-10
substitution O 0 1.9883641400042507e-09
that O 0 1.1015018758220307e-10
is O 0 3.357629452249711e-11
not O 0 1.149450760268289e-11
associated O 0 3.002479376235101e-10
with O 0 1.9421833932775634e-11
any O 0 4.461012892420513e-09
obvious O 0 4.693231403507525e-07
phenotype O 0 4.039703327407551e-08
in O 0 7.069165808282207e-10
homozygous O 0 1.3249612962340507e-08
individuals O 0 1.1878914740748314e-08
. O 0 8.83948928276368e-07

Founder O 0 0.0002186807250836864
BRCA1 O 0 9.378049071528949e-06
and O 0 1.5183029233867273e-07
BRCA2 O 0 1.4851934793114197e-07
mutations O 0 3.659087033369701e-09
in O 0 1.5587385548965216e-10
French O 0 1.1945992639539327e-07
Canadian O 0 1.9196459106751718e-05
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.181065970167765e-08
. O 0 1.957269546437601e-08

We O 0 3.5491904526452345e-08
have O 0 1.1540564059941971e-09
identified O 0 3.814833338111612e-09
four O 0 1.9334836509621312e-10
mutations O 0 2.401912280181051e-10
in O 0 4.0575973137002563e-11
each O 0 1.8882982677492777e-10
of O 0 4.68750585014277e-08
the O 0 2.6294472263543867e-05
breast B-Disease 1 0.989087700843811
cancer I-Disease 0 0.14663085341453552
- O 0 5.023711082685622e-07
susceptibility O 0 7.128136303435895e-07
genes O 0 4.904796213622831e-08
, O 0 6.042061961863965e-09
BRCA1 O 0 5.422108628749811e-08
and O 0 6.351488668343563e-09
BRCA2 O 0 4.145041643255354e-08
, O 0 1.0972577707546449e-10
in O 0 1.1112363113019441e-10
French O 0 1.7746424418874085e-07
Canadian O 0 5.688056603503355e-07
breast B-Disease 0 0.00034623692044988275
cancer I-Disease 1 0.8313824534416199
and O 0 0.004166778177022934
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.8728941448008527e-09
from O 0 2.670288656858588e-09
Quebec O 0 9.200333295211749e-08
. O 0 4.319164403909781e-08

To O 0 1.8037719939911767e-07
identify O 0 1.8858311250369297e-06
founder O 0 3.8342732295859605e-05
effects O 0 5.8399538829689845e-05
, O 0 6.081545933511734e-09
we O 0 1.0155996044147741e-09
examined O 0 3.3966478518721033e-09
independently O 0 2.6619741966271704e-09
ascertained O 0 3.177350720307004e-07
French O 0 3.992959207721469e-08
Canadian O 0 1.5116819795935044e-08
cancer B-Disease 0 6.361284388134436e-09
families O 0 5.171406358694952e-11
for O 0 4.777023394908486e-12
the O 0 5.4860772175091554e-11
distribution O 0 4.459692060088116e-10
of O 0 4.829670552375376e-10
these O 0 1.0288342400244233e-09
eight O 0 3.459812702999443e-08
mutations O 0 1.1485866480143159e-06
. O 0 8.014683885448903e-07

Mutations O 0 1.5214409359032288e-06
were O 0 7.348238995064094e-08
found O 0 2.801883169922803e-09
in O 0 6.955892528637264e-10
41 O 0 5.057625074300631e-08
of O 0 9.631368591556111e-09
97 O 0 4.09602478157467e-07
families O 0 4.638650707988745e-08
. O 0 2.7043782324653876e-07

Six O 0 4.4894218831359467e-07
of O 0 9.012407531372446e-08
eight O 0 2.4611830795606693e-08
mutations O 0 2.1514777515108108e-08
were O 0 3.957080885186315e-09
observed O 0 6.899132820592513e-09
at O 0 1.1259866816715203e-08
least O 0 8.424922093297482e-09
twice O 0 7.408782209950004e-08
. O 0 1.9158963482368563e-07

The O 0 2.5127033040917013e-06
BRCA1 O 0 3.0519458960043266e-06
C4446T O 0 1.7541792658448685e-06
mutation O 0 1.6625838483719235e-08
was O 0 5.36221866909159e-09
the O 0 2.8231891824326283e-10
most O 0 1.5062093239315288e-10
common O 0 3.261461101189411e-10
mutation O 0 1.3396536102661116e-09
found O 0 5.640880540447313e-10
, O 0 1.0019116786219584e-10
followed O 0 7.462868656382682e-10
by O 0 4.6207557224953177e-10
the O 0 2.1424203566766664e-07
BRCA2 O 0 1.218100715050241e-05
8765delAG O 0 2.0881070668110624e-06
mutation O 0 3.241489423544408e-07
. O 0 3.2866060450942314e-07

Together O 0 5.811372716379992e-08
, O 0 6.782798323001771e-09
these O 0 6.707610578082779e-10
mutations O 0 9.229295550028382e-09
were O 0 9.284997215530666e-10
found O 0 2.2532137267106123e-10
in O 0 7.949634006632067e-11
28 O 0 1.2257114434532923e-08
of O 0 4.1924526072989465e-09
41 O 0 3.403445703042962e-08
families O 0 1.2278869032655848e-09
identified O 0 5.3758997253794405e-09
to O 0 1.9343586732389895e-09
have O 0 1.6443170158808584e-09
a O 0 1.5452329193976766e-08
mutation O 0 2.206822102834849e-07
. O 0 2.4883388505259063e-07

The O 0 4.315788544317911e-07
odds O 0 9.620720220482326e-07
of O 0 2.0418318147363834e-09
detection O 0 5.7494635719024245e-09
of O 0 9.149960789045508e-10
any O 0 3.098622691766195e-09
of O 0 8.248228056118023e-08
the O 0 2.0230687880484766e-07
four O 0 5.991672225036382e-08
BRCA1 O 0 3.4852234875870636e-07
mutations O 0 7.639968657713325e-08
was O 0 3.1941880251906696e-07
18 O 0 6.269489176702336e-07
. O 0 7.426729098369833e-07

7x O 0 0.0004617303784471005
greater O 0 1.6116732695081737e-06
if O 0 1.8766888842947083e-07
one O 0 1.167553786984854e-08
or O 0 1.384388992331509e-10
more O 0 1.0847675188663253e-11
cases O 0 9.764691277780457e-10
of O 0 1.3787688146749133e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 3.0264393213741414e-09
also O 0 3.5851908247730435e-11
present O 0 1.0190880778138123e-10
in O 0 4.109432238941224e-10
the O 0 2.5607880260736238e-08
family O 0 5.6062201991835536e-08
. O 0 2.694654597235058e-07

The O 0 2.3224147582823207e-07
odds O 0 7.086437676662172e-07
of O 0 9.199992434538729e-10
detection O 0 2.8712399124941612e-09
of O 0 4.109691198461718e-10
any O 0 1.1959843115860735e-09
of O 0 3.667333814405538e-08
the O 0 7.632758780573567e-08
four O 0 4.0838930459585754e-08
BRCA2 O 0 2.5845972118077043e-07
mutations O 0 2.9168239379373517e-08
was O 0 1.5118413898562721e-07
5 O 0 3.912966519692418e-07
. O 0 3.7569245137092366e-07

3x O 0 4.660707872972125e-06
greater O 0 6.465703705771375e-08
if O 0 1.1928820597972845e-08
there O 0 5.54570300792534e-09
were O 0 4.028851918747023e-09
at O 0 1.8449931582509294e-09
least O 0 2.2032610458300184e-10
five O 0 1.190131049266796e-10
cases O 0 4.3906259183934537e-10
of O 0 1.2108401392652013e-08
breast B-Disease 0 1.8503808405512245e-06
cancer I-Disease 0 4.781727966474136e-06
in O 0 5.646459744212962e-09
the O 0 2.5254283286813006e-07
family O 0 8.49440553452041e-08
. O 0 2.1238835756776098e-07

Interestingly O 0 1.7844938611233374e-06
, O 0 5.9831046783642705e-09
the O 0 4.924825880436856e-09
presence O 0 2.0979543435828418e-08
of O 0 3.8988713413345977e-07
a O 0 3.139351179015648e-07
breast B-Disease 0 2.0583474906743504e-06
cancer I-Disease 0 6.742980929175246e-08
case O 0 2.0080608287287305e-09
< O 0 2.134155741018162e-09
36 O 0 8.030626830191068e-09
years O 0 7.883201869063328e-10
of O 0 2.3472310761718518e-09
age O 0 1.432717677829487e-08
was O 0 1.3383715247172745e-09
strongly O 0 2.8592574488617295e-11
predictive O 0 1.417652106816547e-09
of O 0 4.642257411813233e-10
the O 0 3.096092826559982e-10
presence O 0 5.172228201288931e-10
of O 0 1.1778085173830277e-09
any O 0 3.07153724676823e-09
of O 0 3.9802607432193327e-08
the O 0 5.5059921066913375e-08
eight O 0 1.6024939597514276e-08
mutations O 0 1.5585534640649712e-07
screened O 0 3.8188034068298293e-07
. O 0 4.152053350026108e-07

Carriers O 0 1.0707171149704209e-08
of O 0 9.477151508008319e-08
the O 0 3.0815204610235014e-08
same O 0 2.2969939283967733e-09
mutation O 0 1.2287140194189305e-09
, O 0 3.079847141207459e-11
from O 0 7.115873862373334e-11
different O 0 1.5798100327923947e-10
families O 0 2.4357020844689714e-09
, O 0 2.2019965018049703e-10
shared O 0 4.062214453703916e-10
similar O 0 5.765427579795812e-10
haplotypes O 0 4.866978997597471e-08
, O 0 2.575912538826941e-10
indicating O 0 5.063964358953399e-09
that O 0 9.975793802130539e-11
the O 0 2.2892654438777527e-09
mutant O 0 5.208086406582879e-09
alleles O 0 1.5068422065667164e-09
were O 0 2.6516870921255986e-09
likely O 0 1.08372633089715e-09
to O 0 2.7275018354977476e-10
be O 0 3.158422412496975e-10
identical O 0 2.0285095825300914e-09
by O 0 3.69155622736983e-10
descent O 0 1.1318002535176674e-08
for O 0 2.949475941260715e-10
a O 0 1.873132760010776e-09
mutation O 0 2.6631623573081242e-09
in O 0 9.411376122869797e-10
the O 0 3.1536703914980535e-08
founder O 0 6.653144737356342e-07
population O 0 2.1262339444660938e-08
. O 0 1.8384501743184956e-07

The O 0 3.4495186707061976e-09
identification O 0 9.443279935794635e-09
of O 0 9.747911811075483e-09
common O 0 1.2604229482349183e-07
BRCA1 O 0 2.250842771900352e-05
and O 0 7.337775969062932e-07
BRCA2 O 0 7.407227826661256e-07
mutations O 0 6.682049136230717e-09
will O 0 7.519417033474696e-11
facilitate O 0 4.4132028587107186e-10
carrier O 0 9.514938142940466e-11
detection O 0 2.160573053799908e-09
in O 0 5.623649323993618e-10
French O 0 2.383339960942976e-06
Canadian O 0 8.245997378253378e-06
breast B-Disease 1 0.9997286200523376
cancer I-Disease 1 0.9999982118606567
and O 0 0.05613507330417633
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.87631145567957e-08
. O 0 2.0425416025204868e-08

Are O 0 2.667739451567286e-08
Dp71 O 0 1.3033788491156884e-05
and O 0 2.720314284943015e-08
Dp140 O 0 3.1356905765278498e-06
brain O 0 9.502651892034919e-07
dystrophin O 0 3.823496967925166e-07
isoforms O 0 2.532943454980341e-08
related O 0 3.716064567171884e-09
to O 0 2.1742306566263636e-10
cognitive B-Disease 0 1.5427672224177513e-06
impairment I-Disease 0 0.00010572001338005066
in O 0 1.0675933737047671e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 0 0.2246943861246109

Molecular O 0 9.183412998936547e-07
study O 0 1.3505140117331393e-08
and O 0 3.109046631255552e-10
neuropsychological O 0 3.1477673800850425e-09
analysis O 0 5.943058489776831e-09
were O 0 2.2573229951916574e-09
performed O 0 3.779444812668231e-10
concurrently O 0 2.694107825718106e-09
on O 0 8.696964259868878e-10
49 O 0 7.1205517038208654e-09
patients O 0 5.925496898706584e-11
with O 0 7.673023882937002e-10
Duchenne B-Disease 1 0.9999169111251831
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0004264604358468205
DMD B-Disease 1 1.0
) O 0 1.2008158356557885e-10
in O 0 2.809961638372549e-11
order O 0 4.7898716243333084e-11
to O 0 2.4338794868405955e-11
find O 0 3.2222652324165324e-10
a O 0 1.7771227545093637e-10
molecular O 0 1.9291672703758422e-09
explanation O 0 2.8315709776904896e-09
for O 0 1.4362182276794755e-10
the O 0 1.388219139641933e-08
cognitive B-Disease 0 4.574678314384073e-06
impairment I-Disease 0 1.82822884653433e-06
observed O 0 1.9393432637571095e-08
in O 0 9.918575960554676e-10
most O 0 1.8894565911864447e-08
DMD B-Disease 1 1.0
patients O 0 2.7644707856211426e-08
. O 0 1.3311017710293527e-07

Complete O 0 7.55382334460819e-09
analysis O 0 1.1427502499827824e-08
of O 0 7.973468107991266e-09
the O 0 9.615655827133196e-09
dystrophin O 0 1.554713122686735e-07
gene O 0 1.2867905851976502e-08
was O 0 1.0761183943941433e-07
performed O 0 4.37273897646584e-11
to O 0 4.900533798202211e-11
define O 0 1.6444926531633541e-09
the O 0 6.171428257317757e-09
localization O 0 1.8199278883912484e-07
of O 0 2.4280778276875026e-08
deletions O 0 8.587603872456384e-08
and O 0 1.4175014051431845e-08
duplications O 0 5.223503762863402e-07
in O 0 5.736056962746261e-09
relation O 0 1.3278200761135395e-08
to O 0 1.7497387982956525e-09
the O 0 1.743736177672872e-08
different O 0 1.4196366748819855e-07
DMD B-Disease 1 1.0
promoters O 0 3.42954954248853e-05
. O 0 4.754272140417015e-06

Qualitative O 0 5.294404559208488e-07
analysis O 0 3.691608796430046e-08
of O 0 6.388438578142086e-08
the O 0 1.3240043017503922e-07
Dp71 O 0 5.193890956434188e-06
transcript O 0 2.3795399783921312e-07
and O 0 3.9876429935858937e-10
testing O 0 8.489080965956575e-11
for O 0 1.0146853496317831e-10
the O 0 1.6288345117132508e-09
specific O 0 1.5260823715834704e-09
first O 0 3.0614950574658906e-09
exon O 0 4.388920338271873e-09
of O 0 9.721474469870373e-08
Dp140 O 0 7.298490913854039e-07
were O 0 4.661186991938848e-08
also O 0 8.298009390728112e-09
carried O 0 3.7726785251379624e-08
out O 0 5.037253814066389e-08
. O 0 3.6709872119899956e-07

Neuropsychological O 0 3.6218372656549036e-07
analysis O 0 3.375877710709574e-08
assessed O 0 7.711118144015927e-08
verbal O 0 8.725734090830883e-08
and O 0 1.228374912898289e-08
visuospatial O 0 2.4662685973453335e-06
intelligence O 0 1.0253109650193437e-07
, O 0 1.491322976221454e-08
verbal O 0 1.3840265467024437e-07
memory O 0 0.00012826929742004722
, O 0 2.9490907493823215e-08
and O 0 9.823765800831552e-09
reading O 0 7.510504360652703e-07
skills O 0 1.081002778846596e-06
. O 0 1.5214873201330192e-06

Comparison O 0 2.8035046852892265e-06
of O 0 4.0656996702637116e-07
molecular O 0 4.795775794264046e-07
and O 0 7.342015440059413e-09
psychometric O 0 5.690932312063524e-07
findings O 0 7.545647662254851e-08
demonstrated O 0 1.3413519184268807e-08
that O 0 1.0960325980136076e-09
deletions O 0 1.9628624059464528e-08
and O 0 2.4989099678407456e-09
duplications O 0 7.158766379689041e-08
that O 0 1.5877313908063684e-09
were O 0 1.291028284278184e-09
localized O 0 4.5766583411932515e-08
in O 0 4.93962204473064e-10
the O 0 3.6873004649606855e-09
distal O 0 1.5962044130901631e-07
part O 0 9.085705521272303e-09
of O 0 4.3253396597719984e-07
the O 0 3.048857593057619e-07
gene O 0 1.1861730264683956e-08
seemed O 0 6.247977779594294e-08
to O 0 3.6260705549295835e-10
be O 0 1.6380430345463992e-10
preferentially O 0 4.221097249512695e-09
associated O 0 1.223310430731317e-08
with O 0 4.2685983636658875e-09
cognitive B-Disease 0 0.2919835150241852
impairment I-Disease 1 0.7795481085777283
. O 0 1.6662179405102506e-06

Two O 0 5.765009518654551e-07
altered O 0 1.3689192428500974e-06
Dp71 O 0 1.162331500381697e-05
transcripts O 0 2.811607089370227e-07
and O 0 1.063193533212825e-08
two O 0 3.3688007938792452e-09
deleted O 0 1.7142610886367038e-08
Dp140 O 0 1.3415872857081013e-08
DNA O 0 9.799955291711626e-10
sequences O 0 1.3110106056313242e-10
were O 0 3.962713213123692e-10
found O 0 7.356797115942726e-11
in O 0 1.6922649045958416e-11
four O 0 1.7420778361532108e-11
patients O 0 3.184637969999571e-11
with O 0 7.971772547632483e-11
severe O 1 0.9986182451248169
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 0.9967036843299866
. O 0 1.2139084901718888e-06

These O 0 1.557320246092786e-07
findings O 0 1.7417956144072377e-07
suggest O 0 8.537770490590901e-09
that O 0 1.022873730160967e-10
some O 0 7.423511111381842e-11
sequences O 0 2.21363177788092e-10
located O 0 2.225291284574382e-09
in O 0 1.6016306336741337e-10
the O 0 4.103474005034968e-09
distal O 0 1.8195424900113721e-07
part O 0 4.670181574795151e-09
of O 0 5.225262711405776e-08
the O 0 8.088075276191375e-08
gene O 0 3.2890556944664695e-09
and O 0 1.9237374360159265e-08
, O 0 6.10557826519198e-10
in O 0 1.9250642746548863e-10
particular O 0 1.3712603275095603e-09
, O 0 1.2894624257242526e-10
some O 0 1.1340642869228645e-09
DMD B-Disease 1 0.9999998807907104
isoforms O 0 4.806792119893544e-08
expressed O 0 4.732510827665237e-09
in O 0 3.266810599811265e-09
the O 0 5.242912948233425e-08
brain O 0 1.478364026752388e-07
may O 0 8.807003459843088e-10
be O 0 3.93927460096144e-11
related O 0 4.777592765847771e-10
to O 0 3.3010960631685293e-10
the O 0 2.2417790290774064e-08
cognitive B-Disease 0 1.9226133645133814e-06
impairment I-Disease 0 1.017652607515629e-06
associated O 0 2.613502942949708e-07
with O 0 4.1263863437279724e-08
DMD B-Disease 1 1.0
. O 0 1.206460353841976e-07
. O 0 2.1865474764126702e-07

I1307K O 0 3.551819099811837e-05
APC O 0 1.3785048622594331e-06
and O 0 1.2942143357008717e-08
hMLH1 O 0 3.31033362499511e-07
mutations O 0 1.6042921657799525e-08
in O 0 1.3053149672259678e-09
a O 0 3.866771791649626e-09
non O 0 2.2662329968170525e-07
- O 0 2.511113983416635e-08
Jewish O 0 4.339794941188302e-06
family O 0 3.6846641293664106e-09
with O 0 2.981774271937354e-10
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.4504854536644416e-06

We O 0 1.1056201287829026e-08
describe O 0 2.9223521380572492e-09
a O 0 5.370055511377814e-10
French O 0 1.6963458193686165e-08
Canadian O 0 4.829961142149841e-08
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 8.399156286031939e-07
HNPCC B-Disease 0 0.442705363035202
) O 0 2.467347159917921e-10
kindred O 0 5.0399158624259144e-08
which O 0 4.3708380664808644e-11
carries O 0 5.305488270934688e-10
a O 0 1.205936600578994e-10
novel O 0 3.3236080554388536e-09
truncating O 0 7.256149103795906e-08
mutation O 0 1.3816153554557786e-08
in O 0 1.0803709926676675e-08
hMLH1 O 0 6.107452009018743e-06
. O 0 1.920084741868777e-06

Interestingly O 0 4.4405451262719e-06
, O 0 1.5406625308855837e-08
the O 0 4.372278539221952e-08
I1307K O 0 4.128040131945454e-07
APC O 0 5.4428937801276334e-08
polymorphism O 0 1.8635121890042683e-08
, O 0 5.015706183719715e-10
associated O 0 2.566360901568032e-09
with O 0 2.895732958974051e-11
an O 0 1.0728665178483254e-10
increased O 0 2.647613683848249e-09
risk O 0 1.8600077567043627e-07
of O 0 0.11802852153778076
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.6938425106971522e-09
is O 0 2.0792121496748805e-11
also O 0 1.1996179223594527e-11
present O 0 3.264378350964492e-11
in O 0 1.5026024868802779e-10
this O 0 2.604255255889143e-09
family O 0 9.830310432334954e-08
. O 0 2.838121417880757e-07

The O 0 4.010874761206651e-07
I1307K O 0 3.715167053996993e-07
polymorphism O 0 6.108635375312588e-08
has O 0 2.0771451225698456e-09
previously O 0 2.4074724436218276e-09
only O 0 3.473211440674362e-10
been O 0 4.800007613603441e-10
identified O 0 6.344027525528873e-10
in O 0 8.837928305860387e-11
individuals O 0 2.2990398473865525e-10
of O 0 2.8696481635392956e-08
self O 0 2.172063489069842e-07
- O 0 8.25949769023282e-07
reported O 0 3.662538858861808e-07
Ashkenazi O 0 1.0764632918380812e-07
Jewish O 0 5.179894628781767e-07
origins O 0 9.282912287744693e-07
. O 0 1.8793610934153548e-07

In O 0 4.1156880570270005e-08
addition O 0 1.99445011617172e-08
, O 0 6.211600123151584e-10
in O 0 2.9148744529194914e-10
this O 0 6.889188108871735e-10
family O 0 7.45868877771727e-09
, O 0 1.1149325213066774e-10
there O 0 1.3302066392828493e-10
appears O 0 4.713059942318409e-10
to O 0 5.393148080901078e-11
be O 0 2.7910007638354273e-10
no O 0 1.2616484523775284e-09
relationship O 0 5.246619250165452e-10
between O 0 4.5146997251777066e-09
the O 0 6.199742941248587e-09
I1307K O 0 8.253385530565538e-09
polymorphism O 0 8.626091507757394e-10
and O 0 1.6412987635661125e-10
the O 0 1.4336737352849127e-09
presence O 0 1.1853566128650073e-08
or O 0 5.7808826170457905e-08
absence O 0 3.263665348640643e-05
of O 0 1.5675480824484112e-07
cancer B-Disease 0 3.638503187630704e-07
. O 0 2.3497138457173605e-08
. O 0 1.5930808672237617e-07

Identification O 0 1.6867634400341558e-08
of O 0 1.2048870345893192e-08
a O 0 6.4406141531137e-10
novel O 0 1.0464721311720382e-09
mutation O 0 8.603153189845614e-10
of O 0 8.631917958190627e-10
the O 0 1.2869722176844789e-08
CPO O 0 2.182664076144647e-07
gene O 0 9.857884508690518e-10
in O 0 2.2663437793113417e-09
a O 0 1.1696087653945142e-08
Japanese O 0 7.141513833630597e-07
hereditary B-Disease 1 0.9109687805175781
coproporphyria I-Disease 1 0.8963462710380554
family O 0 1.359466182293545e-06
. O 0 4.5837433049200627e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 0 0.009744110517203808
HCP B-Disease 1 1.0
) O 0 1.924449399837158e-08
is O 0 5.508780653862289e-10
an O 0 5.930964164235775e-09
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
characterized O 0 3.5544642229545786e-10
by O 0 3.566718751943365e-12
a O 0 1.9079640645180973e-10
deficiency B-Disease 0 5.086821147415321e-06
of I-Disease 0 1.3677962670044508e-05
coproporphyrinogen I-Disease 0 3.242047387175262e-05
oxidase I-Disease 0 3.2058757426511875e-08
( O 0 1.9551718022370324e-09
CPO O 0 8.021414998893306e-08
) O 0 2.2096274462923837e-11
caused O 0 2.881024863121695e-10
by O 0 1.8034213011830502e-11
a O 0 2.757085393323422e-10
mutation O 0 8.735167589257742e-10
in O 0 6.050996370632333e-10
the O 0 4.48746995118654e-08
CPO O 0 1.8835753508028574e-06
gene O 0 7.117512978993545e-08
. O 0 1.162616968031216e-06

Only O 0 2.5018448468472343e-07
11 O 0 2.4236874196503777e-07
mutations O 0 1.0543306672161634e-07
of O 0 1.0226488456055449e-07
the O 0 1.9779630378025104e-08
gene O 0 4.710591028356248e-09
have O 0 4.079827142788872e-09
been O 0 2.684428901389424e-09
reported O 0 6.321009937693134e-09
in O 0 2.500750495570969e-09
HCP B-Disease 1 0.997286319732666
patients O 0 2.481201306636649e-07
. O 0 1.0551148079684936e-06

We O 0 5.785945944580817e-08
report O 0 1.0251560489393796e-08
another O 0 6.754444226153566e-10
mutation O 0 1.2929552983820258e-09
in O 0 4.5519032987328956e-10
a O 0 3.406502857572491e-09
Japanese O 0 6.718359202295687e-08
family O 0 5.4480974398529725e-08
. O 0 1.9788618033089733e-07

Polymerase O 0 1.2084686318303284e-07
chain O 0 1.7837101040640846e-07
reaction O 0 2.8220076941920524e-08
- O 0 1.6558935556076904e-08
single O 0 6.780945249751369e-10
strand O 0 7.325701711913268e-10
conformational O 0 3.0269861617249205e-10
polymorphism O 0 4.804339703845528e-10
and O 0 1.4258109970466393e-10
direct O 0 2.905805374098236e-09
sequence O 0 1.096053581228773e-09
analyses O 0 7.476121943739145e-09
demonstrated O 0 7.567335202907088e-09
a O 0 1.3517717611932767e-08
C O 0 1.5558417487682163e-07
to O 0 2.5933750702478164e-09
T O 0 1.0887323043107244e-08
substitution O 0 8.055137667994927e-10
in O 0 2.2307126978926561e-10
exon O 0 3.5805322595727773e-10
1 O 0 3.620702182516311e-09
of O 0 6.2792642196995985e-09
the O 0 7.818415781457588e-08
CPO O 0 3.9162071630016726e-07
gene O 0 2.916716423939647e-09
at O 0 1.8512757549160597e-08
nucleotide O 0 1.2091276424541775e-08
position O 0 3.161728656664309e-08
85 O 0 2.4898906048065328e-08
, O 0 1.1441666364353509e-10
which O 0 1.2612316746540841e-10
lies O 0 6.061037449711648e-09
in O 0 7.319653771986623e-10
the O 0 4.246480145297937e-08
putative O 0 1.6523196109119453e-06
presequence O 0 3.643517345608416e-07
for O 0 3.2615934397739466e-09
targeting O 0 6.877247216152682e-08
to O 0 2.632629048093804e-08
mitochondria O 0 3.923619260604028e-06
. O 0 3.895135705533903e-06

This O 0 1.8715471394870065e-09
mutation O 0 3.0718947385821593e-09
changes O 0 1.1860797899387876e-09
the O 0 3.0387015126365213e-09
codon O 0 3.428168859898051e-09
for O 0 1.3238737883725094e-10
glutamine O 0 2.5458257724153555e-09
to O 0 3.3865546478217823e-10
a O 0 4.901726136097295e-09
termination O 0 9.58735427047941e-07
codon O 0 1.4036933180250344e-06
at O 0 1.0604097724353778e-06
amino O 0 4.053829059103009e-07
acid O 0 1.594400202975521e-07
position O 0 3.06393872051558e-07
29 O 0 2.4704304451006465e-06
. O 0 9.705853472041781e-07

MaeI O 0 4.728453131974675e-05
restriction O 0 7.421836585308483e-07
analysis O 0 6.692140885888875e-08
showed O 0 1.4457183006300056e-08
two O 0 2.0097917774464236e-10
other O 0 5.900639699074617e-11
carriers O 0 2.571209911650385e-10
in O 0 4.667579101003128e-10
the O 0 4.092845529157785e-08
family O 0 8.570079046421597e-08
. O 0 2.981533100410161e-07

The O 0 6.006879175401991e-06
C O 1 0.9203745126724243
- O 0 5.187088390812278e-05
T O 0 1.0813213293658919e-06
mutation O 0 3.910472390344921e-09
is O 0 9.492841235303473e-11
located O 0 5.375118128370104e-10
within O 0 1.3360319794930575e-10
a O 0 5.54608081682062e-10
recently O 0 3.411046167745013e-10
proposed O 0 1.2743035793238988e-10
putative O 0 8.917861116231052e-09
alternative O 0 1.5003808195857005e-09
translation O 0 3.924879088401667e-09
initiation O 0 1.853974418430937e-09
codon O 0 7.2590559341279e-08
( O 0 1.0042774611918048e-08
TIC O 0 3.019026095785193e-08
- O 0 1.651200598473679e-08
1 O 0 8.75896244423302e-09
) O 0 3.561663117213065e-11
, O 0 4.712590734312627e-11
supporting O 0 8.967043080287951e-11
that O 0 2.9802957324243096e-10
TIC O 0 4.629438610237457e-09
- O 0 1.8510876165223067e-09
1 O 0 5.627579735545396e-09
is O 0 2.7815835745848005e-10
the O 0 5.15222353669742e-09
real O 0 1.9993639455151424e-07
TIC O 0 2.9963324266191194e-08
rather O 0 3.4471114851442053e-09
than O 0 7.570049476157692e-09
TIC O 0 5.240303480036346e-08
- O 0 2.6921521012468475e-08
2 O 0 4.0965161929307214e-08
. O 0 9.841619963424364e-09
. O 0 8.481276125849035e-08

Human B-Disease 0 3.897577016687137e-08
complement I-Disease 0 2.42208159306756e-07
factor I-Disease 0 3.446526307016029e-06
H I-Disease 1 1.0
deficiency I-Disease 0 0.0009208323317579925
associated O 0 5.094251537229866e-05
with O 0 9.082110045710579e-05
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999998807907104

This O 0 1.4463250153085028e-08
study O 0 2.2393804588460853e-09
reports O 0 2.547263511232245e-09
on O 0 3.3990504855196946e-10
six O 0 2.900951527606832e-11
cases O 0 1.877094452096273e-10
of O 0 1.5681684839563559e-09
deficiency B-Disease 0 1.7848091715677583e-07
in I-Disease 0 1.4457119945632257e-09
the I-Disease 0 4.7379389300772345e-09
human I-Disease 0 3.5975225576301284e-10
complement I-Disease 0 7.160029236175092e-10
regulatory I-Disease 0 1.2517921144095112e-09
protein I-Disease 0 3.32850049744593e-08
Factor I-Disease 0 1.5652469542715153e-08
H I-Disease 1 0.9999995231628418
( O 0 6.429373922145487e-09
FH O 0 1.3309673363437469e-07
) O 0 7.689219920503643e-12
in O 0 3.910019009956134e-12
the O 0 8.920366181830452e-12
context O 0 2.0682568158125747e-10
of O 0 5.626564839045223e-11
an O 0 2.146328892393967e-09
acute B-Disease 1 0.9999995231628418
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 8.215920388465747e-07

Five O 0 2.63710262515815e-07
of O 0 1.81078636529719e-08
the O 0 9.370322295865208e-10
cases O 0 2.487353378821666e-10
were O 0 1.0228073943352456e-10
observed O 0 4.785187524003476e-11
in O 0 2.912248567299436e-12
children O 0 1.3430446858808676e-11
presenting O 0 1.073108601978845e-09
with O 0 3.3757603379314105e-09
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999998807907104
HUS B-Disease 1 1.0
) O 0 6.604971645174373e-07
. O 0 1.633631768527266e-06

Two O 0 2.415145239353933e-08
of O 0 1.36381679283204e-08
the O 0 6.654449880016955e-09
children O 0 6.536924335165395e-10
exhibited O 0 1.9992491218090436e-08
a O 0 1.8247020561190652e-09
homozygous O 0 5.851893547514919e-08
deficiency O 0 7.158164407883305e-07
characterized O 0 1.8334026519184476e-09
by O 0 1.9086446312321925e-10
the O 0 2.1218632184627495e-07
absence O 0 3.670333171612583e-06
of O 0 7.161401782695975e-08
the O 0 1.937398508289334e-08
150 O 0 3.935035852720148e-09
- O 0 1.614476552447286e-09
kD O 0 8.68698390998901e-10
form O 0 7.924020467564574e-11
of O 0 8.587972000206889e-10
Factor O 0 7.970990090200303e-09
H O 1 1.0
and O 0 4.075613802001499e-08
the O 0 1.2896965984054987e-07
presence O 0 8.531422679425305e-09
, O 0 5.829295934844936e-10
upon O 0 4.9682542524465134e-09
immunoblotting O 0 4.913438829134975e-07
, O 0 8.039450771768486e-10
of O 0 8.427397446553186e-09
the O 0 4.149059762426077e-08
42 O 0 1.1750024242473955e-07
- O 0 2.4223975714221524e-08
kD O 0 1.4464795583535306e-08
Factor O 0 6.1148353047713044e-09
H O 0 0.001270214095711708
- O 0 8.935469963944342e-08
like O 0 3.50862916498329e-09
protein O 0 7.028113913065681e-08
1 O 0 6.655924522647183e-08
( O 0 2.2989621317748288e-09
FHL O 0 4.3013332629016077e-07
- O 0 8.706162901717107e-09
1 O 0 3.361432687754018e-09
) O 0 1.4835415881875313e-11
and O 0 4.8051711915020334e-11
other O 0 3.878684595726156e-10
FH O 0 9.597555816753811e-08
- O 0 6.3753016199541435e-09
related O 0 1.106217073498783e-08
protein O 0 1.07327537079982e-07
( O 0 6.305524102856452e-09
FHR O 0 1.8086300769937225e-05
) O 0 1.5565378985726852e-09
bands O 0 3.491393840704404e-08
. O 0 1.0229473446088377e-07

Southern O 0 3.0220394364732783e-06
blot O 0 1.6988963125186274e-06
and O 0 9.089237140713635e-10
PCR O 0 2.4280950583488448e-09
analysis O 0 4.684837517920926e-10
of O 0 2.234042395521385e-10
DNA O 0 1.47553991247662e-09
of O 0 1.186903464400757e-09
one O 0 1.9765167280638707e-10
patient O 0 9.03368824189954e-10
with O 0 9.109556164954569e-11
homozygous O 0 2.105731589097104e-08
deficiency O 0 1.3298372323333751e-06
ruled O 0 1.193201057958504e-07
out O 0 8.109137250578158e-10
the O 0 6.110948969073604e-10
presence O 0 4.4997389148093703e-10
of O 0 6.194421087180046e-10
a O 0 1.6355361509567956e-10
large O 0 2.7758331744287545e-10
deletion O 0 1.3749111849037376e-09
of O 0 5.920961054783902e-09
the O 0 1.8173674121158e-08
FH O 0 2.3457828035589046e-07
gene O 0 4.693727628790612e-10
as O 0 2.1003074834879953e-09
the O 0 4.932882990971166e-09
underlying O 0 8.664553519110996e-08
defect O 0 3.855814867392837e-08
for O 0 1.3123054642960597e-08
the O 0 9.294852134189568e-06
deficiency O 0 0.4297090768814087
. O 0 2.7158223474543775e-06

The O 0 5.9428799659144715e-08
other O 0 1.2182570507945911e-09
four O 0 1.5695630350975875e-09
children O 0 3.4046110375385297e-10
presented O 0 2.144585398156096e-09
with O 0 3.361751432784388e-10
heterozygous O 0 2.8854879374762277e-08
deficiency O 0 2.493665078873164e-07
and O 0 8.559843944766499e-10
exhibited O 0 1.7023364762280835e-07
a O 0 1.902405344367253e-09
normal O 0 9.501349751417365e-08
immunoblotting O 0 4.6374429985007737e-07
pattern O 0 7.523429701450368e-08
of O 0 3.3660521037148783e-09
proteins O 0 9.839475900719208e-10
of O 0 2.1008492723240124e-08
the O 0 1.806912308666142e-07
FH O 0 3.6337227356852964e-05
family O 0 3.9530399931209104e-07
. O 0 6.823284479651193e-07

Factor B-Disease 0 0.0001026922618621029
H I-Disease 1 1.0
deficiency I-Disease 1 0.9995310306549072
is O 0 3.897634659466576e-09
the O 0 3.454166952465698e-09
only O 0 1.5593169422345454e-08
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 5.437714776235225e-07
with O 0 1.380361513980688e-08
HUS B-Disease 1 1.0
. O 0 3.983804162999149e-06

These O 0 3.604504428267319e-08
observations O 0 2.521356634588301e-07
suggest O 0 7.249727485003632e-09
a O 0 1.3807031074009046e-09
role O 0 1.1685601375432952e-09
for O 0 1.959405304674533e-09
FH O 0 2.5682431896711932e-06
and O 0 8.455202760160319e-09
/ O 0 7.642854882305983e-08
or O 0 6.1131557593796515e-09
FH O 0 1.1425544954590805e-07
receptors O 0 1.8202596097083301e-09
in O 0 1.0638558090025896e-10
the O 0 1.1968697144482121e-09
pathogenesis O 0 7.046051450743107e-06
of O 0 3.5009566801136316e-08
idiopathic O 0 0.2301701456308365
HUS B-Disease 1 1.0
. O 0 8.865390555001795e-07
. O 0 1.8776067918224726e-06

Further O 0 3.478631427356049e-08
evidence O 0 1.3097298356967713e-08
for O 0 1.8246523736387132e-10
a O 0 4.6537024234183377e-10
major O 0 2.2137005561972956e-09
ancient O 0 3.283215832539099e-08
mutation O 0 2.455631715747586e-07
underlying O 0 1.1189605686467985e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.4875758402865813e-08
linkage O 0 3.660426273199846e-07
disequilibrium O 0 2.6537333042142563e-07
studies O 0 8.622669800395499e-10
in O 0 5.639199524010152e-11
the O 0 4.0158917857802123e-10
Japanese O 0 9.460477734535289e-09
population O 0 1.3267156262486424e-09
. O 0 2.7096984211993913e-08

The O 0 1.006475145004515e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.001670170808211e-05
DM B-Disease 1 1.0
) O 0 4.2549561096727473e-10
mutation O 0 1.0332057431838848e-09
is O 0 5.2521632876167956e-11
an O 0 6.854350420582023e-10
unstable O 0 7.252371574395511e-07
( O 0 2.83735719364131e-08
CTG O 0 2.9923292458988726e-05
) O 0 1.62728175379101e-09
n O 0 4.2817429601882395e-09
repeat O 0 5.347388309928647e-09
, O 0 5.078102383038186e-10
present O 0 9.48019884816631e-10
at O 0 1.533590254787498e-09
a O 0 6.269013780313415e-11
copy O 0 7.021528358741591e-10
number O 0 4.6387169105877035e-10
of O 0 1.7931469642462616e-09
5 O 0 1.0066094624505695e-08
- O 0 8.77193606640958e-09
37 O 0 6.100531635411244e-08
repeats O 0 1.7186252421197423e-08
on O 0 3.479799204342271e-08
normal O 0 2.4699017941998136e-08
chromosomes O 0 5.067268382674683e-09
but O 0 3.423797245716287e-09
amplified O 0 3.4706371110360124e-09
to O 0 1.4146809279580452e-09
50 O 0 1.8487316566506706e-08
- O 0 3.0185065558185897e-09
3000 O 0 1.7920324113518404e-09
copies O 0 2.676209476248914e-08
on O 0 4.386018872537534e-07
DM B-Disease 1 0.9999998807907104
chromosomes O 0 1.610768208593072e-06
. O 0 1.538661877020786e-06

Previous O 0 3.681533087274147e-07
findings O 0 2.8924695527621225e-08
in O 0 4.457276769898044e-10
Caucasian O 0 1.7619836256699273e-08
populations O 0 3.0689080166013127e-09
of O 0 2.5546689208510998e-09
a O 0 6.686029507818603e-08
DM B-Disease 1 1.0
founder O 0 5.4666164942318574e-05
chromosome O 0 6.619804082674818e-08
raise O 0 7.960718306776471e-09
a O 0 6.67683519584017e-10
question O 0 1.3038742308069118e-09
about O 0 9.713639614883363e-11
the O 0 9.110203702533681e-10
molecular O 0 2.1483355094886747e-09
events O 0 5.062629204743985e-10
involved O 0 3.2041672093363616e-10
in O 0 7.212072050677421e-10
the O 0 8.631494630151337e-09
expansion O 0 1.7115729633587762e-07
mutation O 0 1.2751465305882448e-07
. O 0 1.5738963554667862e-07

To O 0 2.778505781009244e-08
investigate O 0 2.5473571696466024e-08
whether O 0 6.982374678443648e-09
a O 0 9.116327248648304e-09
founder O 0 2.8146970976195007e-08
chromosome O 0 1.9619930125003293e-09
for O 0 2.829896039724389e-10
the O 0 1.7533878349240695e-08
DM B-Disease 1 1.0
mutation O 0 5.425040416895399e-10
exists O 0 8.476460505724148e-11
in O 0 1.5395381150473675e-11
the O 0 2.5851212837046944e-10
Japanese O 0 3.9712957367044055e-09
population O 0 4.1378336868014287e-10
, O 0 2.1163351626718452e-10
we O 0 8.942691032132188e-10
genotyped O 0 1.9262017758592265e-07
families O 0 6.34955976686058e-10
using O 0 1.7815211805771725e-10
polymorphic O 0 5.502493127806929e-09
markers O 0 1.8377946275904833e-07
near O 0 4.6976920202723704e-06
the O 0 2.697698619158473e-06
( O 0 1.3671483145571983e-07
CTG O 0 6.6705033532343805e-06
) O 0 1.675872107753662e-09
n O 0 7.899159548685475e-09
repeat O 0 1.3932856646192704e-08
region O 0 6.819148268277786e-08
and O 0 2.4347929894474873e-08
constructed O 0 1.8295945665158797e-06
haplotypes O 0 9.024910468724556e-06
. O 0 1.1582775414353819e-06

Six O 0 1.98206691948144e-07
different O 0 1.2111773806111614e-08
haplotypes O 0 3.9017950825837033e-07
were O 0 3.401899428823185e-09
found O 0 8.708351262320946e-10
and O 0 7.645326038918654e-10
DM B-Disease 1 1.0
alleles O 0 5.619266829626213e-09
were O 0 6.28814555980739e-09
always O 0 3.3747111771731397e-09
haplotype O 0 3.846072047508642e-07
A O 0 2.8406334422470536e-06
. O 0 1.4838063862043782e-06

To O 0 2.7757973697362104e-09
find O 0 1.2473946320312734e-09
an O 0 7.222751563507046e-11
origin O 0 9.228182107356986e-10
of O 0 3.3866272008964415e-09
the O 0 3.07071310601259e-08
( O 0 7.855887496077685e-09
CTG O 0 2.632908490340924e-06
) O 0 9.898015740361643e-10
n O 0 2.7344000397278023e-09
repeat O 0 3.374704737879597e-09
mutation O 0 1.69696634522154e-09
and O 0 5.843486111656304e-11
to O 0 4.552552432257606e-11
investigate O 0 2.1132172400850635e-10
the O 0 4.399990372050411e-10
mechanism O 0 2.8155062725687685e-09
of O 0 5.733767349802577e-10
the O 0 4.3738254684733135e-10
expansion O 0 1.935787086182472e-09
mutation O 0 9.394387351369105e-11
in O 0 4.00180513726589e-11
the O 0 3.6466138442214913e-10
Japanese O 0 1.510079061795011e-09
population O 0 1.9551558982922046e-10
we O 0 1.8945106594614458e-10
have O 0 1.154033882344585e-10
studied O 0 2.176007374288247e-09
90 O 0 5.223635302087359e-09
Japanese O 0 7.78353950181554e-08
DM B-Disease 1 0.9999996423721313
families O 0 4.769474148957897e-09
comprising O 0 3.2875865918491343e-10
190 O 0 7.573858762377483e-10
affected O 0 9.551273105756763e-10
and O 0 5.84244153056801e-10
130 O 0 9.553063229361669e-09
unaffected O 0 3.971389048729179e-07
members O 0 4.2101380159920154e-09
. O 0 2.742911249242752e-07

The O 0 1.5609736010446795e-06
results O 0 1.6871116770289518e-07
suggest O 0 2.4224068084777173e-08
that O 0 3.0064617462244314e-10
a O 0 9.064203276842875e-10
few O 0 2.8422035835973247e-09
common O 0 1.4554287774970476e-09
ancestral O 0 2.750501515436099e-08
mutations O 0 3.4197640275124286e-09
in O 0 5.7346971615857e-10
both O 0 1.096628454710924e-09
Caucasian O 0 5.5012234767559676e-09
and O 0 2.107408969553859e-10
Japanese O 0 8.093457459779074e-09
populations O 0 8.722148003847963e-10
have O 0 3.528429631804997e-11
originated O 0 2.839520008013352e-10
by O 0 1.3069478659033518e-11
expansion O 0 1.2409737237817353e-08
of O 0 3.5346099380717533e-09
an O 0 4.223118743595933e-09
ancestral O 0 1.2035347651817574e-07
n O 0 9.550803703461952e-09
= O 0 2.2943197564018192e-08
5 O 0 1.79361983043691e-08
repeat O 0 2.598574022627531e-09
to O 0 1.0289799234897146e-08
n O 0 3.3218288564285103e-08
= O 0 9.029975700514115e-08
19 O 0 5.059883392277698e-07
- O 0 5.2106326364764755e-08
37 O 0 8.258302841568366e-08
copies O 0 3.2563363561166625e-08
. O 0 1.5917109408292163e-07

These O 0 6.113411998853735e-09
data O 0 8.262694528582415e-09
support O 0 2.1059434196502025e-09
multistep O 0 1.8065659901367326e-07
models O 0 1.9675390205975418e-07
of O 0 7.751004318379273e-07
triplet O 0 1.4372330952028278e-06
repeat O 0 1.187452554063384e-07
expansion O 0 5.090710146760102e-07
that O 0 1.7655958917117687e-09
have O 0 3.658080505175576e-10
been O 0 1.5598627944868326e-10
proposed O 0 1.0480896012188268e-10
for O 0 3.2576749631196833e-10
both O 0 8.082970737177675e-08
DM B-Disease 1 1.0
and O 0 4.241647673097759e-07
Friedreichs B-Disease 0 2.831512756529264e-05
ataxia I-Disease 0 0.10771561414003372
. O 0 6.190033445818699e-07
. O 0 1.2624117289306014e-06

The O 0 2.313805680387304e-08
molecular O 0 5.7882306947476536e-08
basis O 0 1.4824412630787265e-07
of O 0 2.7849608841279405e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.183503517410145e-09
the O 0 8.978856547159353e-10
western O 0 8.92405527253004e-09
Cape O 0 4.231504036056322e-09
, O 0 1.9213410029639277e-10
South O 0 5.9068732127798285e-09
Africa O 0 1.041107200450142e-08
. O 0 1.6828516891109757e-07

Deficiency B-Disease 0 9.764876267581712e-06
of I-Disease 0 1.7991795857597026e-06
the I-Disease 0 4.592704669903469e-07
sixth I-Disease 0 4.944787974636711e-07
component I-Disease 0 5.8640832634182516e-08
of I-Disease 0 6.095132398797887e-09
human I-Disease 0 4.5837844631080316e-09
complement I-Disease 0 5.1020876412621874e-08
( O 0 5.740697250899984e-09
C6 O 0 1.4268688573793042e-05
) O 0 2.3250533442986665e-10
has O 0 1.7858417522553793e-10
been O 0 9.782246540579465e-11
reported O 0 4.75279871015033e-10
in O 0 2.0385221288776734e-11
a O 0 7.085834002884539e-11
number O 0 1.9915134819026292e-10
of O 0 5.376942779911076e-10
families O 0 2.7653751510925417e-10
from O 0 1.4454363261862113e-09
the O 0 3.104432044764849e-09
western O 0 3.381374824584782e-08
Cape O 0 2.4970434608917458e-08
, O 0 1.8425736492133638e-09
South O 0 9.912680454249312e-09
Africa O 0 2.1210249556702365e-08
. O 0 2.2254202747262752e-07

Meningococcal B-Disease 0 0.0017430551815778017
disease I-Disease 0 0.00014900519454386085
is O 0 1.3019377242962094e-10
endemic O 0 4.8635755145465254e-11
in O 0 1.3496030681903193e-11
the O 0 4.4545828137287913e-10
Cape O 0 1.1698134683157946e-09
and O 0 1.6875814981553994e-11
almost O 0 6.429073245994843e-11
all O 0 1.0125135972705035e-11
pedigrees O 0 9.998090355622935e-09
of O 0 5.519764201267208e-09
total O 0 2.989977929246379e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 6.159964982543897e-07
C6Q0 O 1 0.9919165968894958
) O 0 5.566099248177636e-10
have O 0 8.047638944130853e-11
been O 0 1.256319354103752e-10
ascertained O 0 5.924805179802206e-08
because O 0 2.3629709300365676e-09
of O 0 2.2630100460219182e-08
recurrent O 0 2.253267666674219e-05
disease O 0 6.826917797297938e-06
. O 0 2.9130109169273055e-07

We O 0 2.809237109602236e-08
have O 0 5.087758547794863e-10
sequenced O 0 2.262836362731946e-09
the O 0 1.4270823411877132e-09
expressed O 0 1.227687951299572e-09
exons O 0 5.33925827994608e-08
of O 0 1.7979019162339682e-07
the O 0 2.6866283064919116e-07
C6 O 0 1.5926023024803726e-06
gene O 0 1.213993683357728e-09
from O 0 3.920913371757706e-09
selected O 0 5.506753386619323e-10
cases O 0 8.96023880092578e-11
and O 0 2.7800546587020136e-11
have O 0 2.1019885484974132e-11
found O 0 2.0154769519997728e-10
three O 0 4.390291186151529e-10
molecular O 0 6.223987156772637e-07
defects O 0 9.96881408354966e-06
leading O 0 2.3461809917080245e-07
to O 0 5.024307192513788e-09
total O 0 2.660478628513374e-07
deficiency O 0 5.608430001302622e-06
879delG O 0 4.003119556728052e-06
, O 0 5.270047176431092e-10
which O 0 3.138184503925778e-11
is O 0 3.096776654554212e-11
the O 0 3.8847405847697303e-10
common O 0 1.1002887490008106e-09
defect O 0 1.2021438955400754e-08
in O 0 2.6342248382604794e-09
the O 0 2.297526009442663e-07
Cape O 0 1.5813014897503308e-07
and O 0 1.0870121691652912e-08
hitherto O 0 1.471422706345038e-06
unreported O 0 2.5423685201531043e-06
, O 0 2.4583950430923096e-09
and O 0 3.884209398563598e-09
1195delC O 0 3.223375699690223e-07
and O 0 1.207399247249441e-08
1936delG O 0 1.9248537341809424e-07
, O 0 7.469675433746659e-10
which O 0 2.781806451856994e-10
have O 0 3.8099590149442975e-10
been O 0 1.4534896619622373e-09
previously O 0 2.363115259029769e-09
reported O 0 3.274396531693924e-09
in O 0 1.4236785084165149e-09
African O 0 1.557111772854114e-08
- O 0 1.1584306491840834e-07
Americans O 0 7.349416364377248e-08
. O 0 4.5745812826680776e-07

We O 0 7.428464954273295e-08
also O 0 5.126373991970468e-09
show O 0 6.776355587767569e-10
that O 0 2.450835888401226e-11
the O 0 4.842768963619903e-10
879delG O 0 4.985010448876892e-08
and O 0 4.489813409946919e-09
1195delC O 0 1.8867251583287725e-06
defects O 0 7.959468348417431e-06
are O 0 9.038342296818769e-10
associated O 0 6.415950792870717e-08
with O 0 1.2222236556169719e-08
characteristic O 1 0.999983549118042
C6 O 1 0.9999997615814209
/ O 0 6.311925244517624e-05
C7 O 0 2.4227538233390078e-05
region O 0 3.83170224438345e-08
DNA O 0 5.371085620708982e-08
marker O 0 2.710815749651374e-07
haplotypes O 0 9.740666229163253e-08
, O 0 1.5742941394947252e-09
although O 0 5.688083892785301e-10
small O 0 1.3405533350052679e-09
variations O 0 2.167409185460656e-08
were O 0 1.5584607382379545e-08
observed O 0 1.4407858373033378e-07
. O 0 2.6440275746608677e-07

The O 0 4.3505048097358667e-07
1936delG O 0 2.3695672553003533e-06
defect O 0 5.156188080945867e-07
was O 0 1.0090587920785765e-07
observed O 0 2.500015972017877e-09
only O 0 3.7584754752906235e-10
once O 0 1.3128406139983895e-09
in O 0 3.4920297209417583e-10
the O 0 2.093549156256813e-08
Cape O 0 5.1379963394992956e-08
, O 0 5.377271405926365e-10
but O 0 1.040362351822921e-09
its O 0 1.0646153958404625e-09
associated O 0 1.1982979941649319e-08
haplotype O 0 1.2738290422475984e-07
could O 0 1.7446740940840755e-08
be O 0 2.2352040218720504e-08
deduced O 0 9.091963875107467e-06
. O 0 1.362001853522088e-06

The O 0 1.0615667633828707e-07
data O 0 1.7253746875667275e-08
from O 0 5.698065574932798e-09
the O 0 5.080110110355918e-09
haplotypes O 0 5.371751399252389e-08
indicate O 0 6.744419245308109e-09
that O 0 5.710038344930446e-11
these O 0 1.6579905504077175e-10
three O 0 5.77522307754208e-10
molecular O 0 5.9465197210784027e-08
defects O 0 1.1035579916551796e-07
account O 0 1.6356493937053074e-09
for O 0 8.309598564792964e-10
the O 0 1.5741680954306503e-06
defects O 1 0.6672219038009644
in O 0 2.0195001226852582e-08
all O 0 1.706933083767126e-08
the O 0 1.148149237906182e-07
38 O 0 1.386412407100579e-07
unrelated O 0 5.2561496488578996e-08
C6Q0 O 0 5.528972451429581e-06
individuals O 0 1.4953640548043268e-09
we O 0 4.7938524261326165e-09
have O 0 6.838797306230049e-10
studied O 0 8.020830222221775e-09
from O 0 3.0990718880019585e-09
the O 0 3.443794582835835e-08
Cape O 0 1.9204311740850244e-07
. O 0 1.1117742104715944e-07

We O 0 6.076469816207464e-08
have O 0 2.8121895923050033e-09
also O 0 4.386541407885858e-10
observed O 0 3.154318140019541e-09
the O 0 1.5512947593165904e-09
879delG O 0 1.4464580999629106e-07
defect O 0 3.451797425668701e-08
in O 0 4.006315279525552e-09
two O 0 4.944792664218767e-08
Dutch O 1 1.0
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 5.317252544045914e-06
, O 0 4.608450843157641e-10
but O 0 2.674956645076776e-10
the O 0 2.1860913079763122e-09
879delG O 0 5.5808495602605035e-08
defect O 0 3.223645350658444e-08
in O 0 8.756106062435265e-09
the O 0 1.1128704500151798e-06
Cape O 0 2.0528749189452355e-07
probably O 0 1.4126969816175006e-08
did O 0 2.1037873665363804e-09
not O 0 8.712903731833421e-10
come O 0 5.745999231976384e-09
from O 0 2.9782700750047297e-08
The O 0 2.7743432440274773e-08
Netherlands O 0 3.4263599957284896e-08
. O 0 3.5898626293828784e-08
. O 0 3.793322491674189e-07

Complement B-Disease 1 0.8731364011764526
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 5.941143133014748e-09
seven O 0 3.1138371880956583e-09
further O 0 9.390580757440148e-09
molecular O 0 6.37662151348195e-06
defects O 0 0.004477206617593765
and O 0 8.203556056685102e-09
their O 0 8.542918372711483e-09
associated O 0 4.683275165007217e-06
marker O 0 5.3009822295280173e-05
haplotypes O 0 7.9547326095053e-06
. O 0 1.2649835525735398e-06

Seven O 0 1.6073221331680543e-07
further O 0 2.6284544318855296e-08
molecular O 0 1.0842565956181716e-07
bases O 0 2.1402678385129548e-07
of O 0 0.14232133328914642
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 5.357436805297766e-08
described O 0 1.3918571539761615e-07
. O 0 1.282608366182103e-07

All O 0 8.493365122319574e-09
these O 0 1.8457604333832478e-09
new O 0 6.43084563378693e-09
molecular O 0 1.3767309781087533e-07
defects O 0 1.1898522700448666e-07
involve O 0 2.6768156580203595e-09
single O 0 7.214111974462867e-09
- O 0 2.3562392925668973e-08
nucleotide O 0 3.586146846146221e-08
events O 0 3.2078332878882065e-08
, O 0 1.5879524362105712e-09
deletions O 0 9.548436707973451e-09
and O 0 1.0143451634192502e-09
substitutions O 0 9.055032279547959e-09
, O 0 7.850131655828818e-10
some O 0 2.6991329171721645e-09
of O 0 2.0404766587489576e-07
which O 0 1.761788936960329e-08
alter O 0 5.181169626666815e-07
splice O 0 1.9915819393645506e-06
sites O 0 4.978948027201113e-07
, O 0 8.478215463014749e-09
and O 0 1.0778681946987945e-08
others O 0 7.25515292288037e-08
codons O 0 4.054059900227003e-06
. O 0 2.5974416075769113e-06

They O 0 1.112371883493779e-08
are O 0 1.6938546398836962e-10
distributed O 0 2.3533186510604764e-09
along O 0 6.417367526267981e-09
the O 0 2.561432665970642e-08
C7 O 0 5.192308663026779e-07
gene O 0 1.6075627495837352e-09
, O 0 3.676595972113006e-10
but O 0 1.112697642358107e-10
predominantly O 0 8.336883960957664e-11
towards O 0 2.5247135493344786e-09
the O 0 4.634889361199157e-09
3 O 0 4.523468177808354e-08
end O 0 2.988459186781256e-07
. O 0 6.953298452572199e-07

All O 0 5.663190805194063e-08
were O 0 1.2531998550002754e-08
found O 0 1.0432714692143463e-09
in O 0 2.6900653926631435e-10
compound O 0 1.364977464390904e-08
heterozygous O 0 6.089670989695151e-09
individuals O 0 3.986739827155361e-09
. O 0 1.5600197400544857e-07

The O 0 3.052277315873653e-05
C6 O 1 0.9938250780105591
/ O 0 0.0001074781030183658
C7 O 0 2.702516758290585e-05
marker O 0 4.1159637476084754e-07
haplotypes O 0 1.0491950774849101e-07
associated O 0 2.1300495589571256e-08
with O 0 8.7683527105753e-10
most O 0 3.577932375264936e-06
C7 B-Disease 1 1.0
defects I-Disease 1 1.0
are O 0 9.70537499256352e-08
tabulated O 0 1.1072852430515923e-06
. O 0 1.0671129047068462e-07
. O 0 3.5677746268447663e-07

A O 0 2.6503252229304053e-05
genome O 0 2.739570277299208e-07
- O 0 4.3311018771419185e-08
wide O 0 3.6931213642787952e-09
search O 0 1.0329752608839726e-09
for O 0 8.8526727615168e-11
chromosomal O 0 2.9859037908863684e-07
loci O 0 3.9078312852325325e-07
linked O 0 1.1887050277437083e-06
to O 0 1.6278591807861176e-09
mental O 0 0.0006236626068130136
health O 0 1.296018012908462e-07
wellness O 0 1.182243352104706e-07
in O 0 4.819308840886549e-10
relatives O 0 9.991459393177138e-08
at O 0 1.9127099903926137e-08
high O 0 1.4684542470888573e-08
risk O 0 3.677208093577633e-09
for O 0 1.1177777592408233e-09
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 0.041364654898643494
the O 0 8.243559932452627e-06
Old O 0 2.2955131839808018e-07
Order O 0 1.851120323692612e-08
Amish O 0 1.1225491789446096e-06
. O 0 3.6231881495041307e-07

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 9.025129111250862e-05
BPAD B-Disease 1 1.0
; O 0 5.917202361160889e-05
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 5.015208803804683e-10
is O 0 1.7907935551120246e-11
characterized O 0 7.598797459318352e-12
by O 0 3.009625968580787e-12
episodes O 0 3.508519863526516e-10
of O 0 5.442462591709329e-10
mania B-Disease 0 6.800869645218199e-09
and O 0 1.6718240125612738e-09
/ O 0 2.8512564753668812e-08
or O 0 7.110671607080121e-09
hypomania B-Disease 0 5.492926788974728e-07
interspersed O 0 1.2290803041992149e-08
with O 0 1.056944740063237e-10
periods O 0 8.60427746829373e-08
of O 0 3.004573301268465e-08
depression B-Disease 0 1.2035994814141304e-06
. O 0 2.3152210815169383e-07

Compelling O 0 8.486468345836329e-07
evidence O 0 4.78932200564941e-08
supports O 0 5.347571718772315e-09
a O 0 2.3069639254469365e-10
significant O 0 1.077625211287625e-09
genetic O 0 5.568395522459468e-09
component O 0 1.4583083185470969e-08
in O 0 2.812300670118617e-10
the O 0 1.674856031641525e-09
susceptibility O 0 9.484547547344846e-08
to O 0 1.2096259105476292e-08
develop O 0 3.7791858176206006e-06
BPAD B-Disease 1 1.0
. O 0 1.6263247744063847e-05

To O 0 2.2476275063354478e-08
date O 0 1.250198465641006e-06
, O 0 7.268640800361936e-09
however O 0 1.281773887029658e-08
, O 0 2.078103911173912e-09
linkage O 0 1.8065848905735038e-07
studies O 0 6.029524879380688e-09
have O 0 9.453831467665097e-11
attempted O 0 2.434308754573067e-09
only O 0 1.8268253576536608e-10
to O 0 2.895690076609725e-10
identify O 0 1.547808103907755e-08
chromosomal O 0 2.0097534161322983e-06
loci O 0 3.644545927272702e-07
that O 0 2.1848907127974826e-09
cause O 0 5.520766777067365e-08
or O 0 7.969131465834778e-10
increase O 0 1.0553176110761342e-09
the O 0 1.7690713338680553e-09
risk O 0 1.8543360624789784e-08
of O 0 2.4202316595278717e-08
developing O 0 3.041752961507882e-06
BPAD B-Disease 1 1.0
. O 0 5.127304575580638e-06

To O 0 1.8594715101016845e-08
determine O 0 5.2650797499609325e-08
whether O 0 1.7038948030290157e-08
there O 0 5.0891588720958225e-09
could O 0 2.2503245933336302e-09
be O 0 7.73420716360107e-10
protective O 0 2.8122393302965065e-08
alleles O 0 1.0243605075288542e-08
that O 0 7.383847977493474e-10
prevent O 0 7.331156570700159e-09
or O 0 5.202953179406222e-09
reduce O 0 1.1837705926609488e-08
the O 0 7.629568088418637e-09
risk O 0 4.795903407739388e-08
of O 0 3.810864512843182e-08
developing O 0 3.797998942900449e-06
BPAD B-Disease 1 1.0
, O 0 9.67005586716141e-10
similar O 0 1.4818596349996938e-10
to O 0 1.3492743033971522e-10
what O 0 2.453999226048609e-10
is O 0 2.1374695416409573e-11
observed O 0 1.549454731186728e-10
in O 0 4.448483942320891e-11
other O 0 5.721142226633447e-09
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 7.275266500350597e-10
we O 0 7.047420286232509e-11
used O 0 3.82058384928996e-10
mental O 0 1.3986674218813278e-07
health O 0 3.184910113418482e-08
wellness O 0 3.8971836602286203e-07
( O 0 4.748920146013802e-10
absence O 0 6.72160140879896e-08
of O 0 3.5160452327431813e-09
any O 0 8.26321500113636e-09
psychiatric B-Disease 0 1.8112434190697968e-05
disorder I-Disease 0 1.037604775433465e-07
) O 0 1.257877222521353e-11
as O 0 4.437704370641171e-11
the O 0 2.7192634255435166e-10
phenotype O 0 2.448492963935678e-09
in O 0 3.815820714958562e-10
our O 0 9.697581404566336e-09
genome O 0 7.739671126216763e-09
- O 0 3.727999953184735e-08
wide O 0 1.20689776395011e-07
linkage O 0 3.465034126293176e-07
scan O 0 1.6784680667569774e-07
of O 0 1.0994632049232678e-07
several O 0 6.8861730539993e-08
large O 0 9.859807050816016e-07
multigeneration O 0 0.0001011015847325325
Old O 0 1.928224719449645e-06
Order O 0 4.181665147484637e-08
Amish O 0 1.0162647186007234e-06
pedigrees O 0 5.283681048240396e-07
exhibiting O 0 2.550065403283952e-07
an O 0 5.642023737095769e-09
extremely O 0 3.8064694507511376e-08
high O 0 3.390743472664326e-07
incidence O 0 0.0012766782892867923
of O 0 2.079310070257634e-05
BPAD B-Disease 1 1.0
. O 0 9.784211579244584e-05

We O 0 2.5028950290106877e-07
have O 0 5.57040369386641e-09
found O 0 1.7049602840657485e-09
strong O 0 1.1805411093135376e-09
evidence O 0 7.30432658802016e-10
for O 0 4.5332473885828506e-11
a O 0 6.90597523611558e-10
locus O 0 7.51546735955344e-09
on O 0 7.792404055351199e-09
chromosome O 0 1.904777633399135e-07
4p O 0 3.120220935670659e-05
at O 0 1.8698662529459398e-07
D4S2949 O 0 1.1124465970624442e-07
( O 0 3.115196156588951e-10
maximum O 0 1.8630785802997707e-08
GENEHUNTER O 0 6.043694156687707e-06
- O 0 8.322501088287027e-08
PLUS O 0 4.810772580299272e-08
nonparametric O 0 7.241494159870854e-08
linkage O 0 3.703873829863369e-08
score O 0 2.0996916205717753e-08
= O 0 7.242982658084429e-09
4 O 0 1.4369924805635037e-08
. O 0 1.4622626443028253e-09
05 O 0 1.1202866545545476e-07
, O 0 3.0368592085494583e-09
P O 0 2.406143266853178e-07
= O 0 5.806794156626438e-09
5 O 0 5.4146851447001154e-09
. O 0 3.075897592186294e-10
22 O 0 2.0856167903815503e-09
x O 0 5.867806240900109e-09
10 O 0 2.323091941036637e-08
( O 0 1.4959118388446768e-09
- O 0 5.560637283963388e-09
4 O 0 6.707025157481894e-09
) O 0 7.004991725567677e-11
; O 0 7.759977105337157e-10
SIBPAL O 0 8.342278761119815e-07
Pempirical O 0 3.7151803411461515e-08
value O 0 4.65721239351069e-09
< O 0 4.87377416202861e-10
3 O 0 9.943351697572211e-10
x O 0 3.297800033053022e-09
10 O 0 1.0728267163528926e-08
( O 0 6.835185195619431e-10
- O 0 4.189167235324476e-09
5 O 0 4.737613856775624e-09
) O 0 7.458538647808766e-11
) O 0 1.6508266975634456e-11
and O 0 2.8366602469742652e-11
suggestive O 0 4.07854167105981e-10
evidence O 0 3.435098872017761e-10
for O 0 4.7408993397723975e-11
a O 0 1.9923656058296046e-09
locus O 0 6.394607510173955e-08
on O 0 1.8431654780215467e-07
chromosome O 0 6.965298325667391e-06
4q O 0 8.0206009442918e-05
at O 0 3.719704579907557e-07
D4S397 O 0 6.516054895655543e-07
( O 0 1.7210417535551414e-09
maximum O 0 1.4652135860160342e-07
GENEHUNTER O 0 7.913194167485926e-06
- O 0 1.3574745594269189e-07
PLUS O 0 1.4207473952865257e-07
nonparametric O 0 1.246387455466902e-07
linkage O 0 2.9307431148595242e-08
score O 0 4.3324316578718935e-08
= O 0 9.015447943738764e-09
3 O 0 1.8229219023169208e-08
. O 0 2.141442134728777e-09
29 O 0 1.015207402588203e-07
, O 0 9.02614871733931e-09
P O 0 3.181019110343186e-07
= O 0 5.2571094144582275e-09
2 O 0 3.765071365791073e-09
. O 0 1.7046472566839554e-10
57 O 0 1.937807914131895e-09
x O 0 2.2813106959063134e-09
10 O 0 1.0860319754613101e-08
( O 0 6.882883707426402e-10
- O 0 2.0779455933706004e-09
3 O 0 3.5813536580775462e-09
) O 0 3.9017365727200826e-11
; O 0 3.983036678256724e-10
SIBPAL O 0 4.6250454488472315e-07
Pempirical O 0 1.591382492449611e-08
value O 0 1.8433469195500152e-09
< O 0 5.338621211770089e-10
1 O 0 1.3478396176935803e-09
x O 0 6.303383592864975e-09
10 O 0 2.1149087814364975e-08
( O 0 1.850448683171635e-09
- O 0 5.335142549967031e-09
3 O 0 5.0013793106984394e-09
) O 0 2.295358174364548e-11
) O 0 5.025123546442689e-12
that O 0 1.1091795884543565e-11
are O 0 3.631951683846779e-11
linked O 0 1.2857970688173737e-08
to O 0 8.288012054435967e-09
mental O 1 0.9999337196350098
health O 0 0.049340832978487015
wellness O 0 0.00014629426004830748
. O 0 7.994606789907266e-07

These O 0 3.041463259023658e-08
findings O 0 7.798324475061236e-08
are O 0 2.805592980159588e-10
consistent O 0 1.2039175878442165e-08
with O 0 3.154483618761361e-11
the O 0 3.3567282287094713e-10
hypothesis O 0 1.0636695968457843e-09
that O 0 2.976043890490221e-12
certain O 0 2.992068814933191e-10
alleles O 0 2.3019630646103906e-09
could O 0 6.020641762916057e-09
prevent O 0 1.731830145956792e-08
or O 0 5.6108171442303956e-09
modify O 0 1.587244824463596e-08
the O 0 1.855293918495704e-09
clinical O 0 1.0015917872863156e-08
manifestations O 0 2.3689385386660433e-07
of O 0 2.1190400900650275e-07
BPAD B-Disease 1 1.0
and O 0 1.0130961625165469e-09
perhaps O 0 9.688573276989132e-10
other O 0 5.841605532630467e-10
related O 0 2.7021999926546414e-07
affective B-Disease 1 0.9995785355567932
disorders I-Disease 0 0.00707657216116786
. O 0 1.7884294720715843e-06

Segregation O 0 8.190414519049227e-06
distortion O 0 1.971176425286103e-05
in O 0 4.865744926974003e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 1.9791743397945538e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.6699031591415405
DM B-Disease 1 1.0
) O 0 1.5474951098326528e-08
is O 0 3.4453481734253444e-10
an O 0 2.180111868810286e-09
autosomal B-Disease 1 0.9999749660491943
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
which O 0 9.081746465966489e-11
, O 0 5.842713899500973e-12
in O 0 1.0496535064741241e-11
the O 0 8.830703945861273e-10
typical O 0 7.683704339456199e-09
pedigree O 0 1.8156280034986594e-08
, O 0 2.1573189068480048e-10
shows O 0 6.012525477494535e-10
a O 0 8.477353818925337e-10
three O 0 1.590580556154464e-09
generation O 0 4.481756121776925e-08
anticipation O 0 5.289902560434712e-07
cascade O 0 3.563616246538004e-06
. O 0 1.4948208217901993e-06

This O 0 1.1147097689345742e-09
results O 0 3.229915446212317e-09
in O 0 4.1133535466642e-10
infertility B-Disease 1 0.9620363712310791
and O 0 5.719606477327943e-08
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.3487376665798365e-07
CDM B-Disease 0 2.2585177816836222e-07
) O 0 5.7262315548978204e-12
with O 0 1.4012139972624515e-12
the O 0 4.3133149829621686e-10
disappearance O 0 1.405910410312572e-07
of O 0 2.2707546065703355e-07
DM B-Disease 1 1.0
in O 0 2.7158090887269282e-08
that O 0 7.200983365152069e-09
pedigree O 0 2.156619302695617e-06
. O 0 8.371638955395611e-07

The O 0 3.9225234615969384e-08
concept O 0 2.8523876594022113e-08
of O 0 2.0926828270262376e-08
segregation O 0 9.61459605264281e-08
distortion O 0 3.093100815476646e-07
, O 0 3.6475875098140875e-10
where O 0 2.636168783265447e-10
there O 0 2.3293535503232654e-11
is O 0 4.53325354685119e-12
preferential O 0 9.056529970408178e-10
transmission O 0 1.4279645244030803e-09
of O 0 4.4161918566487657e-10
the O 0 1.2438878815856924e-09
larger O 0 3.909040202643155e-09
allele O 0 2.531310983044932e-08
at O 0 3.007497539897486e-08
the O 0 1.891000351861294e-07
DM B-Disease 1 1.0
locus O 0 8.013585528487965e-08
, O 0 3.6970186911844394e-09
has O 0 7.53009876675037e-10
been O 0 1.0560987639962605e-09
put O 0 6.269223806754098e-09
forward O 0 3.928580838419293e-08
to O 0 5.790811830053144e-09
explain O 0 8.215600644234655e-08
partially O 0 2.5837101702563814e-07
the O 0 7.12184222706469e-09
maintenance O 0 6.675988117876841e-08
of O 0 9.40259283765954e-08
DM B-Disease 1 1.0
in O 0 7.230090748322482e-09
the O 0 1.9043667975893186e-08
population O 0 3.262613734733577e-09
. O 0 2.4795875575023274e-08

In O 0 1.3606728188619854e-08
a O 0 1.4532768766173376e-08
survey O 0 3.5002553744334364e-08
of O 0 1.0059569177656158e-08
DM B-Disease 1 1.0
in O 0 1.577438979438739e-08
Northern O 0 1.938099529752435e-07
Ireland O 0 4.986082213775944e-09
, O 0 1.0267450001322231e-08
59 O 0 1.490457748332119e-07
pedigrees O 0 5.896479819966771e-07
were O 0 7.382207911632577e-08
ascertained O 0 1.3777510503132362e-05
. O 0 7.807141173543641e-07

Sibships O 0 1.7361287973471917e-05
where O 0 9.930658073642462e-09
the O 0 1.6130421442994702e-09
status O 0 4.413263976488224e-09
of O 0 2.7293143300965994e-09
all O 0 1.8660177569795877e-10
the O 0 4.780658091618761e-09
members O 0 1.0850722403921154e-10
had O 0 1.5410791531778045e-09
been O 0 1.5255256780033477e-10
identified O 0 4.4039111246618745e-10
were O 0 1.100907490170222e-10
examined O 0 3.0354677105215444e-10
to O 0 1.7632855245364176e-11
determine O 0 4.056639746341517e-10
the O 0 5.395712765476901e-10
transmission O 0 5.67409763618798e-09
of O 0 2.4460469205678237e-09
the O 0 3.65546171110509e-08
DM B-Disease 1 1.0
expansion O 0 2.1437200814489188e-07
from O 0 1.969650575972537e-08
affected O 0 2.6315746026739362e-08
parents O 0 5.113298229275642e-09
to O 0 6.24519946867963e-09
their O 0 8.062384182494498e-08
offspring O 0 2.203710664616665e-06
. O 0 8.559270554542309e-07

Where O 0 2.9584091620904474e-08
the O 0 2.3459611142584436e-08
transmitting O 0 3.3538202615090995e-07
parent O 0 1.1288729240277462e-07
was O 0 9.224001473739918e-08
male O 0 6.570215482781805e-09
, O 0 3.7768668192939e-09
58 O 0 3.1011995815788396e-07
. O 0 1.946499708083138e-07

3 O 0 4.317010962040513e-07
% O 0 7.133588386665224e-09
of O 0 2.5815602988643604e-09
the O 0 3.342393251060116e-09
offspring O 0 8.17456591306609e-09
were O 0 2.6295061683612175e-09
affected O 0 6.383113593244616e-09
, O 0 1.022300299968748e-10
and O 0 6.586532014241087e-11
in O 0 1.114668843338329e-10
the O 0 7.646317468079644e-10
case O 0 1.3994345682277753e-09
of O 0 2.9557905012467245e-09
a O 0 7.672793955748602e-09
female O 0 3.8336395391525e-08
transmitting O 0 6.739998070770525e-07
parent O 0 1.991920584032414e-07
, O 0 2.2212764960727327e-08
68 O 0 1.6368318256354542e-06
. O 0 1.0325314860892831e-06

7 O 0 6.241490154934581e-06
% O 0 1.0325427979296364e-07
were O 0 1.532830751216352e-08
affected O 0 8.636701664954671e-08
. O 0 2.2330823412630707e-07

Studies O 0 1.9654930838441942e-07
on O 0 2.8555831477206084e-08
meiotic O 0 3.158715458084771e-07
drive O 0 1.0776506798038099e-07
in O 0 2.484321548479329e-08
DM B-Disease 1 1.0
have O 0 3.774819623547643e-10
shown O 0 1.2708181729159662e-10
increased O 0 1.4500579903486965e-10
transmission O 0 7.690415526617755e-10
of O 0 1.427010870580503e-10
the O 0 2.350814265472678e-10
larger O 0 1.2449844488671147e-09
allele O 0 6.861731183249731e-09
at O 0 9.896849562096577e-09
the O 0 2.5780778400985582e-08
DM B-Disease 1 1.0
locus O 0 2.49132057206225e-08
in O 0 7.69163754910096e-09
non O 0 1.9625424101832323e-05
- O 0 0.00036611247924156487
DM O 1 1.0
heterozygotes O 0 3.0101257380010793e-06
for O 0 7.490940845400473e-08
CTGn O 0 5.450381286209449e-05
. O 0 1.542853965474933e-06

This O 0 7.286439540621359e-08
study O 0 4.1191414723584785e-09
provides O 0 8.785326910398794e-10
further O 0 6.855500611635534e-10
evidence O 0 4.3384829062631525e-09
that O 0 8.630831049849519e-10
the O 0 7.974899745022412e-07
DM B-Disease 1 1.0
expansion O 0 4.6626414587080944e-06
tends O 0 5.116335088928281e-08
to O 0 7.961443726500761e-10
be O 0 2.826202383232612e-09
transmitted O 0 4.141832832260661e-08
preferentially O 0 2.5602270170566044e-07
. O 0 2.9456231231961283e-07

Diagnosis O 0 0.0005977855762466788
of O 0 2.321260944881942e-05
hemochromatosis B-Disease 1 1.0
. O 1 0.9994410872459412

If O 0 2.209586000390118e-06
untreated O 1 1.0
, O 0 3.663893721750355e-08
hemochromatosis B-Disease 1 1.0
can O 0 2.183040805903147e-07
cause O 1 0.9999804496765137
serious O 0 0.001928999088704586
illness O 1 1.0
and O 0 3.842610396542767e-10
early B-Disease 0 5.7673474884722964e-08
death I-Disease 0 6.416195219571819e-08
, O 0 1.3209881799536305e-10
but O 0 2.7908836353063293e-10
the O 0 2.8890936309977633e-09
disease O 0 2.2014571499084923e-08
is O 0 1.1658547738324643e-10
still O 0 4.233447759016684e-10
substantially O 0 3.0973360765074176e-08
under O 0 5.584213340625865e-07
- O 0 0.0001720018481137231
diagnosed O 0 5.65633172300295e-06
. O 0 3.7791392060171347e-07

The O 0 2.027282562266919e-06
cornerstone O 0 1.0926059985649772e-05
of O 0 2.2383311204521306e-08
screening O 0 1.417011397109036e-09
and O 0 6.538018737511919e-11
case O 0 1.37202360583899e-10
detection O 0 1.1420480117152465e-09
is O 0 2.3302066873287508e-11
the O 0 1.9355497760109586e-10
measurement O 0 2.3238895252575276e-08
of O 0 1.0680980544464092e-08
serum O 0 3.511938118094804e-08
transferrin O 0 2.3403283933021157e-07
saturation O 0 2.3779472257956513e-07
and O 0 7.042724181616222e-09
the O 0 2.1205961431292053e-08
serum O 0 3.3065884963434655e-07
ferritin O 0 3.7377444641606417e-06
level O 0 1.622861532268871e-06
. O 0 6.920379860275716e-07

Once O 0 8.73259125455661e-07
the O 0 4.489995930612167e-08
diagnosis O 0 9.122363167080039e-07
is O 0 1.595551579747223e-09
suspected O 0 3.692109018516021e-08
, O 0 8.309598564792964e-10
physicians O 0 8.796393613508258e-10
must O 0 6.828539400594025e-10
use O 0 1.2498531098970034e-08
serum O 0 3.0046132906136336e-06
ferritin O 0 2.002620203711558e-05
levels O 0 1.2401631011016434e-06
and O 0 1.0380639992035867e-07
hepatic O 1 0.9998335838317871
iron O 0 0.0004552954633254558
stores O 0 1.8195656593888998e-05
on O 0 6.604341820093396e-07
liver O 0 1.3520858601623331e-06
biopsy O 0 1.839438823481032e-08
specimens O 0 2.2777975061671896e-09
to O 0 1.9513483884292526e-10
assess O 0 7.998250062257739e-09
patients O 0 6.723954726339798e-10
for O 0 3.460865205529018e-10
the O 0 1.7505508154158633e-08
presence O 0 1.9722074284800328e-07
of O 0 3.51790936292673e-06
iron B-Disease 0 0.000221306414459832
overload I-Disease 0 0.00011689101665979251
. O 0 3.966577423852868e-06

Liver O 0 0.0006139134638942778
biopsy O 0 4.0055554563878104e-05
is O 0 6.547610009732807e-09
also O 0 1.6548311332353904e-10
used O 0 2.339045797328243e-11
to O 0 4.767249789372485e-11
establish O 0 4.196893055308237e-09
the O 0 1.0185624788050518e-08
presence O 0 1.9659948335970512e-08
or O 0 2.524146758275947e-08
absence O 0 5.645716009894386e-05
of O 0 2.4047687929851236e-07
cirrhosis B-Disease 0 0.00025519056362099946
, O 0 3.393123559902733e-10
which O 0 4.29795574130587e-11
can O 0 2.938251586481755e-10
affect O 0 2.0468245054416911e-07
prognosis O 0 0.00014248456864152104
and O 0 4.166013667372681e-08
management O 0 2.348898959780854e-07
. O 0 4.542679619135015e-07

A O 0 1.6702205130059156e-06
DNA O 0 9.927764210715395e-08
- O 0 1.1812061551097486e-08
based O 0 1.0276614004212092e-09
test O 0 5.450458834266314e-11
for O 0 1.9048695953927108e-10
the O 0 3.016781491282927e-08
HFE O 0 5.408827291830676e-06
gene O 0 1.419963879811803e-08
is O 0 9.844544068826622e-10
commercially O 0 1.94845584111647e-09
available O 0 1.0337242173363848e-09
, O 0 9.186556376716837e-11
but O 0 1.7596982204715061e-10
its O 0 2.4791879660313043e-10
place O 0 9.099475839491333e-09
in O 0 2.9165206361092544e-10
the O 0 1.5402710218381799e-09
diagnosis O 0 1.2272207072783203e-07
of O 0 3.3069095906057555e-08
hemochromatosis B-Disease 1 1.0
is O 0 1.7208891733844212e-07
still O 0 2.58882977277608e-08
being O 0 1.2324583131828604e-08
evaluated O 0 1.5000446751400887e-07
. O 0 3.086135507146537e-07

Currently O 0 6.361760824802332e-07
, O 0 3.782475221925097e-09
the O 0 3.345391075271209e-09
most O 0 3.5023889344287795e-10
useful O 0 1.6008373515674634e-09
role O 0 1.146219855141517e-10
for O 0 6.25957480293593e-11
this O 0 1.3571722912164574e-10
test O 0 9.086043029071789e-11
is O 0 5.6246979296403765e-11
in O 0 3.65108013267168e-11
the O 0 2.0206927797694618e-10
detection O 0 1.1930003651627885e-08
of O 0 1.2613627475843714e-08
hemochromatosis B-Disease 1 1.0
in O 0 1.0060877286832692e-07
the O 0 5.529808504434186e-07
family O 0 1.0881012535435275e-08
members O 0 1.8481760566402272e-10
of O 0 1.5104708595004013e-09
patients O 0 1.0020224927576038e-10
with O 0 9.516512577967262e-12
a O 0 1.2248362046829442e-10
proven O 0 5.739285047212661e-09
case O 0 3.561625883108377e-09
of O 0 2.526015308035312e-08
the O 0 1.5970238109730417e-07
disease O 0 7.904919243628683e-07
. O 0 1.5210390813535923e-07

It O 0 2.9392899225655356e-09
is O 0 1.422228446124052e-10
crucial O 0 3.2453724152503582e-09
to O 0 3.1087101781679394e-09
diagnose O 1 0.8520098924636841
hemochromatosis B-Disease 1 1.0
before O 1 1.0
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 2.7020805148936233e-08
because O 0 2.1368347369321583e-10
phlebotomy O 0 1.1240665998002441e-07
therapy O 0 7.694538339819701e-10
can O 0 4.0025302516788486e-11
avert O 0 1.077640447988415e-07
serious O 0 1.1003018016708666e-06
chronic O 1 0.999901294708252
disease O 0 0.38721343874931335
and O 0 8.787753164041234e-11
can O 0 3.399184753116735e-11
even O 0 7.350545172535305e-10
lead O 0 1.3964136513777703e-09
to O 0 8.393225559011341e-10
normal O 0 9.010740598114353e-08
life O 0 9.986806936979065e-09
expectancy O 0 1.1309160186101508e-07
. O 0 4.974152201242532e-09
. O 0 1.4490316857518337e-07

Prevalence O 0 4.6324453251145314e-06
of O 0 4.652695295703779e-08
the O 0 4.6223295413483356e-08
I1307K O 0 4.384655198919063e-07
APC B-Disease 0 6.370282079615208e-09
gene O 0 1.5366198591326707e-10
variant O 0 1.4571008843944355e-09
in O 0 1.672614269310202e-10
Israeli O 0 1.920474623773316e-08
Jews O 0 1.5016748955432035e-09
of O 0 2.528326437101214e-10
differing O 0 2.3774420210287417e-09
ethnic O 0 7.811536417712261e-10
origin O 0 2.3097082024747806e-09
and O 0 5.019821225360488e-10
risk O 0 5.3267566357817486e-08
for O 0 3.313261345283536e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.7873724118544487e-06

BACKGROUND O 0 0.0001893821608973667
& O 0 1.5883188098086976e-06
AIMS O 0 1.337322942163155e-06
Israeli O 0 2.0095694708288647e-06
Jews O 0 1.9750835633658426e-07
of O 0 5.7794494523477624e-08
European O 0 4.486964755301415e-08
birth O 0 5.844536872245953e-07
, O 0 1.0267841688005319e-08
i O 0 1.1055104387480696e-08
. O 0 3.6923466506522118e-09
e O 0 1.5965684330154772e-09
. O 0 2.177605873399102e-09
, O 0 2.5648341228645677e-09
Ashkenazim O 0 2.9510499643947696e-07
, O 0 8.767516157526245e-10
have O 0 1.660287879401423e-10
the O 0 7.495254195077905e-09
highest O 0 3.0745277399546467e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 1.9062024136928812e-07
of O 0 1.2816209205013251e-10
any O 0 3.302846884878363e-10
Israeli O 0 2.6204836558463285e-06
ethnic O 0 9.337360040717613e-08
group O 0 1.4096286804488045e-08
. O 0 3.9721459899055844e-08

The O 0 3.0543451430276036e-06
I1307K O 0 8.117057404888328e-06
APC B-Disease 0 1.0849123555090046e-07
gene O 0 5.7930322761023945e-09
variant O 0 9.134327427773314e-08
was O 0 2.3221129907824434e-08
found O 0 8.038238963337108e-10
in O 0 7.612237507004238e-10
6 O 0 2.544065864640288e-07
. O 0 2.1136087013928773e-07

1 O 0 5.012679480387305e-07
% O 0 8.214798619121666e-09
of O 0 2.5606399223221388e-09
American O 0 1.6649759349007809e-09
Jews O 0 2.4897848227567465e-09
, O 0 7.047232242207713e-11
28 O 0 9.353613883433809e-09
% O 0 2.455292635872297e-09
of O 0 5.711470851821332e-09
their O 0 5.0019880291074514e-05
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 2.553939459915e-08
, O 0 2.963702200320384e-11
but O 0 3.617074695316802e-11
not O 0 7.131091550593993e-11
in O 0 1.4270823411877132e-09
non O 0 1.5823862042907422e-07
- O 0 1.0055889276827656e-07
Jews O 0 6.958831022529921e-07
. O 0 8.732840797165409e-07

We O 0 2.2790414888618216e-08
assessed O 0 1.4987433871738176e-07
the O 0 6.20743412227398e-09
I1307K O 0 1.774409099652985e-07
prevalence O 0 5.240300637865403e-09
in O 0 2.6486817947257713e-11
Israeli O 0 1.1157887946922074e-08
Jews O 0 1.204293664791578e-09
of O 0 1.1428318014150562e-10
differing O 0 1.2382493919105286e-09
ethnic O 0 2.8855290379325993e-10
origin O 0 1.54794899120958e-09
and O 0 2.965988288305965e-10
risk O 0 2.155976019935224e-08
for O 0 1.2505617519309453e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.05037359441485e-07

METHODS O 0 8.55944165323308e-07
DNA O 0 5.089258436896671e-08
samples O 0 3.6209024667499534e-09
from O 0 2.898332907008694e-09
500 O 0 7.299285065265337e-10
unrelated O 0 3.6243088530341083e-09
Jews O 0 3.997743025507816e-09
of O 0 3.0556961405636685e-09
European O 0 5.341434849981397e-09
or O 0 2.4950712607108017e-09
non O 0 1.9535473683163218e-08
- O 0 8.797014228179023e-10
European O 0 3.988700203461093e-10
origin O 0 2.255446496235436e-09
, O 0 4.5188994907130464e-11
with O 0 8.974943184469897e-12
or O 0 9.047513432891563e-11
without O 0 3.322015440510029e-10
a O 0 8.294239184358787e-10
personal O 0 2.0114734766707443e-08
and O 0 9.940209544367917e-09
/ O 0 6.89859618319133e-08
or O 0 1.265729743238353e-08
family O 0 9.885511076390685e-09
history O 0 2.072215465886984e-08
of O 0 3.409434512491316e-09
neoplasia B-Disease 0 5.5509438823264645e-08
, O 0 1.0518149684557443e-09
were O 0 1.0068547107167092e-09
examined O 0 4.303538414518471e-09
for O 0 4.991903557183264e-10
the O 0 5.188147689239031e-09
I1307K O 0 1.345805866748151e-08
variant O 0 8.10244316085118e-10
by O 0 8.077395002858978e-11
the O 0 2.6648494522163446e-09
allele O 0 2.7562665483316096e-09
- O 0 4.826496091681065e-09
specific O 0 4.712406465046115e-09
oligonucleotide O 0 8.204222581298382e-07
( O 0 1.309036150587417e-07
ASO O 0 7.488663868571166e-06
) O 0 1.4192185204819907e-09
method O 0 1.546056012102781e-07
. O 0 3.041260754343966e-07

RESULTS O 0 5.981378308206331e-06
In O 0 3.7146259401765747e-09
persons O 0 1.5863397706539217e-08
at O 0 7.482055863761161e-09
average O 0 9.6330587950888e-09
risk O 0 2.6993698387656195e-09
for O 0 1.7631672122320197e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.25124788308284e-09
I1307K O 0 2.196734172343895e-08
was O 0 3.4543250482244048e-09
found O 0 4.105162876300028e-10
in O 0 1.1382337294918443e-09
5 O 0 9.724349325779258e-08
. O 0 2.4911454943321587e-07

0 O 0 3.4939526472044236e-07
% O 0 9.646517362682516e-09
of O 0 2.942762478141958e-09
120 O 0 8.190453648637686e-09
European O 0 5.701631611287894e-09
and O 0 8.446997767919129e-09
1 O 0 3.1144455192588794e-07
. O 0 1.5865069258325093e-07

6 O 0 7.30097326595569e-06
% O 0 2.6209352910200323e-08
of O 0 5.595683472137125e-09
188 O 0 1.163268059656275e-08
non O 0 4.611620951777695e-08
- O 0 5.563639771111184e-09
European O 0 1.2563924123298875e-08
Jews O 0 6.646169481427933e-08
( O 0 2.900467643840443e-09
P O 0 2.7546238356990216e-07
= O 0 7.851708616612996e-09
0 O 0 1.0512419379438143e-08
. O 0 2.586439507012983e-09
08 O 0 4.0104687570874376e-08
) O 0 2.1781998427172766e-09
. O 0 4.9815792380059065e-08

It O 0 5.5976080659547733e-08
occurred O 0 1.0541673418629216e-06
in O 0 1.4283302540718523e-08
15 O 0 3.826875172308064e-07
. O 0 2.9406129442577367e-07

4 O 0 4.6971717893029563e-07
% O 0 4.172779455302589e-09
of O 0 1.163072305132573e-09
52 O 0 2.0216353036062173e-08
Ashkenazi O 0 2.1848043374461668e-08
Israelis O 0 6.576699718152668e-08
with O 0 1.167974161830898e-09
familial O 0 6.2240742408903316e-06
cancer B-Disease 0 0.4695281684398651
( O 0 1.5147413989780034e-08
P O 0 3.410240879020421e-06
= O 0 5.8831370886025525e-09
0 O 0 2.628272710580859e-09
. O 0 2.201463317197394e-10
02 O 0 6.067801261444572e-10
) O 0 3.4730356611445412e-12
and O 0 1.5736351458017772e-11
was O 0 4.374101081339177e-10
not O 0 3.5598430453420704e-11
detected O 0 9.90443616011305e-10
in O 0 4.848378920563334e-10
51 O 0 3.527620862087133e-08
non O 0 1.2386307446377032e-07
- O 0 1.4273824788801903e-08
European O 0 1.7316981626436245e-08
Jews O 0 2.764379587461008e-07
at O 0 4.7016804671784485e-08
increased O 0 3.344244348113534e-08
cancer B-Disease 0 2.920326380717597e-07
risk O 0 8.917048432977026e-08
. O 0 1.482390388218846e-07

Colorectal B-Disease 0 0.0008737889002077281
neoplasia I-Disease 0 0.00014003422984387726
occurred O 0 8.520207484252751e-05
personally O 0 1.5652677376465363e-08
or O 0 4.207149628676632e-10
in O 0 8.180484761810547e-11
the O 0 3.206643284237032e-10
families O 0 3.8732064777668995e-10
of O 0 6.977525224272085e-10
13 O 0 9.38334743239011e-09
of O 0 7.62430545364623e-08
20 O 0 5.059651471128745e-07
Ashkenazi O 0 1.645303768782469e-07
I1307K O 0 6.574241950829673e-08
carriers O 0 7.530788215248663e-10
, O 0 1.3997408787602694e-10
8 O 0 2.0412711521089477e-09
of O 0 8.18617529318999e-09
whom O 0 8.754390279364088e-08
also O 0 2.8388079442720482e-08
had O 0 1.5856500112931826e-08
a O 0 2.238842444768352e-09
personal O 0 4.8194333857054517e-08
or O 0 2.521504960384391e-08
family O 0 1.3759140493618816e-08
history O 0 3.509494206355157e-08
of O 0 8.630377834606406e-08
noncolonic O 0 1.346113276667893e-05
neoplasia B-Disease 0 6.676660996163264e-05
. O 0 3.533571543812286e-06

CONCLUSIONS O 0 0.0001282010634895414
The O 0 3.556937144821859e-07
I1307K O 0 4.577419076667866e-06
APC O 0 2.1178641418373445e-07
variant O 0 4.928202201881504e-08
may O 0 2.0890487117952716e-09
represent O 0 1.6423360449380198e-09
a O 0 2.983636004927348e-09
susceptibility O 0 2.9471339146880382e-08
gene O 0 1.4109788892824326e-08
for O 0 9.935891398527019e-08
colorectal B-Disease 1 1.0
, I-Disease 0 1.7103028326914682e-08
or I-Disease 0 6.578579014870911e-09
other I-Disease 0 1.9812290474874317e-08
, I-Disease 0 6.694039988985878e-09
cancers I-Disease 0 1.3437235679703008e-07
in O 0 2.972428969627572e-09
Ashkenazi O 0 2.9799066325608692e-08
Jews O 0 8.993844602400713e-08
, O 0 2.2160409063332054e-09
and O 0 2.331204562722178e-09
partially O 0 1.1130239130352493e-07
explains O 0 5.58764190472516e-09
the O 0 3.167924811364742e-10
higher O 0 1.6534887237185103e-08
incidence O 0 4.088440164196072e-06
of O 0 3.0707136033925053e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.3363614659311907e-09
European O 0 7.607016350164031e-09
Israelis O 0 1.2447387121028441e-07
. O 0 7.317761685499136e-08

Systematic O 0 3.88613052848541e-08
analysis O 0 1.4949227633564988e-08
of O 0 1.5475306369694408e-08
coproporphyrinogen O 0 1.1176630323461723e-06
oxidase O 0 1.362379578040418e-07
gene O 0 8.696108011463366e-07
defects O 1 0.944770336151123
in O 0 6.062739288381636e-08
hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
and O 0 5.927359580937264e-08
mutation O 0 4.897551164617653e-08
update O 0 1.0390187554776276e-07
. O 0 8.681923446829387e-08

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 0 9.487489478487987e-06
HC B-Disease 1 1.0
) O 0 8.764606818090215e-10
is O 0 5.0013933966530644e-11
an O 0 4.6335701942012975e-10
acute O 1 0.9999982118606567
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 1 0.9999622106552124
autosomal O 1 1.0
dominant O 1 1.0
inheritance O 0 4.3910804379265755e-06
caused O 0 4.8001314922885285e-08
by O 0 6.842068578372107e-11
deficient B-Disease 0 1.1927318688265132e-08
activity I-Disease 0 8.069427792634087e-09
of I-Disease 0 1.8080795749497725e-09
coproporphyrinogen I-Disease 0 1.308209789385728e-07
III I-Disease 0 1.336494278803002e-06
oxidase I-Disease 0 1.123524313584312e-07
( O 0 4.533124098315966e-08
CPO O 0 3.0354763111972716e-06
) O 0 3.9250438454985215e-09
. O 0 8.009703833522508e-08

Clinical O 0 9.86927148005634e-07
manifestations O 0 0.00015463503950741142
of O 0 2.0334813655153994e-07
the O 0 3.0922123528398515e-08
disease O 0 6.698397925219979e-08
are O 0 2.631338506461911e-12
characterized O 0 5.7573342794603466e-12
by O 0 1.0688826126287188e-12
acute O 0 5.8187374918361456e-08
attacks O 0 2.736601834030239e-09
of O 0 3.3982055924752785e-07
neurological B-Disease 1 1.0
dysfunction I-Disease 1 0.9999998807907104
often O 0 9.410231704976013e-09
precipitated O 0 4.894382676923215e-09
by O 0 5.180825213280116e-11
drugs O 0 1.2126931681066822e-09
, O 0 4.3629938550893144e-10
fasting O 0 1.955303119416385e-08
, O 0 3.099592360555903e-09
cyclical O 0 2.278393367305398e-05
hormonal O 0 1.8442819964548107e-06
changes O 0 2.9368857212830335e-07
, O 0 7.518481481838535e-08
or O 0 5.938873641753162e-07
infectious B-Disease 0 1.8840386474039406e-05
diseases I-Disease 0 2.4896210106817307e-06
. O 0 2.056713697129453e-07

Skin O 1 0.9999833106994629
photosensitivity O 1 0.9999998807907104
may O 0 3.805495725828223e-05
also O 0 2.0130547895291784e-08
be O 0 2.670884402533602e-09
present O 0 3.426974259923554e-08
. O 0 3.2646951808601443e-07

The O 0 4.054312228163326e-07
seven O 0 8.56274340321761e-08
exons O 0 2.0757664742632187e-07
, O 0 4.243417617288969e-09
the O 0 7.69806529632433e-09
exon O 0 1.610107425165097e-08
/ O 0 2.1067439348598782e-08
intron O 0 2.995235348635106e-08
boundaries O 0 1.0355520885241276e-08
and O 0 5.859929763651905e-10
part O 0 1.5446338652580494e-09
of O 0 2.517040975646978e-08
3 O 0 1.6515471656930458e-08
noncoding O 0 9.265700207095051e-09
sequence O 0 2.536538978858971e-09
of O 0 7.590222139697289e-08
the O 0 2.514378536488948e-07
CPO O 0 6.800891583225166e-07
gene O 0 5.087780419188448e-09
were O 0 1.2563253548592002e-08
systematically O 0 1.033149121809629e-08
analyzed O 0 1.5092901373137124e-09
by O 0 1.453051012845208e-10
an O 0 5.677862069397577e-10
exon O 0 3.0222266356183525e-10
- O 0 1.2598714294043134e-09
by O 0 1.918262437783369e-09
- O 0 7.63064846864836e-08
exon O 0 2.6666507224604175e-08
denaturing O 0 1.8171908777731005e-06
gradient O 0 5.178729338695121e-07
gel O 0 4.2571852532091725e-07
electrophoresis O 0 9.401122014196517e-08
( O 0 4.57973214906815e-08
DGGE O 0 0.00011225613707210869
) O 0 7.157913151090156e-10
strategy O 0 1.0423764074118935e-09
followed O 0 8.969095605104727e-11
by O 0 9.544052180510132e-12
direct O 0 5.866639396501228e-10
sequencing O 0 3.261790837427725e-10
in O 0 2.3292390238793814e-10
seven O 0 8.756456892911046e-09
unrelated O 0 1.0485609180932443e-07
heterozygous O 0 9.935834555108158e-08
HC B-Disease 0 1.3280679922900163e-05
patients O 0 8.088735903299948e-09
from O 0 2.3484323818934172e-08
France O 0 2.4222726935363426e-08
, O 0 1.6778390898863904e-09
Holland O 0 1.0502438918535972e-08
, O 0 2.06638084421229e-09
and O 0 1.155016526865893e-09
Czech O 0 6.66003927562997e-08
Republic O 0 5.622989647235954e-07
. O 0 3.56223677044909e-06

Seven O 0 6.910394745318627e-07
novel O 0 5.5788270003631624e-08
mutations O 0 7.623661701927631e-09
and O 0 1.0507402725679071e-09
two O 0 8.251949124016278e-10
new O 0 5.715219852930886e-09
polymorphisms O 0 8.955602481819369e-08
were O 0 6.194107271539906e-08
detected O 0 7.123875320758088e-07
. O 0 2.4671385290275794e-07

Among O 0 6.091346449466073e-08
these O 0 6.327668611305626e-09
mutations O 0 2.4870333348303575e-08
two O 0 2.096721241073851e-09
are O 0 2.2378891795238331e-10
missense O 0 1.3758541683728254e-07
( O 0 4.223811522763299e-09
G197W O 0 4.500258512507571e-07
, O 0 2.4359856354294607e-09
W427R O 0 4.0983607618727547e-08
) O 0 5.814989809116433e-11
, O 0 1.3978039559159328e-10
two O 0 5.33532329427544e-10
are O 0 6.406137842418502e-10
nonsense O 0 1.052460163464275e-07
( O 0 5.6355928812479306e-09
Q306X O 0 4.544452281152189e-07
, O 0 4.386493390740043e-09
Q385X O 0 1.184446247748383e-07
) O 0 2.1796242588578707e-10
, O 0 2.387014474969362e-10
two O 0 8.64777083275925e-10
are O 0 8.506184090428803e-10
small O 0 2.8013875663646104e-08
deletions O 0 5.708173489438195e-07
( O 0 2.57447112517184e-08
662de14bp O 0 8.897559951037692e-07
; O 0 1.806849780905395e-08
1168del3bp O 0 6.877194209664594e-07
removing O 0 4.5571550089107404e-08
a O 0 2.7028228544168087e-08
glycine O 0 3.6578331474856896e-08
at O 0 9.565027170310714e-08
position O 0 1.787867986990932e-08
390 O 0 3.3068827676174806e-09
) O 0 9.810830967071915e-12
, O 0 2.8035695293082696e-11
and O 0 4.4128388443365196e-11
one O 0 2.8119037653873136e-10
is O 0 8.8975153633708e-11
a O 0 1.0052849663821917e-09
splicing O 0 8.09298299486727e-08
mutation O 0 5.726833052221991e-08
( O 0 1.5719185952889347e-08
IVS1 O 0 4.712454483524198e-06
- O 0 4.418842181053151e-08
15c O 0 1.6572339234244282e-07
- O 0 7.578861982437957e-09
- O 0 3.683750415817144e-09
> O 0 6.913935535202143e-10
g O 0 6.686610154460482e-10
) O 0 6.022048137932501e-11
which O 0 5.2023326618799715e-11
creates O 0 1.6281137549256641e-09
a O 0 1.5976833189768058e-09
new O 0 8.942150131474591e-09
acceptor O 0 1.2582684405515465e-07
splice O 0 1.1508428542583715e-05
site O 0 5.555367351917084e-06
. O 0 1.1876126109200413e-06

The O 0 3.130847403554071e-08
pathological O 0 1.7375231209371123e-06
significance O 0 1.2191594578325748e-06
of O 0 2.7011745373783924e-07
the O 0 2.479067973126803e-07
point O 0 7.118259190974641e-07
mutations O 0 4.12694483031828e-08
G197W O 0 1.7707408517253498e-07
, O 0 7.31037563816983e-10
W427R O 0 1.3027145939759066e-07
, O 0 7.176066962877314e-10
and O 0 1.147502315390625e-09
the O 0 3.408331039622681e-08
in O 0 6.4123391041448485e-09
- O 0 4.399818465117278e-08
frame O 0 1.3166759060823097e-07
deletion O 0 2.3356744094371606e-08
390delGly O 0 5.1055437211289245e-08
were O 0 1.3652475816527954e-09
assessed O 0 7.08893654888243e-09
by O 0 2.7057500684435354e-10
their O 0 4.128139163839251e-09
respective O 0 1.11690070525583e-07
expression O 0 7.096555521002301e-08
in O 0 3.866270414931705e-09
a O 0 3.6807303871455588e-09
prokaryotic O 0 5.131108871125889e-09
system O 0 2.6486339788078794e-09
using O 0 1.9430153042065967e-09
site O 0 2.745146332472359e-07
- O 0 5.529998858833096e-08
directed O 0 2.0085673568814855e-08
mutagenesis O 0 4.292274752515368e-06
. O 0 2.99102225653769e-07

These O 0 1.7951325759213432e-08
mutations O 0 3.571668472091005e-08
resulted O 0 1.866421861507206e-08
in O 0 3.809842996638224e-10
the O 0 4.979657575177043e-09
absence O 0 3.12024788229337e-08
or O 0 1.7228604654029311e-10
a O 0 1.9000399864577133e-10
dramatic O 0 7.47190220806715e-09
decrease O 0 8.025072162354263e-08
of O 0 1.962919355946724e-07
CPO O 0 6.601474160561338e-05
activity O 0 4.447949322639033e-06
. O 0 1.4026094277141965e-06

The O 0 1.450426623250678e-07
two O 0 6.045577816138348e-09
polymorphisms O 0 3.263150460952602e-08
were O 0 1.063040877546939e-09
localized O 0 9.451496474355281e-09
in O 0 1.5308686263093563e-10
noncoding O 0 5.921164891731223e-09
part O 0 1.0829410701518327e-09
of O 0 3.935630843443505e-08
the O 0 1.019077444652794e-08
gene O 0 6.160968957225066e-10
1 O 0 1.4566015060779591e-08
) O 0 2.6178436154933316e-11
a O 0 7.386031231071399e-10
C O 0 1.5103159611840056e-08
/ O 0 6.102003902164199e-10
G O 0 1.9673442874790226e-09
polymorphism O 0 3.333789910797691e-10
in O 0 3.797668846061697e-10
the O 0 1.4005968829167159e-08
promotor O 0 1.2222491250213352e-06
region O 0 5.475004627442104e-08
, O 0 9.02573571437415e-09
142 O 0 1.1860061732704708e-07
bp O 0 1.1453386150606093e-07
upstream O 0 4.2184274207102135e-07
from O 0 2.4035829326862768e-08
the O 0 2.8022640208291705e-08
transcriptional O 0 1.4859742236694728e-07
initiation O 0 1.3818208799420972e-08
site O 0 1.1195540849939789e-07
( O 0 8.394505646158734e-10
- O 0 1.1625494344968956e-08
142C O 0 7.4747276812559e-08
/ O 0 1.801027105230446e-09
G O 0 4.851369528324767e-09
) O 0 3.897734565661004e-11
, O 0 6.903482646647419e-11
and O 0 3.293547379268347e-11
2 O 0 5.339150788152836e-10
) O 0 1.0253519387715126e-11
a O 0 8.756786962216268e-10
6 O 0 1.980922981204003e-08
bp O 0 2.055759118491096e-09
deletion O 0 1.1665597654531012e-10
polymorphism O 0 1.101004620807089e-09
in O 0 6.705844768362113e-10
the O 0 3.282819793781755e-09
3 O 0 9.601178518892084e-09
noncoding O 0 3.256410963103917e-08
part O 0 4.333140068979446e-09
of O 0 4.4551644151624714e-08
the O 0 6.045603981874592e-07
CPO O 0 2.0244231109245447e-06
gene O 0 6.2732783412400295e-09
, O 0 6.211555714230599e-09
574 O 0 1.0908092917816248e-07
bp O 0 2.1688029150368493e-08
downstream O 0 1.4192549713243352e-07
of O 0 4.007790099791464e-09
the O 0 2.54665644128238e-09
last O 0 5.728138519067727e-10
base O 0 1.632488921821107e-09
of O 0 8.02440613956179e-10
the O 0 4.763746286329251e-09
normal O 0 1.133211213755203e-07
termination O 0 3.060127653498057e-07
codon O 0 6.535260013151856e-07
( O 0 9.140392620565763e-08
+ O 0 1.883568188532081e-06
574 O 0 4.314292709750589e-06
delATTCTT O 0 9.006338586914353e-06
) O 0 3.3548499089874895e-08
. O 0 3.627644673542818e-07

Five O 0 3.829798970400589e-06
intragenic O 0 9.184110967908055e-05
dimorphisms O 0 2.602018321340438e-05
are O 0 4.349253401869646e-09
now O 0 1.676332517241974e-09
well O 0 3.951422244963254e-10
characterized O 0 4.588278368355958e-10
and O 0 2.21125895372154e-11
the O 0 1.6206894160042395e-10
high O 0 8.472618162613799e-10
degree O 0 1.7875193547567392e-09
of O 0 6.830453980199991e-10
allelic O 0 7.099723831061056e-08
heterogeneity O 0 1.2021880024803977e-07
in O 0 4.510499529430945e-09
HC B-Disease 0 0.2308504581451416
is O 0 4.141783804811894e-09
demonstrated O 0 5.052040119579715e-09
with O 0 7.175734312303561e-11
seven O 0 1.0469073385976913e-09
new O 0 1.689820922079477e-10
different O 0 2.8192058063036818e-11
mutations O 0 3.571869189311627e-10
making O 0 6.387284451347952e-11
a O 0 1.4468366782427466e-10
total O 0 5.7088545002415e-10
of O 0 1.096626967012071e-08
nineteen O 0 3.3348414945066907e-06
CPO O 0 3.6593584809452295e-05
gene B-Disease 0 1.5951893601595657e-06
defects I-Disease 0 0.0023309693206101656
reported O 0 5.665880848937377e-07
so O 0 4.796651076333092e-09
far O 0 5.2775970260654503e-08
. O 0 1.0896443747299145e-08
. O 0 1.2508085944773484e-07

Coincidence O 0 4.015255399281159e-06
of O 0 6.201969426911091e-08
two O 0 2.2218813455765485e-09
novel O 0 1.3996382719483336e-08
arylsulfatase O 0 1.854647990739977e-07
A O 0 4.771942130332718e-08
alleles O 0 7.01367541822151e-09
and O 0 3.88725540645396e-09
mutation O 0 4.602534886544163e-08
459 O 0 5.822678872391407e-08
+ O 0 1.226805323994995e-07
1G O 0 2.903995209635468e-06
> O 0 2.1690800267037957e-08
A O 0 6.655302797753393e-08
within O 0 5.532190705537232e-09
a O 0 3.371372292448882e-09
family O 0 5.907538014326974e-09
with O 0 2.4568573842032038e-09
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 2.560902323534009e-10
molecular O 0 1.5115141360766415e-09
basis O 0 2.2090185236578463e-09
of O 0 1.2773166968571559e-09
phenotypic O 0 4.439413032741868e-07
heterogeneity O 0 7.986682612681761e-05
. O 0 7.865928637329489e-06

In O 0 2.0976022696572727e-08
a O 0 9.894961294776294e-09
family O 0 3.196550801831677e-09
with O 0 8.090501185664678e-11
three O 0 1.0069430844694693e-09
siblings O 0 1.0723909760201877e-08
, O 0 1.1863755811081234e-10
one O 0 2.9156291964094194e-11
developed O 0 7.052933931328553e-11
classical O 0 1.3759586359185505e-08
late O 0 5.542583312490024e-05
infantile O 1 1.0
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 2.525524145369218e-08
MLD B-Disease 1 1.0
) O 0 1.724675263714559e-10
, O 0 3.268816051171797e-10
fatal O 0 8.547567631467246e-08
at O 0 2.7715666206518108e-08
age O 0 6.473947422591664e-08
5 O 0 1.97234228949128e-08
years O 0 3.404684312258155e-09
, O 0 1.3906982510025756e-10
with O 0 7.239688015747703e-11
deficient O 0 5.964045612927293e-08
arylsulfatase O 0 1.5406558304675855e-06
A O 0 7.412842023768462e-06
( O 0 5.819758897018801e-08
ARSA O 0 3.867559826176148e-06
) O 0 3.005269366695984e-10
activity O 0 4.037606249340797e-09
and O 0 1.1049738207757898e-10
increased O 0 1.0217086732211555e-08
galactosylsulfatide O 0 2.885108415284776e-06
( O 0 7.618142205956246e-08
GS O 1 1.0
) O 0 4.551430521360089e-08
excretion O 0 4.6360815986190573e-07
. O 0 1.657123362974744e-07

The O 0 2.6048834911307495e-07
two O 0 4.682115140042242e-09
other O 0 2.2456381199020825e-09
siblings O 0 1.1038400771212764e-07
, O 0 2.9871323192764976e-09
apparently O 0 4.1789704141592665e-07
healthy O 0 8.491068825833281e-08
at O 0 1.587632993960142e-07
12 O 0 2.9270449175555768e-08
( O 0 3.665484027415289e-10
1 O 0 4.443317891400511e-08
/ O 0 2.375696750434031e-09
2 O 0 2.6594466628893088e-09
) O 0 1.9787034857832175e-11
and O 0 9.431749825594693e-11
15 O 0 7.566465787256504e-10
years O 0 9.90107329457146e-10
, O 0 2.1686807905041405e-10
respectively O 0 1.1056090487571169e-09
, O 0 4.3411874095511394e-10
and O 0 1.182779096886577e-09
their O 0 2.280689770373101e-08
father O 0 4.012346380477538e-06
, O 0 5.983495299233255e-08
apparently O 0 8.134323365993623e-07
healthy O 0 7.391869338846391e-09
as O 0 1.1429196478118797e-09
well O 0 3.798668601895372e-10
, O 0 4.744574177983907e-10
presented O 0 6.365644367178902e-08
ARSA O 0 3.572585410438478e-05
and O 0 1.3678736365818622e-07
GS O 1 1.0
values O 0 2.2960096046631406e-08
within O 0 5.482766685105389e-09
the O 0 4.859574520565957e-09
range O 0 1.4409891946343123e-07
of O 0 1.079485727473184e-07
MLD B-Disease 1 1.0
patients O 0 1.502939994679764e-07
. O 0 3.479395331851265e-07

Mutation O 0 5.633725308484827e-08
screening O 0 7.267074497718795e-09
and O 0 3.1088626117892204e-10
sequence O 0 3.2386057724487216e-10
analysis O 0 7.678455649084981e-10
disclosed O 0 6.545661790369195e-09
the O 0 1.1789209608537021e-09
involvement O 0 2.333896409467684e-09
of O 0 4.014453658385264e-09
three O 0 2.2870996763124651e-10
different O 0 2.3629169731975708e-09
ARSA O 0 6.905236659804359e-06
mutations O 0 1.579980413168869e-08
being O 0 7.788165112820877e-10
the O 0 3.0040200882375245e-10
molecular O 0 3.4133644799538843e-09
basis O 0 7.911795663062549e-09
of O 0 4.805653208705962e-09
intrafamilial O 0 2.7805469926533988e-06
phenotypic O 0 1.4495599316433072e-06
heterogeneity O 0 0.00010470940469531342
. O 0 5.594465619651601e-06

The O 0 2.9784331445625867e-07
late O 0 6.689802830806002e-05
infantile O 1 0.9988334774971008
patient O 0 5.3772151176190164e-08
inherited O 0 1.6056122831287212e-07
from O 0 3.916595048281124e-08
his O 0 1.3227699469098297e-07
mother O 0 4.5368693690761575e-08
the O 0 5.4502562463198956e-09
frequent O 0 3.448847651910114e-09
0 O 0 3.650821156497841e-08
- O 0 6.005356567584386e-08
type O 0 1.942516405506467e-07
mutation O 0 2.3947700356075075e-07
459 O 0 7.408810631659435e-08
+ O 0 2.9109106236546722e-08
1G O 0 3.377540451765526e-07
> O 0 3.2633233892909175e-09
A O 0 4.758418015171628e-08
, O 0 1.166248347894694e-10
and O 0 5.2609961526117743e-11
from O 0 2.055374759279971e-09
his O 0 7.919103595099841e-09
father O 0 4.648443852062201e-09
a O 0 6.29220953118903e-10
novel O 0 1.3258505404678544e-09
, O 0 3.8048158373937824e-11
single O 0 2.8802996099308587e-10
basepair O 0 2.4606578108432586e-07
microdeletion O 0 3.218737276711181e-07
of O 0 3.5025795597221077e-08
guanine O 0 3.5620892901988555e-08
at O 0 6.453802114947393e-08
nucleotide O 0 3.61997898323807e-08
7 O 0 8.316852273537734e-08
in O 0 3.0156870334252517e-09
exon O 0 1.697413942736148e-08
1 O 0 2.1051617693501612e-07
( O 0 1.4868581921234636e-08
7delG O 0 9.918989007928758e-07
) O 0 1.488643075475693e-08
. O 0 2.940761874015152e-07

The O 0 1.0026701602328103e-07
two O 0 1.705676844210302e-08
clinically O 0 0.0015775521751493216
unaffected O 0 1.5961663848429453e-06
siblings O 0 7.901920895392323e-08
carried O 0 2.0317555637916485e-08
the O 0 1.0888736134972987e-08
maternal O 0 7.265857107086049e-07
mutation O 0 8.072878898701674e-08
459 O 0 5.9546916730823796e-08
+ O 0 4.704380529574337e-08
1G O 0 5.364119033401948e-07
> O 0 8.345482527261083e-09
A O 0 9.276437396010806e-08
and O 0 7.483821895526432e-10
, O 0 1.2327344700580056e-10
on O 0 1.2110703551115876e-09
their O 0 4.661066532740676e-10
paternal O 0 5.867294134986878e-07
allele O 0 9.097185227346927e-09
, O 0 5.318092077821746e-10
a O 0 3.9032121978976875e-10
novel O 0 2.5368873668440983e-09
cytosine O 0 1.2150176420533398e-09
to O 0 6.282039888283464e-10
thymidine O 0 3.5547193988350045e-07
transition O 0 1.3352173766634223e-07
at O 0 1.2804989069081785e-07
nucleotide O 0 3.4214008337585256e-07
2435 O 0 2.6052114208141575e-06
in O 0 7.409005409186875e-09
exon O 0 1.4163662243049657e-08
8 O 0 3.899644340776831e-08
, O 0 1.3029462231362032e-10
resulting O 0 4.0856035221636944e-10
in O 0 3.787019309253736e-11
substitution O 0 3.7856944246073e-09
of O 0 1.2796926185387747e-08
alanine O 0 1.6940801117470983e-07
464 O 0 1.769754760516662e-07
by O 0 9.516802634834676e-08
valine O 0 8.566228643758222e-05
( O 0 1.5918567441985942e-07
A464V O 0 4.921823347103782e-06
) O 0 2.958081779524946e-08
. O 0 2.1167939223687426e-07

The O 0 6.755274171155179e-07
fathers O 0 7.125336196622811e-07
genotype O 0 4.635935368924038e-08
thus O 0 2.612340921359646e-08
was O 0 8.094294656757484e-08
7delG O 0 2.9507109502446838e-06
/ O 0 1.5320932789109065e-06
A464V O 0 1.1308160537737422e-05
. O 0 9.004123739941861e-07

Mutation O 0 7.253256626427174e-07
A464V O 0 3.6444109809963265e-06
was O 0 5.0479393109981174e-08
not O 0 1.9586270105786951e-10
found O 0 3.8742259400592616e-10
in O 0 1.741793098641864e-10
18 O 0 1.608330357782961e-08
unrelated O 0 4.390797982978256e-07
MLD B-Disease 1 1.0
patients O 0 1.0630353486362765e-08
and O 0 2.2029764679132313e-09
50 O 0 5.363192556728791e-08
controls O 0 2.409183252893854e-07
. O 0 4.816345722247206e-07

A464V O 0 6.516131543321535e-05
, O 0 2.2896598395050205e-08
although O 0 1.0978031816932798e-08
clearly O 0 3.157148853460967e-08
modifying O 0 4.434343736647861e-07
ARSA O 0 0.0011403217213228345
and O 0 1.5366001662187045e-06
GS O 1 1.0
levels O 0 1.7154178522105212e-06
, O 0 2.592188241834492e-09
apparently O 0 3.8740228802680576e-08
bears O 0 8.787413463551275e-08
little O 0 2.2055075543647717e-09
significance O 0 1.2155466855290342e-08
for O 0 2.73205236211993e-10
clinical O 0 1.8537489765435566e-08
manifestation O 0 3.0662413337267935e-06
of O 0 3.959000878239749e-07
MLD B-Disease 1 1.0
, O 0 1.5394553187775273e-08
mimicking O 0 3.152335636968928e-07
the O 0 8.045057597882987e-08
frequent O 0 9.555642463965341e-07
ARSA O 0 0.0006435159593820572
pseudodeficiency O 0 3.619397830334492e-05
allele O 0 2.6872969556279713e-06
. O 0 1.0742559197751689e-06

Our O 0 1.4780721357965376e-07
results O 0 2.119027442404331e-08
demonstrate O 0 3.7284819676131065e-09
that O 0 6.910372968293998e-11
in O 0 3.963126701811426e-11
certain O 0 8.607486390310726e-10
genetic O 0 4.756975258146667e-08
conditions O 0 2.2404418587029795e-07
MLD B-Disease 1 1.0
- O 0 3.106719532297575e-06
like O 0 9.542577572574373e-08
ARSA O 0 0.00013162325194571167
and O 0 2.266029781594625e-07
GS O 1 1.0
values O 0 7.323735395914355e-09
need O 0 4.518685980947623e-10
not O 0 1.8790861922024504e-10
be O 0 2.2756728446093888e-10
paralleled O 0 6.657575113422354e-08
by O 0 5.892837329213307e-10
clinical O 0 1.202346169293378e-07
disease O 0 1.5622320859165484e-07
, O 0 7.82832756951457e-11
a O 0 1.4309083085084495e-10
finding O 0 1.5979667589149926e-09
with O 0 7.427519016500739e-11
serious O 0 8.066349366231407e-09
diagnostic O 0 8.762342673662715e-08
and O 0 6.55453202824674e-09
prognostic O 1 0.9952123165130615
implications O 0 1.4337326319946442e-05
. O 0 4.233042091073003e-06

Moreover O 0 1.3468016959450324e-06
, O 0 2.3500724921632354e-08
further O 0 8.553933525945467e-07
ARSA O 0 0.0010305350879207253
alleles O 0 1.9399062978209258e-07
functionally O 0 1.2401602589307004e-07
similar O 0 5.103649725057835e-10
to O 0 7.908638743892027e-10
A464V O 0 9.475615314613606e-08
might O 0 1.1541004818482747e-09
exist O 0 1.2914985747514152e-09
which O 0 6.700526800074158e-10
, O 0 3.496214984188839e-10
together O 0 1.4907100553962493e-10
with O 0 3.5017141963855636e-10
0 O 0 3.232450040968615e-08
- O 0 1.5215286808256678e-08
type O 0 7.32374916267986e-09
mutations O 0 7.855363470810062e-09
, O 0 5.112427703402034e-10
may O 0 1.057253729008778e-09
cause O 0 1.479221367617356e-07
pathological O 0 0.0005611325614154339
ARSA O 1 0.9642482995986938
and O 0 4.798195732291788e-06
GS O 1 1.0
levels O 0 9.215206659973774e-07
, O 0 1.35518055111028e-10
but O 0 4.7139660230843816e-11
not O 0 1.784683165140244e-11
clinical O 0 1.1157648138748755e-09
outbreak O 0 7.602476870260944e-09
of O 0 2.578691260524124e-09
the O 0 2.2977664215773075e-08
disease O 0 5.999185503924309e-08
. O 0 6.507619332296599e-09
. O 0 7.719918926341052e-08

Human O 0 0.00010591727186692879
MLH1 O 1 1.0
deficiency O 1 0.9999986886978149
predisposes O 0 0.0003987057425547391
to O 0 9.412658386054318e-08
hematological B-Disease 1 1.0
malignancy I-Disease 1 0.9999783039093018
and O 0 8.535768536432897e-09
neurofibromatosis B-Disease 0 0.10052212327718735
type I-Disease 0 1.1122774594696239e-05
1 I-Disease 0 5.598093048320152e-05
. O 0 5.626068286801456e-07

Heterozygous O 0 5.294162406244141e-07
germ O 0 5.660368060489418e-06
- O 0 2.5318334451185365e-07
line O 0 2.974336155148194e-08
mutations O 0 8.840932985698657e-10
in O 0 3.498161135762068e-11
the O 0 2.6657429041954117e-10
DNA O 0 4.1156880570270005e-08
mismatch O 0 4.9156969907926396e-06
repair O 0 3.3341545986331766e-06
genes O 0 8.348382607437088e-07
lead O 0 6.864953547847108e-07
to O 0 6.443875832928825e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.6590177526486514e-07

The O 0 2.1990985032971366e-08
disease O 0 4.930900487920553e-08
susceptibility O 0 1.3770272033752917e-08
of O 0 1.3695038436623008e-09
individuals O 0 4.0262687628356275e-10
who O 0 3.420771008677548e-07
constitutionally O 0 3.280474203393169e-08
lack O 0 1.159056139954373e-07
both O 0 3.83654885638407e-09
wild O 0 6.910330085929672e-08
- O 0 2.1720484966181175e-08
type O 0 2.307855417882365e-08
alleles O 0 4.32607949463204e-09
is O 0 1.940141380885052e-09
unknown O 0 5.799419113827753e-07
. O 0 3.296302395483508e-07

We O 0 3.229886402777993e-08
have O 0 1.4714955920425155e-09
identified O 0 6.81490686105235e-09
three O 0 3.5517466745460524e-10
offspring O 0 1.6293750793039408e-09
in O 0 1.2247707015244913e-10
a O 0 8.865423062331956e-09
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.3706334733853964e-08
who O 0 3.730768471932322e-11
developed O 0 3.6059721875147943e-10
hematological B-Disease 0 6.144724466139451e-06
malignancy I-Disease 0 0.00012894501560367644
at O 0 1.8713981475571018e-08
a O 0 8.42816538781932e-10
very O 0 3.543450810550297e-10
early O 0 1.5106444095636107e-08
age O 0 1.2434828278173882e-08
, O 0 2.9403146584172646e-10
and O 0 2.562808298911534e-10
at O 0 4.097701733485337e-09
least O 0 1.0488100388172938e-09
two O 0 3.3418817713126714e-10
of O 0 5.137305025826322e-10
them O 0 1.723721582136406e-10
displayed O 0 3.8500974852695435e-08
signs O 0 9.882592877374918e-08
of O 0 3.060200270965652e-08
neurofibromatosis B-Disease 0 0.00015406133024953306
type I-Disease 0 5.263064394966932e-06
1 I-Disease 0 0.00013061027857474983
( O 0 6.599601078960404e-07
NF1 B-Disease 0 0.00053018779726699
) O 0 1.0831610808281766e-07
. O 0 5.293919684845605e-07

DNA O 0 3.0001409356827935e-08
sequence O 0 4.350481752624091e-09
analysis O 0 2.6673412367728133e-09
and O 0 2.5770130474001007e-10
allele O 0 3.681487059647992e-10
- O 0 1.1343493505622249e-10
specific O 0 5.129537766768166e-11
amplification O 0 5.652275314460553e-10
in O 0 1.4191176012090523e-10
two O 0 1.8148584857158312e-09
siblings O 0 1.198822019432555e-07
revealed O 0 2.977406943216465e-08
a O 0 1.7656104134289308e-08
homozygous O 0 3.420666701003938e-07
MLH1 O 0 9.990916441893205e-05
mutation O 0 1.291384137402929e-07
( O 0 1.544345984427764e-08
C676T O 0 4.749776678636408e-07
- O 0 1.2739675980810716e-07
- O 0 1.6163021143711376e-07
> O 0 5.894124299743453e-08
Arg226Stop O 0 4.630730359167501e-07
) O 0 3.7852037060304156e-09
. O 0 4.099533157386759e-08

Thus O 0 1.5546611109584774e-07
, O 0 3.373662016414869e-09
a O 0 3.736733145132121e-09
homozygous O 0 5.5207987514904744e-08
germ O 0 1.0953749551845249e-05
- O 0 6.913334686942108e-07
line O 0 2.560322229783196e-07
MLH1 O 0 9.776207662071101e-06
mutation O 0 7.171103266756518e-09
and O 0 1.538934119027502e-10
consequent O 0 7.6676124081132e-06
mismatch O 1 0.9998878240585327
repair O 1 0.9999959468841553
deficiency O 1 1.0
results O 0 3.225849695809302e-06
in O 0 4.323505997660959e-09
a O 0 1.490808188009396e-08
mutator O 0 2.1636028577631805e-06
phenotype O 0 1.782291114693635e-08
characterized O 0 2.5304444650764424e-10
by O 0 4.562723115997258e-11
leukemia B-Disease 0 1.7341993952868506e-05
and O 0 4.038694001451404e-08
/ O 1 0.9914018511772156
or O 0 3.37918390869163e-05
lymphoma B-Disease 1 1.0
associated O 0 1.2749925417665509e-06
with O 0 1.2073180233329595e-09
neurofibromatosis B-Disease 1 0.9974550604820251
type I-Disease 0 1.1019054909411352e-05
1 I-Disease 0 4.450720552995335e-06
. O 0 1.24893322350772e-08
. O 0 6.40951682839841e-08

Missense O 0 1.7563790606800467e-05
mutations O 0 4.955301164955017e-07
in O 0 8.462446743351393e-09
the O 0 4.447894497161542e-09
most O 0 2.6035734679297207e-10
ancient O 0 7.708938376538299e-09
residues O 0 1.8637964060985723e-08
of O 0 3.105711465778427e-09
the O 0 4.2726735927089976e-08
PAX6 O 0 5.277347008814104e-05
paired O 0 9.493270880511773e-08
domain O 0 4.083612736849318e-08
underlie O 0 5.0285180464015866e-08
a O 0 6.011034447972463e-10
spectrum O 0 1.4746353826922132e-07
of O 0 1.783022085533048e-08
human O 0 0.08901505917310715
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 2.9600814741570503e-05

Mutations O 0 4.6104821649350924e-07
of O 0 1.8335191143137308e-08
the O 0 2.375207364124776e-09
human O 0 4.990135415994246e-09
PAX6 O 0 6.695565389236435e-05
gene O 0 7.718106189713581e-07
underlie O 1 0.9997643828392029
aniridia B-Disease 1 1.0
( O 0 0.034835778176784515
congenital B-Disease 1 1.0
absence I-Disease 1 0.9999990463256836
of I-Disease 0 0.0673595517873764
the I-Disease 0 1.045744284056127e-06
iris I-Disease 0 1.972546073147896e-07
) O 0 1.1043965741919237e-10
, O 0 2.6705557903961008e-11
a O 0 1.0112462256461896e-10
rare O 0 9.541849266270219e-08
dominant O 1 1.0
malformation B-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 1 0.9999996423721313
eye I-Disease 1 0.9999964237213135
. O 0 6.272215955505089e-07

The O 0 2.2515369835218735e-07
spectrum O 0 4.5813931137672625e-06
of O 0 1.0828207450686023e-06
PAX6 O 0 0.0006405607564374804
mutations O 0 2.239782588731032e-06
in O 0 6.716796008277015e-08
aniridia B-Disease 1 1.0
patients O 0 8.374204440997346e-08
is O 0 9.435928705059382e-10
highly O 0 4.588613045086731e-09
biased O 0 9.71674722904936e-08
, O 0 1.054598700034326e-10
with O 0 2.2501632501725766e-11
92 O 0 3.9645012606115415e-08
% O 0 4.538396880526818e-10
of O 0 2.166076346066248e-10
all O 0 4.053282987026563e-10
reported O 0 1.5761155935933857e-08
mutations O 0 1.8319914474318466e-08
leading O 0 1.0106552039701455e-08
to O 0 9.957985547259796e-10
premature O 0 7.834736948097998e-07
truncation O 0 9.265186236007139e-06
of O 0 1.8042827605313505e-06
the O 0 3.700721663335571e-06
protein O 0 4.4239204726181924e-06
( O 0 3.715166130291436e-08
nonsense O 0 9.933427946862139e-08
, O 0 3.27870242067263e-09
splicing O 0 1.7139569763457985e-08
, O 0 2.032165324905577e-09
insertions O 0 1.4328733755064604e-08
and O 0 2.697002399187909e-09
deletions O 0 1.5440603462479885e-08
) O 0 3.23737037177807e-10
and O 0 1.7089062387398712e-09
just O 0 1.1569287750035073e-08
2 O 0 2.2124943654944218e-08
% O 0 8.629350012334669e-10
leading O 0 3.3933694743026876e-10
to O 0 1.1235136085363528e-11
substitution O 0 2.151542277673002e-09
of O 0 1.0128570870904241e-08
one O 0 8.525534056502693e-09
amino O 0 7.485824404795949e-09
acid O 0 1.140876726424267e-09
by O 0 3.697714912043182e-10
another O 0 6.021379306275776e-08
( O 0 2.8128400941795917e-08
missense O 0 1.523695914329437e-06
) O 0 2.9114602284607827e-08
. O 0 2.6726240776042687e-07

The O 0 5.8332393138016414e-08
extraordinary O 0 8.394222206220547e-09
conservation O 0 2.5195481256901076e-08
of O 0 3.3515095143599183e-09
the O 0 1.1303225022629704e-08
PAX6 O 0 8.261876587312145e-07
protein O 0 3.0328664024636964e-08
at O 0 1.587823028614821e-08
the O 0 6.995665380316041e-09
amino O 0 4.673819731237927e-08
acid O 0 2.8454540057509803e-08
level O 0 4.287932142688078e-08
amongst O 0 4.64396237020992e-08
vertebrates O 0 2.573531503458071e-07
predicts O 0 8.624306957472072e-08
that O 0 2.6563442556692962e-09
pathological O 0 4.6973873395472765e-06
missense O 0 3.6012243072036654e-06
mutations O 0 2.3259744352799316e-07
should O 0 3.683862992431841e-09
in O 0 2.2901038843059496e-09
fact O 0 5.252859924809172e-09
be O 0 8.055751621327545e-10
common O 0 9.567500125484685e-10
even O 0 6.698354093614967e-10
though O 0 1.066932875382065e-09
they O 0 3.4698147133305213e-10
are O 0 6.447361533545859e-10
hardly O 0 1.0763463365037751e-07
ever O 0 2.997224157752498e-08
seen O 0 1.1670665855945117e-07
in O 0 5.969018701534878e-08
aniridia B-Disease 1 1.0
patients O 0 2.2067189320296166e-07
. O 0 2.815954474044702e-07

This O 0 7.1998162987085834e-09
indicates O 0 4.940182662949155e-08
that O 0 2.736589843621573e-10
there O 0 3.5435052114785037e-10
is O 0 6.17898371357839e-11
a O 0 4.380939222503599e-10
heavy O 0 6.240069296836737e-07
ascertainment O 0 5.7322289649164304e-05
bias O 0 2.20293100028357e-06
in O 0 2.100491780510083e-09
the O 0 5.995202112529796e-09
selection O 0 1.8374540999843703e-08
of O 0 4.909492368199153e-09
patients O 0 5.724053453448619e-10
for O 0 1.3124474840253697e-09
PAX6 O 0 3.309085059299832e-06
mutation O 0 5.886481968531143e-09
analysis O 0 2.496166162657687e-09
and O 0 1.544986777402002e-10
that O 0 1.8636132914640058e-10
the O 0 2.142354560419335e-08
missing O 0 3.890220341418171e-06
PAX6 O 0 0.00022613363398704678
missense O 0 1.9828808945021592e-05
mutations O 0 8.884874773684714e-07
frequently O 0 2.2563124701946435e-08
may O 0 1.656007420081096e-08
underlie O 0 4.879518201050814e-06
phenotypes O 0 9.390919331053738e-06
distinct O 0 1.8754113284558116e-07
from O 0 1.1705935065720041e-07
textbook O 0 7.689418453082908e-06
aniridia B-Disease 1 1.0
. O 0 2.795665977828321e-06

Here O 0 2.7530111879059405e-07
we O 0 7.231194310008959e-09
present O 0 4.865352565275316e-09
four O 0 2.138841992405105e-09
novel O 0 5.4844004893084275e-08
PAX6 O 0 1.7503558410680853e-05
missense O 0 1.5787353504492785e-06
mutations O 0 1.8000635293446976e-07
, O 0 4.784653562239782e-09
two O 0 1.1428804569391104e-09
in O 0 4.973390033136127e-10
association O 0 2.379588082135342e-09
with O 0 1.5388695873141955e-10
atypical O 0 6.431449719457305e-07
phenotypes O 0 3.352579369675368e-07
ectopia B-Disease 0 3.2657462725182995e-06
pupillae I-Disease 0 2.422442548777326e-06
( O 0 1.1152606615993932e-09
displaced B-Disease 0 1.383754835160289e-07
pupils I-Disease 0 1.5828216959334895e-08
) O 0 7.601994034267534e-10
and O 0 5.3520766414294485e-06
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9999933242797852
( O 0 1.1704389457634079e-08
searching B-Disease 0 2.626170214625745e-07
gaze I-Disease 0 4.210164377127512e-07
) O 0 3.7487148801806924e-11
, O 0 1.0574004866148456e-10
and O 0 2.5594470987044815e-10
two O 0 1.9318922017674822e-09
in O 0 3.0184721389048264e-09
association O 0 1.2083900102766165e-08
with O 0 2.054080378011136e-10
more O 0 3.712048002313395e-09
recognizable O 0 0.0011254551354795694
aniridia B-Disease 1 1.0
phenotypes O 0 4.9532627599546686e-05
. O 0 1.7207298697030637e-06

Strikingly O 0 2.1100446247146465e-05
, O 0 2.882489980038372e-08
all O 0 5.627171617561544e-09
four O 0 8.529111639177245e-09
mutations O 0 8.551852559435247e-09
are O 0 1.1647678654913562e-10
located O 0 1.2159983020509912e-09
within O 0 8.423102215715517e-10
the O 0 1.1166876845436491e-07
PAX6 O 0 4.200200783088803e-05
paired O 0 8.378789573271206e-08
domain O 0 2.2432205426525798e-08
and O 0 7.1610988250370156e-09
affect O 0 3.85282334036674e-07
amino O 0 1.1230700636133406e-07
acids O 0 2.861673564780176e-08
which O 0 3.3598027138204145e-10
are O 0 3.32781024958706e-11
highly O 0 4.760419280991357e-10
conserved O 0 3.114371871504318e-09
in O 0 1.3676869636825018e-09
all O 0 5.147321679999095e-09
known O 0 4.829316324617139e-08
paired O 0 7.09804552911919e-08
domain O 0 8.611041835138167e-08
proteins O 0 8.656013505969895e-08
. O 0 4.896986069979903e-07

Our O 0 4.905058403892326e-07
results O 0 6.56663416975789e-08
support O 0 9.159061953312175e-09
the O 0 3.912456580934531e-09
hypothesis O 0 5.87816817443354e-09
that O 0 9.27942878786725e-12
the O 0 2.165151113953101e-10
under O 0 6.835185195619431e-10
- O 0 9.628681185702703e-10
representation O 0 5.645490297467859e-09
of O 0 3.2501812796681406e-08
missense O 0 5.902049906580942e-07
mutations O 0 7.250228151178817e-08
is O 0 8.393000738848855e-10
caused O 0 2.4273079102243855e-09
by O 0 1.3657501796160432e-09
ascertainment O 1 0.9998224377632141
bias O 0 0.00739339180290699
and O 0 2.7108291167365905e-09
suggest O 0 4.892926508404116e-09
that O 0 1.0303261716027023e-10
a O 0 6.013144981942276e-10
substantial O 0 5.8522953594319915e-08
burden O 0 2.3045115540298866e-06
of O 0 2.929636320914142e-05
PAX6 B-Disease 1 1.0
- I-Disease 1 0.9999973773956299
related I-Disease 1 0.9941934943199158
disease I-Disease 1 0.9999998807907104
remains O 0 6.329638324586995e-08
to O 0 2.8501498383626256e-10
be O 0 1.737248456201712e-09
uncovered O 0 1.3983284929963702e-07
. O 0 1.9872278045340863e-08
. O 0 1.4698055395001575e-07

The O 0 7.926087164378259e-08
chromosomal O 0 2.0498953290370991e-07
order O 0 3.008920401725845e-08
of O 0 5.668994518259751e-08
genes O 0 1.0259153526703813e-07
controlling O 0 9.650474339650827e-07
the O 0 2.6062800770887407e-06
major O 0 8.402969911003311e-07
histocompatibility O 0 1.6110786873468896e-06
complex O 0 1.4061116644370486e-06
, O 0 4.112021834146162e-09
properdin O 0 2.2981659242304886e-07
factor O 0 1.8197468421021767e-08
B O 0 1.041111659105809e-07
, O 0 2.3849758279403943e-10
and O 0 3.9745520763467823e-10
deficiency B-Disease 0 1.1630904737103265e-06
of I-Disease 1 0.9927852153778076
the I-Disease 0 0.07996673136949539
second I-Disease 0 5.040790824750729e-07
component I-Disease 0 3.4548807548162586e-07
of I-Disease 0 5.948017189894017e-08
complement I-Disease 0 1.4758762745259446e-07
. O 0 1.2864491054642713e-06

The O 0 2.082469663378106e-08
relationship O 0 9.061234429452725e-09
of O 0 3.440282014821605e-08
the O 0 3.4198552878450528e-09
genes O 0 3.0633801051394016e-10
coding O 0 2.25639751327833e-09
for O 0 4.3723158427155795e-10
HLA O 0 2.6108667228186277e-08
to O 0 3.0484179069922845e-10
those O 0 4.648104956483934e-10
coding O 0 1.491251921947878e-08
for O 0 2.0416797141820098e-09
properdin O 0 7.152978582780634e-07
Factor O 0 2.0960943203363058e-08
B O 0 1.801812032908856e-07
allotypes O 0 1.3398617682014446e-07
and O 0 2.2243523689624567e-10
for O 0 3.2527078253075103e-10
deficiency B-Disease 0 1.4468058395777916e-07
of I-Disease 0 1.4572746920293866e-07
the I-Disease 0 1.8302172222206536e-08
second I-Disease 0 3.2036187036510455e-09
component I-Disease 0 1.5071016434831108e-08
of I-Disease 0 2.4467947667972112e-08
complement I-Disease 0 2.5131360104069245e-08
( O 0 8.062765566307917e-09
C2 O 0 4.60225386689217e-08
) O 0 1.9782478433150175e-10
was O 0 3.4665486037255278e-09
studied O 0 4.89158991090477e-10
in O 0 3.0797180777808464e-11
families O 0 1.8753196218135315e-10
of O 0 3.9197672885293855e-10
patients O 0 1.5604676439906484e-09
with O 0 8.87838513818906e-09
connective O 1 0.9999979734420776
tissue O 1 1.0
disorders O 1 1.0
. O 0 5.4168544920685235e-06

Patients O 0 3.779910073831161e-08
were O 0 3.6525884539173603e-09
selected O 0 1.12369680227431e-09
because O 0 2.8049776390481895e-10
they O 0 5.2674926920293075e-11
were O 0 3.4178906926918273e-10
heterozygous O 0 1.600983901006714e-09
or O 0 3.0927418404047557e-09
homozygous O 0 1.675528693567685e-07
for O 0 1.98858310795913e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 5.263460934656905e-06

12 O 0 1.7518136701255571e-06
families O 0 2.3193198472881704e-08
with O 0 6.228090265736341e-10
15 O 0 4.348044768676118e-08
matings O 0 1.1291975852145697e-06
informative O 0 3.408413704164559e-06
for O 0 9.930195119522978e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 1.1295254864762683e-07
found O 0 3.591540931324744e-08
. O 0 1.5085949200965842e-07

Of O 0 3.9944134186953306e-05
57 O 0 1.8564418496680446e-05
informative O 0 7.396977252938086e-07
meioses O 0 2.9857151275791693e-06
, O 0 1.3985940183758316e-09
two O 0 6.234603389110305e-10
crossovers O 0 4.725613322875688e-08
were O 0 1.3342195126497813e-09
noted O 0 5.125396551619588e-09
between O 0 2.0081920126813202e-08
the O 0 9.085688361665234e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999886751174927
gene O 0 2.6180260181973836e-09
and O 0 1.944928440522631e-09
the O 0 1.176513553247105e-08
HLA O 0 2.6611613179738924e-07
- O 0 1.7853109284260427e-06
B O 0 5.022882305638632e-07
gene O 0 5.644733569454274e-10
, O 0 1.0915673920308677e-10
with O 0 2.3757838144705667e-12
a O 0 5.832340166378458e-11
recombinant O 0 8.005461571425343e-11
fraction O 0 4.933635722181862e-09
of O 0 1.670422378197145e-08
0 O 0 3.226463149985648e-07
. O 0 4.807342861568031e-07

035 O 0 0.005436226725578308
. O 0 3.569932596292347e-05

A O 0 3.053366526728496e-06
lod O 0 1.0263562217005529e-05
score O 0 7.872090890259642e-08
of O 0 1.4324854191727354e-08
13 O 0 1.2101613933168665e-08
was O 0 1.8258649037150576e-09
calculated O 0 1.4594651043253748e-09
for O 0 1.4851023188988677e-10
linkage O 0 4.9418881644669455e-06
between O 0 1.4274785826273728e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.7847395500657512e-08
HLA O 0 1.8813349242918775e-06
- O 0 5.955684628133895e-06
B O 0 2.2323506527754944e-06
at O 0 3.433644479855502e-10
a O 0 1.7693823836650857e-12
maximum O 0 1.43170475475074e-11
likelihood O 0 1.277793704179686e-10
value O 0 4.049048873966399e-10
of O 0 5.422082227646285e-10
the O 0 7.133951762661184e-10
recombinant O 0 4.932334540797001e-10
fraction O 0 9.60773594016473e-09
of O 0 2.4964577960417955e-08
0 O 0 2.9740590434812475e-07
. O 0 5.152599555913184e-07

04 O 0 0.0015550642274320126
. O 0 2.893824603233952e-05

18 O 0 7.110115802788641e-06
families O 0 1.0186094812070223e-07
with O 0 2.17770135257922e-09
21 O 0 1.2233552126872382e-07
informative O 0 3.243851409706622e-08
matings O 0 1.3733973958096612e-07
for O 0 6.363675808529479e-09
both O 0 8.845732679674256e-08
properdin O 0 7.868891771067865e-06
Factor O 0 2.9041069637969485e-07
B O 0 1.2670529940805864e-06
allotype O 0 4.77935714116029e-07
and O 0 1.3651543895321083e-08
HLA O 0 5.502826070369338e-07
- O 0 5.3938319979351945e-06
B O 0 8.483752935717348e-06
were O 0 1.0539080719240701e-08
found O 0 1.0086120383334674e-08
. O 0 4.0354137809117674e-08

Of O 0 5.5048050853656605e-05
72 O 0 1.7392309018759988e-05
informative O 0 3.0369415071618278e-06
meioses O 0 1.9959090423071757e-05
, O 0 1.4700431094638589e-08
three O 0 1.7585255918106668e-08
recombinants O 0 4.082891791767906e-06
were O 0 3.4016998995411996e-08
found O 0 4.4387586939365065e-09
, O 0 1.383607672877929e-10
giving O 0 2.9219549002590384e-10
a O 0 5.465493613243666e-10
recombinant O 0 1.5212000548103788e-09
fraction O 0 3.792894887055809e-08
of O 0 9.173226800385237e-08
0 O 0 1.0328229791412014e-06
. O 0 1.0202909379586345e-06

042 O 0 0.0034736208617687225
. O 0 2.80927761195926e-05

A O 0 3.1614683848602e-06
lod O 0 8.205253834603354e-06
score O 0 5.821701520858369e-08
of O 0 2.0811594225733643e-08
16 O 0 5.9032149835047676e-08
between O 0 2.7342553110543122e-08
HLA O 0 1.3326671250979416e-06
- O 0 1.896368871712184e-06
B O 0 3.4011688399004925e-07
and O 0 1.5234380423834182e-10
Factor O 0 7.074709706955673e-10
B O 0 2.4796820596861835e-08
allotypes O 0 2.0144296897228742e-08
was O 0 1.122174020373734e-09
calculated O 0 1.5325141156097288e-09
at O 0 1.5599400937649222e-10
a O 0 1.326868736412079e-11
maximum O 0 3.725877939508848e-10
likelihood O 0 1.112579361972621e-09
value O 0 1.978505581590184e-09
of O 0 2.8075000102489867e-09
the O 0 3.853857233337976e-09
recombinant O 0 1.608268185293582e-09
fraction O 0 2.3114941072321926e-08
of O 0 4.250612661849118e-08
0 O 0 4.983637040822941e-07
. O 0 7.40669122478721e-07

04 O 0 0.001562175340950489
. O 0 1.9668368622660637e-05

A O 0 5.941762992733857e-07
crossover O 0 3.736015230515477e-08
was O 0 1.4692021821360868e-08
shown O 0 9.120004057505682e-11
to O 0 1.0188432042479434e-10
have O 0 2.226682865869023e-10
occurred O 0 3.8850263450740385e-08
between O 0 5.711293660226602e-10
genes O 0 8.609982726781595e-10
for O 0 5.578097983516273e-10
Factor O 0 5.4201820809396395e-09
B O 0 4.840538991857102e-08
and O 0 3.3047262704144487e-09
HLA O 0 2.271564767397649e-07
- O 0 1.0722293382059433e-06
D O 0 9.344255147425429e-08
, O 0 1.392535753375057e-09
in O 0 7.94757648581168e-10
which O 0 8.580112731415568e-10
HLA O 0 7.532778312224764e-08
- O 0 4.436382425865304e-07
D O 0 5.6644118728854664e-08
segregared O 0 2.3038055019242165e-07
with O 0 9.387675081740099e-10
HLA O 0 3.036183500171319e-07
- O 0 1.0874197187149548e-06
A O 0 0.0001390667021041736
and O 0 1.7239404570545958e-08
B O 0 1.4284248663898325e-06
. O 0 4.9588084749530026e-08

These O 0 2.498396511896317e-08
studies O 0 1.4060921316172426e-08
suggest O 0 1.698753915313489e-09
that O 0 2.955686043137895e-11
the O 0 2.641498964006672e-10
genes O 0 1.1386586812323074e-10
for O 0 9.121396693512196e-11
Factor O 0 2.0127822963900144e-08
B O 0 0.00019693757349159569
and O 0 2.5570852812961675e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 3.7985619094627054e-09
located O 0 3.942993842542819e-08
outside O 0 2.797804476983856e-08
those O 0 1.1586483994463492e-09
for O 0 1.5625137850250326e-09
HLA O 0 1.8951310210013617e-07
, O 0 4.0555567237809953e-10
that O 0 7.274458813100182e-11
the O 0 4.367006756211822e-10
order O 0 1.4646799328943416e-09
of O 0 2.460375725377162e-08
genese O 0 7.630239338141109e-07
is O 0 5.689811732878525e-09
HLA O 0 1.0838575548177687e-07
- O 0 3.0007794293851475e-07
A O 0 6.990549445617944e-05
, O 0 7.367068732833104e-09
- O 0 1.419173312200428e-08
B O 0 4.1299369257785656e-08
, O 0 1.4082036647877771e-09
- O 0 5.888795229225252e-09
D O 0 1.984068243032766e-09
, O 0 2.813309307736489e-10
Factor O 0 5.572018402233425e-09
B O 0 4.992326466890518e-06
allotype O 0 8.498663373757154e-05
, O 0 7.874529728724156e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 2.6667193453455695e-10
that O 0 5.7384114821035226e-12
the O 0 1.0615450185547104e-10
genes O 0 7.48049677756768e-10
coding O 0 1.2662561665877092e-08
for O 0 5.6040818208202836e-08
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 7.749449970617661e-09
Factor O 0 4.9090825626763035e-08
B O 0 4.23569730401141e-07
allotypes O 0 1.3900425699375774e-07
are O 0 2.0909052267370498e-10
approximately O 0 1.9556043451274263e-09
3 O 0 5.250665680023303e-09
- O 0 1.7085152181905983e-09
- O 0 2.3009711913601905e-09
5 O 0 2.4502260220771177e-09
centimorgans O 0 1.482681000197772e-08
from O 0 1.3835660395145055e-09
the O 0 4.066713188422e-09
HLA O 0 7.386288469746205e-09
- O 0 6.986637934858209e-09
A O 0 9.510324616712751e-08
and O 0 6.314089251446831e-10
HLA O 0 5.064604380322635e-08
- O 0 1.761055585802751e-07
B O 0 5.918514034419786e-08
loci O 0 6.656960538364842e-10
, O 0 4.568026165663319e-11
and O 0 2.1475171901180756e-12
that O 0 5.077242337496457e-13
the O 0 1.9611081855663848e-11
apparent O 0 2.509772167869073e-09
lack O 0 2.7420146153644964e-09
of O 0 3.2827383034117474e-09
recombinants O 0 3.045004461910139e-07
between O 0 1.1162140101106388e-09
the O 0 4.4385215502984465e-09
Factor O 0 8.276922258687591e-09
B O 0 3.173398681610706e-07
gene O 0 2.505870781988051e-07
and O 1 0.9998528957366943
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 2.3274560945196754e-08
suggests O 0 2.1349547907334454e-08
that O 0 3.852266075576871e-11
these O 0 3.888349017766579e-11
two O 0 1.8747722818623913e-10
genes O 0 2.453130143464932e-09
lie O 0 8.660715700159471e-09
in O 0 1.013328088106391e-09
close O 0 1.0186676746570811e-07
proximity O 0 7.97798804796912e-07
to O 0 4.831883781974966e-09
one O 0 4.77033132995075e-08
another O 0 2.8065790047548944e-07
. O 0 6.212008543116099e-07

Distribution O 0 2.8350373781904636e-07
of O 0 2.5086492883019673e-07
emerin O 0 4.480996722122654e-06
and O 0 1.1744172745409287e-08
lamins O 0 1.219111800310202e-05
in O 0 2.3176262686774862e-08
the O 0 1.743748157423397e-06
heart O 0 3.8928820345063286e-07
and O 0 3.030077966315048e-09
implications O 0 7.334278961934615e-08
for O 0 1.3949555288661486e-08
Emery B-Disease 0 0.0013547544367611408
- I-Disease 1 0.9999648332595825
Dreifuss I-Disease 1 0.9999998807907104
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 8.774632442509755e-05

Emerin O 0 0.00013670757471118122
is O 0 2.4431479062059225e-08
a O 0 1.365513835338561e-08
nuclear O 0 8.720593314137659e-08
membrane O 0 1.3730826253777195e-08
protein O 0 1.0450365017788954e-08
which O 0 2.885842953492812e-10
is O 0 1.827076268057226e-10
missing O 0 3.932089143177109e-08
or O 0 4.264399500186755e-09
defective O 0 4.669747397656465e-07
in O 0 2.5336586162438834e-08
Emery B-Disease 1 0.9997237324714661
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.004394810181111097
EDMD B-Disease 1 1.0
) O 0 4.1963026831126626e-08
. O 0 1.729530225702547e-07

It O 0 7.820903036304117e-09
is O 0 5.389202417660499e-10
one O 0 5.23822929476836e-10
member O 0 7.038155058758377e-10
of O 0 9.132616440865604e-09
a O 0 1.698132834349053e-08
family O 0 3.3419368605791533e-07
of O 0 1.3543584600483882e-06
lamina O 1 0.9999170303344727
- O 0 0.0008136557298712432
associated O 0 0.00018279468349646777
proteins O 0 6.593175783109473e-09
which O 0 3.1425409496854684e-10
includes O 0 9.847360704640096e-10
LAP1 O 0 0.00047804496716707945
, O 0 2.0007901113672233e-08
LAP2 O 1 0.9988162517547607
and O 0 5.918136025684362e-07
lamin O 0 0.0002930063637904823
B O 0 0.00010171874600928277
receptor O 0 2.9450120564433746e-05
( O 0 3.992543952335836e-06
LBR O 0 0.24860882759094238
) O 0 4.3234010149717506e-08
. O 0 3.485093884592061e-07

A O 0 9.189559932565317e-05
panel O 0 2.1119878965691896e-06
of O 0 6.136639854048553e-07
16 O 0 2.606730049592443e-07
monoclonal O 0 1.1926026388664468e-07
antibodies O 0 5.764378130379555e-08
( O 0 7.732706919227894e-09
mAbs O 0 6.090603221764468e-08
) O 0 4.662311647862794e-10
has O 0 3.879787047189609e-10
been O 0 3.444323160017859e-10
mapped O 0 3.1246891740721594e-09
to O 0 2.7984528583324675e-10
six O 0 1.1286522827447243e-09
specific O 0 1.380581982068918e-09
sites O 0 6.722088841115692e-08
throughout O 0 3.154686822881558e-08
the O 0 3.6197928920955746e-07
emerin O 0 1.3812406223223661e-06
molecule O 0 6.964484988714048e-09
using O 0 3.332030873437475e-09
phage O 0 6.508487526701856e-09
- O 0 6.370889593654283e-09
displayed O 0 1.9577624854605347e-08
peptide O 0 9.084072938314591e-10
libraries O 0 1.8135227763949047e-09
and O 0 8.220624736487991e-10
has O 0 2.524837561246329e-10
been O 0 1.2060860643536842e-10
used O 0 1.2986044184426504e-10
to O 0 9.25225673853447e-10
localize O 0 1.3263514802019927e-06
emerin O 0 2.9200582503108308e-06
in O 0 6.842101551995938e-09
human O 0 2.904809548454068e-08
and O 0 9.326947747467784e-08
rabbit O 0 8.932247510529123e-07
heart O 0 6.005459454172524e-07
. O 0 5.784290237897949e-07

Several O 0 7.446053587045753e-07
mAbs O 0 1.9343578969710506e-06
against O 0 6.595354307137313e-08
different O 0 3.9062395984501563e-08
emerin O 0 5.133185368322302e-06
epitopes O 0 6.193387207531487e-07
did O 0 2.2083456840960025e-08
not O 0 4.35925251451863e-09
recognize O 0 3.019222205580263e-08
intercalated O 0 3.6191750041325577e-07
discs O 0 4.482064142052877e-08
in O 0 3.3141457578267364e-08
the O 0 2.2279143649939215e-06
heart O 0 2.0670687206347793e-07
, O 0 1.7420132003564959e-09
though O 0 1.9476682489028008e-09
they O 0 1.1524550203034778e-09
recognized O 0 2.8214479641519574e-08
cardiomyocyte O 0 8.630984780211293e-07
nuclei O 0 3.3744558436410443e-07
strongly O 0 4.578430790047605e-08
, O 0 1.7157910647824792e-09
both O 0 5.831478411266744e-09
at O 0 7.107548185558699e-07
the O 0 7.348883173108334e-07
rim O 0 5.051243192610855e-07
and O 0 6.507395511334835e-09
in O 0 1.1599315286048295e-08
intranuclear O 0 1.1376544534869026e-05
spots O 0 4.5345350372372195e-06
or O 0 2.832815937381383e-07
channels O 0 1.5717304222562234e-06
. O 0 6.90357751409465e-07

A O 0 1.2162898201495409e-05
polyclonal O 0 8.628988325654063e-06
rabbit O 0 4.301251124161354e-07
antiserum O 0 1.3941914858150994e-06
against O 0 5.738521835496613e-08
emerin O 0 3.7445374800881837e-06
did O 0 7.120252831782636e-09
recognize O 0 1.199041044230853e-08
both O 0 2.0699243208355256e-08
nuclear O 0 4.556694364055147e-07
membrane O 0 7.363686194139518e-08
and O 0 3.369302170597166e-09
intercalated O 0 1.1736495508785083e-07
discs O 0 2.7290553816783358e-08
but O 0 9.5206305061879e-09
, O 0 7.237013210925625e-10
after O 0 1.4444001550373287e-09
affinity O 0 9.333044337367369e-10
purification O 0 5.208580233784232e-10
against O 0 1.1828941159919282e-09
a O 0 1.132746163534648e-08
pure O 0 1.597712184775446e-07
- O 0 9.08352646433741e-08
emerin O 0 9.001135481412348e-07
band O 0 1.298031282459533e-08
on O 0 1.3873852289236766e-08
a O 0 2.891828110307415e-09
western O 0 1.1641964192676824e-07
blot O 0 1.2296920886001317e-06
, O 0 1.102143376563447e-09
it O 0 9.910596787676695e-10
stained O 0 4.138335896186618e-07
only O 0 5.984154949345566e-09
the O 0 5.3036224301195034e-08
nuclear O 0 8.788232435108512e-07
membrane O 0 1.3312608189153252e-06
. O 0 3.277210112173634e-07

These O 0 3.879961241182173e-08
results O 0 2.063640636151831e-08
would O 0 9.618806862121687e-10
not O 0 3.0764787939396854e-10
be O 0 4.195370162385359e-10
expected O 0 4.435085632081837e-09
if O 0 1.399592797213245e-08
immunostaining O 0 3.2842169730429305e-06
at O 0 8.551155161740098e-08
intercalated O 0 8.025332931538287e-08
discs O 0 2.609681715171064e-08
were O 0 3.602495635135483e-09
due O 0 3.5425673505784516e-09
to O 0 1.7761400683546924e-10
a O 0 4.4252645992060025e-10
product O 0 5.330890839871927e-09
of O 0 1.4015750338103317e-08
the O 0 4.93369469722893e-08
emerin O 0 8.078313840087503e-07
gene O 0 9.841694570411619e-09
and O 0 4.1457056454419217e-08
, O 0 1.8325077011382973e-09
therefore O 0 6.467946622734644e-09
, O 0 4.68669658637566e-10
cast O 0 1.881141908910422e-09
some O 0 2.780581043193564e-10
doubt O 0 5.913693090775496e-09
upon O 0 1.745512290263207e-09
the O 0 6.019892362374435e-10
hypothesis O 0 1.6865897123352624e-08
that O 0 4.4223114059604995e-10
cardiac B-Disease 0 2.225975094916066e-06
defects I-Disease 0 3.308332452434115e-05
in O 0 2.1365072200296709e-07
EDMD B-Disease 1 1.0
are O 0 1.0153401452939192e-09
caused O 0 5.675396153037582e-09
by O 0 2.502457407960179e-10
absence O 0 1.3593208905149368e-06
of O 0 5.172086048332858e-07
emerin O 0 3.7959918699925765e-05
from O 0 4.511383622229914e-07
intercalated O 0 5.293796220939839e-06
discs O 0 2.9952520890219603e-06
. O 0 1.835256625781767e-06

Although O 0 3.851001508792251e-07
emerin O 0 1.3696028872800525e-05
was O 0 7.691684089650153e-08
abundant O 0 6.807387364915485e-08
in O 0 1.1643508379677314e-09
the O 0 3.910399470896664e-08
membranes O 0 8.345438828882834e-08
of O 0 1.2095870260964148e-07
cardiomyocyte O 0 7.223696911751176e-07
nuclei O 0 1.0027734020923162e-07
, O 0 1.0721674659208702e-09
it O 0 2.3827795292419296e-10
was O 0 1.3032658507938777e-08
absent O 0 1.2457832099244115e-08
from O 0 3.5929577091309284e-09
many O 0 5.777120559713467e-09
non O 0 4.094556231848401e-07
- O 0 1.1393424159678034e-07
myocyte O 0 4.448104959919874e-07
cells O 0 1.2608192712093569e-08
in O 0 4.2978700598439445e-09
the O 0 1.877515956039133e-07
heart O 0 5.418892214947846e-07
. O 0 4.942529585605371e-07

This O 0 2.936981102763525e-09
distribution O 0 6.428984278272765e-08
of O 0 8.38000389080662e-08
emerin O 0 9.086035788641311e-06
was O 0 1.1259565724230924e-08
similar O 0 5.022845681046384e-11
to O 0 9.680772156128725e-11
that O 0 2.259462755782593e-10
of O 0 1.5334681080503287e-08
lamin O 0 4.5696374399994966e-06
A O 0 9.373095963383093e-06
, O 0 2.1848407527613745e-09
a O 0 3.6099931932653817e-09
candidate O 0 1.8148698543996034e-08
gene O 0 1.4580183727019858e-09
for O 0 2.6458668589413037e-09
an O 0 6.765020543753053e-09
autosomal O 0 6.424804155358288e-08
form O 0 3.53624365345695e-08
of O 0 9.927801329467911e-06
EDMD B-Disease 1 1.0
. O 0 1.73779517353978e-05

In O 0 9.063640504791692e-08
contrast O 0 4.4841505086878897e-07
, O 0 5.5990177827425214e-08
lamin O 0 0.0001055426400853321
B1 O 0 0.0012423410080373287
was O 0 1.0094039680552669e-05
absent O 0 9.738232620293275e-06
from O 0 9.411040196027898e-07
cardiomyocyte O 0 4.503574473346816e-06
nuclei O 0 5.236062747826509e-07
, O 0 3.088120648087056e-09
showing O 0 3.527768654976171e-08
that O 0 2.928519116096595e-08
lamin O 0 4.6737066440982744e-05
B1 O 0 1.003149100142764e-05
is O 0 6.483727998940481e-10
not O 0 9.055627775422792e-11
essential O 0 1.3387442265866412e-09
for O 0 5.16831299979259e-10
localization O 0 5.875166380064911e-07
of O 0 1.0322612098434547e-07
emerin O 0 6.347976523102261e-06
to O 0 2.6984958267917136e-08
the O 0 5.77394530409947e-07
nuclear O 0 1.913260348374024e-05
lamina O 1 0.9927256107330322
. O 0 4.882087523583323e-06

Lamin O 0 0.0024933607783168554
B1 O 0 0.0008856681524775922
is O 0 3.887049970785483e-08
also O 0 3.919492730375396e-09
almost O 0 2.079913308250525e-08
completely O 0 3.1803276101527445e-07
absent O 0 2.565824388511828e-06
from O 0 3.872269189741928e-07
skeletal O 0 8.767749022808857e-06
muscle O 0 8.895777909856406e-07
nuclei O 0 4.9442725867265835e-05
. O 0 8.863683547133405e-07

In O 0 9.410986763214169e-07
EDMD B-Disease 1 1.0
, O 0 2.5351460930522762e-09
the O 0 3.480220833740333e-10
additional O 0 1.4330393538486419e-09
absence O 0 3.129748904484586e-08
of O 0 1.1011043454800529e-07
lamin O 0 0.00021532518439926207
B1 O 0 0.000662043399643153
from O 0 2.7708627385436557e-05
heart O 1 0.9999204874038696
and O 0 3.4319247788516805e-05
skeletal O 0 0.09181410074234009
muscle O 0 1.5709931631135987e-06
nuclei O 1 0.644616425037384
which O 0 4.408840581504592e-08
already O 0 3.7516731943298964e-09
lack O 0 1.4815310578342178e-07
emerin O 0 2.4860526082193246e-06
may O 0 9.367700393170253e-09
offer O 0 4.103669404287302e-09
an O 0 5.229046085020173e-10
alternative O 0 4.861613778217588e-09
explanation O 0 8.335353385291455e-08
of O 0 2.0428300828712054e-08
why O 0 1.4672195902676322e-08
these O 0 1.3734021031552857e-08
tissues O 0 4.296823163940644e-08
are O 0 1.945833938421515e-09
particularly O 0 1.1289241541589945e-08
affected O 0 2.501686680034254e-08
. O 0 1.6557294202357298e-08
. O 0 1.7184095213451656e-07

Genetic O 0 1.2237613589149987e-07
mapping O 0 1.032192287198086e-07
of O 0 5.634714383973005e-08
the O 0 1.4736315279151313e-07
copper B-Disease 0 3.911081876140088e-06
toxicosis I-Disease 0 5.21371875947807e-05
locus O 0 1.435981999975411e-07
in O 0 1.3661051845303973e-08
Bedlington O 0 1.8598371752887033e-05
terriers O 0 2.494831051080837e-06
to O 0 6.133875185554416e-09
dog O 0 3.0174259535442616e-08
chromosome O 0 1.1550656431325024e-08
10 O 0 1.625539169936019e-08
, O 0 1.2802577054049635e-10
in O 0 1.006130526115534e-10
a O 0 1.940841043435171e-09
region O 0 2.59927954715522e-08
syntenic O 0 2.8992778311476286e-07
to O 0 2.537410059844092e-09
human O 0 1.5002614262016323e-08
chromosome O 0 4.491456309096975e-07
region O 0 3.1854361282057653e-07
2p13 O 0 3.935499080398586e-06
- O 0 9.141069199358753e-07
p16 O 0 1.5563210808977601e-06
. O 0 3.4017332950497803e-07

Abnormal O 1 1.0
hepatic B-Disease 1 1.0
copper I-Disease 0 0.00015849847113713622
accumulation I-Disease 0 1.1650015039776918e-05
is O 0 1.6854882767258772e-10
recognized O 0 1.7419657383221931e-10
as O 0 1.991916076526934e-10
an O 0 1.8141179669584062e-09
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 5.111253642553493e-08
man O 0 7.147087899284088e-08
, O 0 4.886582249952198e-10
mouse O 0 4.015526133827052e-09
, O 0 3.000562909249993e-09
rat O 0 3.4220690281472343e-08
and O 0 1.0046837140009757e-08
dog O 0 7.029225912447146e-07
. O 0 1.7074758034141269e-06

The O 0 4.913485440738441e-08
major O 0 2.2113853503924474e-07
cause O 0 0.0018885908648371696
of O 0 0.00789834838360548
hepatic B-Disease 1 1.0
copper I-Disease 0 0.16064897179603577
accumulation I-Disease 1 0.9999868869781494
in O 0 9.886549605653272e-07
man O 0 0.0004308380885049701
is O 0 9.213074747549399e-10
a O 0 2.4358788319744917e-09
dysfunctional O 0 1.6799029367575713e-07
ATP7B O 0 0.00021248095436021686
gene O 0 3.38107177810798e-08
, O 0 8.284534835922841e-09
causing O 0 1.494234879828582e-06
Wilson B-Disease 0 9.247886509911041e-07
disease I-Disease 1 0.538502037525177
( O 0 6.668606999937765e-08
WD B-Disease 0 3.054280750802718e-05
) O 0 2.4238209661575638e-08
. O 0 3.017484004885773e-07

Mutations O 0 1.861155396909453e-06
in O 0 7.333285623190022e-08
the O 0 4.065548466769542e-07
ATP7B O 0 0.0005589270149357617
genes O 0 1.1690825196808419e-08
have O 0 3.889671362777847e-10
also O 0 1.3371714846499572e-10
been O 0 3.8556619702534434e-11
demonstrated O 0 3.5373598494814473e-10
in O 0 6.954353759525134e-10
mouse O 0 2.8953950348409307e-08
and O 0 9.486301877359438e-08
rat O 0 1.0785951189973275e-06
. O 0 4.0998077110998565e-07

The O 0 6.458755706262309e-06
ATP7B O 0 0.0012216526083648205
gene O 0 9.422664248859292e-08
has O 0 5.612872389093582e-09
been O 0 1.0475664780074112e-09
excluded O 0 6.822866271960493e-09
in O 0 8.343612606376283e-11
the O 0 2.9965349646055017e-10
much O 0 4.2658857002386696e-10
rarer O 0 2.4252736352536886e-07
human O 0 5.478556275306801e-08
copper B-Disease 0 1.929987320181681e-06
overload I-Disease 0 2.0606081307050772e-05
disease O 0 4.4191005144966766e-05
non B-Disease 0 0.006366954650729895
- I-Disease 0 3.869241936627077e-06
Indian I-Disease 0 1.3153325539860816e-08
childhood I-Disease 0 9.730747478897683e-07
cirrhosis I-Disease 1 0.9454935789108276
, O 0 1.0951944906523181e-09
indicating O 0 6.058080970205992e-08
genetic O 0 1.6197151353480876e-07
heterogeneity O 0 4.047658876515925e-06
. O 0 1.1272974234088906e-06

By O 0 6.91744439507147e-10
investigating O 0 2.1999699839625464e-09
the O 0 1.9956210017824105e-09
common O 0 2.119059772098808e-08
autosomal O 1 0.9999881982803345
recessive O 1 0.9999998807907104
copper B-Disease 1 0.9976963400840759
toxicosis I-Disease 1 0.9879266619682312
( O 0 2.0693111935088382e-07
CT B-Disease 0 3.6376230127643794e-05
) O 0 5.103542588535959e-10
in O 0 7.635420296026041e-09
Bedlington O 0 4.581617031362839e-05
terriers O 0 3.8454636523965746e-05
, O 0 6.90106727319062e-09
we O 0 7.407758295663314e-10
have O 0 8.520582850390923e-11
identified O 0 6.726648127397539e-10
a O 0 2.503731943992449e-10
new O 0 6.436942090459752e-10
locus O 0 2.0222514773848843e-09
involved O 0 6.44238329350344e-10
in O 0 7.487309439113687e-09
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 9.093649566693784e-08

We O 0 6.319469036952796e-08
examined O 0 7.000834045811644e-08
whether O 0 4.430174005420895e-09
the O 0 3.282577409891019e-08
WD B-Disease 0 8.054687896219548e-06
gene O 0 3.303966025214322e-07
ATP7B O 1 0.9999996423721313
was O 0 6.290234750849777e-07
also O 0 1.4277085069736017e-09
causative O 0 2.0449272497558013e-08
for O 0 8.061346590260143e-10
CT B-Disease 0 1.9443254473117122e-07
by O 0 1.5988103896358297e-10
investigating O 0 4.844461720665549e-09
the O 0 4.0177575044708647e-08
chromosomal O 0 1.0427407914903597e-06
co O 0 1.2645840286040766e-07
- O 0 6.85151988477628e-08
localization O 0 8.896711847228289e-07
of O 0 4.246399214480334e-07
ATP7B O 0 0.00041158177191391587
and O 0 8.628827430356978e-09
C04107 O 0 1.9265746686869534e-07
, O 0 2.3898616419160135e-10
using O 0 4.399098793572698e-11
fluorescence O 0 4.252783902813917e-09
in O 0 3.493097366913389e-09
situ O 0 2.0239275499989162e-07
hybridization O 0 6.193434387569141e-08
( O 0 1.418512862727539e-08
FISH O 0 7.588934295199579e-06
) O 0 9.589867566717203e-09
. O 0 2.2939047994441353e-07

C04107 O 0 8.685340435476974e-05
is O 0 1.3202489768104897e-08
an O 0 3.238409762573724e-09
anonymous O 0 3.651016200478807e-08
microsatellite O 0 9.90211788121087e-07
marker O 0 1.4922810578354984e-06
closely O 0 6.790904905074058e-08
linked O 0 7.46946739127452e-07
to O 0 7.590713835270435e-08
CT B-Disease 0 0.023602761328220367
. O 0 8.254930889961543e-07

However O 0 5.22231130162254e-06
, O 0 5.362195452107699e-07
BAC O 0 2.4617926101200283e-05
clones O 0 1.271234566502244e-07
containing O 0 2.212561867054319e-08
ATP7B O 0 0.00010343042231397703
and O 0 5.830521843108727e-09
C04107 O 0 3.743141405720962e-07
mapped O 0 8.717495170174061e-09
to O 0 9.060193151277929e-10
the O 0 1.7561591292292178e-08
canine O 0 2.3239478252889967e-07
chromosome O 0 1.308838761815423e-07
regions O 0 1.0655163862338668e-07
CFA22q11 O 0 1.5840712421777425e-06
and O 0 2.100228257972958e-08
CFA10q26 O 0 1.6455278455396183e-06
, O 0 2.8597950674225103e-09
respectively O 0 3.4175731133956333e-09
, O 0 5.001491443223927e-10
demonstrating O 0 3.2409432915159186e-09
that O 0 4.8850563594271534e-09
WD B-Disease 0 1.7319744074484333e-06
cannot O 0 7.78532083245409e-08
be O 0 1.9498546777185766e-08
homologous O 0 6.966547516640276e-08
to O 0 4.0514561305826646e-07
CT B-Disease 0 0.0002502683491911739
. O 0 1.3559416629504994e-06

The O 0 3.563442805898376e-05
copper O 0 1.1630279004748445e-05
transport O 0 1.8570244719740003e-06
genes O 0 4.5852388552702905e-07
CTR1 O 0 0.36301153898239136
and O 0 6.640289740289518e-08
CTR2 O 1 0.999998927116394
were O 0 1.0721336707320006e-07
also O 0 4.442773260393551e-09
excluded O 0 3.661015668399159e-08
as O 0 3.116951141635127e-09
candidate O 0 8.184348310180667e-09
genes O 0 2.3220185774164293e-09
for O 0 1.2772753965606398e-09
CT B-Disease 0 9.436744221602567e-07
since O 0 1.803395544008879e-09
they O 0 4.978857326420894e-10
both O 0 7.365295040528963e-10
mapped O 0 5.821576554154717e-09
to O 0 2.351456585003575e-09
canine O 0 5.285969564283732e-07
chromosome O 0 4.043523915697733e-07
region O 0 1.386519784318807e-06
CFA11q22 O 0 4.341233579907566e-05
. O 0 2.124536877090577e-06

2 O 0 6.0930538893444464e-05
- O 0 1.086270458472427e-05
22 O 0 1.0806392310769297e-05
. O 0 6.42026634523063e-07

5 O 0 0.0001400980690959841
. O 0 8.13263250165619e-06

A O 0 3.360019263709546e-06
transcribed O 0 4.4240202612400026e-08
sequence O 0 2.0972570347055353e-09
identified O 0 6.964711474211072e-09
from O 0 3.6646188306121985e-09
the O 0 3.76410147495676e-09
C04107 O 0 5.024089233529594e-08
- O 0 2.4727664360568724e-09
containing O 0 1.5267141995067846e-09
BAC O 0 2.5770609113351384e-07
was O 0 3.603292997311769e-09
found O 0 3.519006960828186e-11
to O 0 4.436688516573639e-11
be O 0 2.837040602443608e-10
homologous O 0 3.255513358890738e-10
to O 0 7.323522344115929e-10
a O 0 2.885640615346574e-09
gene O 0 1.5022830979205537e-08
expressed O 0 1.3653367325616728e-08
from O 0 1.1387554010866552e-08
human O 0 3.259261527333024e-09
chromosome O 0 4.805719200362546e-08
2p13 O 0 1.7372501304180332e-07
- O 0 8.613107560506705e-09
p16 O 0 7.93933807585745e-09
, O 0 5.654644461006164e-11
a O 0 1.6752386977625378e-10
region O 0 3.2530136362396433e-09
devoid O 0 2.1242644265839772e-07
of O 0 1.953565087475795e-09
any O 0 4.459745017726391e-09
positional O 0 1.531652060293709e-06
candidate O 0 7.066313173709204e-06
genes O 0 2.5210804324160563e-06
. O 0 2.0245563518983545e-06

Molecular O 0 7.024615911177534e-08
analysis O 0 1.4844977691552685e-08
of O 0 2.0604943529178854e-08
the O 0 3.438969997660024e-08
APC B-Disease 0 1.876702526715235e-08
gene O 0 5.683647996690411e-10
in O 0 4.199012804129154e-10
205 O 0 7.968082305076507e-10
families O 0 1.8050981542838684e-10
: O 0 3.5437871387378195e-11
extended O 0 9.002079082165437e-09
genotype O 0 8.783040783555407e-08
- O 0 8.429850595348398e-07
phenotype O 0 1.3632426032472722e-07
correlations O 0 2.439525985664659e-07
in O 0 4.252070251453688e-09
FAP B-Disease 0 8.593813305424192e-08
and O 0 6.418389431050997e-11
evidence O 0 7.624443298936967e-10
for O 0 5.4721043668548575e-11
the O 0 1.9492663039244462e-09
role O 0 2.9009876723051775e-09
of O 0 3.453311947509974e-08
APC B-Disease 0 7.810382385287085e-08
amino O 0 2.4977008905580078e-08
acid O 0 5.3654205522946086e-09
changes O 0 7.645125421618104e-09
in O 0 3.929604304175882e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 1.0
. O 0 2.758861796792189e-07

BACKGROUND O 0 0.0020418590866029263
/ O 0 1.7023702412188868e-06
AIMS O 0 3.7887235748712556e-07
The O 0 1.5254101315420598e-09
development O 0 1.458041332114135e-08
of O 0 1.4580794527319085e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.3480077257498344e-11
a O 0 7.994394209120959e-12
variable O 0 1.174261521352804e-10
range O 0 1.1116497306007389e-10
of O 0 4.243089213318285e-11
extracolonic O 0 2.0478671558521455e-07
manifestations O 0 1.5736758314233157e-06
in O 0 1.179765618530837e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 5.431631322494468e-08
FAP B-Disease 0 2.819090241246158e-07
) O 0 1.3822300075350125e-11
is O 0 2.3948102615550804e-12
the O 0 8.602635964694016e-12
result O 0 2.799595555380563e-10
of O 0 1.1136727096072718e-09
the O 0 4.283850607578188e-09
dominant O 0 6.343524887597596e-07
inheritance O 0 6.806531018810347e-06
of O 0 2.690858991627465e-06
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 3.339900729315559e-07
APC B-Disease 0 1.327949803453521e-07
) O 0 1.6943337843855488e-09
gene O 0 1.7074997415988946e-08
mutations O 0 1.0578351066214964e-06
. O 0 6.403370775842632e-07

In O 0 5.687981285973365e-08
this O 0 2.4664166264898313e-09
study O 0 9.69916813531313e-10
, O 0 2.4693608269288347e-11
direct O 0 2.7338040164970323e-10
mutation O 0 1.4492976263547064e-10
analysis O 0 1.575416880283953e-10
of O 0 1.925329451424318e-09
the O 0 6.3558514007411304e-09
APC B-Disease 0 1.0501336689117124e-08
gene O 0 1.8992076800117275e-09
was O 0 2.0283788870756325e-08
performed O 0 5.445304623874492e-11
to O 0 9.89321541355892e-11
determine O 0 4.936516084796949e-09
genotype O 0 1.4352153243635257e-07
- O 0 3.2160247087631433e-07
phenotype O 0 3.177816765287389e-08
correlations O 0 2.998184456259878e-08
for O 0 1.0256405724717865e-09
nine O 0 4.240749618134032e-08
extracolonic O 0 1.483039568483946e-06
manifestations O 0 1.134050151563315e-07
and O 0 2.087542083639704e-10
to O 0 1.1035500985245861e-10
investigate O 0 1.053505505055341e-09
the O 0 3.1212761264498567e-09
incidence O 0 2.1368996385717764e-06
of O 0 1.8529641820919096e-08
APC B-Disease 0 1.3441338353459287e-07
mutations O 0 1.40271353643584e-07
in O 0 3.945687154782718e-08
non O 1 1.0
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.930695010647469e-07

METHODS O 0 1.4996388927102089e-05
The O 0 9.776045999387861e-07
APC B-Disease 0 4.1357003510711365e-07
gene O 0 2.0013246171401988e-08
was O 0 1.4483077848126413e-07
analysed O 0 1.2065843435493662e-08
in O 0 7.50892958922833e-10
190 O 0 9.94828930345193e-09
unrelated O 0 1.7552684639099425e-08
FAP B-Disease 0 3.2312763664776867e-07
and O 0 2.2852346681645486e-09
15 O 0 1.9425868913458544e-07
non O 1 0.9998830556869507
- O 1 0.9999990463256836
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 2.6158697430389566e-09
using O 0 1.6790836776525708e-10
denaturing O 0 2.3539578819509188e-07
gradient O 0 1.0321529941847984e-07
gel O 0 4.966987177112969e-08
electrophoresis O 0 1.2032312035614723e-08
, O 0 1.2105300095655025e-09
the O 0 5.267889680027338e-09
protein O 0 1.9631171355172228e-08
truncation O 0 1.748131772671968e-08
test O 0 1.014871520155225e-09
, O 0 9.166222780798705e-10
and O 0 1.1557261814232334e-09
direct O 0 5.625360799399459e-08
sequencing O 0 2.11500221780625e-07
. O 0 6.535496481774317e-07

RESULTS O 0 0.0001191323681268841
Chain O 0 9.341347890767793e-07
terminating O 0 3.5969432587990013e-07
signals O 0 3.5556407596004647e-08
were O 0 6.886061165722879e-10
only O 0 1.9332144218786596e-10
identified O 0 1.1543161981819594e-09
in O 0 8.076640051202233e-11
patients O 0 1.0733863797796062e-10
belonging O 0 3.9099182225221796e-10
to O 0 6.453451106835928e-10
the O 0 1.1970568891683797e-07
FAP B-Disease 0 2.05232981898007e-06
group O 0 6.156544163360422e-09
( O 0 1.0325970078994828e-09
105 O 0 1.5984072376795666e-07
patients O 0 3.989562014083958e-09
) O 0 3.6397505009944098e-09
. O 0 2.4176205215553637e-07

Amino O 0 1.2784602176907356e-06
acid O 0 2.2124689635916184e-08
changes O 0 1.3022611877744339e-09
were O 0 6.411051689525493e-10
identified O 0 7.391893763752933e-10
in O 0 7.400862561679489e-11
four O 0 7.374371946422542e-11
patients O 0 1.796938639553325e-11
, O 0 9.688341275071455e-12
three O 0 7.406341512306014e-11
of O 0 7.560731773992302e-08
whom O 0 4.365380846138578e-06
belonged O 0 0.003987953532487154
to O 0 2.5856913055122277e-08
the O 0 2.3923328171804314e-06
non O 0 1.7812137230066583e-05
- O 0 5.885530072191614e-07
FAP O 0 1.190689636132447e-05
group O 0 4.808772757769475e-08
of O 0 0.000281009852187708
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.009690284729003906
. O 0 8.729796263651224e-08

Genotype O 0 7.183514298958471e-06
- O 0 3.7791426166222664e-06
phenotype O 0 3.8782894762334763e-07
correlations O 0 5.3465242899619625e-08
identified O 0 3.36041972026635e-09
significant O 0 5.3906852315321885e-09
differences O 0 4.952227072863025e-09
in O 0 8.52325265920939e-10
the O 0 7.712850802477078e-09
nature O 0 9.119561994452852e-09
of O 0 1.51272550041881e-09
certain O 0 1.2284029793363516e-08
extracolonic O 0 4.7002108658489306e-06
manifestations O 0 1.2144046479534154e-07
in O 0 7.776542743087589e-10
FAP B-Disease 0 4.913129103556457e-08
patients O 0 6.034926725018153e-11
belonging O 0 1.068722610408912e-10
to O 0 1.9048515542685607e-10
three O 0 2.284049172018854e-09
mutation O 0 2.0851611282068916e-07
subgroups O 0 6.388279985003464e-07
. O 0 4.155963324592449e-07

CONCLUSIONS O 0 5.946038800175302e-05
Extended O 0 1.309899289481109e-06
genotype O 0 8.444600325674401e-07
- O 0 5.069906023891235e-07
phenotype O 0 1.4813672066793515e-07
correlations O 0 1.5414907750255225e-07
made O 0 4.298698286220315e-09
in O 0 4.712071288714981e-10
this O 0 2.1086875301445929e-10
study O 0 3.9049100064580955e-10
may O 0 5.342501996352667e-10
have O 0 2.9785057753528577e-10
the O 0 2.8947031438519844e-09
potential O 0 2.8495585890908615e-09
to O 0 7.081352171312005e-10
determine O 0 1.8359932241196475e-08
the O 0 1.1362994101205004e-08
most O 0 9.805770639914613e-10
appropriate O 0 5.4018629569441146e-09
surveillance O 0 1.2329050669279695e-08
and O 0 3.817905103176145e-09
prophylactic O 0 3.245195046019944e-07
treatment O 0 8.216945346362081e-09
regimens O 0 2.54202170424378e-09
for O 0 2.0655564758609302e-10
those O 0 8.41114178307123e-10
patients O 0 3.723888697404476e-10
with O 0 5.241534983824181e-11
mutations O 0 3.524202707438917e-09
associated O 0 2.3484938438400604e-09
with O 0 7.933184664743465e-11
life O 0 3.68051988886009e-09
threatening O 0 6.681593589519252e-08
conditions O 0 3.2503612601431087e-07
. O 0 4.060604226197029e-07

This O 0 3.0128941119755837e-08
study O 0 4.112014284629595e-09
also O 0 4.4073796695576206e-11
provided O 0 1.8361875908645686e-10
evidence O 0 5.512554301922989e-10
for O 0 6.02618441258862e-11
the O 0 2.8171447397085103e-09
pathological O 0 2.4764124191278825e-06
nature O 0 5.937713254411392e-08
of O 0 3.8356287035412606e-08
amino O 0 2.9573483217859575e-08
acid O 0 3.4251428360221325e-09
changes O 0 7.496450682431544e-10
in O 0 3.238039170128104e-09
APC O 0 7.15686780949909e-08
associated O 0 4.180564516786944e-08
with O 0 1.0642459136178672e-09
both O 0 6.9246026690450435e-09
FAP B-Disease 0 5.409854111348977e-06
and O 0 3.766322720366588e-08
non O 1 1.0
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 2.070351570182538e-07
. O 0 8.33254798493499e-10
. O 0 7.284129299733877e-09

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 0 2.432978760680271e-07
cancer B-Disease 1 0.9998307228088379
risk O 0 9.958013436062174e-08
of O 0 3.4383141667149175e-08
the O 0 7.574386273745404e-08
APC O 0 1.8591104833376448e-07
I1307K O 0 2.3080718847268145e-07
polymorphism O 0 7.247988520475701e-08
. O 0 2.013178175275243e-07

Germ O 0 5.628658618661575e-05
- O 0 1.5431278370670043e-05
line O 0 5.291714160193806e-07
and O 0 5.264862990017605e-10
somatic O 0 1.53981133621528e-07
truncating O 0 4.784446261396624e-08
mutations O 0 1.2570061436179003e-08
of O 0 2.3451379504990655e-08
the O 0 1.8154617364984915e-08
APC B-Disease 0 1.511410907539812e-08
gene O 0 1.7641685889913106e-09
are O 0 4.104567519203073e-10
thought O 0 6.386593476293001e-10
to O 0 3.5359837280424244e-10
initiate O 0 2.0168486969396326e-07
colorectal B-Disease 1 1.0
tumor I-Disease 0 1.578051524120383e-05
formation O 0 1.1124487286906515e-07
in O 0 2.9838652437774726e-08
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 1.2039319585710473e-07
sporadic O 1 0.999785840511322
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 6.099065785747371e-08
respectively O 0 1.9291174169211445e-07
. O 0 2.78411363296982e-07

Recently O 0 8.668617965668091e-07
, O 0 7.217965780625946e-09
an O 0 1.4892054700510471e-08
isoleucine O 0 1.451020210652132e-07
- O 0 2.4899144079881808e-08
- O 0 7.282132230557181e-08
> O 0 1.7137313790271946e-08
lysine O 0 3.244445423433717e-08
polymorphism O 0 1.2619331357655028e-08
at O 0 1.667309312836096e-08
codon O 0 4.3785711056898435e-08
1307 O 0 1.924479420267744e-07
( O 0 9.128101052802151e-10
I1307K O 0 2.3149709704739507e-08
) O 0 5.172294537114652e-11
of O 0 1.7157124609923358e-09
the O 0 7.534412205245644e-09
APC B-Disease 0 5.66467894813627e-09
gene O 0 9.500327191602764e-10
has O 0 9.45765910032037e-10
been O 0 3.124902281381736e-10
identified O 0 3.5600208891928276e-10
in O 0 2.5000623793403065e-10
6 O 0 1.5053464252900994e-08
% O 0 1.7822493481034485e-09
- O 0 4.880099657711412e-10
7 O 0 5.18474463362395e-09
% O 0 1.1904266461471025e-09
of O 0 1.8592047901222486e-09
the O 0 1.3980186786000104e-08
Ashkenazi O 0 2.02680485728024e-08
Jewish O 0 4.7735991159925106e-08
population O 0 4.350440008238365e-09
. O 0 2.690776490510416e-08

To O 0 3.5766227757250135e-09
assess O 0 8.766019732320274e-08
the O 0 5.084365817253911e-09
risk O 0 1.135198957058492e-08
of O 0 7.880645580549128e-10
this O 0 7.142226393641593e-11
common O 0 9.363391173522473e-10
APC B-Disease 0 3.0439935017056996e-08
allelic O 0 6.916012296187546e-08
variant O 0 2.651120212249225e-07
in O 0 8.473530499486515e-08
colorectal O 1 1.0
carcinogenesis O 1 0.9999974966049194
, O 0 1.9251469751679906e-08
we O 0 3.2974225572246496e-09
have O 0 4.611827308931282e-10
analyzed O 0 3.11710546263555e-09
a O 0 5.173421691040403e-10
large O 0 3.4986851193963275e-09
cohort O 0 3.5838084500028344e-08
of O 0 1.580818498325698e-08
unselected O 0 0.00028781837318092585
Ashkenazi O 0 4.7159878135971667e-07
Jewish O 0 3.92267656934564e-06
subjects O 0 2.8815728114750527e-07
with O 0 8.438655996201305e-09
adenomatous B-Disease 0 3.717452727869386e-06
polyps I-Disease 0 3.6103810430176964e-07
and O 0 3.621579258705765e-09
. O 0 4.1778864812158645e-08
or O 1 0.9999881982803345
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 5.635890643063135e-10
for O 0 2.223164707881864e-10
the O 0 1.8585142314009317e-08
APC O 0 1.9075554291703156e-07
I1307K O 0 5.83790210839652e-07
polymorphism O 0 2.898954676311405e-07
. O 0 6.711045443807961e-07

The O 0 2.163852514058817e-06
APC O 0 2.1303069388523e-06
I1307K O 0 6.895609203638742e-07
allele O 0 1.7738127411348614e-08
was O 0 1.4507677725816848e-08
identified O 0 1.4275831627941216e-09
in O 0 5.026240534888871e-10
48 O 0 2.8128077644851146e-08
( O 0 3.024152595010321e-10
10 O 0 2.9877018636881303e-09
. O 0 5.568647765130663e-10
1 O 0 1.2409548055813957e-08
% O 0 1.7488179793190284e-09
) O 0 2.7043346728650164e-11
of O 0 1.06779196595852e-09
476 O 0 3.602978537742274e-08
patients O 0 1.1056791038299707e-08
. O 0 1.7675249353032996e-07

Compared O 0 4.6722488100670034e-09
with O 0 2.4325798320123937e-11
the O 0 2.1777543657286458e-10
frequency O 0 1.9083644386963527e-10
in O 0 1.2306617530599695e-11
two O 0 1.1655227998008666e-11
separate O 0 2.4053127545276e-11
population O 0 5.682236278725661e-11
control O 0 9.456428001763939e-11
groups O 0 1.1578966951919512e-10
, O 0 2.3282707706240302e-10
the O 0 9.310325843614464e-09
APC O 0 7.868202800409563e-08
I1307K O 0 8.72253878014817e-08
allele O 0 3.0495475034086894e-09
is O 0 1.1505481289919572e-10
associated O 0 6.267391050585047e-10
with O 0 2.223931282185898e-11
an O 0 6.470630281585343e-11
estimated O 0 2.3001495152996654e-10
relative O 0 2.1416720841216375e-08
risk O 0 2.3870533993886056e-08
of O 0 8.014303887193819e-08
1 O 0 3.6966512197977863e-06
. O 0 1.5267170283550513e-06

5 O 0 4.782126416102983e-05
- O 0 2.7607038646237925e-06
1 O 0 2.934473968707607e-06
. O 0 3.306203666397778e-07

7 O 0 5.200869964028243e-06
for O 0 1.0036823283599006e-07
colorectal B-Disease 1 1.0
neoplasia I-Disease 0 6.198816117830575e-05
( O 0 3.795587133481604e-08
both O 0 9.751299501203903e-08
P O 0 2.1082501916680485e-05
= O 0 7.167045623646118e-08
. O 0 1.1391986021180855e-08
01 O 0 2.8149233344265667e-07
) O 0 3.5562903732966333e-09
. O 0 6.491269743946759e-08

Furthermore O 0 1.186356143989542e-06
, O 0 2.031484136466588e-08
compared O 0 3.172705120846331e-08
with O 0 2.0498662767209908e-09
noncarriers O 0 2.6467723728273995e-06
, O 0 7.846093552643651e-09
APC O 0 2.206114402270032e-08
I1307K O 0 2.504130947045269e-08
carriers O 0 5.293308569243038e-10
had O 0 1.4682062510207317e-10
increased O 0 3.251182101315919e-10
numbers O 0 1.2694766349241604e-09
of O 0 1.4438444218001223e-08
adenomas B-Disease 0 0.0007139092776924372
and O 0 0.0001783411717042327
colorectal B-Disease 1 1.0
cancers I-Disease 1 1.0
per O 0 1.0448177079069865e-07
patient O 0 2.7112802669648772e-08
( O 0 3.500540746159686e-09
P O 0 1.8498551526135998e-06
= O 0 4.0366689546544876e-08
. O 0 1.2093676282631804e-08
03 O 0 2.3224318468351157e-08
) O 0 6.956419468240327e-11
, O 0 1.3095936834961464e-10
as O 0 4.0743197704529166e-10
well O 0 6.905211402674638e-10
as O 0 2.0049837345936794e-09
a O 0 1.0258015770148177e-08
younger O 0 4.703815079665219e-07
age O 0 1.9133751266053878e-05
at O 0 8.539075224689441e-07
diagnosis O 0 2.145308371837018e-06
. O 0 2.099563971569296e-07

We O 0 3.583856411637498e-08
conclude O 0 1.1425653667629376e-07
that O 0 7.459594608683062e-10
the O 0 1.0415660334217591e-08
APC O 0 1.9887261260009836e-07
I1307K O 0 3.24314044064522e-07
variant O 0 1.269966958261648e-07
leads O 0 3.049136410027131e-08
to O 0 1.5079951731777896e-09
increased O 0 7.786165383549815e-07
adenoma B-Disease 1 1.0
formation O 0 9.089485502045136e-07
and O 0 4.427664901385242e-09
directly O 0 5.677670333881224e-09
contributes O 0 2.0678714296451517e-09
to O 0 1.641398961194085e-10
3 O 0 9.679250290162145e-09
% O 0 1.3533524301223565e-09
- O 0 4.036264378282084e-10
4 O 0 1.6366417110447173e-09
% O 0 2.601548143577048e-10
of O 0 2.0155192792525867e-10
all O 0 1.2852225950155116e-09
Ashkenazi O 0 1.446181045139383e-06
Jewish O 1 0.9999755620956421
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.502646623270266e-07

The O 0 1.2791781500709476e-07
estimated O 0 9.029131575744032e-08
relative O 0 2.673322683222068e-07
risk O 0 1.5413032627975554e-08
for O 0 1.8927769074306156e-10
carriers O 0 1.7890952053178921e-09
may O 0 1.444805164396712e-09
justify O 0 1.4871956999229496e-08
specific O 0 1.863042164984563e-09
clinical O 0 2.3855957209661938e-09
screening O 0 1.1389889031931943e-10
for O 0 1.7556818499020466e-10
the O 0 2.928596032347741e-09
360 O 0 3.5802061315592937e-09
, O 0 1.2812569061271262e-10
000 O 0 3.5500959949530397e-09
Americans O 0 1.6404569369576905e-10
expected O 0 1.4718155583182124e-09
to O 0 1.167631102916289e-09
harbor O 0 4.537059794529341e-07
this O 0 4.702949141233148e-10
allele O 0 6.2589369242971316e-09
, O 0 3.5100061746007327e-10
and O 0 1.0441249254089513e-10
genetic O 0 2.4631716111223056e-10
testing O 0 6.239787159190158e-11
in O 0 1.4547786586494027e-10
the O 0 2.942644572456743e-09
setting O 0 1.3410449639650324e-08
of O 0 4.862980063080613e-08
long O 0 2.3061392795398206e-08
- O 0 6.968035393128957e-08
term O 0 4.002140201464499e-07
- O 0 7.959811654245641e-08
outcome O 0 1.0840125952427115e-07
studies O 0 5.660174995369971e-09
may O 0 4.816579357580508e-10
impact O 0 2.995406589434424e-08
significantly O 0 3.083581816554215e-07
on O 0 6.262620445340872e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 2.7562734317143622e-08
in O 0 2.0103465767085105e-11
this O 0 4.6207357384808745e-11
population O 0 9.7426466894035e-10
. O 0 2.592526016087504e-08

Localization O 0 1.0429337180539733e-06
of O 0 2.686156790332461e-07
human O 0 7.981231675557865e-08
BRCA1 O 0 9.507441234291036e-08
and O 0 1.3881231719636844e-09
its O 0 6.783882344763015e-10
loss O 0 2.680223376572144e-09
in O 0 1.973267105270793e-09
high O 0 1.0128329449798912e-05
- O 0 1.3696661653739284e-06
grade O 0 8.366239853785373e-06
, O 0 2.7858826001647685e-07
non B-Disease 1 1.0
- I-Disease 1 1.0
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.002271495060995221

Although O 0 9.326606154047568e-09
the O 0 5.832813343431553e-09
link O 0 6.661830553866821e-08
between O 0 3.766459144571854e-08
the O 0 1.77810179025073e-07
BRCA1 O 0 2.9028433345956728e-06
tumour B-Disease 1 0.9999997615814209
- O 0 8.628173020497343e-08
suppressor O 0 2.1606736311241548e-07
gene O 0 6.334768265503499e-09
and O 0 1.7483918313132563e-08
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 1.2337836308162764e-10
established O 0 8.828863334864323e-11
, O 0 9.467106786009705e-12
the O 0 3.298301631815548e-10
role O 0 4.057692515324618e-10
, O 0 7.970099580312251e-11
if O 0 1.4340777176879982e-10
any O 0 1.8638026677564312e-09
, O 0 8.850077337640982e-10
of O 0 1.8602378304422018e-08
BRCA1 O 0 2.697946115404193e-07
in O 0 5.0276362628665083e-08
non B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
familial I-Disease 1 0.9994732737541199
cancers I-Disease 1 0.9999935626983643
is O 0 6.8607102221562855e-09
unclear O 0 2.493546276127745e-07
. O 0 2.754770775936777e-07

BRCA1 O 0 9.555392352922354e-06
mutations O 0 2.751520469246316e-07
are O 0 5.920484102972523e-10
rare O 0 4.071680326234173e-09
in O 0 2.585610836547403e-09
sporadic B-Disease 0 2.446960388624575e-05
cancers I-Disease 0 0.00014913825725670904
, O 0 3.283375515916731e-10
but O 0 3.621107858009509e-10
loss O 0 5.149809112481307e-08
of O 0 2.1666328109404276e-07
BRCA1 O 0 7.156690884357886e-08
resulting O 0 1.398248006267977e-08
from O 0 2.4711630519647088e-09
reduced O 0 7.579498806364882e-09
expression O 0 3.849735641381358e-09
or O 0 2.5998729835663426e-09
incorrect O 0 9.491604657796415e-08
subcellular O 0 4.686738066084217e-06
localization O 0 5.762860268987424e-07
is O 0 3.9121657025020795e-09
postulated O 0 1.1837370550438209e-07
to O 0 1.9642472093295282e-09
be O 0 2.4882751414878612e-09
important O 0 1.814201766592305e-08
in O 0 9.536824663314292e-09
non B-Disease 0 0.003375470172613859
- I-Disease 0 0.1500912457704544
familial I-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 1.466932189941872e-06

Epigenetic O 0 0.0002681300975382328
loss O 0 0.009113680571317673
, O 0 4.027017652674658e-08
however O 0 2.883754746108025e-08
, O 0 2.746682326026928e-10
has O 0 9.16558409030932e-12
not O 0 1.628350557690561e-12
received O 0 9.751546792280408e-11
general O 0 6.559468523903433e-10
acceptance O 0 3.7930232288374555e-09
due O 0 1.760316781229676e-09
to O 0 1.0473781564268592e-10
controversy O 0 3.2890556944664695e-09
regarding O 0 3.2844795772035695e-09
the O 0 6.9336953956167235e-09
subcellular O 0 2.043457789113745e-05
localization O 0 7.759799700579606e-06
of O 0 3.884288616973208e-06
BRCA1 O 0 3.465077043074416e-07
proteins O 0 8.421356056942386e-09
, O 0 5.987120244022037e-10
reports O 0 4.165678024747876e-09
of O 0 1.900838375590297e-09
which O 0 2.147629990512101e-10
have O 0 2.5568222539185115e-10
ranged O 0 8.570030729515565e-08
from O 0 4.161032407523635e-09
exclusively O 0 2.2099710950129747e-09
nuclear O 0 2.4029596090713312e-08
, O 0 4.360340144504704e-10
to O 0 1.6954457837670134e-09
conditionally O 0 1.8357381748046464e-07
nuclear O 0 1.321501628126498e-07
, O 0 1.3431331602475893e-09
to O 0 2.265937437684329e-09
the O 0 9.002063166008156e-07
ER O 0 5.829326619277708e-05
/ O 0 1.2775372226769832e-07
golgi O 0 7.038442504381237e-07
, O 0 4.682177756620831e-09
to O 0 6.909813166089407e-09
cytoplasmic O 0 1.8251437268190784e-06
invaginations O 0 9.729896191856824e-06
into O 0 1.196763577127058e-07
the O 0 2.494949455922324e-07
nucleus O 0 1.6204025996557903e-06
. O 0 4.250191523169633e-07

In O 0 4.447829127229852e-08
an O 0 1.1730762139450235e-08
attempt O 0 9.403521517015179e-09
to O 0 1.6595860241608307e-09
resolve O 0 5.902694333315139e-09
this O 0 1.0395014848896267e-09
issue O 0 9.634859132745532e-09
, O 0 1.6081087572672459e-09
we O 0 2.1868669097813154e-09
have O 0 3.5662208741626955e-09
comprehensively O 0 2.5648458290561393e-07
characterized O 0 1.0092782787296528e-07
19 O 0 8.85417023255286e-07
anti O 0 1.2355543503872468e-06
- O 0 3.5325099361216417e-06
BRCA1 O 0 4.5330378384278447e-07
antibodies O 0 8.963378661519528e-08
. O 0 1.0557312180026202e-07

These O 0 1.8127495593489584e-07
reagents O 0 1.7796298834582558e-06
detect O 0 7.359951581520363e-08
a O 0 3.7518681494930206e-08
220 O 0 5.541994241298198e-08
- O 0 1.8284517011579737e-08
kD O 0 7.505382981776165e-09
protein O 0 1.4664075509429608e-09
localized O 0 3.350518751332743e-09
in O 0 6.510020300609654e-11
discrete O 0 3.0756588387248485e-09
nuclear O 0 1.86161148718611e-08
foci O 0 2.2042979708203347e-07
in O 0 4.331536906931888e-09
all O 0 4.512581863735932e-09
epithelial O 0 1.245028471430487e-07
cell O 0 2.003280457074652e-07
lines O 0 1.6169241945362955e-08
, O 0 4.908569384287631e-11
including O 0 1.181053345400418e-11
those O 0 2.2532482824022537e-10
derived O 0 4.432001432519428e-08
from O 0 5.27422116647358e-07
breast B-Disease 0 1.147279363067355e-05
malignancies I-Disease 0 6.345706424326636e-06
. O 0 5.168629400031932e-07

Immunohistochemical O 0 9.084838529815897e-05
staining O 0 1.9390054148971103e-05
of O 0 5.455994482872484e-07
human O 0 4.24104086960142e-07
breast O 0 3.6733445085701533e-06
specimens O 0 5.727728691340417e-08
also O 0 2.9714937177516276e-09
revealed O 0 3.876328946716967e-08
BRCA1 O 0 8.009716339074657e-07
nuclear O 0 3.7051111689834215e-07
foci O 0 7.223859938676469e-06
in O 0 1.1501997221330384e-07
benign O 1 1.0
breast O 1 0.9999842643737793
, O 0 1.5659134078305215e-07
invasive B-Disease 0 8.283786883112043e-05
lobular I-Disease 1 0.9997777342796326
cancers I-Disease 1 1.0
and O 0 0.004458927549421787
low B-Disease 1 1.0
- I-Disease 1 1.0
grade I-Disease 1 1.0
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.00014828417624812573

Conversely O 0 2.8767944968421943e-06
, O 0 8.457707423303873e-08
BRCA1 O 0 7.289344239325146e-08
expression O 0 1.727245013682932e-08
was O 0 3.00256814966815e-08
reduced O 0 6.89200385650679e-09
or O 0 5.350099252510176e-10
undetectable O 0 6.2459140082182785e-09
in O 0 6.043012618084376e-11
the O 0 6.369853533527703e-10
majority O 0 1.487057976756745e-10
of O 0 4.9052264472493334e-08
high O 0 0.0004015218000859022
- O 0 0.0005914884968660772
grade O 0 1.52490420077811e-05
, O 0 5.716055966331623e-07
ductal B-Disease 1 0.999319314956665
carcinomas I-Disease 1 1.0
, O 0 5.428158811326966e-09
suggesting O 0 1.2162378659752449e-08
that O 0 5.782807011023294e-10
absence O 0 1.3192178585086367e-06
of O 0 4.114923797260417e-07
BRCA1 O 0 1.2484669298373774e-07
may O 0 1.473894450931823e-09
contribute O 0 6.096245730446981e-10
to O 0 2.9035546189604133e-10
the O 0 7.1233769993739315e-09
pathogenesis O 0 1.3124601991876261e-06
of O 0 8.799967976536038e-10
a O 0 2.1679155692844176e-10
significant O 0 1.331517740510435e-08
percentage O 0 2.622111196615151e-06
of O 0 1.0657984148565447e-06
sporadic B-Disease 1 0.9999822378158569
breast I-Disease 1 0.999990701675415
cancers I-Disease 1 0.9999603033065796
. O 0 1.9924829075534944e-07
. O 0 5.267712026579829e-07

